Annual Report

2015
Augmented Version

Five-Year Summary: Bayer on Track for Success
DAHSC@ ADENQDRODBH@KHSDLR

R@KDR
Å™ ELOOLRQ

Å™ ELOOLRQ


  



Æ

CAGR 2











Æ

CAGR 2

2011-2015

    

    

D@QMHMFRODQRG@QD 

L@QJDSB@OHS@KHY@SHNM

Å™

Å™ ELOOLRQ

 

 



 Æ
CAGR 2



 




2011-2015

    

QCDWODMRDR Å™ ELOOLRQ

QDBNQC@AKDHMBHCDMS
Q@SDQHQ











CAGR 2



Æ




 
 

2011-2015

    

 Æ
CAGR 2 2011-2015

    



2011-2015

Å‹Æ

CAGR 2 2011-2015
    

ILJXUHVUHVWDWHGILJXUHVIRU Å‹ DVODVWUHSRUWHG
&RPSRXQG DQQXDOJURZWKUDWH

Cover picture // Bayer is focusing exclusively on its Life Science businesses.
Our cover picture shows scientists Dr. Wen Chang from Crop Science and
Dr. Daniel Forler (right) from Pharmaceuticals with a projected image of DNA.

You can read more about Life Sciences
in the Magazine section of this
Annual Report beginning on page 10.

Five-Year Summary
Change
from 2014
(%)

2011

2012

2013

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Sales

36,528

39,741

40,157

41,339

46,324

+ 12.1

EBIT 1

4,149

3,928

4,934

5,395

6,250

+ 15.8
+ 21.2

Bayer Group

EBIT before special items 2

5,025

5,639

5,773

5,833

7,069

EBITDA3

6,918

6,916

7,830

8,315

9,583

+ 15.2

EBITDA before special items 4

7,613

8,280

8,401

8,685

10,266

+ 18.2

EBITDA margin before special items 5

20.8%

20.8%

20.9%

21.0%

22.2%

Income before income taxes

3,363

3,176

4,207

4,414

5,245

+ 18.8

Net income

2,470

2,403

3,189

3,426

4,110

+ 20.0

Earnings per share (â‚¬) from continuing and
discontinued operations 6

2.99

2.91

3.86

4.14

4.97

+ 20.0

Core earnings per share (â‚¬) from continuing operations 7

4.83

5.30

5.61

5.89

6.83

+ 16.0

5,172

4,556

5,832

6,707

6,999

+ 4.4

Gross cash flow 8
Net cash flow from continuing and
discontinued operations 9

5,060

4,530

5,171

5,810

6,890

+ 18.6

Net financial debt

7,013

7,022

6,731

19,612

17,449

â€“ 11.0

Capital expenditures as per segment table

1,666

2,012

2,155

2,484

2,556

+ 2.9

Research and development expenses

2,932

3,013

3,406

3,537

4,281

+ 21.0

Return on equity

13.0%

13.0%

16.2%

16.8%

17.9%

Equity ratio

36.5%

36.1%

40.5%

28.8%

34.4%

Bayer AG

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

1,125

889

2,498

2,454

1,361

(239)

(682)

761

593

(706)

.

Total dividend payment

1,364

1,571

1,737

1,861

2,067

+ 11.1

Dividend per share (â‚¬)

1.65

1.90

2.10

2.25

2.50

+ 11.1

111,800

110,000

112,400

117,400

116,800

â€“ 0.5

8,726

9,194

9,430

9,693

11,203

+ 15.6

22

23

25

26

28

Net income
Allocation to (withdrawal from) retained earnings

â€“ 44.5

Employees
Number of employees 10 (Dec. 31)
Personnel expenses (including pension expenses)
(â‚¬ million)
Proportion of women in senior management (%)
Number of nationalities in the Group Leadership Circle

22

23

31

35

33

Proportion of employees with health insurance (%)

94

94

95

96

96

â€“ 5.7

Proportion of employees covered by collective agreements
on pay and conditions (%)

54

53

54

52

53

Recordable Incident Rate for Bayer employees (RIR)

0.56

0.49

0.47

0.43

0.42

â€“ 1.6

Lost Time Recordable Incident Rate for Bayer employees
(LTRIR)

0.31

0.27

0.26

0.22

0.21

â€“ 6.4

â€“

0.38

0.35

0.23

0.22

â€“ 7.7

Safety 11

Loss of Primary Containment Incident Rate (LoPC-IR) 12

2011

2012

2013

2014

2015

Change
from 2014
(%)

Environmental Protection11
Primary energy consumption (petajoules13/ a)

50.10

49.05

47.58

45.57

43.00

â€“ 5.7

Secondary energy consumption (petajoules13/ a)

34.85

34.14

33.27

39.74

40.19

+ 1.1

Energy efficiency (MWh / t) 14

3.63

3.50

3.44

3.37

3.34

â€“ 0.6

Direct greenhouse gas emissions
(CO2 equivalents in million t) 15

4.23

4.24

4.09

4.02

4.41

+ 9.7

â€“

4.72

4.91

5.53

5.30

â€“ 4.1

Indirect greenhouse gas emissions
(CO2 equivalents in million t),
according to the market-based method 15
Specific greenhouse gas emissions
(CO2 equivalents in t / manufactured sales volume in t),
according to the market-based method 15,16

â€“

1.06

1.09

1.12

1.19

+ 6.0

Volatile organic compounds (VOC) (thousand t / a) 17

2.69

2.60

2.27

2.12

1.61

â€“ 24.0

Total organic carbon (TOC) (thousand t / a)

1.50

1.42

1.53

1.20

1.16

â€“ 3.3

Hazardous waste generated (thousand t / a)

474

603

467

487

541

+ 11.1

Water use (million mÂ³/ a)

411

384

361

350

346

â€“ 1.1

2014 figures restated; figures for 2011 â€“ 2013 as last reported.
1
EBIT = income after income taxes, plus income taxes, plus financial result.
This indicator is not defined in the International Financial Reporting
Standards.
2
EBIT before special items = EBIT plus special charges, minus special gains.
This indicator is not defined in the International Financial Reporting Standards. See also Combined Management Report, Chapter 14.2 â€œCalculation of
EBIT(DA) Before Special Items.â€
3
EBITDA = EBIT plus the amortization of intangible assets and the depreciation of property, plant and equipment, plus impairment losses and minus
impairment loss reversals, recognized in profit or loss during the reporting
period. This indicator is not defined in the International Financial Reporting
Standards. See also Combined Management Report, Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
4
EBITDA before special items = EBITDA plus special charges, minus special
gains. This indicator is not defined in the International Financial Reporting
Standards. For details, see Combined Management Report, Chapter 14.2
â€œCalculation of EBIT(DA) Before Special Items.â€
5
The EBITDA margin before special items is calculated by dividing EBITDA
before special items by sales. This indicator is not defined in the International Financial Reporting Standards. For details, see Combined Management
Report, Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
6
Earnings per share as defined in IAS 33 = net income divided by the average
number of shares. For details, see Note [16] to the Consolidated Financial
Statements.
7
Core earnings per share = earnings per share, plus / minus amortization and
impairment losses / impairment loss reversals of intangible assets, impairment losses / impairment loss reversals on property, plant and equipment,
plus special charges, minus special gains (other than amortization and impairment losses / impairment loss reversals), plus / minus the related tax effects and the share of the adjustments attributable to noncontrolling interest.
This indicator facilitates the comparability of performance over time. It is not
defined in the International Financial Reporting Standards.
For details, see Combined Management Report, Chapter 14.3 â€œCore Earnings Per Share.â€

8

9
10
11
12

13
14

15
16

17

Gross cash flow = income after income taxes, plus income taxes, plus
financial result, minus income taxes paid or accrued, plus depreciation,
amortization and impairment losses, minus impairment loss reversals,
plus / minus changes in pension provisions, minus gains / plus losses on
retirements of noncurrent assets, minus gains from the remeasurement of
already held assets in step acquisitions. The change in pension provisions
includes the elimination of noncash components of EBIT. It also contains
benefit payments during the year. Gross cash flow is not defined in the
International Financial Reporting Standards. For details, see Combined
Management Report, Chapter 14.5 â€œLiquidity and Capital Expenditures of
the Bayer Group.â€
Net cash flow = cash flow from operating activities according to IAS 7
Full-time equivalents
Percentage changes not based on rounded figures
LoPC-IR: rate of incidents in which chemicals leak from their primary
container, such as pipelines, pumps, tanks or drums, per 200,000 working
hours in areas relevant to plant safety
1 petajoule = 1015 joules
Energy efficiency: quotient of total energy consumption and manufactured
sales volume. For Covestro, only manufactured sales volumes that also form
the basis for calculating Covestro-specific emissions are taken into account.
Portfolio-adjusted in accordance with the Greenhouse Gas Protocol
Specific Group emissions are calculated from the total volume of direct
emissions and indirect â€“ calculated using the market-based method of the
new Scope 2 GHG Protocol â€“ emissions of the subgroups, including the
emissions at the Belford Roxo site and emissions from the vehicle fleet, both
reported for the Group as a whole, divided by the manufactured sales volume of the three subgroups in metric tons. Quantities attributable to the
supply of energy to external companies are deducted from the direct and
indirect emissions. At Covestro, neither the by-products sodium hydroxide
solution and hydrochloric acid generated during production nor trade products are included in the manufactured sales volume.
Volatile organic compounds (VOC) excluding methane

1

CHAIRMANâ€™S LET TER
MAGAZINE

Life Science company
For the heart
Fit in old age
Defying the weather
Living with dengue
Covestro on the stock market

30

ABOUT THIS REPORT
TO OUR STOCKHOLDERS

10
12
16
20
26
29

Board of Management
Report of the Supervisory Board
,QYHVWRU,QIRUPDWLRQ

32
34


01
COMBINED MANAGEMENT
REPORT OF THE BAYER GROUP
AND BAYER AG

Bayer at a Glance
Strategies of the Segments
Economic Environments of the Subgroups
5HVHDUFK'HYHORSPHQW,QQRYDWLRQ
Sustainability Management and Governance
Employees
Procurement, Production, Logistics, Distribution
Product Stewardship
Safety
Environmental Protection
Social Commitment

46
58
62
63
79
86
97
112
123
131
143

Report on Economic Position
Overview of Sales, Earnings and Financial Position
Business Development by Subgroup, Segment and Region
Earnings; Asset and Financial Position of the Bayer Group
Earnings; Asset and Financial Position of Bayer AG

148
153
168
178

Corporate Governance Report
Events After the End of the Reporting Period
Future Perspectives
7DNHRYHU5HOHYDQW,QIRUPDWLRQ

182
208
209


Bayer Group Consolidated Income Statements
Bayer Group Consolidated Statements of Comprehensive Income
Bayer Group Consolidated Statements of Financial Position
Bayer Group Consolidated Statements of Cash Flows
Bayer Group Consolidated Statements of Changes in Equity

230
231
232
233
234

02
CONSOLIDATED
FINANCIAL STATEMENTS
OF THE BAYER GROUP

RESPONSIBILIT Y STATEMENT

337

AUDITORâ€™S REPORT

338

03
FURTHER INFORMATION

Governance Bodies
Organization Chart
*5,*&RQWHQW,QGH[ZLWK81*&3ULQFLSOHV
Glossary
Financial Calendar

COVER

Five-Year Summary
Masthead, Disclaimer

343
346

362
366

Chairmanâ€™s Letter

Investment in the future

2015 marked a decisive year in the history of our company. We successfully executed all the necessary steps to transform Bayer into
an integrated Life Science company. For more than 150 years, the
core of Bayerâ€™s business model has been to invent new molecules
and turn them into innovative products. Now we are focusing solely
JIOCJN@HJG@>PG@NOC<ODIÂ¿P@I>@OC@=DJ>C@HD><GKMJ>@NN@NRDOCDI
living organisms.
With the enormous and ongoing progress being made in the Life
.>D@I>@NJPM<=DGDOTOJOPMIN>D@IODÂ¾>Â¾I?DIBNDIOJDIIJQ<ODQ@KMJ?ucts and solutions continues to grow. We are harnessing this potential to improve the health of humans, animals and plants. As a Life
Science company, we can now sharpen the focus of our entire organDU<ODJIJIAPGÂ¾GGDIBJPMHDNNDJIf<T@M.>D@I>@!JM@OO@M'DA@ g

*PMKJMOAJGDJDNR@GG?DQ@MNDÂ¾@?<I?=<G<I>@?=JOCDIO@MHNJA
KMJÂ¾O<=DGDOT<I?MDNFN *PM?DQDNDJIN<M@CDBCGT>JHK@ODODQ@CJG?ing leadership positions in their markets. And our focused busiI@NNHJ?@GJAA@MNNDBIDÂ¾><IOKJO@IOD<GOJG@Q@M<B@NTI@MBD@N
across the board â€“ from research to product approval processes
and from operations to talent development. It is important to
sustain this momentum and continue reaping the fruits of our
strategy.
In order to leverage our focus, we have given our organization a
clear, integrated and more operations-based structure. Since January 2016, the heads of our new divisions â€“ Pharmaceuticals, Consumer Health and Crop Science â€“ have been members of the Board
of Management of Bayer AG. This enhances operational accountability and accelerates decision-making, which are important for
an innovation company. In this connection, Iâ€™m proud of the extensive measures we have taken to broaden Bayerâ€™s diversity in terms
JAB@I?@M<I?>PGOPM@ /CDNDNIJR<GNJM@Â¿@>O@?DIOC@H@H=@MNCDK
of the Board of Management.
Bayerâ€™s transformation into a pure Life Science company has
>JINDNO@IOGT=@@I<>>JHK<ID@?=TMJ=PNOÂ¾I<I>D<GM@NPGON *Q@M
OC@G<NOÂ¾Q@T@<MNR@NCJR@?Q@MTBJJ?K@MAJMH<I>@ $O?@HJIstrates the strength of our company and the commitment of our
employees.
In 2015, revenues from continuing operations rose to a record
level of more than â‚¬46 billion. On a currency- and portfolioadjusted basis, this is an increase of 2.7 percent. Our clean ebitda
rose substantially by more than 18 percent to â‚¬10.3 billion, and
core earnings per share advanced by 16 percent to â‚¬6.83. Our innovative new products especially contributed to this success and
also played a substantial role in making 2015 another record year
for Bayer. All three new divisions posted above-market growth.
2

Dialogue at a pharmacy in Germany: Bayer CEO Dr. Marijn Dekkers meets pharmacist Valeska Pritz-Gottschall from Cologne.

Sales of our Pharmaceuticals segment climbed by 9.9 percent on a
>PMM@I>TÃ®<I?KJMOAJGDJÃ®<?EPNO@?=<NDN *PMÂ¾Q@M@>@IOGTG<PI>C@?
products â€“ Xareltoâ„¢, Eyleaâ„¢, Stivargaâ„¢3JÂ¾BJâ„¢ and Adempasâ„¢ â€“
3

again contributed to this pleasing performance with combined sales
of â‚¬4.2 billion, compared with â‚¬2.9 billion in 2014.
At Consumer Care (now called Consumer Health), currencyand portfolio-adjusted sales growth was 6.1 percent. During the
past year, we successfully integrated the business acquired from
Merck & Co., Inc.
Despite a weaker market environment, CropScience raised sales
by 1.7 percent on a currency- and portfolio-adjusted basis. Of the
regions, Europe showed the strongest growth, which was driven by
the positive development of crop protection products and seeds.
Thanks to the ongoing support of our investors, Bayer continued to
have the highest market capitalization of all the dax companies in
2015. And despite a challenging market environment, we successAPGGTÂ¿J<O@?JPMAJMH@M(<O@MD<G.>D@I>@NP=BMJPKJIOC@NOJ>F
market in October 2015 â€“ nine months before the end of our original roadmap. It is now a legally and economically independent
>JHK<ITJQ@NOMJ 2@RDNCJPMAJMH@M>JGG@<BP@N@Q@MTNP>>@NN
for the future!
In addition to the ipo of Covestro, we undertook further transactions
in support of our strategy. In June 2015, we signed an agreement to
sell the Diabetes Care business to Panasonic Healthcare Holdings
Co., Ltd., Tokyo, Japan. In July 2015, we closed the acquisition of
SeedWorks India Pvt. Ltd., based in Hyderabad, India.
Over the years, our portfolio strategy has consistently enhanced our
KMJÂ¾G@<N<'DA@.>D@I>@>JHK<IT $IK<MOD>PG<MOC@<>LPDNDODJINJA
the consumer health businesses of Merck and Dihon in 2014 gave
our Consumer Health business the necessary critical mass to operate as a separate division.

4

Being successful as a Life Science company requires a pronounced
innovation culture that is the breeding ground for new ideas and
facilitates their translation into successful products. It often all
starts in the laboratory which is why, between 2011 and 2015, we
increased our annual research and development spending by â‚¬1.4
billion to â‚¬4.3 billion. This is a substantial investment in our future.
At the same time, we have become better and faster at bringing
our innovations to market.
At the end of 2015, we established our new Bayer Life Science
Center. This strategic innovation unit has been designed to help
uncover, encourage and unlock breakthrough cross-species technologies and know-how for Bayer by enabling collaborations with
@IOM@KM@I@PMD<G=@NOÃ®DIÃ®>G<NN>JHK<ID@N /C@Â¾MNOJAOC@N@K<MOnerships is a joint venture with crispr Therapeutics AG, a company specialized in utilizing the new crispr-cas9 gene editing technology. Together we aim to discover, develop and commercialize
groundbreaking therapeutics to cure blood disorders, blindness
<I?>JIB@IDO<GC@<MO?DN@<N@ 2@>JPG?PN@<ITÂ¾I?DIBNOC<OBJ
beyond these three indications in nonhuman applications as well â€“
for example, in agriculture.
.P>>@NNAPGDIIJQ<ODJIM@LPDM@N<IJIBJDIBM@<NN@NNH@IO<I?M@Â¾I@Ã®
ment of processes and partnerships. The freedom to experiment
and the determination to execute with precision must be well balanced. Today, Bayer is one of the most innovative companies in
our industry. As a Life Science company, we are in very good shape
OJ>JIODIP@OJ?@GDQ@MKMJÂ¾O<=G@BMJROC
With our innovations we address major societal challenges on a
global scale. Around 9.7 billion people will be living on our planet

5

by 2050. How can humankind succeed in feeding so many people,
@NK@>D<GGTDIM@BDJINRC@M@<BMD>PGOPM@DN?DAÂ¾>PGOT?@Q@GJKDIB
better seeds and new products to protect crops, Bayer is helping to
ensure an adequate food supply for the worldâ€™s population.
At the same time, average life expectancy continues to increase.
How can humankind ensure that a high quality of life is preserved
<O<I<?Q<I>@?<B@T?@Q@GJKDIBDIIJQ<ODQ@NJGPODJIN<I?I@R
medications, Bayer is helping people tackle diseases and lead an
active life longer.
But itâ€™s not just through our innovations, but also through our activities, that we are helping people lead a better life. We seek to achieve
economic growth in harmony with ecological and social responsibility. As evidence of this commitment, we adhere to the fundamentals of sustainable development and the ten principles of the United
Nations Global Compact.
In this context, it is essential to maintain an open and active dialogue with all our stakeholders. We act responsibly, have good arguments and need not shun controversy. Ultimately, no one can
?@ITOC@CPB@=@I@Â¾O?@GDQ@M@?=TOC@DIIJQ<ODJINAMJHJPMG<=JM<tories. In the life science industry, itâ€™s all too easy to overlook the
NDBIDÂ¾><IO?JRIND?@JAIJO?@KGJTDIBOC@N@DIIJQ<ODJIN 2@I@@?
the societal acceptance and appreciation to continue to contribute
OCJN@=@I@Â¾ON
The best ambassadors for our company are our employees. With
their passion to innovate, they live our mission each and every day.
On behalf of the entire Board of Management, I would like to thank
them for their dedication. Their daily efforts are what make Bayer a
great company and a good investment.

6

This is my last Chairmanâ€™s Letter to you as ceo of Bayer. I am thankful for your continued trust and support. It has been an extremely
rewarding experience for me to have the opportunity to lead such a
fantastic company to new heights. I have enjoyed working with so
many great colleagues, and while I contributed with my know-how
to our joint success, I feel I learned just as much in turn.
Bayer is an iconic brand, offering an endless source of innovation.
With its solid foundation and a deep management bench in place,
I am convinced that Bayer can continue its journey as one of the
most innovative companies in our industry.

Sincerely,

Dr. Marijn Dekkers
Dr
Chairman of the Board of Management of Bayer AG

7

magazine

li fe s ci ence

Bayer:
Science
For A
Better Life

Our
Products

Our broad product portfolio includes many
world-famous brands which have shaped the
iconic Bayer brand. Some of them have been
helping our customers for decades, others only
recently came out of our labs. Their active
DIBM@?D@ION <M@ ?@NDBI@? OJ DIÂ¿P@I>@ OC@ =DJÃ®
chemical processes in living organisms. As
different as people, animals and plants might
seem, common rules govern the molecular
mechanisms in all life forms. The active ingredients promote or enable positive processes
or they prevent or suppress negative processes.
Thatâ€™s what Life Science is all about. And
with our innovative products, we help to make
life better.

B RAN D S*
SC I EN C E
BE TT ER L I FE

Reducing
pest infestation

Controlling
nematodes
Protecting against
fungal infestation

* Not all products are marketed by Bayer in all countries.

Seed with improved
properties

Science For

A Better Life

O
PR

MO

R ENABLE P
TE O
OS
IT
I

VE

PR

O
C

E

SS
ES

Protecting companion
animals from infections
and parasites

Myocardial infarction, stroke,
pulmonary hypertension

Protecting
against weeds

Contraception and
menopausal disorders
PR

EV

EN
T
R

Various
types of cancer

O

Protecting and
treating farm animals

SU

PP

RE

SS

NEG

ATIVE PROCE

SS

ES

Hemophilia A

Multiple sclerosis

Pain,
LQÄ DPPDWLRQIHYHU

Vitamins and
dietary supplements

Sun protection
and wound care
Eye ailments

12

Bayer Annual Report 2015

13

Bayer Annual Report 2015

Magazine // Life Science

Life Science // Magazine

For the
heart
A heart attack is invariably a severe
setback in life. Leading a healthy lifestyle
and regularly taking the right medication
can reduce the risk of a second heart
attack or secondary complication.

Cardiologist Dr. Anne-Katrin SchÃ¤tzle examines
her patient Axel Vogel at the Cardiology Center
of Cologne University Hospital.

Cologne // germany. â€œNothing is ever the same again,â€ says Axel Vogel.
Six years ago, a myocardial infarction threw life off course for the now
57-year-old from Kerpen, Germany. Remigius MÃ¼ller (52) from Rottweil,
near Stuttgart, survived the same life-changing experience. A blood clot
in a coronary vessel turned his life upside down in a matter of seconds:
MÃ¼ller suffered a heart attack at age 45. Until then, the plant manager had
always thought: â€œHow could anything stop me?â€ This attitude helped him
cope with a busy life for years. Both men have changed their habits since
their heart attacks. As they now know: â€œItâ€˜s an experience you never want
to go through again.â€

14

Bayer Annual Report 2015
Magazine // Life Science

But both men are also aware that they might have to.
â€œWhen people have already survived one heart attack, the
risk of having another increases for the rest of their lives,
meaning that long-term medical care is imperative,â€ explains Dr. Wolfgang Steffen, a cardiologist in Rottweil
and MÃ¼llerâ€™s attending physician. Alongside the management of cardiovascular risk factors in line with standard
care practice and any necessary lifestyle changes, an especially important part of treatment is that patients regularly take their prescribed medication, including drugs
that counteract blood-clotting and therefore help prevent
another heart attack. â€œItâ€™s also very important for patients
to be aware of the many things they can do to help their
heart recover,â€ Steffen emphasizes. â€œIn concrete terms,
that means no smoking, a different diet, regular exercise,
minimized alcohol intake, stress reduction and, if necessary, treatment for depression.â€ His patient, Remigius
MÃ¼ller, has taken this advice to heart. He wouldnâ€™t even
think of skipping his medications. Apart from acetylsalicylic acid, which inhibits platelet aggregation, he also
takes blood pressure- and cholesterol-lowering medication. â€œIâ€™m certain that the drugs are the reason I feel well
again today,â€ he says.
Axel Vogel is likewise thankful for the opportunities
afforded by modern medicine. â€œThey enable me to reach
the best level of performance I am still capable of.â€
Vogelâ€™s heart sustained permanent damage from his

17.3

million

people worldwide die every year of a
FDUGLRYDVFXODUGLVHDVH7KLVÄŸJXUHLV
forecast to increase to over 23 million
by 2030.
(Source: American Heart Association: 2015 Heart Disease and
Stroke Statistics Update)

heart attack. He suffers from arrhythmia and had a
pacemaker implanted three years ago. In addition,
his heart function has deteriorated over the years
and along with it his performance capabilities.
Just climbing a few stairs wears him out. Because
of his extreme heart failure, Vogel has been in
treatment for some time under Professor Volker
Rudolph, Chief Senior Physician of the Cardiology
Center at Cologne University Hospital.
Heart failure is one of the potential complications
following a heart attack. â€œTwenty to 30 percent of
patients who have had a heart attack subsequently
develop heart failure,â€ reports Rudolph. It is a
very serious condition, especially in its advanced
stages. The heart is unable to pump blood through
the body, causing the energy levels of sufferers to
drop dramatically. â€œThe survival time for severe
C@<MOA<DGPM@DNNDBIDÂ¾><IOGTNCJMO@MOC<IAJMNJH@
types of cancer,â€ Rudolph points out. â€œAt present,
the options for using drugs to treat this disease are
limited. A lot of research needs to be done in the
Â¾@G?gOC@><M?DJGJBDNON<TN f$AR@>JPG?NP>>@@?
in halting or possibly even healing pathological
changes in the heart and blood vessels by means
of regenerative therapy, it would be a major step
forward.â€
Developing innovative active substances to
treat heart failure is one of Bayerâ€™s main areas of
research. Several projects involving different
treatment methods are currently in the advanced
phases of clinical development. Furthermore,
Bayer scientists in the cardiovascular research unit
are working on novel active ingredients to treat
severe diseases of the cardiovascular system such
as coronary heart disease, stroke, thrombosis and
pulmonary hypertension, as well as certain kidney
diseases. â€œCardiovascular diseases are a strategic
priority for Bayer. Our pipeline covers a wide
range of heart, circulatory and vascular diseases,
for which patients and physicians are desperately
waiting for further improved treatments,â€ says
Professor Andreas Busch, head of Drug Discovery
in the Pharmaceuticals Division.

15

Bayer Annual Report 2015
Life Science // Magazine

A heart attack has severe
repercussions. Patient
Remigius MÃ¼ller (right) has
largely taken the advice of
his cardiologist Dr. Wolfgang
Steffen (below) to heart and is
feeling well again.
Patient Axel Vogel, by contrast,
suffers from severe heart
failure. He is receiving treatment from Professor Volker
Rudolph, Chief Senior Physician of the Cardiology Center
at Cologne University Hospital
(below right).

Bayer also offers physicians and patients digital solutions to support drug-based treatments. For example,
<AO@MM@BDNO@MDIBK<OD@IONRDOC<OMD<GÂ¾=MDGG<ODJI><I
receive a daily text message reminding them to take
their pills. â€œIn the future, apps like this will offer even
more possibilities,â€ says Johannes Schubmehl, Chief
$IAJMH<ODJI*AÂ¾>@M<O+C<MH<>@POD><GN *I@@S<HKG@
is sending patient data to the attending physician.

A study of this is currently being conducted in
Canada on patients with pulmonary hypertension.
Cardiologist Volker Rudolph believes in the future
of digital apps in medicine. â€œPatients wonâ€™t need
OJH<F@<NH<ITQDNDONOJOC@?J>OJMeNJAÂ¾>@<I?
we physicians will have faster access than ever
before to critical results.â€

16

Bayer Annual Report 2015
Magazine // Life Science

Fit in
old age
Every second, two people celebrate
their 60th birthday. Through their
research and the resulting products,
Bayerâ€™s experts are helping the growing
group of senior citizens live a life that
is as active as possible. And younger
generations can take steps to help
prevent diseases as well, so that they
can remain healthy well into their
senior years.

Delray Beach, Florida // United States. Itâ€™s seven oâ€™clock in the
HJMIDIB #@IMTJC@IDNEPNOÂ¾IDNCDIBCDNÂ¾MNOOM<DIDIBN@NNDJI 
He climbs energetically out of the swimming pool. His handshake is as powerful as a weightlifterâ€™s. Henry is 85 and lives in
a neighborhood that is specially designed for elderly people.
Active senior citizens like him are increasingly common. AccordDIBOJOC@0IDO@?)<ODJIN2JMG?+JKPG<ODJI+MJNK@>ONM@KJMO
901 million people worldwide were aged above 60 in 2015, and
by 2050 this number will have doubled to more than 2 billion â€“
OC<OeN<GHJNO@Q@MTÂ¾AOCK@MNJIJIOC@KG<I@O 

17

Bayer Annual Report 2015
Life Science // Magazine

18

Bayer Annual Report 2015
Magazine // Life Science

901

million

people worldwide were aged above 60 in 2015.
By 2050WKLVÄŸJXUHZLOOKDYHGRXEOHGWR
approximately 2ELOOLRQÅ‹DOPRVWHYHU\ÄŸIWK
person on the planet.

Source: un report, World Population Prospects, 2015

Whether yoga, a healthy diet, exercise or just
a relaxing break with a four-legged friend:
There are plenty of options available to those
ZKRZDQWWRVWD\ÄŸWZHOOLQWRROGDJHOLNHu.s.
retirees Nora Gerson and Henry Cohen (above).

19

Bayer Annual Report 2015
Life Science // Magazine

Henry is an example which shows that being old doesnâ€™t
automatically mean being sick. â€œBut the rising life expectancy also means a higher risk for numerous disorders,
many of which are chronic conditions,â€ says Dieter
Weinand, member of Bayerâ€™s Board of Management and
head of the Pharmaceuticals Division. Typical age-related
disorders include cardiovascular diseases such as stroke
and heart attacks, eye disorders and cancer. â€œWe are
<GR<TNGJJFDIBAJMI@R<I?CDBCGTNK@>DÂ¾>OC@M<K@POD>
approaches to be able to provide even better help to
patients in the future,â€ explains Weinand. Accordingly,
Bayerâ€™s scientists are concentrating on new therapeutic
options for conditions such as heart failure, wet agerelated macular degeneration, and prostate and lung cancer. The results of this research could make it possible
for elderly people to live an active life for longer.
In Delray Beach, there are regular information evenings
on health issues. Dietary advisors and speakers from a
number of different disciplines explain how senior citiU@IN><INO<TÂ¾OAJM<NGJIB<NKJNND=G@<I?CJRIJI
prescription medicines can help them achieve that aim.
These events are organized by Nora Gerson. â€œMany of my
acquaintances and neighbors here suffer from classic risk
factors such as hypertension and high cholesterol levels,
which can be minimized through diet, exercise and an
overall healthy lifestyle,â€ says the 79-year-old.
Nora leads a yoga group for participants aged between
60 and 93. Henry is one of her students, too. Nora stands
RDOCC@MG@BNÂ¾MHGTKG<IO@?<I?AJG?NC@M<MHN<MJPI?
themselves in front of her chest. Her body is calm and
relaxed, her gaze focused on the middle distance. The retiree has suffered from osteoporosis and minor arthritis
for more than 30 years, but you wouldnâ€™t know it from
looking at her. Sometimes the pain is overwhelming. â€œBut
I decided for myself that I wonâ€™t let it negatively affect my
daily life,â€ says Nora. Thatâ€™s why she does a lot of exercise and, like many of her friends, takes mild analgesics
AJMOC@DMK<DIÃ®M@GD@QDIB<I?<IODÃ®DIÂ¿<HH<OJMT@AA@>ON 
The senior citizens in Delray Beach are by no means exceptions. Many patients today are well aware of the ben@Â¾ONJAKM@Q@IODJI<I?<C@<GOCTGDA@NOTG@<I?<M@R@GGDIformed about their health and the therapeutic options
available, thanks in great part to the internet and digital
media. â€œPatients are increasingly selecting medicinal
products to treat minor ailments themselves,â€ says Erica
Mann, member of the Board of Management of Bayer,
head of the Consumer Health Division and Chair of the
World Self-Medication Industry (wsmi). â€œIndividuals can
take steps to stay healthy and productive by easily
OM@<ODIB>JG?NJMÂ¿PC@<?<>C@N<I?JOC@MHDIJMC@<GOC

problems.â€ Prevention is also becoming increasDIBGTNDBIDÂ¾><IODI<GG<B@BMJPKNN<TN(<II 
Sunscreen, for example, can help to prevent skin
cancer, particularly in sunny regions such as
Florida. And probiotics support healthy intestinal
Â¿JM<RCDG@?D@O<MTNPKKG@H@ION@INPM@<I<?@quate supply of calcium and vitamins D and B12,
for example.
Bayer is the worldâ€™s second largest provider of
nonprescription medicinal products and dietary
supplements, and the number one in the worldâ€˜s
largest otc (over-the-counter) market, the United
States. Whether to treat pain, gastrointestinal complaints, hair loss or dry eyes, these products are
designed to help people live a self-determined and
satisfying life for as long as possible.

â€œNowadays, everybody can
take steps to stay healthy and
productive by easily treating
colds or ï¬‚u, headaches and
other minor health problems.â€
Erica Mann, head of the Consumer Health Division

JHK<IDJI<IDH<GNJAO@I<NNPH@<NDBIDÂ¾><IO
role in our families, but above all have a special
place in the lives of millions of older people, as a
study by the International Federation on Ageing
(ifa) in Toronto, Canada, shows. â€œDecreases in
debilitating conditions such as depression, anxiety
and high blood pressure are all associated with
the quiet companionship of humans and pet dogs,â€
says Dr. Jane Barratt, Secretary General of the ifa.
Owners had increased self-esteem, greater life
satisfaction and more positive moods, thanks to the
increased levels of relaxation-promoting messenger substances in the body. Companion animals
are a high-impact and low-cost solution to remaining more active and less vulnerable to loneliness.
#@IMT><I>JIÂ¾MHOC<O f$<GR<TNB@O>C<OODIB
to people when Iâ€™m out for a walk with our dog
Stella.â€ At the moment, theyâ€™re both sitting on the
couch, but Henry will soon be on his way out
again; the next training session in the pool is due
to start. But thatâ€™s one activity where Stella canâ€™t
join in!

20

Bayer Annual Report 2015

21

Bayer Annual Report 2015

Magazine // Life Science

Life Science // Magazine

Rice growing in northern Vietnam:
farmers Do Thi Tuyen (at the front of the boat)
and Doan Thi Gai on the Halong Bay in
Ninh Binh province, Vietnam.

Defying
the
weather
Bayer is searching for new solutions to the massive
challenges facing agriculture in the 21st century:
KHDWGURXJKWDQGÄ RRGVDQGWKHJURZLQJZRUOG
populationâ€™s rising demand for food.

Ninh Binh // vietnam. â€œFarmers like us have only one
boss, and thatâ€™s nature. Our work is dictated by the
sun, the rain, the wind, the change of seasons. But in
the past few years, nature has become a temperamental boss. Quite simply, we can no longer depend on the
seasons. It has all become mixed up,â€ says Do Thi

Tuyen, a rice farmer in the northern Vietnamese
province of Ninh Binh. First of all, an extreme
drought last year delayed germination of the rice
N@@?N /C@IÂ¿JJ?DIB<AO@MC@<QTM<DIA<GGOCM@<O@I@?
to destroy the delicate rice plants.

22

Bayer Annual Report 2015
Magazine // Life Science

+ 30%

By 2030, rice yields will have to rise by
30 percent â€“ from the same area of arable
land â€“ to guarantee food security.

Despite this, Do Thi Tuyen was optimistic about her most
recent harvest. â€œMy advisor Quyet Nguyen Van from
Bayer showed me how I can employ innovative technologies and growing techniques to defy nature.â€ This year,
the farmer planted Bayerâ€™s Arizeâ„¢ hybrid rice which
offers increased resilience against extreme weather conditions. And, as in previous years, she has protected her
rice plants against stress factors such as pests and
diseases, taking proactive steps to boost the health of her
crop. The result: â€œWe were able to improve the quality
of our rice and even increase yields.â€ Too much water,
too little water, or both are a major challenge for the rice
farmers of North Vietnam. Do Thi Tuyen is happy that for
many years now, she has not lost her entire harvest.
Mekong Delta // vietnam. In the south of Vietnam, in the
Mekong Delta, the situation is more serious for many
farmers. When the rainy season starts late and brings
less rain than usual so that the Mekong River carries less
R<O@MOC@N@<Â¿JJ?NDIOJOC@DIO@MDJMJAOC@>JPIOMT<I?
salinizes the soil. This can have devastating consequences. â€œMany rice growers in our region had to stop
A<MHDIBOC@DMÂ¾@G?NG<NOT@<M=@><PN@OC@NOMJIBGTN<GDnated water destroyed the rice shortly after it was planted,â€ says Phan Van Giang, who has farmed a fourhectare rice farm in the Mekong Delta for 20 years. He
has grown Bayerâ€™s Arizeâ„¢ b-te1 variety ever since he
heard about this new variety a few years ago at a semiI<M #@R<NOC@Â¾MNOA<MH@MDICDNM@BDJIOJOMTDOJPO 
â€œCompared with traditional rice, the hybrid rice Arizeâ„¢
C<NBM@<O@MOJG@M<I>@OJN<GDIDU<ODJI?MJPBCO<I?Â¿JJ?ing, it is less susceptible to disease, and it produces
HP>CCDBC@MTD@G?N@Q@IDI?DAÂ¾>PGOT@<MNGDF@G<NOT@<M g

Rice is an important staple food for more than
3.5Åµ=DGGDJIK@JKG@K<MOD>PG<MGTDIND< /C@H<DI
producers are approximately 200 million small
farmers like Do Thi Tuyen and Phan Van Giang.
They are exposed to extreme weather situations
and need innovative technologies and state-of-theart agricultural knowledge. Help is available
through Bayerâ€™s â€œMuch More Riceâ€ program. â€œThis
program is a comprehensive package of solutions
that helps small farmers in many countries in Asia
to optimally employ innovative technologies such
as Bayerâ€™s Arizeâ„¢ seeds and crop protection solutions,â€ explains Mahesh Girdhar, Bayer Global
Crop Manager Rice. â€œOur experts also show farmers how they can increase the quality and quantity
JAOC@DMMD>@C<MQ@NON@Q@IPI?@M?DAÂ¾>PGOR@<OC@M
conditions.â€ For example, the seed treatment
Gauchoâ„¢ shields rice plants against stress during
the initial, particularly vulnerable stage. The treatment strengthens the rice plantâ€™s root and shoot
growth and helps it to withstand drought and heat
phases. The fungicide Nativoâ„¢ promotes photosynthesis and positively impacts the plantâ€™s productivity under heat stress.

â€œOur experts show farmers
how they can increase the
quality and quantity of their
rice harvests even under
difï¬cult conditions.â€
Mahesh Girdhar, Bayer Global Crop Manager Rice

As extreme weather is likely to continue to be a
major problem in the future, Bayer has developed
seed that is able to survive being immersed for
14 days. The market introduction is scheduled for
2016. In 2017, Bayer plans to launch a new Arizeâ„¢
seed variety which will survive twice the level
of salinity compared to previous varieties. For rice
growers like Do Thi Tuyen and Phan Van Giang,
that is good news.

23

Bayer Annual Report 2015
Life Science // Magazine

Rice farmer Do Thi Tuyen (top) feeds
her ducks in northern Vietnam. She is
glad that she hasnâ€™t lost her entire harvest
in years. Phan Van Giang farms in the
southern Mekong Delta (left), where soil

200

salinization is a problem. He uses a hybrid
rice variety from Bayer, which produces
KLJKHU\LHOGVHYHQLQGLIÄŸFXOW\HDUV

million

Rice is an important staple food particularly
in Asia. The main producers are approximately
200 million small farmers like Do Thi Tuyen
and Phan Van Giang.

24

Bayer Annual Report 2015
Magazine // Life Science

On his farm in Monument, Kansas,
United States, Craig Reed is
battling the consequences of
persistent drought in particular.
Heâ€™s hoping for new wheat
varieties and a broader spectrum
of innovative herbicides.

Approximately

15

%

of the worldâ€™s arable land is planted with
wheat. Wheat is a crucial factor for the food
security of more than 2 billion people.

25

Bayer Annual Report 2015
Life Science // Magazine

+ 60%

The demand for wheat will increase by
approximately 60 percent by 2050.

Kansas // United States. *IOC@JOC@MND?@JAOC@+<>DÂ¾>
some 14,000 kilometers to the east of Vietnam in the u.s.
state of Kansas, wheat farmer Craig Reed is just as embattled by the vagaries of the weather as his colleagues in
Asia. â€œDrought is the main reason for harvest failures in
wheat,â€ he says. â€œWe need about 50 centimeters of precipitation per year. But in some years, we only get 25 centimeters. That means that we farmers risk everything for the
harvest on an annual basis. But no matter how often Mother Nature tries to trip us up, we always get up again and
start afresh the following year. â€œ
As a result of the dry conditions, Reed and many of his
colleagues have decided against tilling in order to retain
as much moisture in the soil as possible. But that has one
major disadvantage, as Reed explains. â€œThe weeds spread
faster every year.â€ Reed is particularly worried about increasing herbicide resistance, particularly in the weed
species â€œkochiaâ€ (burningbush). This weed competes with
wheat plants for light, nutrients and moisture, and can
have a dramatic impact on harvests. â€œWhat we urgently
need is a greater spectrum of new herbicides for the future to prevent resistances from developing so that existing herbicides will remain effective,â€ says Reed.
While climate and resistance problems have been
impacting the yields of wheat growers all over the world
since the 1990s, what is really urgently needed is bigger
harvests. â€œThe demand for staple foods will rise by
60 percent by 2050,â€ says Steve Patterson, Bayer Global
Crop Manager Cereals. â€œFor wheat, the major driver is the
growing world population, followed by the shifting diets
of the new middle classes in emerging countries.â€

Production, however, is unable to keep up. In
addition, a recent study revealed that the wheat
harvest could decline by six percent with every
degree of climate warming. â€œTo close this gap
and safeguard the wheat supply, we need a
technological breakthrough in wheat research,â€
says Patterson. Miracles should not be expected
though. â€œWeâ€™re never going to be able to grow
wheat in the Sahara and we canâ€™t bring withered
plants back to life. But we can help to compensate
for drought-related harvest losses. We can help
the plants to perform better in key phases of
drought and heat stress.â€

â€œWe need a technological
breakthrough in wheat
research.â€
Steve Patterson, Bayer Global Crop Manager Cereals

Scientists are looking for chemical innovations to
serve as a protective shield to plants in emergency
situations. Meanwhile, researchers are also working on developing wheat varieties with greater vitality and enhanced heat tolerance. To adapt wheat
varieties to the respective climate conditions,
Bayerâ€™s breeding work is carried out all over the
world with locally adapted varieties being bred for
greater environmental tolerance and robustness at
breeding stations in Canada, Belgium, Germany,
France, Ukraine, Australia and the United States.
The breakthrough is expected to arrive after 2023.
For wheat farmer Reed, this is a perspective that
offers him hope. â€œTo achieve this quantum leap in
global nutrition, we need companies and organizations that can see the big picture, or we will never
solve the problem.â€

26

Bayer Annual Report 2015

27

Bayer Annual Report 2015

Magazine // Life Science

Life Science // Magazine

Living
with
dengue
Rodolfo Siqueira Rodrigues from Ubatuba,
Brazil, loves water sports. The warehouse
technician has already had dengue fever
twice. His doctor, Dr. Juan MatÃ­as Jaco (top),

One billion people around the globe â€“ or one in seven â€“
suffer from a tropical disease, according to the World
Health Organization (who). Bayer is supporting the international community in the battle against these diseases
as part of its corporate citizenship activities.

can only treat the symptoms.

Ubatuba // brazil. â€œAll of my co-workers have had dengue
fever, and Iâ€™ve had it twice already myself,â€ says Rodolfo
Siqueira Rodrigues, a resident of Ubatuba, a city on the
Atlantic coast of Brazil. Now the 23-year-old is afraid of
developing hemorrhagic fever should he ever become infected again. â€œAll of us are afraid of the fever, because
then it really gets serious. If things go wrong, you could
die of internal bleeding.â€ He did not go to his physician,

Dr. Juan MatÃ­as Jaco, because Rodolfo learned it
was pointless as no treatment exists for this disease anyway. â€œWe can do nothing but treat the
NTHKOJHNRDOCKG@IOTJAÂ¿PD?NA@Q@MÃ®M@?P>DIB
drugs and painkillers,â€ says Dr. Jaco. Some 1,200
people in Ubatuba, a city with a population of
80,000, contracted dengue fever in 2014. Over
3,000><N@NR@M@M@KJMO@?DIOC@Â¾MNOIDI@HJIOCN

28

Bayer Annual Report 2015
Magazine // Life Science

100

million

dengue fever infections are reported
worldwide every year in the tropical and
subtropical regions of the Americas,
Africa and Asia.

of 2015 alone, and in the state of SÃ£o Paulo as a
whole, the total is up to 900,000. â€œPhysicians in all
specialties have dengue top of mind when making
any diagnosis,â€ Jaco says.
One hundred million dengue infections are
reported every year in the tropical and subtropical
regions of the Americas, Africa and Asia. Like
Rodolfo, however, many sufferers treat themselves
and therefore do not show up in the statistics.
According to who, the actual number of cases is
closer to 390 million a year. â€œHalf of the global
population is threatened by this disease. Dengue
has been named the disease of the future by who,â€

says Frederic Baur, head of Vector Control at Bayer. â€œThe
carrier of the disease, the tiger or Aedes mosquito, lives
and breeds in the innumerable water reservoirs, both
large and small, found in cities. Rising urbanization and
possibly climate change are creating increasingly favorable habitat conditions for the mosquito.â€ Dengue fever is
currently endemic in more than 100 countries and is continuing to spread. The disease can be curbed effectively by
combating its vector.
Bayer can help protect those at risk with larvicides to control mosquito larvae in water reservoirs and insecticide
sprays to impregnate surfaces in residential buildings and
on roadways. Bayer active ingredients for mosquito sprays
also provide personal protection against bites. To prevent
or break resistances to existing active ingredients, Bayer
is also involved in several global research projects on new
mechanisms of action. The company has considerably
increased its overall investment in research into dengue
fever in recent years. A new spray for treating building
facades and municipal parks is now in the advanced
stages of development. It is expected to be available by
2018 and promises an extended duration of action thanks
to its resistance to rain and uv radiation.

Children swimming in a jungle river close to
Ubatuba in Brazilâ€™s SÃ£o Paulo state: Dengue fever
is a major problem in the region.

29

Bayer Annual Report 2015
Life Science // Magazine

While dengue fever can affect all population
groups and receives widespread attention, other
tropical diseases plague the poorest of the poor
in our world. These diseases are referred to as
â€œneglected tropical diseases.â€ In 2012, institutions such as who, the World Bank, international
government authorities and companies such as
Bayer joined forces under the London Declaration on Neglected Tropical Diseases to stem or,
if possible, eliminate ten of these diseases by
2020, including Chagas disease, which is widespread in Latin America, and African sleeping
sickness. Bayer has been supplying who with
free drugs to treat these diseases for over ten
years, and their active ingredients are on the
who List of Essential Medicines. â€œWe have guaranteed who continuous availability of the active
ingredients and a free supply of the drugs for as
long as African sleeping sickness and Chagas
disease exist,â€ explains Kemal Malik, the member of the Bayer Board of Management responsible for Innovation.

â€œWe can provide drugs to treat
patients and offer solutions to
control the vectors.â€

Covestro
on the stock
market

ceo Patrick Thomas (left) and
cfo Frank H. Lutz rang in a new era for
Covestro as a listed company.

Kemal Malik, member of the Bayer Board of Management
responsible for Innovation

One particularly insidious tropical disease, known
as river blindness, is caused by nematodes that
produce millions of young inside the human
body. The medicines available at present are only
capable of controlling the parasites in the early
stage of their development. The drug must therefore be taken for more than 15 years, the length
of time that adult nematodes â€“ which can grow up
to 70 centimeters long â€“ live in the human body.
/JB@OC@MRDOCOC@IJIKMJÂ¾OMPBNAJM)@BG@>O@?
Diseases Initiative (DNDi), Bayer is currently developing a new drug that will be able to eliminate
adult worms as well.
â€œOur corporate citizenship activities include supKJMODIBOC@Â¾BCO<B<DINOI@BG@>O@?OMJKD><G?DNeases. As a Life Science company we are uniquely
positioned to do so, by both providing medicines
to treat patients, as well as offering innovative
solutions to control vectors,â€ says Malik.

In a rapid ascent, Covestro AG<GM@<?TÂ¾BPM@?<HJIB
the 80 most important listed companies in Germany
around two months after its ipo. In December 2015,
the materials manufacturer â€“ formerly Bayer MaterialScience â€“ was included in the mdax stock index.
The mdax includes the 50 companies that rank immediately below the 30 dax titles. â€œWe are delighted to be
included in the mdax and proud that this step has occurred so quickly,â€ said Covestro cfo Frank H. Lutz. â€œIt
M@Â¿@>ONOC@BM<ODATDIBK@MAJMH<I>@JAJPMNOJ>F<I?OC@
BM@<ODIO@M@NO?DNKG<T@?=TDIQ@NOJMNNDI>@JPMÂ¿JO<ODJI
on October 6, 2015. Membership in the mdax will further enhance the perception of Covestro on the global
Â¾I<I>D<GH<MF@ON g/C@JQ@NOMJNC<M@DNIJRIJGJIger listed only on the Frankfurt Stock Exchange, but on
every other German stock exchange as well.
/C@NOJ>FH<MF@OÂ¿JO<ODJIR<N<APMOC@MDHKJMO<IONO@K
for Covestro in a new era of independence. The gross
issue proceeds of â‚¬1.5 billion were mainly used to pay
down debt to the Bayer Group, not least with the aim of
achieving a good investment-grade rating.

30

Bayer Annual Report 2015
About this Report

About this Report

This integrated Annual Report combines our financial and
our sustainability reporting. Our aim is to elucidate the
interactions between financial, ecological and societal
factors and underline their influence on our companyâ€™s
long-term development, thus providing our stakeholders
with comprehensive and transparent information.
We are reporting on fiscal 2015 and thus refer to the
organizational structure that was in place until December
31, 2015. Exceptions are those chapters in the Management Report which discuss forward-looking issues â€“ strategy, targets and key performance indicators â€“ as well as
the Report on Future Perspectives and on Opportunities
and Risks. These are aligned to the organizational structure as of January 1, 2016, which is described in Chapter
1.2 â€œCorporate Structure.â€
The consolidated financial statements of the Bayer Group
as of December 31, 2015, comply with the International Financial Reporting Standards (ifrs) valid at the closing date
and with the provisions of the German Commercial Code in
conjunction with German financial reporting standards.
The combined management report complies with these requirements and provides an overview of the financial position and results of operations of the Bayer Group.
The Compensation Report for the Board of Management
and the Supervisory Board complies with the recommendations of the German Corporate Governance Code. The
consolidated financial statements and the combined man-

agement report are published in line with statutory disclosure requirements.
The Bayer Groupâ€™s sustainability reporting is aligned to
the guidelines of the Global Reporting Initiative (gri) and
the 10 principles of the u.n. Global Compact (ungc). In
fiscal 2015, we applied the gri G4 Guidelines in compliance with the â€œcomprehensiveâ€ option for the first time.
The detailed gri content index with the corresponding
ungc principles can be found in the â€œFurther Informationâ€
section in the augmented version of the Annual Report.
Online only, we also publish a separate pdf file with a
summary of the u.n. Global Compact Progress Report
based on the criteria of the Blueprint for Corporate Sustainability Leadership.

gri
G4-23

Our reporting is also aligned to international guidelines
and recommendations, including those on the definition
and selection of nonfinancial indicators and on reporting
such as those of the oecd and the iso 26000 standards.
In selecting and measuring our key data we also take into
account the recommendations of the European Federation
of Financial Analysts Societies (effas) in the case of
nonfinancial indicators, and those of the Greenhouse Gas
Protocol regarding greenhouse gas emissions. We also
consider the recommendations of the World Business
Council for Sustainable Development (wbcsd) and the
European Chemical Industry Council (cefic). This year we
will again submit a declaration of conformity with the
German Sustainability Code.

Data collection and reporting thresholds
gri
g4-17

We collected the data of all relevant organizational units
and companies worldwide that fell within the scope of
the Bayer Groupâ€™s consolidated financial statements between January 1, 2015, and December 31, 2015.

occupational injuries, transport accidents and environmental incidents are collected at all sites worldwide.
Environmentally relevant indicators are measured at all
production sites.

We mainly use sap systems to collect financial data
worldwide. We use the global sap hr information system
and the associated reporting application â€“ the Sustainability Management Annual Reporting Tool (smart) â€“ to
collect hr indicators and social data. All hse (health,
safety and environmental protection) performance indicators for the Group are collated in our Group-wide site
information system (BaySIS). The hse data cover all fully
consolidated companies in which Bayer owns at least
50% of the shares. The performance indicators of these
companies are fully consolidated, irrespective of the
exact proportion of the shares held by Bayer. Data on

In accordance with ifrs 5 (Non-current Assets Held
for Sale and Discontinued Operations), financial indicators are given for continuing operations unless otherwise
explicitly indicated. The same applies to hr indicators
and our social data. In the case of hse indicators, the
value shown is the total for the Bayer Group; no distinction is made between continuing and discontinued
operations.
As the indicators in this report are stated in accordance
with commercial rounding principles, totals and percentages may not always be exact.

gri
G4-22

31
About this Report

SO@MI<GQ@MDÂ¾><ODJI
PricewaterhouseCoopers Aktiengesellschaft
WirtschaftsprÃ¼fungsgesellschaft has audited the
consolidated financial statements statements (including the notes thereto) of Bayer AG, Leverkusen,
and the combined management report for the fiscal
year from January 1, 2015, to December 31, 2015,
and has issued an unqualified opinion. All the online

annexes that supplement the management report
in the augmented online version of the Bayer
Annual Report 2015 (â€œAnnual Report 2015 â€“ Augmented Versionâ€) for the fiscal year from January 1
to December 31, 2015, have been reviewed by
PricewaterhouseCoopers AG WirtschaftsprÃ¼fungsgesellschaft on a limited assurance basis.

Additional information
The integrated Bayer Annual Report 2015 is
available in a print version (â€œAnnual Report 2015â€)
and in an augmented online version (â€œAnnual
Report 2015 â€“ Augmented Versionâ€). The online
version contains the notes to the consolidated
financial statements of the Bayer Group, along
with additional information. The print version contains numbered online annexes which refer the
reader to additional information in the Augmented
Version. You can enter these numbers in a search

mask on any page of the online Annual Report to
directly access the annexes.
Both versions of the Annual Report are available in
pdf format for download from the Bayer website.
For further guidance, the Annual Report contains
references to other chapters, to (Bayer) websites
and, in the Augmented Version, to gri g4 materiality disclosures.

Online annexes
Cross-references within the Annual Report
References to internet sites

The â€œAnnual Report 2015 â€“
Augmented Versionâ€ can be found
at www.bayer.com/ar15.

The â€œAnnual Report 2015 â€“ Augmented Versionâ€
is also available as an app in the Apple App Store.
Please search for â€œBayer Annual Reports.â€

32

Bayer Annual Report 2015

33

Bayer Annual Report 2015

To our Stockholders

To our Stockholders

Board of Management

Board of Management

On January 1, 2016, the Board of Management of
Bayer AG was enlarged to include the heads of the
Pharmaceuticals, Consumer Health and Crop Science
divisions. Management of the company has thus been
aligned more strongly with business operations.

Board of Management

KEMAL MALIK

DIETER WEINAND

WERNER BAUMANN 1

DR. HARTMUT KLUSIK*

DR. MARIJN DEKKERS 1

JOHANNES DIETSCH

Innovation Â·
Latin America region

Pharmaceuticals Â·
North America region

Strategy and Portfolio
Management Â· Europe / Middle
East / Africa region

Human Resources Â·
Technology and Sustainability

Chief Executive Officer
of Bayer

Chief Financial Officer of
Bayer Â· Asia / Pacific region

Kemal Malik studied medicine
and worked in a London hospital. After holding different positions of increasing responsibility at Bristol-Myers Squibb, he
joined Bayer in 1995. In 2007
Malik became a member of the
Executive Committee, head of
Global Development and Chief
0HGLFDO2IÄŸFHURI%D\HU+HDOWKCare. He was appointed to the
Bayer Board of Management in
February 2014.

Dieter Weinand studied pharmacology,
toxicology and biology in New York.
After holding positions at various companies in the pharmaceutical industry
LQFOXGLQJ3ÄŸ]HUDQG%ULVWRO0\HUV
Squibb, he was President Global Commercialization & Portfolio Management
at Otsuka Pharmaceutical Development &
Commercialization Inc. in Princeton.
In 2014, Weinand became President of
the Pharmaceuticals Division at Bayer.
He was appointed to the Bayer Board
of Management in January 2016.

Werner Baumann studied economics
in Aachen and Cologne, joining Bayer
AG in 1988. After holding positions of
increasing responsibility in Spain and
the United States, he became a member of the Board of Management of
Bayer HealthCare. He was appointed
to the Bayer Board of Management in
2010ÄŸUVWDV&KLHI)LQDQFLDO2IÄŸFHU
and then as Chief Strategy and PortIROLR2IÄŸFHU+HZDVDGGLWLRQDOO\DSSRLQWHG&KLHI([HFXWLYH2IÄŸFHURI
Bayer HealthCare in 2015.

Hartmut Klusik studied chemistry in
Marburg. After gaining a Ph.D., he began
his professional career at Wolff Walsrode
in 1984. He transferred to crop protection
production at Bayer in Brazil in 1990. Following assignments in the United States
and Australia and after holding positions
of increasing responsibility at Bayer
CropScience, he was appointed to the
Board of Management of Bayer HealthCare with responsibility for Product Supply. He was appointed to the Bayer Board
of Management in January 2016.

Marijn Dekkers studied chemistry and chemical engineering in
Nijmegen and Eindhoven. After
gaining a Ph.D., he began a
career in research with General
Electric in the United States.
Having held various positions
in the United States, latterly as
&KLHI([HFXWLYH2IÄŸFHUDQG
President of Thermo Fisher
6FLHQWLÄŸF,QF'HNNHUVWRRN
RYHUDV&KLHI([HFXWLYH2IÄŸFHU
of Bayer in October 2010.

Johannes Dietsch completed his
training with Bayer as a commercial
assistant and business administrator
in 1984. He subsequently held various managerial positions within the
company, including one in Japan.
In 2002, Dietsch took over as head
of the Finance Department in the
Corporate Center. He became Senior
Bayer Representative and cfo of
Bayer in China in 2011. He was
appointed to the Bayer Board of
Management in September 2014.

* Labor Director

1

ERICA MANN
Consumer Health

LIAM CONDON

Erica Mann holds a degree in analytical chemistry and a marketing diploma from her studies in Johannesburg, South Africa. She began her
career with Eli Lilly & Company and
held positions at Johnson & Johnson,
Lederle Laboratories and Wyeth
before moving into senior managePHQWDW3ÄŸ]HULQWKH8QLWHG6WDWHV
She became head of Consumer Care
at Bayer HealthCare in 2011. She
was appointed to the Bayer Board of
Management in January 2016.

Liam Condon studied international
marketing in Dublin and Berlin. He
held various positions of increasing responsibility with the former Schering
AG, Berlin, Germany, and with Bayer
HealthCare in Europe and Asia, including Managing Director of Bayer
HealthCare China and head of Bayer
HealthCare in Germany. Condon beFDPH&KLHI([HFXWLYH2IÄŸFHURI%D\HU
CropScience in 2012. He was appointed to the Bayer Board of Management
in January 2016.

Effective May 1, 2016, Werner Baumann will become the new Chairman of the Board of Management of Bayer AG.
Dr. Marijn Dekkers will leave the company at his own request on April 30, 2016.

Crop Science

34

Bayer Annual Report 2015
To our Stockholders
Report of the Supervisory Board

Report of the Supervisory Board

During 2015, the Supervisory Board monitored the conduct of the companyâ€™s business by the Board
of Management on a regular basis with the aid of detailed written and oral reports received from the
Board of Management, and also acted in an advisory capacity. In addition, the Chairman of the Supervisory Board and the Chairman of the Board of Management maintained a constant exchange of information. In this way the Supervisory Board was kept continuously informed about the companyâ€™s
intended business strategy, corporate planning (including financial, investment and human resources
planning), earnings performance, the state of the business and the situation in the company and the
Group as a whole.
Where Board of Management decisions or actions required the approval of the Supervisory Board,
whether by law or under the Articles of Incorporation or the rules of procedure, the draft resolutions
were inspected by the members at the meetings of the full Supervisory Board, sometimes after preparatory work by the committees, or approved on the basis of documents circulated to the members. The
Supervisory Board was involved in decisions of material importance to the company. We discussed at
length the business trends described in the reports from the Board of Management and the prospects
for the development of the Bayer Group as a whole, the individual organizational units and the principal
affiliated companies in Germany and abroad.
CHANGES ON THE SUPERVISORY BOARD AND THE BOARD OF MANAGEMENT
The Vice Chairman of the Supervisory Board, Thomas de Win, stepped down effective June 30, 2015.
He was succeeded as a member of the Supervisory Board by Heinz Georg Webers, who had been elected as a substitute for de Win. The Supervisory Board elected Oliver ZÃ¼hlke as its new Vice Chairman.
Peter Hausmann stepped down from the Supervisory Board effective October 31, 2015. The Local Court
of Cologne appointed Frank LÃ¶llgen as his successor.
In connection with Bayer's focus on the Life Science business and the reorganization of the Bayer
Group, the Board of Management was expanded to include the heads of the new divisions. The Supervisory Board therefore appointed Dieter Weinand (Pharmaceuticals), Erica Mann (Consumer Health)
and Liam Condon (Crop Science) to the Board of Management effective January 1, 2016. Also with
effect from January 1, 2016, the Supervisory Board appointed Dr. Hartmut Klusik as new Labor Director
with responsibility for Human Resources, Technology and Sustainability on the Board of Management
of Bayer AG. He succeeds Michael KÃ¶nig, who had requested that his contract not be extended.
WORK OF THE SUPERVISORY BOARD
Six meetings of the full Supervisory Board took place during 2015. No member of the Supervisory
Board attended only half or fewer than half of its meetings or those of the committees on which he / she
served. The average attendance rate by Supervisory Board members at the meetings of the full Supervisory Board and of its committees held in 2015 was approximately 97 percent.
The members of the Board of Management regularly attended the meetings of the Supervisory Board.

35

Bayer Annual Report 2015
To our Stockholders
Report of the Supervisory Board

Werner Wenning, Chairman of the Supervisory Board of Bayer AG

The deliberations of the Supervisory Board focused on questions relating to Bayerâ€™s strategy, portfolio
and business activities, as well as personnel decisions. The discussions at the respective meetings in
2015 centered on various topics. At the February meeting, the Supervisory Board discussed the 2014
Annual Report and the agenda for the 2015 Annual Stockholdersâ€™ Meeting. It also dealt with the Bayer
Groupâ€™s risk management system, matters relating to the Board of Management's compensation and the
results of the efficiency audit of the Supervisory Board.
At the May meeting, the Supervisory Board dealt with the planned sale of the Diabetes Care business
and discussed the business performance to date in 2015 and the imminent Annual Stockholdersâ€™ Meeting. At an extraordinary meeting in August, the Supervisory Board discussed in detail the stock market
flotation of Bayerâ€™s MaterialScience unit under the name Covestro.
At the September meeting, the Supervisory Board discussed Bayerâ€™s strategy and the future organization of the Bayer Group effective January 1, 2016. With effect from January 1, 2016, the Supervisory
Board appointed four new members to the Board of Management â€“ Erica Mann, Dieter Weinand, Liam
Condon and Hartmut Klusik â€“ and approved the departure of Michael KÃ¶nig from the Board of Management. In connection with the new appointments, the Supervisory Board also discussed in detail
matters related to the Board of Managementâ€™s compensation. In addition, the Supervisory Board once
again discussed the planned stock market flotation of Covestro against the background of the market
environment at that time. Finally, the Supervisory Board resolved upon changes to the rules of procedure of the Board of Management and the Supervisory Board and established an additional Supervisory
Board committee, the Innovation Committee.
At an extraordinary meeting in October, the Supervisory Board again discussed the stock market flotation of Covestro and resolved upon the volume of the flotation and the issue price range. At its meeting
in December 2015, the Supervisory Board undertook the routine review of the pension amounts of the

36

Bayer Annual Report 2015
To our Stockholders
Report of the Supervisory Board

former members of the Board of Management. Also at this meeting, the Board of Management presented its planning for the business operations in the years 2016 through 2018 and provided information
on the current rating situation. The Supervisory Board also approved the proposed financing framework
for 2016. In addition, the Supervisory Board once again dealt with the companyâ€™s strategy, including
developments in the crop science industry, and with the collaboration between Bayer and crispr Therapeutics. Furthermore, the Supervisory Board resolved to designate Deloitte & Touche GmbH
WirtschaftsprÃ¼fungsgesellschaft as its first choice with regard to the bidding process for the audit of the
financial statements for the years 2017 through 2021. In addition, the Supervisory Board resolved to
issue an unqualified declaration of compliance with the German Corporate Governance Code. Following
the meeting, an information and discussion forum took place on the topic of Life Sciences.
COMMITTEES OF THE SUPERVISORY BOARD
The Supervisory Board has a Presidial Committee, an Audit Committee, a Human Resources Committee,
a Nominations Committee and an Innovation Committee. The current membership of the committees is
shown in the â€œFurther Informationâ€ section under â€œGovernance Bodies.â€
The meetings and decisions of the committees, and especially the meetings of the Audit Committee,
were prepared on the basis of reports and other information provided by the Board of Management.
Reports on the committee meetings were presented at the meetings of the full Supervisory Board.
Presidial Committee: This comprises the Chairman and Vice Chairman of the Supervisory Board along
with a further stockholder representative and a further employee representative. The Presidial Committee serves primarily as the mediation committee pursuant to the German Codetermination Act. It has the
task of submitting proposals to the Supervisory Board on the appointment of members of the Board of
Management if the necessary two-thirds majority is not achieved in the first vote at a plenary meeting.
Certain decision-making powers in connection with capital measures, including the power to amend the
Articles of Incorporation accordingly, have also been delegated to this committee. The Presidial Committee may also undertake preparatory work for full meetings of the Supervisory Board.
In 2015, the Presidial Committee was not required to convene in its capacity as the mediation committee. Based on the corresponding authorization by the Supervisory Board, it resolved in writing in 2015
on the issue and redemption of hybrid bonds. At a meeting in September, the Presidial Committee discussed in detail the planned stock market flotation of Covestro and submitted a proposal to the Supervisory Board concerning the volume of the flotation and the issue price range.
Audit Committee: The Audit Committee comprises three stockholder representatives and three employee representatives. The Chairman of the Audit Committee in 2015, Dr. Klaus Sturany, satisfies the
statutory requirements concerning the independence and the expertise in the field of accounting or
auditing that a member of the Supervisory Board and the Audit Committee is required to possess. The
Audit Committee meets regularly four times a year.
Its tasks include in particular oversight of the financial reporting process, the effectiveness and ongoing
development of the internal control system, the risk management system, the internal audit system, the
compliance system and the audit of the financial statements. The Audit Committee prepares the resolutions of the Supervisory Board concerning the financial statements and management report of Bayer AG
and the proposal for the use of the distributable profit, the consolidated financial statements and management report of the Bayer Group and the agreements with the auditor (particularly the awarding of
the audit contract, the determination of the main areas of focus for the audit and the audit fee agreement). The committee submits a proposal to the full Supervisory Board concerning the auditorâ€™s appointment, and takes appropriate measures to determine and monitor the auditor's independence. The
audit focuses particularly on whether the financial statements have been prepared in compliance with
the statutory requirements and whether the financial reporting provides a true and fair view of the
financial position and results of operations of the company and the Group.
The Audit Committee discusses developments in the area of corporate compliance at each of its meetings where necessary.

37

Bayer Annual Report 2015
To our Stockholders
Report of the Supervisory Board

The Chairman of the Board of Management and the Chief Financial Officer regularly attended the meetings of the Audit Committee. Representatives of the auditor were also present at all the meetings and
reported in detail on the audit work and the audit reviews of the interim financial reports.
The meetings focused on a number of topics. At the February meeting, the Audit Committee discussed
the financial statements and the Groupâ€™s tax strategy and tax risks. It also carefully considered the risk
report, which covered the risk management system, planning and market risks, legal risks, corporate
compliance, the report on process and organizational risks and the internal control system, and the
report by the Internal Audit department. At this meeting, the Audit Committee also made a recommendation to the full Supervisory Board concerning the resolution to be submitted to the Annual Stockholdersâ€™ Meeting on the appointment of the auditor of the financial statements.
The April meeting mainly dealt with the yearly report of the Group Compliance Officer, the determination of the main areas of focus for the audit of the 2015 financial statements and the bidding process for
the audit of the financial statements for 2017 and the fiscal years thereafter. At its July meeting, the
Audit Committee again addressed the bidding process for the audit of the financial statements. As at
every meeting, the quarterly financial statements were also discussed, along with legal and compliance
issues. At its meeting in October, the Audit Committee once more discussed the bidding process for the
audit of the financial statements in addition to the regular items on the agenda.
Human Resources Committee: On this committee, too, there is parity of representation between stockholders and employees. It consists of the Chairman of the Supervisory Board and three other members.
The Human Resources Committee prepares the personnel decisions of the full Supervisory Board, which
resolves on appointments or dismissals of members of the Board of Management. The Human Resources Committee resolves on behalf of the Supervisory Board on the service contracts of the members
of the Board of Management. However, it is the task of the full Supervisory Board to resolve on the total
compensation of the individual members of the Board of Management and the respective compensation
components, as well as to regularly review the compensation system on the basis of recommendations
submitted by the Human Resources Committee. The Human Resources Committee also discusses the
long-term succession planning for the Board of Management.
The Human Resources Committee convened on two occasions in 2015. The matters discussed at these
meetings concerned the compensation and contracts of the members of the Board of Management and
the preparation of the appointment of the new members of the Board of Management.
Nominations Committee: This committee carries out preparatory work when an election of stockholder representatives to the Supervisory Board is to be held. It suggests suitable candidates for the
Supervisory Board to propose to the Annual Stockholdersâ€™ Meeting for election. The Nominations
Committee comprises the Chairman of the Supervisory Board and the other stockholder representative
on the Presidial Committee.
On several occasions outside of the meetings in 2015, the members of the Nominations Committee
discussed candidates for the elections to the Supervisory Board that are due to take place in 2016, along
with the medium-term planning for the composition of the stockholder side of the Supervisory Board.
Innovation Committee: The Innovation Committee was established in September 2015. It is primarily
concerned with the innovation strategy and innovation management, the strategy for the protection of
intellectual property, and major research and development programs at Bayer. It is also responsible for
advising and overseeing the management and preparing any Supervisory Board decisions. The Committee comprises the Chairman of the Supervisory Board and five other members, with parity of representation between stockholder and employee representatives. The Chairman of the Board of Management
and the member of the Board of Management responsible for Innovation regularly attend the meetings
of the Innovation Committee.
In 2015, the Innovation Committee convened once in December and dealt at this meeting with new
technologies in the area of Life Sciences.

38

Bayer Annual Report 2015
To our Stockholders
Report of the Supervisory Board

CORPORATE GOVERNANCE
The Supervisory Board dealt with the ongoing development of corporate governance at Bayer, partly
through the amendment of the rules of procedure of the Supervisory Board, taking into account the May
5, 2015, version of the German Corporate Governance Code. In December, the Board of Management
and the Supervisory Board issued a new declaration concerning the German Corporate Governance
Code.
FINANCIAL STATEMENTS AND AUDITS
The financial statements of Bayer AG were prepared according to the requirements of the German
Commercial Code and Stock Corporation Act. The consolidated financial statements of the Bayer Group
were prepared according to the German Commercial Code and the International Financial Reporting
Standards (ifrs). The combined management report was prepared according to the German Commercial Code. The auditor, PricewaterhouseCoopers Aktiengesellschaft, WirtschaftsprÃ¼fungsgesellschaft,
Essen, has audited the financial statements of Bayer AG, the consolidated financial statements of the
Bayer Group and the combined management report. The conduct of the audit is explained in the auditorâ€™s reports. The auditor finds that Bayer has complied, as appropriate, with the German Commercial
Code, the German Stock Corporation Act and / or the International Financial Reporting Standards endorsed by the European Union, and issues an unqualified opinion on the financial statements of Bayer
AG and the consolidated financial statements of the Bayer Group. The financial statements of Bayer AG,
the consolidated financial statements of the Bayer Group, the combined management report and the
audit reports were submitted to all members of the Supervisory Board. They were discussed in detail by
the Audit Committee and at a meeting of the full Supervisory Board. The auditor submitted a report on
both occasions and was present during the discussions.
We examined the financial statements of Bayer AG, the proposal for the use of the distributable profit,
the consolidated financial statements of the Bayer Group and the combined management report. We
have no objections, thus we concur with the result of the audit.
We have approved the financial statements of Bayer AG and the consolidated financial statements of the
Bayer Group prepared by the Board of Management. The financial statements of Bayer AG are thus
confirmed. We are in agreement with the combined management report and, in particular, with the
assessment of the future development of the enterprise. We also concur with the dividend policy and the
decisions concerning earnings retention by the company. We assent to the proposal for the use of the
distributable profit, which provides for payment of a dividend of â‚¬2.50 per share.
The Supervisory Board would like to thank the Board of Management and all employees for their dedication and hard work in 2015.

Leverkusen, February 24, 2016
For the Supervisory Board:

WERNER WENNING
Chairman

39

Bayer Annual Report 2015
To our Stockholders
Investor Information

Investor Information

Performance of Bayer Stock in 2015

[Graphic 2.1]

(Indexed; 100 = Xetra closing price on December 31, 2014; source: Bloomberg)

130

120

110

100

90

80
Jan

Feb

Bayer + 4.2%

Mar
DAX + 9.6%

Apr

May

June

July

Aug

Sep

Oct

Nov

Dec

DJ EURO STOXX 50 + 6.4%

// Bayer stock yields approximately 4 percent in 2015
// Successful stock market debut for Covestro
// Board of Management and Supervisory Board
propose dividend increase to â‚¬2.50 per share
for 2015

40

Bayer Annual Report 2015
To our Stockholders
Investor Information

The Stock Market in 2015
STOCK MARKETS END THE YEAR WITH GAINS FOLLOWING EXTREME FLUCTUATIONS
Fiscal 2015 was characterized worldwide by high volatility. The program to purchase certain bonds
announced by the European Central Bank in the spring stimulated optimism and increasing share
prices. As the year progressed, however, the investment climate was dampened by speculation as to
Greeceâ€™s exit from the eurozone, economic concerns in China and the decline in the global oil price.
Additionally, the capital market environment was influenced by the Fed rate increase in the United
States at the end of 2015.
The dax reached its high for the year in the second quarter of 2015, closing at 12,375 points on April
10. This was also an all-time record for the index. From that time until September, the dax dropped
almost 3,000 points to 9,428 points in a development characterized by strong fluctuations. In the closing
months of the year, the index recovered to close at 10,743 points for a year-on-year gain of 9.6 percent.
The European equities index euro stoxx 50 (performance index) rose 6.4 percent, ending the year at
6,226 points. Share prices in the United States and Japan varied in their performance. The s&p 500
index was largely unchanged, while the Nikkei 225 increased by around 9 percent.
BAYER STOCK YIELDS FOUR PERCENT FOR THE YEAR
Including the dividend of â‚¬2.25 per share paid at the end of May, the return on Bayer stock was
4.2 percent in 2015. Bayer stock ended the year at â‚¬115.80, having reached a high for the year and an
all-time high of â‚¬146.20 in April.
Following a period of significantly above-average value creation from 2012 to 2014, the yield of Bayer
stock in 2015 was below that of the reference indices, with the exception of the euro stoxx Chemicals
Index (performance index). The euro stoxx Chemicals Index (performance index) climbed by
3.6 percent in 2015, while the euro stoxx Health Care Index (performance index) rose by 19.2 percent.
More than 90 percent of the roughly 30 equity analysts who regularly rate our company had a buy or
hold recommendation on our stock at the end of last year.

Bayer Stock Data

[Table 2.1]
2014

2015

4.14

4.97

â‚¬

5.89

6.83

â‚¬

8.11

8.46

Equity per share

â‚¬

24.45

30.77

Dividend per share

â‚¬

2.25

2.50

Earnings per share

â‚¬

Core earnings per share from continuing operations1
Gross cash flow per share

Year-end priceÂ²

â‚¬

113.00

115.80

High for the yearÂ²

â‚¬

120.95

146.20

Low for the yearÂ²

â‚¬

91.51

108.00

Total dividend payment

â‚¬ million

1,861

2,067

million shares

826.95

826.95

â‚¬ billion

93.4

95.8

million shares

2.1

2.3

Price / EPSÂ²

27.3

23.3

Price / core EPSÂ²

19.2

17.0

Price / cash flowÂ²

13.9

13.7

2.0

2.2

Number of shares entitled to the dividend (Dec. 31)
Market capitalization (Dec. 31)
Average daily share turnover on German stock exchanges

Dividend yield

%

2014 figures restated
1 For details on the calculation of core earnings per share, see Combined Management Report, Chapter 14.3.
2 Xetra closing prices (source: Bloomberg)

41

Bayer Annual Report 2015
To our Stockholders
Investor Information

GOOD FINANCING CONDITIONS FOR BAYER IN VOLATILE MARKETS
The environment for corporate bonds remained favorable in 2015 â€“ a year that, however, was marked by
sharp fluctuations in the interest markets and a trend toward increased borrowing cost mark-ups. Particularly stark mark-ups were observed for the interest rate level, which saw its long-term downward
trend cease at the end of the first quarter of 2015. The subsequent volatility occurred at a historically
low absolute interest rate level. Against this background, investors sought medium- to long-term maturities. Interest in subordinated bonds remained high, even though investors increasingly demanded higher new issue premiums as the year progressed.
The development of risk premiums is apparent from the trend in credit default swaps (cds) shown in
Graphic 2.2. On the derivatives market, the price of these tradable insurance contracts, which are used
to hedge against default of a borrower, shows how a companyâ€™s credit standing is rated. The graphic
shows the trend toward higher borrowing cost mark-ups and considerable volatility over the course of
the year.
Benefiting from the still very positive market environment at the end of the first quarter, Bayer issued a
hybrid bond with a volume of â‚¬1.3 billion and a coupon of 2.375 percent. Further details of outstanding
bonds are given in Note [27] to the consolidated financial statements.

Rates for Five-Year Credit Default Swaps (CDS) 2015

[Graphic 2.2]

In basis points 1

100
80
60
40
20
iTraxx Europe 2

Jan

Feb

Mar

Apr

May

June

July

Aug

Sep

Oct

Nov

Bayer CDS

Dec

1 Source:
2 iTraxx

Bloomberg
Europe is a CDS index comprising the CDS of 125 companies (including financial institutions) with investment-grade ratings.

LONG-TERM RETURN ON BAYER STOCK STILL AHEAD OF THE MARKET
A long-term investor who purchased Bayer shares for â‚¬10,000 five years ago and reinvested all dividends would have seen the value of the position grow to â‚¬23,545 as of December 31, 2015, giving
an average annual return of 18.7 percent. That was well above the return on the dax and the euro
stoxx 50 (performance index) in the same period. Bayer stock also outperformed these indices on a
three-year view.

Long-Term Returns on Bayer Stock in % p. a. (Dividends Reinvested)
Annual returns

[Table 2.2]
1 year 2015

3 years 2013 - 2015

5 years 2011 - 2015

%

%

%

Bayer

4.2

19.6

18.7

DAX

9.6

12.2

9.2

EURO STOXX 50

6.4

10.4

6.4

42

Bayer Annual Report 2015
To our Stockholders
Investor Information

DIVIDEND INCREASE TO â‚¬2.50 PER SHARE
The Board of Management and the Supervisory Board will propose to the Annual Stockholdersâ€™
Meeting that the dividend be increased by â‚¬0.25 to â‚¬2.50 per share. Thus we once again intend that our
stockholders should participate in last yearâ€™s positive business performance. The resulting payout ratio
of 37 percent calculated on core earnings per share is within our target corridor of 30 percent to
40 percent (for details of the calculation of core earnings per share, see Chapter 14.3 of the Combined
Management Report).
The dividend yield calculated on the share price of â‚¬115.80 at year end 2015 amounts to 2.2 percent
and the total dividend payment to â‚¬2,067 million.

Dividends Per Share and Total Dividend Payments
2006

2007

2008

[Graphic 2.3]
2009

2010

2011

2012

2013

2014

2015

â‚¬2.50

2.5

â‚¬2.10

â‚¬2.25

â‚¬1.90

2.0

â‚¬1.50
â‚¬1.35

1.5

â‚¬1.40

â‚¬1.65

â‚¬1.40

â‚¬1.00

1.0
0.5
0.0

â‚¬764 million

â‚¬1,032 million â‚¬1,070 million â‚¬1,158 million â‚¬1,240 million â‚¬1,364 million â‚¬1,571 million â‚¬1,737 million â‚¬1,861 million â‚¬2,067 million

Dividend per share (â‚¬)

GRI
G4-26

www.bayer.com/en/
awards.aspx

Total dividend payment (â‚¬ million)

A SUSTAINABLE INVESTMENT
We continued our dialogue with sustainability-oriented investors, analysts and rating agencies in 2015.
In numerous conversations, we explained our strategy and the implementation of our nonfinancial
targets, and provided information on the most important fields of our sustainability activity. This direct
contact serves as the basis for transparent and fair evaluation.
In 2015, Bayer again qualified for inclusion in major sustainability indices that assess companies according to environmental, social and governance criteria: Dow Jones Sustainability World, ftse4Good
(Europe, Global and Environmental Leaders Europe 40), msci Low Carbon Target, nyse Euronext Low
Carbon 100 Europe, stoxxÂ® Global esg Leaders and Access to Medicine Index.
INTERNATIONAL OWNERSHIP STRUCTURE
The number of Bayer stockholders rose substantially in 2015. At the end of 2015, approximately
300,000 stockholders were listed in our share register â€“ an increase of about 33,000 compared with the
previous year. Our ownership structure shows the international distribution of our capital stock. The
highest proportion of our outstanding shares, almost 28 percent, is held by investors in the United
States and Canada, followed by Germany with nearly 21 percent. From a regional perspective, Bayer has
a stable ownership structure that has altered only slightly in recent years. Bayer has a 100 percent free
float as defined by Deutsche BÃ¶rse, the operator of the Frankfurt Stock Exchange.

43

Bayer Annual Report 2015
To our Stockholders
Investor Information

Ownership Structure by Country

[Graphic 2.4]

Not covered by survey 6.9%
Denmark, Finland,
Norway, Sweden 3.4%
Benelux 2.5%

U.S.A., Canada 27.7%

Austria, Switzerland,
Liechtenstein 4.2%
Other countries 5.1%

Germany 20.6%

France, Spain,
Italy, Portugal 10.7%
U.K., Ireland 18.9%
Source: IPREO

INVESTOR RELATIONS FOCUSED ON THE COVESTRO STOCK MARKET FLOTATION
Bayerâ€™s investor relations (ir) activities last year were dominated by the focus on the Life Science businesses, and thus by the stock market flotation announced in 2014 of our former Bayer MaterialScience
subgroup. Under the new name Covestro AG, these activities were successfully listed on the Frankfurt
Stock Exchange at the beginning of October by way of an ipo (initial public offering). We handled many
questions particularly from private investors in the period prior and subsequent to the listing.
Bayerâ€™s management and the ir team last year spent nearly 60 days communicating directly with analysts and investors during roadshows and investor conferences.
Our Meet Management conferences in Berlin and New York gave investors and analysts an opportunity
for direct dialogue with Bayerâ€™s top management.
As in previous years, private investors also had an opportunity to find out about our company at various
stockholder forums at which the Investor Relations team was present.
We received awards for our ir work again in 2015. In the Thomson Reuters Extel Survey 2015, investors and analysts named Bayer the company with the best investor relations work in the chemicals
sector. We took third place in the same category in the Pan European Survey. We were also ranked
second among dax 30 companies in a report by the German Investor Relations Association (dirk) and
the German business magazine Wirtschaftswoche.

44

Bayer Annual Report 2015
Combined Management Report

01
Combined
Management Report
of the Bayer Group and Bayer AG as of December 31, 2015

Fundamental Information About the Group
1.
1.1
1.2
1.3
1.4
1.5
1.6
1.7
2.
3.
4.
4.1
4.2
4.3
5.
6.
6.1
6.2
6.3
7.
7.1
7.2
7.3
7.4

Bayer at a Glance
46
Corporate Profile
48
Corporate Structure
49
Group Strategy
51
Targets and Performance Indicators
52
Internal Management System
55
Value Creation
56
Corporate Environment
57
Strategies of the Segments
58
Economic Environments of the Subgroups
62
Research, Development, Innovation
63
HealthCare
65
CropScience
74
Covestro
78
Sustainability Management and Governance
79
Employees
86
Utilizing Potential to the Full:
Personnel Development at Bayer
89
Diversity and Internationality
93
Employee Compensation and Variable Pay
94
Procurement, Production, Logistics, Distribution 97
Procurement and Supplier Management
97
Production
104
Logistics
107
Distribution
108

8.
8.1
8.2
8.3
9.
9.1
9.2
9.3
10.
10.1
10.2
10.3
10.4
10.5
10.6
11.

Product Stewardship
HealthCare
CropScience
Covestro
Safety
Occupational Health and Safety
Process and Plant Safety
Transportation Safety
Environmental Protection
International Standards and Certifications
Energy Consumption
Air Emissions
Use of Water and Emissions into Water
Waste and Recycling
Biodiversity
Social Commitment

112
117
119
123
123
124
126
128
131
132
132
134
138
140
142
143

Report on Economic Position
12.
13.
13.1
13.2
13.3
13.4
13.5

Overview of Sales, Earnings and
Financial Position
Business Development by Subgroup, Segment
and Region
HealthCare
CropScience
Covestro
Business Development by Region
Business Development in the Emerging Markets

148
153
153
160
163
166
166

45

Bayer Annual Report 2015
Combined Management Report

14.
14.1
14.2
14.3
14.4
14.5
14.6
14.7
15.
15.1
15.2

Earnings; Asset and Financial Position
of the Bayer Group
Earnings Performance of the Bayer Group
Calculation of EBIT(DA) Before Special Items
Core Earnings per Share
Value Management
Liquidity and Capital Expenditures
of the Bayer Group
Asset and Capital Structure of the Bayer Group
Financial Management of the Group
Earnings; Asset and Financial Position
of Bayer AG
Earnings Performance of Bayer AG
Asset and Financial Position of Bayer AG

168
168
169
170
172
173
176
177
178
179
180

Corporate Governance
16.
16.1 
16.2
16.3

Corporate Governance Report
Declaration Concerning the German
Corporate Governance Code
Governance
Compliance

182
182
183
188

16.4
Compensation Report
16.4.1 Compensation of the Board of Management
16.4.2 Disclosures Pursuant to the Recommendations
of the German Corporate Governance Code
16.4.3 Compensation of the Supervisory Board
16.4.4 Further Information

191
192
202
206
208

Events After the End of the Reporting Period
17.

Events After the End of the Reporting Period

208

Report on Future Perspectives and on
Opportunities and Risks
18.
18.1
18.2
18.3
18.3.1

Future Perspectives
Economic Outlook
Forecast for Key Data
Opportunities and Risks Report
Group-wide Opportunity and
Risk Management System
18.3.2 Opportunities and Risks
19.
Takeover-Relevant Information

209
209
211
214
214
218
226

46

Bayer Annual Report 2015

47

Bayer Annual Report 2015
Combined Management Report

Combined Management Report

1. Bayer at a Glance

1. Bayer at a Glance

Fundamental Information
About the Group
1. Bayer at a Glance
The Bayer Group in 2015

[Graphic 3.1.1]

employees

sales

+2.7%
Å˜ million

1

ebitda before special items

NORTH AMERICA

EUROPE

â‚¬12,740 (â‚¬9,953)2 million

â‚¬15,949 (â‚¬15,312)2 million

16,000 (15,800)2

55,900 (54,600)2

â‚¬1,051 (â‚¬866)2 million

â‚¬2,947 (â‚¬2,412)2 million

employee engagement

87%

+18.2%
Å˜ million

proportion of women in
senior management

net income

28%

+ 20.0%
Å˜ million

supplier management

core earnings per share

84%

+16.0%
Å˜

LATIN AMERICA / AFRICA /
MIDDLE EAST

research and development

+21.0%
Å˜ million

2014 figures in parentheses
1 Currency- and portfolio-adjusted
2 2014 figures restated

116,800

â‚¬7,371 (â‚¬7,007)2 million
16,100

(16,800)2

â‚¬69 (â‚¬61)2 million

ASIA / PACIFIC

â‚¬10,264 (â‚¬9,067)2 million
28,800 (30,200)2
â‚¬214 (â‚¬198)2 million

of all strategically important suppliers
evaluated since 2012

energy efficiency

LPSURYHPHQWRI

4%

VLQFH

48

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

1.1 Corporate Profile
Bayer is a Life Science company with a more than 150-year history and core competencies in the areas
of health care and agriculture. With our innovative products, we are contributing to finding solutions to
some of the major challenges of our time. The growing and increasingly aging world population requires improved medical care and an adequate supply of food. Bayer is improving peopleâ€™s quality of
life by preventing, alleviating and treating diseases. And we are helping to provide a reliable supply of
high-quality food, feed and plant-based raw materials.
We develop new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Our research and development activities are based on a profound understanding of the biochemical processes in living organisms.
Our goal is to achieve and sustain leadership positions in our markets, thus creating value for our customers, stockholders and employees. To this end, our strategy is designed to help solve some of the
most pressing challenges facing humankind, and by doing this exceptionally well we aim to strengthen
the companyâ€™s earning power.
We are committed to operating sustainably and addressing our social and ethical responsibilities as a
corporate citizen, while at the same time respecting the interests of all our stakeholders. Employees
with a passion for innovation enjoy excellent development opportunities at Bayer.
All this goes to make up our mission â€“ Bayer: Science For A Better Life.
EXCLUSIVE FOCUS ON THE LIFE SCIENCE BUSINESSES
Following the economic and legal independence of our former MaterialScience subgroup, now
Covestro, Bayer has charted the course for its successful development as a Life Science company. Our
businesses hold leading positions in innovation-driven growth markets. Together they make up a strong,
attractive and balanced portfolio that is resistant to fluctuations in demand and to potential risks. The
previous structure â€“ comprising a strategic management holding company and operational subgroups â€“
has thus been replaced by an integrated organization under the umbrella of the strong Bayer brand.
The chapters in this report dealing with corporate strategy and future perspectives are based on the
new structure because they look ahead. All other chapters reflect the organizational structure in effect
through December 31, 2015.
OUR VALUES
Bayerâ€™s values play a central role in our daily work and are intended to guide us in fulfilling our mission
â€œBayer: Science For A Better Life.â€ They are represented by the acronym life, which stands for Leadership, Integrity, Flexibility and Efficiency.
These values apply to everyone at Bayer and are firmly integrated into our global performance management system for managerial employees. Our value culture ensures a common identity throughout
the enterprise across national boundaries, management hierarchies and cultural differences.

49

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

1.2 Corporate Structure
CORPORATE STRUCTURE IN 2015
Until December 31, 2015, Bayer AG, headquartered in Leverkusen, Germany, served as a strategic
management holding company, defining common values, goals and strategies for the entire Bayer
Group. It was also responsible for resource allocation and managerial appointments. Under its direction,
the three subgroups â€“ HealthCare, CropScience and Covestro (formerly MaterialScience) â€“ conducted
their business operations on their own responsibility in line with predefined goals, supported by three
service companies. Following the signing of a sales agreement with Panasonic Healthcare Holdings,
Ltd. on June 8, 2015, the Diabetes Care business is no longer reported under continuing operations.

Bayer Group Structure 2015

[Graphic 3.1.2]

BAYER
Corporate Center

HealthCare
Pharmaceuticals

Consumer
Health

CropScience

Covestro

Consumer
Care

Crop Protection / Seeds

Polyurethanes

Medical
Care

Environmental Science

Polycarbonates

Animal
Health

Business
Services

Technology
Services

Coatings, Adhesives, Specialties
Currenta
(60%)

Industrial Operations

Key Data by Subgroup and Segment

[Table 3.1.1]
Sales

EBIT

EBITDA before special items 1

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

HealthCare

19,075

22,874

3,470

4,050

5,357

6,419

Pharmaceuticals

12,052

13,745

2,371

2,807

3,699

4,195

Consumer Health

7,023

9,129

1,099

1,243

1,658

2,224

CropScience

9,494

10,367

1,806

2,103

2,360

2,416

11,651

11,982

555

635

1,187

1,659

1,119

1,101

(436)

(538)

(219)

(228)

41,339

46,324

5,395

6,250

8,685

10,266

Covestro
Reconciliation
Group
1

For definition see Chapter 14.2 â€Calculation of EBIT(DA) Before Special Items.â€œ

In 2015, the Bayer Group comprised 307 consolidated companies in 77 countries throughout the world.

50

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

NEW CORPORATE STRUCTURE EFFECTIVE 2016
With the companyâ€™s focus now on the Life Science businesses, a new organizational structure was
introduced effective January 1, 2016. The companyâ€™s operations are now managed in three divisions â€“
Pharmaceuticals, Consumer Health and Crop Science â€“ and the Animal Health business unit. The former Bayer HealthCare subgroup has been dissolved. The Radiology and Pharmaceuticals businesses
have been merged to form the Pharmaceuticals Division. The Consumer Health Division now consists
entirely of the consumer care business. Animal Health has become a separate reporting segment. The
Bayer CropScience subgroup is now the Crop Science Division. The former MaterialScience subgroup,
renamed Covestro, became legally and economically independent on September 1, 2015. Covestro AG
was floated on the stock market on October 6, 2015. Bayer currently still owns around 69% of
Covestro AG. Covestro therefore remains a reporting segment of the Bayer Group because Bayer AG
continues to exercise control.
Effective January 1, 2016, the Board of Management of Bayer AG was enlarged to include the heads of
the new Pharmaceuticals, Consumer Health and Crop Science divisions. The business continues to be
supported by Business Services and Currenta, while Technology Services is being integrated into
Bayer AG, forming the Engineering & Technology function.

Bayer Group Structure in 2016

[Graphic 3.1.3]

STI

BOARD OF MANAGEMENT

Pharmaceuticals

Consumer Health

Crop Science
Animal Health

Corporate Functions and Business Services

Currenta (60%)

Covestro ( around 69%)

Pro Forma Key Data by New Segment

[Table 3.1.2]
Sales

EBIT

EBITDA before special items 1

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Pharmaceuticals

13,512

15,308

2,627

3,027

4,081

4,615

Consumer Health

4,245

6,076

609

769

991

1,456

Crop Science

9,494

10,367

1,806

2,103

2,360

2,416

Animal Health

1,318

1,490

234

254

285

348

Reconciliation 2

1,119

1,101

(436)

(538)

(219)

(228)

Total Life Sciences 3

29,688

34,342

4,840

5,615

7,498

8,607

Covestro

11,651

11,982

555

635

1,187

1,659

Group

41,339

46,324

5,395

6,250

8,685

10,266

1

For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
Reconciliation includes the Business Services and Currenta service companies (â€œOther segmentsâ€) as well as the corporate functions and
consolidation effects.
3 Including service companies
2

51

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

The Pharmaceuticals Division focuses on prescription products, especially for cardiology and womenâ€™s
healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The
division also comprises the radiology business, which markets diagnostic imaging equipment together
with the necessary contrast agents.
The Consumer Health Division markets mainly nonprescription products in the dermatology, dietary
supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care, sun protection and cardiovascular risk prevention categories. These products include globally known brands such as Claritinâ„¢,
Aspirinâ„¢, Aleveâ„¢, Bepanthenâ„¢ / Bepantholâ„¢, Canestenâ„¢, Dr. Schollâ€™sâ„¢1 and Coppertoneâ„¢.
The Crop Science Division has businesses in seeds, crop protection and nonagricultural pest control. It
is organized into two operating units: Crop Protection / Seeds and Environmental Science. Crop Protection / Seeds markets a broad portfolio of high-value seeds along with innovative chemical and biological
pest management solutions, while at the same time providing extensive customer service for modern
and sustainable agriculture. Environmental Science focuses on nonagricultural applications, with a
broad portfolio of pest control products and services designed for applications ranging from the home
and garden sector to forestry.
The Animal Health Business Unit offers products and services for the prevention and treatment of
diseases in companion and farm animals.
The corporate functions and Business Services operate as Group-wide competence centers in which
business support services are bundled. Currenta is the service company responsible for managing and
operating the Chempark sites in Leverkusen, Dormagen and Krefeld-Uerdingen.
Covestro is a leading supplier of high-tech polymer materials and develops innovative product solutions
for a wide variety of everyday uses.

1.3 Group Strategy
Our mission â€œBayer: Science For A Better Lifeâ€ continues to guide our endeavors. The steadily growing
and aging global population needs new and better medicines and an adequate food supply. With our
Life Science innovations, we offer answers to these challenges.

OUR OBJECTIVE: PROFITABLE GROWTH
Our corporate strategy is aligned toward profitable growth that will increase the companyâ€™s value in the
long term. As well as expanding in growth markets, we attach special importance to the development of
new products that create significant value for our stakeholders.

THE FOUNDATION FOR OUR SUCCESS: INNOVATION
Science-based innovations have made us the globally successful company we are today. Going forward,
we will continue to strengthen this important foundation for our success. In 2016 alone, we plan to
invest around â‚¬4.5 billion in research and development â€“ more than ever before. Our scientists will
continue to collaborate across divisional boundaries, supported in part by the new Bayer Life Science
Center, which has been created to identify innovative technologies developed by startups and universities and make them available for our fields of activity. We are also driving forward new business models
that include utilizing the opportunities offered by digitization for our company and our customers.

1

Trademark rights and distribution only in certain countries outside the European Union

52

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

A FUNDAMENTAL PREMISE: SUSTAINABILITY
Sustainable business practices are essential to our companyâ€™s future viability. We apply our scientific
expertise and innovation strength to help solve global challenges. Our goal in developing, manufacturing and marketing our products is to balance commercial success with societal and ecological requirements while increasing enterprise value. We aim to ensure broad social acceptance for our business
through responsible practices in areas such as product stewardship, environmental protection, safety,
compliance, supplier management and human resources policy, taking into account the expectations of
relevant stakeholders.

OUR MOST IMPORTANT RESOURCE: THE EMPLOYEES
Our employees are the key to our companyâ€™s success. We therefore create a working environment in
which each employee can unfold his or her full potential, drive forward innovations and achieve performance excellence. Our objective as an employer is to partner an employee throughout his or her career
and not just at a certain phase. We live up to this aspiration with flexible worktime models, a firm commitment to social responsibility and the provision of wide-ranging development opportunities across the
company. A diverse employee structure is also vital for our companyâ€™s future competitiveness. We therefore strive for a good cultural and gender balance in all areas.

1.4 Targets and Performance Indicators
To consistently implement our strategy, we have set ambitious targets for our company and measure
their attainment annually in terms of selected performance indicators. This program encompasses not
only financial targets and innovation goals, but also sustainability objectives that are aligned to important areas along the value chain. Our aim is to make clear the challenges we have identified in our
core business in the context of sustainable development, and at the same time to highlight the continuous improvements we are committed to making across the enterprise.
Following the legal independence and stock market flotation of Covestro, this company is not included
in the new innovation, sustainability and employee targets. Where necessary, we have adjusted the
reference data for unchanged targets to eliminate the contributions for Covestro.
The current status of our progress in respect of our targets and performance indicators is documented
in the following table and the respective chapters.

53

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

Bayer Group Targets

Target

(Graphic 3.1.4)

Target attainment (as of 2015)

New or adjusted target

Profitable Growth
Increase in Group sales (Fx & portfolio adj.); forecast
issued in February 2015: low-single-digit percentage
increase to approx. â‚¬46 billion

2.7% increase to â‚¬46.3 billion

Low-single-digit percentage increase
(Fx & portfolio adj.) to more than
â‚¬47 billion

Increase in ebitda before special items; forecast
issued in February 2015: low- to mid-teens percentage increase

18.2% increase

Mid-single-digit percentage increase

Increase in core earnings per share; forecast issued
in February 2015: low-teens percentage increase

16.0% increase

Mid-single-digit percentage increase

Group: increase in r&d investment to over
â‚¬4.0 billion (2015)

â‚¬4.3 billion

Increase in r&d investment to
â‚¬4.5 billion (2016)

HealthCare: transition of more than 10 new
molecular entities (nmes) into development (2015)

12 new molecular entities (nmes)
transferred

Pharmaceuticals: transition of
10 new molecular entities (nmes) into
development (2016)

Innovation

Consumer Health: transition of
20 consumer-validated concepts into
early development (2016)
CropScience: transfer of 2 new molecular entities
(nmes) or plant traits into confirmatory technical
proof-of-concept field studies (2015)

Start of field studies on 1 new plant
trait, 1 new molecular entity (nme)
and 2 new biologics

Transfer of 3 new molecular entities
(nmes), plant traits or biologics into
confirmatory technical proof-ofconcept field studies

Covestro (formerly MaterialScience): improvement
in production process technology to achieve better
energy efficiency (2015)

Further use of improved production
technologies (e.g. in tdi, mdi and
chlorine production)

-

Evaluation of all strategically important suppliers
(2017)

84%

Target unchanged

Evaluation of all potentially high-risk suppliers with
significant Bayer spend (2020)

73%

Target unchanged

Development and establishment of a new
sustainability standard for our supply base (2020)

In implementation

Target unchanged

See Chapters 4 and 10 for more information

Sustainability
SUPPLIER MANAGEMENT

See Chapter 7 for more information

54

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

Bayer Group Targets

Target

(Graphic 3.1.4 [continued])

Target attainment (as of 2015)

New or adjusted target

RESOURCE EFFICIENCY
Improvement of 10% in Group-wide energy
efficiency (2020); reference year 2012: 3.50 MWh/t

3.34 MWh / t (4% improvement)

Target unchanged; new reference
value (2012): 8.86 MWh / t

Reduction of 20% in Group-wide specific greenhouse
gas emissions (2020); reference year 2012:
0.98 t co2 / t

1.09 t co2 / t (+ 11%)

Reduction of 15% in Group-wide
specific greenhouse gas emissions
(2020); new reference value (2012):
1.88 t co2 / t

Establishment of water management at all sites
in water-scarce areas

Approx. 58%

Target unchanged

Reduction of 35% in occupational safety
incident rate (2020); reference year 2012:
rir (Recordable Incident Rate) 0.49

rir 0.42 (â€“ 14%)

Target unchanged; new reference
value (2012): rir 0.50

Reduction of 30% in transport incidents (2020);
reference year 2012: 6 incidents

12 (+ 100%)

Target not being continued

Reduction of 30% in process and plant safety
incidents (2020); reference year 2012: LoPC-ir
(Loss of Primary Containment Incident Rate) 0.38

LoPC-ir 0.22 (â€“ 42%)

Target unchanged; new reference
value (2012): LoPC-ir 0.21

66%

Target unchanged

Conducting of precautionary risk assessments
in all three subgroups (2015)

Successfully completed

â€“

Annual compliance training for all Bayer
managers (> 99%)

97%

Annual compliance training
for close to 100% of Bayer
managers

Continuous improvement in employee engagement;
reference year 2012: 85%

87%

Target unchanged

Increase in the proportion of women in senior management to 30% (2015); reference year 2010: 21%

28%

Increase in the proportion of women
in senior management to 35%
(2020); reference value remains

Increase in the proportion of senior managers from
outside the European Union, the United States or
Canada to 25% (2015); reference year 2013: 18%

21%

Increase in the proportion of senior
managers from outside the European
Union, the United States or Canada to
25% (2020)

See Chapter 10 for more information

SAFETY

See Chapter 9 for more information

PRODUCT STEWARDSHIP
Conclusion of assessment of hazard potential of all
substances (> 99%) used in quantities exceeding one
metric ton per annum (2020)
See Chapter 8 for more information

COMPLIANCE

See Chapter 16.3 for more information

Employees

See Chapter 6 for more information

55

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

Details of further key financial data are found in Chapter 18 â€œFuture Perspectives.â€ Information on
Bayer Group targets is also provided in the relevant chapters, indicated by â€œBayer Group Targetâ€ in the
margin.

See Chapter 18

1.5 Internal Management System
The economic planning and steering for the business units is carried out within a framework laid down
by the Board of Management that is refined during the strategic planning process. Operational planning
then translates this framework into specific, measurable targets. Continuous monitoring of business
developments complements the planning and management process, and key management and performance indicators are regularly updated. This process also involves tracking the implementation of the
strategic objectives and adopting countermeasures in the event of deviations from the budget.
One of the prime objectives of the Bayer Group is to steadily increase enterprise value. We use the
following steering parameters to plan, steer and monitor the development of our business.
The key performance indicators at the strategic level are cash value added (cva), which is a value-based
steering parameter, and cash flow return on investment (cfroi). These indicators support management
in its decision-making, especially in the areas of strategic portfolio optimization and the allocation
of resources for acquisitions and capital expenditures. In fiscal 2015, Bayer achieved a positive cva of
â‚¬1,285 million and a cfroi of 9.6%. (See Chapter 14.4 â€œValue Managementâ€ for further details.)

See Chapter 14.4

The principal economic steering parameters within the Bayer Group at the operational level are sales
and earnings figures. With regard to earnings, special attention is paid to ebitda (ebit plus the amortization of intangible assets and the depreciation of property, plant and equipment, plus impairment
losses and minus impairment loss reversals, recognized in profit or loss during the reporting period)
before special items. The ebitda margin before special items, which is the ratio of ebitda before special
items to sales, serves as a relative indicator for the internal and external comparison of operational
earning power. In 2015, ebitda before special items amounted to â‚¬10,266 million, resulting in an ebitda
margin before special items of 22.2%. (See Chapter 14.2 â€œCalculation of ebit(da) Before Special Itemsâ€
for further details.)

See Chapter 14.2

The Board of Management and the relevant committees steer the sustainable alignment of the company,
defining responsibilities and framework conditions by way of Group directives, for example. Operations
are steered using defined targets and performance indicators in areas such as innovation, supplier
management, safety, product stewardship and environmental protection. On the basis of a materiality
analysis, Bayer has determined the principal activities in these areas and established the relevant management systems, committees and working groups, which have been implemented by the subgroups.
The ongoing review and revision of guidelines and regular internal audits ensure that our management
systems are continuously improved and aligned to the specific requirements at any given time.

56

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

1.6 Value Creation

See Chapter 5 for
more information
about our areas
of activity along
the value chain.

Bayer creates sustainable value in various ways for its stakeholders at all stages of the value chain
(Graphic 3.1.5) by focusing on innovative products and solutions in its core businesses. Moreover, we
operate production sites throughout the world, invest in research and development, work with international and local suppliers and contribute to the economic development of our target markets. As an
employer, we provide jobs in industrialized, emerging and developing economies and create purchasing power through the salaries we pay. We also support public infrastructure through the payment of
taxes and other contributions.

Value Chain Stages

Research,
development
and innovation

[Graphic 3.1.5]

Supply chain

Production

Logistics

Distribution
and
marketing

Use

The value added statement shows Bayerâ€™s direct contribution to public and private incomes and is a
measure of the direct financial value created for stakeholders by its business activities. We define value
added as the companyâ€™s total operating performance in the previous fiscal year less the costs of procured and consumed goods and services, depreciation and amortization.
The total operating performance of the Bayer Group in 2015 was â‚¬47.8 billion. Value added amounted
to â‚¬17.5 billion. Of the value added, â‚¬11.2 billion (64%) was distributed to employees, â‚¬2.1 billion
(12%) to stockholders, â‚¬0.8 billion (4%) to lenders and â‚¬1.5 billion (9%) to governments. The remainder was allocated to reserves.
Bayer Group Value Added 2015

[Graphic 3.1.6]

â‚¬3.3 billion

â‚¬11.2 billion (64%)

Depreciation,
amortization,
impairments

Employees

â‚¬2.1 billion (12%)
Stockholders1

â‚¬47.8 billion

Total operating
performance2

â‚¬17.5 billion
Value added

â‚¬0.8 billion (4%)
Lenders

â‚¬1.5 billion (9%)
â‚¬27.0 billion
Material costs /
Other expenses

1
2

Bayer AG dividend proposal for 2015
Total operating performance = sales + other operating income + financial incomeà¯—/à¯—equity-method income (loss)

Taxes

â‚¬1.9 billion (11%)
Reserves / Other

57

Bayer Annual Report 2015
Combined Management Report
1. Bayer at a Glance

1.7 Corporate Environment
Bayerâ€™s business activities are impacted by economic and social conditions. At the same time, the
company contributes to shaping these conditions.
ECONOMIC ENVIRONMENT
In 2015, the global economy grew at a slightly slower pace than in the previous year. Momentum
decreased in the emerging economies in particular; growth in China declined further but remained
strong while economic output in Russia and Brazil contracted significantly. By contrast, growth in the
European Union accelerated, supported by very low interest rates, an exchange rate favorable to the
eurozone and sinking oil prices. At the same time, the United States continued its robust recovery,
driven above all by private consumption and rising employment.

Economic Environment

[Table 3.1.3]
Growth1
2014

Growth1
2015

World

+ 2.7%

+ 2.5%

European Union

+ 1.4%

+ 1.8%

+ 1.6%

+ 1.5%

United States

+ 2.4%

+ 2.4%

Emerging MarketsÂ²

+ 4.4%

+ 3.7%

of which Germany

2014 figures restated
1 Real GDP growth, source: IHS Global Insight
2 Including about 50 countries defined by Global Insight as Emerging Markets in line with the World Bank
As of February 2016

For more information on the economic environments of our subgroups in 2015, see Chapter 3 â€œEconomic Environments of the Subgroups.â€
SOCIAL ENVIRONMENT
Our economic activity is closely linked with the social environment. Certain stakeholders have become
increasingly significant to our business operations in recent years. Their expectations affect public
acceptance of Bayer and thus our commercial success. They provide important input for the continuing
development of our business processes, risk management and reporting. We therefore take the wideranging requirements of our stakeholders seriously and consider them wherever possible in our
business activities. At the same time, open dialogue with our stakeholders gives us an opportunity to
explain the value of our products and services for society. This is of growing importance for the success
of our business model.

See Chapter 3

GRI
G4-25, G4-26, G4-27

58

Bayer Annual Report 2015
Combined Management Report
2. Strategies of the Segments

GRI
G4-24

Stakeholder Dialogue: Our Most Important Interest Groups

Customers
Suppliers
Employees
Associations
Universitiesà¯—à¯—/à¯—schools

[Graphic 3.1.7]

Financial
market
participants

Partners

Investors
Banks
Rating agencies

BAYER
General public
NGOs
Local communities
Competitors

See Chapter 5

Social
interest
groups

Regulators

Lawmakers
Politicians
Authorities

Read more about Bayerâ€™s commitment to its stakeholders in Chapter 5 â€œSustainability Management and
Governance.â€

2. Strategies of the Segments
See Chapter 1.3
for Bayer Group
strategy

PHARMACEUTICALS
At Pharmaceuticals, our largest division in terms of sales, we focus on researching, developing and
marketing innovative medicines with a positive cost-benefit ratio primarily in the therapeutic areas of
cardiology, oncology, gynecology, hematology and ophthalmology. In this way, we are addressing the
growing requirements of patients, physicians, health care payers and regulatory agencies.
As part of the Bayer Groupâ€™s reorganization, we have dissolved the Medical Care Division and integrated
the Radiology business unit into our Pharmaceuticals Division.
To achieve our medium-term growth targets, we are continuing to rely on marketing our recently
launched products Xareltoâ„¢, Eyleaâ„¢, Stivargaâ„¢, Xofigoâ„¢ and Adempasâ„¢. We plan to steadily expand
the indications for these medicines through comprehensive study programs â€“ some of them in collaboration with other pharmaceutical companies â€“ and thus make them available to further patient groups.

59

Bayer Annual Report 2015
Combined Management Report
2. Strategies of the Segments

To safeguard long-term growth, we will further increase our investment in research and development.
Besides expanding early research, we are concentrating on the clinical development of active drug
substance candidates in the therapeutic areas of cardiology, oncology, hematology and gynecology. In
addition, we are selectively expanding and supplementing our development portfolio through licensing
agreements and acquisitions.
To improve access to our products in developing and emerging countries (Access to Medicine), we
augment our philanthropic activities (see Chapter 11 for more information) with economically feasible
concepts.
online annex: 3-2-1:
As an innovation company, we aim to address current challenges in order to improve peopleâ€™s quality
of life in the areas of disease prevention and therapy. Within the scope of our entrepreneurial possibilities in a dynamic market environment, we seek to make a responsible contribution for the benefit
of society. Through our Access to Medicine (atm) activities, we aim to enable access to our products
for certain patients, aligning these efforts to our companyâ€™s expertise and our specific product portfolio. Here we distinguish between not-for-profit and economically feasible activities. The former include our efforts in respect of neglected tropical diseases (ntds). In this connection, we provide the
who free of charge with two of our active ingredients to treat African sleeping sickness and Chagas
disease. Other activities in this area are our education programs and the development of products to
treat ntds.
Our family planning programs are economically feasible and facilitate improved access to hormonal
contraceptives for women in developing countries. These programs, which are anchored in our business strategy, provide international development partners with our products at preferential prices.
In some countries, where sections of the population have no access to innovative medicines via
health care systems, we have established patient assistance programs for selected products. These
aim particularly to provide access to oncology and cardiovascular products and products to treat
chronic diseases such as multiple sclerosis and hemophilia. Such programs exist in, for example, the
United States and China as well as a number of countries in South and Southeast Asia and Southeastern Europe.
CONSUMER HEALTH
As part of the Bayer Groupâ€™s reorganization, the Consumer Care Division will be renamed Consumer
Health. The strategy of the new Consumer Health Division is aimed at building on our strong position in
the market for over-the-counter (otc) products, nutritional supplements and other self-care products in
selected consumer health categories.
We aim to strengthen our established brands, such as Aspirinâ„¢, Aleveâ„¢, Bepanthenâ„¢, Beroccaâ„¢,
Canestenâ„¢, Claritinâ„¢, Coppertoneâ„¢, Dr. Schollâ€™sâ„¢, Elevitâ„¢, MiraLAXâ„¢ and Supradynâ„¢, by driving
organic growth through product innovation and geographical expansion. We are also seeking to expand
our position in important markets such as the United States, Brazil, Russia and China.
Alongside the ongoing integration of the consumer care businesses acquired in 2014 from Merck & Co.,
Inc., United States, and Dihon Pharmaceutical Group Co. Ltd., China, we continue to pursue external
growth opportunities arising from the progressive global consolidation of the otc industry. In this way,
we aim to further expand in selected categories and markets where it makes strategic sense to do so
and can contribute to increasing Bayerâ€™s enterprise value.

www.bayer.com/atm

60

Bayer Annual Report 2015
Combined Management Report
2. Strategies of the Segments

CROP SCIENCE
We are aligning our Crop Science business to the long-term trends of the agricultural markets, from
which we have derived three focuses for our strategy:
â€¢ Improvement in agricultural sustainability â€“ in other words the most responsible possible deployment of our resources
â€¢ Increase in agricultural productivity through innovation â€“ in other words higher crop yields and
quality
â€¢ Full leveraging of digitization opportunities to help farmers make the right decisions and to make
product applications even safer
Our aim is to help shape the future of the agricultural industry with innovative offerings that increase its
productivity, thus generating profitable and sustainable growth for Crop Science and our customers and
enabling the production of sufficient food, animal feed and renewable raw materials for a growing world
population despite the limited amount of available arable land. Crop Scienceâ€™s strategy is built on four
key elements:
â€¢
â€¢
â€¢
â€¢

Enhancing the Crop Protection and Environmental Science portfolio
Expanding the Seeds business
Increasing customer centricity along the entire value chain
Leading the way in innovation

We aim to enhance our Crop Protection and Environmental Science portfolios by adding new and improved products, concentrating on core brands and offering integrated solutions in major crops. Support for this endeavor is provided by our innovative technology platform for both chemical and biological crop protection. We are continuously investing in the expansion of our production capacities to meet
rising demand for our products.
We continue to work on the expansion of our Seeds business. We plan to further strengthen our positions in our established crops â€“ cotton, oilseed rape / canola, rice and vegetables â€“ and to establish competitive positions in soybeans and wheat. We intend to gain long-term access to high-quality breeding
material through acquisitions, in-licensing and partnerships and to steadily expand our existing breeding expertise.
Another major part of our strategy is to strengthen customer centricity along the entire value chain and
continuously optimize distribution. We are steadily expanding our successful food chain partnerships.
In these projects, Crop Science works with all participants in the food chain to safeguard and increase
yields, and to improve the quality of harvested produce. With the Bayer Forward Farming initiative,
Crop Science cooperates with farmers to demonstrate innovative crop solutions and services for sustainable agriculture to interested stakeholders. Crop Science will also increasingly concentrate on developing solutions especially tailored to help smallholder farmers increase their profitability while ensuring environmentally friendly cultivation, thus lastingly improving their standard of living.
To lead the way in innovation and develop holistic solutions, we aim to build on our expertise in the
integration of seed technology with chemical and biological crop protection and to support our customers with new and improved solutions. New areas of innovation, such as digitization in agriculture, account for another major part of this. We intend to support this development in the future by making use
of proprietary digital platforms and data models that can enable us to give farmers special agronomic
recommendations. The aim here is to make agriculture more sustainable.

61

Bayer Annual Report 2015
Combined Management Report
2. Strategies of the Segments

ANIMAL HEALTH
Our Animal Health business aims to strengthen its position in the already heavily consolidated market
for veterinary medicines. Here we rely on organic growth through the expansion of our r&d activities
and the increased use of our existing distribution channels, particularly specialist retail chains. We also
intend to strengthen our position with targeted in-licensing and acquisitions.
COVESTRO
As a global supplier of high-tech polymer materials and application solutions for many areas of modern
life, Covestro aims to generate profitable growth in the long term. Over the coming five years, the company aims to build on its leading positions in its industry sectors and participate in the growth that
experts are predicting for its customer industries. Covestro supplies key industry sectors worldwide
such as the automotive, construction and electronics industries. It develops and manufactures components for polyurethane foams, the high-tech plastic polycarbonate and raw materials for coatings, adhesives and sealants, as well as specialty products such as films and elastomers.
Growth impetus is expected to come from macro trends such as climate change, the diminishing availability of fossil resources, the expanding global population, urbanization and increasing mobility.
Through its products, Covestro aims to help master these challenges in line with its vision â€œTo make the
world a brighter place.â€ In keeping with this, the companyâ€™s activities are embedded in a comprehensive sustainability strategy.
Covestroâ€™s large-scale facilities around the world have been extended and are capable of serving the
anticipated growth in demand. Therefore, the company does not predict any greater need for expansion
in the foreseeable future.
At the same time, Covestro intends to further optimize its network of sites and its cost structures. To this
end, the company has initiated a structured profitability program.
Covestro is focusing on continuous product and process innovation as a means of safeguarding and
building its competitive position in the global marketplace. Research and development is steered by
targets aligned to the needs of the companyâ€™s customer industries.
The Polyurethanes (pur) business unit intends to further expand its strong position as an integrated
raw material and systems supplier, mainly for rigid and flexible foams. While flexible foam ensures
added comfort in everyday life through its use in products such as mattresses and upholstery, rigid foam
serves above all as an insulating material for buildings and refrigerated appliances, and thus helps to
lower energy consumption and greenhouse gas emissions.
In the automotive, electronics and construction sectors, in particular, rising demand is anticipated for
polycarbonate, an engineering thermoplastic characterized by positive properties such as low weight,
transparency, stability and design flexibility. The Polycarbonates (pcs) business unit aims to further
strengthen its technological leadership and is focusing on, for example, polycarbonate-based composite
materials as a low-cost substitute for solutions based on glass and metal.
The Coatings, Adhesives, Specialties (cas) business unit develops and manufactures mainly polyurethane-based raw materials primarily for coatings and adhesives. The main areas of application are automotive and transportation, infrastructure and construction, wood processing and furniture. The business unit aims to secure and build its position in its core business and to achieve accelerated growth in
specialties.

Covestro
helps to address
global challenges

62

Bayer Annual Report 2015
Combined Management Report
3. Economic Environments of the Subgroups

3. Economic Environments of the Subgroups
See Chapter 1.7
for corporate
environment

The economic environments in which the subgroups operated are outlined below.

Economic Environments of the Subgroups

[Table 3.3.1]
Growth 1
2014

Growth 1
2015

Pharmaceuticals market

+ 9%

+ 9%

Consumer care market

+ 4%

+ 5%

Medical care market 2

â€“ 1%

+ 1%

Animal health market

+ 5%

+ 5%

+ 7%

Å¯ 0%

Automotive

+ 3%

+ 2%

Construction

+ 3%

+ 2%

Electrical / electronics

+ 4%

+ 3%

Furniture

+ 4%

+ 4%

HealthCare

CropScience
Seed and crop protection market
Covestro
(main customer industries)

2014 figures restated
1 Bayerâ€™s estimate, except pharmaceuticals. Source for pharmaceuticals market: IMS Health., IMS Market Prognosis.
Copyright 2015. All rights reserved, currency-adjusted
2 Excluding the diabetes care market
As of February 2015

HEALTHCARE
Growth in the pharmaceuticals market in 2015 was flat with the prior year. In the United States in
particular, new products especially continued to drive ongoing growth. In Japan and Europe, growth
rates increased slightly, whereas demand in the emerging markets was unchanged against the previous
year.
The global consumer care market saw somewhat stronger growth than a year earlier. In the medical
care category, slight growth was seen in the market for contrast agents and medical equipment. The
animal health market expanded at the same rate as in the prior year.
CROPSCIENCE
Overall, the global seed and crop protection market receded in 2015. While the demand for high-value
seeds remained at the previous yearâ€™s level, worldwide crop protection sales declined.
Market volumes decreased in Latin America, particularly in Argentina and Brazil, primarily as a result of
political uncertainties, macroeconomic developments and lower pest pressure. The market also declined
in North America, mainly due to a reduction in corn and cotton acreages and because of lower overall
price levels for agricultural commodities than in the previous year. Positive growth impetus for the seed
and crop protection market in 2015 came from the Asia / Pacific and Europe regions. Growth rates in the
Mediterranean area were above average.
COVESTRO
Growth in the principal customer industries for Covestro (automotive, construction, electrical / electronics and furniture) in 2015 was slightly weaker than in the previous year. One of the main reasons for this
was slower demand in China and other emerging economies, which could not be compensated by positive stimuli such as the expansionary monetary policy of the industrialized countries and the lower oil
price.

63

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

4. Research, Development, Innovation
Scientifically founded innovations and the skills of our employees form the basis for our success as a
company. To drive innovation in the future as well, we continuously develop new molecules, technologies and business models in the research-intensive fields of medicine and modern agriculture, invest in
research and development projects and expand our activities through targeted acquisitions and collaborations with external partners (open innovation). We plan to invest around â‚¬4.5 billion in research and
development in 2016 alone. We also promote our culture of innovation in all areas of the company to
face the challenges of our time and safeguard profitable growth for our company.

Group target 2015:
increase in R&D
investment to over
â‚¬4 billion

See also Chapter
1.4 for Group
targets

Bayer maintains a global network of research and development locations in which 14,673 researchers
around the world focus on improving the health of people, animals and plants. The focuses of the research projects are determined by the r&d strategies of the subgroups. On this basis, projects are set up
that are managed in the development pipeline through defined processes and targets. The budgets
requested for this purpose are checked annually and allocated per area. In 2015, we raised our research
and development spend by 15.9% (Fx adj.) to â‚¬4,281 million. Adjusted for special items of â‚¬67 million
(2014: â‚¬2 million), this represented a 14.1% increase (Fx adj.) and was equivalent to 9.1% of sales. The
following table shows the development of r&d key data in the individual segments:

Research and Development Expenses Full Year 2015

Research and
development
expenses

[Table 3.4.1]

Research and
development
expenses before
special items

2014

2015

2014

2015

Share of R&D
expenses
2014

2015

R&D expenses
before
special items / sales
2014

2015

R&D employees
2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

%

%

%

%

FTE

FTE

HealthCare

2,264

2,834

2,260

2,768

64.0

66.2

11.8

12.1

7,968

8,594

Pharmaceuticals

1,878

2,333

1,876

2,285

53.1

54.5

15.6

16.6

7,066

7,741

Consumer
Health

386

501

384

483

10.9

11.7

5.5

5.3

902

853

CropScience

974

1,089

974

1,089

27.5

25.4

10.3

10.5

5,004

5,073

Covestro
Group 1

210

262

213

261

5.9

6.1

1.8

2.2

923

1,005

3,537

4,281

3,535

4,214

.

.

8.6

9.1

13,900

14,673

2014 figures restated
1 Sum of the segments plus reconciliation

We augment our own research capacities through collaborations and strategic alliances with industrial
and academic research partners around the world. These include leading universities, public research
institutes, partner and start-up companies, and science and innovation centers established by Bayer to
give young companies access to features such as suitable laboratory and office infrastructure in the
direct vicinity of Bayerâ€™s own research facilities. These are supplemented by our crowdsourcing platforms through which researchers around the world can offer their expertise for collaboration with
Bayer. With the newly established strategic innovation unit, the Bayer LifeScience Center (blsc), we
additionally want to drive the development of decisive interspecies research with the aid of a network of
external partnerships. On the initiative of blsc we signed an agreement at the end of 2015 with the
biotech company crispr Therapeutics AG based in Basel, Switzerland, with the goal of discovering,
developing and marketing new treatment methods for blood disorders, blindness and heart disease
based on the crispr-Cas9 technology for gene editing.
We also invest in venture capital funds that finance promising Life Science start-up companies, among
other projects. In this way we support the development of new therapies in areas with a high unmet
medical need and drive innovation in the Life Sciences.

More information
on this can be
found in the
sections for the
individual
subgroups.

64

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

GRI
G4-26

online annex: 3-4-1
Scientists from our company are involved in constant dialogue with renowned research institutes and
support partnership projects in the public and private sectors. Of these, more than 50 projects
worldwide were supported in 2015 by public funding worth around â‚¬5 million. This is equivalent to
roughly 0.1% of our annual r&d expenses.
We also participate in industry associations, hold professorships at universities worldwide and regularly invite scientists, university students and schoolchildren to attend events such as symposiums on
health topics or research days for school students. We view this as an investment in the future, because as a research-based company, we rely on the availability of talented and highly trained people
and on societyâ€™s acceptance of technology.
We promote our innovation capability not just by increasing our research and development budget and
expanding external collaborations, but also by strengthening our internal innovation culture, which
promotes fascination, creativity, willingness to experiment, customer centricity and cooperation among
all disciplines. In this connection, we have launched a number of programs and initiatives in recent
years to honor the achievements of our scientists and provide them with suitable platforms and projects
for scientific discourse and cross-subgroup cooperation in scientific matters, as well as to give employees throughout all organizational units the opportunity to help jointly generate ideas or solve problems.
online annex: 3-4-2
The following table lists the most important programs/initiatives for strengthening the innovation culture at Bayer:

Programs / Initiatives for Strengthening Bayerâ€™s Innovation Culture

[Table 3.4.1-1]

Program

Objective

Approach

Life Sciences Fund

Strengthen
interdisciplinary research
in the Life Sciences

Since 2012, supports scientists at HealthCare and
CropScience involved in interdisciplinary projects aimed at
achieving a better understanding of diseases, identifying
mechanisms of action, individualizing therapies or
explaining resistance mechanisms

Expert Career

Strengthen recognition
for scientific success

Initiative by the Board member responsible for Innovation
aimed at fostering the cross-company scientific exchange
between leading experts in research and development

Otto Bayer Medals

Awards for scientific
success

Research prize for outstanding development work that is
awarded biennially to teams of Bayer scientists

Hype

Collaborative definition
of ideas in information
technology

Intranet-based platform for the collaborative generation of
ideas by our employees; the most promising ideas are
allocated an initial budget which is used by an
interdisciplinary team to elaborate the concept within just a
few weeks.

WeSolve

Collaborative problemsolving

Current problems in research and development, marketing
and production are publicized via the internal WeSolve
platform for discussion by employees from all subgroups and
service companies; the best solutions are then identified.

Bayer Ideas Pool
employee suggestion
program and Ideas Forum

Promotion of innovative
ideas from the working
environment

Application and honoring of employee suggestions for the
improvement of processes, occupational safety and health
protection. In total, 5,446 ideas were submitted in 2015.
Around 46% of the suggestions for improvement evaluated
in 2015 were implemented. In the first year of
implementation alone, more than â‚¬9 million was saved
through those improvements that allowed calculation. In
2015, Bayer distributed bonuses of around â‚¬2 million to
employees for the implemented proposals.

65

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

Globally reliable protection of intellectual property rights is essential for an innovation company like
Bayer. The Bayer Group endeavors to obtain patent protection for its products and technologies in the
major markets. The degree of protection a patent provides varies from one country to another and depends on the type and scope of the patent claim and the options available for enforcing our rights. At
the end of 2015, we owned approximately 66,700 valid patent applications and patents worldwide relating to some 7,200 protected inventions.
online annex: 3-4-3
Patent terms vary according to the laws of the country granting the patent. In view of the high investment required for product research and development, the European Union member states, the
United States, Japan and some other countries extend patent terms or issue supplementary protection certificates to compensate for the shortening of the effective patent protection period due to
regulatory approval processes for new drugs. We endeavor to obtain such extensions wherever possible.
The term of a patent is normally 20 years. Since it takes an average of 12 years to develop a new
medicine, for example, only eight years of patent protection generally remain following the productâ€™s
approval. In most cases it would be impossible to cover the substantial costs incurred in the research
and development of innovative medicines or of new indications or dosage forms for existing drugs
without patent protection. We are therefore committed to protecting both the international patent
system and our own intellectual property worldwide. Further details are given in the political positions posted on our website.

4.1 HealthCare
PHARMACEUTICALS
Research areas and sites
Drug discovery in the Pharmaceuticals segment focuses on indications with high medical need in the
areas of cardiology, oncology, ophthalmology, hematology and gynecology. We conduct research and
development activities at several locations, the most important of which are as follows:

Research and Development Sites

[Table 3.4.2]

Site

Country

Berlin

Germany

Focus
R&D in oncology, gynecology and non-indication-specific areas

Wuppertal

Germany

R&D in cardiology, ophthalmology and non-indication-specific areas

Mission Bay, San Francisco

U.S.A.

Research in the areas of hematology and biologicals

Berkeley

U.S.A.

Development in the areas of hematology and biologicals

Turku

Finland

Development of hormone-releasing intrauterine devices and implants
for contraception

Oslo

Norway

Research on thorium conjugates for the treatment of cancer

Cooperation
We augment our own research capacities through collaborations and strategic alliances with external
industrial and academic research partners. In this way we gain access to complementary technologies
and external innovation potential. A number of examples are listed in the table on the following pages:

www.bayer.com/
political-position-ip

66

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

Pharmaceuticals Cooperation Partners

Partner

[Table 3.4.3]

Cooperation objective

Cardiology
Broad Institute

Strategic partnership in the field of genome and drug research in cardiology
aimed at using findings from human genetics to develop new cardiovascular
therapies

Ionis Pharmaceuticals, Inc.

Development of an antisense molecule for the prevention of thrombosis

Janssen Research & Development,
LLC of Johnson & Johnson

Development of Xareltoâ„¢ (rivaroxaban)

Ludwig Boltzmann Institute

Research into lung vascular disease, especially pulmonary hypertension

Merck & Co., Inc.

Development collaboration in the field of soluble guanylate cyclase (sGC)
modulation

Oncology
Amgen Research GmbH

Access to BiTEâ„¢ antibodies for developing novel tumor therapies

Ardea Biosciences Inc. of Astra Zeneca

Codevelopment of oncology products based on MEK
(mitogen-activated ERK kinase) inhibitors

Broad Institute

Strategic partnership in oncology to discover and develop active substances
that specifically target tumor-specific gene mutations

Compugen Ltd.

Collaboration for the research and development of new immunotherapy
approaches in oncology

German Cancer Research Center

Strategic partnership for the research and development of new therapeutic
options in oncology, especially in immunotherapy

Dyax Corp.

Access to antibody library with the option to in-license antibodies for the
development and commercialization of novel tumor therapies

ImmunoGen Inc.

Development of antibody-drug conjugates (ADCs) for novel tumor therapies

OncoMed Pharmaceuticals Inc.1

Discovery and development of novel therapeutics relating to cancer stem cells

Onyx Pharmaceuticals Inc. of Amgen Inc.

Codevelopment of Nexavarâ„¢ (sorafenib) for various types of cancer

Orion Corporation

Development of ODM-201 for the treatment of patients with prostate cancer

Qiagen Manchester Ltd.

Development of diagnostic tests in personalized oncology treatment

Seattle Genetics Inc.

Access to technology for antibody-drug conjugates (ADCs) for novel tumor
therapies

Sprint Bioscience

Research and development of oncological drug candidates

Ophthalmology
Inception 4, Inc.

Research into new approaches for the treatment of various eye diseases

Johns Hopkins University

Research and development of innovative drug products to treat serious backof-the-eye diseases

Regeneron Pharmaceuticals Inc.

Development of Eyleaâ„¢ (aflibercept) to treat various eye diseases
Development of a PDGFR-beta antibody for ophthalmology

Hemophilia
Dimension Therapeutics, Inc.

Development of a novel gene therapy for hemophilia A

Gynecology
Evotec AG

Research collaboration to identify and validate development candidates in
endometriosis

University of Oxford

Strategic research alliance for the development of novel gynecological
therapies

Infectious diseases
Merck & Co., Inc.

Codevelopment of tedizolid to treat various infections

Novartis AG

Development of a targeted antibiotic inhalation therapy for lung infections
(ciprofloxacin DPI)

Nektar Therapeutics

Codevelopment of a targeted antibiotic inhalation therapy for lung infections
(amikacin inhale)

General
BioInvent International AB

Access to antibody library with in-licensing of antibodies

Peking University

Research cooperation and establishment of a research center for joint projects

Tsinghua University

Research cooperation and establishment of a research center for joint projects

1

Bayer is not active in the area of human embryonic stem cell research.

67

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

We also operate our own science and innovation centers. We coordinate primarily our research partnerships in Asia through our science hubs in Beijing, China; Singapore; and Osaka, Japan. In Berlin, Germany, and San Francisco, California, United States, we operate the â€œCoLaboratorâ„¢,â€ an incubator model
for young life science companies. The objective of the global CoLaboratorâ„¢ concept is to offer these
companies suitable laboratory and office infrastructure in the direct vicinity of Bayerâ€™s own research
facilities. In the area of crowdsourcing, we are very successfully continuing our â€œGrants4Targetsâ„¢â€
program. We supplemented â€œGrants4Leadsâ„¢,â€ which concentrates on small molecules, with â€œPartnerYourAntibodiesâ„¢,â€ a program that focuses on the evaluation of biological actives. Furthermore, the
â€œGrants4Appsâ„¢ Accelerator Programâ€ offers mentoring to start-up companies that can offer innovative
solutions relevant to health care and therapy. In the area of venture capital, we are active with the
â€œHigh-Tech GrÃ¼nderfondsâ€ and Versant Ventures.
Clinical trials
Clinical trials account for a major portion of the development process for medicines. They are an essential tool for determining the efficacy and compatibility of new developmental products before they can
be used to treat diseases. The benefits and potential risks of new medicines must always be scientifically proven and well documented. All studies at Bayer satisfy strict international guidelines and quality
standards, as well as the respective applicable national laws and standards.
online annex: 3-4.1-1
Bayer publishes information about clinical trials in line with the respective applicable national laws
and according to the principles of the European (efpia) and North American (PhRMA) pharmaceutical associations, these principles being defined in a joint position paper.
HealthCare publishes information on its own clinical trials both in the publicly accessible register
www.ClinicalTrials.gov and in its own â€œTrial Finderâ€ database. In the case of approved products,
summarized results of Phase ii, iii and iv clinical trials are accessible online through the â€œTrial
Finder.â€ Upon request, scientists can receive access to anonymized data at the patient level via the
portal www.clinicalstudydatarequest.com.
Further information on our globally uniform standards, the monitoring of studies and the role of the
ethics committees can be found on the internet.
Activities in 2015
In line with our targets for 2015 we transferred 12 new molecular entities from our research pipeline
into preclinical development in the reporting year. We define a new molecular entity (nme) as a new
chemical or biological substance that has not been in development to date. In preclinical trials these
substances are examined further in various models with respect to their suitability for clinical trials and
linked â€œfirst-in-manâ€ studies. In 2015, we conducted clinical trials with several drug candidates from our
research and development pipeline. We strengthened products that were already on the market through
life cycle management activities to improve their application and / or expand their spectrum of indications.

www.bayer.com/
ethics-in-rnd

Group target 2015:
HealthCare â€“
transition of more than
10 new molecular
entities (NMEs) into
development

More details on
our drug candidates
can be found in
Table 3.4.6

68

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

We are investigating some of our development candidates with respect to their potential for the treatment of rare diseases, also known as orphan diseases. In February 2015, copanlisib received orphan
drug designation from the u.s. Food and Drug Administration (fda) for the treatment of follicular lymphoma, a histological subtype of non-Hodgkin lymphoma.
The following tables show our most important drug candidates currently in Phase ii or iii of clinical
testing:

Research and Development Projects (Phase II) 1

Phase II projects

Indication

Anetumab ravtansine (mesothelin ADC)

Cancer

BAY 1067197
(partial adenosine A1 agonist)

Heart failure

BAY 1007626 (progestin IUS)

Contraception

BAY 1142524 (chymase inhibitor)

Heart failure

BAY 2306001 (IONIS-FXIRx)

Prevention of thrombosis 2

BAY 98-7196 + anastrozole
(intravaginal ring)

Endometriosis

Copanlisib (PI3K inhibitor)

Recurrent / resistant non-Hodgkin lymphoma (NHL)

Molidustat (HIF-PH inhibitor)

Renal anemia

PDGFR-beta + aflibercept

Wet age-related macular degeneration3

Radium-223 dichloride

Bone metastases in breast cancer

Radium-223 dichloride

Cancer, various studies

Refametinib (MEK inhibitor)

Cancer

Regorafenib

Cancer

Riociguat

Pulmonary hypertension (IIP)

Riociguat

Diffuse systemic sclerosis

Riociguat

Cystic fibrosis

Rivaroxaban

Secondary prevention of acute coronary syndrome (ACS) 4

Roniciclib (CDK inhibitor)

Small-cell lung cancer (SCLC)

Vericiguat
(BAY 1021189, sGC stimulator)

Chronic heart failure

Vilaprisan (S-PRM)

Symptomatic uterine fibroids

Vilaprisan (S-PRM)

Endometriosis

1

[Table 3.4.4]

As of January 27, 2016
2 Sponsored by Ionis Pharmaceuticals, Inc.
3 Sponsored by Regeneron Pharmaceuticals, Inc.
4 Sponsored by Janssen Research & Development, LLC
The nature of drug discovery and development is such that not all compounds can be expected to meet the predefined project goals. It is possible
that any or all of the projects listed above may have to be discontinued due to scientific and / or commercial reasons and will not result in
commercialized products. It is also possible that the requisite Food and Drug Administration (FDA), European Medicines Agency (EMA) or other
regulatory approvals will not be granted for these compounds.

69

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

Research and Development Projects (Phase III) 1

Phase III projects

[Table 3.4.5]

Indication

Amikacin Inhale

Pulmonary infection

BAY 1841788 (ODM-201, AR antagonist)

Prostate cancer

Damoctocog alfa pegol
(BAY 94-9027, long-acting rFVIII)

Hemophilia A

Ciprofloxacin DPI

Pulmonary infection

Copanlisib (PI3K inhibitor)

Various forms of non-Hodgkin lymphoma (NHL)

Finerenone (MR antagonist)

Chronic heart failure

Finerenone (MR antagonist)

Diabetic kidney disease

Radium-223 dichloride

Combination treatment of castration-resistant prostate cancer

Regorafenib

Refractory liver cancer

Riociguat

Pulmonary arterial hypertension (PAH) in patients who do not sufficiently
respond to PDE-5i / ERA

Rivaroxaban

Prevention of major adverse cardiac events (MACE)

Rivaroxaban

Anticoagulation in patients with chronic heart failure 2

Rivaroxaban

Long-term prevention of venous thromboembolism

Rivaroxaban

Prevention of venous thromboembolism in high-risk patients after discharge
from hospital 2

Rivaroxaban

Embolic stroke of undetermined source (ESUS)

Rivaroxaban

Peripheral artery disease (PAD)

Tedizolid

Pulmonary infection

1

As of January 27, 2016
by Janssen Research & Development, LLC
The nature of drug discovery and development is such that not all compounds can be expected to meet the predefined project goals. It is possible
that any or all of the projects listed above may have to be discontinued due to scientific and / or commercial reasons and will not result in
commercialized products. It is also possible that the requisite Food and Drug Administration (FDA), European Medicines Agency (EMA) or other
regulatory approvals will not be granted for these compounds.
2 Sponsored

We regularly evaluate our research and development pipeline in order to prioritize the most promising
pharmaceutical projects.
Following the completion of the required studies with a number of these drug candidates, we submitted
applications to one or more regulatory agencies for approvals or approval expansions.
The most important drug candidates in the approval process are:

Products Submitted for Approval 1

[Table 3.4.6]

Indication
Bay 81-8973 (rFVIII)

E.U., U.S.A., Japan; treatment of hemophilia A

LCS-16 (ULD LNG Contraceptive System)

E.U., U.S.A.; contraception

Radium-223 dichloride

Japan; treatment of prostate cancer patients with bone metastases

Rivaroxaban2

U.S.A.; secondary prophylaxis of acute coronary syndrome (ACS)

1

As of February 4, 2016
2 Submitted by Janssen Research & Development, LLC

70

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

In 2015, we achieved further progress in various therapeutic areas:
Cardiology
Xareltoâ„¢ (active ingredient: rivaroxaban) has been approved for more indications in the area of venous
and arterial thromboembolism than any of the other non-vitamin-K-dependent oral anticoagulants.
Xareltoâ„¢ is approved in more than 130 countries worldwide across all indications, its approval status
varying from country to country. Xareltoâ„¢ is marketed in the United States by Janssen Pharmaceuticals,
Inc., a subsidiary of Johnson & Johnson.
In May 2015, Xareltoâ„¢ was approved by the China Food and Drug Administration (cfda) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation and for the treatment
of deep vein thrombosis (dvt). The approval also includes the use of Xareltoâ„¢ to reduce the risk of
recurrent dvt and pulmonary embolism following acute dvt. In September 2015, Xareltoâ„¢ was approved by the Japanese Ministry of Health, Labour and Welfare (mhlw) for the treatment and secondary
prevention of pulmonary thromboembolism and deep vein thrombosis.
In addition to the already approved indications, the use of rivaroxaban is also being investigated in
other cardiovascular diseases such as prevention of major adverse cardiac events, embolic stroke of
undetermined source or peripheral artery disease.
Rivaroxaban was invented by Bayer and is being jointly developed with Janssen Research & Development, llc, United States, a subsidiary of Johnson & Johnson.
Adempasâ„¢ (active ingredient: riociguat) is the first member of a new class of vasodilation agents
known as soluble guanylate cyclase (sGC) modulators. Administered in tablet form, riociguat is currently being investigated as an innovative, specific approach for the treatment of various forms of pulmonary hypertension.
Adempasâ„¢ is approved in the United States and Europe for the treatment of particular forms of chronic
thromboembolic pulmonary hypertension (cteph) and pulmonary arterial hypertension (pah). In Japan,
Bayer was granted marketing authorization for cteph in 2014 and for pah in February 2015.
The trial program for riociguat also includes studies outside of the pulmonary hypertension indication.
For example, riociguat is also in Phase ii testing for the treatment of patients with diffuse systemic
sclerosis.
Another representative of the sGC modulator class is vericiguat, currently in Phase IIb clinical testing to
treat chronic heart failure.
The development and commercialization of sGC modulators is part of our strategic collaboration with
Merck & Co., Inc., United States.
The active ingredient finerenone (bay 94-8862) is a novel oral nonsteroidal mineralcorticoid receptor
antagonist (mra) that is currently in Phase iii clinical development. In September 2015, two Phase iii
trials were initiated to investigate the efficacy and safety of finerenone in patients with diabetic kidney
disease. Another Phase iii trial is being prepared in the indication chronic heart failure.
The development candidate molidustat is being investigated for the treatment of patients with anemia
accompanied by chronic kidney disease and / or end-stage kidney failure.

71

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

In March 2015, we expanded our partnership with the Broad Institute at the Massachusetts Institute of
Technology (mit) and Harvard University, United States, to include collaboration on cardiovascular
genomics and drug discovery.
In April 2015, furthermore, we entered into an exclusive license agreement with Ionis Pharmaceuticals,
Inc., United States, pertaining to ionis-FXIRx (bay 2306001), an antisense drug in clinical development
for the prevention of thrombosis. Under the agreement, Bayer will further develop and commercialize
bay 2306001 in areas of high medical need. Antisense drugs bind to the mRNA molecules in the cell in
a targeted way and inhibit the production of proteins that may become significant in the course of a
disease. The novel mechanism of inhibiting Factor xi synthesis may offer an additional treatment option
for patients for whom none is currently available.
Oncology
Stivargaâ„¢ (active ingredient: regorafenib) is an oral multikinase inhibitor. It inhibits various signal
pathways that are responsible for tumor growth. Stivargaâ„¢ is approved in the United States, Europe,
Japan and other countries for the treatment of patients with metastatic colorectal cancer (mCRC) and
gastrointestinal stromal tumors (gist).
In March 2015, we suspended enrollment in a Phase iii trial with regorafenib due to insufficient patient
recruitment at that time. The trial is investigating regorafenib as an adjuvant treatment option for patients with colorectal cancer following resection of liver metastases with curative intent. The results of a
further Phase iii trial with regorafenib as a second-line treatment for liver cancer are expected in 2016.
Stivargaâ„¢ was developed by Bayer. In 2011, Bayer and Onyx Pharmaceuticals, Inc., a subsidiary of
Amgen Inc., United States, agreed that Onyx would receive royalties on global sales of Stivargaâ„¢ in the
area of cancer treatment.
Xofigoâ„¢ (active ingredient: radium-223 dichloride) is approved in the e.u. and the United States for the
treatment of adult patients with castration-resistant prostate cancer (crpc) with symptomatic bone metastases but no known visceral metastases. In April 2015, we submitted an application to the Japanese
health authority mhlw for marketing authorization for radium-223 dichloride for the treatment of prostate carcinoma with bone metastases. The active ingredient is being investigated in additional trials in
prostate cancer and in Phase ii trials involving breast cancer patients.
The active ingredient copanlisib is a novel, intravenous phosphatidylinositol 3-kinase (pi3k) inhibitor. In
2015, we expanded our global clinical development program. A new Phase ii and two Phase iii trials are
designed to investigate the safety and efficacy of copanlisib in patients with recurring indolent nonHodgkin lymphoma (nhl) and diffuse large b-cell lymphomas (dlbcl), an aggressive subtype of nhl.
Another active ingredient, bay-1841788 (odm-201), is being jointly developed with Orion Corporation,
Espoo, Finland. This novel oral androgen receptor inhibitor is in Phase iii clinical development for the
treatment of patients with prostate cancer.
In July 2015, we entered into a collaboration and license agreement with Sprint Bioscience ab, Sweden,
for the research, development and commercialization of oncological drug candidates. Under the agreement, we will receive the license for a research program currently undergoing preclinical development
that is geared toward the inhibition of tumor cell metabolism.

72

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

Ophthalmology
Eyleaâ„¢ (active ingredient: aflibercept) is our joint development project with Regeneron Pharmaceuticals, Inc., United States. Aflibercept blocks the natural growth factor vegf (vascular endothelial growth
factor), thus preventing the abnormal formation of new blood vessels that tend to leak fluid. The medication is administered directly into the eye. Regeneron Pharmaceuticals, Inc., United States, holds exclusive rights to the product in the United States, while in other countries it is marketed by Bayer.
Eyleaâ„¢ is approved for the treatment of wet age-related macular degeneration (amd), visual impairment
due to macular edema secondary to central retinal vein occlusion (crvo) and diabetic macular edema
(dme). In Japan, Eyleaâ„¢ is additionally approved for the treatment of myopic choroidal neovascularization (mCNV).
In February 2015, the European Commission extended marketing authorization for Eyleaâ„¢ to include
the treatment of patients with visual impairment due to macular edema secondary to branch retinal vein
occlusion (brvo). Eyleaâ„¢ therefore can be used in Europe by all patients with visual impairment due to
macular edema resulting from retinal vein occlusion (rvo). In June 2015, the product was approved in
this indication in Japan. In October 2015, Eyleaâ„¢ was approved by the European Commission for the
treatment of myopic choroidal neovascularization (mCNV).
A Phase IIa clinical study with regorafenib eye drops did not show the desired results and the project is
therefore being discontinued. The study investigated the use of regorafenib for the treatment of wet
age-related macular degeneration (amd).
In June 2015, we entered into a strategic research alliance with Johns Hopkins University, United States,
concerning the discovery and development of innovative drugs for the treatment of serious back-of-theeye diseases that affect many people worldwide. The five-year collaboration will aim to develop new
ophthalmic therapies for various retinal diseases.
Hematology
In June 2015, we submitted an application to the Japanese mhlw for marketing authorization for the
recombinant Factor viii compound bay 81-8973 for the treatment of hemophilia A. The approval process has been under way in the United States and Europe since the end of 2014. In December 2015,
the European Committee for Medicinal Products for Human Use (chmp) recommended approval. bay
81-8973 is a further development of recombinant Factor viii (rFVIII) which has demonstrated clinical
evidence of efficacy when used for prophylaxis twice or three times per week, with standard dosages.
Damoctocog alfa pegol (bay 94-9027) is a long-acting recombinant Factor viii that is currently in Phase
iii clinical development.
Gynecology
Vilaprisan (sPRM) is a novel oral progesterone receptor modulator that is currently being investigated in
Phase ii trials for the treatment of uterine fibroids and endometriosis. In June 2015, an additional Phase
ii trial began that is investigating the efficacy of vilaprisan compared with its major competitor product.
In November 2015, we filed for marketing authorization for the new intrauterine system (ius) lcs-16 in
the European Union and the United States. This low-dose, levonorgestrel-releasing product enables
contraception for a period of up to five years.

73

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

CONSUMER HEALTH
Research and development at Consumer Health is performed essentially at the following sites:

Research and Development Sites

Site

[Table 3.4.7]

Country

Focus

Morristown

U.S.A.

Allergy, analgesic, cough & cold and dermatological products

Memphis

U.S.A.

Suncare, footcare and dermatological products; consumer research
testing center

Gaillard

France

Nutritional supplements, dermatological and gastrointestinal
products

Darmstadt

Germany

Herbal medicines

Chengdu

China

Over-the-counter (OTC) products and herb-based traditional
Chinese medicines (TCM)

Consumer Care

Medical Care (Radiology)
Pittsburgh

U.S.A.

Medical devices, sterile disposables, informatics

Berlin

Germany

Contrast agents

Monheim

Germany

Antiparasiticides, anti-infectives and pharmaceuticals

Shawnee

U.S.A.

Antiparasiticides, anti-infectives and pharmaceuticals

Auckland

New Zealand

Dairy cattle health

SÃ£o Paulo

Brazil

Antiparasiticides

Animal Health

In Consumer Care, research and development activities focus on the development of nonprescription
(over-the-counter = otc) medications as well as skin and foot care products, sunscreens, dietary supplements and other self-medication products. Placing the consumer at the center of everything we do,
our development strategies are geared toward expanding and improving our brand portfolio. We want
to achieve this through new product developments, forms, formulations, claims, pack designs and other
innovations. We introduced a number of new product line extensions to various markets in 2015. They
included new delivery forms and uses and innovations for existing brands such as Aspirinâ„¢, Elevitâ„¢,
Beroccaâ„¢, Canestenâ„¢, Bepanthenâ„¢ / Bepantholâ„¢ and Coppertoneâ„¢. We also actively pursue the reclassification of current prescription medicines as otc products.
The goal of our research and development activities in Medical Care is steadily to improve our contrast
agents and our contrast injection systems in order to build on our leadership position in the field of
radiology.
In March 2015, we received approval in Japan for Gadovistâ„¢ (active ingredient: gadobutrol) injection for
use with resonance imaging (mri). Gadovistâ„¢ is the first high concentration / high relaxivity gadoliniumbased contrast agent to be made available in Japan. In July 2015, Gadovistâ„¢ was approved by the European Commission for use in children under two years of age. This label extension applies to all indications that have already been approved.
In August 2015, the MRXperion injection system was approved by the fda for the injection of contrast
agents. Our system optimizes injection workflow, provides enhanced point-of-care capabilities and can
be connected to our Radimetricsâ„¢ Enterprise platform.
In 2015, we also worked to expand the capabilities of our informatics product offerings by developing
new software applications to improve contrast agent and radiation dosage management across ct, mri
and nuclear medicine modalities.

74

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

At Animal Health we focus our research and development activities on antiparasitics, antibiotics, medicines to treat noninfectious disorders and nonantibiotic alternatives for infectious diseases. Our central
research activities are conducted as part of our Life Sciences platform in conjunction with pharmaceutical research and in close collaboration with our researchers at CropScience. We also reinforce the business by continually identifying further product development candidates through our existing collaborations.
Since August 2015, our innovative immunostimulant Zelnateâ„¢ has been available in the United States.
It was approved by the United States Department of Agriculture (usda) to aid in the treatment of bovine
respiratory disease caused by Mannheimia haemolytica bacteria. The product offers veterinarians and
farmers a new approach alongside vaccines and antibiotics for mitigating this complex infectious disease that has substantial negative impact on the cattle industry.

4.2 CropScience
Research fields and sites
CropScience maintains a global network of research and development facilities. Our largest r&d sites
are as follows:

Research and Development Sites

[Table 3.4.8]

Site

Country

Focus

Monheim

Germany

R&D of crop protection products, focus on insecticides

Frankfurt

Germany

R&D of crop protection products, focus on herbicides

Lyon

France

R&D of crop protection products

Sophia Antipolis

France

R&D of crop protection products

Raleigh / Research Triangle Park

U.S.A.

R&D of crop protection products; research center for seeds

Sacramento

U.S.A.

R&D of crop protection products

Ghent

Belgium

Research center for seeds

Nunhem

Netherlands

Research center for vegetable seeds

Lubbock

U.S.A.

Research center for seeds, focus on cotton

Morrisville

U.S.A.

Research center for seeds

While research is carried out centrally at a small number of sites, our development and plant breeding
activities take place both at these sites and at numerous field testing stations across the globe. This
ensures that future active ingredients and crop varieties can be tested according to specific regional and
local requirements. The research centers of the Seeds unit focus on improving seed and targeted seed
traits through seed technology and breeding.
In November 2015, CropScience opened three new institutes within the research and innovation center
at PaulÃ­nia, Brazil: the companyâ€™s first applications technology center outside of Germany, a resistance
monitoring laboratory and a center for agriculture in tropical regions.
CROP PROTECTION / SEEDS
Research fields
In Crop Protection / Seeds our scientists working across the fields of improved seed traits, seed technology, seed breeding, agricultural chemistry and biologics closely collaborate as part of our integrated
research approach. This optimally bundles the technical expertise acquired in chemical and biological
research and field development, aligning it with our long-term research objectives and business strategies for the various crops.

75

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

In the Crop Protection unit, we pursue the goal of identifying and developing innovative, safe products
for use as insecticides, fungicides, herbicides or seed treatments in sustainable agriculture. In the fields
of chemistry, biology and biochemistry, modern technologies such as high-throughput screening and
bioinformatics play an important role in identifying new chemical lead structures. In addition, we are
broadening the range of uses for our active ingredients by developing new mixtures or innovative formulations to enable their application in additional crops or in different regions and make them easier to
handle. Successful collaborations with external partners complement our own activities.
Research in our Seeds unit is devoted to optimizing plant traits. We are developing new varieties in our
existing core crops â€“ cotton, oilseed rape / canola, rice and vegetables. We have now expanded our
research activities to include two further core crops â€“ wheat and soybeans. Our work focuses on improving the agronomic traits of these crops. Our researchers are working to increase the quality and yield
potential of crop plants â€“ for example by improving the profile of rapeseed oil or enhancing the properties of cotton fibers. We are also targeting the development of plants that have high tolerance to external stress factors such as drought, and can more efficiently utilize water. Further areas of focus include
developing new herbicide tolerance technologies based on alternative modes of action, and improving
insect resistance and disease tolerance. To do this we employ modern breeding techniques ranging
from marker-assisted breeding to plant biotechnology methods.
Technological advances offer farmers faster and more accurate methods of monitoring their plants.
Such digital solutions can help them to better understand processes in their fields and enable them to
make quicker and simpler decisions and calculate the risks more effectively. We would like to support
this development in the future by giving farmers specific agronomic recommendations. Therefore, in
addition to our conventional research projects, we are developing digital products in which we augment
field analyses and statistical models with additional data that we can adapt or individualize for a certain
field in order to help our customers to make decisions.
New products and registrations
In 2015, CropScience once again attained a series of important new registrations. In January 2015, for
example, we received regulatory approval from the u.s. Environmental Protection Agency (epa) for the
new insecticide Sivantoâ„¢, which controls sucking pests on fruits and vegetables as well as most broadacre crops. Based on the active ingredient flupyradifurone, Sivantoâ„¢ is a novel systemic insecticide.
CropScience received marketing authorization for this product in Mexico and South Korea in the spring
of 2015, and flupyradifurone was approved by the European Commission in November 2015. We anticipate attaining the first national registrations for Sivanto primeâ„¢ in European countries in 2016; its market launch is planned for 2017.
The product Councilâ„¢ was already granted regulatory approval in South Korea in 2014 and it has been
available there since the 2015 planting season. The new rice herbicide will considerably improve weed
control, as it features a favorable environmental profile and outstanding compatibility â€“ characteristics
that make Councilâ„¢ an environmentally friendly and future-oriented product in the Asian rice market.
In August 2015, CropScience received marketing authorization from the European Commission for
terpenoid blend qrd 460, the active ingredient in the product Requiemâ„¢. This biological insecticide
serves to control sucking pests. Its market launch in Europe is scheduled for 2017.
In September 2015, CropScience opened a new building for its European Wheat Breeding Center in
Gatersleben, Germany. Our wheat activities focus primarily on the development of hybrid seed that
promises considerably improved yield stability compared with conventional seed and is scheduled for
launch after 2020. CropScience announced in September 2014 that it will invest a total of â‚¬1.5 billion in
the research and development of wheat seed and crop protection between 2010 and 2020. Here CropScience combines the discovery and development of plant traits, molecular breeding and the latest it
applications in order to optimize the genetic potential of wheat seed in terms of increased yields. In
2015, we took the first step in this direction by launching our first conventional wheat seed in Ukraine.

76

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

With many crops, such as vegetables, major success can be achieved using conventional plant breeding
methods. As vegetables are intended especially to be marketed and eaten fresh, merchants and consumers have particularly strict requirements regarding their appearance, nutrient content, taste and
shelf life. We are launching a succession of new vegetable seed varieties that satisfy these requirements.
Acquisitions and cooperation
In February 2015, representatives of Bayer CropScience and globalg.a.p. signed an agreement to further intensify their collaboration. The partners aim to implement sustainable cultivation methods and
help fruit and vegetable growers worldwide to meet globalg.a.p. certification standards.
Around the world, weed resistances to herbicides jeopardize agricultural efficiency and sustainability.
CropScience has significantly expanded its herbicides research capacities in order to be able to more
rapidly offer new solutions to global agricultural problems: in June 2015, CropScience and the Grains
Research & Development Corporation (grdc) entered into a five-year innovation partnership centered
partly on the accelerated discovery and development of new active ingredients to manage major and
resistant weed species. The grdc will finance the expansion of existing capacities at the global herbicides research center of CropScience in Frankfurt to include some 40 additional scientists and technicians.
In June 2015, CropScience announced the acquisition of SeedWorks India Pvt. Ltd., headquartered in
Hyderabad, India. The company is specialized in the breeding, production and marketing of hybrid
seeds of tomato, hot pepper, okra and gourds. Existing and forthcoming varieties will be marketed
under CropScienceâ€™s Nunhemsâ„¢ brand.
In September 2015, CropScience and the Round Table on Responsible Soy (rtrs) announced that they
would jointly assist soybean producers in the certification of their crops according to rtrs standards.
rtrs certification guarantees that soybeans â€“ whether used as a raw material or in processed products â€“
originate from environmentally friendly, socially compatible and economically viable production. This
collaboration will initially be focused on Brazil.
Special mention should be made of our food chain partnerships, in which CropScience supports all the
players in the food chain â€“ from farmers and food processors to importers, exporters, wholesalers and
retailers. CropScience has participated worldwide in food chain partnership projects for 10 years, particularly in Asia, Latin America and Europe. Some 7,400 Bayer experts advise farmers on sustainable
cultivation methods â€“ from seed selection and the controlled, eco-friendly use of crop protection products to the transparent monitoring of production and assistance in attaining certifications.
online annex: 3-4.2-1
Our cooperation with partner organizations in these joint projects is now an internationally successful business model for all participants in the food chain. Smallholder farmers in developing countries
and Emerging Markets draw particular benefit from the improved production and marketing structures. Since 2014, we have significantly expanded our partnership with Unilever. This includes a
food chain partnership project in Kenya focused on rapeseed whose integrated solution comprises
crop protection, seed and support in certification attainment and agronomic training measures. The
goal of the project is to stabilize or even increase harvest yields and quality, and thus farmersâ€™ incomes.

77

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

CropScience is part of a global network of research and industry partners from diverse segments of the
agriculture industry, chemical and biological research, and the food industry. An overview of the major
research partnerships is contained in
online annex: 3-4.2-2

CropScience: Important R&D Collaborations

[Table 3.4.8-1]

Partner

Cooperation objective

CSIRO

Increase in wheat yields by means of native plant traits â€“ discovery, validation and
integration

Elemental Enzymes

Use of microbes to improve soil health and thereby increase crop productivity

GRDC

Herbicide Innovation Partnership for the discovery and development of innovative
weed management solutions

IVCC

Joint development of new substances to control mosquitoes that transmit diseases
such as malaria and dengue fever

Targenomix

Development and application of systems biology approaches to achieve a better
understanding of metabolic processes in plants

Integrated research and development pipeline
Our integrated product pipeline for crop protection and seed technology contains numerous new crop
protection products, seed varieties and enhanced products (life cycle management) that have estimated
launch dates between 2014 and 2019. We believe these products have a combined peak sales potential
in excess of â‚¬5 billion. In line with our Group target 2015 we launched confirmatory technical proof-ofconcept field studies for one new molecular entity, one new plant trait and two new biologics. A new
plant trait is a specific characteristic that has not yet been available or offered at Bayer for the crop
plant in question.
The table lists a selection of products launched in 2015 and market launches expected through 2019:

Innovation Pipeline1

[Table 3.4.9]

Indication / crop

Product / plant trait

Product group

Insecticide

SivantoTM

Chemical crop protection

Market launchÂ²
2015

Herbicide

CouncilTM

Chemical crop protection

2015

Wheat

Conventional seed

Seeds

2015

Oilseed rape / canola

Dual herbicide tolerance

Seeds

2016

Insecticide

New active ingredient

Biological crop protection

2017

Cotton

Dual herbicide tolerance and insect resistance

Seeds

2017
2017

Oilseed rape / canola

Dual herbicide tolerance

Seeds

Oilseed rape / canola

Herbicide tolerance

Seeds

2017

Soybeans

Dual herbicide tolerance

Seeds

2017

Insecticide

New active ingredient

Chemical crop protection

2019

Fungicide

New active ingredient

Chemical crop protection

2019

Soybeans

Triple herbicide tolerance

Seeds

2019

Soybeans

Dual herbicide tolerance

Seeds

2019

1 Selected

new products
2 2016-2019: planned market launch
As of January 6, 2016

Group target 2015:
transfer of two new
molecular entities
(nmes) or plant traits
into confirmatory
technical proof-ofconcept field studies
See also
Chapter 1.4 for
Group targets

78

Bayer Annual Report 2015
Combined Management Report
4. Research, Development, Innovation

ENVIRONMENTAL SCIENCE
Research fields
Environmental Science offers consumers and professional users chemically and biologically based pest
and weed control solutions by tailoring substances from our Crop Protection unit or external partners
for use in the garden, on golf courses, on road- or railways or in forestry.
Activities in 2015
Environmental Science expanded its product range for professional users in the Middle East by introducing various innovative formulations of our insecticide Maxforceâ„¢. The new biological product
Dedevap Greenâ„¢ is available in Germany for use in granaries. Environmental Science also cooperates
with companies in Brazil and Argentina to promote sustainable forestry â€“ through the use of products
such as our herbicide Esplanade Forestâ„¢, which enables reduced application of herbicides thanks to its
long-lasting effect. We are continuously expanding our range of fungicides. Examples here include the
launch of Dedicateâ„¢ in Europe, Chipco Signature Xtraâ„¢ in the United States and the biological nematicide Norticaâ„¢.
For consumers we continued to work in 2015 on the development of innovative and user-friendly packaging and the expansion of our range of biological solutions. We rounded out our range of pest
and weed control products with the launch of the new fungicides Consentoâ„¢ and Emeraldâ„¢ in central
Europe and Italy, the snail control product Dismoâ„¢ in France and Austria and new formulations of
Decis Gartenâ„¢ in Italy and the Benelux countries.
For more than 50 years, Bayer has played an active role in the fight against malaria, which remains one
of the most dangerous tropical diseases to this day. Environmental Science is a leading supplier of indoor spray insecticides that control malaria-transmitting mosquitoes, protecting some 50 million people
a year from the disease. In 2015, Environmental Science received support from the World Health Organization of the United Nations (who) for the use of the Fludoraâ„¢ brand to combat malaria within the
context of integrated pest management. Environmental Science is also currently developing a new outdoor spray, K-Othrine Polyzoneâ„¢, to combat dengue fever in Southeast Asia. This product is targeted for
launch in 2017.

4.3 Covestro
Covestro operates major Innovation Centers in Leverkusen, Germany; Pittsburgh, Pennsylvania, United
States; and Shanghai, China. With its strong global presence, the company endeavors to account particularly for regional market trends and customer needs.
Essential in this context is also cooperation with external scientific institutions, start-up companies and
academic spin-offs. These collaborations are mainly based in Germany, the United States, China or
Japan. Our partners in Germany include rwth Aachen University, while in China Covestro maintains a
close alliance with Tongji University, and in the United States Covestro supports research activities at a
number of renowned universities.
Research and development is a core element of Covestroâ€™s corporate strategy so that the company can
maintain and build on its own competitive position. The company continuously works to evolve and
improve its products and manufacturing, processing and business procedures. It is ensured through
targeted management that ongoing projects and the project pipeline satisfy the current and future
needs of customer industries and ultimately the consumer markets.

79

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

The thematic focus is on high-end applications, the enhancement of functionalities, design flexibility,
cost-reducing production processes and sustainability, whereby the company also endeavors to find
alternatives to petrochemical raw materials.
The Polyurethanes (pur) Business Unit focuses among other things on driving forward new technologies such as microcellular foams that enable the development of even more efficient insulation of buildings and refrigeration chains. It also works to increase the flame-retardant properties of its materials.
Another current theme is lightweight composite materials, including applications in the automotive
industry that lead to weight savings and at the same time higher productivity and improved comfort.
In the area of process development, the business unit is progressing with the use of carbon dioxide as a
new source of carbon in order to reduce dependence on petrochemical raw materials. The pur Business
Unitâ€™s first priority in 2016 is to launch an innovative co2-based form of the polyurethane component
polyol.
Activities in the Polycarbonates (pcs) Business Unit are mainly geared to the development of products
for the automotive and electrical / electronics industries. The focus here is on reducing weight, improving energy efficiency and safety, and enabling greater design freedom.
Light-emitting diodes contribute to sustainability in vehicles and in other applications, as they require
less energy and last longer than traditional light sources. pcs has developed special materials for channeling, scattering and reflecting led light and for discharging the generated heat. In addition, the business unit is channeling its focus on fiber-reinforced composites based on polycarbonates. These can
improve performance in high-grade it products and automotive components in particular.
The Coatings, Adhesives, Specialties (cas) Business Unit is actively involved in the development
primarily of polyurethane-based raw materials for high-performance coatings, colorants, adhesives,
sealants and specialty products. One of the goals here is to open up new application possibilities and
markets for the core products. cas is also driving forward technologies such as processes that make use
of sustainable raw materials, focusing consistently on the needs of the market here as well.
In April 2015, for example, the business unit presented an innovative curing agent for polyurethane
coatings and adhesives for which 70% of the raw materials are derived from biomass that does not
compete with food production. cas has also developed a thermolatent curing agent for automotive coatings that can be applied at significantly lower temperatures than standard products. This in turn lowers
energy consumption and shortens production times. For textiles and artificial leather, furthermore, cas
offers a new generation of polyurethane dispersions that also conserve natural resources and do not
require the use of any organic solvents.

5. Sustainability Management and Governance
To us, sustainability basically means future viability and, as part of corporate strategy, is integrated into
everyday procedures.
We underline our mission as a sustainably operating company through our commitment to the u.n.
Global Compact with its internationally recognized 10 principles and to the Responsible Careâ„¢ initiative, and through our active global involvement in leading (industry) forums such as the World Business
Council for Sustainable Development (wbcsd).
Bayer also expressly backs the comprehensive approach of the new Sustainable Development Goals
(sdgs) agreed by the u.n. in September 2015 for the period to 2030. In our core business we support in
particular the goals that focus on combating hunger and ensuring good health care provision across the
globe. The other sdgs are also in line with our internal requirements relating to responsible business
practices.

www.bayer.com/
sustaincommitment

80

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

Responsibility for steering and aligning our Group-wide sustainability strategy lies with the Board of
Management member responsible for Human Resources, Technology and Sustainability in his function
as Chief Sustainability Officer, and with a Sustainability Council chaired by the Environment & Sustainability corporate function.
Structure of Sustainability Management

[Graphic 3.5.1]

S U STA I N A B I L I TY M A N AG E M E N T
Organization

Major areas of activity

Steering, measurement
and documentation

Member of the Board of
Management responsible for
Human Resources, Technology
and Sustainability

Product and process innovation

Environment & Sustainability
corporate function

Human capital

Group regulations on, for example,
â€¢ Human Rights
â€¢ Compliance
â€¢ Sustainable Development
â€¢ Responsible Marketing

Business ethics

Targets / Indicators

Group committees focusing on
sustainability and HSEQ issues

Product stewardship

HSEQ management systems
and audits

Access to health care
Sustainable food supply

Safety
Environmental protection
Supplier management

Opportunity and risk management
Integrated Annual Report with
independent auditing

Stakeholder engagement / Partnering
Societal engagement

Commitment to standards and organizations such as wbcsd, gri, u.n. Global Compact, Responsible Care

See also Chapter
1.3 for Group
strategy
www.bayer.com/
policies

GRI
G4-18, G4-26, G4-27

www.bayer.com/
materiality

The Sustainability Council sets targets, draws up initiatives, management systems and Group regulations, and is responsible for their implementation. In order to operationalize the Group strategy and
make it measurable, we have set ambitious nonfinancial targets and indicators all along the value chain.
Internal Group regulations ensure our sustainability principles are implemented in business operations,
where they are realized through corresponding management systems, regulations and processes.
We regularly check that our areas of activity are up to date and relevant. To do so, we analyze and evaluate what the major stakeholders expect and require and match this against our own assessment.
Thanks to this approach, we are quick to identify sustainability-related opportunities and risks and can
incorporate these into our strategy. In 2014, we used a multi-stage process to identify issues of relevance to us and prioritized these in respect of sales, costs, risk and reputation. We summarized the 24
areas of activity that are relevant to Bayer in a materiality matrix.
In 2015, we once again discussed the results of the materiality analysis at internal workshops and
reconciled these with current developments and the Group targets. We also analyzed the resultsâ€™ relevance for the Bayer value chain (see graphic) and reporting in line with the new gri g4 guidelines.
During this process, the original 24 areas of activity were condensed into 11, presented to the Board of
Management and approved by it. The graphic below shows the assignment of our areas of activity to
the stages of the value chain.

81

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

Areas of Activity Across the Different Stages of the Value Chain
Value chain stages
Areas of activity

Research,
development,
innovation

Supply
chain

[Graphic 3.5.2]

Production

Logistics

Distribution
and
marketing

Use

Product and process innovation
Access to health care
Sustainable food supply
Human capital
Business ethics
Product stewardship
Safety
Environmental protection
Supplier management
Stakeholder engagement /
Partnering
Societal engagement

In the augmented version of the Annual Report you will find a detailed gri content index with the corresponding ungc principles and the gri aspects to which we have assigned our areas of activity. There we
indicate whether our scope for exercising influence lies within or outside the company. An overview of
our areas of activity, their definition, the corresponding Group targets and the assigned gri aspects is
available online.

www.bayer.com/
gri-content-index

www.bayer.com/
key-areas-of-activity

STAKEHOLDER DIALOGUE AT BAYER
We consider the maintenance of constant contact and continuous dialogue with our stakeholders at a
global and local level to be very important. Bayer is a part of society and of public life. Societyâ€™s acceptance and appreciation of our corporate activities are therefore essential to Bayerâ€™s reputation and
business success. Involving the different interest groups is a vital element of the companyâ€™s activities
with the goal of creating better mutual understanding and trust in respect of our work and products.
online annex: 3-5-1
We believe that systematic dialogue with the stakeholders relevant to us offers a vital key to
understanding their viewpoints and expectations and being able to incorporate them into our
business decision-making processes as far as possible. This procedure helps us to identify social and
market trends and developments early, avoid risks, assess our contribution and thereby set focus
areas for our corporate activities.
We systematically involve our stakeholders in various ways, including the Stakeholder Engagement
Process. This describes how, throughout the Group, stakeholder groups for a project can be identified, their expectations charted and dialogue with them steered. The engagement process requires
regular review and needs to be reflected against social trends.

GRI
G4-25

82

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

GRI
G4-25

Stakeholder Engagement Process

[Graphic 3.5.2-1]

St a k e ho

l de r

ma

pp

in

g

Identiï¬cation

Controlling

wea k nesses

E nga

ge m

en

t

Preparation

Characterization

Strategy
development

e ng

ths /

Interaction

Clustering
ga

ge

me

ys

En

is

of

st r

Prioritization

An

nt p

lannin

al

g

To ensure the long-term acceptance and appreciation of our business, we seek to link the interests of
our stakeholders even more closely to our corporate strategy. It is important to approach key social
and political players right from the start of a new project and, early on, to canvass their support,
identify risks and opportunities and seek open dialogue. The Group has developed a guide to
engaging stakeholders in strategic decision-making processes such as investment projects and the
launch of new products. The Virtual Resource Center platform that emerged from this provides
online tools and a tutorial to help identify social and political trends at an early stage so that they can
be successfully incorporated into project planning. The concept is currently being applied to various
projects at Bayer, and the practical experience gathered is being channeled back into further
refinements. In addition, senior managers are systematically undergoing specific training to improve
interaction with critical stakeholders.
GRI
G4-26

Bayerâ€™s day-to-day stakeholder activities range from targeted dialogue at local, national and
international level and active involvement in committees and specialist workshops, through to
comprehensive information programs and participation in international initiatives and collaborations.
Our stakeholder dialogue includes both communication and active interaction with individual target
groups and also issue-related multi-stakeholder events.

GRI
G4-24

We basically divide the stakeholders with whom we mainly interact into four groups: partners, regulators, financial market players and social interest groups. In the following and in the relevant chapters, we use examples to provide an insight into the commitment Bayer has shown in 2015.

GRI
G4-27

OUR PARTNERS
Customers and suppliers
More on this topic can be found in Chapter 7 â€œProcurement, Production, Logistics, Distribution.â€
Employees
More information about internal communications can be found in Chapter 6 â€œEmployees.â€

83

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

Universities and scientific institutions
Bayerâ€™s research and development activities are supported by an international network of collaborations with leading universities, public-sector research institutes and partner companies. More about
this can be found in Chapter 4 â€œResearch, Development, Innovation.â€

GRI
G4-26, G4-27

Schools and universities
You can find more information on Bayerâ€™s comprehensive activities in dialogue with school and university students in Chapter 11 â€œSocial Commitment.â€
Associations
Alongside our business activities, Bayer is also an active member of, or holds leadership positions
on, numerous national, European and international associations and their committees such as the
Federation of German Industries (bdi, Vice-Presidency from 2015), the German Chemical Industry
Association (vci, Presidency), the German Equities Institute (dai, Presidency), the European Chemical Industry Council (cefic, membership of the Board and Executive Committee), BusinessEurope
and the International Council of Chemical Associations (icca). Bayer also currently chairs econsense,
the Forum for Sustainable Development of German Business.
The subgroups are also active members of their respective industry associations. For example,
HealthCare is on the boards of both the European (efpia) and the American (PhRMA) pharmaceutical
trade associations, CropScience is represented on the boards of the international crop protection association CropLife International, the regional associations (CropLife America, Latin America, Africa &
Middle East) and the European Crop Protection Association (ecpa), and the ceo of Covestro is the
President of PlasticsEurope, the association of plastics manufacturers.
FINANCIAL MARKET PLAYERS
More information on our dialogue with the capital market â€“ stockholders, capital investment companies, institutional investors, banks and rating agencies â€“ can be found in the Chapter â€œInvestor Information.â€
REGULATORS
Legislators, authorities and politicians
The framework for the companyâ€™s operations is determined by authorities, legislators and politicians
through statutory regulations and licensing, for example. The dialogues Bayer is currently pursuing
with authorities and ministries at local, national and international level include targeted discussions
with political decision-makers and active involvement in specialist workshops and cooperation projects. Our active participation in political decision-making processes is also explicitly sought by the
key players involved.
Lobbying
In its Bayer Group Regulation â€œCode of Conduct for Responsible Lobbying,â€ Bayer sets out clear and
binding rules for its involvement in political matters, aiming to ensure transparency in any collaboration with the representatives of political institutions. The Groupâ€™s Public and Governmental Affairs
Committee is responsible for the strategic planning of Bayerâ€™s political work. This especially includes
developing the companyâ€™s political standpoints, as well as determining the position of the Bayer
Board of Management on important political issues. In 2015, Bayerâ€™s political lobbying again focused
on the acceptance of products and technologies in society, on submitting proposals for creating sustainable health care systems, on dismantling obstacles to innovation, on chemicals and energy policy,
on trade policy and on climate protection. Bayer actively promotes the protection of intellectual
property in order to be able to continue developing innovative products. In addition, Bayer makes
suggestions relating to the regulatory framework for crop protection products and seeds. More information on our political principles can be found on the internet.

www.bayer.com/
pol-involvement

84

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

www.bayer.com/
eu-transparencyregister

www.bayer.com/uslobbying-disclosure

Our liaison offices in Berlin, Brussels, Washington, Moscow, Brasilia and Beijing are key points of
contact between the Group and the political arena. Bayer actively participates in existing transparency initiatives. It publishes details of costs, employee numbers and any of the other statistics required
in each country, e.g. in the transparency registers of the European institutions and the u.s. Congress.
Bayer goes way beyond the statutory requirements in doing so. For instance, the Group also publishes data for countries, e.g. in Germany, where there is no legal requirement to publish such information. In 2015, the costs incurred at the liaison offices for human resources, material and projects
totaled approximately: â‚¬1.2 million in Berlin, Germany; â‚¬2 million in Brussels, Belgium; â‚¬6.9 million
in Washington, United States; â‚¬0.14 million in Moscow, Russia; â‚¬1.1 million in Brasilia, Brazil; and
â‚¬1 million in Beijing, China.
In keeping with our Group regulation, we have committed not to make any direct donations to political parties, politicians or candidates for political office. However, some associations to which the
Group belongs make donations on their own initiative, in compliance with statutory regulations.

www.fec.gov

In the United States, a number of employees use the Bayer Corporation Political Action Committee
(BayPac) to make private donations supporting candidates for parliamentary office. Political action
committees in the United States are state-regulated, legally independent employee groups. In the
United States, companies are legally prohibited from donating to political candidates directly. Consequently, such donations are not donations made by the company. The BayPac contributions are regularly reported to the u.s. Federal Election Commission and can be viewed on its website.
SOCIAL INTEREST GROUPS
Nongovernmental organizations, the public, local community, competitors
Bayer is involved in a variety of projects, thematic initiatives and specialist conferences at a national
and international level in order to play an active role in the common task of shaping sustainable development. Alongside exchange and cooperation with nongovernmental organizations (ngos) and supranational organizations, this primarily involves dialogue with the public.
Among other involvement, Bayer is actively engaged in the u.n. Global Compact and its initiatives,
the ceo Water Mandate and Caring for Climate, as well as the Global Compact lead network and
local Global Compact networks. We have also acted as an organizational stakeholder in the Global
Reporting Initiative since 2004.

GRI
G4-26, G4-27

HealthCare is an active participant in the social dialogue addressing sustainability issues and creates
forums to encourage exchange and develop viable problem-solving approaches together with partners. The subgroup supports the International Dialogue on Population and Sustainable Development
conference in close collaboration with various governmental and nongovernmental organizations.
The concept of this political dialogue involves finding solutions for internationally relevant issues in
reproductive health and sharing experiences of implementing the Millennium Development Goals.
Together with the dsw (Deutsche Stiftung Weltbevoelkerung â€“ the German foundation for world
population), HealthCare organizes a series of parliamentary evenings where experts in development
cooperation and representatives from the political sphere, foreign agencies, medical research, international ngos and think tanks discuss issues related to development policy and population growth.

85

Bayer Annual Report 2015
Combined Management Report
5. Sustainability Management and Governance

CropScience wants to strengthen and expand societal dialogue about the need for and benefits of
science and innovation in agriculture and inform the public of the potential and challenges in todayâ€™s
agriculture. The Agricultural Education program is primarily aimed at encouraging young people to
take a greater interest in agriculture and food production. The program includes practical exercises
in student laboratories, agricultural science scholarships and sharing ideas about the future of agriculture at international youth conferences such as the Youth Ag-Summit.

GRI
G4-26, G4-27

In 2015, the second Youth Ag-Summit was held in Canberra, Australia, in partnership with the Australian agricultural youth organization ffn (Future Farmers Network). The focus was on nutrition for
the growing global population. At the end of the year, delegates from the Youth Ag-Summit presented a declaration by the young people on specific campaigns and recommendations for safeguarding
food supplies to the United Nationsâ€™ Committee of World Food Security in Rome, Italy.
The neighborhoods near Bayerâ€™s sites are a key subject in our stakeholder dialogue. The Group is
working at all sites on being recognized as a reliable partner and attractive employer that is aware of
its social responsibility. For example, the involvement of the local community plays a decisive role in
the success of any investment project.
CropScience regularly uses forums, print media and personal discussions with citizensâ€™ initiatives,
representatives of the church communities and the regional press to keep its neighbors continually
informed, for instance at the Dormagen, Frankfurt-Hoechst and Knapsack sites in Germany. Stakeholder dialogue is also taking place with the communities around sites in other countries, such as
Muskegon, United States, and Hangzhou, China.
Covestro engages in dialogue with neighbors, the public and non-governmental organizations (ngos)
on a case-by-case basis. The communities around the sites are proactively informed and involved
when it comes to investment projects. One example is the intensive voluntary information policy
adopted by Covestro and the German Chempark operator Currenta with respect to the relocation of a
section of the existing carbon monoxide pipeline under the Rhine between Dormagen and Leverkusen. The permit documentation for the culvert could be openly viewed by interested parties in both
cities affected and was additionally accessible on a specially dedicated website. For more detailed
up-to-date information go to www.dueker.chempark.de (in German only). Both the media and local
residents are kept informed about the planned carbon monoxide pipeline between the German sites
of Dormagen and Krefeld-Uerdingen. The dialogue forum initiated by Covestro also plays an important role in the exchange of information with a critical public
In the United States, Covestroâ€™s site dialogue takes place through local Community Advisory Panels
(caps). These, for example, organize regular meetings with local government or the community, in
order to provide information on current issues or news from the area of site safety. In Germany, dialogue with the community is conducted through the Chempark neighborhood offices run by Currenta
at the Lower Rhine sites.
Among other things, Covestro is a member of the u.n. Global Compact and is active in econsense. It
also maintains various partnerships with ngos as part of a commitment to wider society, for instance
with Habitat for Humanity, which seeks to build sustainable and affordable housing in India.

www.bayer.com/
COV-CO-pipeline

86

Bayer Annual Report 2015
Combined Management Report
6. Employees

6. Employees
Our business success is based to a large extent on the knowledge, skills, commitment and satisfaction of
our employees. The aim of human resources work at Bayer is to create a working environment that
encourages personal development and where every employee can drive forward innovations and
achieve an excellent performance. Our corporate culture therefore builds on integrity, fosters strengths,
identifies potential and helps us in our common goal of attracting the most talented employees and
retaining them in the company in the long term.
Our human resources work starts with selecting and hiring new employees. We reward achievement
and encourage ongoing development. We constantly develop our organizational structures and adapt
them to the changing business environment. In addition, we have a wide range of initiatives and offerings to help managers lead their teams and enable employees to perform optimally.
The global strategy introduced by the Human Resources (hr) Committee helps us meet present and
future business requirements. The hr Committee sets binding policies and defines priorities for all
regions and organizational units. It is chaired by the member of the Board of Management responsible
for human resources.
GRI
G4-26

See Chapter 1.4
for Group targets

To monitor the effectiveness of our human resources work, we conduct a Group-wide Employee Survey
every two years. This is supplemented by institutionalized feedback processes and analyses. The information we receive in this way is used to steadily improve our activities. One area of focus derived from
the results of the last Employee Survey was improving our innovation culture. Cultivating innovation has
therefore been integrated into the Bayer Competency Model as one of the key leadership competencies
and we have introduced new initiatives such as the â€œWeSolveâ€ knowledge platform. Further information
on Bayerâ€™s innovation culture can be found in Chapter 4 â€œResearch, Development, Innovation.â€

See Chapter 4 for
more details

At the end of 2015 we had 116,800 employees worldwide.

Group target:
continuous
improvement in
employee engagement

Employees by Region and Gender 2015

[Graphic 3.6.1]

North America

Europe

16,000 (15,800)

55,900 (54,600)

9,700 men

34,900 men

6,300 women

21,000 women

Latin Americaà¯—/à¯—Africaà¯—/à¯—Middle East

16,100 (16,800)

116,800
(117,400)

Asiaà¯—/à¯—Pacific

28,800 (30,200)

10,100 men

18,500 men

6,000 women

10,300 women

2014 figures restated and in parentheses
Number of employees converted into full-time equivalents (FTE)
Values rounded to the nearest hundred

IDENTIFYING TALENTS
Bayer actively encourages its employees to develop their individual abilities, talents and strengths.
Scientific innovations, changing customer requirements and a strong competitive environment are just
some of the reasons why we welcome open-minded employees. A professional approach to attracting
suitable talents is key to this. In 2015 we successfully continued the rollout of our uniform employer
branding â€œPassion to Innovate | Power to Change.â€ This message expresses what Bayer expects of its
employees and, at the same time, what it can offer them. The employer branding â€œPassion to Innovate |
Power to Changeâ€ was deployed worldwide for internal communication with employees in 2015 and
was also used to position Bayer as an employer in many key markets. In addition, in 2015 we took the
first steps toward further optimizing Group-wide recruitment of new employees. This was supported by

87

Bayer Annual Report 2015
Combined Management Report
6. Employees

an increased presence in social media. Our excellent reputation as an employer is shown by many external rankings, awards and accolades.
online annex: 3-6-1

New Hires1 by Region and Gender

[Table 3.6.0-1]
Women

Men

Total

2014

2015

2014

2015

2014

2015

Asia / Pacific

1,745

1,569

2,758

2,762

4,503

4,330

Europe

2,717

2,359

3,104

3,162

5,821

5,521

Latin America / Africa / Middle East

1,080

820

1,670

1,400

2,750

2,220

990

2,359

1,510

1,406

2,500

3,765

6,532

5,772

9,042

8,729

15,574

14,502

Region

North America
Total
The figures also include the discontinued operations.
1 Converted into full-time equivalents (FTE)

Vocational training plays an important role at Bayer in order to meet the need for skilled employees. We
provide sound training in more than 20 different occupations and offer more vocational training places
than required to meet our needs. In Germany alone, around 920 young people embarked on a vocational training course at Bayer in 2015. We also give young people an opportunity to gain an insight into
working for our company at any early age. Overall, Bayer provided around 2,900 demanding professional internships for students around the world in 2015.
PRESENT EMPLOYEE DATA
On December 31, 2015, Bayer had around 116,800 employees worldwide, a slight decrease compared
with the previous year. In Germany we had some 36,700 employees (2014: approximately 35,700),
which was 31% of the total Group workforce.

Employment Data1

[Table 3.6.1]
2014

2015

FTE

FTE

Production

49,300

47,800

Marketing and distribution

45,100

44,700

Research and development

13,900

14,700

Employees by function

General administration
Total
Apprentices

9,100

9,600

117,400

116,800

2,600

2,600

2014 figures restated
Values rounded to the nearest hundred
1 The number of employees on either permanent or temporary contracts is stated in full-time equivalents and rounded to the nearest hundred. Parttime employees are included on a pro-rated basis in line with their contractual working hours.

www.bayer.com/
career

88

Bayer Annual Report 2015
Combined Management Report
6. Employees

The breakdown by age group was as follows:

Employees by Age Group
Age in years

[Table 3.6.2]
< 20

20 â€“ 29

30 â€“ 39

40 â€“ 49

50 â€“ 59

> 60

2014

0.1%

15.8%

30.2%

28.2%

22.3%

3.4%

2015

0.1%

15.3%

30.0%

27.7%

23.0%

3.9%

Of the total Group workforce, 112,100 employees had permanent contracts while 4,700 had temporary
contracts.
online annex: 3-6-2

Employees 1 by Employment Status, Region and Gender 2015

[Table 3.6.2-1]

Permanent employees

Europe
North America
Asia / Pacific
Latin America / Africa / Middle East
Total
1

Temporary employees

Women

Men

Total

Women

Men

Total

19,900

33,500

53,400

1,100

1,400

2,500

6,200

9,600

15,800

100

100

200

10,100

17,700

27,800

200

800

1,000

5,700

9,400

15,100

300

700

1,000

41,900

70,200

112,100

1,700

3,000

4,700

The number of employees on either permanent or temporary contracts is stated in full-time equivalents (FTE) and rounded to the nearest
hundred. Part-time employees are included on a pro-rated basis in line with their contractual working hours.

The voluntary fluctuation rate shows that we were again successful in retaining staff in the company
long-term. On the reporting date, our employees had worked for the company for an average of 11
years. The proportion of employee-driven terminations (voluntary fluctuation) was 5.0% in 2015, level
with the previous yearâ€™s figure. Group-wide, the fluctuation rate was around 13.9% and thus up 2.5
percentage points on the previous year. This figure includes all employer- and employee-driven terminations, retirements and deaths.

Employee Fluctuation

[Table 3.6.3]
Voluntary fluctuation

Total

2014

2015

2014

2015

5.3%

5.8%

11.6%

13.9%

Men

4.6%

4.5%

11.3%

13.9%

Total

4.8%

5.0%

11.4%

13.9%

Women

89

Bayer Annual Report 2015
Combined Management Report
6. Employees

online annex: 3-6-3

Employee Fluctuation1 by Region, Gender and Age Group

Europe
2014

Women
< 302

2015

North America
2014

2015

[Table 3.6.3-1]

Asia / Pacific
2014

2015

Latin America /
Africa / Middle East
2014

2015

Total
2014

2015

%

%

%

%

%

%

%

%

%

%

8.2

7.8

14.8

15.7

15.2

22.2

13.6

19.0

11.6

13.9

23.6

19.5

31.0

36.1

17.7

24.9

23.6

29.6

21.5

24.5

30 â€“ 49

6.2

6.5

13.1

14.1

13.6

20.4

11.3

17.1

9.8

12.6

>= 503

5.3

5.4

13.6

13.2

19.5

29.1

9.9

12.9

8.5

9.1

Men

6.8

6.7

15.8

13.2

16.1

23.6

13.0

21.8

11.3

13.9

< 302

32.1

23.8

40.0

35.8

21.4

31.3

27.4

41.9

26.8

30.7

30 â€“ 49

4.4

4.7

13.5

10.0

14.3

21.7

10.3

17.5

9.4

12.3

>= 503

4.1

4.9

14.1

12.8

13.2

17.2

9.4

20.2

7.3

8.7

Total

7.4

7.1

15.4

14.2

15.8

23.1

13.2

20.7

11.4

13.9

1

The data include all employer- and employee-driven terminations, retirements and deaths.
The comparatively high proportion of employees in the <30 age group is due to the inclusion of employees on temporary contracts
(working for 2â€“6 months of the year) and other short-term employees. It does not include apprentices.
3 The fluctuation rates for the >= 50 age group are mainly due to retirements.
2

At our significant locations of operation, which represent a selection of countries in which we generate
around 68% of our total sales, Bayer also uses temporary personnel from staffing agencies on a small
scale, based on stringent rules that are rooted in the life values.
online annex: 3-6-4
Temporary personnel from staffing agencies are primarily used where this is necessary as a result of
short-term personnel requirements, fluctuations in order levels, temporary projects or long-term illness. The proportion of temporary staff employed in Germany is around 2.9% of the total workforce,
and the average for the significant locations of operation is 7.5%.

6.1 Utilizing Potential to the Full:
Personnel Development at Bayer
We aim to develop our employees on the basis of their abilities. To ensure this, in 2015 we introduced
the Bayer Competency Model as a uniform, Group-wide standard. It comprises 16 clearly defined core
and leader competencies, which are derived from our business strategy and life values. They enable
both employees and managers to use a common language and enhance transparency of the skills and
behaviors we expect from both current and future employees.
This common understanding facilitates development opportunities for employees and at the same time
gives them guidance on their career path. The Bayer Competencies are now used as criteria for many
employee development tools, ranging from recruitment interviews through the Development Dialogue
to various Assessment Centers to identify future managers. In 2015, 28,000 nonmanagerial staff and
23,000 managerial staff around the world were trained to use the competencies in interviews and Development Dialogues.
The aim of the Development Dialogue is to draw up an individual development plan that fosters employeesâ€™ strengths and addresses areas in which they would like to develop further. 30,000 Development
Dialogues were held in 2015. They are an opportunity for employees to discuss their personal strengths
and development needs, career expectations and professional aspirations with their supervisor. This tool
is to be rolled out Group-wide and given a firm place in our global leadership culture. In 2015, the Development Dialogue was extended to nonmanagerial employees in Germany.

90

Bayer Annual Report 2015
Combined Management Report
6. Employees

Thanks to its wide-ranging business activities, Bayer is able to offer employees throughout the Group
good opportunities for development. Vacancies throughout the Bayer Group, from nonmanagerial right
up to senior management level, are advertised via a globally accessible platform. In 2015, we posted
around 13,000 vacancies in 61 countries on this platform.
Selective training is also part of our philosophy of personnel development. We actively encourage â€œlifelong learningâ€ by our employees as an integral element in the management of demographic change.
Our aim is to empower all employees to broaden their knowledge and skills and keep up with the latest
changes throughout their working lives.
www.bayer.com/
training

We have training programs for all employees throughout the company. An overview of the various programs, together with details of their aims and uptake can be found on the internet.
At the heart of our ongoing training concept is the Group-wide Bayer Academy, which bundles our
extensive range of continuing education offerings. Alongside systematic development of managerial
employees, it offers continuous professional training through various functional academies. Managers
from different management levels have taken a total of 31,966 training courses through the programs
offered by the Bayer Academy for managers since 2013, including 11,623 in 2015. In 2015, the Bayer
Academy was honored with the renowned Brandon Hall Group Excellence Award in bronze for its training offerings to enhance the performance and feedback culture. A total of 302,205 training sessions in
Skill & Competency were taken by managers across all managerial levels.
Every employee at our significant locations of operation received an average of 20.0 hours of vocational
and ongoing training.
online annex: 3-6.1-1

Training Activities in Hours in 2015 by Employee Group and Gender 1

[Table 3.6.3-2]

Women

Men

Total

Senior management

18.3

15.9

16.3

Junior management

33.2

24.4

27.4

Specialists

19.9

14.3

16.4

Overall average

24.1

17.7

20.0

Employee group

The figures also include the discontinued operations.
1 Selected training activities in the 14 largest countries covered by the global training system, in which we generate 71.8% of our sales;
the gender-specific averages do not include the United States or Japan as statutory regulations preclude differentiation by gender in these
countries.

ACHIEVING EXCELLENT PERFORMANCE â€“ FOSTERING FLEXIBILITY
Above-average performance is only possible in an environment where fairness and respect are key
elements of the corporate culture. That includes observing Bayer-wide standards of conduct and protecting employees from discrimination, harassment and retaliation. These standards are set forth in the
corporate policy on Fairness and Respect at Work.
Specific and differentiated feedback forms the basis for positive personal development. Bayer encourages a culture of candid feedback to help employees achieve their individual goals. The global performance management system is part of this culture. Employees agree individual objectives with their
supervisor that are directly based on corporate goals. Alongside continuous feedback throughout the
year, attainment of the objectives is assessed by the supervisor at the end of the year and discussed
personally with each employee. The results are documented in the employee portal and made available
to each employee on an individual basis. In 2015, this system covered more than 88,000 employees, i.e.
about 75% of our total workforce. Of the participants, 42% were female and 58% male. The system is
mandatory for all managerial employees. This ensures that they receive feedback on how well they have
applied our corporate values in the fulfillment of their individual objectives. Applying the life values is
as important as meeting business targets and therefore affects the level of their variable compensation.

91

Bayer Annual Report 2015
Combined Management Report
6. Employees

Bayerâ€™s corporate culture is shaped by its employees. As a modern employer, Bayer endeavors to respond to employeesâ€™ widely differing lifestyles. The company therefore offers employees in all countries
a wide range of options to help them balance employment with their personal and family lives. Todayâ€™s
employees and prospective employees attach great importance to flexible working arrangements and to
support in caring for children and close relatives. Bayer offers a variety of flexible working opportunities
throughout the world. In many countries, these go well beyond the statutory requirements. We significantly expanded our benefits and services in this area in 2015, for example in China.
In 2015, Bayer concluded a new General Works Agreement with the Works Council in Germany on a
binding and uniform framework for short-term mobile working. For the first time, this agreement is
applicable throughout the Group.
We regularly conduct extensive global surveys of family-friendly working arrangements. In 2015, these
showed further progress at our significant locations of operation. New and improved programs for
flexible working from home, flextime and caring for relatives have been introduced. In 2015, the Bayer
Group had some 10,200 part-time employees, in particular in Europe. This figure represents 8.5% of
the total headcount.
online annex: 3-6.1-2
Percentage of Part-Time Employees by Region and Gender

[Table 3.6.3-3]
Women

Men

Total

2014

2015

2014

2015

2014

2015

%

%

%

%

%

%

Region
Asia / Pacific

2.2

2.1

0.3

0.1

1.0

0.8

23.5

24.1

11.2

12.2

15.9

16.9

Latin America / Africa / Middle East

0.1

0.2

0.0

0.0

0.1

0.1

North America

1.6

1.2

0.1

0.2

0.7

0.6

12.1

12.7

5.3

6.0

7.9

8.5

Europe

Total

Bayer enables both men and women to take parental leave. Since national parental leave regulations
vary widely from country to country, we only compile data for our significant locations of operation.
Group-wide 1,315 women and 788 men took parental leave in 2015. By the end of the year, around
1,847 employees on parental leave had returned to work. 81% of women and 99% of men who took
parental leave in 2015 returned to work in the same year.
online annex: 3-6.1-3
The next table shows the number of employees who have returned after the standard statutory parental leave program and Bayerâ€™s more far-reaching â€œFamily & Careerâ€ model in the past seven years,
using Germany as an example. By the end of 2015, 82.6% had returned to work.

92

Bayer Annual Report 2015
Combined Management Report
6. Employees

Employees Returning from Parental Leave using Germany as an Example

Employees who have taken parental leave since 2009
Returnees by 2015
Women

%

Absolute

100.0

3,178

82.6

2,624

58.7

1,867

Still on parental leave / with a dormant employment contract

17.2

321

Returned by 2015

72.4

1,352

Left the company1
Men
Still on parental leave / with a dormant employment contract

1

[Table 3.6.3-4]

10.4

194

41.3

1,311

1.3

17

Returned by 2015

97.0

1,272

Left the company1

1.7

22

Includes employees who have left the company due to employer- and employee-driven terminations, severance agreements and expiration
of contracts

The General Works Agreement on caring for close relatives helps Bayer employees in Germany to combine working with their role as carers.
online annex: 3-6.1-4
Under this agreement, employees can take up to 10 daysâ€™ paid leave to provide emergency care for
family members. For longer periods, they are entitled to work part-time. During this time, their salary
can be topped up by drawing funds from their long-term account. Alternatively, employees who need
to care for close relatives full-time can take unpaid leave for up to six months (or up to one year in
exceptional cases). The new General Works Agreement on mobile working, which includes working
from home for short periods, also offers employees greater flexibility in dealing with personal emergencies.

GRI
G4-26

EMPLOYEE COMMUNICATION
We regard providing regular, up-to-date information for our employees and involving them through
active dialogue as an integral part of modern human resources and talent management based on competitive structures and processes. To ensure this, Bayer stepped up open and transparent communication with employees in 2015. The previously separate intranet sites providing hr information, company
news, country-specific information and background facts have been combined, offering extensive information on career paths, compensation, training and benefits.
Communication with employees also includes meeting national and international obligations to inform
staff promptly and extensively about upcoming changes in the Group.
In Germany we combine providing timely information to the employee representatives on the Economics Committee of the company concerned with coordinating and jointly deciding on the proposed communication measures.
We also actively involve our employees in dialogue through a range of offerings and specifically encourage open discussion. These include regular employee assemblies, information events for managers and
the European Forum, where employee representatives from all European sites engage in discussion with
the Board of Management. Particular attention is paid to explaining strategic issues, business performance, research, innovation and sustainability.

93

Bayer Annual Report 2015
Combined Management Report
6. Employees

6.2 Diversity and Internationality
A diverse employee structure is vital for our companyâ€™s future competitiveness. Diversity improves our
understanding of changing markets and consumer groups, gives us access to a broader pool of talented
employees, and enables us to benefit from the enhanced innovative and problem-solving abilities that
are demonstrably associated with a high cultural diversity within the company.
A better gender and cultural balance at management level is especially important for our success as a
company. Our activities in this area are bundled in â€œLeading Across Cultures and Genders.â€ At the heart
of this program are special training sessions for managers. These provide an opportunity for them to
consider the economic benefits of greater diversity, cultural and gender-specific differences and positive
examples from within the Group in order to develop action plans for their own areas of responsibility.
online annex: 3-6.2-1
Since November 2014, Bayer has been a member of the Gender Parity Council of the World Economic Forum in Davos. It is also a founding member of the new â€œChefsacheâ€ network sponsored by the
German Chancellor Angela Merkel, which was set up in the summer of 2015. The members of this initiative are committed to working together to develop practically oriented strategies to drive diversity
and gender balance in their organizations.
Overall, the Bayer Group employs people from around 150 different nations. Of the members of our
Group Leadership Circle, in which 33 nationalities are currently represented, around 67% come from
the country in which they are employed. The Group Leadership Circle comprises managers who perform senior functions in the Group. At the end of 2013, 82% of senior managers in our five top contract
levels came from Western Europe, the United States and Canada and 18% came from other countries.
By the end of 2015, the proportion of employees in the latter group had increased by three percentage
points to 21%. We aim to increase this to 25% by 2020.

Group target 2015:
increase in the
proportion of senior
managers from outside
the E.U., the United
States or Canada to
25%

In 2010, Bayer set itself the voluntary target of raising the proportion of women at the five highest management levels throughout the Group to 30% by the end of 2015. In just five years, we have increased
the proportion of women in this management segment from 21% to around 28%. We aim to raise this
to 35% by 2020.

Group target 2015:
increase in the
proportion of women
in senior management
to 30%

In the Group Leadership Circle â€“ the top management level below the Board of Management â€“ the ratio
likewise improved from 93% men and 7% women at the end of 2010 to 87% men and 13% women at
the end of 2015.
online annex: 3-6.2-2
Bayer Group Workforce Structure1

[Table 3.6.3-5]
Women

Men

Total

2014

2015

2014

2015

2014

2015

Senior management

2,800

3,100

7,700

7,900

10,500

11,000

Junior management

10,900

11,300

16,600

16,700

27,500

28,000

Skilled employees

30,200

29,300

49,200

48,500

79,400

77,800

Total

43,900

43,700

73,500

73,100

117,400

116,800

800

800

1,800

1,800

2,600

2,600

Apprentices

2014 figures restated
1 Number of employees converted into full-time equivalents (FTE) and rounded to the nearest hundred

See Chapter 1.4
for Group targets

94

Bayer Annual Report 2015
Combined Management Report
6. Employees

6.3 Employee Compensation and Variable Pay
Compensation at Bayer combines a basic salary reflecting performance and responsibility with elements
based on the companyâ€™s success, plus extensive additional benefits. In this way, we aim to offer our
employees working conditions that give them a high degree of security and reliability. Adjustments
based on continuous benchmarking are designed to ensure that our compensation is always internationally competitive. We also attach great importance to equal pay for men and women, providing fair
and competitive compensation worldwide and informing our employees transparently about the overall
structure of their compensation.
online annex: 3-6.3-1
At Bayer, individual salaries are based on each employeeâ€™s personal and professional abilities and the
level of responsibility assigned to them. At managerial level, this is based on uniform evaluation of all
positions throughout the Group using the internationally recognized Hay method. In areas of the
Group and jobs that fall within the scope of binding collective bargaining agreements, there are no
differences in pay based on gender either. This also applies for the compensation of trainees. In the
Emerging Markets and developing countries, too, compensation levels are aligned to local market
conditions. To provide a transparent overview of their compensation, including all additional benefits
provided by the company and employer pension and social insurance contributions, more than
30,000 employees in 12 countries up to now annually receive an extensive â€œTotal Reward Statementâ€
containing all relevant information. This will be rolled out successively to further countries in the
next few years.
Our compensation concept also includes variable one-time payments. More than â‚¬1,100 million is earmarked for bonus awards to employees for 2015 under the Group-wide short-term incentive (sti) program. In many countries, employee stock programs enable our staff to purchase Bayer shares at a discount. This offers them a further opportunity to participate in the company and its business performance. We also offer senior managers throughout the Group â€œAspire,â€ a uniform long-term compensation program based on the development of the share price (see note [26.6] to the consolidated financial
statements). For members of the Group Leadership Circle, an appropriate personal investment in Bayer
stock is the prerequisite for participating in this program.
In the continuing operations, our personnel expenses amounted to â‚¬11,203 million in 2015 (2014:
â‚¬9,693 million). The change was mainly due to currency effects, an increase in average employee numbers, and higher employee bonuses. Offering a stable income and financial security is a basic principle
of our global compensation strategy. This also applies to financial security in old age. More than 70% of
Bayer employees worldwide are included in a Bayer pension plan. Pension provision is available to most
employees for the period after their retirement. The way these benefits are provided varies according to
the legal, fiscal and economic conditions of each country, the benefits generally being based on employee compensation and years of service. Further details of pension provision and pension obligations
are given in note [29] to the consolidated financial statements.

95

Bayer Annual Report 2015
Combined Management Report
6. Employees

Personnel Expenses and Pension Obligations

Personnel expenses
of which pension and social security
contributions
Pension obligations1

[Table 3.6.4]
2011

2012

2013

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

8,726

9,194

9,430

9,693

11,203

1,672

1,823

1,845

1,818

2,191

19,310

22,588

20,682

27,771

26,809

2014 figures restated; figures for 2011 â€“ 2013 as last reported
1 Present value of defined-benefit obligations for pensions and other post-employment benefits for continuing and discontinued operations

HUMAN RIGHTS AND SOCIAL RESPONSIBILITY
Our social responsibility as a company and an employer is based on our corporate values and our unreserved commitment to supporting and fostering human rights in our sphere of influence. Bayerâ€™s Human Rights Position is set out in a binding Group-wide policy. We are committed to respecting, fostering and reporting transparently on human rights both internally and within our sphere of influence. That
means, in particular, that we have policies, processes and monitoring systems to enforce human rights
in our business operations. Alongside working conditions in the Bayer Group, these outline our expectation that human rights will be respected at all stages in the supply chain, as detailed in our Supplier
Code of Conduct. In addition, our life values and Corporate Compliance Policy commit all employees
around the world to fair and lawful conduct toward staff, colleagues, business partners and customers.
We are a founding member of the un Global Compact and respect the United Nationsâ€™ Declaration of
Human Rights and a range of globally recognized declarations applicable for multinational corporations.

See Chapter 7.1

online annex: 3-6.3-2
These include, in particular, the oecd Guidelines for Multinational Enterprises, the Tripartite Declaration of Principles Concerning Multinational Enterprises and Social Policy, and the core labor standards of the International Labour Organization (ilo). We also observe the u.n. Guiding Principles on
Business and Human Rights, which were adopted in 2011. To implement these, in 2015, we played
an active part in the consultation process, which aims to support the German government in drafting
a national action plan.
To enhance our employeesâ€™ awareness of the importance of human rights in their day-to-day activities,
we trained around 52% of our workforce in the main aspects of our Human Rights Position at various
courses with a total duration of 201,000 hours in 2015. That included training for internal and external
security staff. The compliance organizations at Group and country levels monitor compliance with the
relevant corporate policies. If there are signs of violation, employees can contact their Compliance Officer at any time, anonymously if required. Alternatively, they can contact the Group-wide compliance
hotline, which is available worldwide to the general public as well as to employees. For further details
see Chapter 16.3 â€œCompliance.â€
At Bayer, social responsibility includes ensuring safe working conditions and thus an environment
where our employees can work and undertake international business travel without fear. We support
our employees by providing training to prepare them for business trips, including training in the correct
conduct in emergencies.

See Chapter 16.3

96

Bayer Annual Report 2015
Combined Management Report
6. Employees

Our social responsibility is also reflected in our approach to necessary changes and restructuring
measures. In Germany, which remains the companyâ€™s largest operational base with 36,700 employees,
business-related dismissals are excluded through the end of 2020 for a large proportion of employees
under an agreement with the employee representatives.
In 2015, the working conditions for around 53% of our employees worldwide were governed by collective or company agreements. The contractually agreed working hours of our employees do not exceed
48 hours a week in any country. At various country companies, the interests of the workforce are represented by elected employee representatives who have a right to be consulted on certain personnelrelated decisions.
online annex: 3-6.3-3

Percentage of Collective Agreements by Region

[Table 3.6.4-1]
Percentage of employees covered by collective agreements,
especially on compensation and working conditions 1
2014

2015

%

%

Asia / Pacific

14

15

Europe

87

88

Latin America / Africa / Middle East

45

45

Region / area

North America
Total
1 Collective

5

5

52

53

or company agreements

Our understanding of our role as a socially responsible company includes a commitment to helping
disadvantaged people. We employ some 2,500 people with disabilities in 29 countries. That is around
2% of our total workforce. 35% are female and 65% male. Most employees with disabilities work for
our companies in Germany, where they made up 4.9% of the workforce in 2015.
An important part of our sustainable human resources policy is ensuring a high level of social protection
for our employees. For example, nearly all employees worldwide either have statutory health insurance
or can obtain health insurance through the company. In 2015, we once again expanded or improved the
quality of the health benefits provided for employees in many countries. 78% of employees have access
to a company pension plan.

Health Insurance and Pension Coverage

[Table 3.6.5]
Health insurance1

Pension plansÂ²

2014

2015

2014

2015

%

%

%

%

Asia / Pacific

95

95

57

64

Europe

99

99

86

86

Latin America / Africa / Middle East

94

93

59

56

North America

92

93

99

99

96

96

77

78

Region

Total
1

State or employer- / employee-funded
2 Programs to supplement statutory pension plans

97

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

Employeesâ€™ health and vitality are important to Bayer. The company therefore specifically encourages
health awareness and healthy lifestyles. We have therefore introduced a wide range of workplace
health management programs at all levels, which are being expanded in response to employee surveys.
Further information can be found in Chapter 9.1 â€œOccupational Health and Safety.â€

7. Procurement, Production, Logistics,
Distribution
We strive to offer our customers innovative products and high-quality solutions. This requires efficient
processes all along the value chain for our products â€“ in procurement, production, logistics and distribution. Economic factors play a role here, as do ecological and social criteria such as comprehensive
product stewardship, human rights and a clear commitment to safety and environmental protection.
At our production sites throughout the world, we continuously work to improve our cost structure, react
more rapidly to market fluctuations through increased flexibility and achieve our ambitious quality and
safety objectives. The quality requirements for our products and services vary due to divergent regulatory demands: the manufacture of pharmaceutical and medical devices in particular is subject to extraordinarily stringent requirements.
This chapter presents the (internal) value chain: how we procure, manufacture and transport our products, as well as how we market and distribute them.

7.1 Procurement and Supplier Management
Bayerâ€™s procurement organization supplies our internal business partners around the world with goods
and services while operating in accordance with the ethical, ecological, social and economic principles
established in our procurement directive. This directive is binding for all employees. Our procurement
activities aim to ensure security of supply, provide a financial value contribution and meet quality and
sustainability requirements. Procurement makes a substantial value contribution to the Bayer Group by
centrally pooling know-how, leveraging network effects and economies of scale throughout the organization and facilitating access to innovation.
We exert significant influence on society and the environment in many regions as a result of our procurement activities, which in 2015 took place in 151 (2014: 147) countries and accounted for a procurement spend of some â‚¬22.2 billion (2014: â‚¬20.3 billion) from transactions with approximately
112,500 (2014: approximately 112,000) suppliers in all areas.
In 2015, our procurement spend in Germany, the United States and Japan accounted for nearly 67% of
our expenditures in oecd (Organisation for Economic Cooperation and Development) countries, which
in turn made up about 53% of the Bayer Groupâ€™s global procurement spend. Brazil, India and China
together accounted for about 68% of expenditures in the non-oecd countries or about 14% of the total
spend.

See Chapter 9.1

98

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

online annex: 3-7.1-1
Procurement Spend and Number of Suppliers in OECD and Non-OECD Countries in 2015

[Table 3.7.0-1]

Spend

Suppliers

â‚¬ billion

%

Number

%

Germany

5.4

24.3

22,286

19.8

United States

5.3

23.9

11,515

10.2

Japan

1.1

4.8

1,888

1.7

Other

5.8

26.3

43,461

38.7

Total

17.6

79.3

79,150

70.4

3.6

OECD countries

Non-OECD countries
China

2.1

9.5

4,032

India

0.5

2.5

3,738

3.3

Brazil

0.5

2.1

2,387

2.1

Other

1.5

6.7

23,103

20.6

Total

4.6

20.7

33,260

29.6

Where possible, Bayer buys locally. In 2015, this applied to 75% of our procurement spend at our
main business locations, and 71% of our total worldwide procurement spend. This enables us to align
our procurement activities to the requirements of our sites in the regions and to help strengthen local
economies.
Bayer minimizes procurement-specific risks for goods and services of strategic importance, such as
supply bottlenecks or major price fluctuations, through long-term contracts and active supplier management. In this way we ensure both the companyâ€™s global competitiveness and smooth production
processes.
Indirect goods that are not of relevance to production are procured by the respective major user within
the Bayer Group. The individual procurement organizations were coordinated during the reporting
period by the Group Procurement Committee, which reports directly to the Chief Financial Officer. In
line with the companyâ€™s procurement strategy, direct and production-related procurement in the Bayer
Group is organized decentrally in the subgroups so that Bayer can act in accordance with differentiated market and production requirements. The composition of HealthCareâ€™s supplier portfolio has
changed as a result of the acquisitions of the nonprescription medicines businesses of Merck & Co.,
Inc. and Dihon Pharmaceutical Group Co. Ltd., as well as the divestiture of the Diabetes Care business.

99

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

online annex: 3-7.1-2
Main Procurement Products by Subgroup / Segment

Subgroup / segment

[Table 3.7.0-2]

Main procurement products

HealthCare
Pharmaceuticals

Zetia (finished product), cell media culture (raw material),
Betaferon (interferon-beta-1b) (bulk product)

Consumer Health

Consumer Care: Supradyn (finished product), naproxen (active ingredient),
Berocca (finished product)
Radiology: iopamidol (active ingredient), iodine (raw material), cyclen (raw material)
Animal Health: moxidectin (active ingredient), Avenge (finished product),
Baycox-isocyanate (intermediate)

CropScience
CropScience

Packaging materials, adjuvants and solvents (e.g. rapeseed oil, soybean oil, toluene,
ammonia), complex intermediates (e.g. pyridine polyfluoride) and active ingredients
(e.g. mancozeb)

Covestro
Covestro

Key basic raw materials are benzene and phenol, propylene oxide, toluene, acetone
and hexamethylenediamine.

The use of renewable raw materials currently plays only a subordinated role at Bayer. We use them
more intensively when it makes technical, economic and ecological sense to do so.
online annex: 3-7.1-3
A number of hormones are synthesized at HealthCare through certain sterols and phytosterols
that result as byproducts during the production of plant oils from soybeans, oilseed rape /
canola or sunflowers, as well as during wood processing. Palm oil or palm kernel oil is not
used here due to its low sterol content. We additionally purchase various steroids that are
manufactured from diosgenin or its intermediate stages. Today, this substance is usually obtained from yam grown in countries such as China. We also use raw materials such as water,
glucose, yeast, soybean starch, castor oil and corn steep water in our fermentation processes.
Extracts of plant leaves (Centella asiatica) are used in some Consumer Care products. This
plant is widely found in Asia and is not an endangered species. We also take great care with
the cultivation and harvesting of the raw materials for manufacturing plant-based pharmaceuticals for holistic treatments. They are collected and cultivated in line with the gacp (Good Agricultural and Collection Practice) guidelines of the European Medicines Agency.
On the European market, CropScience offers a mild weed control product based on fatty acids
derived from palm oil. As the production of palm oil is often associated with social and ecological problems, Bayer takes part in the Round Table for Sustainable Palm Oil (rspo). This underscores our commitment to responsible materials procurement. In 2015, Bayer for the second time purchased GreenPalm certificates, which support the production of sustainable palm
oil.
Covestro is developing processes for the replacement of raw materials derived from crude oil.
In 2016, for example, the company is planning the commercial production and market launch
of pentamethylene diisocyanate (pdi), an isocyanate produced from a novel renewable raw material derived in turn from biomass.

100

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

Sustainability in supplier management
Bayer regards adherence to sustainability standards within its supply chain as both a crucial factor for
value creation and an important lever for minimizing risks. For this reason, not just economic standards,
but also ethical and environmental, social and governance (esg) standards apply for the selection of new
as well as established suppliers. These standards are defined in Bayerâ€™s Supplier Code of Conduct,
which is based on the principles of the u.n. Global Compact and our Human Rights Position. It forms
the basis for our collaboration with suppliers and is available online in 14 languages. The Code of Conduct is integrated into electronic ordering systems and contracts throughout the Bayer Group. Since
2015, furthermore, relevant new and renewed supply contracts have contained special clauses that
request suppliers to observe the sustainability requirements defined in the Code of Conduct and authorize Bayer to monitor this.
Group targets: supplier
management
See also Chapter
1.4 for Group
targets

In order to consistently drive sustainability in supplier management, Bayer has set ambitious targets. By
2017, we plan to evaluate all strategically important suppliers i.e. those with a major influence on business in terms of, for example, procurement spend and long-term collaboration prospects (3-5 years)
according to sustainability-relevant criteria (target attainment as of 2015: 84%). By 2020, we also aim
to include in the evaluation all those suppliers with a significant procurement spend (> â‚¬1 million p.a.)
that are regarded as potential high-risk suppliers (target attainment as of 2015: 73%). Risk definition is
based on a country- and material-based approach. Another objective is the development and establishment of a sustainability standard for our supply base by 2020. Here we are working with both the Together for Sustainability (TfS) initiative and the Pharmaceutical Supply Chain Initiative (psci). The goals
include standardizing and sharing sustainability assessments and audits of suppliers in the same industry and describing clear expectations regarding sustainability so as to establish appropriate sustainability practices among our suppliers. The TfS initiative counts 16 and the psci 19 participating companies.
A key challenge for sustainable supplier management in the Bayer Group is to prevent child labor in the
seed supply chain of our CropScience subgroup.
Our Human Rights Position is unequivocal and includes a strict ban on child labor. We therefore also
obligate our suppliers along our supply chain strictly to refrain from employing children. For many
years, CropScience has taken systematic action to prevent child labor in the seed supply chain in India,
Bangladesh and the Philippines through its Child Care Program. Special teams from Bayer visit the
fields used, for example, in cotton, rice and vegetable seed production without prior notice throughout
the cultivation season in order to raise awareness of the issue and the Bayer requirements and to determine the age of the workers there. Thanks to this stringent monitoring system, which is supported by
local educational initiatives, there are now only very few incidences of child labor among our contractors, and we are closely tracking these cases. Further risk assessments were carried out in vegetable
and rice seed production for Bayer in Thailand, China, Indonesia and Vietnam. It is planned to introduce
the Child Care Program in these countries as well in 2016. We measure the success of our comprehensive program using the indicators â€œChild labor incidence per monitored kmÂ²â€ and â€œChild labor incidence as a percentage of total monitorings of laborers.â€
In the following diagram depicting the latter indicator, we demonstrate the continued elimination of
child labor in Indian cotton and vegetable seed production sites contracted by Bayer based on the results of field monitoring.

101

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

50,000

0.15

40,000

45,000

0.20

2014 / 2015

85,000

2013 / 2014

67,000

65,000

0.25

2012/2013

64,000

104,000

0.30
Child labor incidence in %

2011 / 2012

91,000

2010 / 2011

86,000

2009 / 2010

114,000

2008 / 2009

[Graphic 3.7.1]

80,000

Child Labor Incidence in the Production of Cotton and Vegetable Seed for Bayer in Relation to the Total Number of Monitorings1

0.10
0.05
0
Number of monitorings of laborers (cotton)
Number of monitorings of laborers (vegetables) 2

Child labor incidence in relation to number of monitorings (cotton)
Child labor incidence in relation to number of monitorings (vegetables)2

1The

figures cover several growing cycles per cultivation year. In India the cultivation year runs from the middle of one year to the middle of the next, depending on climatic
conditions and the various different seed types. Cumulated depiction on the basis of control inspections performed (at least 3 per cultivation season for vegetables and up
to 6 per season for cotton)
2 Vegetable seed included in field monitoring from 2010 / 2011 onward; for vegetables, cultivation areas and number of monitorings refer to a combination of various
different seed types. Each type of seed has its own monitoring intensity.

Below you will find a graphic for the indicator â€œChild labor incidence per monitored kmÂ²â€ and further
information on our Child Care Program.
online annex: 3-7.1-4

Child Labor Incidence in the Production of Cotton and Vegetable Seed for Bayer in Relation to the Cultivation Area Monitored 1
2009 / 2010

2010 / 2011

2011 / 2012

2012 / 2013

2013 / 2014

2014 / 2015

108
85

2.5

1

35

41

49

47

56

57

65

2
1.5

92

3

44

Child labor incidence per monitored km2

121

2008 / 2009

[Graphic 3.7.1-1]

0.5
0
Cotton seed cultivation area monitored (in km2)
Vegetable seed cultivation area monitored (in km2) 2

Child labor incidence per monitored km2 (cotton)
Child labor incidence per monitored km2 (vegetables) 2

The figures cover several growing cycles per cultivation year. In India the cultivation year runs from the middle of one year to the middle of the next, depending on
climatic conditions and the various different seed types. Cumulated depiction on the basis of control inspections performed (at least 3 per cultivation season for
vegetables and up to 6 per season for cotton)
2 Vegetable seed included in field monitoring from 2010 / 2011 onward; for vegetables, cultivation areas and number of monitorings refer to a combination of various
different seed types. Each type of seed has its own monitoring intensity.
1

Once a year, the audit firm ey (formerly Ernst & Young), India, conducts unannounced inspections of
randomly selected farms on behalf of Bayer.

102

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

Suppliers who can verify that they strictly observe our ban on child labor receive a bonus from Bayer
along with training in raising agricultural efficiency. Graduated sanctions are applied for noncompliance. These range from written warnings to termination of the contract in the case of repeated noncompliance.
Bayer regards school attendance not only as essential for childrenâ€™s development but also as an effective tool to drive the elimination of child labor. We therefore also visit the parents of children we
find working in the fields to convince them of the importance of school education. We promote this
with the â€œLearning for Lifeâ€ initiative within our Child Care Program. This initiative aims to ensure
that children and young people get a proper education and covers everything from reintegrating
children into the regular school system to vocational training measures. Between 2005 and the end
of 2015, the â€œLearning for Lifeâ€ educational programs benefited more than 6,100 children and young
people.
The Child Care Program Advisory Council, comprised of international experts and recognized professionals, supports Bayer in the protection of childrenâ€™s rights and the obligation of seed production
without child labor. The annual meeting of the Advisory Council, which took place in India in May
2015, focused on the effectiveness of the Child Care Program and on a project concerning minimum
wages in the seed supply chain.
Evaluating the sustainability performance of our suppliers
Bayer verifies the observance of sustainability requirements by our suppliers through online assessments and on-site audits. Suppliers are selected for these evaluations based on a combination of country and material risks as well as strategic importance in accordance with our Group targets.
The online assessments are carried out on Bayerâ€™s behalf by EcoVadis, an established provider of sustainability performance evaluations. They are comprised of a web-based, modular questionnaire completed by the supplier, coupled with accompanying verification documents and 360Â° screening. The
evaluation criteria comprise the areas environment, labor practices and human rights, fair business
practices and sustainable procurement.
Together with external, independent auditors, Bayer carries out on-site audits of its suppliers based on
the psci and TfS sustainability criteria. In addition, internal auditors evaluate suppliers with a focus on
health and safety, environmental protection and sustainability.
Through cooperation with the industry initiatives psci and TfS, we leverage synergies through the
exchange of comparable, high-quality supplier assessments and / or audits among members using the it
platforms of the respective initiatives.
An overview of the number of supplier assessments and audits can be found in
online annex: 3-7.1-5

Supplier Assessments and Audits for 2015

1

Sustainability assessments via the EcoVadis platform

[Table 3.7.0-3]
2014

2015

692

521

Sustainability auditsÂ² by external auditors

56

71

HSEÂ³ / sustainability audits by Bayer auditors

94

107

1 Supplier
2
3

assessments initiated by Bayer as well as assessments of suppliers working for Bayer exchanged as part of the TfS initiative
Initial and follow-up audits initiated by Bayer of suppliers working for Bayer and exchanged as part of the TfS and PSCI initiatives
Health, safety, environment

103

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

Within the scope of the TfS initiative, a total of 2,580 supplier assessments using EcoVadis and 179
audits â€“ performed, for example, in China, India and Brazil â€“ were successfully completed in 2015. A
total of 40 joint and / or shared audits were carried out in 2015 through psci, for example in Turkey,
Brazil and Uruguay.
Alongside consideration of our sustainability criteria in the selection of suppliers, CropScience and
HealthCare undertake separate evaluations of suppliers with regard to the contract manufacturing of
quality-relevant goods and services. These evaluations encompass the areas of health, safety and environmental protection among others and are performed prior to the start of operations. Since 2015,
furthermore, HealthCare has obligated newly selected suppliers with a prospective annual procurement spend in excess of â‚¬1 million to undergo an EcoVadis sustainability assessment or an on-site
audit after being awarded business. The suppliers evaluated in 2015 in this context satisfied our sustainability requirements.
Moreover, Bayer monitors suppliers who process minerals such as tin, tungsten, tantalum and gold to
establish whether these originate in conflict regions. In this way we want to rule out that such materials
find their way into our products through supply chains. To tighten up our requirements, the issue of
conflict materials has also been included in our Supplier Code of Conduct.
online annex: 3-7.1-6
International regulations such as the Dodd-Frank Act in the United States obligate companies to disclose the origin of certain raw materials to rule out that conflict minerals from the Democratic Republic of the Congo or its neighboring countries find their way into products through supply chains.
Bayer has questioned about 100 suppliers who could potentially be impacted by this issue. Nearly
60% of them confirmed to us that they do not procure potential conflict minerals. The status of the
remaining suppliers is being clarified.
All online assessments and audits are comprehensively analyzed and documented so that â€“ in the event
of unsatisfactory results â€“ specific improvement measures can be defined together with the suppliers to
ensure the future observance of social, ethical and environmental standards. In 2015, 33 suppliers
(equivalent to 6% of those evaluated) posted a critical result. These suppliers were requested by Bayer
to rectify the identified weaknesses with the help of corrective instructions or action plans.
online annex: 3-7.1-7
The corrective action established together with the suppliers in 2015 mainly related to the areas of
occupational health, occupational safety, fair business practices and sustainable procurement. In
2015, we monitored the implementation of the stipulated improvements among 324 suppliers by
means of reassessments through the EcoVadis platform; approximately 73% improved their sustainability performance to a relevant degree. In 2015, Bayer was not prompted to end any supplier relationship due solely to sustainability performance or serious sustainability deficiencies.
Training measures and dialogue on the issue of sustainability
We support our hseq and procurement employees in the implementation of our sustainability requirements with targeted Group-wide training measures. In the reporting period, 162 of these employees
completed training courses dealing with the EcoVadis sustainability assessment process. CropScience
carried out additional training courses on the subject of sustainability audits. HealthCare organized
supplementary sustainability workshops for selected procurement employees. In addition, we also offer
our suppliers a wide range of training and dialogue opportunities in order to familiarize them with
Bayerâ€™s sustainability requirements.
online annex: 3-7.1-8
In 2015, Bayer once again held Supplier Days, which are an important dialogue platform for our
subgroups. CropScience organized special training courses on quality, health and safety, and environmental protection for selected suppliers. The TfS initiative organized Supplier Days in China and
Brazil that dealt, for example, with environmental protection and occupational safety. In India, psci
held an education conference where suppliers were trained in occupational safety, environmental
protection, process and plant safety, and labor and business ethics. Both initiatives offer extensive
supplementary information material and online training courses on their websites.

GRI
G4-26

104

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

7.2 Production
Bayer operates production facilities at more than 120 sites in 35 countries. We deploy our competencies
and experience at all our sites to continuously optimize production processes and technologies, as well
as infrastructure. That is because product quality and the efficiency of materials and energy are crucial
competitive factors.
The safe and responsible operation of our facilities and the comprehensive safety of our employees and
the people who live near our sites are of utmost importance to Bayer. Bayer also places great importance on protecting the environment and using natural resources responsibly. Accordingly, management systems have been established for the areas of health, safety, environmental protection and
quality (hseq) that apply throughout the Bayer Group. They are integrated into all business processes
and regularly audited and updated. All relevant hseq performance indicators from our production sites
are compiled in a Group-wide Bayer site information system (BaySIS). Extensive information on the
topics of safety, product stewardship, environmental protection and the corresponding management
systems can be found in chapters 8, 9 and 10.
HEALTHCARE
SITES
HealthCare operates production sites around the world at which active ingredients are manufactured
and at which formulation and packaging services are performed for the product portfolio of all
HealthCare divisions. The importance of the production sites within the network is regularly assessed,
giving consideration to site- and product-specific criteria. Product supply strategies and site strategies
are further developed and / or adjusted on this basis. The most important production and formulation

HealthCare Sites
Segment / site

[Table 3.7.1]
Main activity

Pharmaceuticals
Bergkamen, Germany

Active ingredient production

Berkeley, California, U.S.A.

Active ingredient production based on biotechnological processes

Berlin, Germany

Formulation and packaging

Leverkusen, Germany

Formulation and packaging

Turku, Finland

Formulation and packaging of intrauterine systems

Weimar, Germany

Formulation and packaging

Wuppertal, Germany

Active ingredient production

Consumer Health
Bitterfeld-Wolfen, Germany

Formulation and packaging

Cimanggis, Indonesia

Formulation and packaging

Grenzach, Germany

Formulation, filling and packaging

Kiel, Germany

Formulation and packaging of animal health products

Myerstown, Pennsylvania, U.S.A.

Formulation and packaging

Pittsburgh, Pennsylvania, U.S.A.

Manufacture of medical devices such as contrast agent injectors and
consumables

Wuppertal, Germany

Active ingredient production

sites for global product supply in 2015 are listed in the following table.

105

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

QUALITY MANAGEMENT
The manufacturing of pharmaceutical and medical devices is subject to extraordinarily stringent quality
requirements that are based on internationally recognized standards. Compliance with these requirements at Bayer is regularly audited by internal experts, regulatory authorities and external consultants.
online annex: 3-7.2-1
Quality standards are developed on the one hand according to regulatory requirements, approvals
and authorizations, and relevant standards of nongovernmental organizations and industry associations, and on the other hand according to customer expectations. These requirements are evaluated
by HealthCare and integrated into an internal quality management (qm) system that is based on international standards of the iso (e.g. iso 9001 and iso 13485) and the ich (International Conference
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use), as
well as on rules for good working practice (GxP) in the development and manufacture of pharmaceuticals (e.g. Good Manufacturing Practices (gmp), Good Distribution Practices (gdp) and Good Clinical
Practices (gcp)). With the help of our qm system, we effectively and transparently implement and
manage the quality control processes and responsibilities according to established, documented and
binding procedures and methods. The goal is to ensure the quality of our products throughout their
entire life cycle and safeguard the value chain over the long term.
INVESTMENTS IN PROPERTY, PLANT AND EQUIPMENT
HealthCare continuously invests in its global production network in order to ensure security of supply,
provide the necessary capacities and satisfy regulatory requirements. Further production capacities for
the manufacture of hemophilia A products are being established at the Wuppertal and Leverkusen sites
through the biggest current capital expenditure program with a total volume of more than â‚¬500 million.
Another major project with a volume of some â‚¬100 million is aimed at expanding production capacities
in Beijing, China.
CROPSCIENCE
SITES
The products of the Crop Protection and Environmental Science units are mainly produced at the companyâ€™s own production and formulation sites, the largest of which are listed in the following table:

CropScience Sites

[Table 3.7.2]

Site

Main activity

Dormagen, Germany

Development of new production processes and manufacture of
Crop Protection and Environmental Science products

Frankfurt am Main, Germany

Manufacture of Crop Protection and Environmental Science products

Nunhem, Netherlands

Vegetable seed production

Kansas City, Missouri, U.S.A.

Manufacture of Crop Protection and Environmental Science products

Knapsack, Germany

Manufacture of Crop Protection and Environmental Science products

Vapi, India

Development of new production processes and manufacture of
Crop Protection and Environmental Science products

Numerous decentralized formulation and filling sites enable the company to quickly react to the needs
of local markets. At these sites the active ingredients are processed into herbicides, fungicides, insecticides, seed treatment products and Environmental Science products according to local requirements
and application areas. Packaging of the products also takes place in these facilities.
Production of seeds takes place at locations close to our customers in Europe, Asia, and North and
South America at our own farms or under contract.

See Chapter 14.5

106

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

QUALITY MANAGEMENT
Our CropScience products are manufactured according to high quality standards based on iso 9001, to
which more than 80% of CropScience production sites are certified. The compliance of the production
processes and registered product specifications is regularly monitored by external auditors. All our
products are reviewed and registered by the national authorities in the various countries, and thus fulfill
the respective requirements with regard to quality and user safety.
INVESTMENTS IN PROPERTY, PLANT AND EQUIPMENT
We invest continuously in our global production network in order to generate capacities for new products and technologies and to improve manufacturing processes. We plan to significantly increase our
capital investment to meet the steadily rising demand. We intend to invest approximately â‚¬2.4 billion in
property, plant and equipment between 2013 and 2016.
The construction of a new crop protection facility for the production of methane phosphorous acid ester
(mpe), an important precursor for the active ingredient glufosinate-ammonium, commenced at the
Knapsack site. The capital expenditure volume is more than â‚¬150 million. In September 2015, we expanded our capacity for oilseed rape / canola through the construction of a new production site in Monheim, Germany.
COVESTRO
Covestro operates a large number of locations worldwide, including eight world-scale production sites.
The company also maintains specialized technical centers around the world that offer customers individually tailored solutions and that are designed for regional supply. Covestro thus guarantees not just a
global presence, but also above all customer centricity with short supply times and flexible service. At
these production sites Covestro pursues the ambitious goal of assuming and further expanding its leading position in the future, too, with regard to production volume, quality, efficiency and safety. Innovative and environmentally friendly production processes are employed as a result of the continuous technological improvement of our facilities. The selectively backwards-integrated production process enables Covestro to procure key raw materials such as chlorine and propylene oxide from within the company or through joint ventures so as to reduce the dependency on external supply sources.
SITES
Covestroâ€™s most important production sites are listed in the following table:

Covestro Sites

[Table 3.7.3]

Site

Main activity

Leverkusen, Germany

Coatings, adhesives and specialties production; technical laboratories; chlorine
production

Uerdingen, Germany

Polycarbonates and polyurethanes (MDI) production; chlorine and CO production

Dormagen, Germany

Polyurethanes (TDI, PET) and coatings, adhesives and specialties production;
chlorine and nitric acid production

Baytown, Texas, U.S.A.

Polyurethanes (MDI, TDI), polycarbonates and coatings, adhesives and specialties
production

Shanghai and Shanghai
Chemical Industry Park, China

Polyurethanes (MDI, TDI), polycarbonates and coatings, adhesives and specialties
production; chlorine production

BrunsbÃ¼ttel, Germany

Polyurethanes (MDI) production

Antwerp, Belgium

Polyurethanes (PET) and polycarbonates production

Map Ta Phut, Thailand

Polycarbonates and coatings, adhesives and specialties production

To serve our differentiated businesses, we maintain several production facilities in selected countries
that include systems houses where we formulate and supply customized polyurethane systems, as well
as plants where we compound polycarbonate granules to meet specific customer requirements or
manufacture semi-finished products (polycarbonate sheets). We also operate regional production facilities for derivatives of the Coatings, Adhesives, Specialties Business Unit and for functional films made
of polycarbonate or thermoplastic polyurethane.

107

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

QUALITY MANAGEMENT
Covestro applies very high standards for the quality of the raw materials it uses and their further processing into high-tech plastics and polymer precursors. A quality management system was implemented
for this purpose that is certified to the international standard iso 9001. In terms of total energy consumption, over 99.97% of the reporting production and nonproduction sites of Covestro worldwide are
certified. This is regularly monitored by internal and external auditors.
INVESTMENTS IN PROPERTY, PLANT AND EQUIPMENT
To safeguard competitiveness, Covestro continuously invests in a global production network so as to
maintain the production facilities and their infrastructure, optimize production processes and, in the
case of profitable growth prospects, appropriately expand capacities. Due to the significant expansion
of capacities in recent years, Covestro plans to invest less through 2020 and focus on maintaining and
optimizing existing production facilities.

7.3 Logistics
Logistics at Bayer does not just involve the transport, handling or warehousing of goods. On the contrary, it comprises the entire planning, steering, coordination, implementation and monitoring of all
internal and intercompany flows of goods and the related information. Not only are individual business
functions combined into process chains, all processes are integrated â€“ from the procurement of raw
materials to the sale to end users. We work continuously to develop efficient and environmentally
friendly logistics concepts with the goal of reducing transport and storage complexity.
The safe transport of our materials and products is very important to Bayer. With this objective in mind,
we have installed management systems and directives with global validity, implemented an agile corporate structure and carefully selected contracted logistics services suppliers. You can find out more in
Chapter 9 â€œSafety.â€
Concrete production and logistics planning depends on the products to be transported and the resulting
specific requirements. Logistics processes are therefore decentrally organized at Bayer. Each subgroup
maintains its own logistics units to account for the demands of different business models.
HEALTHCARE
Among other activities, the internal Product Supply organization steers all logistics services at
HealthCare across divisions â€“ from suppliers to the companyâ€™s own sites, within the production network
and from the company to its customers. This also includes warehouse and transport management and
the steering of supplier-, production- and customer-specific material streams. HealthCare both utilizes
internal capacities and employs external logistics partners to meet its storage and transport needs.
Warehouse sites and transport flows are established and continuously optimized accordingly. Service,
quality and costs are continuously monitored according to corresponding guidelines and indicators.
The means of transport is generally selected in a standardized process between the production site and
the recipient country, with consideration given to demand, costs and environmental aspects. These
aspects also serve to continually optimize transport processes. To this end, hubs are established in the
distribution network, planning processes are optimized and air transport reduced. These globally
steered measures are supported by greater standardization and transparency along the supply chain.

See Chapter 9

108

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

CROPSCIENCE
CropScience manages the transport and storage of products through a multi-stage system that is
aligned to production and distribution. Subsequent to production, active ingredients are distributed to a
global network of specialized warehouses and then forwarded to our regional formulation and filling
sites for further processing depending on current demand. The finished products manufactured there
are then transferred to local distribution warehouses in the respective destination countries where the
products are stored, commissioned after release and shipped to customers. The logistics process at
Seeds encompasses the various stages of production all the way to ready-to-sell seed, which is distributed to customers via local distribution warehouses.
CropScience generally deploys trucks for land transportation, while container ships are primarily used
for overseas traffic. Air freight is only selected in exceptional cases, and accounts for less than 1% of
the transport volume.
COVESTRO
At Covestro, logistics in the regions are centrally organized in Supply Chain Centers. Transport is handled by logistics service suppliers that are selected according to stringent safety, environmental and
quality criteria. The preferred mode of transport is by rail or intermodal â€“ in other words employing a
combination of road, rail and water transport. This increases energy efficiency and reduces co2 emissions. Customers are supplied from close-to-production warehouses, wherever transport times and
supply security allow this. In the case of longer distances, goods are temporarily stored in regional
distribution centers and then dispatched at short notice. Logistics are steered according to indicatorbased management that is aligned toward safety, environmental and supply security aspects.

7.4 Distribution
Bayer markets its products worldwide through a market- and customer-specific distribution network.
The marketing and distribution units play a key role in communicating to customers the benefits and
advantages of our high-quality products and services. Our distribution activities are geared toward the
long-term retention of existing customers and the acquisition of new clients. In this connection, we offer
smooth business processing from ordering to delivery in adequate time. Responsible conduct is also a
top priority for Bayer in marketing and distribution. The necessary rules of conduct, which do not permit legal violations in marketing, are established in our Group Responsible Marketing & Sales Policy.
This Group regulation and the respective training programs are implemented decentrally in the subgroups. A high level of customer satisfaction is essential for the long-term success of our business. We
therefore systematically analyze both the needs and satisfaction of, as well as complaints voiced by, our
customers, and thus foster partnership-based cooperation and dialogue with them.
HEALTHCARE
Our pharmaceutical products are primarily distributed through wholesalers, pharmacies and hospitals.
Co-promotion and co-marketing agreements serve to optimize our distribution network.
Consumer Careâ€™s products are generally sold in pharmacies, with supermarket chains and other large
retailers also playing a significant role in certain important markets such as the United States. The contrast agents and medical equipment of our Medical Care Division are marketed to radiologists, cardiologists and other specialists in medical imaging in hospitals and out-patient clinical sites through a global
direct sales organization, supplemented in some cases by local distributors. Depending on local regulatory frameworks, we market our animal health products through veterinarians and other distribution
channels such as pharmacies or retail stores.

109

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

RESPONSIBLE BUSINESS PRACTICES IN MARKETING AND DISTRIBUTION
In the development, sale and marketing of its products, HealthCare does not tolerate bribery or any other
form of improper exertion of influence on our business partners. Furthermore, Bayer is committed to
ethical advertising and communication for all its products and services. Our minimum standards are
derived from three basic sources: laws and other statutory regulations, industry codes and internal rules.
The marketing and distribution of pharmaceuticals and medical devices are strictly regulated and subject to relevant laws that we are committed to observing. Also applicable at the global or regional levels
are industry codes adopted by associations of the pharmaceuticals, medical devices and animal health
industries. In many countries, furthermore, these standards are further concretized by local codes â€“ all
of which apply to prescription pharmaceuticals and many of which additionally apply to nonprescription
medicines.
online annex: 3-7.4-1
All codes of the International Federation of Pharmaceutical Manufacturers & Associations (ifpma)
serve as a binding global minimum global standard for all products marketed by HealthCare. In addition, Bayer observes the codes of the European Federation of Pharmaceutical Industries and Associations (efpia) for dealings with health care professionals and patient organizations. The whoâ€™s Ethical
Criteria for Medicinal Drug Promotion, together with national ethical standards that are usually enshrined in industry codes at the local level, represent the minimum global standard for the advertising of pharmaceutical products at HealthCare. All the aforementioned codes contain provisions governing, among other issues, advertising material standards, the distribution of samples, cooperation
with members of medical and pharmaceutical specialist groups in connection with speaker and consultancy contracts, and scientific studies. Adherence to these codes is designed to ensure the independence of both health care professionals and patient organizations. Based on the new efpia transparency code and beginning in June 2016 at the latest, furthermore, Bayer will disclose any grants to
health care professionals and organizations annually for the preceding calendar year.
The most important Bayer Group regulation in this connection is our Anti-Corruption Procedure, which
establishes minimum global standards on this topic for the entire company. HealthCare has summarized
the key requirements and the minimum global standard for compliant and ethical conduct in the AntiCorruption Compliance Manual, which applies worldwide in all divisions. The main principles for ethically and legally acceptable advertising for pharmaceuticals and medical devices are also set out in an
internal HealthCare directive. The goal of these directives is to help HealthCare employees to always act
in compliance with all applicable regulations. Should several regulations be relevant, HealthCare principally applies the more stringent standards.
Training measures on product-related communication and anti-corruption are fundamental elements of
the system at Bayer. They are directed toward certain employee groups and are tailored to account for
the special risks these employees are exposed to. The principles presented in these training courses
provide an overview of globally applicable minimum requirements for cooperation with key stakeholders
of HealthCare, such as physicians, hospitals or patient organizations. The courses not only explain general compliance principles but also give specific instructions in relation to nonreciprocal benefits and
the exchange of services with health care professionals.
As part of our compliance management system, we register and investigate any suspected violation of
our responsible marketing principles. This applies to complaints both from within the company and as
notified to us from outside.

See Chapter 16.3

110

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

GRI
G4-26

CUSTOMER DIALOGUE
A keen understanding of manifold customer needs is especially important if HealthCareâ€™s products are
to be successful in the market. Our customers include patients, physicians, caretakers, health policy
decision-makers and opinion leaders, partners from research and development, and health care payers.
Due to the stark distinctions between these groups, the individual HealthCare divisions take specific
steps to enter into dialogue with customers and measure their satisfaction.
Different legal requirements apply for prescription medicines than for nonprescription or medical devices. This makes the conditions under which customer satisfaction data are gathered in the health
sector correspondingly complex. For example, it is not permitted to directly survey patients about the
effects and side effects of prescription medicines. HealthCare therefore conducts primary market and
data research in this area.
online annex: 3-7.4-2
We use market research projects to identify the needs of the various customer groups and thus further strengthen customer orientation at Pharmaceuticals. We also carry out systematic internet analyses that give us a better understanding of our stakeholdersâ€™ opinions, interests and networks. To
measure customer satisfaction, Pharmaceuticals conducts international surveys of its customer
groups according to therapeutic areas. The results of the studies are regularly integrated into brand
planning. To continuously optimize customer service, moreover, we support our medical sales force
through product- and country-specific training courses.
Following the success of pilot projects in key markets, Consumer Care in 2015 began introducing its
excellence program to improve customer orientation worldwide. The program is designed to identify
examples of best practices in the areas of market launch strategies, distribution and trading. It has
already been successfully implemented in 13 countries, and others will follow in 2016.
Animal Health also conducts studies on customer satisfaction and customer retention, applying varying methods according to the respective market segment. From studies that track long-term customer behavior, performance indicators are developed that in turn are used to measure customer satisfaction.
Complaints, customer services for orders, product and delivery information, information on health
care topics or the handling of general inquiries pertaining to HealthCare are processed by the relevant business units and country organizations. The respective contact information is available online.
As the Bayer Group is headquartered in Germany, HealthCare operates a customer service center in
that country with a quality management system certified to iso 9001:2008.
CROPSCIENCE
DISTRIBUTION
CropScience markets its products in more than 120 countries. We market our crop protection products
mainly through wholesalers or directly through retailers. We also sell products directly to customers in
selected markets where market conditions require this mode of distribution.
Distribution activities for seeds are focused on the crops cotton, oilseed rape / canola, rice, soybeans and
vegetables from our own research laboratories and breeding facilities. In our core crops, we have
achieved strong market positions and are internationally represented. Our seeds are sold to growers,
seedling companies, specialist retailers and the processing industry. Plant traits developed using modern breeding methods are either incorporated into our own seed varieties or licensed to other seed
companies.

111

Bayer Annual Report 2015
Combined Management Report
7. Procurement, Production, Logistics, Distribution

The Environmental Science products are mainly sold through wholesalers and specialist retailers. We
market our range of pest and weed control products to professional users in the green industry (including public parks and golf courses), forestry, industrial vegetation management and professional pest
control. In the area of public health, an example being vector control to combat malaria and dengue
fever, much of our business is transacted in response to tendering by government agencies and nongovernmental organizations. We also offer pest control and plant care products to private customers in
the home and garden sector.
RESPONSIBLE BUSINESS PRACTICES IN MARKETING AND DISTRIBUTION
CropScience follows the guidelines of its Product Stewardship Policy with regard to the distribution and
use of its crop protection products. This policy, which also satisfies the requirements of the Group Responsible Marketing & Sales Policy, is based on the International Code of Conduct issued by the Food
and Agriculture Organization of the United Nations (fao). Training materials to explain this Group policy have been distributed throughout the global organization and are available to the employees on the
Bayer intranet.
online annex: 3-7.4-3
Responsible business practices in marketing and sales are addressed at CropScience in compliance
training courses and are also an integral element of marketing and sales excellence training
measures. In 2015, we trained a total of 600 (2014: 2,400) CropScience employees worldwide in
three- and one-day training courses.
CUSTOMER DIALOGUE
CropScience sees tremendous value in the satisfaction of its customers. Our goal is to establish longterm customer relationships that ensure the business success and meet the expectations of both parties.
We strive to fulfill the high expectations of our customers through targeted communication, smooth
business processing and effective complaint management. We regularly determine these expectations
through our commercial excellence activities so that we can offer our customers tailored solutions. In
addition to the customer surveys we conduct through our country organizations every two years according to a standardized process, we analyze all channels of interaction with our customers. We use the
findings of these analyses to align our distribution and marketing processes around the world to the
respective customer needs. In general, we aim to make our dialogue with customers more target groupand region-specific and to continuously improve it. We improve our customer processes in part with the
help of a customer relationship management database that is now used in more than 60 of our country
organizations. We assess our performance using a system of qualitative and quantitative indicators.
CropScience is also intensifying its direct cooperation with farmers through the Bayer Forward Farming
initiative. Our solutions for sustainable agriculture in practice are demonstrated at Bayer ForwardFarms.
The first farms have been established in Belgium, France, Germany and the Netherlands, and further
collaborations are being prepared in Spain and Brazil. CropScience will successively expand this type of
cooperation worldwide.
COVESTRO
DISTRIBUTION AND CUSTOMER DIALOGUE
Covestroâ€™s products are mainly supplied to the automotive and transportation, construction, wood processing and furniture, and electrical / electronics industries. Other customer industries are the sports
and leisure, cosmetics and health care sectors, as well as the chemical industry.
Covestro markets its products mostly through regional and local distribution channels. Here three regional Supply Chain Centers serve as the central link to the customer. Covestro makes use of ecommerce platforms and other channels for order processing. Customer satisfaction is systematically
analyzed on a global basis, enabling the development of improvement measures.

GRI
G4-26

112

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

online annex: 3-7.4-4
The Supply Chain Centers pool all information streams from order acceptance to dispatch planning,
delivery and complaint acceptance in the Europe / Middle East / Africa/Latin America, North America
and Asia / Pacific regions. This ensures a high level of expertise particularly in order management
and in transaction, supply chain and logistics solutions. Using the â€œOrder@Covestroâ€ online information platform, customers can at any time place orders, call up material safety data sheets and
track the status of their orders.
Covestroâ€™s highest quality objective is faultlessness so as to attain a high level of customer satisfaction. To systematically increase customer satisfaction and ensure optimal quality of service, complaints registered in the global management system and by the individual business units are regularly evaluated. Customer evaluations are also analyzed in detail. Through dialogue with internal stakeholders, preventive and corrective measures are undertaken to further increase quality and customer
satisfaction while at the same time lowering the error rate and thus also the incidence of complaints.
In 2015, for example, a total of 5,178 complaints by around 2,088 customers were registered worldwide. This yields a rate of 7.61 complaints per 1,000 deliveries, about the same as in 2014 (7.75
complaints per 1,000 deliveries).
Covestro also works with trading houses and local distributors who are responsible for business with
small customers. Major customers with global operations are serviced directly by key account managers.
RESPONSIBLE BUSINESS PRACTICES IN MARKETING AND DISTRIBUTION
In the marketing of its products, Covestro also takes into account all the requirements of the Bayer
Groupâ€™s Responsible Marketing & Sales Policy. The importance of observing antitrust law and preventing corruption is regularly emphasized in training programs, internal communications and discussions
with management. In 2015, training focused on export control. Around 4,980 Covestro managerial
employees took part in web-based compliance training courses and supplementary target grouporiented, on-site training sessions.

8. Product Stewardship
Our products and services are designed to benefit people and improve their quality of life. We consider
product stewardship to mean that our products are safe for people, animals and the environment when
properly used. This is a key factor in creating lasting trust in our products and maintaining our business
foundation over the long term.
All substances and finished products undergo extensive testing and evaluation to ensure a high degree
of safety. We assess the possible health and environmental risks of a product along the entire value
chain â€“ starting with research and development and continuing through production, marketing and use
by the customer through to disposal. From this we derive suitable steps to mitigate risks based on the
observation of legal requirements and internal standards that go beyond these.
Bayer has put in place suitable directives and management systems for the implementation of regulatory and voluntary product stewardship requirements that are steered by our hseq (health, safety, environmental protection and quality) departments. These efforts are underscored by the Bayer Groupâ€™s
target of completing the assessment of the hazard potential of all substances (>99%) used in quantities
exceeding one metric ton per annum by 2020.
IMPLEMENTING STATUTORY REQUIREMENTS
Extensive legal regulations apply to all products manufactured by Bayer. Chemical substances are
subject to the European chemicals regulation reach (Registration, Evaluation, Authorisation and Restriction of Chemicals) and the clp regulation (Regulation on Classification, Labelling and Packaging of
Substances and Mixtures). The classification and labeling of chemicals is intended to clearly inform
employees and consumers in the European Union about the risks associated with chemicals.

113

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

online annex: 3-8-1
The registration obligation under reach applies irrespective of marketing activities for all substances
that we produce or import in quantities of more than one metric ton. There is also an authorization
procedure that limits the use of particularly hazardous substances or can lead to their replacement or
ban. To fulfil the complex requirements of reach, we have approved Group-wide and subgroupspecific regulations. Already registered substances are also regularly evaluated by the authorities.
For Bayer substances this can result in additional testing requirements, new risk management
measures or inclusion in the reach authorization procedure. This is indeed the case for some Bayer
substances. The authorities enforce the implementation of reach through regular inspections. So far
none of the inspections at Bayer has resulted in complaints. As we also use many substances from
other manufacturers, we maintain close contacts with our suppliers and ensure that they reassure
conformity with reach for the substances they supply.
In the European Union, the Globally Harmonized System (ghs) for the classification and labeling of
chemicals is implemented through the clp regulation. The purpose of the ghs is to achieve a globally standardized system for classifying chemicals and labeling them appropriately on packaging and
in material safety data sheets. Bayer assesses all its marketed products and implements the ghs
worldwide.
Before any product is introduced to the market, we assess it under this stringent process to determine
whether it is safe for people, animals and the environment.
Furthermore, the end products from our Life Science units â€“ such as pharmaceuticals, crop protection
products and biocides â€“ are subject to specific approval / authorization procedures.
VOLUNTARY COMMITMENT
Since 1994, Bayer has supported the voluntary Responsible Careâ„¢ initiative of the chemical industry,
which was globalized in 2006 with the introduction of the Responsible Careâ„¢ Global Charter. We cover
all main elements of the charter at all Group sites with our hseq management systems and activities. We
are also actively involved in the further development of scientific risk assessment through our work in
associations and initiatives.
online annex: 3-8-2
International associations such as the European and international chemical industry associations
(cefic,à¯—icca) and the oecd (Organisation for Economic Co-operation and Development), as well as initiatives such as ecetoc (European Centre for Ecotoxicology and Toxicology of Chemicals) and the
epaa (European Partnership for Alternative Approaches to Animal Testing), work to evolve the scientific assessment of chemicals, develop new test methods and oversee the implementation of statutory
regulations. Bayer actively supports these efforts through its activities in the associations. We are also involved in the icca Long-Range Research Initiative, for example, and endorse the goals of the
who and e.u. action plans for improving health and environmental protection. We also support the
Global Product Strategy (gps), a voluntary commitment of the chemical industry initiated by the International Council of Chemical Associations (icca). Its objective is to improve knowledge about
chemical products, especially in Emerging Markets and developing countries, and thus increase safety in the handling of these products.
We concern ourselves intensively with our substancesâ€™ properties and regularly evaluate them already at
the research and development stage. In application of the precautionary principle, the development of
substances with undesirable properties is discontinued.
online annex: 3-8-3
We accept the precautionary principle as explained in Principle 15 of the Rio Declaration of the United Nations and communiquÃ© com (2000) 1 of the European Commission as a possible consumer protection and risk management tool. It is applied whenever there is no final scientific certainty in a given area and evidence also exists that people or the environment could suffer significant or irreversible damage that must be rectified. There should not be a unilateral focus on hazard potential, but rather a balanced risk-benefit evaluation.

114

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

To assess the effects of our products, especially on human health, but also on nature and the environment, animal studies are legally required. Wherever possible, we use existing data or approved alternative test methods to avoid animal studies. We set high animal welfare standards in this regard. For more
information, see the section â€œFocusing on Animal Welfare.â€

Group target 2020:
assessment of the
hazard potential of all
substances > 1 metric
ton p.a.
See also Chapter
1.4 for Group target

The safe handling of chemicals is a top priority in the manufacture of our products (see also Chapter 9).
In Europe we operate under strict legal requirements. We voluntarily apply comparable standards around
the world, independent of the respective national legislation. In this way we exceed statutory requirements and are ensuring that substance assessments comparable to those established under reach will
also be applied at Bayer sites that are not subject to this European regulation. How we aim to realize this
target is established in our Bayer Group Regulation â€œSubstance Information and Availability.â€
To ensure the safe handling of chemicals, risk assessments are carried out applying recognized scientific methods such as the Guidance on Information Requirements and Chemical Safety Assessment of
the echa (European Chemicals Agency).
Should the assessment or new findings reveal that it is not safe to use a certain chemical, we take the
steps to mitigate risks. We support our customers in the safe handling and use of our products through
close, trust-based cooperation. Bayer compiles material safety data sheets for all products regardless of
whether or not they are legally required. All end consumer products come with suitable packaging
information, an example being package inserts for pharmaceuticals.
online annex: 3-8-4
Risk mitigation measures can range from revised application recommendations through the withdrawal of support for a certain application to the substitution of a substance. In this case, a replacement substance must be sought that is economically and technically feasible. The substitution of
chemicals is basically a continuous task of the chemical and pharmaceutical industry to obtain new
or substantially improved products and processes. This is integral to our commitment to Responsible
Care.
Material safety data sheets are the central means of communication for safety-relevant information
about substances and mixtures in the supply chain. Targeting professional users, they contain information on the substanceâ€™s properties and on the safe use of the substance or mixture. In addition,
technical information is provided for professional use.
In accordance with the respective product safety and information obligations, all subgroups compile
product information â€“ regardless of whether it is for raw materials, intermediates or end products. To
ensure worldwide access to this information, Bayer uses appropriate it systems, including those for
product labeling. This data compilation is updated accordingly whenever new legal requirements are
established.
Another important element of our product stewardship is the monitoring of all products that are
already on the market. We have established processes in all subgroups aimed at addressing inquiries on
product safety or problems with our products. This feedback and these experiences are systematically
accounted for in our assessment of risks, which also covers substances that are regarded as potentially
high-risk by regulatory authorities and independent institutions.

115

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

In all subgroups, we examine additional steps that go beyond the legally required disposal
specifications.
PRODUCT STEWARDSHIP IN THE USE OF BIOTECHNOLOGY
Biotechnological methods are used for product development in our Pharmaceuticals and Crop Protection businesses.
Biotechnology has already gained significant importance in pharmaceutical product development. The
HealthCare products Betaferonâ„¢ / Betaseronâ„¢, Eyleaâ„¢ and Kogenateâ„¢ are manufactured by a biotechnological process. Further biotechnologically manufactured active ingredients are undergoing clinical
development.
Plant biotechnology can improve crop yields, yield security and the stress tolerance of plants through
both genetic engineering and conventional breeding methods but with the same input of resources.
Safety is Bayerâ€™s top priority in the use of biotechnology, too. Beyond our observance of all relevant
legal provisions, we have formulated a Bayer Group Regulation â€œPosition on the Responsible Use of
Gene Technologyâ€ and specific regulations for HealthCare and CropScience. We provide our stakeholders with comprehensive, transparent and reliable information about our products and services in accordance with our Bayer Responsible Marketing & Sales Policy.
online annex: 3-8-5
HealthCare has established strict safety measures for handling biological agents in research,
development and production in its â€œBiological Safetyâ€ regulation and its â€œRequirements for the safe
handling of biological agentsâ€ procedure.
CropScience has included the responsible measures taken when utilizing plant biotechnology in both
the Product Stewardship Policy and the Seeds Stewardship Directive. CropScience maintained its focus on product stewardship for customers both within and outside the company through its activities
in the context of the industryâ€™s Excellence Through Stewardship Program (ets). Audits by etscertified auditors are required to maintain our ets membership, and in 2015 CropScience successfully completed audits of its operations in Brazil and Argentina which included for the first time the new
ets Insect Resistance Management best practices for biotechnology-derived plant products.
FOCUSING ON ANIMAL WELFARE
Animal studies are legally required and essential from a scientific viewpoint to assess the safety and
efficacy of pharmaceuticals and other chemical compounds. We aim to minimize the use of study animals and to employ replacement and complementary methods wherever possible.
In our handling of animals, we respect all legal requirements pertaining to animal welfare. Bayerâ€™s
principles on animal welfare and animal studies apply in countries without special animal welfare
legislation, and in the case of external studies compliance with these guidelines is contractually agreed.
Bayerâ€™s in-house Global Animal Welfare Committee â€“ comprised of the animal welfare officers at our
research sites and further Bayer experts â€“ monitors compliance with our principles on animal welfare
and animal studies within the Bayer Group and in external studies. It defines supplementary standards
that are essential for carrying out animal studies in the Bayer Group.
Bayer ensures that international and national laws and directives are strictly observed during all animal
studies. This is verified by both regulatory authorities and internal audits. Bayer additionally deploys its
own animal welfare experts at all sites at which animal studies are carried out.

See Chapter 10.5

116

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

www.
animalstudies.
bayer.com

Our principles also apply to both the research institutes we commission and our suppliers, whose
compliance with our animal welfare requirements we regularly monitor. The information provided in
supplier self-evaluations is verified through on-site audits. Current figures and further information are
available on our website.
online annex: 3-8-6
The Global Animal Welfare Committee has defined performance criteria. Each year we analyze the
development of animal numbers, the distribution according to species, the burden placed on our test
animals and the ratio of regulatorily required studies to exploratory studies, and discuss possible
steps in accordance with the 3rs principle (replace, reduce, refine). We are thus able to demonstrate
that since 2005 the number of study animals used per â‚¬1 million research budget (including animals
in Bayer studies performed by contract research organizations) has declined from 96 animals to
around 31 animals in 2015.
We continuously update our internal database, which combines all information about our own animal
studies and the evaluation of our cooperation partners and makes it available to all employees in this
area. All subgroups apply clear rules to ensure that animal welfare standards are comprehensively
observed by our partners.
Bayer also participates in several European consortia that aim to reduce the number of animal studies or improve their validity, such as the European Partnership for Alternative Approaches to Animal
Testing (epaa). HealthCare is involved in the leadership of the eTOX project and the marcar and
k4dd projects of the Innovative Medicines Initiative (imi). Bayer is a member of the scientific advisory boards of the European Centre for Ecotoxicology and Toxicology of Chemicals (ecetoc) and the
Long Range Research Initiative (lri). In Germany, we support the Foundation for the Promotion of
Alternate and Complementary Methods to Reduce Animal Testing (set).
PROTECTION AGAINST PRODUCT COUNTERFEITING
Counterfeit medicines and crop protection products harbor substantial risks for patients and consumers.
Product counterfeiting is a global problem that can only be addressed internationally through a joint
approach by industry, associations, governmental agencies and nongovernmental organizations. Bayer
consistently advocates the strengthening and expansion of existing laws and provisions aimed at the
identification and confiscation of illegal products. We try to protect patients and our products through
extensive measures of our own.

www.bayer.com/
beware-ofcounterfeits

online annex: 3-8-7
The focus of HealthCareâ€™s activities is on raising awareness and providing information to ensure the
clear identification of our original products, as well as on legal steps aimed at minimizing illegal
trade. Through our â€œBeware of Counterfeitsâ€ campaign, we inform patients on the internet about the
risks of counterfeit pharmaceuticals and provide patients with tips on how they can protect themselves. Through the use of various technological means in production, we constantly strive to ensure
that patients, too, can distinguish between original and counterfeit products.
We also support the establishment of a Europe-wide system for the identification of original pharmaceuticals that satisfies the requirements of the e.u. Falsified Medicine Directive. In addition, Bayer
participates in the Pharmaceutical Industry Initiative to Combat Crime (piicc) of Interpol to counteract pharmaceutical counterfeiting through global prosecution and the elimination of related criminal
networks. We participate in the SecurPharm initiative in Germany. Since 2015, Bayer has contributed
its expertise to a research project (ALPhA) supported by the German Ministry of Education and Research to prevent the sale of counterfeit pharmaceuticals on the internet.

www.illegal
pesticides.eu/

For crop protection products, too, a worldwide increase in the trade of counterfeit and illegal products can be observed. According to a study conducted in 2015 on behalf of the European Commission, such products account for an average of 10% of the total market across all e.u. member states.
To protect against the import of counterfeit and illegal crop protection products into the e.u., CropScience intensively advocates the uniform interpretation and implementation of existing e.u. regulations in all e.u. member states. In addition to supporting regulatory authorities with the identification

117

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

of counterfeit products through chemical analysis, we conduct our own inspections in the market and
also actively support initiatives by associations.
To educate about the potential dangers and risks of counterfeit and illegal crop protection products,
we provide information material and train customers, dealers, farmers and regulatory authorities as
part of our product stewardship programs. We document all indications of suspicious and potentially
counterfeit or illegal CropScience products in an established, systematic process. CropScienceâ€™s efforts yield measurable results: in 2015, for example, we successfully asserted our patent protection
rights against an illegal Chinese producer. In Brazil, counterfeit CropScience products with a market
value in the double-digit million range were confiscated.

8.1 HealthCare
BENEFIT-RISK MANAGEMENT FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES
Patient safety is Bayerâ€™s top priority. HealthCare continuously assesses the medical benefit-risk balance
of its medicinal products and medical devices throughout their entire product life cycle. The efficacy,
safety and tolerability of pharmaceuticals and their behavior in the body are studied in Phases i-iii of
preclinical and clinical development. The documentation submitted to the regulatory authorities contains the results of these studies and comprehensive information on the productâ€™s benefit-risk assessment. Marketing authorization is only granted for a product if it satisfies the safety requirements of the
health and regulatory authorities.
Following registration, HealthCare continues to compile safety-relevant information in an internal
pharmacovigilance database. This information is continuously evaluated and the risk-benefit balance
regularly assessed by medical experts in the Global Pharmacovigilance Department. In this process,
Bayer works closely with the responsible regulatory and supervisory authorities at the international and
national levels. These include the u.s. Food and Drug Administration (fda), the European Medicines
Agency (ema) and Germanyâ€™s Federal Institute for Drugs and Medical Devices (BfArM).
Additional safety-relevant information is also compiled using Post-Authorization Safety Studies (pass)
conducted after approval. Protocols and summaries of pass results are entered into the pass registry in
compliance with e.u. pharmacovigilance legislation.
online annex: 3-8.1-1
HealthCare has a global pharmaceutical monitoring system in which experts from various disciplines
work together in functional safety management teams (smts). These teams jointly evaluate the available benefit and safety data and other relevant product information so as to identify potential safety
concerns at an early stage or detect possible changes in the benefit-risk ratio. In addition to internally compiled safety data from clinical trials, post-marketing studies and ad hoc information on adverse
side effects, the companyâ€™s experts conduct assessments using external databases and the information contained in scientific publications. smts produce detailed safety risk management plans.
These plans are updated as soon as relevant new benefit-risk data become available. Implementation
of risk mitigation activities is coordinated by local smts in the country organizations. All processes
are documented, regularly updated and integrated into a quality management system.

118

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

Should risks be identified during this assessment, Bayer immediately undertakes suitable steps to safeguard the health of patients â€“ such as updating product information for patients and physicians. Further
elements of risk mitigation programs can include targeted information, e.g. patient education brochures
and training measures for medical specialists, as well as direct communication with medical experts
(Direct Healthcare Professional Communication, dhpc) and even product withdrawals if necessary.
These measures are coordinated with the competent authorities.

See Chapter 7.2

HealthCareâ€™s quality and risk management functions also make further contributions to increased safety.
We examine external and internal quality assurance requirements for our products through systematic
internal audits â€“ not just in research and development, but also in production. These audits also cover
both institutes sub-contracted by us and our suppliers. More information on our quality management
can be found in Chapter 7.2 â€œProduction.â€
In line with the statutory requirements, strict safety and quality standards also apply to animal health
products. Within the scope of the approval / authorization procedures, Animal Health also carries out
studies in order to ensure the quality, efficacy and safety of its products.
ANALYSIS OF RESIDUES OF PHARMACEUTICALS IN THE ENVIRONMENT
Active pharmaceutical ingredients can enter the environment, either through human or livestock excreta, improper disposal of unused medicines or during the production process. HealthCare carries out
ecotoxicological investigations of the environmental behavior of residues and degradation products to
assess the potential environmental impact of our pharmaceutical products. In accordance with applicable law regarding human and veterinary pharmaceuticals, an environmental risk assessment takes place
for all active ingredients for which the company is targeting an approval procedure in Europe or the
United States. Here it must be examined whether significant risks may arise for the environment when
the pharmaceuticals are used as instructed.
Based on currently available information derived from measurements carried out by authorities and
scientific institutes, the existing concentrations of individual active pharmaceutical ingredients from
human or veterinary medicines in drinking water do not have any adverse effects on human health. This
subject is dealt with in particular by a who report on pharmaceuticals in drinking water published in
2012 that comes to the conclusion that traceable effects on human health through the current extent of
exposure via drinking water are highly improbable. This estimation corresponds with the studies by
national authorities and institutes known to us.
In the production of our pharmaceuticals, internal company wastewater threshold values ensure that no
risk to the environment results from the release of traces of active ingredients in wastewater from our
production sites. All HealthCare production sites worldwide are evaluated with regard to these threshold
values. Site-specific measures aimed at a further reduction are taken should it not be possible to observe these standards over the long term. This includes substance-specific measures such as filtration,
evaporation, oxidation, incineration or biological clarification in wastewater treatment plants.
online annex: 3-8.1-2
Within the scope of our product stewardship, we actively participate in research projects
aimed at further studying pharmaceutical residues in the environment and introducing targeted measures to prevent them.
Since 2015, we have coordinated the â€œIntelligence-led Assessment of Pharmaceuticals in the
Environmentâ€ project in Europe, which seeks new ways to improve environmental risk assessment. To this end, information from toxicological studies, pharmacological modes of action and computer-based models are analyzed with the goal of developing models and methods for determining possible environmental risks of pharmaceutical substances in early development stages and prioritizing for further environmental assessment existing substances that
previously have not been evaluated.
Bayer was represented on the Scientific Advisory Board of noPILLS, an e.u.-sponsored cooperation project completed in 2015 and involving several European countries with the goal of
reducing pharmaceutical residues in water. The project demonstrated that a reduction in

119

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

pharmaceutical residues in water can only be achieved through cooperation between numerous parties. Educating consumers on the correct disposal of pharmaceuticals, improving
wastewater treatment technology and the collection of excreta in connection with certain medicines proved to be effective approaches for achieving this objective.
In Germany, HealthCare participates in the â€œRisk Management of Emerging Compounds and
Pathogens in the Water Cycleâ€ initiative sponsored by the German Ministry for Education and
Research. HealthCare is a member of the steering committee. The â€œsauber+â€ (â€œClean+â€) project, which is part of this initiative, deals with the study of wastewater from health care industry facilities that is contaminated with active pharmaceutical ingredients and disease pathogens. Here it was determined that these emissions are not higher on average than those from
private households. The reduction of pharmaceutical emissions generally depends on the individual active ingredients and should pursue a holistic approach. HealthCare was a member of
the Stakeholder Advisory Board of that project, which was concluded in 2015.

8.2 CropScience
FOCUSING ON PRODUCT SAFETY
Before crop protection products and technologies can be introduced to the market, they must demonstrate that they are harmless to people and animals and can be used without causing unjustifiable burden on the environment. For this they require official authorization, which is regulated by numerous
international and national laws and provisions. The requirements for marketing authorization, particularly as pertains to the environment, have risen sharply in recent years with the goal of further increasing product safety and minimizing potential risks. CropScience satisfies all the regulatory requirements
of the countries in which our products are sold to protect crops.
Product safety and environmental compatibility of crop protection products and technologies play a
central role in development. CropScience examines the products during the development phase in
stringent tests that are required by law. The tests evaluate a productâ€™s mode of action, its ecotoxicological and toxicological properties and potential remaining trace concentrations in the plants or the environment following proper application. Each new crop protection active ingredient and each new technology must undergo several years of studies and testing to ensure that it can be applied effectively and
that its use is safe for people, animals and the environment.
It takes roughly 10 years for a crop protection product or technology to complete the entire development process including all studies and be launched onto the market. But our product stewardship does
not end there. CropScience also observes the International Code of Conduct on Pesticide Management
of the United Nations Food and Agriculture Organization (fao). The principles of this code cover the
entire life cycle of a product or technology, from its development to its application and beyond. We
implement all major aspects of responsible product handling in our Product Stewardship Program,
which is based on the principles of our Product Stewardship Policy.
online annex: 3-8.2-1
Even beyond its core business, CropScience participates specifically in projects aimed at increased
product stewardship â€“ such as the Better Sugarcane Initiative, which works to promote sustainable
sugarcane cultivation, and the International Sustainability & Carbon Certification organization, which
is working to establish a system for certifying biomass and bioenergy. We are also a member of the
Round Table for Sustainable Palm Oil Production and the Round Table for Responsible Soy (rtrs). In
2015, we signed an agreement with rtrs to support the certification of soybean production in Brazil.
In the United States, the e3 cotton sustainability program was introduced to support farmers in the
production of sustainably grown cotton, which is much in demand by retailers. Farmers who sign up
for the program commit to ensuring that the cultivation of their cotton is certified as traceable, environmentally responsible, economically viable and socially equitable.

120

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

RESPONSIBILITY FOR CUSTOMERS AND PARTNERS
The application of crop protection products requires the greatest possible care. Supporting our customers and partners in the proper and safe handling of our seed and crop protection products is therefore a
focus of our product stewardship. In this connection, we offer targeted training measures worldwide
particularly for farmers and dealers that are designed to promote the responsible handling of our products and thus improve safety for users, the environment and consumers. These training measures are
carried out in all countries in which our products are sold. Responsibility for their implementation lies
with the country organizations, which align their training concepts to the needs of the respective countries.
online annex: 3-8.2-2
We maintained our training activities in the Asia and Latin America regions in 2015. In India, CropScience trained farmers in good agricultural practice. We teach them how they can enhance the
growth of their produce, use crop protection products effectively and safely, and thus increase the
quality of their harvested goods. This opens up new ways of marketing their products that help
smallholder farmers in particular to gain increased profit from them.
Our AgroVida program in Latin America comprises various initiatives with which we have been continuously increasing the farmersâ€™ safety awareness and specialist expertise for more than 20 years.
Safety training offerings for farmers are an important aspect here. In 2015, for instance, we trained
more than 35,100 farmers in the Andean region and almost 30,400 farmers in the Central America
and Caribbean region (excluding Mexico). Together with the international crop protection association CropLife, we also carried out safety training measures in numerous African countries in 2015.
Our product stewardship measures also include internal employee training measures. Our Product
Stewardship Policy also provides information on all principles for the responsible handling of our
products, combined with specific instructions for use for our employees and those who work with
our products.
In addition to training activities, we produce manuals explaining the safe use and scope of protective
clothing and the correct storage and disposal of our products. These manuals are available online to our
customers and partners, an example being the â€œDressCodeâ€ containing information on optimal protective clothing for the handling of our products. They are also distributed in the aforementioned training
courses as brochures or information sheets. Furthermore, we offer farmers our support in implementing
practical steps for user and environmental protection.
Users of our products can contact CropScience through a range of communication channels should they
have complaints or feedback or wish to report any incidents. These include direct contact with our sales
staff; our hotline, which is printed on all our product packaging; and, for example, in Germany, the
â€œAgrar Telefonâ€ hotline. All incoming product complaints and incidents are locally compiled and processed by the respective CropScience experts. Entries necessitating corrective measures are additionally recorded in a global database. An internal Bayer directive governs the processing, communication
and, if necessary, implementation of corrective measures. Employee training courses also take place
regularly here as well.

121

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

CROP PROTECTION PRODUCTS IN THE ENVIRONMENT
Stringent legal regulations apply to the approval and use of crop protection products. They are aimed at
protecting the environment from unwanted side effects, as every farmerâ€™s livelihood depends on an
intact environment and fertile soil. Responsible Care is extremely important in all areas of agriculture to
minimize possible effects and the discharge of crop protection products outside of the treated crops.
Bayer believes its responsibility includes protecting the environment from emissions and optimizing the
safety of its products through extensive stewardship measures.
Protecting water from agricultural emissions and maintaining good groundwater quality are cornerstones of the responsible use of water as a natural resource. It cannot be completely ruled out in agricultural practice that substances can leach into groundwater or be emitted into flowing waters and lakes
through surface runoff. Improper disposal of residual liquids following the cleaning of spraying apparatus can also lead to discharges of crop protection products into surface water. The application of crop
protection products is subject to national water protection regulations, including in Europe the requirements of the Water Framework Directive. CropScience places particular importance on water protection
and supports agriculture in environmentally friendly land cultivation and the disposal of residual liquids
following the application of crop protection products.
online annex: 3-8.2-3
In the area of water pollution mitigation, we promote the biological remediation system Phytobacâ„¢
to customers. This is intended to prevent point source discharges of crop protection active ingredients into water bodies during the disposal of residual liquids that are generated during the filling and
cleaning of spraying devices. There are already some 3,500 Phytobacâ„¢ plants in Europe (primarily in
France).

www.bayer.com/
phytobac

Erosion and runoff processes on agricultural land can also lead to substance emissions into adjacent
water systems. In this context, we are collaborating with external partners on the development of a
web-based geoinformation system for water protection in agriculture. This enables the visualization
of site-related runoff / erosion risks by means of high-resolution risk maps supplemented with suitable
mitigation proposals. It is planned for this system to be used as an advisory tool for water protection
in agriculture.
Pollinator protection is another focus of our product stewardship activities. As a Life Science company
with a long tradition in agriculture and animal health, we know how important healthy bees are â€“ not
just as pollinators for sustainable food production and as honey producers, but also due to the key role
they play in many ecosystems throughout the world. Promoting pollinator health and sustainable agriculture is of central importance for our business activity. In our view, protecting honey bees and wild
bees is a matter that concerns society at large; maintaining their health is everyoneâ€™s responsibility.
Bayer takes its role very seriously in this regard and wants to make a contribution.
In our Bee Care Program, we coordinate and combine all Bayer activities in the area of pollinator health
and pollinator safety in order to advance the development and implementation of suitable solutions.
Within the framework of this program, we proactively approach numerous stakeholder groups â€“ including industry partners, scientists, farmers, beekeepers, governmental agencies, nongovernmental organizations and representatives of the food value chain â€“ to improve our networks with them, address their
questions and concerns and seek opportunities for cooperating with them in the area of pollinator
health. Bee Care Centers exist in Germany and the United States for this purpose. In 2015, furthermore,
we entered into a collaboration in the area of bee health in Latin America with the Fraunhofer Chile
Research Foundation. A global Bee Care network has now been built up.

www.beecare.
bayer.com

122

Bayer Annual Report 2015
Combined Management Report
8. Product Stewardship

The Bayer Bee Care Program combines our well-founded knowledge in the areas of animal health and
crop protection so as to contribute to protecting pollinator health. The objectives here are to:
â€¢ Develop further solutions to promote bee health so that beekeepers can better fight pests and disease pathogens
â€¢ Actively promote the bee-friendly use of our innovative solutions (products, technologies and services) and to enable involved stakeholder groups to ensure bee safety in farming and gardening
â€¢ Expand and improve pollinatorsâ€™ food sources to help offset nutritional deficits
â€¢ Openly and actively promote an honest dialogue and transparent communication on pollinator health
with all involved stakeholders
â€¢ Exchange knowledge and specialist information with all stakeholder groups and institutions (beekeepers, farmers, research institutes, ngos, political decision-makers and registration authorities)
online annex: 3-8.2-4
Bee health is impacted by several factors for which Bayer pursues various solutions.
Bayer is investing in the research and development of a new form of application for products to control the Varroa mite, which scientists consider to be the biggest danger for honey bees. Bayer is also
active in setting up flowering areas that can provide pollinators with a rich food source for pollen and
nectar. The treatment of seed is an important step to protect sensitive crop seedlings from pest pressure. In the sowing of treated seed, however, small amounts of insecticide dust that is potentially
harmful to pollinators can be released. Our â€œZero Dustâ€ project and further cooperation projects to
reduce dust emissions help to minimize the dust release.
Bayer is firmly convinced that neonicotinoids are an important insecticide class with beneficial properties. They are effective against key pests that in many regions have already developed resistances
against other substances. They are especially user-safe due to their low human toxicity. Seed treatment with neonicotinoids is an environmentally friendly application technique because it significantly reduces the likelihood that pollinators and other environmental organisms can come into contact
with crop protection products. Bayer is also convinced that neonicotinoids are safe for bees if they
are used responsibly and properly. This was confirmed by risk evaluations performed during marketing authorization reviews by the responsible authorities of countries outside Europe. In Europe,
however, Bayer products that contain two of our neonicotinoid compounds have been prohibited
since 2013 from use in crops that are attractive to bees. The European Commission has recently instructed the European Food Safety Authority (efsa) to examine all newly available data and reports
from the past two years. The results are expected for the end of 2016.
Bayer has brought the restriction on neonicotinoid use in the e.u. before the Court of Justice of the
European Union in order to clarify the legal basis of the Commissionâ€™s decision. This decision is
based on an assessment by the efsa that in turn is based on neither a validated nor an officially recognized risk assessment system. With a view to future investment decisions, the company is primarily asking that the court clarify the regulatory framework.

123

Bayer Annual Report 2015
Combined Management Report
9. Safety

8.3 Covestro
The products of Covestro satisfy the most stringent of safety requirements. This does not just apply to
those chemical substances subject to standard review in accordance with the European reach Regulation. Within the context of the voluntary Global Product Strategy (gps) of the chemical industry, we also
assess the substances we use and reduce potential health and environmental risks that could result from
our chemicals. The product safety assessments apply to the entire life cycle of a product â€“ from research
and procurement through production and logistics to application, disposal and recycling. Our product
stewardship does not end at the company gate, but also includes suppliers, customers and partners. gps
is accessible at Covestro through the â€œProduct Safety Firstâ€ internet portal, and is available worldwide
in seven languages. Through this website, we inform customers and other stakeholders about our activities and product safety assessments.
online annex: 3-8.3-1
A product safety assessment at Covestro takes place in several steps: first, chemicals that are subject to statutory regulations are identified and the corresponding laws compiled. Then we examine
their risk potential to obtain a basis for the effective minimization of risks. Such steps can include
proposals for technical measures such as protective clothing, or marketing restrictions. Finally, we
produce the legally required material safety data sheets, technical information sheets and labeling
for the chemicals. Here we go beyond the extent prescribed by law and also produce these documents for chemicals that are not subject to this statutory obligation. All product groups undergo
this process.
For especially important products such as mdi, tdi, polycarbonate and polyether, Covestro additionally
works with associations to draw up environmental product declarations and eco-balances certified according to iso 14040 and 14044 based on industry averages.
Covestro follows the scientific discussion about the chemical bisphenol a (bpa), a feedstock for various
plastics with a controversial public profile. Critics are concerned that health risks could result for users
if traces of bpa are released from polymers. As documented by numerous scientifically valid studies,
we are convinced that bpa can be safely used in its existing areas of application â€“ especially those that
involve contact with food. This assessment is consistent with evaluations by the authorities responsible
for food safety in Europe, the United States, Australia, Japan and other countries. In cooperation with
the PlasticsEurope association, we work to make the discussion more objective and more strongly
based on scientific analysis. Covestro actively participates in this dialogue and informs customers and
the public via the internet.

9. Safety
Safety management and the continuous development of a safety culture are a cornerstone of corporate
responsibility in the Bayer Group. Preventing accidents and incidents in day-to-day work, when operating production facilities, and on work-related travel and transportation routes where people or the environment could suffer harm or damage has top priority for us. Responsibility for health, safety, environmental protection and quality (hseq) thus lies directly with the Bayer Board of Management. Our hseq
activities are geared toward ensuring occupational health and safety, the smooth and safe operation of
our facilities, and the safe transportation of our products. In this way, we also reduce running costs by
avoiding damage and disruptions to work and production.

www.bayer.com/
COV-BPA

124

Bayer Annual Report 2015
Combined Management Report
9. Safety

See Chapter 10.1

At the Group level, responsibilities and framework conditions for hseq are regulated through appropriate directives such as our new Bayer Group Regulation â€œSafety at the Bayer Group.â€ Operational responsibility lies with the boards of management / executive boards of the respective subgroups and
service companies and the corresponding line organizations, which have their own management systems, committees and working groups to steer hseq. Continuous review and revision of directives and
regular internal audits and external certification processes ensure our hseq management systems at all
sites meet the specific requirements in each case.
Our safety management is based on four pillars:
Safety Pillars

[Graphic 3.9.1]

Act SAFE, Respect LIFE !

Occupational Health
& Safety

Process
& Plant Safety

Transportation Safety

Product Stewardship

Behavioral Safety Initiative

9.1 Occupational Health and Safety
We regard safeguarding the occupational health and safety of our employees and of contractors and
suppliers working on our company premises and under the supervision of Bayer as one of our core
tasks. This entails preventing work-related accidents and occupational illnesses, identifying and assessing potential hazards, maintaining comprehensive risk management and designing a healthy working environment.

Group target 2020:
reduction of 35% in
occupational safety
incident rate (RIR)
See also Chapter
1.4 for Group
targets

The rate of occupational injuries with lost workdays at Bayer has been falling for several years. In 2015
intensive training and awareness-raising once again helped enable the Bayer subgroups and service
companies to report an overall reduction in injury figures.
We record all injuries to Bayer employees requiring medical treatment that goes beyond simple first aid.
These are indicated by the Recordable Incident Rate (rir), which includes both injuries with lost workdays and those without. In 2015, this rate dropped to 0.42 cases per 200,000 hours worked (2014: 0.43)
throughout the Group, corresponding to 543 occupational injuries worldwide. This means that, in statistical terms, one recordable incident occurred for around every 476,000 hours worked.
The rate of recordable occupational injuries with lost workdays (ltrir, Lost Time Recordable Incident
Rate) also fell. In 2015, it stood at 0.21 (2014: 0.22).
Regrettably, two Bayer employees lost their lives in work-related accidents in 2015. One employee was
killed in a plane crash. Another employee suffered serious burns in a work-related accident at the
Chempark Leverkusen site and later died in a hospital. Investigations into the causes of the latter incident are still ongoing.

125

Bayer Annual Report 2015
Combined Management Report
9. Safety

Occupational Injuries

[Table 3.9.1]
2011

2012

2013

2014

2015

Occupational injuries to Bayer employees with
lost workdays (LTRIR)

0.31

0.27

0.26

0.22

0.21

Recordable occupational injuries to Bayer
employees (RIR)

0.56

0.49

0.47

0.43

0.42

3

2

2

4

2

of which Bayer employees

2

2

1

3

2

of which contractor employees1

1

â€“

1

1

â€“

Fatal injuries (total)

1Employees

working for third parties whose accidents occurred on our company premises and under Bayer supervision

The injury figures varied both within individual regions and between the various subgroups and service
companies and depended, among other aspects, on employeesâ€™ range of activities.
online annex: 3-9.1-1
Recordable Occupational Injuries (RIR 1) by Region

Europe

[Table 3.9.1-1]
2012

2013

2014

2015

0.56

0.72

0.62

0.60

North America

0.53

0.49

0.64

0.58

Asia / Pacific

0.21

0.20

0.14

0.12

Latin America / Middle East / Africa

0.54

0.40

0.33

0.41

Total

0.49

0.47

0.43

0.42

1

RIR = Recordable Incident Rate

Cases of occupational illness are recorded by us in the countries in which this is legally permissible and
are also included in the ltrir parameter, irrespective of whether they are included in the occupational
diseases listed in international registers.
As in previous years, we hardly recorded any sector-typical accidents involving contact with chemicals
in 2015. The absolute number of injuries with lost workdays continued to decline. A significant proportion of our work-related accidents and injuries have behavior-linked causes. To increase the focus on
this area, the Bayer Safety Council headed up by the Chairman of the Board of Management launched
the Behavioral Safety initiative and the program was rolled out in the subgroups in 2015. The subject
was also the focus of our annual global Safety Day in 2015.
online annex: 3-9.1-2
The Behavioral Safety initiative focuses on the promotion of safety-conscious conduct among employees. Behavioral safety involves identifying and preventing unsafe working practices and reinforcing and consolidating safe working methods at all levels. This approach is by no means limited to
production but also covers areas of work such as research & development, marketing & sales and administration. The initiative is rolling out a comprehensive behavioral safety program in the subgroups. The first step of this process involved carrying out an assessment of the existing safety culture at all CropScience production sites in 2015, while the focus at HealthCare was on sites with the
biggest impact on safety performance. At Covestro, a pilot project was conducted at the site in Antwerp, Belgium. As a next step, all subgroups carried out both basic training courses for employees
and manager training courses on behavioral safety at a number of these sites. The successfully
launched program will be intensified next year.

126

Bayer Annual Report 2015
Combined Management Report
9. Safety

We are committed to maintaining and promoting employee health and performance through targeted
shaping of the working environment. As part of our occupational health management activities, we offer
numerous preventive measures, ranging from ergonomic workplaces and stress management to incentive systems to promote healthy behavior. This also includes support for treating illnesses or reintegration measures.
As Bayer is active in countries with major differences in health care infrastructures and legal frameworks, the needs and options in health promotion vary. Bayer aims to provide employees with access to
adequate, affordable and targeted health offerings such as regular medical check-ups, sports programs,
help in overcoming illness and on-site medical care.
Our employee representatives are included in operational health management and are actively involved
in its development.
online annex: 3-9.1-3
At the Bayer European Forum â€“ a joint committee of representatives of management and employees
â€“ both parties signed the Luxembourg Declaration on Workplace Health Promotion in the e.u.. According to the declaration, workplace health promotion covers all joint measures by employers, employees and society to improve health and well-being in the workplace. The objective of the network
is to identify and disseminate best practices on the basis of continuous sharing of experience. So far
around 200 European companies have signed the declaration.
Group-wide initiatives to foster employeesâ€™ health and maintain their employability in view of the rise
in the retirement age include, in Germany, the General Works Agreements on lifetime working and
demographic change and on shaping demographic change for nonmanagerial employees at Bayer.
These innovative agreements contain measures to reduce the workload of shift workers from the age
of 55 and of all other nonmanagerial employees in Germany from the age of 57 and ease the return
to work of nonmanagerial employees after long-term illness, along with an extensive health screening program for all employees. In 2015, more than 97% of those who were eligible took part in the
program to reduce the workload of older employees.

9.2 Process and Plant Safety
We aim to design and operate our processes and facilities in such a way that they do not pose any inappropriate risks to employees, the environment or the community. To improve the safety of our production facilities and processes worldwide, Bayer is continually working to further develop the safety culture and the corresponding standards for identifying and evaluating the associated risks. At the same
time, we promote the skills of relevant employees on a regular basis. The corresponding Bayer Group
Regulation â€œProcess and Plant Safetyâ€ specifies globally harmonized procedures and standards.
online annex: 3-9.2-1
In a key move to maintain and raise safety awareness, the globally binding training program for all
Bayer employees who are able to influence process and plant safety in their work environment has
been further enhanced. The process and plant safety training program is firmly anchored in the subgroupsâ€™ hseq management systems. Both traditional and web-based training has been established
for tradespeople and chemical technicians in the production facilities.

127

Bayer Annual Report 2015
Combined Management Report
9. Safety

The organization and staffing levels of the Bayer Groupâ€™s central competence center for process and
plant safety, together with the Group hseq Platform for Process and Plant Safety, in Leverkusen, Germany, have been strengthened. Together with the regional competence centers in Shanghai, China, and
Kansas City, Missouri, United States, it works closely together in a professional network with plant
safety experts from production sites all over the world. To improve our risk analysis process, an additional system audit on the content and completeness of our safety reviews was conducted this year on a
trial basis. This quality improvement measure is due to be rolled out across HealthCare and CropScience next year and will be mandatory.
online annex: 3-9.2-2
Our experts work in international working groups of the European Chemical Industry Council (cefic)
and the American Petroleum Institute with the goal of developing a global reporting standard for key
performance indicators in plant safety. We also are involved in an intensive exchange of experiences
nationally and internationally in this area at an industrial level.
A globally standardized kpi for plant safety incidents, Loss of Primary Containment (LoPC), applies to all
Bayer plants and is integrated into Group-wide safety reporting. LoPC refers, for example, to chemicals
in amounts above defined thresholds leaking from their primary container, such as pipelines, pumps,
tanks or drums, and is thus an indicator of incidents in production facilities. We use the LoPC Incident
Rate (LoPC-ir) to determine the number of LoPC incidents per 200,000 working hours in areas relevant
to plant safety. In 2015, this was 0.22 (2014: 0.23).

Rate of Plant Safety Incidents (LoPC-IR)

LoPC-IR (Loss of Primary Containment Incident Rate)

[Table 3.9.2]
2012

2013

2014

2015

0.38

0.35

0.23

0.22

More information on the procedures in the case of LoPC incidents can be found in
online annex: 3-9.2-3
The causes of every reported incident are carefully analyzed. The evaluations indicate areas where
there is room for further improving the safety of existing facilities. The results of the cause analysis
are published across the Group. The introduction of both the LoPC-ir parameter and the globally established training program mentioned above is helping us raise employeesâ€™ safety awareness.
The reporting level is set so low that even material and energy leaks that have no impact on employees, neighbors or the environment are systematically recorded and reported. This approach is in line
with our commitment to maintaining the integrity of our facilities at all times.
The global, comprehensive Bayer Emergency Response System (BayERS) is an overarching early warning system for the Group. The subgroups and service companies have integrated their internal reporting
procedures into BayERS and adapted them to it.
online annex: 3-9.2-4
The handling of unusual incidents is the responsibility of the local crisis organization / emergency
response team. For this purpose, organizational precautions with defined responsibilities and procedures have been implemented at the sites / in the countries. Depending on the situation, these involve
business partners and the local community around the sites.

Group target 2020:
reduction of 30%
in process and plant
safety incidents
(LoPC-ir)

See also
Chapter 1.4 for
Group targets

128

Bayer Annual Report 2015
Combined Management Report
9. Safety

9.3 Transportation Safety
Great importance is attached to transportation safety within the Bayer safety culture. This applies to the
transportation of materials on public transportation routes, particularly in the case of hazardous materials. This includes various processes such as loading and unloading, classification, labeling, packaging
and selecting the right logistics partners.
In a dedicated Bayer Group directive, we have defined procedures that ensure all transported materials
are handled in line with applicable regulations and the potential hazard they pose. Logistics service
providers are selected following a defined procedure, and their fulfillment of safety and quality standards is assessed. Under the directive, people responsible for transportation safety are appointed in every
organizational unit concerned. As part of our Responsible Care activities, transportation safety instructions are also drawn up and distribution safety audits performed for nonhazardous materials. We thus
go beyond what is required under transportation legislation. Bayerâ€™s objective is to achieve an appropriate and equally high standard of hseq throughout the world and to continuously improve this, particularly regarding transportation processes. The transportation safety and security management of our
subgroups is part of the audit system of the Bayer Group detailed in the Bayer Group Regulation
â€œHealth, Safety, Environment and Quality (hseq) Audits,â€ which was updated in 2015.
The subgroups have also set up a network of transportation safety experts and users with practical
experience to share and harmonize know-how and procedures for transportation and distribution safety
and security including emergency response management and incident reporting. The Transportation
Safety Platform acts as a global forum for exchanging information and standardizing procedures between the subgroups. In 2015, the platform focused, for example, on regulations management, training
in transportation safety and use of this worldwide, the review of internal process instructions and the
evaluation and selection of our logistics service providers.
In total, well over one million transport movements took place in 2015. Despite our extensive safety
precautions and training activities, residual risks remain and can result in transport incidents. We
classify critical incidents during the transportation of our products as transport incidents. These include accidents that cause personal injury or significant damage to property and environmental impact
through the release of substances or leakage of hazardous materials. We record transport incidents
using defined criteria. Assessment is based on the spilled load, graded according to the volume and
dangerous goods class, personal injury and blocked transportation routes. We take into account both
our own chemical transport movements and those we commission and pay third parties to perform on
our behalf. We carefully analyze and evaluate all transport incidents so that adequate steps can be
taken to prevent a recurrence.

129

Bayer Annual Report 2015
Combined Management Report
9. Safety

TRANSPORT AND ENVIRONMENTAL INCIDENTS
The number of transport incidents in 2015 was 12, the same as last year. These were mainly traffic
accidents.

Group target 2020:
reduction of 30% in
transport incidents

In recent years most transport incidents occurred at Covestro. For this reason, as a Life Science
company Bayer will refrain from continuing with the relevant Group target in the future. Instead, we
shall endeavor to minimize the number of such incidents through preventive measures.

See also Chapter
1.4 for Group
targets

online annex: 3-9.3-1
Transport Incidents by Means of Transport

[Table 3.9.2-1]
2011

2012

2013

2014

2015

Road

6

6

8

11

11

Rail

1

0

0

1

1

Inland waterways

0

0

0

0

0

Sea

0

0

3

0

0

Air

0

0

0

0

0

Pipeline

0

0

0

0

0

Total

7

6

11

12

12

The number of environmental incidents fell from four to two in 2015. Bayer uses the term â€œenvironmental incidentsâ€ to define incidents in the course of our business activities that result in the release of
substances into the environment. Factors that determine whether there is a reporting obligation include,
in particular, the nature and quantity of the substance, the amount of damage caused and any consequences for nearby residents. In accordance with our internal voluntary commitment, we report any
leakage of substances with a high hazard potential from a quantity of 100 kg upward.
online annex: 3-9.3-2

Number of Environmental Incidents

Environmental incidents

[Table 3.9.2-2]
2011

2012

2013

2014

2015

3

5

10

4

2

In total there were 13 incidents reported in 2015, one of which had to be classified both a transport and
an environmental incident. A detailed overview of the transport and environmental incidents can be
found in the table below.

130

Bayer Annual Report 2015
Combined Management Report
9. Safety

online annex: 3-9.3-3

Environmental and Transport Incidents 2015 1

[Table 3.9.2-3]

Environmental

Transport

Personal
injury

Covestro, Illinois, United States, January 15, 2015
At a truck parking lot, approximately 7,600 liters of 36% hydrochloric acid escaped from a leaky
tanker and entered a wastewater pipe, from where it continued in a diluted form into the
wastewater treatment system. No injuries or hazards occurred.

X

No

Covestro, Hubli, India, January 18, 2015
Approximately 1,200 kg of product (hazardous polyisocyanate) leaked from a truck in a transport
incident. Specialist staff ensured expert cleanup and disposal.

X

No

Covestro, California, United States, February 7, 2015
A tanker was accidentally overfilled during loading, resulting in around 1,150 liters of TDI
(hazardous material) leaking into the collection area of the filling station. No injuries or hazards
occurred.

X

No

Covestro, Ward Creek, United States, May 31, 2015
In an accident, an overturned truck tractor lost 1,500 liters of MDI, which spilled onto the road and
into the surrounding area. This accident was also classified as an environmental incident. The
product was cleaned up in a professional manner. No injuries occurred.

X

No

Covestro, Helsinki, Finland, June 4, 2015
An IBC2 was damaged in a vehicle transport incident at a site belonging to the postal service. An
unquantified amount (maximum capacity of the IBC 1,000 kg) of Bayhydrol escaped. 24 people
were endangered by the product leak, 12 of whom underwent hospital examinations as a
precaution and were discharged the same day. The product was cleaned up and disposed of in a
professional manner.

X

No

Covestro, Budapest / Sibiu, Hungary, June 8, 2015
The driver of a tanker was killed in a traffic accident. No product was spilled.

X

Yes

Covestro, Antwerp, Belgium, August 18, 2015
Due to incorrect operation during transfer between a tank container and a flexitank, the flexitank
burst and lost approximately 6,000 kg of Desmophen (not a hazardous material). No injuries or
hazards occurred.

X

No

Covestro, Dormagen, Germany, September 3, 2015
During unloading, around 150 liters of nitric acid (hazardous material) were accidentally spilled.
An employee who came into contact with the acid was treated at a hospital as a precaution and
was then able to resume work. An investigation into the impact on the environment was initiated.

X

X

Yes

Covestro, Laredo, United States, September 28, 2015
A forklift truck pierced a drum filled with Desmodur (TDI). 150 kg of the product spilled onto the
loading ramp. The product was cleaned up and disposed of in a professional manner.

X

No

Covestro, Seelze, Germany, September 30, 2015
Approximately 100 liters of 30% hydrochloric acid escaped from a leaky rail tank car. No injuries
or hazards occurred. An investigation into the incident was initiated.

X

No

Covestro, Cologne, Germany, October 28, 2015
While a truck was being loaded, a forklift truck accidentally pierced a drum filled with Desmodur I
(hazardous material). 150 liters of the product spilled onto the floor of the warehouse and were
cleaned up and disposed of in a professional manner. No personal injury or environmental damage
occurred.

X

No

Covestro, Martinsburg, United States, December 9, 2015
A truck driver noticed a leak in his tanker. This was caused by a leaky drum filled with Desmodur.
The fire department was notified and cleaned up the spilled liquid on the road surface using
binding agent. The remaining product was transferred to a new drum.

X

No

Covestro, Charleston, United States, December 16, 2015
Almost 1,900 liters of a polyalcohol spilled from a tanker truck in a traffic accident. The fire
department sealed up the spillage, thus preventing release into the environment. The driver of the
truck was injured in the accident and treated at a hospital.

X

Yes

1

Standard practice at Bayer is to record every fatality reported to us relating to our business activities. A difference between the number of fatalities in Table 3.9.1
(occupational injuries) and Table 3.9.2-3 may occur because for occupational injuries, by definition, we indicate only fatalities of Bayer and contractor employees who were
under immediate Bayer supervision.
2 IBC (intermediate bulk container)

131

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

The following incident was recorded and analyzed, but is not classed as an environmental or
transport incident according to Bayer criteria.

Further Incidents Not Considered Environmental or Transport Incidents under Bayer Criteria

[Table 3.9.2-4]

Location of the incident

Description

Comments

CropScience, Muskegon,
United States,
October 5, 2015

Small quantity of product
entered the municipal
wastewater system

At the Muskegon site, a small quantity of product entered
the municipal wastewater system. The local community
complained about the odor this caused. The responsible
authorities were notified as a precaution. There were no
hazards. Due to the low quantity, the incident is not
classified as an environmental incident.

10. Environmental Protection
Bayer takes its responsibility to protect the environment very seriously. We are continuously working to
reduce the environmental impact of our business activities and find innovative product solutions that
benefit the environment. Our environmental standards apply worldwide.
An efficient approach to raw materials and energy is now both an ecological and economic imperative.
Eco-efficient processes help reduce environmental impact and at the same time cut the costs associated
with materials, energy, emissions and disposal.
Our use of energy sources, water and other resources, as well as the emissions and waste we generate,
are determined to a great extent by just a few factors. Our product portfolio and demand for our products determine the use of materials and energy. At the same time, we continuously improve our production processes to make them more resource-friendly and lower the emissions they generate. We measure how efficiently we use our resources in relation to manufactured sales volume, which does not include intermediates.
Responsibilities and framework conditions for health, safety, environmental protection and quality
(hseq) are stipulated at the Group level, with Group regulations, targets and performance indicators
(kpis), among other things, serving this purpose. In the field of environmental protection (from, for
example, resource use to air, water and soil emissions and waste generation), operational management
takes place at the subgroup level, with the aid of hseq management systems, committees and working
groups.
Our commitment to environmental protection, health and safety extends beyond the scope of legal
requirements. It includes factoring in environmental aspects in a particular way and performing a voluntary ecological assessment for capital expenditure projects exceeding â‚¬10 million. In the case of acquisitions, we examine prior to the transaction whether the applicable environmental and occupational
safety regulations and fundamental employee rights are complied with at the production sites in question.

132

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

10.1 International Standards and Certifications
To maintain high hseq standards throughout the Group, Bayer has established appropriate management systems that are aligned to acknowledged international standards and are regularly evaluated
and updated. They form an integral part of all our business processes. Regular upkeep of the management systems and appropriate training and certification also demonstrate our commitment to the
chemical industryâ€™s Responsible Careâ„¢ initiative and in particular the guidelines of the Responsible
Care Global Charter.
With regard to the coverage of our business activities with hseq management systems based on energy consumption, in 2015 around 96% of our production sites featured an hse management system
audited by Bayer. Some 93% of our entire business activities were certified externally to at least one
internationally recognized standard. As part of a Group-wide certification plan, it is planned, by 2017,
to achieve virtually complete coverage based on energy consumption by external standards in both
environmental and occupational safety management. One hundred percent coverage is not feasible
owing to the frequent changes in our site portfolio.

Standards and Certifications in % of Business Activities (Based on Energy Consumption)

[Table 3.10.1]

2011

2012

2013

2014

2015

ISO 14001 certification / EMAS validation

66

84

Certified to OHSAS 180011

27

30

84

91

93

30

34

â€“

80

â€“

â€“

40

47

87

89

90

95

93

99

99

99

94

96

Certification to external standards

Certified to ISO 500012
Degree of coverage with certification to at
least one of the above standards
HSE management systems internally
audited by Bayer
HSE management systems audited by Bayer
1

The rise in 2015 is due to enhanced OHSAS 18001 certification at Covestro sites.
2 Group values determined from 2014 onward

See Chapter 7

All subgroups also have industry-specific international quality management systems such as iso 9001,
iso 17025, iso 13485 or gmp (Good Manufacturing Practice). Group-wide, the coverage by this kind of
certification is over 98%. More information about quality management in the various subgroups can be
found in Chapter 7 â€œProcurement, Production, Logistics, Distribution.â€

10.2 Energy Consumption
In 2015, we succeeded in reducing the Groupâ€™s total energy consumption by 2.5% to 83.2 petajoules.
Basically, we differentiate between primary energy consumption â€“ mainly of fossil fuels for our own
generation of electricity and steam â€“ and secondary energy consumption that reflects the purchase of
electricity, steam and refrigeration energy and the use of process heat.

133

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

Primary energy consumption fell by 5.7%. This was mainly due to the reduction in natural gas, which
was primarily achieved through more efficient facility operation at the Uerdingen site in Germany. The
use of coal was approximately at the same level as the previous year, while consumption of liquid fuels
and other primary energy sources was reduced. Waste utilization was significantly higher than the
previous year, mainly owing to the use of liquid waste as a source of energy at Covestroâ€™s site in
Caojing, China. Secondary energy consumption rose by 1.1%. The use of electricity declined, while
consumption of steam and process heat was higher than in 2014 (see Table 3.10.2).
The drop in total energy consumption (primary and secondary energy sources) was mainly caused by
lower energy needs at the Leverkusen and Uerdingen sites in Germany. Moreover, the partial shutdown
of production facilities at the Belford Roxo site in Brazil also contributed to a reduction in total energy
consumption.
In 2015, Bayerâ€™s manufactured sales volume rose by 2.7%. We were able to slightly improve our
energy efficiency, which we define as the total energy consumption in megawatt hours (MWh) per
metric ton of manufactured sales volume, from 3.37 MWh/t in 2014 to 3.34 MWh/t in 2015. This
development confirms the trend of a decoupling of manufactured sales volume from energy consumption identified in previous years. This brings us closer to our Group target of improving energy
efficiency by 10% by 2020.

Energy Consumption in the Bayer Group

[Table 3.10.2]
2011

Primary energy consumption
for the in-house generation of
electricity & steam (TJ)

2013

2014

2015

50,096

49,047

47,582

45,572

42,996

Natural gas

31,162

30,411

29,796

31,580

28,813

Coal

16,776

15,954

15,094

12,611

12,755

Liquid fuels

660

656

416

421

350

Waste

515

1,005

1,282

833

1,523

Other1

983

1,021

994

127

(445)

34,846

34,137

33,266

39,745

40,186

25,475

25,849

25,560

27,177

25,977

Steam

1,054

(121)

(801)

3,579

4,694

Steam from waste heat (process heat)

9,000

9,144

9,146

9,639

9,974

(683)

(735)

(639)

(650)

(459)

84,942

83,184

80,848

85,317

83,182

3.63

3.50

3.44

3.37

3.34

Secondary energy consumption
(net, TJ)
Electricity2

Refrigeration energy
Total energy consumption (TJ)
Energy efficiency 3 (MWh/t)
1

2012

E.g. hydrogen
2 Secondary energy consumption for electricity is based on the raw material mix of the country concerned.
3 Energy efficiency is the quotient of total energy consumption and manufactured sales volume. For Covestro, this includes neither the secondary
products sodium hydroxide solution and hydrochloric acid generated in production nor trade products.

Group target 2020:
improvement of 10%
in Group-wide energy
efficiency
See also Chapter
1.4 for Group
targets

134

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

www.bayer.com/
CDP-climate

More than 90% of our own energy generation comes from combined heat and power processes.
These efficient power plants convert approximately 80% of the fuel energy used into electricity and
heat. In addition, we purchase electricity on the market â€“ through energy exchanges, for example. The
electricity and heat generated and purchased are used in our own production facilities and third-party
facilities (especially of Lanxess Deutschland GmbH as the other shareholder of our service company
Currenta). The proportion of renewable energies is determined by the energy mix of our energy suppliers. We comment in detail on these issues in our cdp (previously Carbon Disclosure Project) Report.

10.3 Air Emissions
At Bayer, air emissions are caused mainly by the generation and consumption of electricity, steam and
process heat. Our commitment to greater energy efficiency helps reduce both costs and emissions. We
also aim to contribute to climate protection on several levels. We have set ambitious targets for resource
efficiency and established relevant measures across the Group.
Our commitment is divided into three areas:
Group target
Covestro:
improvement in
production process
technology to
achieve better
energy efficiency

www.bayer.com/
COV-production

1. More efficient production: we aim to reduce the emissions of greenhouse gases in our own production facilities by increasing energy efficiency, using combined heat and power generation in our power
plants and developing and marketing new, more climate-friendly technologies. Thanks to our own energy management systems and production and process innovations, considerable resources have been
saved in recent years. Energy efficiency projects resulting from structeseâ„¢ (Structured Efficiency
System for Energy) implemented since 2008 lead to annual savings. Taking into account all sustainable
savings effects since the system was introduced, these savings amounted to 1.55 million MWh in the
area of primary energy consumption in 2015.

See also Chapter 4

2. Reducing emissions using market solutions: our products play their part in saving energy and conserving resources in many different ways. We are able to help our customers in the areas of building
insulation, lightweight construction and agriculture in particular. We provide solutions both for reducing
emissions and for adapting to climate change. These include state-of-the-art crop protection products
that enable higher yields, new cultivation methods such as precision farming and the development of
crops that are better able to cope with stress factors such as extreme temperatures and aridity. You can
read more, for example, about combating the growing threat of malaria â€“ resulting from climate change
â€“ in the CropScience section of Chapter 4 â€œResearch, Development, Innovation.â€
3. Reducing emissions in nonproduction areas of Bayer: this includes â€“ with the planned reduction of
specific co2 emissions of newly registered vehicles to 110 g/km through 2020 â€“ an ambitious reduction
target for our vehicle fleet, optimized logistics and enhancement of the environmentally friendly credentials of our information and communication technologies (Green it). Through our EcoFleet initiative, co2
emissions of newly registered vehicles for our global fleet of over 25,000 vehicles were reduced by a
further 7 g/km to 141 g/km in 2015.

135

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

GREENHOUSE GAS EMISSIONS
Bayer reports all Group greenhouse gas emissions in line with the requirements of the Greenhouse Gas
Protocol (ghg Protocol). Direct emissions from our own power plants, waste incineration plants and
production facilities (corresponding to Scope 1 of the ghg Protocol) and indirect emissions that result
from the external procurement of electricity, steam and refrigeration energy (Scope 2) are determined at
all production locations and relevant administrative sites.
Dual reporting was introduced in 2015 with the updating of the ghg guidelines for Scope 2. According
to this, indirect emissions have to be reported using both the location-based and the market-based
methods. The location-based method uses regional or national average emissions factors, while the
market-based method uses provider- or product-specific emissions factors. From 2015, we are reporting
for the first time in line with the new guideline, shown retroactively to 2012. To ensure the comparability of the data we are additionally reporting according to the previous system once more this year.

Group Greenhouse Gas Emissions1

[Table 3.10.3]
Million metric tons of CO2 equivalents
2011

2012

2013

2014

2015

Direct greenhouse gas emissions2

4.23

4.24

4.09

4.02

4.41

Indirect greenhouse gas emissions3, according to the
previous method (reported until 2014)

3.92

4.12

4.29

4.70

4.64

Indirect greenhouse gas emissions3, according to the
location-based method (reported from 2015)

â€“

4.71

4.85

5.03

4.94

Indirect greenhouse gas emissions3, according to the
market-based method (reported from 2015)

â€“4

4.72

4.91

5.53

5.30

8.15

8.36

8.37

8.72

9.05

Total greenhouse gas emissions, according to the
previous method (reported until 2014)
Total greenhouse gas emissions, according to the
market-based method (reported from 2015)5

â€“

8.96

9.00

9.55

9.71

Specific greenhouse gas emissions (t CO2e / t), according
to the previous method (reported until 2014)6

0.95

0.98

1.00

1.02

1.09

Specific greenhouse gas emissions (t CO2e / t),
according to the market-based method (reported from
2015)5,6

â€“

1.06

1.09

1.12

1.19

1

Portfolio-adjusted in accordance with the GHG Protocol
2 In 2015, 86.8% of emissions were CO emissions, 12.7% N O emissions, just under 0.5% partially fluorinated hydrocarbons and 0.04%
2
2
methane.
3 Typically, CO in incineration processes accounts for over 99% of all greenhouse gas emissions. When determining indirect emissions, our
2
calculations are therefore limited to CO2.
4 Back calculation using the market-based method is only possible from 2012, as the RE-DISS factors needed for the calculation were only available
for the first time for that year.
5 The market-based method of the new Scope 2 GHG Protocol most reliably reflects the indirect emissions and the success of emissions reduction
measures, so we used emissions volumes calculated using this method when calculating the total and specific greenhouse gas emissions.
6 Specific Group emissions are calculated from the total volume of direct emissions and indirect â€“ calculated using the market-based method of the
new Scope 2 GHG Protocol â€“ emissions of the subgroups, including the emissions at the Belford Roxo site and emissions from the vehicle fleet,
both reported for the Group as a whole, divided by the manufactured sales volume of the three subgroups in metric tons. Quantities attributable to
the supply of energy to external companies are deducted from the direct and indirect emissions. At Covestro, neither the by-products sodium
hydroxide solution and hydrochloric acid generated during production nor trade products are included in the manufactured sales volume.

136

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

The total volume of Group-wide greenhouse gas emissions rose by 1.7% (Scope 2 market-based) in
2015. Broken down, direct emissions rose by 9.7%, while indirect emissions fell by 4.1% (Scope 2
market-based). The rise in direct emissions is largely due to higher nitrous oxide emissions caused by a
significant increase in nitric acid production at the site in Caojing, China, and to additional emissions
from the incineration of liquid and thermal waste there. Another reason was increased energy consumption by third parties at the CropScience site in Institute, United States.
Group target 2020:
reduction of 20% in
specific greenhouse
gas emissions

In line with our Group target we are endeavoring to reduce specific greenhouse gas emissions (total
emissions divided by the manufactured sales volume) by 20% through 2020. 2015 saw a rise of 6.0%
(Scope 2 being calculated according to the market-based method) owing mainly to the effects described
above.

See also Chapter
1.4 for Group
targets

online annex: 3-10.3-1
Even though a significant proportion of our direct emissions comes from the generation of energy
that is delivered to other companies, we include all greenhouse gas emissions from the conversion of
primary energy sources into electricity, steam or refrigeration energy in our energy balance, in line
with the regulations of the ghg Protocol. Consequently, our absolute figures for greenhouse gas
emissions are higher than the actual emissions resulting from Bayerâ€™s business activities. The level of
specific greenhouse gas emissions is a more meaningful statistic. This indicates only the greenhouse
gas emissions for which Bayer is directly responsible in relation to the manufactured sales volumes
of the three Bayer subgroups.

Greenhouse Gas Emissions by Subgroup and Service Company 1

[Table 3.10.3-1]
Total direct and indirect emissions
in million metric tons of CO2 equivalents
20122

2013

2014

20155

HealthCare

0.60

0.57

0.57

0.57

CropScience

0.96

0.99

0.97

1.05

Covestro

5.29

5.42

6.27

6.41

Currenta 3

1.99

1.92

1.62

1.47

Specific greenhouse gas emissions at Covestro
(metric tons of CO2 equivalents per metric ton of
manufactured sales volume)4

0.93

0.97

1.03

1.10

1

The indirect emissions were calculated according to the market-based method. Since the RE-DISS factors needed for this were only available
from 2012 on, the data are only indicated for the past 4 years.
2 Emissions from the Bayer Groupâ€™s vehicle fleet have been recorded since 2012, but not specific to any subgroup, and are assigned to the
direct Group emissions in Table 3.10.3. In 2015, fleet emissions amounted to 0.14 million metric tons of CO2 equivalents.
3 The emissions reported for Currenta are attributable to the provision of energy to external companies at the Chempark sites.
4 The by-products sodium hydroxide solution and hydrochloric acid generated during production are not included in the manufactured sales
volume, nor are trade products.
5 The emissions from the production site in Belford Roxo, Brazil, totaling 0.06 million metric tons of CO equivalents, are not included in this
2
table but are reported for the Group as a whole in Table 3.10.3.

In 2015, the waste incineration plants operated by Currenta generated just under 1 million metric
tons of steam from the incineration of more than 250,000 metric tons of hazardous waste from the
Chempark sites and some external production companies. Compared to using fossil energy sources,
the use of this steam enables approximately 200,000 metric tons less co2 to be emitted per year.
The reporting of all relevant indirect emissions resulting from the value chain is bindingly regulated by
the ghg Protocol Corporate Value Chain (Scope 3) Accounting & Reporting Standard. Following a thorough examination, Bayer has identified nine essential Scope 3 categories, which we report on in detail
in the cdp Report. We take particular account of those emissions where there is significant potential for
reduction e.g. our transport-related emissions resulting from business trips.

137

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

In 2015, the Bayer Group was involved in European emissions trading with 19 plants in total. The
greenhouse gas emissions of these plants amounted to approximately 2.32 million metric tons of co2
equivalents.
OTHER DIRECT EMISSIONS INTO THE AIR
Emissions of ozone-depleting substances (ods) fell by 20.7%. Emissions of volatile organic compounds
excluding methane (vocs) decreased by 24.0%. The main source of both types of emissions remains the
CropScience site in Vapi, India, which accounts for 55.4% of voc emissions and 94.3% of ods emissions. The project initiated there four years ago to reduce these emissions continues to have an impact.
voc emissions fell by a further 38.3%. ods emissions there also decreased, by 21.1%. A central waste
air treatment system will go into operation at the Vapi site during 2016. This will bring together the
many different sources of emissions there and cause another significant reduction in these emissions.

Emissions of Ozone-Depleting Substances (ODS)1

ODS in metric tons p.a.
1

[Table 3.10.4]
2011

2012

2013

2014

2015

16.3

16.3

15.7

14.8

11.7

Ozone-depleting substances (ODS) in CFC-11 equivalents

Emissions of Volatile Organic Compounds (VOC)1

VOC in 1,000 metric tons p.a.
VOC in kg per metric ton of manufactured sales
volume
1

[Table 3.10.5]
2011

2012

2013

2014

2015

2.69

2.60

2.27

2.12

1.61

0.2457

0.2316

0.2047

0.1864

0.1379

Volatile organic compounds (VOC) without methane

Emissions of sulfur dioxide fell by 4.1%. Particulate emissions also declined, in this case by 8.9%,
caused by reductions at Covestroâ€™s sites in Baytown, Texas, United States, and Caojing, China. Emissions of nitrogen oxides, on the other hand, rose by 2.4% and of carbon monoxide by 2.1%. Both
increases could essentially be attributed to differences in the types of coal used at the Uerdingen site
in Germany.
online annex: 3-10.3-2

Other Important Direct Air Emissions

[Table 3.10.5-1]
1,000 metric tons p.a.

CO

2011

2012

2013

2014

2015

1.31

1.00

0.94

0.91

0.93

NOX

3.66

3.07

2.51

2.36

2.42

SOX

2.27

1.85

1.32

1.22

1.17

Particulates

0.18

0.18

0.16

0.25

0.23

138

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

10.4 Use of Water and Emissions into Water
The continuous availability of clean water in sufficient quantities is essential for supplying our production sites and the surrounding areas. However, this can no longer be taken for granted in many parts of
the world. We plan to design our water supply in such a way that industrial water usage continues not
to lead to local problems such as a shortage of water for the people living in the area.
Our Water Position commits us to compliance with international and local legislation and to fulfilling the
strictest requirements worldwide while at the same time ensuring the reliable operation of our production facilities. The goal is to protect water as a resource and use it efficiently.
In their respective directives, our subgroups have defined responsible water use, ranging from resource-friendly usage to appropriate disposal of wastewater, and anchored implementation in their hseq
management systems.
Group target 2017:
establishment of water
management at all
sites in water-scarce
areas

See also Chapter
1.4 for Group
targets

As part of our Water Position, we used the wbcsd Global Water Toolâ„¢ to identify all Bayer sites that are
located in regions affected or threatened by water shortage. In line with our Group target, these sites
are to establish a water management system with local targets by 2017. The sites concerned are analyzed annually, including an evaluation of their water usage, quality and discharge data. In addition,
site-specific initiatives that enable the reuse of water and thus contribute to reducing water consumption are also examined and evaluated. Results of the current analysis show that an effective water management system is already in place at around 58% of the sites examined.
Although the framework conditions for sites can differ very considerably according to region, some
measures successfully implemented at several sites have already been seen to be effective. These include both in-house water treatment plants to make river water usable and river water reservoirs to
avoid having to take drinking water from local water suppliers even when water levels are low. Further
effective steps for pursuing the water target include continuous analysis of wastewater in line with sitespecific performance indicators and training new employees in responsible water usage.
Awareness of this issue is being raised through ongoing Group-wide dialogue. Equally important in this
is active participation in forums and discussions on this subject with government officials and other
stakeholders. The next step will be to agree specific measures for the targeted development at those
sites with identified potential for improvement.

www.bayer.com/
CDP-water

Bayer supports the ceo Water Mandate of the u.n. Global Compact with the goal of working with key
stakeholders to develop sustainable strategies for water usage. In our annual response to the cdp Water
Disclosure, we report in detail on our water usage, the company-specific water footprint and the associated opportunities and risks. This represents a progress report for the ceo Water Mandate.
WATER CONSUMPTION AND USAGE
In 2015, total water consumption in the Group fell by 1.1% to around 346 million cubic meters.
Some 73% of all water used by Bayer is cooling water. This water is only heated and does not come
into contact with products. It can be returned to the water cycle without further treatment in line with
the relevant official permits. The total volume of once-through cooling water was around 240 million
cubic meters in 2015. In our production activities, we endeavor to use water several times and to recycle it. Water is currently recycled at 35 sites, e.g. in closed cooling cycles, or through the reuse of treated wastewater or the recirculation of steam condensates as process water. A total of 10.5 million cubic
meters of water were reused in 2015.

139

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

online annex: 3-10.4-1
The diagram shows the distribution of the different types of water usage within the Bayer Group.
Water Use in the Bayer Group in 2015 (million m3)

Sources of water
Surface water

212 (61%)

Boreholes / springs

118 (34%)

Drinking water
supplies

10 (3%)

Other sources

6 (2%)

[Graphic 3.10.0-1]

Water usage 1
Cooling water

Water discharged 1

252 (73%)

of which
recycled / reused

10 (3%)

Once-through
cooling water

240 (76%)

Losses due to evaporation 12 (4%)
from cooling water circuits
50 (16%)
Process wastewater
with subsequent treatment

Production 2

94 (27%)

11 (4%)
Process wastewater
without subsequent treatment

1 The

differences between volumes of water consumed and water discharged can be explained, for example, by
unquantified losses due to evaporation, leaks, quantities of water used as raw materials in products and volumes of condensate
generated through the use of steam as a source of energy.
2 Sum from production processes, sanitary wastewater and rinsing and cleaning processes in production

Water was essentially obtained from the same sources as in the previous year.

Net Water Intake by Source

[Table 3.10.6]
2011

2012

2013

2014

2015

411

384

361

350

346

Proportion from surface water (%)

65

64

63

63

61

Proportion from boreholes / springs (%)

31

32

33

32

34

Proportion from public drinking water
supplies (%)

2

2

3

3

3

Proportion from other sources, generally
rainwater (%)

2

2

2

2

2

Water consumption (million mÂ³ p.a.)

WASTEWATER AND WASTEWATER DISCHARGES
The total volume of process wastewater fell by 7.7%. All wastewater is subject to strict monitoring and
analysis before it is discharged into disposal channels. 81.9% of Bayerâ€™s process wastewater worldwide is purified at wastewater treatment plants (Bayer or third-party facilities). Following careful analysis, the remaining volume was categorized as environmentally safe according to official provisions.
Part of it contained nutrients and was therefore used to water gardens and agricultural land, as in the
previous year.

Volume of Process Wastewater

Volume of process wastewater (million mÂ³)

[Table 3.10.7]
2011

2012

2013

2014

2015

72

65

63

66

61

The goal is to minimize emissions into wastewater. Total emissions of nitrogen compounds into
wastewater fell by 26.1% in 2015. The main factors behind this reduction were the decrease in production at CropScienceâ€™s Dormagen site in Germany and the fact that the denitrification process at
Covestroâ€™s Baytown site in Texas in the United States operated without interruption again in 2015.
Discharges of phosphates into wastewater rose by 2.0% in 2015. Total organic carbon (toc) emissions,
however, decreased by 3.3%.

140

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

Emissions into Water

[Table 3.10.8]
2011

2012

2013

2014

2015

Phosphorus (1,000 metric tons p.a.)

0.08

0.15

0.11

0.10

0.10

Nitrogen (1,000 metric tons p.a.)

0.53

0.70

0.69

0.76

0.56

0.0486

0.0624

0.0620

0.0671

0.0483

1.50

1.42

1.53

1.20

1.16

Nitrogen (kg per metric ton of manufactured
sales volume)
TOC1 (1,000 metric tons p.a.)
TOC (kg per metric ton of manufactured
sales volume)

0.137

0.126

0.138

0.105

0.100

0.0108

0.0098

0.0091

0.0063

0.0064

Inorganic salts (1,000 metric tons p.a.)

926

1,048

946

845

927

COD2 (1,000 metric tons p.a.)

4.51

4.25

4.58

3.59

3.48

Heavy metals (1,000 metric tons p.a.)

1
2

Total organic carbon
Chemical oxygen demand; calculated value based on TOC figures (TOC x 3 = COD)

10.5 Waste and Recycling
Systematic waste management minimizes material consumption and disposal volumes. Safe disposal
channels with separation according to the type of waste and economically expedient recycling processes serve this purpose. Production fluctuations and building refurbishment / land remediation work also
influence waste volumes and recycling paths.
In 2015, the total volume of waste generated rose by 4.9%. Although the volume of nonhazardous waste
fell by 2.5%, the volume of hazardous waste generated rose by 11.1%. This contrast is largely due to
the re-categorization of fluidized bed ash from the power plant at the Chempark Leverkusen site, which
now has to be classified as hazardous waste. Increased production at the sites in Wuppertal, Germany,
and Muttenz, Switzerland, also led to greater volumes of hazardous waste.

Waste Generated1

[Table 3.10.9]
2011

2012

2013

2014

2015

Total waste generated (1,000 metric tons p.a.)

958

1,014

899

896

940

Hazardous waste generated 2

474

603

467

487

541

of which hazardous waste from production

354

397

417

442

488

Specific volume of hazardous production waste
(%)

3.23

3.54

3.77

3.89

4.18

1

Waste generated by Bayer only
2 Definition of hazardous waste in accordance with the local laws in each instance

The volume of waste disposed of rose by 5.6%. This increase is mainly due to the construction of new
production facilities at the Knapsack site in Germany. More information about the distribution of waste
according to the different means of disposal is available in:

141

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

online annex: 3-10.5-1
Waste by Means of Disposal

Total volume of waste disposed of 1
(1,000 metric tons p.a.)

[Table 3.10.9-1]
2011

2012

2013

2014

2015

966

1,021

915

898

949

Proportion removed to landfill (%)

38

36

32

28

26

Proportion incinerated (%)

33

33

38

40

39

Proportion recycled (%)

28

29

27

29

31

1

2

2

3

4

OthersÂ² (%)
1

Bayer serves as a certified waste disposal plant operator at various sites. At these locations, Bayer disposes not only of its own waste but also
of waste from third parties (companies not belonging to the Bayer Group). For that reason, the volume of waste disposed of differs slightly
from the volume of waste generated by Bayer.
2 E.g. passed on to third parties (providers / waste disposal companies)

In 2015, the volume of recycled waste was 295,826 metric tons. Expressed as a proportion of the total waste disposed of, this represented an increase from 29% in 2014 to 31% in 2015. Site-specific
reasons such as changes to the product portfolio, other production volumes, variations in the intensity of construction measures and recycling projects were key to this.

Hazardous Waste1 Generated by Means of Disposal

[Table 3.10.9-2]
2011

2012

2013

2014

2015

1,000 metric tons p.a.

Total volume of hazardous waste generated 2

474

603

467

487

Amount removed to landfill

122

175

53

65

75

Amount incinerated / recycled

352

428

414

422

466

1
2

541

Waste generated by Bayer only
Definition of hazardous waste in accordance with the local laws in each instance

RECYCLING
In addition to satisfying economic and environmental criteria, the recycling and treatment of our materials also has to comply with legal requirements. This results in restrictions, in particular in the areas of
pharmaceuticals and crop protection. Throughout the Group, we are developing opportunities for recycling within the framework of legal regulations. Examples of recycling measures provide proof of
Bayerâ€™s commitment to recycling.
online annex: 3-10.5-2
Production-related recycling at HealthCare is conducted in line with the requirements of the relevant
production site. When determining the best means of disposal, recycling options are explicitly included, and are to be considered preferable to landfilling or incineration.
Material-based recycling is important in CropScienceâ€™s active ingredient and intermediate product
production. For reasons of resource efficiency, solvents, catalysts and intermediates are repeatedly
processed and returned to the production process. Since these are recycling steps that are closely
linked with the process, there is no global regulation. Material-based recycling is regulated separately at each production site and production plant. In the global process development of active ingredients and intermediates, material recycling is considered an important development criterion. In accordance with CropScienceâ€™s global Environment Policy, all CropScience sites are obliged to prevent,
recycle and reduce waste and dispose of it safely and in line with good environmental practices.

142

Bayer Annual Report 2015
Combined Management Report
10. Environmental Protection

The subgroups select the best means of disposal for any given waste type at the production site
based on the applicable national or local legal requirements, the technical possibilities available on
site, environmental protection aspects and the internal hierarchy of waste disposal.
No product-related recycling is possible for the HealthCare portfolio because pharmaceutical products are subject to strict quality requirements. Packaging materials are recycled in line with national
regulations as part of the national infrastructure for waste disposal.
CropScience does not generally take back crop protection products it has sold. Packaging materials
are disposed of or recycled in line with national legislation. In many countries where there is no legal
regulation, the industry has set up a returns system in collaboration with other providers.
Returns of obsolete stocks of crop protection products are only conducted in individual cases where
there is good reason. However, the crop protection product industry has set up voluntary initiatives
in various countries that enable farmers to ensure obsolete stocks are disposed of safely. As part of
its activities in the CropLife association, CropScience is working with the United Nationsâ€™ Food and
Agriculture Organization (fao) and the World Bank to support the proper collection and disposal of
obsolete stocks in Africa.
In its own production operations, Covestro also uses material recycled from plastic waste. These
kinds of high-quality secondary raw materials are used to manufacture certain grades of engineering
thermoplastics. A flame-retardant plastic compound for television set housings, for example, comprises 30% recycled pet water bottles.
The Global Sideline Business unit at Covestro sells unwanted plant and tools on the open market,
thus feeding them back into circulation. Approximately 150 tangible assets were sold to third parties
worldwide in 2015. Scrap metal from plants is returned to the material cycle. In 2015, this amounted
to around 1,600 metric tons in Germany alone.
Covestro is actively committed to recycling through its involvement in associations such as
PlasticsEurope and to the avoidance of plastic granule wastage in industrial plants through the Zero
Pellet Loss initiative. The company is also a shareholder of bkv GmbH, German industryâ€™s competence platform for recycling plastic.
Using conventional recycling measures, Currenta was able to return approximately 45,000 metric
tons of building materials, fgd gypsum and slag, 14,300 metric tons of metal and 15,800 metric tons
of chemicals such as sulfuric acid and solvents to the material cycle in 2015.

10.6 Biodiversity
Our Group-wide biodiversity position takes into account influences on biodiversity throughout the entire
value chain. In this position, we commit ourselves to the United Nations Convention on Biological Diversity and its Nagoya Protocol, which regulates access to genetic resources and the fair and equitable
sharing of the benefits arising from their utilization. Our CropScience subgroup passed an internal
regulation in 2015 to ensure that the company only acquires and uses genetic resources in harmony
with international and applicable national legislation.

143

Bayer Annual Report 2015
Combined Management Report
11. Social Commitment

online annex: 3-10.6-1
Biodiversity is essential for successful agriculture, as it promotes the resilience of ecosystems. Various ecological enhancement measures are under discussion to support resilient ecosystems, such as
planting flower strips to provide a refuge for animals or the more extensive cultivation of slopes to
protect against erosion. These measures can help farmers improve soil fertility and water regulation
in their fields, or boost the pollination activities of insects and thus increase their yields.
HealthCare also attaches great importance to maintaining biological diversity. As a member of the
Association of Research-Based Pharmaceutical Companies, it supports the associationâ€™s position on
the u.n. Convention on Biological Diversity. Among other things, this policy, which applies to all
HealthCare sites, takes into account that the subgroup concentrates on the chemical synthesis of
substances using state-of-the-art technologies in medicinal, combinatorial and computational chemistry. Research into natural substances is not a focal point of its work, accounting for less than 5% of
research projects. If such substances are used during research into new pharmaceuticals, they are
first checked with respect to the Convention on Biological Diversity.
Group-wide directives stipulate that new production sites must not be set up in areas that are protected
by statutory requirements of the countries concerned relating to natural characteristics, biodiversity or
other factors.
online annex: 3-10.6-2
In 2013, Bayer Real Estate, the Bayer Groupâ€™s real estate service provider, used its global site register to compare the geographical coordinates of relevant production sites against those of internationally recognized protected areas (asean Heritage, Barcelona Convention, unesco-mab Biosphere Reserve, Wetlands and World Heritage Convention and Ramsar Convention). This comparison revealed
three sites that are less than three kilometers from the protected areas Schorren van de Benenden
Schelde, Belgium; the Wadden Sea of Lower Saxony, Germany; and Blesbokspruit, South Africa,
respectively. Owing to major portfolio changes in the Group (separation of Covestro, formerly
MaterialScience, sale of the Diabetes Care business and acquisition of the consumer care business of
Merck & Co., Inc.) we are planning a new coordinate comparison with an updated range of production sites in 2016.

11. Social Commitment
Bayerâ€™s funding strategy focuses on people embarking on new approaches to problem-solving in the
natural and life sciences and in the key areas of health, education and basic social needs, with the goal
of sustainably improving living conditions. This also applies to a further focus area, sports and culture.
With our support programs we see ourselves as investors, trendsetters and partners for initiatives and
projects that have model character, a long-term effect and thus the potential to achieve systemic
change.

144

Bayer Annual Report 2015
Combined Management Report
11. Social Commitment

The Foundation & Donations Management Department within the Corporate Office of Bayer AG is responsible for strategically aligning and coordinating our social commitment, as well as for monitoring
and reporting activities. The Group-wide donation allocation and management regulations form the
basis for this. The country companies, in collaboration with partner organizations such as nongovernmental organizations, bear responsibility for implementing a large number of the initiatives. An independent panel made up of internal and external judges generally decides how project funding is allocated.
In 2015, we invested a total of â‚¬51 million (2014: â‚¬49 million) in charitable activities worldwide. This
was aimed at improving the quality of life at the companyâ€™s various locations and contributing to solving
social challenges.

Social Commitment in 2015

[Graphic 3.11.1]

Sports and Culture

Health and
Basic Social Needs

â‚¬19

â‚¬18

million

million

â‚¬10 million

â‚¬5 million

Public health, health education,

Cultural affairs

patient groups

â‚¬14 million

â‚¬51 million

Bayer sports clubs

â‚¬6 million
Coummunity projects,
volunteering

â‚¬2 million
Disaster aid

Education
and Science

â‚¬14

million

â‚¬2 million

â‚¬3 million

â‚¬6 million

â‚¬3 million

Fostering

Research

Science education

Scientific excellence

of talent

projects

in schools

Further information can be found in
online annex: 3-11-1
HEALTH AND BASIC SOCIAL NEEDS
In 2015, the Bayer Cares Foundation awarded the Aspirin Social Award to the Jourvie charitable initiative. The first-place prize money of â‚¬15,000 will enable the already successful app for supporting
the treatment of eating disorders to be further developed and disseminated. The foundation entered
into a collaboration with the â€œDiscovering Handsâ€ initiative, which was a prize-winner in 2014. This
will introduce this exemplary social medicine project, which is already established in Germany, to
other countries. Blind women, trained as Medical Tactile Examiners, use their extraordinary sense of
touch to help with the early diagnosis of breast cancer in women. Colombia is the first pilot country
outside Germany. The Latin American Development Bank is another project partner.
Since the Bayer Volunteering Program began in Germany in 2007 and worldwide in 2013, the Bayer
Cares Foundation has provided support for 550 volunteering projects in 65 countries. Through these
projects, employees and citizens work toward improving living conditions in and around the companyâ€™s sites. In 2015, the foundation brought 100 projects in 38 countries into the program, due primarily to their innovative approaches, providing them with a total of around â‚¬304,000 in funding.

145

Bayer Annual Report 2015
Combined Management Report
11. Social Commitment

Bayer is involved in an initiative aimed at eliminating or stemming the incidence of 10 neglected
tropical diseases, which threaten the lives of 1.4 billion people, by 2020. We provide medication to
tackle these diseases and participate in collaborations for developing new medicines. The World
Health Organization (who), governments, nongovernmental organizations and other companies are
partners in this global initiative. Focal points that fit in with Bayerâ€™s product portfolio are Chagas disease, African sleeping sickness, dengue and river blindness.
For more than 10 years, we have donated our active ingredients for the treatment of African sleeping
sickness and Chagas disease, which is widespread in Latin America, to the who free of charge. In
2015, we again supplied one million Lampitâ„¢ tablets (active ingredient: nifurtimox 120 mg) to treat
Chagas disease, as well as providing us$300,000 for logistics and distribution. We are also currently
developing a nifurtimox tablet with a lower dosage that will make it easier to treat children with
Chagas disease.
We are pleased to report that the number of patients affected by the type of African sleeping sickness
primarily found in eastern and southern Africa is in steady decline. We were therefore able to reduce
the amount of Germaninâ„¢ supplied to the who to 10,000 ampoules worth â‚¬114,000 in 2015. We
again provided 300,000 tablets of the active ingredient nifurtimox to be used in a combination therapy with an active ingredient from another manufacturer to treat the most widespread, West African
version of sleeping sickness. We also came to an agreement with the who to further expand support
for patients in the Democratic Republic of Congo, which is the country most severely affected by
sleeping sickness.
In a new product development partnership with the Drugs for Neglected Diseases Initiative, we are
examining whether the active ingredient emodepside, which is currently used in veterinary medicine, could also be used to treat river blindness in humans and thus achieve a significant shortening
of treatment time.
In 2015, Bayer was once again active in supporting people experiencing acute hardship as a result of
natural disasters. For example, we donated medication and money with a total value of â‚¬400,000 for
people affected by the earthquake in Nepal. We contributed money and water purification tablets
with a total value of â‚¬25,000 to help victims of the floods in Myanmar.
We donated antibiotics with the total value of just under â‚¬1.9 million to the aid organization Health
Partners International of Canada (hpic) for the treatment of people in crisis areas and humanitarian
emergencies.
We also made drugs with a market value of just under â‚¬1.5 million available free of charge to aid organizations and authorities in Turkey, Greece and Austria to treat refugees.
EDUCATION AND SCIENCE
The Bayer Science & Education Foundation again awarded prizes in 2015 with the primary goal of
recognizing and raising the profile of pioneering work in life sciences and basic medical research.
Winner of the Hansen Family Award 2015 is the French infection researcher Professor Emmanuelle
Charpentier from the Helmholtz Center in Braunschweig, Germany. She is responsible for key insights in the field of genome editing. In 2015, the Bayer Early Excellence in Science Award and the
Bayer Thrombosis Research Award â€“ the two prizes that promote young scientists â€“ went to young
researchers from Germany and the United States for their successes in the fields of medicine, biology and chemistry, and specifically in thrombosis research.

146

Bayer Annual Report 2015
Combined Management Report
11. Social Commitment

The company awarded 187 scholarships to talented students, postgraduates and trainees in the fields
of natural, life and agricultural science and medicine, with the particular goal of enabling projects
abroad. With regard to our support of schools, the â€œMaking Science Make Senseâ€ initiative in the
United States celebrated its 20th anniversary. This program involves several hundred employees volunteering regularly to visit elementary schools and use everyday experiments to communicate the
fascination and practical importance of science. Bayer implemented similar programs also aimed at
young people in more than 20 countries in 2015.
GRI
G4-26

To this end, our country companies cooperated with museums, universities and other educational institutions, invited schoolchildren to the companyâ€™s own student laboratories or took â€œresearch
trucksâ€ to the schools.
In Germany, the focus was on funding innovative teaching projects with a total of â‚¬500,000 for 63
specific measures at 57 schools and other educational institutions in 31 towns and cities, plus the
awarding of travel scholarships and support of competitions for school students. In addition, the
Humboldt Bayer Mobil, a research laboratory on wheels, regularly visited schools and the four
Baylab student laboratories offered school classes a professional infrastructure. More than 20,000
schoolchildren used these facilities alone in 2015.
Given the huge influx of refugees into Germany, the Bayer Science & Education Foundation has expanded its range of scientific school education programs to also target refugee children. Along with
the Berlin Senate and other educational organizations, the foundation launched a unique pilot project
â€“ the Science4Life Academy.
For the first time, teaching materials specifically for children with no knowledge of German are being
developed and introduced into science lessons, and teachers are receiving targeted training. Our
company also offers talented schoolchildren the chance of individualized support in the form of internships and mentoring. Our other activities to support refugees include a course preparing refugees aged between 18 and 26 for work, involving language training and careers advice.
SPORTS AND CULTURE
In 2015, Bayer further expanded its range of cultural activities. We continued to focus particularly on
encouraging young talent, and brought new artists into the stART program. Another key point was to
enable young people to have greater access to theater. Bayer Arts & Culture also intensified dialogue
with the public. In total, Bayer staged around 120 events in the fields of music, dance, theater and
the fine arts in 2015.
The â€œVersionaleâ€ competition for theater direction, for example, challenged creative theatrical and
cultural minds for the first time to develop short stage works on the topic of â€œScience For A Better
Life.â€
The Bayer clubs again made a key contribution to the broad range of sporting activities near the
German sites in North Rhine-Westphalia. The major clubs also became more intensely involved as
professional service providers for the companyâ€™s occupational health management. In 2015, the
company provided funding of some â‚¬14 million for recreational, disabled and competitive sports activities.
Bayerâ€™s involvement in professional soccer at Bayer 04 Leverkusen GmbH is not part of its social
sports sponsorship activities because it belongs to the companyâ€™s image advertising.

147

Bayer Annual Report 2015
Combined Management Report

Report on Economic Position
FISCAL 2015:

// Focus on the Life Sciences following the successful
stock market flotation of Covestro
// Substantial sales and earnings increases at HealthCare
// Good business development at CropScience despite a weaker
market environment
// Covestro posts strong earnings improvement
// Group sales â‚¬46.3 billion (Fx & portfolio adj. +2.7%)
// ebit â‚¬6.3 billion (+15.8%)
// ebitda before special items â‚¬10.3 billion (+18.2%)
// Net income â‚¬4.1 billion (+20.0%)
// Core earnings per share â‚¬6.83 (+16.0%)
// Forecast for 2016: further growth in sales and earnings

REPORT ON ECONOMIC POSITION

Another record year for Bayer

148

Bayer Annual Report 2015
Combined Management Report
12. Overview of Sales, Earnings and Financial Position

12. Overview of Sales, Earnings
and Financial Position
TA R GET ATT AI NM EN T 2 0 15

Group targets 2015:
Profitable growth

Forecast 2015 1

Adjusted forecast 2015 2

Target attainment

Low-single-digit
percentage increase 3

Unchanged

2.7% increase 3

Approx. â‚¬46 billion

Unchanged

â‚¬46.3 billion

ebitda
before special items

Low- to mid-teens
percentage increase

High-teens percentage
increase

18.2% increase

Core earnings
per share

Low-teens percentage
increase

High-teens percentage
increase

16.0% increase

Group sales

See Chapter 1.4
for Group targets

1
2
3

Issued in February 2015
Issued in October 2015
Currency- and portfolio-adjusted

FULL YEAR 2015
Bayer had a very successful year in 2015, both strategically and operationally. We achieved important
milestones on the path to becoming a Life Science company: In October 2015, we floated our subsidiary
Covestro (formerly MaterialScience) â€“ in which we currently hold around 69% â€“ on the stock exchange.
With the new organizational structure and the realignment of the Board of Management, which took
effect on January 1, 2016, we set the course for the companyâ€™s further development. We also successfully continued integrating the recently acquired consumer care businesses in our Consumer Health segment and continued to invest heavily in our research and development pipeline.
Our operating performance marked another new record in 2015. We registered higher sales and substantial earnings growth of around 18%, supported also by positive currency effects. HealthCare
showed a convincing performance, with strong sales and earnings growth. This was chiefly attributable
to the very good development of our recently launched pharmaceutical products and to expanded business in all Consumer Health divisions. In particular, the products added through the recent acquisitions
contributed additionally to growth at Consumer Care. Despite a weaker market environment, sales at
CropScience were up against the prior year. Earnings also rose. Covestro significantly raised earnings,
due mainly to lower raw material costs, while sales receded as expected. Core earnings per share of the
Bayer Group advanced by 16%.

Changes in Sales

[Table 3.12.1]
2014

2015

%

%

Volume

+ 6.8

+ 4.4

Price

+ 0.4

â€“ 1.7

Currency

â€“ 2.8

+ 5.9

Portfolio

+ 0.8

+ 3.5

Total

+ 5.2

+ 12.1

149

Bayer Annual Report 2015
Combined Management Report
12. Overview of Sales, Earnings and Financial Position

Group sales advanced by 2.7% on a currency- and portfolio-adjusted basis (Fx & portfolio adj.) in 2015,
to â‚¬46,324 million (reported: + 12.1%; 2014: â‚¬41,339 million). Sales of HealthCare improved by 8.1%
(Fx & portfolio adj.; reported: + 19.9%). CropScience sales gained 1.7% (Fx & portfolio adj.; reported:
+ 9.2%) against the prior year. Sales at Covestro declined by 5.1% (Fx & portfolio adj.; reported:
+ 2.8%).
Bayer Group Quarterly Sales

[Graphic 3.12.1]
â‚¬ million

Q1

2014
2015

1,329
1,341

9,023
10,538

10,352
11,879

Q2

2014
2015

1,217
1,249

9,011
10,841

10,228
12,090

Q3

2014
2015

1,174
1,217

8,793
9,819

9,967
11,036

Q4

2014
2015

1,084
1,139

9,708
10,180

10,792
11,319

Total

2014
2015

4,804
4,946

36,535
41,378

41,339
46,324

0

Germany

1,000

2,000

3,000

4,000

5,000

6,000

7,000

8,000

9,000

10,000

11,000

12,000

Other countries

2014 figures restated

ebit of the Bayer Group increased by 15.8% to â‚¬6,250 million (2014: â‚¬5,395 million) after net special
charges of â‚¬819 million (2014: â‚¬438 million). The special charges mainly included â‚¬280 million in expenses for the consolidation of production sites, â‚¬227 million in integration costs for acquired businesses and â‚¬212 million in expenses connected with the carve-out and stock market flotation of Covestro.
Further charges included â‚¬202 million in costs for efficiency improvements, â‚¬91 million for the revaluation of other receivables, and impairment losses of approximately â‚¬40 million in connection with a development project. These amounts were partly offset in ebit by a special gain of around â‚¬300 million
from a litigation in connection with a breach of contract and patent infringement by Dow AgroSciences
(DAS). ebit before special items rose by 21.2% to â‚¬7,069 million (2014: â‚¬5,833 million).
ebitda before special items increased by 18.2% to â‚¬10,266 million (2014: â‚¬8,685 million). The good
sales development was accompanied by higher r&d expenses (up by around â‚¬740 million on the prior
year). Positive currency effects buoyed earnings by about â‚¬680 million. ebitda before special items at
HealthCare improved by 19.8% to â‚¬6,419 million (2014: â‚¬5,357 million). This increase was chiefly
attributable to the very good development of business at Pharmaceuticals and Consumer Health â€“
including particularly the contribution from the acquired businesses at Consumer Care â€“ and currency
effects of around â‚¬250 million. ebitda before special items of CropScience rose by 2.4% to
â‚¬2,416 million (2014: â‚¬2,360 million), mainly because of higher volumes and a positive currency effect
of about â‚¬220 million. ebitda before special items of Covestro rose by a substantial 39.8% to
â‚¬1,659 million (2014: â‚¬1,187 million), primarily due to lower raw material and energy costs and positive currency effects of â‚¬240 million.

150

Bayer Annual Report 2015
Combined Management Report
12. Overview of Sales, Earnings and Financial Position

Bayer Group
Quarterly EBIT

[Graphic 3.12.2]

Bayer Group
Quarterly EBITDA Before Special Items

[Graphic 3.12.3]

â‚¬ million

â‚¬ million

Q1

2014
2015

2,065
1,944

Q1

2014
2015

2,703
2,941

Q2

2014
2015

1,435
1,833

Q2

2014
2015

2,176
2,899

Q3

2014
2015

1,346
1,565

Q3

2014
2015

1,977
2,523

Q4

2014
2015

549
908

Q4

2014
2015

1,829
1,903

Total

2014
2015

5,395
6,250

Total

2014
2015

8,685
10,266

0

500

1,000

1,500

2,000

2,500

0

500

1,000

1,500

2,000

2,500

3,000

2014 figures restated

After a financial result of minus â‚¬1,005 million (2014: minus â‚¬981 million), income before income
taxes was â‚¬5,245 million (2014: â‚¬4,414 million). After tax expense of â‚¬1,227 million (2014:
â‚¬1,071 million), income from discontinued operations after taxes and noncontrolling interest, net income for 2015 came in at â‚¬4,110 million (2014: â‚¬3,426 million). Earnings per share were â‚¬4.97 (2014:
â‚¬4.14). Core earnings per share from continuing operations advanced by 16.0% to â‚¬6.83 (2014: â‚¬5.89),
calculated as explained in Chapter 14.3 â€œCore Earnings Per Share.â€

Gross Cash Flow by Quarter

[Graphic 3.12.4]

Net Cash Flow by Quarter

[Graphic 3.12.5]

â‚¬ million

â‚¬ million

Q1

2014
2015

2,018
2,011

Q1

2014
2015

144
677

Q2

2014
2015

1.665
2,173

Q2

2014
2015

1,569
1,950

Q3

2014
2015

1,466
1,427

Q3

2014
2015

1,781
2,306

Q4

2014
2015

1,558
1,388

Q4

2014
2015

2,203
1,914

Total

2014
2015

6,707
6,999

Total

2014
2015

5,697
6,847

0

2014 figures restated

500

1,000

1,500

2,000

0

500

1,000

1,500

2,000

151

Bayer Annual Report 2015
Combined Management Report
12. Overview of Sales, Earnings and Financial Position

Gross cash flow from continuing operations climbed by 4.4% in 2015 to â‚¬6,999 million (2014:
â‚¬6,707 million), mainly because of the improvement in ebitda. Net cash flow (total) rose by 18.6% to
â‚¬6,890 million (2014: â‚¬5,810 million) due to a substantial decrease in additional cash tied up in working
capital. In 2015, we paid income taxes amounting to â‚¬1,699 million (2014: â‚¬1,835 million). We reduced
net financial debt by â‚¬2.2 billion against December 31, 2014, to â‚¬17.4 billion. The net defined benefit
liability for post-employment benefits â€“ the difference between benefit obligations and plan assets â€“
decreased from â‚¬12.2 billion to â‚¬10.8 billion over the same period, mainly due to a rise in long-term
capital market interest rates for high-quality corporate bonds.
Total assets as of December 31, 2015, increased by 5.2% to â‚¬73.9 billion. Noncurrent assets rose by
4.4% to â‚¬50.1 billion due mainly to currency effects. The carrying amount of current assets climbed to
â‚¬23.8 billion, mainly driven by higher trade accounts receivable. Equity increased by â‚¬5.2 billion to
â‚¬25.4 billion. This was primarily attributable to the net income of â‚¬4.1 billion, the â‚¬1.5 billion capital
increase at Covestro due to the stock market flotation, the â‚¬0.8 billion decline â€“ recognized outside
profit or loss â€“ in post-employment benefit obligations and the exchange differences of â‚¬0.7 billion. The
dividend payment of â‚¬1.9 billion had an opposing effect. Liabilities decreased by â‚¬1.5 billion compared
with December 31, 2014, to â‚¬48.5 billion.

Key Data by Subgroup and Segment

[Table 3.12.2]

Sales

EBIT

EBITDA
before special items 1

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

HealthCare

19,075

22,874

3,470

4,050

5,357

6,419

Pharmaceuticals

12,052

13,745

2,371

2,807

3,699

4,195

Consumer Health

7,023

9,129

1,099

1,243

1,658

2,224

CropScience

9,494

10,367

1,806

2,103

2,360

2,416

11,651

11,982

555

635

1,187

1,659

1,119

1,101

(436)

(538)

(219)

(228)

41,339

46,324

5,395

6,250

8,685

10,266

Covestro
Reconciliation
Group

2014 figures restated
1 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€

FOURTH QUARTER OF 2015
Group sales in the fourth quarter of 2015 rose by 2.4% (Fx & portfolio adj.) to â‚¬11,319 million (reported:
+ 4.9%). Sales of HealthCare gained 8.5% (Fx & portfolio adj.) to â‚¬5,811 million (reported: + 8.6%).
Business in the Pharmaceuticals segment expanded by 9.6% (Fx & portfolio adj.) to â‚¬3,571 million
(reported: + 9.2%), driven by the encouraging development of our recently launched products. Sales at
Consumer Health came in 6.9% ahead of the prior-year quarter at â‚¬2,240 million (reported: + 7.7%).
CropScience sales rose by 5.3% (Fx & portfolio adj.) to â‚¬2,439 million (reported: + 11.1%) due mainly to
increases at Crop Protection / Seeds. Sales of Covestro fell by 10.6% (Fx & portfolio adj.) to
â‚¬2,774 million (reported: â€“ 5.9%), primarily because of much lower selling prices. On the other hand,
volumes increased slightly.

152

Bayer Annual Report 2015
Combined Management Report
12. Overview of Sales, Earnings and Financial Position

ebit of the Bayer Group improved by a significant 65.4% in the fourth quarter of 2015 to â‚¬908 million
(q4 2014: â‚¬549 million), reflecting special charges of â‚¬116 million (q4 2014: â‚¬442 million). The special
charges mainly included â‚¬138 million in expenses for the consolidation of production sites, â‚¬114 million
for efficiency improvement measures, â‚¬50 million in integration costs for acquired businesses and
â‚¬49 million in expenses in connection with the carve-out and stock market flotation of Covestro. Further
charges of approximately â‚¬40 million related to the impairment of a research project. These amounts
were partly offset by a gain of around â‚¬300 million from a litigation. ebit before special items increased
by 3.3% to â‚¬1,024 million (q4 2014: â‚¬991 million).
ebitda before special items improved in the fourth quarter of 2015 by 4.0% to â‚¬1,903 million (q4 2014:
â‚¬1,829 million). This good business development, especially at HealthCare, was accompanied by higher
r&d and selling expenses. Positive currency effects contributed â‚¬200 million to earnings. HealthCare
registered a 7.2% improvement in ebitda before special items to â‚¬1,511 million (q4 2014:
â‚¬1,409 million). At CropScience, ebitda before special items fell by 9.5% to â‚¬334 million (q4 2014:
â‚¬369 million). Earnings of Covestro climbed by a substantial 18.4% to â‚¬257 million (q4 2014:
â‚¬217 million).
After a financial result of minus â‚¬164 million (q4 2014: minus â‚¬347 million), income before income
taxes was â‚¬744 million (q4 2014: â‚¬202 million). The financial result mainly comprised interest cost of
â‚¬67 million (q4 2014: â‚¬111 million) for pension and other provisions, exchange losses of â‚¬67 million
(q4 2014: â‚¬66 million) and net interest expense of â‚¬46 million (q4 2014: â‚¬148 million). The decline in
net interest expense resulted primarily from interest income of â‚¬109 million related to a legal claim.
After income tax expense of â‚¬163 million, income from discontinued operations after taxes and noncontrolling interest, net income in the fourth quarter of 2015 came to â‚¬613 million (q4 2014: â‚¬224 million).
Earnings per share improved to â‚¬0.74 (q4 2014: â‚¬0.27). Core earnings per share from continuing operations fell to â‚¬1.07 (q4 2014: â‚¬1.17). Tax income was recorded in the previous year.
See Chapter 14.3
for an explanation
of the calculation

Gross cash flow from continuing operations of the Bayer Group receded by 10.9% to â‚¬1,388 million
(q4 2014: â‚¬1,558 million). Net cash flow (total) moved back by 15.8% to â‚¬1,877 million (q4 2014:
â‚¬2,230 million). The decline was mainly due to the deferred one-time payment of â‚¬793 million in the
previous year in connection with the sGC collaboration with Merck & Co., Inc., United States. In the
fourth quarter of 2015 we paid income taxes amounting to â‚¬482 million (q4 2014: â‚¬415 million). Net
financial debt fell by â‚¬1.9 billion in the fourth quarter of 2015 to â‚¬17.4 billion (September 30, 2015:
â‚¬19.3 billion), largely as a result of cash inflows from operating activities and the stock market flotation
of Covestro. The net defined benefit liability for post-employment benefits decreased by â‚¬0.8 billion
against September 30, 2015, to â‚¬10.8 billion, mainly due to a rise in long-term capital market interest
rates for high-quality corporate bonds.

Key Data by Subgroup and Segment

[Table 3.12.3]

Sales

EBIT

EBITDA
before special items 1

4th Quarter
2014

4th Quarter
2015

4th Quarter
2014

4th Quarter
2015

4th Quarter
2014

4th Quarter
2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

HealthCare

5,351

5,811

550

777

1,409

1,511

Pharmaceuticals

3,271

3,571

375

551

939

991

Consumer Health

2,080

2,240

175

226

470

520

CropScience

2,195

2,439

191

478

369

334

Covestro

2,948

2,774

43

(79)

217

257

298

295

(235)

(268)

(166)

(199)

10,792

11,319

549

908

1,829

1,903

Reconciliation
Group

2014 figures restated
1 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€

153

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

13. Business Development by Subgroup,
Segment and Region
13.1 HealthCare
Key Data â€“ HealthCare

[Table 3.13.1]
4th Quarter
2014

4th Quarter
2015

Change

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

5,351

5,811

+ 8.6

+ 8.5

19,075

22,874

+ 19.9

+ 8.1

Volume

+ 5.8%

+ 8.1%

+ 6.4%

+ 7.4%

Price

+ 2.0%

+ 0.4%

+ 1.1%

+ 0.7%

Currency

0.0%

0.0%

â€“ 3.7%

+ 4.5%

Portfolio

+ 5.5%

+ 0.1%

+ 1.8%

+ 7.3%

Pharmaceuticals

3,271

3,571

+ 9.2

+ 9.6

12,052

13,745

+ 14.0

+ 9.9

Consumer Health

2,080

2,240

+ 7.7

+ 6.9

7,023

9,129

+ 30.0

+ 5.1

â‚¬ million

â‚¬ million

%

Fx. adj. %

â‚¬ million

â‚¬ million

%

Fx. adj. %

Europe

1,832

1,923

+ 5.0

+ 5.9

6,870

7,404

+ 7.8

+ 8.8

North America

1,514

1,724

+ 13.9

+ 2.5

5,017

7,159

+ 42.7

+ 25.7

Asia / Pacific

1,215

1,376

+ 13.3

+ 6.3

4,427

5,342

+ 20.7

+ 10.3

790

788

â€“ 0.3

+ 29.9

2,761

2,969

+ 7.5

+ 21.5

+ 41.3

3,470

4,050

+ 16.7

Sales

Change

Change in sales

Sales

Sales by region

Latin America / Africa / Middle East
EBIT

550

777

6SHFLDOLWHPV

 



EBIT before special items 1
EBITDA1
6SHFLDOLWHPV
EBITDA before special items 1
EBITDA margin before special items 1



 

926

1,041

+ 12.4

3,801

4,650

+ 22.3

1,062

1,315

+ 23.8

5,059

5,914

+ 16.9

+ 7.2

5,357

6,419

28.1%

28.1%

 



1,409

1,511

26.3%

26.0%



 
+ 19.8

Gross cash flow 2

1,217

820

â€“ 32.6

3,898

4,121

+ 5.7

Net cash flow 2

2,158

1,094

â€“ 49.3

4,331

4,321

â€“ 0.2

2014 figures restated
Fx & p adj. = currency- and portfolio-adjusted; Fx adj. = currency-adjusted
1 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
2 For definition see Chapter 14.5 â€œLiquidity and Capital Expenditures of the Bayer Group.â€

PHOTO // The picture above, taken with a scanning electron microscope,
NCJRN<=GJJ?>GJOÃ°H<BIDÂ¾@?<=JPO7,500 times.

154

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

Sales of the HealthCare subgroup rose by 8.1% (Fx & portfolio adj.) in 2015, to â‚¬22,874 million (reported: + 19.9%). This encouraging growth was driven by our recently launched pharmaceutical products. Business expanded in all divisions of the Consumer Health segment. The considerable reported
sales increase was chiefly attributable to business with products acquired from Merck & Co., Inc., United
States, and to currency effects.

HealthCare Quarterly Sales

[Graphic 3.13.1]
â‚¬ million

Q1

2014
2015

4,369
5,504

Q2

2014
2015

4,615
5,908

Q3

2014
2015

4,740
5,651

Q4

2014
2015

5,351
5,811
0

500

1,000

1,500

2,000

2,500

3,000

3,500

4,000

4,500

5,000

5,500

6,000

ebit of HealthCare advanced by 16.7% in 2015 to â‚¬4,050 million. This figure reflected special
charges of â‚¬600 million (2014: â‚¬331 million). ebit before special items improved by a clear 22.3% to
â‚¬4,650 million. We raised ebitda before special items by a substantial 19.8% to â‚¬6,419 million. This
earnings growth resulted mainly from the very favorable development of business at Pharmaceuticals
and Consumer Health â€“ at Consumer Health especially due to the contributions from the acquired businesses â€“ and from positive currency effects of about â‚¬250 million. Earnings were diminished by increased investment in research and development at Pharmaceuticals and higher selling expenses at
Consumer Health.

HealthCare
Quarterly EBIT

[Graphic 3.13.2]

HealthCare
Quarterly EBITDA Before Special Items

[Graphic 3.13.3]

â‚¬ million

â‚¬ million

Q1

2014
2015

931
986

Q1

2014
2015

1,266
1,556

Q2

2014
2015

927
1,068

Q2

2014
2015

1,314
1,675

Q3

2014
2015

1,062
1,219

Q3

2014
2015

1,368
1,677

Q4

2014
2015

550
777

Q4

2014
2015

1,409
1,511

0

200

400

600

800

1,000

1,200

0

200

400

600

800

1,000 1,200 1,400 1,600

155

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

PHARMACEUTICALS
Key Data â€“ Pharmaceuticals

[Table 3.13.2]
4th Quarter
2014

Sales

4th Quarter
2015

Change

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

3,271

3,571

+ 9.2

+ 9.6

12,052

13,745

+ 14.0

+ 9.9

â‚¬ million

â‚¬ million

%

Fx adj.
%

â‚¬ million

â‚¬ million

%

Fx adj.
%

Change

Sales by region
Europe

1,176

1,294

+ 10.0

+ 10.0

4,396

4,869

+ 10.8

+ 11.0

North America

735

823

+ 12.0

+ 2.7

2,728

3,363

+ 23.3

+ 7.6

Asia / Pacific

884

1,002

+ 13.3

+ 6.0

3,278

3,868

+ 18.0

+ 7.2

Latin America / Africa / Middle East

476

452

â€“ 5.0

+ 25.6

1,650

1,645

â€“ 0.3

+ 15.9

+ 46.9

2,371

2,807

+ 18.4

(286)

(254)

EBIT

375

551

(290)

(149)

EBIT before special items 1

665

700

+ 5.3

2,657

3,061

+ 15.2

EBITDA1

678

884

+ 30.4

3,446

3,987

+ 15.7

(261)

(107)

(253)

(208)

939

991

+ 5.5

3,699

4,195

28.7%

27.8%

30.7%

30.5%

843

546

â€“ 35.2

2,745

2,737

â€“ 0.3

1,719

784

â€“ 54.4

3,266

2,863

â€“ 12.3

Special items

Special items
EBITDA before special items 1
EBITDA margin before special items1
Gross cash flow 2
Net cash flow 2

Fx & p adj. = currency- and portfolio-adjusted; Fx. adj. = currency-adjusted
1 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
2 For definition see Chapter 14.5 â€œLiquidity and Capital Expenditures of the Bayer Group.â€

Sales of the Pharmaceuticals segment climbed by a substantial 9.9% (Fx & portfolio adj.) to
â‚¬13,745 million. This very good performance was driven by our recently launched products Xareltoâ„¢,
Eyleaâ„¢, Stivargaâ„¢, Xofigoâ„¢ and Adempasâ„¢, which posted combined sales of â‚¬4,231 million (2014:
â‚¬2,908 million). Our Pharmaceuticals business registered encouraging growth in all regions on a currency-adjusted basis. Business developed especially well in Germany, Japan and the United States.

+ 13.4

156

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

Best-Selling Pharmaceuticals Products

[Table 3.13.3]
4th Quarter
2014

4th Quarter
2015

Change

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

%

Fx adj.
%

â‚¬ million

â‚¬ million

%

Fx adj.
%

Xareltoâ„¢

516

650

+ 26.0

+ 27.6

1,679

2,252

+ 34.1

+ 34.2

Eyleaâ„¢

219

354

+ 61.6

+ 58.0

759

1,228

+ 61.8

+ 57.4

Kogenateâ„¢

301

286

â€“ 5.0

â€“ 6.0

1,109

1,155

+ 4.1

â€“ 1.1

Mirenaâ„¢ product family

225

226

+ 0.4

â€“ 5.2

819

968

+ 18.2

+ 5.7

Nexavarâ„¢

202

231

+ 14.4

+ 10.9

773

892

+ 15.4

+ 7.4

Betaferonâ„¢ / Betaseronâ„¢

191

190

â€“ 0.5

â€“ 4.6

823

824

+ 0.1

â€“ 8.1

YAZâ„¢ / Yasminâ„¢ / Yasminelleâ„¢

198

168

â€“ 15.2

â€“ 3.8

768

706

â€“ 8.1

â€“ 4.7

Adalatâ„¢

153

152

â€“ 0.7

+ 2.2

588

633

+ 7.7

+ 1.2

Aspirinâ„¢ Cardio

130

131

+ 0.8

+ 2.3

486

524

+ 7.8

+ 2.3

Glucobayâ„¢

133

142

+ 6.8

â€“ 1.6

443

523

+ 18.1

+ 2.4

Avaloxâ„¢ / Aveloxâ„¢

96

85

â€“ 11.5

+ 1.3

381

379

â€“ 0.5

â€“ 2.3

Stivargaâ„¢

63

77

+ 22.2

+ 12.4

224

313

+ 39.7

+ 24.5

Xofigoâ„¢

29

69

+ 137.9

+ 110.5

157

257

+ 63.7

+ 43.2

Levitraâ„¢

56

61

+ 8.9

+ 11.1

245

226

â€“ 7.8

â€“ 8.0

Ciproâ„¢ / Ciprobayâ„¢

52

52

0.0

+ 6.8

191

182

â€“ 4.7

â€“ 3.2

Total

2,564

2,874

+ 12.1

+ 11.8

9,445

11,062

+ 17.1

+ 11.8

Proportion of Pharmaceuticals sales

78%

80%

78%

80%

Change

2014 figures restated
Fx adj. = currency-adjusted

Sales of our oral anticoagulant Xareltoâ„¢ were up substantially in 2015, mainly as a result of expanded
volumes in Germany and Japan. We registered a strong sales gain in the United States, where Xareltoâ„¢
is marketed by a subsidiary of Johnson & Johnson. Following its approval in additional indications, sales
of our eye medicine Eyleaâ„¢ posted substantial gains, particularly in Europe and Japan. Our cancer drug
Stivargaâ„¢ benefited from positive development in the United States and from the reversal of a rebate
provision in France. An encouraging contribution to sales growth was made by our cancer drug
Xofigoâ„¢, thanks primarily to the expansion of volumes in the United States. Sales of Adempasâ„¢ (2015:
â‚¬181 million; 2014: â‚¬89 million) to treat various forms of pulmonary hypertension rose substantially,
especially in the United States. This figure reflects the proportionate recognition of the one-time payment resulting from the sGC collaboration with Merck & Co., Inc., United States.
Growth in sales of the hormone-releasing intrauterine devices of the Mirenaâ„¢ product family â€“ Mirenaâ„¢
and Jaydessâ„¢ / Skylaâ„¢ â€“ resulted especially from higher demand in the United States. The cancer drug
Nexavarâ„¢ posted sales gains, particularly in the United States and Germany. Adalatâ„¢ for the treatment
of hypertension and coronary heart disease, Aspirinâ„¢ Cardio for secondary prevention of heart attacks
and our oral diabetes treatment Glucobayâ„¢ continued to benefit from strong demand in China.
Sales of our blood-clotting medicine Kogenateâ„¢ were down slightly year on year, receding by 1.1%
(Fx adj.), due mainly to the temporary use of production capacities to develop our next-generation hemophilia medicines. Increased competition caused sales of our multiple sclerosis drug Betaferonâ„¢ /
Betaseronâ„¢ to decline in all regions, mainly Europe and the United States. Business with our yazâ„¢ /
Yasminâ„¢ / Yasminelleâ„¢ oral contraceptives was held back especially by generic competition in Europe
and the United States. Sales of the antibiotic Avaloxâ„¢ / Aveloxâ„¢ fell, particularly in Europe and the United States, following the expiration of patent protection during 2014. Sales of the erectile dysfunction
treatment Levitraâ„¢ also receded.

157

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

ebit of the Pharmaceuticals segment rose by a substantial 18.4% in 2015 to â‚¬2,807 million. Special
charges of â‚¬254 million (2014: â‚¬286 million) mostly comprised â‚¬126 million for efficiency improvement
measures, â‚¬67 million for the revaluation of other receivables and â‚¬43 million for the impairment loss on
a research project. ebit before special items increased by 15.2% to â‚¬3,061 million. ebitda before special items improved by 13.4% to â‚¬4,195 million. This earnings increase was primarily attributable to the
very good development of business, particularly for our recently launched products, and to positive
currency effects of about â‚¬140 million. As expected, earnings were diminished by higher research and
development expenses.

CONSUMER HEALTH

Key Data â€“ Consumer Health

[Table 3.13.4]
4th Quarter
2014

4th Quarter
2015

Change

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

2,080

2,240

+ 7.7

+ 6.9

7,023

9,129

+ 30.0

+ 5.1

1,384

1,506

+ 8.8

+ 9.8

4,245

6,076

+ 43.1

+ 6.1

Animal Health

300

319

+ 6.3

+ 3.0

1,318

1,490

+ 13.1

+ 4.5

Medical Care1

396

415

+ 4.8

0.0

1,460

1,563

+ 7.1

+ 2.9

â‚¬ million

â‚¬ million

%

Fx adj.
%

â‚¬ million

â‚¬ million

%

Fx adj.
%

Europe

656

629

â€“ 4.1

â€“ 1.4

2,474

2,535

+ 2.5

+ 4.9

North America

779

901

+ 15.7

+ 2.3

2,289

3,796

+ 65.8

+ 47.3

Asia / Pacific

331

374

+ 13.0

+ 7.3

1,149

1,474

+ 28.3

+ 19.3

Latin America / Africa / Middle East

314

336

+ 7.0

+ 36.3

1,111

1,324

+ 19.2

+ 29.8

+ 29.1

1,099

1,243

+ 13.1

(45)

(346)

Sales
Consumer Care

Change

Sales by region

EBIT

175

226

Special items

(86)

(115)

EBIT before special items 2

261

341

+ 30.7

1,144

1,589

+ 38.9

EBITDA

384

431

+ 12.2

1,613

1,927

+ 19.5

(45)

(297)

+ 10.6

1,658

2,224

23.6%

24.4%

Special items

(86)

(89)

EBITDA before special items 2

470

520

22.6%

23.2%

Gross cash flow 3

374

274

â€“ 26.7

1,153

1,384

+ 20.0

Net cash flow 3

439

310

â€“ 29.4

1,065

1,458

+ 36.9

EBITDA margin before special items 2

2014 figures restated
Fx & p adj. = currency- and portfolio-adjusted; Fx adj. = currency-adjusted
1 Includes the business with contrast agents and medical devices
2 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
3 For definition see Chapter 14.5 â€œLiquidity and Capital Expenditures of the Bayer Group.â€

+ 34.1

158

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

Sales of the Consumer Health segment advanced by 5.1% (Fx & portfolio adj.) in 2015 to
â‚¬9,129 million. All divisions contributed to this growth. The significant reported increase in sales in the
Consumer Care Division resulted from the products added through the recent acquisitions.

Best-Selling Consumer Health Products

[Table 3.13.5]
4th Quarter
2014

4th Quarter
2015

Change

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

%

Fx adj.
%

â‚¬ million

â‚¬ million

%

Fx adj.
%

Claritinâ„¢ (Consumer Care) 1

83

134

+ 61.4

+ 55.5

â€“

627

.

.

Advantageâ„¢ product family
(Animal Health)

105

104

â€“ 1.0

â€“ 8.0

495

547

+ 10.5

â€“ 1.3

Aspirinâ„¢ (Consumer Care) 2

125

128

+ 2.4

+ 0.3

441

473

+ 7.3

+ 1.3

Aleveâ„¢ (Consumer Care)

0.0

+ 5.8

357

413

+ 15.7

+ 4.8

Change

105

105

Bepanthenâ„¢ / Bepantholâ„¢
(Consumer Care)

85

85

0.0

+ 10.1

346

355

+ 2.6

+ 11.5

Ultravistâ„¢ (Medical Care)

84

83

â€“ 1.2

+ 0.5

302

318

+ 5.3

+ 2.1

Gadovistâ„¢ / Gadavistâ„¢
(Medical Care)

65

79

+ 21.5

+ 18.2

233

290

+ 24.5

+ 17.6

Canestenâ„¢ (Consumer Care)

60

66

+ 10.0

+ 44.1

253

267

+ 5.5

+ 17.3

Dr Schollâ€™sâ„¢ (Consumer Care) 3

47

62

+ 31.9

+ 19.0

â€“

253

.

.

Alka-Seltzerâ„¢ (Consumer Care)

74

81

+ 9.5

+ 0.5

225

251

+ 11.6

â€“ 1.7

833

927

+ 11.3

+ 12.1

2,652

3,794

+ 43.1

+ 5.4

40%

41%

38%

42%

Total
Proportion of Consumer Health sales

Fx adj. = currency-adjusted
2014 figures restated
1 Product acquired from Merck & Co., Inc.
2 Total sales of Aspirinâ„¢, also including Aspirinâ„¢ Cardio, which is reflected in sales of the Pharmaceuticals segment, increased by 7.6% (Fx adj. 1.8%) in 2015 to â‚¬997 million
(2014: â‚¬927 million). Total sales of this product in the fourth quarter of 2015 climbed by 2.0% (Fx adj. 1.3%) to â‚¬260 million (Q4 2014: â‚¬255 million).
3 Product acquired from Merck & Co., Inc.; trademark rights and distribution only in certain countries outside the European Union

Business in the Consumer Care Division improved by 6.1% (Fx & portfolio adj.) to â‚¬6,076 million. Sales
of our analgesic Aspirinâ„¢ were up slightly against the prior year, due particularly to gains in Latin
America and Europe that more than offset the decline in the United States. We grew sales of our analgesic Aleveâ„¢, mainly because of price and volume increases in Latin America / Africa / Middle East. Our
skincare product Bepanthenâ„¢ / Bepantholâ„¢ posted considerably higher sales, particularly in the Emerging Markets. Business with our antifungal product Canestenâ„¢ showed pleasing development thanks to
expanded volumes in all regions. The Alka-Seltzerâ„¢ family of products to treat gastric complaints and
cold symptoms registered a decline in demand particularly in the United States that was due partly to a
weaker cold season.

159

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

We achieved sales of â‚¬1,770 million in 2015 with the business acquired from Merck & Co., Inc., United
States, including â‚¬380 million in the fourth quarter of 2015 (q4 2014: â‚¬289 million). We substantially
raised sales of our antihistamine Claritinâ„¢ compared with the fourth quarter of the previous year, thanks
in part to an extended allergy season in the United States. Driven mainly by higher prices in the United
States, business with our Dr. Schollâ€™sâ„¢2 foot care products also showed pleasing development.
Sales of the Medical Care Division increased by 2.9% (Fx & portfolio adj.) to â‚¬1,563 million, mainly as a
result of positive development in the United States. Business with our mri contrast agent Gadovistâ„¢
showed encouraging growth in all regions.
Sales of the Animal Health Division rose by 4.5% (Fx & portfolio adj.) to â‚¬1,490 million. Our Serestoâ„¢
flea and tick collar made a significant contribution to this development, particularly in the United States
and Europe. Sales of the Advantageâ„¢ family of flea, tick and worm control products receded slightly,
however, mainly due to increased competition.
ebit of the Consumer Health segment improved by 13.1% in 2015 to â‚¬1,243 million. Special charges
amounted to â‚¬346 million (2014: â‚¬45 million) and mainly comprised â‚¬225 million in integration costs for
acquired businesses, â‚¬76 million for efficiency improvement measures and â‚¬41 million in costs associated with the relocation of a production facility. ebit before special items significantly rose by 38.9% to
â‚¬1,589 million. ebitda before special items improved by a substantial 34.1% to â‚¬2,224 million. The
earnings contributions from the expansion of business in all divisions and positive currency effects of
â‚¬110 million were partly offset in particular by higher selling expenses associated especially with the
newly acquired consumer care businesses.

2

Only in certain countries outside the European Union

160

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

13.2 CropScience
Key Data â€“ CropScience

[Table 3.13.6]
4th Quarter
2014

4th Quarter
2015

Change

â‚¬ million

â‚¬ million

%

Fx & p adj.
%

Full Year
2015

Change

â‚¬ million

â‚¬ million

%

Fx & p adj.
%

2,195

2,439

+ 11.1

+ 5.3

9,494

10,367

+ 9.2

+ 1.7

Volume

+ 7.6%

Price

+ 0.7%

+ 5.7%

+ 9.1%

+ 1.3%

â€“ 0.4%

+ 2.1%

Currency

+ 0.4%

+ 3.7%

+ 5.1%

â€“ 3.7%

Portfolio

+ 6.9%

+ 0.5%

+ 0.7%

+ 0.2%

+ 0.6%

Crop Protection / Seeds

2,028

2,230

+ 10.0

+ 4.8

8,816

9,548

+ 8.3

+ 1.5

Environmental Science

167

209

+ 25.1

+ 11.4

678

819

+ 20.8

+ 4.1

â‚¬ million

â‚¬ million

%

Fx adj. %

â‚¬ million

â‚¬ million

%

Fx adj. %

Europe

377

386

+ 2.4

+ 2.7

2,957

3,123

+ 5.6

+ 8.2

North America

329

464

+ 41.0

+ 24.0

2,334

2,689

+ 15.2

â€“ 1.6

Asia / Pacific

356

365

+ 2.5

â€“ 2.5

1,374

1,531

+ 11.4

+ 1.3

1,133

1,224

+ 8.0

+ 4.4

2,829

3,024

+ 6.9

â€“ 0.5

191

478

+ 150.3

1,806

2,103

+ 16.4





Sales

Full Year
2014

Change in sales

Sales

Sales by region

Latin America / Africa / Middle East
EBIT
6SHFLDOLWHPV

 



EBIT before special items 1

223

177

â€“ 20.6

1,838

1,881

+ 2.3

EBITDA1

367

629

+ 71.4

2,358

2,638

+ 11.9





â€“ 9.5

2,360

2,416

24.9%

23.3%

6SHFLDOLWHPV
EBITDA before special items 1





369

334

16.8%

13.7%

Gross cash flow 2

382

493

+ 29.1

1,835

1,941

+ 5.8

Net cash flow 2

103

165

+ 60.2

950

761

â€“ 19.9

EBITDA margin before special items 1

Fx & p adj. = currency- and portfolio-adjusted; Fx adj. = currency-adjusted
1 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
2 For definition see Chapter 14.5 â€œLiquidity and Capital Expenditures of the Bayer Group.â€

PHOTO // The scanning electron micrograph above shows part of the

NPMA<>@JA<NJT=@<IKG<IOG@<AÃ°H<BIDÂ¾@?<=JPO4,500 times.

+ 2.4

161

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

CropScience raised sales by 1.7% (Fx & portfolio adj.) in 2015, to â‚¬10,367 million (reported: +9.2%).
We registered growth at both Crop Protection / Seeds and Environmental Science. Fungicides played a
major part in this sales increase. In regional terms, business in Europe saw particularly encouraging
development.

CropScience Quarterly Sales

[Graphic 3.13.4]
â‚¬ million

Q1

2014
2015

2,900
3,092

Q2

2014
2015

2,470
2,723

Q3

2014
2015

1,929
2,113

Q4

2014
2015

2,195
2,439
0

500

1,000

1,500

2,000

2,500

3,000

3,500

Sales in Crop Protection / Seeds increased by 1.5% (Fx & portfolio adj.), to â‚¬9,548 million. Crop Protection posted gratifying sales gains at Fungicides and Herbicides but a distinct decline at Insecticides and
SeedGrowth. In the Seeds business, sales of soybean and canola seed developed particularly well.
Business in Environmental Science advanced by 4.1% (Fx & portfolio adj.) to â‚¬819 million. There was a
sharp increase in business with products for professional users, while the consumer business came in at
the prior-year level.

Sales by Business Unit

[Table 3.13.7]
4th Quarter
2014

4th Quarter
2015

Change

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

Herbicides

517

650

+ 25.7

+ 19.6

2,549

2,830

+ 11.0

+ 5.4

Fungicides

568

677

+ 19.2

+ 11.3

2,490

2,911

+ 16.9

+ 9.5

Insecticides

482

430

â€“ 10.8

â€“ 16.6

1,695

1,596

â€“ 5.8

â€“ 14.0
â€“ 10.6

SeedGrowth

Change

254

252

â€“ 0.8

â€“ 7.9

978

934

â€“ 4.5

1,821

2,009

+ 10.3

+ 3.6

7,712

8,271

+ 7.2

+ 0.4

207

221

+ 6.8

+ 15.4

1,104

1,277

+ 15.7

+ 8.8

Crop Protection / Seeds

2,028

2,230

+ 10.0

+ 4.8

8,816

9,548

+ 8.3

+ 1.5

Environmental Science

167

209

+ 25.1

+ 11.4

678

819

+ 20.8

+ 4.1

Crop Protection
Seeds

Fx & p adj. = currency- and portfolio-adjusted

The sales development of CropScience varied by region.
Sales in Europe rose by 8.2% (Fx adj.) to â‚¬3,123 million, driven by the positive development at Crop
Protection / Seeds. Sales at Herbicides grew by a double-digit percentage, and business at Fungicides
also expanded significantly due to low inventories at the beginning of the year. In addition, we achieved
encouraging gains in our canola and vegetable seed businesses. Environmental Science performed
positively due to strong business with products for professional users.

162

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

Sales in the North America region declined by 1.6% (Fx adj.) to â‚¬2,689 million. This decline was chiefly attributable to the negative development at Crop Protection, particularly at SeedGrowth, which in turn
resulted from high inventories of already treated seed in the market. Business was also down for cotton
seed, fungicides and herbicides. On the other hand, business with canola seed expanded briskly compared with the prior year. Our insecticides business also developed successfully. There was a very significant increase in sales at Environmental Science, especially due to the acquisition of parts of the
DuPont land management business.
Sales in the Asia / Pacific region came in slightly above the prior year level at â‚¬1,531 million (Fx adj.
+1.3%). Contributing to this increase in particular were our SeedGrowth and Herbicides businesses.
Sales of cotton and vegetable seed improved by double-digit percentages. Sales at Insecticides declined
slightly against the previous year. Sales at Environmental Science were down year on year.
Despite a weakened market environment, particularly in Brazil, sales in Latin America / Africa / Middle
East were level year on year at â‚¬3,024 million (Fx adj. â€“0.5%). Sales at Insecticides receded sharply
as a result of declining business in Latin America that was mainly attributable to lower infestation
pressure in Brazil. Business was also down at SeedGrowth, an effect that could not be fully offset by
double-digit-percentage growth in sales at Fungicides and a very gratifying performance of the Seeds
business, especially for soybean and vegetable seed. Sales at Environmental Science also moved
ahead by a double-digit percentage.

CropScience
Quarterly EBIT

[Graphic 3.13.5]

CropScience
Quarterly EBITDA Before Special Items

[Graphic 3.13.6]

â‚¬ million

â‚¬ million

Q1

2014
2015

988
874

Q1

2014
2015

1,098
1,040

Q2

2014
2015

470
571

Q2

2014
2015

615
733

Q3

2014
2015

157
180

Q3

2014
2015

278
309

Q4

2014
2015

191
478

Q4

2014
2015

369
334

0

200

400

600

800

1,000

0

200

400

600

800

1,000

ebit of CropScience climbed by 16.4% in 2015, rising from â‚¬1,806 million to â‚¬2,103 million. There
were net special gains of â‚¬222 million (2014: net special charges of â‚¬32 million), comprising mainly
damage and license payments in connection with the infringement of Bayerâ€™s rights to the LibertyLink
weed control system by Dow AgroSciences (das). ebit before special items increased by 2.3% to
â‚¬1,881 million. ebitda before special items improved by 2.4% to â‚¬2,416 million. In addition to positive
earnings effects due to the satisfactory business development, including higher volumes and slightly
improved selling prices, there was a very positive currency effect of about â‚¬220 million. By contrast,
there was an increase in the cost of goods sold and in research and development expenses.

163

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

13.3 Covestro
Key Data â€“ Covestro

[Table 3.13.8]
4th Quarter
2014

Sales

4th Quarter
2015

Change

â‚¬ million

â‚¬ million

%

Fx & p adj.
%

2,948

2,774

â€“ 5.9

â€“ 10.6

Full Year
2014

Full Year
2015

Change

â‚¬ million

â‚¬ million

%

Fx & p adj.
%

11,651

11,982

+ 2.8

â€“ 5.1

+ 2.6%

Change in sales
Volume

+ 5.7%

+ 1.8%

+ 6.3%

Price

â€“ 0.2%

â€“ 12.4%

â€“ 1.5%

â€“ 7.7%

Currency

+ 4.1%

+ 4.7%

â€“ 0.8%

+ 7.9%

Portfolio

0.0%

0.0%

â€“ 0.3%

0.0%

Sales
Polyurethanes

1,591

1,382

â€“ 13.1

â€“ 17.3

6,285

6,084

â€“ 3.2

â€“ 10.5

Polycarbonates

741

759

+ 2.4

â€“ 3.9

2,820

3,169

+ 12.4

+ 2.0

Coatings, Adhesives, Specialties

460

477

+ 3.7

â€“ 1.3

1,915

2,092

+ 9.2

+ 1.5

Other Covestro business

156

156

0.0

â€“ 2.6

631

637

+ 1.0

â€“ 2.7

â‚¬ million

â‚¬ million

%

Fx adj.
%

â‚¬ million

â‚¬ million

%

Fx adj.
%

Sales by region
Europe

1,036

1,014

â€“ 2.1

â€“ 2.0

4,441

4,395

â€“ 1.0

â€“ 0.9

North America

673

672

â€“ 0.1

â€“ 12.5

2,593

2,885

+ 11.3

â€“ 7.0

Asia / Pacific

885

798

â€“ 9.8

â€“ 18.2

3,245

3,377

+ 4.1

â€“ 10.5

Latin America / Africa / Middle East

354

290

â€“ 18.1

â€“ 13.3

1,372

1,325

â€“ 3.4

â€“ 2.0

EBIT

43

(79)

.

555

635

+ 14.4

6SHFLDOLWHPV

 





 

EBIT before special items 1
EBITDA1
6SHFLDOLWHPV
EBITDA before special items 1

65

65

0.0

598

967

+ 61.7

196

129

â€“ 34.2

1,149

1,368

+ 19.1

+ 18.4

1,187

1,659

10.2%

13.8%

 





 

217

257

7.4%

9.3%

Gross cash flow 2

201

132

â€“ 34.3

961

1,113

+ 15.8

Net cash flow 2

517

603

+ 16.6

880

1,452

+ 65.0

EBITDA margin before special items 1

Fx & p adj. = currency- and portfolio-adjusted; Fx adj. = currency-adjusted
1 For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
2 For definition see Chapter 14.5 â€œLiquidity and Capital Expenditures of the Bayer Group.â€

PHOTO // The scanning electron micrograph above shows a cross-section

OCMJPBC<Â¿@SD=G@KJGTPM@OC<I@AJ<HÃ°H<BIDÂ¾@?<=JPO85 times.

+ 39.8

164

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

Covestro registered a 5.1% (Fx & portfolio adj.) decline in sales in 2015, to â‚¬11,982 million (reported:
+2.8%). This decline resulted from lower selling prices in all business units, particularly Polyurethanes.
On the other hand, Covestro expanded volumes in all business units.

Covestro Quarterly Sales

[Graphic 3.13.7]
â‚¬ million

Q1

2014
2015

2,803
3,014

Q2

2014
2015

2,864
3,185

Q3

2014
2015

3,036
3,009

Q4

2014
2015

2,948
2,774
0

500

1,000

1,500

2,000

2,500

3,000

3,500

The Polyurethanes business unit saw sales fall by 10.5% (Fx & portfolio adj.) to â‚¬6,084 million. This
decline resulted from much lower selling prices for the three product groups toluene diisocyanate (tdi),
diphenylmethane diisocyanate (mdi) and polyether polyols (pet). Volumes came in slightly above the
prior-year level overall.
The Polycarbonates business unit raised sales by 2.0% (Fx & portfolio adj.) to â‚¬3,169 million. This
growth was due to positive volume development, while selling prices were down only slightly.
Sales in the Coatings, Adhesives, Specialties business unit moved forward by 1.5% (Fx & portfolio
adj.) to â‚¬2,092 million. Slightly higher volumes more than offset the effect of modestly lower selling
prices.

165

Bayer Annual Report 2015
Combined Management Report
13. Business Development by Subgroup, Segment and Region

Covestro
Quarterly EBIT

[Graphic 3.13.8]

Covestro
Quarterly EBITDA Before Special Items

[Graphic 3.13.9]

â‚¬ million

â‚¬ million

Q1

2014
2015

219
219

Q1

2014
2015

366
424

Q2

2014
2015

109
278

Q2

2014
2015

270
506

Q3

2014
2015

184
217

Q3

2014
2015

334
472

Q4

2014
2015

43
-79

Q4

2014
2015

217
257

-100 -50

0

50

100

150

200

250

300

0

100

200

300

400

500

ebit of Covestro climbed by 14.4% in 2015 to â‚¬635 million (2014: â‚¬555 million). This figure reflected
special charges of â‚¬332 million (2014: â‚¬43 million) for restructuring measures, chiefly for the carve-out
and stock market flotation of Covestro and for the consolidation of production sites. ebit before special
items climbed by a substantial 61.7% to â‚¬967 million. ebitda before special items also clearly improved by 39.8% to â‚¬1,659 million. Considerably lower raw material prices more than offset the decline
in selling prices. This was due to a more advantageous supply and demand situation, particularly at
Polycarbonates. We also expanded volumes. Furthermore, earnings were buoyed by positive currency
effects of about â‚¬240 million.

166

Bayer Annual Report 2015

167

Bayer Annual Report 2015
Combined Management Report

Combined Management Report

13. Business Development by Subgroup, Segment and Region

13. Business Development by Subgroup, Segment and Region

13.4 Business Development by Region
Sales by Region and Segment (by Market)

[Table 3.13.9]
Europe
2014

2015

â‚¬ million

â‚¬ million

HealthCare

6,870

7,404

Pharmaceuticals

4,396

4,869

Consumer Health

2,474

2,535

CropScience

2,957

Covestro

4,441
15,312

Group (incl. reconciliation)

North America

Change

2014

2015

Fx adj.
%

â‚¬ million

â‚¬ million

+ 7.8

+ 8.8

5,017

+ 10.8

+ 11.0

2,728

+ 2.5

+ 4.9

3,123

+ 5.6

4,395

â€“ 1.0

15,949

+ 4.2

%

Asia / Pacific

Change

2014

2015

%

Fx adj.
%

â‚¬ million

â‚¬ million

7,159

+ 42.7

+ 25.7

4,427

3,363

+ 23.3

+ 7.6

3,278

2,289

3,796

+ 65.8

+ 47.3

+ 8.2

2,334

2,689

+ 15.2

â€“ 0.9

2,593

2,885

+ 11.3

+ 5.2

9,953

12,740

+ 28.0

Latin America / Africa / Middle East

Change

2014

2015

%

Fx adj.
%

â‚¬ million

â‚¬ million

5,342

+ 20.7

+ 10.3

2,761

3,868

+ 18.0

+ 7.2

1,650

1,149

1,474

+ 28.3

+ 19.3

â€“ 1.6

1,374

1,531

+ 11.4

â€“ 7.0

3,245

3,377

+ 4.1

+ 10.8

9,067

10,264

+ 13.2

+ 1.4

Total

Change

2014

2015

Change

%

Fx adj.
%

â‚¬ million

â‚¬ million

%

Fx adj.
%

2,969

+ 7.5

+ 21.5

19,075

22,874

+ 19.9

+ 15.4

1,645

â€“ 0.3

+ 15.9

12,052

13,745

+ 14.0

+ 9.9

1,111

1,324

+ 19.2

+ 29.8

7,023

9,129

+ 30.0

+ 25.0

+ 1.3

2,829

3,024

+ 6.9

â€“ 0.5

9,494

10,367

+ 9.2

+ 2.3

â€“ 10.5

1,372

1,325

â€“ 3.4

â€“ 2.0

11,651

11,982

+ 2.8

â€“ 5.1

7,007

7,371

+ 5.2

+ 8.1

41,339

46,324

+ 12.1

+ 6.2

2014 figures restated
Fx. adj. = currency-adjusted

13.5 Business Development in the Emerging Markets
Sales in the Emerging Markets3 climbed by 6.1% (Fx adj.) in 2015 to â‚¬17,200 million (2014:
â‚¬15,763 million). We posted encouraging growth rates in Eastern Europe and Latin America. The
Emerging Marketsâ€™ share of total sales was 37.1% (2014: 38.1%).



Sales Development in 2015

[Graphic 3.13.10]

37% (Fx adj. + 6%)
63% (Fx adj. + 6%)

HEALTHCARE
HealthCare considerably improved sales in the Emerging Markets by 16.4% (Fx adj.) in 2015, to
â‚¬7,208 million (2014: â‚¬6,336 million). All regions contributed to this increase, with robust currencyadjusted gains in Latin America especially. In Asia, our business in China in particular developed very
well. There, we especially benefited from the acquired consumer care businesses alongside the positive
development of our pharmaceutical products. The Emerging Marketsâ€™ share of total sales of HealthCare
was 31.5% (2014: 33.2%).

Emerging Markets

Industrialized countries

Currency-adjusted changes in parentheses

CROPSCIENCE
CropScience improved sales in the Emerging Markets by 4.6% (Fx adj.) in 2015, to â‚¬4,836 million
(2014: â‚¬4,409 million). We posted substantial gains in the Eastern Europe and Africa / Middle East regions. We also expanded business in Asia, while Latin America experienced a slight decline. The
Emerging Marketsâ€™ share of total CropScience sales in 2015 was 46.6% (2014: 46.4%).
COVESTRO
Sales of Covestro in the Emerging Markets declined by 5.7% (Fx adj.) in 2015 to â‚¬5,089 million (2014:
â‚¬4,951 million). Sales in the Asia region remained well below the prior-year level on a currency-adjusted
basis, and also declined in Latin America. We expanded sales in the Eastern Europe and Africa / Middle
East regions. The Emerging Marketsâ€™ share of total sales at Covestro was 42.5% (2014: 42.5%).
We additionally engage in some Emerging Markets through regional economic development projects, as
shown by the examples contained in 
RQOLQHDQQH[
CropScience aims to contribute to increased agricultural productivity in regions such as Africa and
intends to expand its presence there. Our offerings are tailored to the needs of African farmers and
range from integrated crop solutions based on improved seed varieties through modern crop protection technologies and training in good agricultural practice and environmental protection to product
safety programs. We also engage locally in public-private partnerships (ppps) to help increase the income of smallholder farmers through sustainable agriculture. Activities include expanding local value chains and training measures. This contributes to improving the living situation of the local population and enhancing the availability of staple foods in the project countries. In such ppps, we cooperate with numerous partners including local governments, farmersâ€™ associations and cooperatives,
nongovernmental organizations and agricultural input industries. CropScience is currently participating in ppps associated with the value chains for rice and potatoes in Sub-Saharan Africa, India and
Southeast Asia.

3

For reporting purposes we have defined the Emerging Markets as Asia (excluding Japan), Latin America, Eastern Europe, Africa
and the Middle East.

168

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

Together with representatives of globalg.a.p., one of the worldâ€™s leading quality assurance systems,
CropScience has continued developing the Bayg.a.p. program to provide smallholder farmers in developing countries and Emerging Markets, for example, with access to professional local and global
food markets. In 2015, pilot projects were carried out with food chain partners in the Asia / Pacific
and Latin America regions. The service program includes an intensive training course in good agricultural practice (g.a.p.), individual cultivation advice and subsequent support in meeting the respective local g.a.p. standard. The farmers can sell certified, high-quality produce at higher prices, thus
raising their incomes.
In cooperation with external partners, Covestro is evolving and implementing technical solutions to
help low-income people in developing countries and Emerging Markets gain improved access to
high-quality, safe and easy-to-build yet affordable housing. These activities currently focus on Asia.
The company is mainly contributing its expertise in the field of rigid polyurethane foam for the construction industry.

14. Earnings; Asset and Financial Position of
the Bayer Group
14.1 Earnings Performance of the Bayer Group
Bayer Group Summary Income Statements

[Table 3.14.1]
2014

2015

Change

â‚¬ million

â‚¬ million

%

Net sales

41,339

46,324

12.1

Cost of goods sold

19,909

21,158

6.3

Selling expenses

10,669

12,367

15.9

Research and development expenses

3,537

4,281

21.0

General administration expenses

1,703

2,098

23.2

(126)

(170)

(34.9)

5,395

6,250

15.8

(981)

(1,005)

(2.4)

4,414

5,245

18.8

(1,071)

(1,227)

(14.6)

3,443

4,098

19.0

17

(12)

â€“

3,426

4,110

20.0

Other operating income (+) and expenses (â€“)
EBIT 1
Financial result
Income before income taxes
Income taxes
Income after income taxes (total)
of which attributable to noncontrolling interest
of which attributable to Bayer AG stockholders (net income)
2014 figures restated
1 EBIT = income after income taxes, plus income taxes, plus financial result

Sales of the Bayer Group rose to â‚¬46,324 million (+12.1%). The increase after adjusting for currency
and portfolio effects was 2.7%.
The cost of goods sold increased by 6.3% to â‚¬21,158 million, mainly due to currency and portfolio
effects that drove up costs. Lower raw material costs at Covestro had an opposing effect. The ratio of the
cost of goods sold to total sales was 45.7% (2014: 48.2%). The selling expenses of â‚¬12,367 million
(+ 15.9%) amounted to 26.7% of sales (2014: 25.8%). Research and development (r&d) expenses rose
in 2015 by 21.0% to â‚¬4,281 million, the increase being attributable above all to higher r&d investment
at Pharmaceuticals. The ratio of r&d expenses to sales was 9.2% (2014: 8.6%). General administration

169

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

expenses climbed by 23.2% to â‚¬2,098 million. The ratio of general administration expenses to total
sales therefore increased to 4.5% (2014: 4.1%). The increased other operating expenses of
â‚¬170 million (2014: â‚¬126 million) resulted mainly from negative effects from derivatives to hedge
planned sales that were partly offset by a special gain from damage and license payments in connection
with the infringement by Dow AgroSciences of Bayerâ€™s rights to the Liberty Linkâ„¢ weed control system.
ebit climbed by 15.8% in 2015 to â‚¬6,250 million.
The financial result declined by 2.4% to minus â‚¬1,005 million. It comprised â‚¬455 million (2014:
â‚¬356 million) in net interest expense, â‚¬287 million (2014: â‚¬322 million) in interest cost for pension and
other provisions, and a â‚¬254 million (2014: â‚¬248 million) net exchange loss. The increase in net interest
expense was primarily attributable to higher financing costs in connection with the acquired consumer
care business of Merck & Co., Inc., United States.
Tax expense in 2015 increased to â‚¬1,227 million (2014: â‚¬1,071 million). Income after income taxes
came in at â‚¬4,098 million. Income attributable to noncontrolling interest fell by â‚¬29 million to minus
â‚¬12 million. Bayer Group net income for 2015 was â‚¬4,110 million (2014: â‚¬3,426 million).

14.2 Calculation of EBIT(DA) Before Special Items
ebit (income after income taxes, plus income taxes, plus financial result), which is not defined in the
International Financial Reporting Standards, is influenced by one-time special effects and by the amortization of intangible assets and depreciation of property, plant and equipment, along with impairment
losses and impairment loss reversals. To elucidate the effects of these parameters on the operational
business and facilitate the comparability of operational earning power over time, we determine additional
indicators: ebitda, ebit before special items, ebitda before special items and the ebitda margin before
special items. These indicators also are not defined in the International Financial Reporting Standards.
ebitda (ebit plus the amortization of intangible assets and the depreciation of property, plant and
equipment, plus impairment losses and minus impairment loss reversals, recognized in profit or loss
during the reporting period) serves to characterize the operational business irrespective of the effects of
amortization, depreciation or impairment losses/impairment loss reversals.
ebit before special items and ebitda before special items show the development of the operational
business irrespective of the effects of special items â€“ those that are nonrecurring or do not regularly
recur or attain similar magnitudes. ebit before special items and ebitda before special items are determined by adding special charges and subtracting special gains. They constitute relevant key data for
Bayer.
The ebitda margin before special items, which is calculated by dividing ebitda before special items by
sales, serves as an indicator of relative operational earning power for purposes of internal and external
comparison.
Depreciation, amortization and impairment losses were 14.1% higher in 2015 at â‚¬3,333 million (2014:
â‚¬2,920 million), comprising â‚¬1,802 million (2014: â‚¬1,581 million) in amortization and impairments on
intangible assets and â‚¬1,531 million (2014: â‚¬1,339 million) in depreciation and impairments on property, plant and equipment. A total of â‚¬136 million (2014: â‚¬68 million) in impairments constituted special
items.

170

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

In 2015, the following special effects were taken into account in calculating ebit and ebitda before
special items:

Special Items Reconciliation

Before special items
HealthCare
Impairment losses / impairment loss
reversals
Restructuring

[Table 3.14.2]
EBIT
4th
Quarter
2014

EBIT
4th
Quarter
2015

EBIT
Full Year
2014

EBIT
Full Year
2015

EBITDA
4th
Quarter
2014

EBITDA
4th
Quarter
2015

EBITDA
Full Year
2014

EBITDA
Full Year
2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

991

1,024

5,833

7,069

1,829

1,903

8,685

10,266

(376)

(264)

(331)

(600)

(347)

(196)

(298)

(505)

(29)

(43)

(29)

(43)

â€“

(1)

â€“

(1)

â€“

(155)

â€“

(243)

â€“

(129)

â€“

(190)

Litigations

(88)

(2)

(88)

(16)

(88)

(2)

(88)

(16)

Integration costs

(86)

(50)

(153)

(227)

(86)

(50)

(149)

(227)

â€“

â€“

35

â€“

â€“

â€“

35

â€“

(173)

â€“

(96)

3

(173)

â€“

(96)

3

Settlement of pre-existing relationship
Divestitures
Revaluation of other receivables

â€“

(14)

â€“

(74)

â€“

(14)

â€“

(74)

(32)

301

(32)

222

(2)

295

(2)

222

Litigations

(1)

303

(1)

285

(1)

303

(1)

285

Divestitures

(31)

â€“

(31)

(50)

(1)

(6)

(1)

(50)

â€“

(2)

â€“

(13)

â€“

(2)

â€“

(13)

(22)

(144)

(43)

(332)

(21)

(128)

(38)

(291)

(22)

(143)

(43)

(329)

(21)

(127)

(38)

(288)

â€“

(1)

â€“

(3)

â€“

(1)

â€“

(3)

(12)

(9)

(32)

(109)

(12)

(9)

(32)

(109)

CropScience

Revaluation of other receivables
Covestro
Restructuring
Revaluation of other receivables
Reconciliation
Restructuring

(12)

(9)

(32)

(76)

(12)

(9)

(32)

(76)

Litigations

â€“

â€“

â€“

(32)

â€“

â€“

â€“

(32)

Revaluation of other receivables

â€“

â€“

â€“

(1)

â€“

â€“

â€“

(1)

(442)

(116)

(438)

(819)

(382)

(38)

(370)

(683)

of which cost of goods sold

(68)

(169)

(80)

(440)

(37)

(144)

(49)

(363)

of which selling expenses

(50)

(118)

(63)

(198)

(21)

(107)

(34)

(183)

Total special items

of which research and development
expenses
of which general administration expenses
of which other operating income / expenses
After special items

1

(51)

(2)

(67)

1

(9)

(2)

(23)

(23)

(43)

(55)

(203)

(23)

(43)

(51)

(203)

(302)

265

(238)

89

(302)

265

(234)

89

549

908

5,395

6,250

1,447

1,865

8,315

9,583

2014 figures restated

14.3 Core Earnings per Share
Earnings per share according to ifrs are affected by the purchase price allocation for acquisitions and
other special factors. To demonstrate the impact of these effects on earnings and facilitate the comparability of our performance over time, we determine additional indicators â€“ core ebit, core net income and
core earnings per share â€“ which are not defined in the International Financial Reporting Standards.

171

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

Core ebit is determined by first eliminating from ebit (income after income taxes, plus income taxes,
plus financial result), which is not defined in the International Financial Reporting Standards, all amortization and impairment losses / impairment loss reversals on intangible assets, impairment losses / impairment loss reversals on property, plant and equipment, and special items (other than amortization
and impairment losses / impairment loss reversals). This core ebit is then used to calculate core net
income, which comprises the financial result (as per income statements), income taxes (as per income
statements), income after income taxes attributable to noncontrolling interest (as per income statements), special items in the financial result, special items in income taxes, tax effects related to amortization, impairment losses / impairment loss reversals and special items, and the above-mentioned adjustments attributable to noncontrolling interest.
From this core net income we calculate core earnings per share in the same way as earnings per share.
Core earnings per share form the basis for our dividend policy. Core earnings per share are determined
for both continuing and discontinued operations. In 2015, we improved core earnings per share from
continuing operations by 16.0% to â‚¬6.83 (2014: â‚¬5.89).

Core Earnings per Share

[Table 3.14.3]
4th Quarter
2014

4th Quarter
2015

Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

EBIT (as per income statements)

549

908

5,395

6,250

Amortization and impairment losses / loss reversals
on intangible assets

504

529

1,581

1,802

57

55

96

115

Impairment losses / loss reversals on property, plant and
equipment
Special items (other than amortization and
impairment losses / loss reversals)
Core EBIT
Financial result (as per income statements)

382

38

370

683

1,492

1,530

7,442

8,850
(1,005)

(347)

(164)

(981)

Special items in the financial result

13

(120)

23

(150)

Income taxes (as per income statements)

16

(163)

(1,071)

(1,227)

Special items in income taxes

48

(39)

48

(39)

(245)

(149)

(573)

(755)

(6)

30

(17)

12

Tax effects related to amortization, impairment losses / loss
reversals and special items
Income after income taxes attributable to noncontrolling
interest (as per income statements)
Above-mentioned adjustments attributable
to noncontrolling interest
Core net income from continuing operations

â€“

(39)

â€“

(39)

971

886

4,871

5,647

Shares

Shares

Shares

Shares

826,947,808

826,947,808

826,947,808

826,947,808

Core earnings per share from continuing operations (â‚¬)

1.17

1.07

5.89

6.83

Core earnings per share from discontinued operations (â‚¬)

0.02

0.01

0.13

0.12

Core earnings per share from continuing and
discontinued operations (â‚¬)

1.19

1.08

6.02

6.95

Number of issued ordinary shares

2014 figures restated

The calculation of earnings per share in accordance with ifrs is explained in note [16] to the consolidated financial statements.

Consolidated
Financial
Statements
Note 16

172

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

14.4 Value Management
SYSTEM BASED ON CASH VALUE ADDED
The principal value-based steering parameters in the Bayer Group are the cash value added (cva) and
the cash flow return on investment (cfroi). If the cva is positive, the respective company or business
entity has exceeded the minimum requirements of the equity and debt capital providers and has created
value. The cfroi is a ratio indicating the profitability of the Group or of individual business entities and
must be compared to the cost of capital.
CALCULATING THE COST OF CAPITAL
Bayer calculates the cost of capital according to the debt / equity ratio at the beginning of the year using
the weighted average cost of capital (wacc) formula. The cost of equity capital is the return expected by
stockholders, computed from capital market information. The cost of debt capital used in calculating the
wacc is based on the terms for ten-year Eurobonds issued by industrial companies with an â€œaâ€“â€ rating.

7.6%
Cost of capital for the
Bayer Group

To take into account the different risk and return profiles of our principal businesses, we calculate
individual capital cost factors after income taxes for each of our subgroups. These were 7.9% for
HealthCare, 7.3% for CropScience and 6.9% for Covestro. The capital cost factor for the Group as a
whole in 2015 was 7.6%.
GROSS CASH FLOW, CASH VALUE ADDED AND CASH FLOW RETURN ON INVESTMENT AS
PERFORMANCE YARDSTICKS
The gross cash flow is the measure of our internal financing capability. Bayer has chosen this parameter
because it is relatively free of accounting influences and is therefore a more meaningful performance
indicator.

Positive CVA =
value created

Taking into account the costs of capital and of reproducing depletable assets, we determine the gross
cash flow hurdle. If the gross cash flow hurdle is exceeded, the cva is positive and thus the required
return on equity and debt plus the cost of asset reproduction has been earned.
The cfroi is the difference between the gross cash flow and the cost of reproducing depletable assets,
divided by the capital invested. The capital invested is calculated from the statement of financial position and basically comprises the property, plant and equipment and intangible assets required for operations â€“ stated at the historical cost of acquisition or construction â€“ plus working capital, less interestfree liabilities (such as current provisions). To mitigate the effect of fluctuations in the capital invested
during the year, the cfroi is computed on the basis of the average capital invested for the respective
year.
The gross cash flow hurdle for 2015 was â‚¬5,714 million.
Actual gross cash flow came in at â‚¬6,999 million, exceeding the hurdle by 22.5%. Thus the entire cost
of capital and asset reproduction costs were earned in 2015. The positive cva of â‚¬1,285 million shows
that Bayer exceeded the minimum return and reproduction requirements and created value. A cfroi of
9.6% was achieved in 2015.
Despite negative impact from special items in some cases, all the subgroups exceeded their required
returns (including asset reproduction), achieved a positive cva and thus helped to increase the companyâ€™s value.

173

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

Value Management Indicators by Subgroup

[Table 3.14.4]
HealthCare

CropScience

Covestro

Bayer Group

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Gross cash flow 1 (GCF)

3,898

4,121

1,835

1,941

961

1,113

6,707

6,999

Gross cash flow hurdle

2,369

3,378

902

1,058

1,025

1,092

4,421

5,714

Cash value added (CVA)

1,529

743

933

883

(64)

21

2,286

1,285

13.1%

9.7%

15.3%

14.8%

6.0%

7.0%

11.7%

9.6%

7.9%

7.9%

7.3%

7.3%

6.9%

6.9%

7.6%

7.6%

26,634

37,919

10,841

11,813

10,524

11,156

48,784

61,699

Cash flow return on investment
(CFROI)
WACC
Average capital invested

2014 figures restated
1 For definition see Chapter 14.5 â€œLiquidity and Capital Expenditures of the Bayer Group.â€

14.5 Liquidity and Capital Expenditures
of the Bayer Group
Bayer Group Summary Statements of Cash Flows

Gross cash flow 1
Changes in working capital / other noncash items
Net cash provided by (used in) operating activities (net cash flow), continuing operations
Net cash provided by (used in) operating activities (net cash flow), discontinued operations

[Table 3.14.5]
Full Year
2014

Full Year
2015

â‚¬ million

â‚¬ million

6,707

6,999

(1,010)

(152)

5,697

6,847

113

43

5,810

6,890

Net cash provided by (used in) investing activities (total)

(15,539)

(2,762)

Net cash provided by (used in) financing activities (total)

9,736

(3,974)

Net cash provided by (used in) operating activities (net cash flow) (total)

Change in cash and cash equivalents due to business activities
Cash and cash equivalents at beginning of period
Change due to exchange rate movements and to changes in scope of consolidation
Cash and cash equivalents at end of period

7

154

1,662

1,853

184

(148)

1,853

1,859

2014 figures restated
1 Gross cash flow = income after income taxes, plus income taxes, plus financial result, minus income taxes paid or accrued, plus depreciation,
amortization and impairment losses, minus impairment loss reversals, plus / minus changes in pension provisions, minus gains / plus losses on
retirements of noncurrent assets, minus gains from the remeasurement of already held assets in step acquisitions. The change in pension
provisions includes the elimination of noncash components of EBIT. It also contains benefit payments during the year. Gross cash flow is not
defined in the International Financial Reporting Standards.

OPERATING CASH FLOW
Gross cash flow is not defined in the International Financial Reporting Standards.
Gross cash flow from continuing operations climbed by 4.4% in 2015 to â‚¬6,999 million (2014:
â‚¬6,707 million), mainly because of the improvement in ebitda. Net cash flow (total) rose by 18.6% to
â‚¬6,890 million (2014: â‚¬5,810 million) due to a sharp decrease in additional cash tied up in working
capital. Income taxes paid in 2015 amounted to â‚¬1,699 million (2014: â‚¬1,835 million).
INVESTING CASH FLOW
Net cash outflow for investing activities in 2015 amounted to â‚¬2,762 million. Cash outflows for property,
plant and equipment and intangible assets were 6.2% higher at â‚¬2,517 million (2014: â‚¬2,371 million)
and included â‚¬969 million (2014: â‚¬832 million) at HealthCare, â‚¬722 million (2014: â‚¬686 million) at
CropScience and â‚¬508 million (2014: â‚¬605 million) at Covestro. The â‚¬176 million (2014:
â‚¬13,545 million) in outflows for acquisitions mainly related to the purchase of SeedWorks India Pvt. Ltd.,
Hyderabad, India, and further payments in connection with the purchase of the consumer care business

174

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

of Merck & Co., Inc., United States. The latter was among the major acquisitions in 2014, alongside
that of Algeta asa, Norway. Cash outflows from noncurrent and current financial assets amounted to
â‚¬370 million (2014: â‚¬177 million). Inflows from interest and dividends totaled â‚¬106 million (2014:
â‚¬107 million).
The principal strategic capital expenditures for property, plant and equipment in the
operating segments within the past two years are listed in the following table.

Capital Expenditures for Property, Plant and Equipment
Segment

[Table 3.14.6]

Description

CAPITAL EXPENDITURES 2015
Pharmaceuticals

Expansion of production capacities for new rFactor VIII therapies in Wuppertal,
Germany
Expansion of R&D laboratory capacities in Wuppertal, Germany
Modernization of research facilities in Berlin, Germany
Modernization of site infrastructure in Wuppertal and Leverkusen, Germany
Expansion of production capacities in Beijing, China
Expansion of Quality Control Biologics in Berkeley, California, United States

Consumer Health

â€“

CropScience

Capacity expansions for herbicides in the United States and Germany
Construction of production facilities for insecticides in India and Germany
Additional capacity expansions for fungicides in Germany
Expansion of R&D facilities in Germany
Establishment of breeding stations for various plant species worldwide
Expansion of R&D facilities in North America

Covestro

Construction of a production line for CO2 based polyols in Dormagen, Germany
Continuation of projects started in 2014 for Polycarbonates and Coatings, Adhesives,
Specialties

CAPITAL EXPENDITURES 2014
Pharmaceuticals

Expansion of XareltoTM production capacities in Wuppertal and Leverkusen, Germany
Expansion of production capacities for new rFactor VIII therapies in Wuppertal,
Germany
Expansion of R&D laboratory capacities in Wuppertal, Germany
Modernization of research facilities in Berlin, Germany
Expansion of production capacities in Beijing, China
Expansion of Quality Control Biologics in Berkeley, California, United States

Consumer Health

â€“

CropScience

Completion of capacity expansion for fungicides in Germany and Switzerland
Completion of capacity expansion for herbicides in Germany
Establishment of breeding stations for various plant species worldwide

Covestro

Doubling of production capacities for polycarbonates in Shanghai, China
Doubling of production capacities for hexamethylene diisocyanate (HDI) in Shanghai,
China
Completion of capacity expansion for diphenylmethane diisocyanate (MDI) in
Shanghai, China
Construction of a world-scale production complex for toluene diisocyanate (TDI) based
on gas-phase phosgenation technology in Dormagen, Germany

175

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

FINANCING CASH FLOW
Net cash outflow for financing activities in 2015 amounted to â‚¬3,974 million, including net loan repayments of â‚¬2,929 million (2014: net borrowings of â‚¬11,838 million). Net interest payments were 80%
higher at â‚¬652 million (2014: â‚¬362 million). The cash outflow for dividends amounted to â‚¬1,869 million
(2014: â‚¬1,739 million). The stock market flotation of Covestro led to an inflow of â‚¬1,490 million.
LIQUID ASSETS AND NET FINANCIAL DEBT
Net Financial Debt

[Table 3.14.7]
Dec. 31,
2014

Dec. 31,
2015

â‚¬ million

â‚¬ million

14,964

15,547

4,552

4,525

3,835

2,779

Liabilities under finance leases

441

474

Negative fair values of hedges of recorded transactions

642

753

Bonds and notes / promissory notes
of which hybrid bonds 1
Liabilities to banks

Other financial liabilities

1,976

369

(258)

(350)

Financial liabilities

21,600

19,572

Cash and cash equivalents

(1,853)

(1,859)

Positive fair values of hedges of recorded transactions

Current financial assets 2
Net financial debt

(135)

(264)

19,612

17,449

1

Classified as debt according to IFRS

2

These include short-term loans and receivables with maturities between 3 and 12 months outstanding from banks and other companies as well as
available-for-sale financial assets and held-to-maturity financial investments that were recorded as current on initial recognition.

Net financial debt is not defined in the International Financial Reporting Standards and is calculated as
shown above.
In 2015, net financial debt of the Bayer Group decreased by 11.0% to â‚¬17.4 billion. Cash inflows from
operating activities and the stock market flotation of Covestro were partly offset by cash outflows for
dividends and negative currency effects. As of December 31, 2015, the Group had cash and cash
equivalents of â‚¬1.9 billion (2014: â‚¬1.9 billion). Financial liabilities at the end of the reporting period
amounted to â‚¬19.6 billion (2014: â‚¬21.6 billion), with three subordinated hybrid bonds reflected at
â‚¬4.5 billion overall. Net financial debt should be viewed against the fact that Moodyâ€™s and Standard &
Poorâ€™s treat 50% of the hybrid bonds with nominal volumes of â‚¬1.75 billion and â‚¬1.5 billion issued in
July 2014 and of the hybrid bond with a nominal volume of â‚¬1.3 billion issued in April 2015 as equity.
The hybrid bonds thus have a more limited effect on the Groupâ€™s rating-specific debt indicators than
conventional borrowings. Our noncurrent financial liabilities declined in 2015 from â‚¬18.5 billion to
â‚¬16.5 billion, while current financial liabilities remained unchanged at â‚¬3.4 billion.

176

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

14.6 Asset and Capital Structure of the Bayer Group
Bayer Group Summary Statements of Financial Position

[Table 3.14.8]
Dec. 31,
2014

Dec. 31,
2015

â‚¬ million

â‚¬ million

%

Noncurrent assets

48,007

50,096

+ 4.4

Current assets

22,227

23,624

+ 6.3

â€“

197

â€“

Total current assets

22,227

23,821

+ 7.2

Total assets

70,234

73,917

+ 5.2

Equity

20,218

25,445

+ 25.9

Noncurrent liabilities

34,513

31,492

â€“ 8.8

Current liabilities

15,503

16,868

+ 8.8

Assets held for sale

Provisions directly related to assets held for sale

Change

â€“

112

â€“

15,503

16,980

+ 9.5

Liabilities

50,016

48,472

â€“ 3.1

Total equity and liabilities

70,234

73,917

+ 5.2

Total current liabilities

Total assets as of December 31, 2015, increased by 5.2% to â‚¬73.9 billion. Noncurrent assets rose by
4.4% to â‚¬50.1 billion due mainly to currency effects. The carrying amount of current assets climbed to
â‚¬23.8 billion, due mainly to an increase in trade accounts receivable and other receivables.
Equity increased by â‚¬5.2 billion to â‚¬25.4 billion. The positive effects from the net income of â‚¬4.1 billion
(2014: â‚¬3.4 billion), the exchange differences of â‚¬0.7 billion (2014: â‚¬1.4 billion) and the decline of
â‚¬0.8 billion (2014: negative effect from the increase of â‚¬3.5 billion) â€“ recognized outside profit or loss â€“
in post-employment benefit obligations were offset by the dividend payment of â‚¬1.9 billion (2014:
â‚¬1.7 billion). In addition, the capital increase at Covestro as a result of the successful stock market flotation increased equity by â‚¬1.5 billion. The equity ratio (equity coverage of total assets) as of December
31, 2015 was 34.4% (2014: 28.8%).
Liabilities decreased by â‚¬1.5 billion compared with December 31, 2014, to â‚¬48.5 billion. Decreases in
provisions for pensions and other post-employment benefits and financial liabilities more than offset
increases in other provisions, trade accounts payable and tax liabilities.

Net Defined Benefit Liability for Post-Employment Benefits

Provisions for pensions and other post-employment benefits
Net defined benefit asset
Net defined benefit liability for post-employment benefits

[Table 3.14.9]
Dec. 31,
2014

Dec. 31,
2015

â‚¬ million

â‚¬ million

12,236

10,873

(41)

(30)

12,195

10,843

The net defined benefit liability for pensions and other post-employment benefits decreased from
â‚¬12.2 billion to â‚¬10.8 billion in 2015 due to an increase in long-term capital market interest rates for
high-quality corporate bonds.

177

Bayer Annual Report 2015
Combined Management Report
14. Earnings; Asset and Financial Position of the Bayer Group

Ratios

Cost of sales ratio (%)
R & D expense ratio (%)
Return on sales in (%)
EBIT margin (%)
EBITDA margin before special items (%)

Asset intensity (%)

[Table 3.14.10]

Cost of goods sold
Sales
Research and development expenses
Sales
Income after income taxes
Sales
EBIT
Sales
EBITDA before special items
Sales
Property, plant and equipment
+ intangible assets

2014

2015

48.2

45.7

8.6

9.2

8.3

8.8

13.1

13.5

21.0

22.2

60.4

59.1

165.1

153.1

31.0

35.0

1.6

1.1

3,332

4,334

2.3

2.5

4.5

4.7

3.7

3.6

28.8

34.4

16.8

17.9

8.4

8.4

Total assets
Reinvestment ratio (%)
Liability structure (%)
Gearing

Free operating cash flow (â‚¬ million)

Inventory turnover
Receivables turnover
Payables turnover
Equity ratio (%)
Return on equity (%)

Return on assets (%)

Capital expenditures1
Depreciation1
Current liabilities
Liabilities
Net debt + pension provisions
Equity
Net operating cash flow less cash outflows
for property, plant and equipment and
intangible assets
Cost of goods sold
Inventories
Sales
Trade accounts receivable
Cost of goods sold
Trade accounts payable
Equity
Total assets
Income after income taxes
Average equity
Income before income taxes
and interest expense
Average total assets

2014 figures restated
1 Property, plant and equipment

14.7 Financial Management of the Group
The financial management of the Bayer Group is conducted by Bayer AG. Capital is a global resource,
generally procured centrally and distributed within the Group. The foremost objectives of our financial
management are to help bring about a sustained increase in corporate value and to ensure the Groupâ€™s
liquidity and creditworthiness. This involves optimizing the capital structure and effectively managing
risks. The management of currency, interest rate, raw material price and default risks helps to reduce
the volatility of our earnings.

178

Bayer Annual Report 2015
Combined Management Report
15. Earnings; Asset and Financial Position of Bayer AG

The contracted rating agencies assess Bayer as follows:

Rating

[Table 3.14.11]
Long-term rating

Outlook

Short-term rating

Standard & Poorâ€™s

Aâ€“

stable

Aâ€“2

Moodyâ€™s

A3

stable

Pâ€“2

These credit ratings reflect the companyâ€™s high solvency and ensure access to a broad investor base for
financing purposes. It remains our goal to achieve and maintain financial ratios that support an â€œaâ€
category rating in order to maintain our financial flexibility.
We pursue a prudent debt management strategy to ensure flexibility, drawing on a balanced financing
portfolio. This is based on bonds â€“ predominantly a multi-currency European Medium Term Notes program â€“, syndicated credit facilities, bilateral loan agreements and a global commercial paper program.
We use financial derivatives to hedge against risks arising from business operations or financial transactions, but do not employ contracts in the absence of an underlying transaction. It is our policy to diminish default risks by selecting trading partners with a high credit standing. We closely monitor the execution of all transactions, which are conducted in accordance with Group directives.
Further details of our risk management objectives and the ways in which we account for all the major
types of hedged transactions â€“ along with price, credit and liquidity risks as they relate to the use of
financial instruments â€“ are given in Chapter 18.3 â€œOpportunities and Risks Report.â€

15. Earnings; Asset and Financial Position
of Bayer AG
Until the end of 2015, Bayer AG functioned solely as the management holding company for the Bayer
Group. At the beginning of 2016, it assumed responsibility for the operations of its three divisions. As
the parent company of the Bayer Group, Bayer AG â€“ represented by its Board of Management â€“ performs the principal management functions for the entire Group. These include strategic planning, resource allocation, executive management and financial management. The performance of Bayer AG is
largely determined by the business performance of the Bayer Group.
The financial statements of Bayer AG are prepared in accordance with the German Commercial Code
(hgb) and Stock Corporation Act (AktG).

179

Bayer Annual Report 2015
Combined Management Report
15. Earnings; Asset and Financial Position of Bayer AG

15.1 Earnings Performance of Bayer AG
Bayer AG Summary Income Statements according to the German Commercial Code

[Table 3.15.1]
2014

2015

â‚¬ million

â‚¬ million

3,213

2,444

(341)

(484)

Other financial income â€“ net

129

409

Other operating income

128

99

General administration expenses

(272)

(324)

Other operating expenses

(147)

(177)

2,710

1,967

Income from investments in affiliated companies â€“ net
Interest expense â€“ net

Income before income taxes
Income taxes
Net income
Allocation to / Withdrawal from other retained earnings
Distributable profit

(256)

(606)

2,454

1,361

(593)

706

1,861

2,067

In fiscal 2015, the net income of Bayer AG was â‚¬1,361 million, down by â‚¬1,093 million against the previous year (2014: â‚¬2,454 million). Earnings were held back above all by lower income from investments
in affiliated companies and higher tax expense.
The income from investments in affiliated companies declined year on year by â‚¬769 million to
â‚¬2,444 million (2014: â‚¬3,213 million). Bayer Pharma AG posted income of â‚¬1,793 million (2014:
â‚¬2,158 million), which, as in the previous years, was by far the largest contribution. Despite a substantial increase in business, however, earnings of that company fell by â‚¬365 million, due partly to higher
r&d and selling expenses. Bayer CropScience AG contributed â‚¬964 million (2014: â‚¬787 million) to Bayer
AGâ€™s income, an increase of â‚¬177 million. This was attributable to a slightly improved earnings contribution from business operations and to one-time gains from a litigation, among other factors. Bayer AG
assumed a loss of â‚¬150 million from Covestro Deutschland AG, the former Bayer MaterialScience AG
(bms), from its abbreviated fiscal year ending in August 2015. That company had made a positive earnings contribution of â‚¬154 million in the previous year. The decline in earnings was mainly due to a
payment of â‚¬217 million to clear compensation claims from Bayer AG for the pension expenses of former bms employees. Other significant earnings contributions comprised â‚¬149 million (2014: â‚¬146 million) from a subsidiary that receives foreign dividend income. The service companies Bayer Business
Services GmbH and Bayer Technology Services GmbH assumed losses of â‚¬118 million (2014: â‚¬75 million) and â‚¬12 million (2014: â‚¬18 million), respectively. The reported loss at Bayer HealthCare AG, the
holding company for the global health care business, was â‚¬231 million (2014: â‚¬207 million).
Net interest expense was â‚¬484 million, an increase of â‚¬143 million compared with the previous year.
After offsetting against gains from the fund assets, just the interest portion of the allocation to pension
provisions led to additional expense of â‚¬142 million, and thus to total expense of â‚¬276 million (2014:
â‚¬134 million). Of the remaining â‚¬208 million (2014: â‚¬207 million) balance of interest expenses and
income, â‚¬179 million was attributable to transactions with third parties and â‚¬29 million to intra-Group
transactions.
Other financial income and expenses yielded a positive balance of â‚¬409 million (2014: â‚¬129 million).
This marked increase was due particularly to a payment of â‚¬217 million received from Covestro
Deutschland AG to clear compensation claims from Bayer AG for the pension expenses of former bms
employees. Income from the subgroups and service companies to cover pension expenses for retirees
remaining with Bayer AG following the hive-down of the operating business in 2002 and 2003 amounted to â‚¬178 million (2014: â‚¬180 million). If due to interest rates, pension expenses as such are recognized under interest income / expense; otherwise they are recognized under other financial income and
expenses. There was income of â‚¬15 million in 2015 and expense of â‚¬19 million in the previous year.
Further income of â‚¬6 million (2014: charges of â‚¬20 million) resulted from the translation of foreign
currency receivables and payables and from currency derivatives.

180

Bayer Annual Report 2015
Combined Management Report
15. Earnings; Asset and Financial Position of Bayer AG

General administration expenses relating to Bayer AGâ€™s performance of its functions as the parent company of the Bayer Group amounted to â‚¬324 million (2014: â‚¬272 million). Miscellaneous operating expenses relating to these functions, net of the respective miscellaneous operating income, came to â‚¬78
million (2014: â‚¬19 million). Of the higher expenses totaling â‚¬111 million, â‚¬83 million was in connection
with the carve-out and stock market flotation of Covestro.
Pre-tax income decreased to â‚¬1,967 million (2014: â‚¬2,710 million). Tax expense nonetheless increased
from â‚¬256 million to â‚¬606 million on account of effects associated with the formation of the Covestro
Group and lower tax-free income from investments in affiliated companies. After deduction of taxes, net
income was â‚¬1,361 million (2014: â‚¬2,454 million). A withdrawal of â‚¬706 million was made from other
retained earnings, leaving a distributable profit of â‚¬2,067 million.
The Board of Management and Supervisory Board will propose to the Annual Stockholdersâ€™ Meeting on
April 29, 2016 that the distributable profit be used to pay a dividend of â‚¬2.50 per share (826,947,808
shares) on the capital stock of â‚¬2,117 million entitled to the dividend for 2015.

15.2 Asset and Financial Position of Bayer AG
Bayer AG Summary Statements of Financial Position according
to the German Commercial Code

[Table 3.15.2]
Dec. 31,2014

Dec. 31,2015

â‚¬ million

â‚¬ million

ASSETS
Noncurrent assets
Intangible assets, property, plant and equipment
Financial assets

18

31

40,919

43,737

40,937

43,768

2,729

3,159

460

380

Current assets
Receivables from subsidiaries
Remaining receivables, other assets
Cash and cash equivalents, marketable securities

Total assets

1,243

629

4,432

4,168

45,369

47,936

15,532

15,032

2,406

2,356

EQUITY AND LIABILITIES
Equity
Provisions
Other liabilities
Bonds and notes, liabilities to banks
Payables to subsidiaries
Remaining liabilities

Total equity and liabilities

7,210

7,203

18,204

22,752

2,017

593

27,431

30,548

45,369

47,936

181

Bayer Annual Report 2015
Combined Management Report
15. Earnings; Asset and Financial Position of Bayer AG

The asset and liability structure of Bayer AG is dominated by its role in managing the subsidiaries and
financing corporate activities as the parent company of the Bayer Group. This is primarily reflected in
the high level of investments in affiliated companies and of the receivables from, and payables to, Group
companies.
Total assets of Bayer AG as of December 31, 2015 were â‚¬48.0 billion, up from â‚¬45.4 billion at the start of
the year because of the â‚¬2.8 billion increase in noncurrent assets. By contrast, current assets decreased
by â‚¬0.3 billion in fiscal 2015.
Property, plant and equipment and intangible assets totaled â‚¬31 million (2014: â‚¬18 million) and were
therefore of secondary importance. Financial assets increased by â‚¬2.8 billion to â‚¬43.7 billion (2014:
â‚¬40.9 billion), principally as a result of capital increases at subsidiaries. Investments in affiliated companies continued to account for by far the largest item in total assets, amounting to 89.5% (2014:
88.3%).
Receivables from subsidiaries amounted to â‚¬3.2 billion (2014: â‚¬2.7 billion) while payables to subsidiaries totaled â‚¬22.8 billion (2014: â‚¬18.2 billion). These amounts accounted for 6.6% of total assets and
47.5% of total equity and liabilities, respectively.
Including the deferred charges, the other receivables reflected in current assets, at â‚¬380 million, were
below the prior-year level of â‚¬460 million and were of only secondary importance in relation to total
assets. Cash and cash equivalents were â‚¬614 million lower than in the previous year at â‚¬629 million
(2014: â‚¬1,243 million) due to lower bank deposits.
Bayer AG had equity of â‚¬15.0 billion (2014: â‚¬15.5 billion). The decline in equity, coupled with the increase in total assets, caused the equity ratio to fall to 31.4% (2014: 34.2%). Net income for 2015 was
â‚¬1,361 million while equity was diminished by the â‚¬1,861 million dividend payment for 2014.
Provisions were level year on year at â‚¬2.4 billion. While pension provisions decreased by â‚¬306 million to
â‚¬1,562 million, tax provisions were â‚¬265 million higher at â‚¬664 million. The other provisions were virtually unchanged at â‚¬130 million (2014: â‚¬139 million).
Other liabilities rose by â‚¬3.1 billion to â‚¬30.5 billion (net of deductible receivables; 2014: â‚¬27.4 billion),
mainly due to the â‚¬2.1 billion increase in financial debt. In this connection, external debt of the Group
was reduced at the expense of higher debt to Group companies. Internal financial debt rose by
â‚¬3.2 billion. Bonds in the same amount of â‚¬1.3 billion were issued and repaid in fiscal 2015. The use of
funds from the commercial paper program decreased by â‚¬1.1 billion. Total financial debt at year end
2015 was â‚¬30.3 billion (2014: â‚¬28.2 billion). After deduction of cash and cash equivalents of â‚¬0.6 billion,
net debt was â‚¬2.7 billion higher than in the previous year at â‚¬29.7 billion (2014: â‚¬27.0 billion).

182

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Corporate Governance
16. Corporate Governance Report
This Corporate Governance Report also constitutes the report pursuant to Section 3.10 of the German
Corporate Governance Code.

16.1 Declaration Concerning the German Corporate
Governance Code*
*not part of the audited management report
DECLARATION BY THE BOARD OF MANAGEMENT AND SUPERVISORY BOARD OF
BAYER AG
concerning the German Corporate Governance Code (May 5, 2015 version) pursuant to
Section 161 of the German Stock Corporation Act**

Under Section 161 of the German Stock Corporation Act, the Board of Management and the Supervisory Board of Bayer AG are required to issue an annual declaration that the company has been,
and is, in compliance with the recommendations of the â€œGovernment Commission on the German
Corporate Governance Codeâ€ as published by the Federal Ministry of Justice in the official section
of the Federal Gazette (Bundesanzeiger), or to advise of any recommendations that have not been,
or are not being, applied and the reasons for this. An annual declaration was last issued in December 2014.
With respect to the past, the following declaration refers to the June 24, 2014 version of the Code.
With respect to present and future corporate governance practices at Bayer AG, the following
declaration refers to the recommendations in the May 5, 2015 version of the Code.
Pursuant to Section 161 of the German Stock Corporation Act, the Board of Management and Supervisory Board of Bayer AG hereby declare as follows:
1.

The company has been in compliance with the recommendations of the Code since issuance
of the last annual compliance declaration in December 2014.

2.

All the recommendations of the Code are now being complied with in full.

Leverkusen, December 2015
For the Board of Management

For the Supervisory Board

dr. dekkers

wenning

dietsch

** This is an English translation of a German document. The German document is the official and controlling version, and this English translation in
no event modifies, interprets or limits the official German version.

183

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

16.2 Governance*
*not part of the audited management report
BAYER IN COMPLIANCE WITH THE RECOMMENDATIONS OF THE GERMAN CORPORATE
GOVERNANCE CODE
Bayer has always placed great importance on responsible corporate governance. This will remain the
case in the future. In 2015, the company was again able to issue a declaration that it had fully complied
with the recommendations of the German Corporate Governance Code in the past and continued to do
so.
In 2015, the Board of Management and Supervisory Board again addressed the question of compliance
with the German Corporate Governance Code, including the Code amendments of May 5, 2015. The
resulting declaration, which is reproduced on the previous page, was issued in December 2015 and
posted on Bayerâ€™s website along with previous declarations.
DUTIES AND ACTIVITIES OF THE BOARD OF MANAGEMENT
The Board of Management runs the company on its own responsibility with the goal of sustainably
increasing the companyâ€™s enterprise value and achieving the defined corporate objectives. The Board of
Management performs its tasks according to the law, the Articles of Incorporation and the Boardâ€™s rules
of procedure, and works with the companyâ€™s other governance bodies in a spirit of trust.
The Board of Management of Bayer AG defines the long-term goals and strategies for the company and
the Group and sets forth the principles and directives for the resulting corporate policies. It coordinates
and monitors the most important activities, defines the portfolio, develops and deploys managerial staff,
allocates resources and decides on the Groupâ€™s financial steering and reporting.
The members of the Board of Management bear joint responsibility for running the business as a whole.
However, the individual members manage the areas assigned to them on their own responsibility within
the framework of the decisions made by the full Board. The allocation of functions among the members
of the Board of Management is defined in a written schedule.
The full Board of Management makes decisions on all matters of fundamental importance and in cases
where a decision of the full Board is prescribed by law or otherwise mandatory. The rules of procedure
of the Board of Management contain a list of topics that must be dealt with and resolved by the full
Board.
Meetings of the Board of Management are held regularly. They are convened by the Chairman of the
Board of Management. Any member of the Board of Management may also demand that a meeting be
convened. The Board of Management makes decisions by a simple majority of the votes cast, except
where unanimity is required by law. In the event of a tie, the Chairman has the casting vote.
According to the Board of Managementâ€™s rules of procedure and the functional responsibilities assigned
to its members, the Chairman bears particular responsibility for leading and coordinating the Boardâ€™s
work. He represents the company and the Group in dealings with third parties and the workforce on
matters relating to more than one part of the company or the Group. He also bears special responsibility
for certain corporate functions.
In 2015 special responsibility was assigned to different members of the Board of Management for each
of the following functions:
x
x
x
x

Strategy and Portfolio Management
Finance
Human Resources, Technology & Sustainability (this member also serving as Labor Director)
Innovation

184

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

In addition, three of the members of the Board of Management were each responsible for geographical
regions.
Effective January 1, 2016, functional responsibilities were reallocated in light of the Bayer Groupâ€™s sole
focus on the Life Science business and the enlargement of the Board of Management by three members.
In addition to the function of Board Chairman and the four other existing functions, three functions
were created that each have special responsibility for one of the operating divisions. Responsibilities for
the geographical regions were redistributed among four members.
See Chapter 4 for
more about the
Bayer Life Science
Center

A Deal Committee was established within the Board of Management to make the final decisions on
corporate acquisitions, divestments or licensing transactions above a defined medium size. The membership of this committee varies from case to case. The members responsible for Strategy and Portfolio
Management and for Finance always participate in its decision-making. The third member of the Board
of Management involved in the decisions of the Deal Committee is either the member responsible for
the division to which the transaction relates or â€“ in the case of a transaction of the Bayer Life Science
Center â€“ the member responsible for Innovation. There are no other committees within the Board of
Management.
SUPERVISORY BOARD: OVERSIGHT AND CONTROL FUNCTIONS
The role of the 20-member Supervisory Board is to oversee and advise the Board of Management. Under
the German Codetermination Act, half of the Supervisory Boardâ€™s members are elected by the stockholders, and half by the companyâ€™s employees. The Supervisory Board is directly involved in decisions on
matters of fundamental importance to the company, regularly conferring with the Board of Management
on the companyâ€™s strategic alignment and the implementation status of the business strategy.
The Chairman of the Supervisory Board coordinates its work and presides over the meetings. Through
regular discussions with the Board of Management, the Supervisory Board is kept constantly informed
about business policy, corporate planning and strategy. The Supervisory Board approves the annual
budget and financial framework. It also approves the financial statements of Bayer AG and the consolidated financial statements of the Bayer Group along with the combined management report, taking into
account the reports by the auditor.
COMMITTEES OF THE SUPERVISORY BOARD
The Supervisory Board has the following committees:
Presidial Committee: This comprises the Chairman and Vice Chairman of the Supervisory Board along
with a further stockholder representative and a further employee representative. The Presidial Committee serves primarily as the mediation committee pursuant to the German Codetermination Act. It has the
task of submitting proposals to the Supervisory Board on the appointment of members of the Board of
Management if the necessary two-thirds majority is not achieved in the first vote at a plenary meeting.
Certain decision-making powers in connection with capital measures, including the power to amend the
Articles of Incorporation accordingly, have also been delegated to this committee.
Audit Committee: The Audit Committee comprises three stockholder representatives and three employee representatives. The Chairman of the Audit Committee in 2015, Dr. Klaus Sturany, satisfies the
statutory requirements concerning the independence and the expertise in the field of accounting or
auditing that a member of the Supervisory Board and the Audit Committee is required to possess. The
Audit Committee meets regularly four times a year. Its tasks include oversight of the companyâ€™s financial reporting process, the effectiveness and ongoing development of the internal control system, the
risk management system, the internal audit system, the compliance system and the audit of the financial
statements. It prepares the decisions of the Supervisory Board pertaining to the financial statements of
Bayer AG, the consolidated financial statements of the Bayer Group, the combined management report,
the proposal for the use of the distributable profit of Bayer AG, and the interim financial statements and
management reports of the Bayer Group, all of which are prepared by the Board of Management. On the
basis of the auditorâ€™s report on the audit of the financial statements of Bayer AG, the consolidated financial statements of the Bayer Group and the combined management report, the Audit Committee develops proposals concerning the approval of both sets of financial statements by the full Supervisory

185

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Board. The Audit Committee is also responsible for the companyâ€™s relationship with the external auditor. The Audit Committee submits a proposal to the full Supervisory Board concerning the auditorâ€™s
appointment, prepares the awarding of the audit contract to the audit firm appointed by the Annual
Stockholdersâ€™ Meeting, suggests areas of focus for the audit and determines the auditorâ€™s remuneration.
It also monitors the independence, qualifications, rotation and efficiency of the auditor.
Human Resources Committee: On this committee, too, there is parity of representation between stockholders and employees. It consists of the Chairman of the Supervisory Board and three other Supervisory Board members. The Human Resources Committee prepares the personnel decisions of the full Supervisory Board, which resolves on appointments or revocations of appointments of members of the
Board of Management. The Human Resources Committee resolves on behalf of the Supervisory Board
on the service contracts of the members of the Board of Management. However, it is the task of the full
Supervisory Board to resolve on the total compensation of the individual members of the Board of Management and the respective compensation components, as well as to regularly review the compensation
system on the basis of recommendations submitted by the Human Resources Committee. The Human
Resources Committee also discusses the long-term succession planning for the Board of Management.
Nominations Committee: This committee carries out preparatory work when an election of stockholder
representatives to the Supervisory Board is to be held. It suggests suitable candidates for the Supervisory Board to propose to the Annual Stockholdersâ€™ Meeting for election. The Nominations Committee
comprises the Chairman of the Supervisory Board and the other stockholder representative on the Presidial Committee.
Innovation Committee: The Innovation Committee was established in September 2015. It is primarily
concerned with the innovation strategy and innovation management, the strategy for protection of intellectual property, and major research and development programs. Within its area of responsibility, the
Committee advises and oversees the management and prepares any Supervisory Board decisions. The
Committee comprises the Chairman of the Supervisory Board and five other members of the Supervisory Board, with parity of representation between stockholder and employee representatives.
Detailed information on the work of the Supervisory Board and its committees is provided in the Report
of the Supervisory Board on page 34 of this Annual Report.
OBJECTIVES FOR THE COMPOSITION OF THE SUPERVISORY BOARD
The Supervisory Board should be composed in such a way that its members together possess the necessary expertise, skills and professional experience to properly perform their duties. In view of Bayer AGâ€™s
global operations, the Supervisory Board has set itself the goal of always having several members with
international business experience or an international background. A further objective concerning the
composition of the Supervisory Board is that, absent special circumstances, a member should not hold
office beyond the end of the next Annual Stockholdersâ€™ Meeting following his or her 72nd birthday.
With a view to avoiding potential conflicts of interest, the Supervisory Board has set itself the goal that
more than half of the stockholder representatives be independent and also that at least three quarters of
the total Supervisory Board membership (stockholder and employee representatives) be independent.
The Supervisory Board assesses the independence of its members according to the recommendation
contained in Section 5.4.2 of the the German Corporate Governance Code. In assessing independence,
the Supervisory Board also considers the criteria given in the recommendation of the European Commission of February 15, 2005.4 Finally, the Supervisory Board has set a standard limit on the duration of
any personâ€™s membership of the Supervisory Board in line with the recommendation in Section 5.4.1,
Paragraph 2 (May 5, 2015 version of the Code). Absent special circumstances, no person should remain
a member of the Supervisory Board for more than three full terms of office. For members of the Supervisory Board serving at the time the standard limit was introduced (September 2015) who have already

4

Annex 2 to the recommendation of the European Commission of February 15, 2005, on the role of nonexecutive or supervisory directors of listed
companies and on the committees of the (supervisory) board (2005/162/EC)

186

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

exceeded this limit or will exceed it by the end of their current term of office, the limit will be applied
with effect from the conclusion of their current term of office.
The stated goals refer to the Supervisory Board as a whole unless specified otherwise. However, since
the Supervisory Board can only nominate candidates for election as stockholder representatives, the
goals can only be taken into account in these nominations.
Upon elections to the Supervisory Board to be held after January 1, 2016, it must be ensured that at
least 30% of the members are women and at least 30% are men.
Implementation status of the objectives
The Supervisory Board has several members with international business experience and other international connections. The objective that a member should step down from the Supervisory Board at the
Annual Stockholdersâ€™ Meeting following his or her 72nd birthday â€“ absent special circumstances â€“ is
being met. One member, Ernst-Ludwig Winnacker, who has been elected to serve until the Annual
Stockholdersâ€™ Meeting in 2016, had already reached 72 years of age at the time of the Annual Stockholdersâ€™ Meeting in 2014. However, he was proposed for reelection at that Meeting so that the Supervisory Board would continue to have one member with particular expertise in research until one or more
members with similar experience can be appointed. One member of the Supervisory Board, Werner
Wenning, served as Chairman of the companyâ€™s Board of Management until 2010. One member, ErnstLudwig Winnacker, has been a member of the Supervisory Board since 1997, and thus has served more
than three terms of office. However, neither Werner Wenning nor Ernst-Ludwig Winnacker has any
personal or business relationship with the company or a governance body of the company that in the
opinion of the Supervisory Board gives rise to a material conflict of interest of a more than temporary
nature. There are no indications of any possible lack of independence in the case of the other Supervisory Board members. Thus the Supervisory Board considers all of its members to be independent. The
proportion of women on the Supervisory Board is currently 20%. It is planned to nominate a further
female candidate for election to the Supervisory Board at the Annual Stockholdersâ€™ Meeting in 2016. If
this candidate is elected, the proportion of women among the stockholder representatives will rise to
30% and on the full Supervisory Board to 25%.
TARGETS REGARDING THE PROPORTION OF WOMEN ON THE BOARD OF MANAGEMENT
AND THE FIRST TWO MANAGEMENT LEVELS
The Supervisory Board aims to ensure that there is at least one woman serving on the companyâ€™s Board
of Management. This corresponds to a share of 12.5% on the eight-member Board. The Board of Management has set targets of 20% women on the first management level and 28% women on the second
management level. These targets are to be attained by June 30, 2017.
DISCLOSURE OF SECURITIES TRANSACTIONS BY MEMBERS OF THE BOARD OF
MANAGEMENT OR SUPERVISORY BOARD
Members of the Board of Management or Supervisory Board and their close relatives are required by
law to disclose all transactions involving the purchase or sale of Bayer stock where such transactions
total â‚¬5,000 or more in a calendar year. Bayer publishes details of such transactions immediately on its
website and also notifies the German Financial Supervisory Authority accordingly. This information is
provided to the company register for archiving. The following transactions in 2015 were reported to
Bayer AG:

187

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Securities Transactions by Members of the Board of Management or Supervisory Board

[Table 3.16.1]

Date / place

Name / function

Transaction

Price /
currency

Quantity

Total
transaction
volume

March 3, 2015 /
Xetra

Werner Wenning,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

678

EUR 89,992.16

March 3, 2015 /
Xetra

Dr. Klaus Sturany,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

452

EUR 59,994.77

March 3, 2015 /
Xetra

Dr. Paul Achleitner,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

339

EUR 44,996.08

March 3, 2015 /
Xetra

Dr.Clemens BÃ¶rsig,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

226

EUR 29,997.39

March 3, 2015 /
Xetra

Thomas Ebeling,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

226

EUR 29,997.39

March 3, 2015 /
Xetra

Dr. Helmut Panke,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

291

EUR 38,624.95

March 3, 2015 /
Xetra

Prof. Dr. Ernst-Ludwig
Winnacker,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

226

EUR 29,997.39

March 3, 2015 /
Xetra

Prof. Dr.-Ing Thomas Fischer,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

339

EUR 44,996.08

March 3, 2015 /
Xetra

Michael Schmidt-Kiessling,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

226

EUR 29,997.39

March 3, 2015 /
Xetra

Dr. Simone Bagel-Trah,
Supervisory Board

Shares

DE000BAY0017

Purchase

EUR 132.73

152

EUR 20,175.23

March 3, 2015 /
Over the counter
market (OTC)

Sue H. Rataj,
Supervisory Board

Bayer AG
American
Depositary
Receipts (ADR)

US072730302

Purchase

US$ 148.57

226

US$ 33,576,82

Financial
instrument

ISIN

Information filed with the company by members of the Board of Management and Supervisory Board
shows that, on the closing date for the financial statements, their total holdings of Bayer AG stock or its
derivatives were equivalent to less than 1% of the issued stock.
COMMON VALUES AND LEADERSHIP PRINCIPLES
Bayer has committed itself to the values of Leadership, Integrity, Flexibility and Efficiency, or â€œlifeâ€ for
short. These values provide guidance to all Bayer employees, both for business dealings and for their
collaboration within the company. All employees are obligated to align their work to the life values.
This is taken into account in human resources development and the regular performance evaluations.
SYSTEMATIC RISK MANAGEMENT
Risk management forms an integral part of our control processes. It ensures that we are mindful of risks
involved in our activities and can identify any financial or nonfinancial risks at an early stage. We attempt to avoid or mitigate risks by taking appropriate countermeasures, or to transfer them to third
parties (such as insurers) to the extent possible and economically acceptable.
The internal control system (ics) applied to our accounting processes enables timely risk monitoring. This ensures the accuracy of our financial reporting along with the prevention or, where necessary,
rectification of errors in the processing of business transactions. It also ensures the availability of reliable data on the companyâ€™s financial situation.
However, the control and risk management system cannot provide absolute protection against losses
arising from business risks or fraudulent actions.

188

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

GRI
G4-26

DETAILED REPORTING
To maximize transparency, we provide regular and timely information on the Groupâ€™s position and significant changes in business activities to stockholders, financial analysts, stockholdersâ€™ associations, the
media and the general public. Bayer complies with the recommendations of the Corporate Governance
Code by publishing reports on business trends, financial position, results of operations and related risks
four times a year.
In line with statutory requirements, the members of the companyâ€™s Board of Management provide an assurance that, to the best of their knowledge, the financial statements of Bayer AG, the consolidated financial
statements of the Bayer Group and the combined management report provide a true and fair view.
The financial statements of Bayer AG, the consolidated financial statements of the Bayer Group and the
combined management report are published within 90 days after the end of each fiscal year. In addition,
stockholders and other interested parties are kept informed of developments during the fiscal year by
means of financial reports issued for the half-year and the first and third quarters within 45 days after
the end of the respective reporting period. The half-year financial report is voluntarily subjected to an
audit review by the auditor, whose appointment by the Annual Stockholdersâ€™ Meeting also relates specifically to this audit review.
In addition, Bayer provides information at news conferences and analystsâ€™ meetings. The company also
uses the internet as a platform for the timely announcement of the issue dates of major publications,
such as the annual report and the quarterly financial reports (interim reports), and the date of the Annual Stockholdersâ€™ Meeting.
In line with the fair disclosure principle, all stockholders and the other main target groups are treated
equally as regards the communication of valuation-relevant information. All significant new facts are
disclosed immediately to the general public. Stockholders also have immediate access to the information
Bayer publishes locally in compliance with the respective stock market regulations.
In addition to our regular reporting, we issue ad-hoc statements on developments that otherwise might
not become publicly known but have the potential to materially affect the price of Bayer stock.

16.3 Compliance
Bayer manages its businesses responsibly and in accordance with the statutory requirements of the
countries in which it operates.
We define compliance as legally and ethically impeccable conduct by all employees in their daily work,
because the way they carry out their duties affects the companyâ€™s reputation. Bayer does not tolerate
any violation of applicable laws, relevant codes of conduct or internal regulations. Compliance is essential for our long-term economic success.

189

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

CORPORATE COMPLIANCE
The Board of Management is unreservedly committed to compliance, and Bayer will forgo any business
transaction that would violate our compliance principles. These principles are enshrined in our Corporate Compliance Policy, which is available in 42 languages and sets out our commitment to:
â€¢
â€¢
â€¢
â€¢
â€¢
â€¢
â€¢

Fair competition
Integrity in business dealings â€“ including zero tolerance of corruption
The principles of sustainability and product stewardship
The upholding of foreign trade laws and insider trading laws
The separation of business and personal interests
Proper record-keeping and transparent financial reporting
Fair and respectful working conditions and the avoidance of all forms of discrimination

Every employee is required to observe these rules and to immediately report any violation of the Corporate Compliance Policy. This general reporting requirement does not apply in France due to peculiarities
of national law. Managerial employees have a vital role to play in implementing the Corporate Compliance Policy in the Bayer Group. As role models, they help to ensure this essential code of conduct is
actively adhered to. Managers may lose their entitlement to variable compensation components and be
subject to further disciplinary measures if systematic violations of applicable law have occurred in their
sphere of responsibility. Compliant and lawful conduct factors into the performance evaluations of all
managerial employees.
Adherence to the Corporate Compliance Policy is among the subjects covered in all audits conducted by
Bayerâ€™s Internal Audit. Audits are planned using a function- and risk-based approach that also takes a
corruption awareness index into consideration. Audits of the major companies, which together account
for about 90% of Group sales, are planned to take place every three years. A total of 214 audits were
conducted in 2015. These included 38 preventive or incident-related compliance audits. The head of
Internal Audit regularly attends the meetings of the Audit Committee of the Supervisory Board, presenting a list of conducted audits and their outcomes at least once a year.
COMPLIANCE ORGANIZATION
The Bayer Groupâ€™s compliance organization is headed by the Group Compliance Officer, who regularly
reports directly to the Chairman of the Board of Management and to the Audit Committee of the Supervisory Board. A central compliance department supports the Group Compliance Officer in steering and
implementing the Group-wide compliance activities. In 2015 each subgroup and service company had
its own compliance officer, whose responsibilities included ensuring adherence to subgroup- or industry-specific standards. A central compliance officer â€“ supported where necessary by further compliance
functions â€“ is available in every country or country group to answer questions from all employees regarding lawful and ethical behavior in business-related situations.
The compliance organization operates in accordance with international standards such as the oecd
Recommendations of the Council for Further Combating Bribery of Foreign Public Officials in International Business Transactions.

190

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

The mission and the goals of the Bayer Groupâ€™s compliance organization are set forth in our Compliance
Charter, which forms the basis for proactive, risk-based, collaborative cooperation with the operational
business aimed at early prevention of compliance violations. For compliance to continue developing as a
permanent, active part of Bayerâ€™s corporate culture, it must be integrated into all operational business
units and their work processes.
A Group-wide compliance management system serves the purpose of early prevention. This system is
based on partnership with the operational business and features dialogue, transparency and continuous
improvement. It also includes the punishment of compliance violations.
The preventive approach is driven by the Integrated Compliance Management (icm) project. This promotes close, systematic cooperation between compliance experts and operational business managers.
With the help of icm, relevant business risks can be identified and minimized. A systematic process is in
place involving roundtable meetings to discuss identified compliance risks and coordinate steps to
mitigate them. The participants in these roundtables are the compliance functions and the operational
business managers. The results of the roundtables are entered and tracked in a Group-wide compliance
risk management database.
Group target 2015:
conducting preventive
risk assessments in all
three subgroups
See also Chapter
1.4 for Group
targets

In line with our Group target, we had carried out comprehensive, preemptive risk assessments in the
holding company, all three subgroups and the country organizations by the end of 2015. The project
also includes regular self-monitoring by the operational business units based on appropriate auditing
and inspection procedures. icm is focused on the areas of antitrust law, anticorruption measures, export
control, conflicts of interest, insider trading, antidiscrimination and privacy. At the beginning of 2016,
the project was transferred to the companyâ€™s compliance and privacy organization.
Compliance violations can be reported â€“ anonymously if desired â€“ via a central, global compliance hotline, which was switched in 2015 to a new international provider offering additional services. In 2015
the compliance organization received a total of 185 reports via this compliance hotline (121 of these
anonymous), which is also accessible to the general public. Of these reports, 10 came from Germany
and 175 from other countries. As an alternative to the compliance hotline, suspected compliance violations may also be reported to the compliance officer for the respective country organization or to Internal Audit.
All suspected compliance violations in the Group are recorded according to uniform criteria and dealt
with under the rules set forth in Bayerâ€™s Directive on the Management of Compliance Incidents.
online annex: 3-16.3-1
Where an investigation confirms that a compliance violation has occurred, the company has a graduated set of measures at its disposal. These include a verbal or written warning, transfer to a different
unit, cancellation of a planned promotion, a reduction in the short-term incentive payment, downgrading to a lower collectively agreed pay rate or managerial contract level, and ordinary or extraordinary termination. This does not preclude the company from asserting further claims against the
employee concerned for cost reimbursement or damages or from initiating a criminal prosecution.
The action taken in each case depends on the gravity of the compliance violation and on applicable
law.

191

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

COMPLIANCE TRAINING AND COMMUNICATIONS
Group-wide training programs tailored to requirements and target groups, along with extensive communications activities, help to further raise the employeesâ€™ awareness for compliance issues and the
risks involved. In 2015, 38,609 Bayer managers, or 96.6% of the global total, took a compliance training
program. This was in line with the Group target.
online annex: 3-16.3-2
The aim of these targeted training programs is to ensure that employees do not overstep boundaries
out of ignorance or uncertainty. Our compliance training programs reflect the focus areas of the icm
project and are available in various formats to meet the needs of different employee groups. Some
take the form of web-based training (wbt) programs, while others involve face-to-face training sessions or workshops.

Group target 2015:
annual compliance
training for all Bayer
managers (> 99%)

See also Chapter
1.4 for Group
targets

In 2015, we implemented a new global web-based training program in 83 countries on the subject of
conflicts of interest. This program, initially available in 10 languages, has already been completed by
26,163 employees.
New hires and employees switching to different areas of responsibility within Bayer are regularly invited to participate in the training programs relevant to their functions. This ensures that all new employees receive the appropriate compliance training.
In view of the particularly strict compliance rules in the area of health care, we offer special training
programs for the employees working in this field. Further details are given in Chapter 7 â€œProcurement, Products, Logistics, Distribution.â€
We again ran a broad-based communications campaign in 2015 to provide comprehensive information to all employees about compliance and the availability of advice from compliance staff under
the new partnering concept, as well as to enhance their awareness for compliance-critical situations.
The communications activities in 2015 focused on conflicts of interest and product-related communications. A wide range of internal media offerings was available on both topics. At the start of the
year, a quiz provided the opportunity for employees to refresh their knowledge of various aspects of
compliance.

16.4 Compensation Report
The Compensation Report describes the essential features of the compensation system for the members of the Board of Management and the Supervisory Board and explains the compensation of the
individual members. The report conforms to the requirements of the German Commercial Code including the principles of German Accounting Standard No. 17 (drs 17). It also complies with the recommendations of the German Corporate Governance Code and with the International Financial Reporting
Standards (ifrs).

See Chapter 7.3

192

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

16.4.1 Compensation of the Board of Management
OBJECTIVES
The structure of the compensation system for the Board of Management of Bayer AG is aimed at ensuring performance-oriented corporate governance and a long-term increase in the companyâ€™s value.
The core elements of the system include fixed compensation, which takes into account the tasks and
duties of the Board of Management members, and an incentivized component â€“ the short-term incentive (sti) â€“, which depends on the attainment of the annual corporate performance targets. In addition
to the compensation directly related to each year of service, there are two long-term stock-based components that are directly related to the development of Bayerâ€™s share price over time and thus are
intended to create an incentive for a sustained commitment to the company. The system is also designed to enable the company to successfully compete for highly qualified executives and to ensure
statutory and regulatory compliance. Board of Management compensation is in line with the basic
principles of the compensation structure for managerial employees in the Bayer Group. The appropriateness of the system and the compensation level are regularly reviewed by the Supervisory Board,
which then makes any necessary adjustments.
COMPENSATION STRUCTURE UNTIL DECEMBER 31, 2015
The compensation paid to the members of the Board of Management includes both non-performancerelated and performance-related components. The compensation structure, based on average total
annual compensation and 100% target attainment, is as follows:

Board of Management Compensation Structure (German Commercial Code) 1

[Graphic 3.16.1]

~ 30%

~ 40%

Fixed annual compensation

Long-term variable
cash compensation

~ 30%

~ 10% Aspire

Short-term variable
cash compensation

~ 30% Virtual shares
(50% STI)

(50% STI)

1

Excluding fringe benefits and pension entitlements

The non-performance-related compensation comprises the fixed annual compensation along with fringe
benefits. The performance-related compensation partly comprises a variable component (sti), of which
50% takes the form of short-term variable cash compensation and 50% consists of long-term cash
compensation involving a grant of virtual Bayer shares that are retained for three years. The other performance-related compensation component serving as a long-term incentive is the stock-based cash
compensation program Aspire, where a four-year retention period applies.

193

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

The individual performance-related components are capped at the grant date. The cap on the total compensation is 1.8 times the respective target compensation and is determined annually when the fixed
compensation is set.
The members of the Board of Management also receive pension entitlements for themselves and their
surviving dependents.
Non-performance-related components
Fixed annual compensation
The level of the non-performance-related, fixed annual compensation takes into account the functions
and responsibilities assigned to the members of the Board of Management as well as market conditions.
The fixed compensation is regularly reviewed by the Supervisory Board in light of the consumer price
index and adjusted if necessary. It is paid out in twelve monthly installments.
Fringe benefits
This component mainly includes perquisites such as a company car with driver or the use of the company carpool, payments toward the cost of security equipment, and the reimbursement of the cost of
annual health screening examinations. Fringe benefits are reported at cost or the amount of the pecuniary advantage gained.
Performance-related components
Short-term variable cash compensation
The short-term variable compensation (short-term incentive, or sti) is based on a set percentage of the
fixed annual compensation (target value). This amount is adjusted according to the target attainments of
the Bayer Group, the subgroups and the individual Board of Management member.
The Group component is determined in relation to core earnings per share of the Group, while the subgroup components are governed by the weighted average target attainments of the HealthCare, CropScience and Covestro subgroups. The annual subgroup targets are derived from the respective business
strategies and operational priorities. The target attainment for HealthCare and CropScience is mainly
based on the comparison of target and actual values for the ebitda margin before special items and
sales growth. At Covestro it is measured in terms of the cash flow return on investment (cfroi). Target
attainment also takes into account qualitative objectives including safety, compliance and sustainability
aspects.
The target attainment for the individual component of the variable compensation is determined by the
Supervisory Board. One half of the sti for each year is paid out in the second quarter of the following
year, while the other half is granted in the form of virtual Bayer shares.

194

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Short-Term Variable Compensation (STI) Components

[Graphic 3.16.2]

STI

Group
component

Subgroup
component

Individual
component

1/ 3 of STI target value

1 / 3 of STI target value

1 / 3 of STI target value

Based on Group target
attainment (core earnings
per share)

Based on attainment of
financial and qualitative targets
by the three subgroups
(weighted average)

Based on individual
performance

Long-term variable cash compensation based on virtual Bayer shares
Both the number of virtual shares granted and the amount of the payment at the end of the retention
period are based on the average official closing prices of Bayer shares over the last 30 trading days of the
respective year in the Xetra system of the Frankfurt Stock Exchange. A cash payment with respect to the
number of virtual shares held is made at the end of the three-year period according to the market price of
Bayer shares at that time. In addition, the members of the Board of Management receive an amount
equal to the total dividends paid on the equivalent number of real shares during the period. Payment is
made in January of the year following the end of the three-year retention period. This payment is capped
at 200% of the amount converted into virtual shares at the beginning of the three-year period. No option
exists for the Board of Management members to extend the retention period or defer the payout. When a
member leaves the Board of Management, the retention period for two-thirds of each tranche is shortened to two years. If the member leaves during a fiscal year, payment is made immediately with respect
to two-thirds of any tranche that has already been retained for more than two years. The remaining onethird of each tranche continues to be subject to the three-year retention period.
Long-term stock-based cash compensation (Aspire I)
Members of the Board of Management are eligible to participate in the annual tranches of the long-term
stock-based compensation program Aspire i ("Aspire") on condition that they purchase a certain number of Bayer shares â€“ determined for each individual according to specific guidelines â€“ as a personal
investment and for as long as they continue in the service of the Bayer Group. The payments made
under this program are based on the Aspire Target Opportunity, which is a contractually agreed percentage of fixed annual compensation. Depending on the performance of Bayer stock, both in absolute
terms and relative to the euro stoxx 50 benchmark index, participants are granted an award of between 0% and 300% of their individual Aspire Target Opportunity at the end of the performance period. The payout / performance matrix according to the absolute and relative development of Bayerâ€™s
share price is explained at http://www.investor.bayer.com/en/stock/stock-programs/aspire/.

195

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Tranches of the Aspire Program

[Graphic 3.16.3]

2011 â€“ 2014
2012 â€“ 2015
2013 â€“ 2016
2014 â€“ 2017
2015 â€“ 2018
2011

2012

2013

2014

2015

2016

2017

2018

Performance period

When a member of the Board of Management retires, current tranches may be shortened, thus reducing
their value. In this case, tranches up to the one issued in 2011 were shortened on a pro-rated basis
according to the duration of the memberâ€™s active service on the Board of Management during the period
of the tranche; tranches issued in 2012 or later are shortened according to the duration of the memberâ€™s
active service on the Board of Management during the first year of the tranche.
Expanded Share Ownership Guidelines
On top of the requirement for participants in the Aspire program to make a personal investment in
Bayer shares, the members of the Board of Management have undertaken to comply with expanded
Share Ownership Guidelines. These require the Chairman of the Board of Management to build a position in Bayer shares to the value of 150% of his fixed annual compensation, and the other members to
the value of 100% of their fixed annual salaries, within four years and to continue to hold them for as
long as they remain Board of Management members. Half the number of virtual shares granted to them
through conversion of 50% of the sti into virtual shares counts toward this position. The Board of Management members must provide documentary evidence of their compliance with this obligation for the
first time at the end of the four-year position-building period and again yearly thereafter. In the event of
significant changes in fixed annual compensation, the value to which shares must be held is adjusted
accordingly.
Pension entitlements (retirement and surviving dependentsâ€™ pensions)
The members of the Board of Management appointed prior to 2013 are generally entitled to receive a
lifelong company pension after leaving the Bayer Group, though not before the age of 60. This pension
is normally paid out in the form of a monthly life annuity. Dr. Marijn Dekkers has the option to receive a
capital sum in place of an annuity.
The annual pension granted equals at least 15% of final fixed annual compensation. This percentage
can increase with continuing service on the Board of Management up to a maximum of 60%. The arrangements for surviving dependents basically provide for a widowâ€™s pension amounting to 60% of the
memberâ€™s pension entitlement and an orphanâ€™s pension amounting to 15% of the memberâ€™s pension
entitlement for each child up to an age that has been contractually agreed or set out under insurance
conditions.
Future pension payments are annually reviewed and adjusted based on the development of consumer
prices. Pension rights are suspended if a member of the Board of Management works for a competitor
of Bayer AG or of another Group company before the age of 65 without the prior written consent of the
Supervisory Board.
The annual pension entitlement for members of the Board of Management appointed in 2013 or thereafter is based on contributions. Bayer provides a hypothetical contribution amounting to 33% of the
respective fixed compensation each year. This percentage is comprised of a 6% basic contribution and
a 27% matching contribution â€“ three times the memberâ€™s personal contribution of 9%. The total annual
contribution is converted into a pension module according to the annuity table for the applicable tariff

196

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

of the Rheinische Pensionskasse VVaG pension fund. The annual pension entitlement upon retirement
(at 62 years of age at the earliest) is the total amount of the accumulated pension modules including an
investment bonus. The investment bonus is determined annually based on the net return on the assets
of the Rheinische Pensionskasse VVaG minus the minimum return on the contributions that is guaranteed under the tariff and approved by the German Financial Supervisory Authority. Kemal Malik has
been granted, in addition, a vested entitlement to a fixed annual pension of â‚¬80 thousand starting on his
65th birthday. This is subject to a pro-rated reduction in the event that his term of office ends prior to
his 65th birthday under certain conditions.
The ultimate pension entitlement cannot be precisely determined in advance. It depends on the development of the memberâ€™s compensation, the number of years of service on the Board of Management
and the return on the assets of the Rheinische Pensionskasse VVaG. We currently estimate the achievable total pension entitlement at approximately 45% of a memberâ€™s annual fixed compensation immediately prior to retirement, with roughly 38% financed by the company and 7% by the member of the
Board of Management.
Certain assets are administered by Bayer Pension Trust e.V. under a contractual trust arrangement (cta),
providing substantial additional security for pension obligations resulting from direct commitments for
members of the Board of Management in Germany.
Benefits upon termination of service on the Board of Management
Post-contractual noncompete agreements
Post-contractual noncompete agreements exist with the members of the Board of Management, providing for compensatory payments to be made by the company for the two-year duration of these agreements. The compensatory payment amounts to 100% of the average fixed compensation for the twelve
months preceding their departure. The post-contractual noncompete agreement with Dr. Marijn Dekkers was rescinded without compensation when his service contract was extended in June 2014 in line
with previous practice in a similar case.
Change of control
Agreements exist with the members of the Board of Management providing for severance indemnity in
certain circumstances in the event of a change in control. The amount of any possible severance indemnity in the case of early termination of service on the Board of Management as a result of a change in
control is limited to the value of three yearsâ€™ compensation in line with the recommendation in Section
4.2.3 of the German Corporate Governance Code. Such payments do not exceed the compensation
payable for the remaining term of the service contract.
Unfitness for work
In the event of temporary unfitness for work, members of the Board of Management continue to receive
the contractually agreed compensation. Bayer AG may early terminate the service contract if the member has been continuously unfit for work for at least 18 months and is likely to be permanently incapable of fully performing his duties (permanent incapacity to work). A disability pension is paid in the
event of contract termination before the age of 60 due to permanent incapacity to work. For the members appointed to the Board of Management prior to 2013, the disability pension, like the retirement
pension, amounts to at least 15% of the final fixed compensation and can increase with continuing
service on the Board of Management up to a maximum of 60%. For members of the Board of Management appointed in 2013 or thereafter, the amount of the disability pension under the service contract
corresponds to the entitlement accrued on the date of contract termination, taking into account a fictitious period of service between that date and the memberâ€™s 55th birthday, where applicable.

197

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

COMPENSATION OF THE BOARD OF MANAGEMENT IN 2015
The aggregate compensation for the members of the Board of Management in 2015 totaled â‚¬17,918
thousand (2014: â‚¬15,648 thousand), comprising â‚¬4,662 thousand (2014: â‚¬4,561 thousand) in nonperformance-related components and â‚¬13,256 thousand (2014: â‚¬11,087 thousand) in performancerelated components. The pension service cost amounted to â‚¬1,847 thousand (2014: â‚¬1,385 thousand).
There were no changes in the membership of the Board of Management or the terms of office of the
members in 2015.
Effective January 1, 2016, the Board of Management of Bayer AG was enlarged to eight members. In
addition to the existing functions, three further functions were created that bear special responsibility
for the newly defined operating divisions of the Group. The following new members were appointed to
the Board of Management:
x Dieter Weinand, responsible for the Pharmaceuticals Division
x Erica Mann, responsible for the Consumer Health Division
x Liam Condon, responsible for the Crop Science Division
Also effective January 1, 2016, Dr. Hartmut Klusik succeeded Michael KÃ¶nig as the member of the
Board of Management responsible for Human Resources, Technology and Sustainability.
The following table shows the total compensation of the individual members of the Board of Management who served in 2014 and / or 2015 according to the German Commercial Code:

Board of Management Compensation (German Commercial Code)

Fixed annual
compensation
2014
â‚¬
thousand

2015
â‚¬
thousand

Fringe benefits
2014
â‚¬
thousand

2015
â‚¬
thousand

Short-term
variable cash
compensation
2014
â‚¬
thousand

2015
â‚¬
thousand

[Table 3.16.2]

Long-term variable cash
compensation based on virtual
Bayer shares 1
2014
No. of
shares

2014
â‚¬
thousand

2015

2015

Long-term
stock-based
cash
compensation
(Aspire) 2
2014

2015

Aggregate
compensation
2014

2015

Pension
service cost 3
2014

2015

No. of
shares

â‚¬
thousand

â‚¬
thousand

â‚¬
thousand

â‚¬
thousand

â‚¬
thousand

â‚¬
thousand

â‚¬
thousand

Serving members of the Board of Management as of December 31, 2015
Dr. Marijn
Dekkers
(Chairman)

1,363

1,374

42

40

1,828

1,995

15,809

1,828

16,739

1,995

414

398

5,475

5,802

722

967

Werner
Baumann 4

899

906

67

47

1,051

1,237

9,088

1,051

10,377

1,237

273

262

3,341

3,689

204

227

Johannes
Dietsch

240

725

22

44

280

917

2,424

280

7,698

917

â€“

210

822

2,813

65

220

Michael
KÃ¶nig

719

725

222

36

841

917

7,271

841

7,698

917

218

210

2,841

2,805

176

211

Kemal
Malik

659

725

72

40

771

917

6,665

771

7,698

917

â€“

210

2,273

2,809

216

222

Former members
Prof. Dr.
Wolfgang
Plischke 5
Total

238

â€“

18

â€“

280

â€“

2,485

287

â€“

â€“

73

â€“

896

â€“

2

â€“

4,118

4,455

443

207

5,051

5,983

43,742

5,058

50,210

5,983

978

1,290

15,648

17,918

1,385

1,847

1 Fair

value at conversion date
value at grant date
company contribution to Bayer-Pensionskasse VVaG or Rheinische Pensionskasse VVaG
4 The increased variable compensation for Werner Baumann resulted mainly from his temporary duties as head of Bayer HealthCare in addition to his primary responsibilities as a
member of the Board of Management.
5 Prof. Dr. Plischke stepped down from the Board of Management as of midnight on April 29, 2014. In return for his acceptance of the early change made to the system of variable
cash compensation in 2010, Prof. Dr. Plischke in 2014 received one additional virtual Bayer share resulting from the conversion of the STI into virtual Bayer shares.
2 Fair

3 Including

Fixed annual compensation
The fixed compensation of the members of the Board of Management was adjusted in 2015. The total
fixed compensation of all the members was â‚¬4,455 thousand (2014: â‚¬4,118 thousand).

198

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Short-term variable cash compensation
The total short-term variable cash compensation (short-term portion of the sti) for all the members of
the Board of Management in 2015 totaled â‚¬5,983 thousand (2014: â‚¬5,051 thousand) after deduction of
the solidarity contribution. Provisions of â‚¬5,983 thousand (2014: â‚¬4,771 thousand) were established for
payment of this compensation component to the members of the Board of Management serving as of
December 31, 2015. The solidarity contribution is made by all employees of the companies covered by
the respective agreements with the employee representatives to help safeguard jobs at the German
sites. For 2015 it amounted to 0.20% (2014: 0.27%) of each memberâ€™s total sti award.
Long-term variable cash compensation based on virtual Bayer shares
The conversion of 50% of the sti for 2015 into virtual Bayer shares was based on an average price of
â‚¬119.17 (2014: â‚¬115.66).
The long-term variable cash compensation based on virtual Bayer shares that is included in the aggregate compensation according to the German Commercial Code was valued at â‚¬5,983 thousand (2014:
â‚¬5,058 thousand). The aggregate compensation according to the ifrs also includes a change of â‚¬556
thousand (2014: â‚¬1,559 thousand) in the value of existing entitlements.
Provisions of â‚¬18,663 thousand (2014: â‚¬17,775 thousand) existed as of December 31, 2015, for the
future cash disbursements to currently serving members of the Board of Management based on the
virtual Bayer shares granted in the respective year. This amount also contains the dividend attributable
to the respective prior year.
Long-term stock-based cash compensation (Aspire)
The long-term stock-based cash compensation under the Aspire program is included in the aggregate
compensation according to the German Commercial Code at its fair value of â‚¬1,290 thousand (2014:
â‚¬978 thousand) at the respective grant date.
According to the ifrs, the aggregate compensation includes the fair value of the partial entitlement
earned in the respective year. Grants of stock-based compensation with a four-year performance period
are therefore expensed at their respective fair values over four years starting with the grant year. The
aggregate compensation according to the ifrs also includes the change in the value of existing entitlements under ongoing Aspire tranches granted in prior years as stock-based compensation according to
the ifrs.

Board of Management Compensation â€“ Aspire Program (IFRS)

[Table 3.16.3]

Serving members of the Board of Management
as of December 31, 2015

Stock-based
compensation
entitlements earned in
the respective year 1

Former
members

Dr. Marijn
Dekkers
(Chairman)

Werner
Baumann

Johannes
Dietsch 3

Michael
KÃ¶nig 3

Kemal
Malik 3

Prof. Dr.
Wolfgang
Plischke

Total

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

2015

980

597

225

265

263

â€“

2,330

2014

1,186

684

78

246

247

1,161

3,602

Change in value of
existing entitlements 2

2015

108

71

21

24

48

â€“

272

2014

272

154

18

43

56

144

687

Total

2015

1,088

668

246

289

311

â€“

2,602

2014

1,458

838

96

289

303

1,305

4,289

1 The

newly earned entitlements are derived from the 2012 â€“ 2015 (2014: 2011 â€“ 2014) tranches of the Aspire program because this compensation
was or is being earned over a four-year period. They are stated at their pro-rated fair values in 2014 and 2015, respectively.
2 This line shows the change in the value of the entitlements already earned in 2012, 2013 and 2014 (2014: 2011, 2012 and 2013).
3 The Aspire entitlements earned in 2014 and 2015 and the value changes for Johannes Dietsch, Michael KÃ¶nig and Kemal Malik relate in part to
Aspire tranches granted to them before they joined the Board of Management but not yet fully earned.

199

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

Provisions of â‚¬7,110 thousand (2014: â‚¬7,155 thousand) were established for the Aspire entitlements of
the members of the Board of Management serving as of December 31, 2015.
Pension entitlements
The pension service cost recognized for the members of the Board of Management in 2015 according to
the German Commercial Code was â‚¬1,847 thousand (2014: â‚¬1,385 thousand), while the current service
cost for pension entitlements recognized according to the ifrs was â‚¬2,891 thousand (2014: â‚¬1,716
thousand).

The service cost and the settlement or present value of the pension obligations attributable to the individual members of the Board of Management are shown in the following table.

Pension Entitlements (German Commercial Code and IFRS)

[Table 3.16.4]

Pension service cost 1

German Commercial Code

IFRS

Settlement value of
pension obligation
as of December 31

Present value of defined
benefit pension obligation
as of December 31

Service cost for
pension entitlements

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

Serving members of the Board of Management as of December 31, 2015
Dr. Marijn Dekkers

722

967

8,256

11,014

877

1,418

12,812

14,106

Werner Baumann

204

227

5,738

7,022

259

385

10,701

10,131

Johannes Dietsch

65

220

2,160

2,681

85

355

4,133

3,995

Michael KÃ¶nig

176

211

1,626

2,371

222

361

3,259

3,559

Kemal Malik

216

222

231

516

273

372

1,343

1,700

Former members
Prof. Dr. Wolfgang Plischke 2
Total
1
2

2

â€“

â€“

â€“

â€“

â€“

â€“

â€“

1,385

1,847

18,011

23,604

1,716

2,891

32,248

33,491

Including company contribution to Bayer-Pensionskasse VVaG or Rheinische Pensionskasse VVaG
Prof. Dr. Plischke stepped down from the Board of Management as of midnight on April 29, 2014.

The difference between the pension service cost according to the German Commercial Code and the
service cost for pension entitlements according to the ifrs arises from the difference in the valuation
principles used in calculating the settlement value according to the German Commercial Code and the
present value of the defined benefit pension obligation according to the ifrs.
Benefits upon termination of service on the Board of Management
It was agreed with Michael KÃ¶nig that he be granted benefits of â‚¬1,131 thousand in connection with the
mutually agreed early termination effective December 31, 2015, of his service contract, which originally
ran until March 31, 2016. These benefits comprised fixed compensation, short-term variable compensation components (sti), Aspire and pension contributions â€“ each for the period January 1 to March 31,
2016 â€“, along with the fair value of the accelerated vested portions of the existing Aspire tranches. The
fixed compensation and short-term variable compensation component, together amounting to â‚¬375 thousand, will be paid during the first half of 2016. The payments from the Aspire tranches will be made upon
expiration of each tranche based on the respective Aspire program parameters. In addition, a two-year
non-compete agreement ending on December 31, 2017, exists with Michael KÃ¶nig under his service
contract. The resulting compensatory payment of â‚¬725 thousand per year will be made to him in monthly
installments.

200

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

The aggregate compensation according to ifrs is shown in the following table:

Board of Management Compensation according to IFRS

Fixed annual compensation
Fringe benefits
Total short-term non-performance-related compensation

2014

2015

â‚¬ thousand

â‚¬ thousand

4,118

4,455

443

207

4,561

4,662

Short-term performance-related cash compensation

5,051

5,983

Total short-term compensation

9,612

10,645

Stock-based compensation (virtual Bayer shares) earned in the respective year

5,058

5,983

Change in value of existing entitlements to stock-based compensation (virtual Bayer shares)

1,559

556

Stock-based compensation (Aspire) earned in the respective year

3,602

2,330

687

272

10,906

9,141

Change in value of existing entitlements to stock-based compensation (Aspire)
Total stock-based compensation (long-term incentive)
Service cost for pension entitlements earned in the respective year
Total long-term compensation
Severance indemnity in connection with the termination of a service contract
Aggregate compensation (IFRS)

See Chapter 1.2 for
details of Bayerâ€™s
new corporate
structure effective
2016.

[Table 3.16.5]

1,716

2,891

12,622

12,032

â€“

1,131

22,234

23,808

COMPENSATION STRUCTURE EFFECTIVE JANUARY 1, 2016
The structure of the compensation package for the Board of Management of Bayer AG and the compensation level are intended to be sustainable, performance-based and appropriate. To ensure this, the
Supervisory Board regularly reviews the compensation system and adjusts it as necessary. The most
recent comprehensive review of the system, which the Supervisory Board performed in the third quarter
of 2015, revealed a need for adjustments, mainly in view of the new divisional structure and the increase
in the number of members of the Board of Management from five to eight. The review also showed that
adjustments were necessary in light of the target positioning in relation to the other dax companies.
The review and the new compensation structure are based on an expert report from an independent
compensation consultant.

201

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

The target percentages for the short- and long-term variable compensation are in the future the same
for all the members of the Board of Management. The new structure featuring 100% fixed compensation, 100% target amount for the short-term variable compensation and 150% for the long-term variable compensation is intended to provide even greater encouragement for performance-oriented governance geared to long-term success.
In the future, the short-term variable compensation of the Board of Management will still be based on
the attainment of targets set for three sub-components â€“ a Group component, a segment component
and an individual performance component â€“ each of which will be given a weighting of one-third when
evaluating the performance of each member of the Board. The Group component, which is based on the
core earnings per share of the Group (including Covestro), and the individual performance subcomponents based on the responsibilities of each member of the Board are basically unchanged. The
segment component will be incentivized based on the average performance of the operating segments,
with Pharmaceuticals having a 50% weighting, Consumer Health 20% and Crop Science (including
Animal Health) 30%. In the case of the Board members responsible for an operating segment, however,
this one-third is incentivized based on the profitability of the respective business only. In light of the
legal and economic independence of Covestro and its stock market flotation in October 2015, it is no
longer included in the evaluation of the segment-based component.
In addition, a new stock-based cash compensation program is being introduced from 2016. In the future
the target amounts â€“ expressed in numbers of virtual shares â€“ will be derived from the contractually
agreed target percentage and the individual sti payment factors of the Board members in the year prior
to the issuance of the respective tranche. The cash payment amounts will be determined after four years
based on the share price then applicable, the performance of the Bayer share relative to the EuroStoxx
50 and the dividends paid in the meantime. The cap on the payments to be made under this long-term
compensation program newly introduced from 2016 is 250%, compared to 300% under the predecessor program. Thus the new compensation system maintains consistency between the Board of Management and other management levels. In the case of the Board of Management, however, an additional
payment hurdle related to the EuroStoxx 50 has been introduced for the lti plan.
To reduce complexity and enhance transparency, the long-term variable cash compensation component
based on the conversion of part of the sti into virtual Bayer shares is now discontinued and the Share
Ownership Guidelines have been simplified. Caps continue to apply to each variable cash compensation
component and to the maximum total cash compensation for a given year in line with the recommendation in the German Corporate Governance Code.
The contribution-based pension has been adjusted in line with market conditions. Until now, Bayer has
provided to the members of the Board of Management appointed in 2013 or thereafter a hypothetical
contribution amounting to 33% of the respective fixed compensation each year. This hypothetical contribution has now been increased to 42% of the respective fixed compensation, and, as in the past, is
converted into a pension module according to the annuity table for the applicable tariff of the
Rheinische Pensionskasse VVaG pension fund.

202

Bayer Annual Report 2015

203

Bayer Annual Report 2015

Combined Management Report

Combined Management Report

16. Corporate Governance Report

16. Corporate Governance Report

16.4.2 Disclosures Pursuant to the Recommendations of the
German Corporate Governance Code
In accordance with the recommendations of the German Corporate Governance Code, the following
tables show the compensation â€“ including fringe benefits â€“ granted for 2015, indicating the target values and the maximum and minimum achievable values for the variable compensation components,
along with the allocation of compensation.

Compensation and Benefits Granted for 2015

[Table 3.16.6]
Serving members of the Board of Management as of December 31, 2015
Dr. Marijn Dekkers
(Chairman)

Werner Baumann
(Strategy)

Johannes Dietsch 1
(Finance)

Joined Jan. 1, 2010

Joined Jan. 1, 2010

Joined Sept. 1, 2014

Serving members of the Board of Management as of December 31, 2015
Michael KÃ¶nig
(Human Resources)

Former members

Kemal Malik 1
(Innovation)

Joined April 1, 2013

Joined Feb. 1, 2014

Prof. Dr. Wolfgang Plischke
Stepped down April 29, 2014

Target
value
2014

Target
value
2015

Min.
2015

Max.2
2015

Target
value
2014

Target
value
2015

Min.
2015

Max.2
2015

Target
value
2014

Target
value
2015

Min.
2015

Max.2
2015

Target
value
2014

Target
value
2015

Min.
2015

Max.2
2015

Target
value
2014

Target
value
2015

Min.
2015

Max.2
2015

Target
value
2014

Target
value
2015

Min.
2015

Max.
2015

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

1,363

1,374

1,374

1,374

899

906

906

906

240

725

725

725

719

725

725

725

659

725

725

725

238

â€“

â€“

â€“

42

40

40

40

67

47

47

47

22

44

44

44

222

36

36

36

72

40

40

40

18

â€“

â€“

â€“

Total annual fixed compensation

1,405

1,414

1,414

1,414

966

953

953

953

262

769

769

769

941

761

761

761

731

765

765

765

256

â€“

â€“

â€“

Short-term variable
cash compensation
(50% of STI)

1,466

1,477

0

2,955

843

849

0

1,699

225

679

0

1,359

674

679

0

1,359

618

679

0

1,359

225

â€“

â€“

â€“

2014
(Jan. 1, 2014 â€“ Dec. 31, 2017)à¯—

545

â€“

â€“

â€“

359

â€“

â€“

â€“

107

â€“

â€“

â€“

288

â€“

â€“

â€“

135

â€“

â€“

â€“

96

â€“

â€“

â€“

2015
(Jan. 1, 2015 â€“ Dec. 31, 2018)à¯—

â€“

550

0

1,649

â€“

362

0

1,087

â€“

290

0

870

â€“

290

0

870

â€“

290

0

870

â€“

â€“

â€“

â€“

2014
(Jan. 1, 2015 â€“ Dec. 31, 2017)à¯—

1,466

â€“

â€“

â€“

843

â€“

â€“

â€“

225

â€“

â€“

â€“

674

â€“

â€“

â€“

618

â€“

â€“

â€“

230

â€“

â€“

â€“

2015
(Jan. 1, 2016 â€“ Dec. 31, 2018)à¯—

â€“

1,477

0

5,909

â€“

849

0

3,397

â€“

679

0

2,718

â€“

679

0

2,718

â€“

679

0

2,718

â€“

â€“

â€“

â€“

5,716

2,577

2,409

761

5,708

2,102

2,413

765

5,712

807

â€“

â€“

â€“

Fixed annual compensation
Fringe benefits

Long-term stock-based
compensation (Aspire) 3

Long-term variable cash
compensation
(virtual Bayer shares) 4

Total
Service cost / benefit expense
Total compensation
1 The

4,882

4,918

1,414

11,927

3,011

3,013

953

7,136

819

2,417

769

722

967

967

967

204

227

227

227

65

220

220

220

176

211

211

211

216

222

222

222

2

â€“

â€“

â€“

5,604

5,885

2,381

12,894

3,215

3,240

1,180

7,363

884

2,637

989

5,936

2,753

2,620

972

5,919

2,318

2,635

987

5,934

809

â€“

â€“

â€“

compensation and fringe benefits paid to Johannes Dietsch and Kemal Malik in 2014 relate solely to their service on the Board of Management.
The 2014 Aspire tranche was granted to Johannes Dietsch and Kemal Malik prior to the dates on which they were appointed to the Board of Management. The vesting periods
for these tranches extend past those dates.
2 The maximum achievable variable compensation shown here does not yet take into account the caps applicable. Payments in a single year are limited to 1.8 times the target
compensation (see â€œCompensation structureâ€ in Chapter 16.4.1).
3 Capped at 300%
4 Capped at 200% of the maximum short-term variable cash compensation (50% of STI)

204

Bayer Annual Report 2015

205

Bayer Annual Report 2015

Combined Management Report

Combined Management Report

16. Corporate Governance Report

16. Corporate Governance Report

Allocation of Compensation for 2014 and 2015

[Table 3.16.7]
Serving members of the Board of Management as of December 31, 2015
Dr. Marijn Dekkers
(Chairman)

Werner Baumann
(Strategy)

Joined Jan. 1, 2010

Serving members of the Board of Management as of December 31, 2015

Johannes Dietsch
(Finance)

Joined Jan. 1, 2010

Michael KÃ¶nig
(Human Resources)

Joined Sept. 1, 2014

Joined April 1, 2013

Former members

Kemal Malik
(Innovation)

Prof. Dr. Wolfgang
Plischke

Joined Feb. 1, 2014

Stepped down April 29, 2014

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

1,363

1,374

899

906

240

725

719

725

659

725

238

â€“

42

40

67

47

22

44

222

36

72

40

18

â€“

1,405

1,414

966

953

262

769

941

761

731

765

256

â€“

1,828

â€“

1,051

â€“

280

â€“

841

â€“

771

â€“

280

â€“

â€“

1,995

â€“

1,237

â€“

917

â€“

917

â€“

917

â€“

â€“

960

â€“

759

â€“

â€“

â€“

35

â€“

â€“

â€“

759

â€“

â€“

1,459

â€“

769

â€“

297

â€“

191

â€“

384

â€“

â€“

2010
(Jan. 1, 2011 â€“ Dec. 31, 2013)

1,594

â€“

978

â€“

â€“

â€“

â€“

â€“

â€“

â€“

1,026

â€“

2011
(Jan. 1, 2012 â€“ Dec. 31, 2014)

â€“

2,841

â€“

1,307

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

Fixed annual compensation
Fringe benefits
Total
Short-term variable cash
compensation
for 2014
for 2015 1
Long-term stock-based cash
compensation (Aspire)
2010
(Jan. 1, 2010 â€“ Dec. 31, 2013) 2
2011
(Jan. 1, 2011 â€“ Dec. 31, 2014)
Long-term cash compensation
(virtual Bayer shares)

Advance payment of 2/3 of longterm cash compensation (virtual
Bayer shares)
2011
(Jan. 1, 2012 â€“ Dec. 31, 2014)
Total
Service costà¯—/à¯—benefit expense
Total compensation
1 The

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

915

â€“

5,787

7,709

3,754

4,266

542

1,983

1,817

1,869

1,502

2,066

3,236

â€“

220

176

211

216

222

2

â€“

2,203

1,993

2,080

1,718

2,288

3,238

â€“

722
6,509

967
8,676

204
3,958

227
4,493

65
607

increased variable compensation for Werner Baumann resulted mainly from his temporary duties as head of Bayer HealthCare in addition to his primary responsibilities as a
member of the Board of Management.
2 The payment to Michael KÃ¶nig from the 2010 Aspire tranche and the payments to Johannes Dietsch, Michael KÃ¶nig and Kemal Malik from the 2011 Aspire tranche related to
vesting periods that began before they joined the Board of Management. The tranches were not yet fully vested at the dates on which they joined the Board of Management.

206

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

16.4.3 Compensation of the Supervisory Board
The Supervisory Board is compensated according to the relevant provisions of the Articles of
Incorporation.
The members of the Supervisory Board receive fixed annual compensation of â‚¬120,000 plus reimbursement of their expenses.
In accordance with the recommendations of the German Corporate Governance Code, additional compensation is paid to the Chairman and Vice Chairman of the Supervisory Board and for chairing and
membership of committees. The Chairman of the Supervisory Board receives fixed annual compensation of â‚¬360,000, the Vice Chairman â‚¬240,000. These amounts also cover membership and chairmanship of committees. The other members receive additional compensation for committee membership.
The chairman of the Audit Committee receives an additional â‚¬120,000, the other members of the Audit
Committee â‚¬60,000 each. The chairmen of the remaining committees receive â‚¬60,000 each, the other
members of those committees â‚¬30,000 each. No additional compensation is paid for membership of the
Nominations Committee. A Supervisory Board member who is a member of more than two committees
receives compensation only for the two committees with the highest compensation. If changes are made
to the Supervisory Board and / or its committees during the year, members receive compensation on a
pro-rated basis. The members of the Supervisory Board also receive an attendance fee of â‚¬1,000 each
time they personally attend a meeting of the Supervisory Board or a committee. The attendance fee is
limited to â‚¬1,000 per day.
The members of the Supervisory Board have given a voluntary pledge that they will each purchase
Bayer shares for 25% of their pre-tax fixed compensation, including any additional compensation for
committee membership, and hold these shares for as long as they remain members of the Supervisory
Board. This does not apply to members who are prevented from purchasing shares due to a service or
employment contract with a company or who transfer at least 85% of their fixed compensation to the
Hans BÃ¶ckler Foundation in accordance with the rules of the German Trade Union Confederation or
whose service or employment contract with a company requires them to transfer such compensation to
that company. If less than 85% of the fixed compensation is transferred, the voluntary pledge applies to
the portion not transferred. By voluntarily pledging to invest in and hold Bayer shares, the Supervisory
Board members reinforce their interest in the long-term, sustainable success of the company.

207

Bayer Annual Report 2015
Combined Management Report
16. Corporate Governance Report

COMPENSATION OF THE SUPERVISORY BOARD IN 2015
The following table shows the components of each Supervisory Board memberâ€™s compensation
for 2015.

Compensation of the Members of the Supervisory Board of Bayer AG in 2015

[Table 3.16.8]

Fixed compensation

Attendance fee

Total

2014

2015

2014

2015

2014

2015

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

â‚¬ thousand

Members of the Supervisory Board as of December 31, 2015
Dr. Paul Achleitner

180

180

5

5

185

185

81

120

3

4

84

124

Dr. Clemens BÃ¶rsig

120

120

4

4

124

124

AndrÃ© van Broich

120

129

5

6

125

135

Thomas Ebeling

120

120

4

4

124

124

Dr. Thomas Fischer

180

180

9

9

189

189

Reiner Hoffmann

180

180

8

5

188

185

YÃ¼ksel Karaaslan

120

135

5

6

125

141

Petra Kronen

150

150

5

6

155

156

â€“

19

â€“

1

â€“

20

Dr. Helmut Panke

155

180

5

8

160

188

Sue H. Rataj

120

120

4

5

124

125

Petra Reinbold-Knape

120

130

4

5

124

135

Michael Schmidt-Kiessling

120

120

5

5

125

125

Dr. Klaus Sturany

240

240

8

9

248

249

Werner Wenning (Chairman)

360

360

10

11

370

371

Heinz Georg Webers 2

â€“

60

â€“

3

â€“

63

Prof. Dr. Otmar D. Wiestler 3

0

49

0

3

0

52

Prof. Dr. Dr. Ernst-Ludwig
Winnacker

120

137

5

6

125

143

Oliver ZÃ¼hlke (Vice Chairman) 4

150

195

5

9

155

204

Dr. Simone Bagel-Trah

Frank LÃ¶llgen 1

Members who left the Supervisory Board in 2014 / 2015
Peter Hausmann 5

150

125

4

5

154

130

Thomas de Win 6

240

119

7

4

247

123

Prof. Dr. Ekkehard D. Schulz 7

59

â€“

3

â€“

62

â€“

Dr. Klaus Kleinfeld 7

90

â€“

3

â€“

93

â€“

3,175

3,168

111

123

3,286

3,291

Total
1 Member

of the Supervisory Board since November 3, 2015
of the Supervisory Board since July 1, 2015
3 Prof. Dr. Wiestler has received compensation for his membership of the Supervisory Board since September 1, 2015. Previously, his office as
Chairman of the Management Board of the German Cancer Research Center precluded his acceptance of this compensation.
4 Vice Chairman of the Supervisory Board since July 1, 2015
5 Member of the Supervisory Board until October 31, 2015
6 Member and Vice Chairman of the Supervisory Board until June 30, 2015
7 Member of the Supervisory Board until 2014
2 Member

208

Bayer Annual Report 2015
Combined Management Report
17. Events After the End of the Reporting Period

In addition to their compensation as members of the Supervisory Board, those employee representatives who are employees of Bayer Group companies receive compensation unrelated to their service on
the Supervisory Board. The total amount of such compensation in 2015 was â‚¬741 thousand (2014:
â‚¬737 thousand).
No compensation was paid or benefits granted to members of the Supervisory Board for personally
performed services such as consultancy or agency services. The company has purchased insurance for
the members of the Supervisory Board to cover their personal liability arising from their service on the
Supervisory Board.

16.4.4 Further Information
ADVANCES OR LOANS TO MEMBERS OF THE BOARD OF MANAGEMENT
OR SUPERVISORY BOARD
There were no advances or loans to members of the Board of Management or the Supervisory Board
outstanding as of December 31, 2015, nor at any time during 2015 or 2014.
PENSION PAYMENTS TO FORMER MEMBERS OF THE BOARD OF MANAGEMENT
OR THEIR SURVIVING DEPENDENTS
We currently pay retired members of the Board of Management a monthly pension equal to a maximum
of 80% of the fixed compensation received immediately prior to retirement. The pensions paid to former members of the Board of Management or their surviving dependents are reassessed annually and
adjusted, taking into account the development of consumer prices. The pensions paid to former members of the Board of Management or their surviving dependents in 2015 totaled â‚¬13,416 thousand
(2014: â‚¬13,457 thousand). These benefits are paid in addition to any amounts they receive under previous employee pension arrangements. The present value of the defined benefit pension obligation for
former members of the Board of Management and their surviving dependents according to the ifrs
amounted to â‚¬172,767 thousand (2014: â‚¬187,759 thousand), while the settlement value of the pension
obligation according to the German Commercial Code amounted to â‚¬148,632 thousand (2014: â‚¬146,341
thousand).

Events After the End of the
Reporting Period
17. Events After the End of the
Reporting Period
DIABETES CARE BUSINESS
Implementation of the agreement concerning the sale of the Diabetes Care business to Panasonic
Healthcare Holdings Co, Ltd., Tokyo, Japan, began on January 4, 2016, and thus after the closing date
for the financial statements. A payment of â‚¬0.9 billion was made in January 2016 in connection with the
sale. Bayer has entered into further significant obligations, which are to be met over the next two years.
REDEMPTION OF FINANCIAL LIABILITIES
On January 25, 2016, Bayer AG redeemed at maturity a bond with a nominal volume of â‚¬500 million
issued under the multi-currency European Medium Term Notes program. In addition, commercial
paper and promissory notes in a total amount of â‚¬383 million were repaid in January and February,
2016, respectively.

209

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Report on Future Perspectives
and on Opportunities and Risks
18. Future Perspectives
18.1 Economic Outlook
GLOBAL ECONOMY

Economic Outlook

[Table 3.18.1]

Growth 1
2015

Growth
forecast 1
2016

World

+ 2.5%

+ 2.8%

European Union

+ 1.8%

+ 1.9%

+ 1.5%

+ 2.0%

United States

+ 2.4%

+ 2.7%

Emerging markets Â²

+ 3.7%

+ 4.0%

of which Germany

Growth 2015 restated
1 Real growth of gross domestic product, source: IHS Global Insight
2 Including about 50 countries defined by IHS Global Insight as emerging markets in line with the World Bank
As of February 2016

We anticipate somewhat accelerated growth for the global economy in 2016 compared with the previous year. Although further interest rate hikes by the u.s. Federal Reserve are expected following the first
upward step in December 2015, interest rates will likely remain low overall worldwide, thus continuing
to help stimulate the economy. A supporting effect will come from the low oil price, which will provide
relief to consumers and strengthen private demand.
Impetus is expected above all from the United States, where employment and consumption will probably further increase. In Europe, too, we anticipate an ongoing recovery. While the pace of economic
growth continues to be held back by high unemployment, particularly in a number of southern European countries, growth in Germany will presumably pick up further. In this connection, the eurozone
countries will benefit especially from the favorable euro exchange rate.
In the Emerging Markets as well, we expect rising growth rates again overall following a relatively weak
prior year. By contrast, we foresee a further slowdown in growth in China. Economic output in Russia
and Brazil will likely decline in 2016, albeit less severely than in the previous year.

210

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Economic Outlook for the Segments

[Table 3.18.2]

Growth 1
2015

Growth
forecast 1
2016

Pharmaceuticals market

+ 9%

+ 5%

Consumer health market

+ 5%

+ 4%

Seeds and crop protection market

Å¯ 0%

0%

Animal health market

+ 5%

+ 4%

1 Bayerâ€™s

estimate, except pharmaceuticals. Source for pharmaceuticals market: IMS Health. IMS Market Prognosis. Copyright 2015.
All rights reserved; currency-adjusted; 2015 data provisional
As of February 2016

We expect growth in the pharmaceuticals market to be slower in 2016 than in the previous year. In
Europe we anticipate low-single-digit percentage growth that is below the prior-year level. The pace of
growth is likely to slacken in the Emerging Markets, while the Japanese pharmaceuticals market will
probably stagnate. We are expecting positive momentum from the United States, where persistent
growth, supported above all by new product launches, is forecasted.
We anticipate that the consumer health market will grow somewhat more slowly in 2016 than in the
previous year. We expect the cold season to be weaker than in 2015 and anticipate that fewer products
will be reclassified as nonprescription products, particularly in the United States. Due to the economic
development in Brazil, Russia and China, we are assuming a lower pace of growth in these countries
than in the previous year.
Following a weak prior year, we predict that the global seed and crop protection market will stagnate
overall in 2016 due to high inventories and low prices for agricultural commodities. As in the previous
year, we expect positive growth impulses to come from Europe and the Asia / Pacific region. For Asia we
anticipate a further expansion of agricultural production. By contrast, we predict a tight market situation
in both North and South America, with growth slower than global development.
Following growth impetus in the animal health market over the past two years as a result of successful
product launches, especially in the companion animals segment, we expect a slightly slower pace of
growth for the market overall in 2016.
Covestro foresees an improved economic climate in 2016 for its main customer industries (automotive, construction, electrical and electronics, and furniture). The company believes that growth impetus
in North America will come from an increase in private consumption and an increase in public spending. For the European Union Covestro anticipates a continuation of the economic recovery in view of the
ongoing expansionary monetary policy and the weak euro. China will once again grow more slowly
overall due to industrial overcapacities and a high debt level, while positive growth signals will come
from India and Japan.

211

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

18.2 Forecast for Key Data
The following forecast is based on the business development described in this report, taking into account the potential risks and opportunities and assuming the inclusion of the Covestro business for the
full year. It refers to the new organizational structure following the restructuring of the Bayer Group
with effect from January 1, 2016 (for more information see Chapter 1.2 â€œCorporate Structureâ€œ).

Pro Forma Key Data by New Segment

[Table 3.18.3]
EBITDA
before special items 1

Sales
2014

2015

Change

2014

2015

Change

â‚¬ million

â‚¬ million

%

4,081

4,615

+ 13.1
+ 46.9

â‚¬ million

â‚¬ million

%

Fx & p
adj. %

Pharmaceuticals

13,512

15,308

+ 13.3

+ 9.1

Consumer Health

4,245

6,076

+ 43.1

+ 6.1

991

1,456

Crop Science

9,494

10,367

+ 9.2

+ 1.7

2,360

2,416

+ 2.4

Animal Health

1,318

1,490

+ 13.1

+ 4.5

285

348

+ 22.1

Reconciliation 2

1,119

1,101

â€“ 1.6

â€“ 1.1

(219)

(228)

â€“ 4.1

29,688

34,342

+ 15.7

+ 5.7

7,498

8,607

+ 14.8

Covestro

11,651

11,982

+ 2.8

â€“ 5.1

1,187

1,659

+ 39.8

Group

41,339

46,324

+ 12.1

+ 2.7

8,685

10,266

+ 18.2

Total Life Sciences 3

1

For definition see Chapter 14.2 â€œCalculation of EBIT(DA) Before Special Items.â€
2 Reconciliation comprises the Business Services and Currenta service companies (â€œOther segmentsâ€), corporate functions and
consolidation effects.
3 Including the service companies

Our forecast for fiscal 2016 is based on the exchanges rates at the closing date on December 31, 2015,
including rates of us$1.09 to the euro. A 1% appreciation (depreciation) of the euro against all other
currencies would decrease (increase) sales on an annual basis by some â‚¬300 million and ebitda before
special items by about â‚¬90 million.
BAYER GROUP
In 2016, we are planning sales of more than â‚¬47 billion for the Bayer Group, including Covestro. This
corresponds to a low-single-digit percentage increase on a currency- and portfolio-adjusted basis. We
plan to increase ebitda before special items by a mid-single-digit percentage. We aim to increase core
earnings per share from continuing operations (calculated as explained in Chapter 14.3 â€œCore Earnings
Per Shareâ€) by a mid-single-digit percentage as well. It should be borne in mind that only 69% of
Covestro will be reflected for the full year 2016. From the sale of the Diabetes Care business, we expect
core earnings per share of just under â‚¬0.40 for discontinued operations.

212

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

LIFE SCIENCES TOTAL
We plan sales of approximately â‚¬35 billion for the Life Science activities, i.e. the Bayer Group excluding
Covestro. This corresponds to a mid-single-digit percentage increase on a currency- and portfolioadjusted basis. We plan to increase ebitda before special items by a mid-single-digit percentage. Our
planning includes dissynergies of around â‚¬130 million from the legal independence of Covestro and
from divestments.
PHARMACEUTICALS
Despite declining price developments in some areas, we expect sales of approximately â‚¬16 billion at
Pharmaceuticals â€“ including the Radiology business. This corresponds to a mid-single-digit percentage
increase on a currency- and portfolio-adjusted basis. We plan to raise sales of our recently launched
products to more than â‚¬5 billion. We expect a mid- to high-single-digit percentage increase in ebitda
before special items. Also, we aim to improve the ebitda margin before special items.
CONSUMER HEALTH
In the Consumer Health Division, we expect sales to come in at more than â‚¬6 billion. We plan to grow
sales by a mid-single-digit percentage on a currency- and portfolio-adjusted basis. We aim to improve
ebitda before special items by a mid-single-digit percentage.
CROP SCIENCE
At Crop Science we expect sales to be at the prior-year level. This corresponds to a low-single-digit
percentage increase on a currency- and portfolio-adjusted basis. We plan to increase ebitda before
special items by a low-single-digit percentage.
ANIMAL HEALTH
At Animal Health we expect sales slightly above the prior-year level. We plan a currency- and portfolioadjusted sales gain and an increase in ebitda before special items, each by a low- to mid-single-digit
percentage.
RECONCILIATION
For 2016, we expect sales to be level with the previous year. We are planning ebitda before special
items of roughly minus â‚¬0.2 billion.
COVESTRO
For 2016, Covestro is budgeting sales at the prior-year level and a decline in ebitda after adjustment for
special items.
FURTHER INFORMATION AND BAYER GROUP KEY DATA
We expect to take special charges in the region of â‚¬0.5 billion in 2016, with the integration of the acquired consumer care businesses and charges in connection with the reorganization of the Bayer Group
accounting for most of this amount.

213

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Research and Development Budget 2016

6%

[Graphic 3.18.1]

2%
Reconciliation

Covestro

25%

â‚¬4.5 billion

58%

Pharmaceuticals

Crop Science

6%

3%

Consumer Health

Animal Health

Capital Expenditure Budget 2016

[Graphic 3.18.2]

11%
Reconciliation

18%

32%
Pharmaceuticals

Covestro

â‚¬2.9 billion

8%
Consumer Health

29%
Crop Science

2%
Animal Health

We intend to increase our research and development spending in 2016 to approximately â‚¬4.5 billion.
We have budgeted capital expenditures of about â‚¬2.5 billion for property, plant and equipment and
â‚¬0.4 billion for intangible assets. Depreciation and amortization are estimated at about â‚¬3.1 billion,
including â‚¬1.6 billion in amortization of intangible assets.
We predict the financial result to come in at around minus â‚¬1.2 billion. The effective tax rate is likely to
be about 24%. We expect net financial debt to be below â‚¬16 billion at the end of 2016.
BAYER AG
As the parent company of the Bayer Group, Bayer AG derives most of its income from its subsidiaries.
The earnings of the major subsidiaries in Germany are transferred directly to Bayer AG under profit and
loss transfer agreements. The earnings of Bayer AG are therefore expected to reflect the positive business development anticipated in the Bayer Group. A concerted dividend policy within the Group ensures
the availability of sufficient distributable income. Based on these factors, we expect Bayer AG to report
a distributable profit that will again enable our stockholders to adequately participate in the Bayer
Groupâ€™s earnings.

214

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

18.3 Opportunities and Risks Report
// Opportunity and risk management is integral to Bayerâ€™s Group-wide corporate
governance system.
// No risks that could endanger the Bayer Groupâ€™s continued existence are currently identified.

18.3.1 Group-wide Opportunity and
Risk Management System
Responsible corporate governance forms the basis for sustainable growth and profitability. Key elements of corporate governance are the systematic identification and use of opportunities and the avoidance of risks to the companyâ€™s success.

Corporate Governance

[Graphic 3.18.3]

Corporate Governance
Business processes
Risk management

Opportunity
management

Internal control and monitoring systems

Strategic
& planning
processes

Internal
control system

Compliance
management
system

Risk early warning
system

(Process risks)

(Compliance risks)

(Risks that could endanger the companyâ€™s
continued existence)

Identification // Evaluation // Management // Monitoring // Reporting

Process-independent monitoring

The entrepreneurial decisions we make daily in the course of business processes are based on balancing opportunities and risks. We therefore regard opportunity and risk management as an integral aspect
of business management rather than the task of a specific organizational unit. Our opportunity and risk
management is rooted in our strategy and planning processes. Based on these, we determine relevant
external and internal opportunities along with economic, ecological and social challenges. Opportunities and risks are identified by observing and analyzing trends along with macroeconomic, industryspecific, regional and local developments. These opportunities and risks are then evaluated and incorporated into business-specific strategic and operational frameworks. We attempt to avoid or mitigate
risks by taking appropriate countermeasures, or to transfer them to third parties (such as insurers) to
the extent possible and economically acceptable. We consciously accept and bear manageable and
controllable risks that stand in a reasonable relation to the anticipated opportunities. They are an aspect

215

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

of general entrepreneurial risk. Opportunities and risks are continuously monitored so that changes in
the economic or legal environment, for example, can be identified at an early stage and suitable countermeasures can be initiated if necessary.
To enable the Board of Management and the Supervisory Board to monitor material business risks as
legally required, the following systems are in place: an internal control system ensuring proper and
effective financial reporting pursuant to Section 289, Paragraph 5 and Section 315, Paragraph 2, No. 5
of the German Commercial Code; a compliance management system; and a risk early warning system
pursuant to Section 91, Paragraph 2 of the German Stock Corporation Act.
The various management systems are based on different risk types, risk levels and timelines. Different
processes, methods and it systems are therefore applied to identify, evaluate, manage, and monitor
risks. The principles underlying the various systems are documented in Group directives that are contained in our Management Regulations (Margo) database and are accessible to all employees via the
Bayer intranet. System owners and coordinators are named at the management level in the divisions,
service companies, country companies and central functions of the Bayer Group. The overall responsibility for the effectiveness and appropriateness of the systems lies with the Chief Financial Officer.
The different systems are described below.
INTERNAL CONTROL SYSTEM FOR (GROUP) ACCOUNTING AND FINANCIAL REPORTING
(Report pursuant to Sections 289, Paragraph 5 and 315, Paragraph 2, No. 5 of the German Commercial
Code)
Bayer has an internal control system (ics) in place for the (Group) accounting and financial reporting
process. This process comprises defined structures and workflows implemented throughout the organization. The purpose of our ics is to ensure proper and effective accounting and financial reporting in
accordance with Section 289, Paragraph 5 and Section 315, Paragraph 2, No. 5 of the German Commercial Code.
The ics is designed to guarantee timely, uniform and accurate accounting for all business processes and
transactions based on applicable statutory regulations, accounting and financial reporting standards and
the internal Group directives that are binding upon all consolidated companies.
The ics is based on the coso i (Committee of the Sponsoring Organizations of the Treadway Commission) and cobit (Control Objectives for Information and Related Technology) frameworks and addresses
misreporting risks in the consolidated financial statements. Risks are identified and evaluated, and steps
are taken to counter them. Mandatory ics standards such as system-based and manual reconciliation
processes and functional separation have been derived from these frameworks and promulgated
throughout the Group by the Accounting unit of Bayer AG.
The management of each Group company holds responsibility for implementing the ics standards at the
local level. Using Bayerâ€™s shared service centers, the Group companies prepare their financial statements locally and transmit them with the aid of a standard Group data model that is based on the Group
accounting directive. This ensures the regulatory compliance of the consolidated financial statements.

216

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

The effectiveness of the ics processes for accounting and financial reporting is evaluated on the basis of
a cascaded self-assessment system that starts with the persons directly involved in the processes, then
involves the principal responsible managers and ends with the Board of Management. The system also
makes use of internal and external audits. An it application in use throughout the Bayer Group ensures
uniform and audit-proof documentation and transparent presentation of all ics-relevant business processes, focusing especially on the relevant risks, controls and effectiveness evaluations.
The Board of Management has confirmed the effective functioning of the internal control system for
accounting and financial reporting and the relevant criteria for the 2015 fiscal year. However, it should
be noted that an internal control system, irrespective of its design, cannot provide absolute assurance
that material misstatements in the accounting will be avoided or identified.
COMPLIANCE MANAGEMENT SYSTEM
Our compliance management system is aimed at ensuring lawful, responsible and sustainable conduct
by our employees. It is designed to identify potential violations in advance and systematically prevent
their occurrence. The compliance management system thus contributes significantly to the integration
of compliance into our operating units and their processes.
In light of the Bayer Groupâ€™s diversified structure and international focus, we are active in different
industry sectors, markets and geographical regions worldwide, each of which has its own local legislation and industry codes. Compliance risks are identified by performing a trend analysis based on cases
reported from around the world. We embarked on the global implementation of an integrated compliance management system in 2014. This system enhances the systematic and preventive identification
and assessment of risks. Risk identification is carried out both from the bottom up via the country organizations and from the top down via the global functions, taking global, local and business-specific
aspects into account. In addition, compliance program audits are performed by Internal Audit. These
audits proactively evaluate the implementation of the Corporate Compliance Policy in the country organizations. All the results are discussed by the local business units, the local compliance officers and representatives of the headquarters functions at a round table and are entered into a risk database.
RISK EARLY WARNING SYSTEM PURSUANT TO SECTION 91, PARAGRAPH 2 OF THE
GERMAN STOCK CORPORATION ACT
A process known as BayRisk has been established to enable the early identification of any adverse developments that are material and / or could endanger the companyâ€™s continued existence, thus satisfying
the legal requirements regarding an early warning system for corporate risks pursuant to Section 91,
Paragraph 2 of the German Stock Corporation Act. This process is steered by a central unit within the
Corporate Center to ensure the implementation of a consistent framework and standards for Bayerâ€™s risk
early warning system.
The BayRisk process follows a bottom-up approach in order to identify corporate risks as fully as possible. The early identification, evaluation, management and reporting of risks is the responsibility of the
respective divisions, service companies and central functions. The process takes into account not only
risks that could directly impact our financial targets, but also those that could affect the achievement of
qualitative objectives such as the preservation of our reputation. Evaluation is based on both financial
and nonfinancial criteria. Risk coordinators are appointed to evaluate, manage and monitor the identified risks.

217

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

This results in a multidimensional evaluation which estimates the probability of occurrence, potential
damage and relevance for our external stakeholders. The following matrix illustrates the financial criteria for rating a risk as high, medium or low.

Risk Rating Matrix According to Financial Criteria

[Table 3.18.4]
Likelihood of occurrence
Low

Medium

High

Accumulated impact (â‚¬ million)
> 1,250

H

H

H

500 â€“ 1,250

M

M

H

L

L

L

< 500
H = high risk, M = medium risk, L = low risk

All risks that exceed defined and annually updated value thresholds, together with the respective countermeasures, are entered in a Group-wide database. The risk portfolio is reviewed three times a year.
Significant changes are documented and reported to the Board of Management. The risk portfolio is also
documented in a management information system and is thus accessible to the members of the Group
Leadership Circle at all times. A report on the risk portfolio is submitted to the Audit Committee of the
Supervisory Board once a year.
PROCESS-INDEPENDENT MONITORING
The effectiveness of our management systems is audited and evaluated at regular intervals by Internal
Audit, which performs an independent and objective audit function focused on verifying compliance
with laws and directives. Internal Audit also supports the company in achieving its goals by systematically evaluating the efficiency and effectiveness of governance, risk management and control processes
and helping to improve them. The selection of audit targets follows a risk- and cycle-based approach.
Internal Audit applies internationally recognized standards and performs reliable audit services. This is
confirmed by a quality assessment undertaken in 2012 by the American Institute of Internal Auditors
(iia). A report on the internal control system and its effectiveness is presented annually to the Audit
Committee of the Supervisory Board.
Risks in the areas of occupational health and safety, plant safety, environmental protection and product
quality are assessed through specific hseq (health, safety, environment and quality) audits.
In addition, the external auditor, as part of its audit of the annual financial statements, assesses the
basic suitability of the early warning system for identifying at an early stage any risks that could endanger the companyâ€™s continued existence. The auditor regularly reports to the Board of Management and
the Supervisory Board on the identification of any weaknesses in the internal control system.
Audit outcomes are taken into account in the continuous enhancement of our management processes.

218

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

18.3.2 Opportunities and Risks
As a global enterprise with a diversified portfolio, the Bayer Group is constantly exposed to a wide
range of internal or external developments or events that could significantly impact the achievement of
our financial and nonfinancial objectives.
This chapter outlines the opportunities and risks which are classified in our risk matrix as â€œmediumâ€ or
â€œhigh.â€ Risks that occur in comparable forms in different parts of the company are described in general
terms. The sequence in which the risks are listed does not imply any order of significance. The opportunities and risks described apply to all divisions unless otherwise indicated. Also outlined in the following are risks that are of high relevance for the company but may be impossible to quantify directly,
accurately or in financial terms. The impact on the Bayer Group of risks attaching to the Covestro business is affected by the size of Bayerâ€™s shareholding in that company.
BUSINESS ENVIRONMENT
Ethical conduct is a matter of essential importance for society. Many stakeholders evaluate companies
according to whether they conduct themselves not just â€œlegallyâ€ but also â€œlegitimately.â€ The Bayer
Group is dedicated to sustainable development in all areas of its commercial activity. This voluntary
commitment is reflected in our responsible corporate governance, which is geared toward generating
not only economic but also ecological and societal benefit.
In the Emerging Markets â€“ particularly Asia and Latin America â€“ we see growth opportunities, such as
those arising out of increasing affluence and the associated rise in demand for pharmaceutical products.
Bayer is therefore systematically expanding its business in these regions in particular.
At the same time, however, the risk exists that our growth could be impeded by increasing global cost
pressure on health systems. Pharmaceutical products are subject to regulatory price controls and regulations in many markets, and government reimbursement systems often favor less expensive generic
medicines over branded products. In addition, in some markets, major health care providers can exert
substantial pressure on prices. Price controls and pricing pressure reduce earnings from our pharmaceutical products and may occasionally make the market launch of a new product unprofitable. As a
result, it may be necessary to choose indirect marketing options in order to provide access to pharmaceuticals. We expect the current extent of regulatory controls and market pressures on pricing to persist
or increase. Changes in the business conditions in our key markets are continuously monitored. Depending on the intensity of such price controls and the pressure on prices, it could be necessary to
adjust our business model.
In some countries the marketing rights for certain pharmaceutical products are held by third parties. An
inadequate performance by collaboration partners could adversely affect the development of our sales
and costs. Therefore, we have established an Alliance Management unit to monitor the most important
collaborations and provide relevant support to the operational functions.
Further opportunities and risks may arise if actual market developments vary from those we predict in
Chapter 18.1 â€œEconomic Outlook.â€ Where macroeconomic developments deviate from forecasts, this
may either positively or negatively impact our sales and earnings expectations.
For Covestro, an economic downturn, changes in competitorsâ€™ behavior or the market entry of new
competitors may lead to more intense competition and thus to overcapacities or increased pressure on
prices.

219

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Continuous analysis of the economic environment and of economic forecasts enables us to pursue the
identified opportunities and to mitigate risks by adjusting our business strategy.
INNOVATION
We analyze global trends and develop innovative solutions to address them, thereby mastering the
challenges and taking advantage of the opportunities they provide.
Increase in life expectancy
Certain diseases, such as cancer or chronic cardiovascular disorders, are on the rise as a consequence
of higher life expectancy. In response to the growing demand for innovative health care products to
treat age-related diseases, Bayerâ€™s Pharmaceuticals Division is focusing its r&d activities on relevant
therapeutic areas such as oncology and cardiology.
Shortage of arable land and increasing demand for food
The challenges associated with ensuring an adequate food supply worldwide continue to increase,
driven by global population growth, the reduction in available arable land and the consequences of
climate change. In addition, the anticipated increase in affluence in the emerging countries is boosting
the demand for animal-based food products. We expect there to be an increasing need for high-value
seed and crop protection products to allow sufficient food and animal feed to be produced to satisfy
rising demand despite limited acreages. The Crop Science Division is therefore developing processes to
more effectively protect plants against climate and environmental stresses and increase crop yields, for
example.
Conserving natural resources and protecting the climate
The finite nature of certain natural resources and efforts to protect the climate are boosting the demand
for innovative products and technologies that reduce resource consumption and lead to lower emissions. This trend is being reinforced by increasingly stringent regulatory requirements and growing
consumer awareness for the need to use resources sustainably. In this context, Covestro is developing
new materials that help to raise energy efficiency and reduce emissions. For example, polyurethane
from Covestro is used in the construction industry for thermal insulation, giving a positive energy balance, while the companyâ€™s polycarbonate is used in the automotive industry to reduce vehicle weight.
To enhance our innovation strength, we attach special importance to networking and cooperation both
within and outside of our company. One example is interdisciplinary research at the interface between
human, animal and plant health, which is being driven forward by our Life Sciences Fund. This enables
us to achieve research synergies and investigate new mechanisms of action that in the long term may
provide new impetus to product development. Our strategy also encompasses research projects with
outside partners from science and industry that give us access to complementary technologies and
external innovation potential.
For further information, see Chapter 4 â€œResearch, Development, Innovationâ€ and Chapter 2 â€œStrategies
of the Divisions.â€
Despite all our efforts, we cannot assure that all of the products we are currently developing or will
develop in the future will achieve planned approval / registration or commercial success. For example, a
drug candidate may fail to meet trial endpoints. The Bayer Group pursues a holistic portfolio management strategy in order to estimate the probability of success and prioritize its development projects.
Furthermore, the expectations of the public and the regulatory authorities with regard to the safety and
efficacy of chemical and pharmaceutical products are constantly rising. Against this background, we
continue to anticipate increasing regulatory requirements for clinical or (eco)toxicological studies, for
example. This increases product development costs and the time it takes to obtain registration or marketing approval. Special projects are set up to coordinate and ensure the successful implementation of
new regulations.

220

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

ACQUISITIONS
Where it appears strategically advantageous, we supplement our organic growth by acquiring companies or parts of companies. Failure to successfully integrate a newly acquired business or unexpectedly
high integration costs could jeopardize the achievement of qualitative or quantitative targets and adversely impact earnings. Teams of experts therefore manage both the due diligence process and the
subsequent integration of acquired companies. Due diligence includes reviewing risk-relevant factors
such as compliance with applicable environmental regulations and occupational health and safety
standards at production sites.
PATENT PROTECTION
Patents protect our intellectual property. When our products are successfully commercialized, some of
the profits can be used to continue investing in research and development. Due to the long period of
time between the patent application and the market launch of a product, Bayer generally only has a few
years in which to earn an adequate return on its investment in research and development. This makes
effective and reliable patent protection all the more important.
Most of our products, primarily in the Life Sciences, are covered by patents. Generic manufacturers, in
particular, attempt to contest patents prior to their expiration. Sometimes a generic version of a product
may even be launched â€œat riskâ€ prior to the issuance of a final patent decision. We are currently involved in legal proceedings to enforce patent protection for our products. Details of the risks arising
from these proceedings are given in note [32] to the consolidated financial statements. When a patent
defense is unsuccessful, or if one of our patents expires, our prices are likely to come under pressure
because of increased competition from generic products entering the market. Legal action by third
parties for alleged infringement of patent or proprietary rights by Bayer may impede or even halt the
development or manufacturing of certain products or require us to pay monetary damages or royalties
to third parties. Our patents department regularly reviews the patent situation in collaboration with the
respective operating units and monitors for potential patent infringements so that legal action can be
taken if necessary.
PRODUCTS AND PRODUCT STEWARDSHIP
Bayer systematically and continuously evaluates the potential health and environmental risks of a product along the entire value chain â€“ from research and development, production, commercialization and
use by the customer to disposal.
Despite extensive studies prior to approval or registration, it is possible that products could be partially
or completely withdrawn from the market due to the occurrence of unexpected side effects or other
factors. Such a withdrawal may be voluntary or result from legal or regulatory measures. Furthermore,
the presence of traces of unwanted genetically modified organisms in agricultural products and / or
foodstuffs cannot be entirely excluded. Potential payments of damages in connection with the above
risks may have a substantial negative impact on our earnings.
Our Life Science businesses counter these risks through a holistic organizational structure and process
organization in the areas of pharmaceutical and crop protection product safety and testing. In addition,
a comprehensive product stewardship program is in place in the Crop Science Division. For further
information, see Chapter 8 â€œProduct Stewardship.â€

221

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Another risk we face is that of illegal trading of counterfeit medicines and crop protection products by
criminal third parties. In most cases, the composition and / or the quality of counterfeit products do not
correspond to those of the original products. In addition, the fact that no local regulatory authority is
involved in assuring the quality of the manufacturing or distribution process precludes any official
product recall. Products originating from illegal third-party manufacturing not only endanger patients,
users, animals and the environment, but also jeopardize the good reputation of our company and products and undermine our competitive position.
Bayer actively assists authoritiesâ€™ efforts to combat product counterfeiting by adopting preventive
measures and prosecuting offenders.
PROCUREMENT AND PRODUCTION
To ensure the sustainability of our activities along the entire value chain, Bayer has introduced a
Supplier Code of Conduct. This sets forth our sustainability principles, explains what we expect from
our partners and requires them to observe our standards in areas including environmental protection
and occupational safety. A further essential element is the respect of human rights. This means, for
example, that no form of child labor may be employed. Violations of the Code may harm our companyâ€™s
reputation. Through supplier assessments and audits, we verify whether our partners along the supply
chain actually implement and comply with our Code of Conduct (see Chapter 7 â€œProcurement, Production, Logistics and Distributionâ€).
Despite its modern facilities and optimized manufacturing processes, Bayer requires significant quantities of energy and petrochemical feedstocks for the production of chemicals. Procurement prices for
energy and raw materials may fluctuate significantly. This can provide opportunities but may also put
our product margins at risk when oil prices are low, for example. Experience has shown that higher
production costs cannot always be passed on to our customers through price adjustments. This applies
especially to Covestro.
We attach great importance not only to product safety but also to protecting our employees and the
environment. Risks associated with the manufacturing, filling, storage or shipping of products are mitigated by means of integrated quality, health, environmental protection and safety management. The
materialization of such risks may result in personal injury, property and environmental damage, loss of
production, business interruptions and / or liability for compensation payments.
Operations at our sites may be disrupted by natural disasters, fires or explosions, sabotage or supply
shortages for our principal raw materials or intermediates. Disruption may also result from possible
regulatory or legislative changes in the respective countries. The complexity of multistage manufacturing processes for active ingredients or biotechnology products strengthens the potential for disruption
and may limit product availability. If we are unable to meet demand, sales may undergo a structural
decline. We counter this risk by distributing production for certain products among multiple sites or by
building up safety stocks. Furthermore, an emergency response system has been implemented for all
our production sites as a mandatory component of our hseq management. It is aimed at protecting
employees, neighbors, the environment and production facilities from the risks described. The Group
Regulation â€œSafety and Crisis Managementâ€ forms the basis for this.

222

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Increased ecological awareness creates opportunities for Covestro in two ways. On the one hand, the
development of innovative materials for our customers (see Chapter 4 â€œResearch, Development, Innovationâ€) opens up market potential. On the other hand, if we succeed in increasing the energy efficiency of
our own production processes, we can mitigate environmental impacts and achieve cost savings at the
same time. By developing new production technologies and applying internationally recognized energy
management systems, we aim to help meet increasing environmental requirements, further reduce
emissions and waste, and increase energy efficiency. In this way we not only contribute to sustainable
climate protection and the conservation of natural resources, but also achieve cost and competitive
advantages.
EMPLOYEES
Skilled and dedicated employees are essential for the companyâ€™s success. There is keen competition
among companies for highly qualified personnel, particularly in countries with full employment and in
the emerging economies of Asia and Latin America. If we are unable to recruit a sufficient number of
employees in these countries and retain them within Bayer, this could have significant adverse consequences for the companyâ€™s future development.
Based on our analysis of future requirements, we design appropriate employee recruitment and development measures. These include extensive employer marketing activities, such as our employer branding campaign, aimed at convincing our target groups of the advantages of working for Bayer. Competitive compensation containing performance-related components as well as an extensive range of training
and development opportunities are among the essential elements of our human resources policies,
which are based on the principles enshrined in our Human Rights Position, our corporate values and
our Corporate Compliance Policy. In addition, our focus on diversity enables us to tap the full potential
of the employment market. In times of considerable strategic and organizational transition at Bayer,
deliberate and transparent change management forms an integral part of our human resources management, enabling us to motivate our employees for the long term and alleviate uncertainties.
For more information, see Chapter 6 â€œEmployees.â€
INFORMATION TECHNOLOGY
Business and production processes and the internal and external communications of the Bayer Group
are increasingly dependent on global it systems.
A significant technical disruption or failure of it systems could severely impair our business and production processes. Technical precautions such as data recovery and continuity plans are defined and
continuously evolved in close cooperation with our internal it organization.
The confidentiality of internal and external data is of fundamental importance to us. A loss of data confidentiality, integrity or authenticity could lead to manipulation and / or the uncontrolled outflow of data
and know-how. We have measures in place to counter this risk, including an authorization system.
Furthermore, a committee has been established to determine the fundamental strategy, architecture and
safety measures for the Bayer Group. These measures are designed to provide optimum protection
based on state-of-the-art technology.

223

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

LAW AND COMPLIANCE
The Bayer Group is exposed to risks from legal disputes or proceedings to which we are currently a
party or which could arise in the future, particularly in the areas of product liability, competition and
antitrust law, patent law, tax law and environmental protection.
Investigations of possible legal or regulatory violations, such as potential infringements of antitrust law
or certain marketing and / or distribution methods, may result in the imposition of civil or criminal penalties â€“ including substantial monetary fines â€“ and / or other adverse financial consequences, harm
Bayerâ€™s reputation and ultimately hamper our commercial success.
Bayer has established a global compliance management system to ensure the sustainable observance of
laws and regulations (see Chapter 16.3 â€œComplianceâ€).
Legal proceedings currently considered to involve material risks are described in note [32] to the consolidated financial statements.
FINANCIAL OPPORTUNITIES AND RISKS
The Bayer Group has financial opportunities at its disposal in the form of the market prices it can command, and is exposed to financial risks in the form of liquidity, credit and market price risks, as well as
risks resulting from pension obligations.
The following paragraphs provide details of these and other financial opportunities and risks and how
they are managed.
The management of financial opportunities and risks takes place using established, documented processes. One component is financial planning, which serves as the basis for determining the liquidity risk
and the future foreign currency and interest-rate risks and covers all Group companies that are relevant
from a cash-flow perspective. Financial planning comprises a planning horizon of 12 months and is
regularly updated.
Further information is provided in Chapter 14.7 â€œFinancial Management of the Group.â€

See Chapter 14.7

Liquidity risk
Liquidity risks result from the possible inability of the Bayer Group to meet current or future payment
obligations due to a lack of cash or cash equivalents. The liquidity risk is determined and managed by
the Finance department as part of our same-day and medium-term liquidity planning.
Payment obligations from financial instruments are explained according to their maturity in note [30.2]
to the consolidated financial statements.
The Bayer Group holds sufficient liquidity to ensure the fulfillment of all planned payment obligations at
maturity. In addition, a reserve is maintained for unbudgeted shortfalls in cash receipts or unexpected
disbursements. The amount of this liquidity reserve is regularly reviewed and adjusted as necessary
according to circumstances.
Liquid assets are held mainly in the form of overnight and term deposits. Credit facilities also exist with
banks. These include, in particular, an undrawn â‚¬3.5 billion syndicated credit facility. Additionally, credit
facilities totaling â‚¬2.7 billion are available to the Covestro Group.

Consolidated
Financial
Statements
Note 30.2

224

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Credit risks
Credit risks arise from the possibility that the value of receivables or other financial assets of the Bayer
Group may be impaired because counterparties cannot meet their payment or other performance obligations. The Bayer Group does not conclude master netting arrangements with its customers for nonderivative financial instruments. Here, the total value of the financial assets represents the maximum
credit risk exposure. In the case of derivatives, positive and negative market values may be netted under
certain conditions.
To manage credit risks from trade receivables, the respective invoicing companies appoint credit managers who regularly analyze customersâ€™ creditworthiness. Some of these receivables are collateralized,
and the collateral is used according to local conditions. It includes credit insurance, advance payments,
letters of credit and guarantees. Reservation of title is generally agreed with our customers. Credit limits
are set for all customers. All credit limits for debtors where total exposure is â‚¬10 million or more are
evaluated by local credit management and submitted to the Bayer Groupâ€™s Financial Risk Committee.
Credit risks from financial transactions are managed centrally in the finance department. To minimize
risks, financial transactions are only conducted within predefined exposure limits and with banks and
other partners that preferably have investment-grade ratings. All risk limits are based on methodical
models. Adherence to the risk limits is continuously monitored.

Consolidated
Financial
Statements
Note 30.3

Opportunities and risks resulting from market price changes
Opportunities and risks resulting from changes in market currency and interest rates are managed by
the central finance department. Risks are eliminated or mitigated through the use of derivative financial
instruments. Further details on derivatives are given in note [30.3] to the consolidated financial statements.
The type and level of currency and interest-rate risks are explained in the following paragraphs using
sensitivity analyses based on hypothetical changes in risk variables (such as interest curves) to determine the potential effects of market price fluctuations on equity and earnings. The assumptions used in
the sensitivity analyses reflect our view of the changes in currency exchange and interest rates that are
reasonably possible over a one-year period. These assumptions are regularly reviewed.
Foreign currencies
Foreign currency opportunities and risks for the Bayer Group result from changes in exchange rates and
the related changes in the value of financial instruments (including receivables and payables) and of
anticipated payment receipts and disbursements in the functional currency.
Receivables and payables in liquid currencies from operating activities and financial items are generally
fully exchange-hedged through forward exchange contracts and cross-currency interest-rate swaps.
Anticipated exposure from planned payment receipts and disbursement in the future is hedged according to the rules agreed between the Board of Management, the finance department and the operating
units. Hedging takes place through forward exchange contracts and currency options.
Sensitivities were determined on the basis of a hypothetical adverse scenario in which the euro depreciates by 10% against all other currencies compared with the year-end exchange rates. In this scenario,
the estimated hypothetical loss of cash flows from derivative and nonderivative financial instruments
would have diminished earnings and equity (other comprehensive income) as of December 31, 2015 by
â‚¬303 million (December 31, 2014: â‚¬295 million). Of this amount, â‚¬108 million is related to the u.s. dollar, â‚¬66 million to the Chinese renminbi, â‚¬41 million to the Japanese yen and â‚¬28 million to the Canadian dollar. Currency effects on anticipated exposure are not taken into account.

225

Bayer Annual Report 2015
Combined Management Report
18. Future Perspectives

Derivatives used to hedge anticipated currency exposure that are designated for hedge accounting
would have diminished other comprehensive income by â‚¬313 million.
Interest rates
Interest-rate opportunities and risks result for the Bayer Group through changes in capital market interest rates, which in turn could lead to changes in the fair value of fixed-rate financial instruments and
changes in interest payments in the case of floating-rate instruments.
Interest-rate opportunities and risks are managed over a target duration established by management for
Bayer Group debt. This target duration is subject to regular review. Interest-rate swaps are concluded to
achieve the target structure for Bayer Group debt.
A sensitivity analysis based on our net floating-rate receivables and payables position at year end 2015,
taking into account the interest rates relevant for our receivables and payables in all principal currencies, produced the following result: a hypothetical increase of 1 percentage point in these interest rates
(assuming constant currency exchange rates) as of January 1, 2015 would have raised our interest expense for the year ended December 31, 2015 by â‚¬29 million (December 31, 2014: â‚¬53 million).
Financial risks associated with pension obligations
The Bayer Group has obligations to current and former employees related to pensions and other postemployment benefits. Changes in relevant measurement parameters such as interest rates, mortality
and salary increase rates may raise the present value of our pension obligations. This may lead to increased costs for pension plans or diminish equity due to actuarial losses being recognized as other
comprehensive income in the statement of comprehensive income. A large proportion of our pension
and other post-employment benefit obligations is covered by plan assets including fixed-income securities, shares, real estate and other investments. Declining or even negative returns on these investments
may adversely affect the future fair value of plan assets. Both these effects may negatively impact the
development of equity and / or the companyâ€™s earnings and / or may necessitate additional payments by
the company. Further details are given in note [25] to the consolidated financial statements.
We address the risk of market-related fluctuations in the fair value of our plan assets through balanced
strategic investment, and we constantly monitor investment risks in regard to our global pension obligations.
OVERALL ASSESSMENT OF OPPORTUNITIES AND RISKS
The risks reported above do not endanger the companyâ€™s continued existence. Nor could we identify
any risk interdependencies that could combine to endanger the companyâ€™s continued existence.
Risks rated as â€œmediumâ€ or â€œhighâ€ did not change significantly compared with the previous year.
Based on our product portfolio, our know-how and our innovation strength, we are convinced that we
can take advantage of the opportunities resulting from our entrepreneurial activity and successfully
master the challenges resulting from the risks stated above.

Consolidated
Financial
Statements
Note 25

226

Bayer Annual Report 2015
Combined Management Report
19. Takeover-Relevant Information

19. Takeover-Relevant Information
Explanatory report pursuant to Sections 289, Paragraph 4 and 315, Paragraph 4 of the
German Commercial Code (HGB)
The capital stock of Bayer AG amounted as of December 31, 2015 to â‚¬2,117 million, divided into
826,947,808 no-par registered shares. The capital stock and the number of shares were thus unchanged
from the end of the previous year. Each share confers one voting right.
A small number of shares may be subject to temporary trading restrictions, such as retention periods, in
connection with employee stock participation programs.
We received no notifications in 2015 of direct or indirect holdings of shares in Bayer AG that exceed
10% of the capital stock. The company thus is not in possession of any notifications of holdings that
exceed 10% of the capital stock.
www.bayer.com/
ownershipstructure

The appointment and dismissal of members of the Board of Management are subject to the provisions
of Sections 84 and 85 of the German Stock Corporation Act, Section 31 of the German Codetermination
Act and Section 6 of the companyâ€™s Articles of Incorporation. Pursuant to Section 84, Paragraph 1 of the
German Stock Corporation Act, the members of the Board of Management are appointed and dismissed
by the Supervisory Board. Since Bayer AG falls within the scope of the German Codetermination Act,
the appointment or dismissal of members of the Board of Management requires a majority of two thirds
of the votes of the members of the Supervisory Board on the first ballot pursuant to Section 31, Paragraph 2 of that act. If no such majority is achieved, the appointment is resolved pursuant to Section 31,
Paragraph 3 of the Codetermination Act on a second ballot by a simple majority of the votes of the
members of the Supervisory Board. If the required majority still is not achieved, a third ballot is held.
Here again, a simple majority of the votes of the members suffices, but in this ballot the Chairman of the
Supervisory Board has two votes pursuant to Section 31, Paragraph 4 of the Codetermination Act. Under Section 6, Paragraph 1 of the Articles of Incorporation of Bayer AG, the number of members of the
Board of Management is determined by the Supervisory Board but must be at least two. The Supervisory Board may appoint one member of the Board of Management to be the Chairman of the Board of
Management pursuant to Section 84, Paragraph 2 of the German Stock Corporation Act and Section 6,
Paragraph 1 of the Articles of Incorporation.
Any amendments to the Articles of Incorporation are made pursuant to Section 179 of the German Stock
Corporation Act and Sections 10 and 17 of the Articles of Incorporation. Under Section 179, Paragraph
1 of the German Stock Corporation Act, amendments to the Articles of Incorporation require a resolution of the Stockholdersâ€™ Meeting. Pursuant to Section 179, Paragraph 2 of the German Stock Corporation Act, this resolution must be passed by a majority of three quarters of the voting capital represented
at the meeting, unless the Articles of Incorporation provide for a different majority. However, where an
amendment relates to a change in the object of the company, the Articles of Incorporation may only
specify a larger majority. Section 17, Paragraph 2 of the Articles of Incorporation of Bayer AG utilizes
the scope for deviation pursuant to Section 179, Paragraph 2 of the German Stock Corporation Act and
provides that resolutions may be passed by a simple majority of the votes cast or, where a capital majority is required, by a simple majority of the capital represented. Pursuant to Section 10, Paragraph 6 of
the Articles of Incorporation, the Supervisory Board may resolve on amendments to the Articles of Incorporation that relate solely to their wording.
Provisions of the Articles of Incorporation concerning Authorized Capital i and Authorized Capital ii are
entered in the commercial register of Bayer AG. With the approval of the Supervisory Board and until
April 28, 2019, the Board of Management may use the Authorized Capital i to increase the capital stock
by up to a total of â‚¬530 million. New shares may be issued against cash contributions and / or contributions in kind, but capital increases against contributions in kind may not exceed a total of â‚¬423 million.
If the Authorized Capital i is used to issue shares in return for cash contributions, stockholders must
normally be granted subscription rights. The Board of Management may only exclude stockholdersâ€™
subscription rights to a volume of shares issued out of the Authorized Capital i that did not represent
more than 20% of the existing capital stock at the time the respective resolution was adopted by the
Annual Stockholdersâ€™ Meeting on April 29, 2014. Absent a further resolution on the exclusion of stock-

227

Bayer Annual Report 2015
Combined Management Report
19. Takeover-Relevant Information

holdersâ€™ subscription rights, the Board of Management also may only exclude stockholdersâ€™ subscription rights to a volume of shares issued under other authorizations regarding capital measures (Authorized Capital ii, bonds with warrants or convertible bonds, purchase and disposal of own shares) that did
not represent more than 20% of the existing capital stock at the time the respective resolution was
adopted by the Annual Stockholdersâ€™ Meeting on April 29, 2014.
With the approval of the Supervisory Board and until April 28, 2019, the Board of Management is authorized to increase the capital stock by up to â‚¬212 million in one or more installments by issuing
shares out of the Authorized Capital ii against cash contributions. The stockholders must normally be
granted subscription rights. However, the Board of Management is authorized, with the approval of the
Supervisory Board, to exclude subscription rights for stockholders provided the volume of shares issued
out of the Authorized Capital ii against cash contributions does not exceed 10% of the capital stock
existing at the time this authorization is registered or at the time the new shares are issued and the
issue price of the new shares is not significantly below the market price of the already listed shares.
Conditional capital of â‚¬212 million exists in connection with an authorization â€“ valid through April 28,
2019 â€“ to issue bonds with warrants or convertible bonds, profit-sharing rights or profit participation
bonds (collectively referred to as â€œbondsâ€) with a total face value of â‚¬6 billion. The Board of Management may, with the consent of the Supervisory Board and under certain conditions, exclude the bond
subscription rights that would otherwise be granted to stockholders. One of the conditions is that the
total volume of shares required to service the bonds exceed neither 10% of the capital stock that existed at the time the respective resolution was adopted by the Annual Stockholdersâ€™ Meeting on April 29,
2014 nor 10% of the capital stock existing at the time this authorization is exercised. Any other shares
issued without granting subscription rights to the stockholders in direct or analogous application of
Section 186, Paragraph 3, Sentence 4 of the German Stock Corporation Act shall be credited against this
10% limit. Further, by resolution of the Annual Stockholdersâ€™ Meeting on April 29, 2014, the Board of
Management is authorized to purchase and dispose of own shares representing up to 10% of the capital
stock existing at the time the resolution was adopted. The authorization to purchase own shares also
includes the purchase of own shares using put or call options (derivatives) up to a volume of 5% of the
capital stock existing at the time the resolution was adopted or at the time the authorization is exercised. This authorization also expires on April 28, 2019.
A material agreement that is subject to the condition precedent of a change of control pertains to the
undrawn â‚¬3.5 billion syndicated credit facility arranged by Bayer AG and its u.s. subsidiary Bayer Corporation. This facility is available until December 2020. The participating banks are entitled to terminate
the credit facility in the event of a change of control at Bayer and demand repayment of any loans that
may have been granted under this facility up to that time. A similar clause is contained in the agreement
on a syndicated credit facility granted to Bayer subsidiary Bayer World Investments b.v., Netherlands, in
2014 and guaranteed by Bayer AG. The facility still amounts to us$900 million (as of December 31, 2015)
and matures in May 2018.
The terms of the nominal â‚¬4.2 billion (as of December 31, 2015) in notes issued by Bayer in the years
2006 to 2014 under its multi-currency European Medium Term Notes program also contain a change-ofcontrol clause. Holders of these notes have the right to demand the redemption of their notes by Bayer
AG in the event of a change of control if Bayer AGâ€™s credit rating is downgraded within 120 days after
such change of control becomes effective. The terms of the us$7 billion bond in 144a / Reg S format
issued in October 2014 also contain a clause to this effect.
Agreements exist for the members of the Board of Management in compliance with Section 4.2.3 of the
German Corporate Governance Code to cover the eventuality of a takeover offer being made for
Bayer AG. Under these agreements, payments promised in the event of early termination of the service
contract of a Board of Management member due to a change of control are limited to the value of three
yearsâ€™ compensation and may not compensate more than the remaining term of the contract.

228

Annual Report 2015
Consolidated Financial Statements

02
Consolidated Financial Statements

Bayer Group Consolidated Income
Statements

230

Bayer Group Consolidated Statements
of Comprehensive Income

231

Bayer Group Consolidated Statements
of Financial Position

232

Notes to the Income Statements

Bayer Group Consolidated Statements
of Cash Flows

233

Bayer Group Consolidated Statements
of Changes in Equity

234

Notes to the Consolidated Financial
Statements of the Bayer Group

236

1.
2.
3.
4.
5.
6.
6.1
6.2
6.3

Key data by segment and region
General information
Effects of new financial reporting standards
Basic principles, methods and critical
accounting estimates
Segment reporting
Scope of consolidation; subsidiaries
and affiliates
Changes in the scope of consolidation
Business combinations and other acquisitions
Divestitures, material sale transactions and
discontinued operation

236
238
238
241
256
260
260
263
268

7.
8.
9.
10.
11.
12.
13.
13.1
13.2
13.3
14.
15.
16.

Net sales
Selling expenses
Research and development expenses
Other operating income
Other operating expenses
Personnel expenses and employee numbers
Financial result
Income (loss) from investments in affiliated
companies
Net interest expense
Other financial income and expenses
Taxes
Income / losses attributable to noncontrolling
interest
Earnings per share

271
271
271
272
273
274
274
275
275
276
276
280
280

Notes to the Statements of Financial Position
17.
18.
19.
20.
21.
22.
23.
24.
25.

Goodwill and other intangible assets
Property, plant and equipment
Investments accounted for using
the equity method
Other financial assets
Inventories
Trade accounts receivable
Other receivables
Equity
Provisions for pensions and other
post-employment benefits

281
286
288
289
290
291
292
293
297

229

Annual Report 2015
Consolidated Financial Statements

26.
26.1
26.2
26.3
26.4
26.5
26.6
26.7
27.
28.
29.
30.
30.1
30.2
30.3
31.
32.

Other provisions
Other taxes
Environmental protection
Restructuring
Trade-related commitments
Litigations
Personnel commitments
Miscellaneous provisions
Financial liabilities
Trade accounts payable
Other liabilities
Financial instruments
Financial instruments by category
Maturity analysis
Information on derivatives
Contingent liabilities and other financial
commitments
Legal risks

307
308
308
308
308
308
309
311
311
314
315
315
315
321
324

Notes to the Statements of Cash Flows

326
327

39.

33.
34.
35.

Net cash provided by (used in)
operating activities
Net cash provided by (used in)
investing activities
Net cash provided by (used in)
financing activities

332
332
332

Other Information
36.
37.
38.

Audit fees
Related parties
Total compensation of the Board of
Management and the Supervisory Board,
advances and loans
Events after the end of the reporting period

333
333

335
336

230

Bayer Annual Report 2015
Consolidated Financial Statements
Bayer Group Consolidated Income Statements

Bayer Group Consolidated Income Statements
[Table 4.1]
Note

Net sales

[7]

Cost of goods sold
Gross profit

2014

2015

â‚¬ million

â‚¬ million

41,339

46,324

(19,909)

(21,158)

21,430

25,166

Selling expenses

[8]

(10,669)

(12,367)

Research and development expenses

[9]

(3,537)

(4,281)

(1,703)

(2,098)

General administration expenses
Other operating income

[10]

710

1,110

Other operating expenses

[11]

(836)

(1,280)

5,395

6,250

EBIT1
Equity-method loss

[13.1]

Financial income
Financial expenses
Financial result

[13]

Income before income taxes
Income taxes

[14]

Income from continuing operations after income taxes
Income from discontinued operations after income taxes

[6.3]

Income after income taxes
of which attributable to noncontrolling interest

[15]

(13)

(9)

343

371

(1,311)

(1,367)

(981)

(1,005)

4,414

5,245

(1,071)

(1,227)

3,343

4,018

100

80

3,443

4,098

17

(12)

3,426

4,110

â‚¬

â‚¬

Basic

4.02

4.87

Diluted

4.02

4.87

Basic

0.12

0.10

Diluted

0.12

0.10

Basic

4.14

4.97

Diluted

4.14

4.97

of which attributable to Bayer AG stockholders (net income)

Earnings per share

[16]

From continuing operations

[16]

From discontinued operations

From continuing and discontinued operations

2014 figures restated
1 EBIT: earnings before financial result and taxes

[16]

[16]

231

Bayer Annual Report 2015
Consolidated Financial Statements
Bayer Group Consolidated Statements of Comprehensive Income

Bayer Group Consolidated Statements
of Comprehensive Income
[Table 4.2]
Note

Income after income taxes
of which attributable to noncontrolling interest

[15]

of which attributable to Bayer AG stockholders

2015
â‚¬ million

3,443

4,098

17

(12)

3,426

4,110

Remeasurements of the net defined benefit liability
for post-employment benefit plans

[25]

(5,159)

1,216

Income taxes

[14]

1,621

(430)

(3,538)

786

(3,538)

786

(146)

(266)

(46)

304

57

(25)

(135)

13

â€“

(5)

Other comprehensive income from remeasurements of the
net defined benefit liability for post-employment benefit plans
Other comprehensive income that will not be reclassified subsequently
to profit or loss
Changes in fair values of derivatives designated as cash flow hedges

[30.3]

Reclassified to profit or loss
Income taxes

[14]

Other comprehensive income from cash flow hedges
Changes in fair values of available-for-sale financial assets

[20]

Reclassified to profit or loss
Income taxes
Other comprehensive income from available-for-sale financial assets
Changes in exchange differences recognized on translation
of operations outside the eurozone
Changes in exchange differences recognized on translation of operations
outside the eurozone, relating to associates accounted for using the equity method
Reclassified to profit or loss
Other comprehensive income from exchange differences
Other comprehensive income that may be reclassified subsequently to profit or loss
Effects of changes in scope of consolidation
Total other comprehensive income 1

[14]

â€“

1

(2)

(2)

(2)

(6)

1,424

748

(40)

(20)

â€“

â€“

1,384

728

1,247

735

â€“

â€“

(2,291)

1,521

of which attributable to noncontrolling interest

11

33

of which attributable to Bayer AG stockholders

(2,302)

1,488

1,152

5,619

Total comprehensive income

1

2014
â‚¬ million

of which attributable to noncontrolling interest

28

21

of which attributable to Bayer AG stockholders

1,124

5,598

total changes recognized outside profit or loss

232

Bayer Annual Report 2015
Consolidated Financial Statements
Bayer Group Consolidated Statements of Financial Position

Bayer Group Consolidated Statements
of Financial Position
[Table 4.3]
Note

Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

Noncurrent assets
Goodwill

[17]

15,347

16,096

Other intangible assets

[17]

15,653

15,178

Property, plant and equipment

[18]

11,428

12,375

Investments accounted for using the equity method

[19]

223

246

Other financial assets

[20]

1,107

1,092

Other receivables

[23]

447

430

Deferred taxes

[14]

3,802

4,679

48,007

50,096

Current assets
Inventories

[21]

8,478

8,550

Trade accounts receivable

[22]

9,097

9,933

Other financial assets

[20]

723

756

Other receivables

[23]

1,488

2,017

Claims for income tax refunds
Cash and cash equivalents
Assets held for sale and discontinued operations

[6.3]

588

509

1,853

1,859

â€“

197

22,227

23,821

70,234

73,917

Capital stock of Bayer AG

2,117

2,117

Capital reserves of Bayer AG

6,167

6,167

Other reserves

11,822

15,981

Equity attributable to Bayer AG stockholders

20,106

24,265

Total assets
Equity

[24]

Equity attributable to noncontrolling interest

112

1,180

20,218

25,445

10,873

Noncurrent liabilities
Provisions for pensions and other post-employment benefits

[25]

12,236

Other provisions

[26]

1,593

1,740

Financial liabilities

[27]

18,484

16,513

423

475

Other liabilities

[29]

1,088

1,065

Deferred taxes

[14]

Income tax liabilities

689

826

34,513

31,492

Current liabilities
Other provisions

[26]

4,530

5,045

Financial liabilities

[27]

3,376

3,421

Trade accounts payable

[28]

5,363

5,945

Income tax liabilities
Other liabilities

[29]

Liabilities directly related to assets held for sale and discontinued operations

[6.3]

Total equity and liabilities
2014 figures restated

445

923

1,789

1,534

â€“

112

15,503

16,980

70,234

73,917

233

Bayer Annual Report 2015
Consolidated Financial Statements
Bayer Group Consolidated Statements of Cash Flows

Bayer Group Consolidated Statements
of Cash Flows
[Table 4.4]
Note

2014

2015

â‚¬ million

â‚¬ million

Income after income taxes

3,343

4,018

Income taxes

1,071

1,227

Financial result
Income taxes paid or accrued
Depreciation, amortization and impairments
Change in pension provisions
(Gains) losses on retirements of noncurrent assets
Gross cash flow
Decrease (increase) in inventories

981

1,005

(1,304)

(2,258)

2,920

3,333

(334)

(221)

30

(105)

6,707

6,999

(748)

(187)

(1,072)

(1,061)

(Decrease) increase in trade accounts payable

485

402

Changes in other working capital, other noncash items

325

694

5,697

6,847

Decrease (increase) in trade accounts receivable

Net cash provided by (used in) operating activities (net cash flow)
from continuing operations
Net cash provided by (used in) operating activities (net cash flow)
from discontinued operations
Net cash provided by (used in) operating activities (net cash flow)

[33]

Cash outflows for additions to property, plant, equipment and intangible assets

113

43

5,810

6,890

(2,371)

(2,517)

Cash inflows from sales of property, plant, equipment and other assets

143

193

Cash inflows from divestitures

304

2

Cash inflows from (outflows for) noncurrent financial assets

(10)

(26)

(13,545)

(176)

Cash outflows for acquisitions less acquired cash
Interest and dividends received
Cash inflows from (outflows for) current financial assets
Net cash provided by (used in) investing activities

[34]

Proceeds from shares of Covestro AG
Dividend payments
Issuances of debt

107

106

(167)

(344)

(15,539)

(2,762)

â€“

1,490

(1,739)

(1,869)

27,584

16,620

(15,746)

(19,549)

Interest paid including interest-rate swaps

(541)

(812)

Interest received from interest-rate swaps

179

160

Retirements of debt

Cash outflows for the purchase of additional interests in subsidiaries
Net cash provided by (used in) financing activities
Change in cash and cash equivalents due to business activities
Cash and cash equivalents at beginning of year
Change in cash and cash equivalents due to changes in scope of consolidation
Change in cash and cash equivalents due to exchange rate movements
Cash and cash equivalents at end of year
2014 figures restated

[35]

(1)

(14)

9,736

(3,974)

7

154

1,662

1,853

â€“

5

184

(153)

1,853

1,859

234

Bayer Annual Report 2015

235

Bayer Annual Report 2015
Consolidated Financial Statements

Consolidated Financial Statements

Bayer Group Consolidated Statements of Changes in Equity

Bayer Group Consolidated Statements of Changes in Equity

Bayer Group Consolidated Statements
of Changes in Equity
[Table 4.5]
Accumulated total comprehensive income

Dec. 31, 2013

Capital stock
of Bayer AG

Capital reserves
of Bayer AG

Retained
earnings
including
net income

â‚¬ million

â‚¬ million

â‚¬ million

2,117

6,167

14,817

Revaluation
surplus

Equity
attributable
to Bayer AG
stockholders

Equity
attributable
to noncontrolling
interest

Equity

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

99

31

20,718

86

20,804

(1,737)

(2)

(1,739)

(2,302)

11

(2,291)

3,426

17

3,443

20,106

112

20,218

(1,861)

(8)

(1,869)

422

1,055

1,477

1,488

33

1,521

4,110

(12)

4,098

24,265

1,180

25,445

Exchange
differences

Fair-value
measurement
of securities

Cash flow
hedges

â‚¬ million

â‚¬ million

32

(2,545)

Equity transactions with owners
Capital increase / decrease
Dividend payments

(1,737)

Other changes
Other comprehensive income

(3,538)

Income after income taxes
Dec. 31, 2014

(5)

6
1,373

(2)

(135)

3,426
2,117

6,167

12,974

(1,172)

30

(36)

26

1

1

Equity transactions with owners
Capital increase / decrease
Dividend payments

(1,861)

Other changes
Other comprehensive income
Income after income taxes
Dec. 31, 2015

582

(155)

776

705

(5)
(6)

13

4,110
2,117

6,167

16,581

(622)

24

(23)

21

236

Bayer Annual Report 2015

237

Bayer Annual Report 2015
Consolidated Financial Statements

Consolidated Financial Statements

Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Consolidated Financial Statements
of the Bayer Group
1. Key data by segment and region
Key Data by Segment

[Table 4.6]
HealthCare
Pharmaceuticals

Net sales (external)
Change
Currency-adjusted change
Intersegment sales
Net sales (total)
Other operating income

CropScience

Consumer Health

CropScience

Covestro

Reconciliation

Covestro

Corporate Center and
Consolidation

All Other Segments

Group

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

12,052

13,745

7,023

9,129

9,494

10,367

11,651

11,982

1,112

1,097

7

4

41,339

46,324

+7.7%

+14.0%

+4.4%

+30.0%

+7.7%

+9.2%

+3.7%

+2.8%

â€“4.9%

â€“1.3%

â€“

â€“42.9%

+5.6%

+12.1%

+11.6%

+9.9%

+8.3%

+25.0%

+11.4%

+2.3%

+4.5%

â€“5.1%

â€“4.4%

â€“0.8%

â€“

â€“42.9%

+8.5%

+6.2%

99

38

8

5

49

34

59

64

2,243

2,249

(2,458)

(2,390)

â€“

â€“

12,151

13,783

7,031

9,134

9,543

10,401

11,710

12,046

3,355

3,346

(2,451)

(2,386)

41,339

46,324

184

137

150

129

208

644

81

67

16

69

71

64

710

1,110

EBIT

2,371

2,807

1,099

1,243

1,806

2,103

555

635

(11)

(39)

(425)

(499)

5,395

6,250

EBIT before special items

2,657

3,061

1,144

1,589

1,838

1,881

598

967

21

43

(425)

(472)

5,833

7,069

EBITDA before special items

3,699

4,195

1,658

2,224

2,360

2,416

1,187

1,659

200

238

(419)

(466)

8,685

10,266

Gross cash flow

2,745

2,737

1,153

1,384

1,835

1,941

961

1,113

331

147

(318)

(323)

6,707

6,999

Capital invested

17,288

17,661

19,718

21,172

11,772

11,854

11,019

11,293

1,197

757

(117)

(217)

60,877

62,520

CFROI

15.3%

14.1%

9.8%

5.9%

15.3%

14.8%

6.0%

7.0%

â€“

â€“

â€“

â€“

11.7%

9.6%

3,266

2,863

1,065

1,458

950

761

880

1,452

360

26

(824)

287

5,697

6,847

Equity-method income (loss)

1

1

â€“

â€“

â€“

(1)

(14)

(9)

â€“

â€“

â€“

â€“

(13)

(9)

Equity-method investments

2

3

6

11

â€“

4

215

227

â€“

â€“

â€“

1

223

246

19,377

19,477

19,387

20,263

12,676

14,230

9,347

9,360

2,253

2,324

7,194

8,263

70,234

73,917

668

701

202

288

699

737

647

514

261

311

7

5

2,484

2,556

Additions to noncurrent assets from acquisitions

2,645

(122)

10,153

126

166

98

â€“

27

â€“

â€“

821

â€“

13,785

129

Depreciation, amortization and impairments

1,075

1,180

514

684

552

535

594

733

179

195

6

6

2,920

3,333

39

48

69

73

100

35

11

69

6

4

â€“

â€“

225

229

â€“

â€“

â€“

(1)

â€“

â€“

(2)

â€“

â€“

â€“

â€“

â€“

(2)

(1)

7,075

7,487

3,079

3,172

5,214

5,344

3,520

3,740

4,682

4,814

26,446

23,915

50,016

48,472

Net cash flow

Assets
Capital expenditures

of which impairment losses
of which impairment loss reversals
Liabilities
Research and development expenses

1,878

2,333

386

501

974

1,089

210

262

29

32

60

64

3,537

4,281

Number of employees (as of Dec. 31)

39,069

38,927

20,130

18,894

23,060

23,496

14,122

15,770

20,256

19,015

734

709

117,371

116,811

2014 figures restated

Key Data by Region

[Table 4.7]

Europe

Net sales (external) â€“ by market
Change

North America

Asia / Pacific

Latin America /
Africa / Middle East

Reconciliation

Total

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

15,312

15,949

9,953

12,740

9,067

10,264

7,007

7,371

â€“

â€“

41,339

46,324

+5.2%

+4.2%

+7.0%

+28.0%

+5.7%

+13.2%

+4.4%

+5.2%

â€“

â€“

+5.6%

+12.1%
+6.2%

+6.3%

+5.2%

+8.4%

+10.8%

+8.7%

+1.4%

+12.9%

+8.1%

â€“

â€“

+8.5%

16,999

17,704

9,787

12,450

8,820

10,023

5,733

6,147

â€“

â€“

41,339

46,324

Change

+5.6%

+4.1%

+6.6%

+27.2%

+5.1%

+13.6%

+4.5%

+7.2%

â€“

â€“

+5.6%

+12.1%

Currency-adjusted change

+6.7%

+5.1%

+8.0%

+9.4%

+8.2%

+1.5%

+14.8%

+11.3%

â€“

â€“

+8.5%

+6.2%

9,096

10,865

3,294

3,995

719

828

545

695

(13,654)

(16,383)

â€“

â€“

324

572

146

109

70

107

170

322

â€“

â€“

710

1,110

Currency-adjusted change
Net sales (external) â€“ by point of origin

Interregional sales
Other operating income

3,481

4,019

808

1,490

594

546

937

694

(425)

(499)

5,395

6,250

29,378

33,420

23,035

20,522

8,540

9,492

5,479

5,804

3,802

4,679

70,234

73,917

Capital expenditures

1,286

1,424

639

588

403

402

156

142

â€“

â€“

2,484

2,556

Depreciation, amortization and impairments

1,795

1,860

655

834

381

496

83

137

6

6

2,920

3,333

32,120

28,914

12,298

13,461

3,436

3,583

1,473

1,688

689

826

50,016

48,472

EBIT
Assets

Liabilities
Research and development expenses

2,412

2,947

866

1,051

198

214

61

69

â€“

â€“

3,537

4,281

Number of employees (as of Dec. 31)

54,595

55,892

15,819

15,985

30,132

28,818

16,825

16,116

â€“

â€“

117,371

116,811

2014 figures restated

238

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

2. General information
The consolidated financial statements of the Bayer Group as of December 31, 2015, were prepared by BayerAktiengesellschaft (Bayer AG) according to the International Financial Reporting Standards (ifrs) issued by the
International Accounting Standards Board (iasb), London, and the interpretations of the ifrs Interpretations Committee (ifrs ic), both as endorsed by the European Union and in effect at the end of the reporting period. The applicable further requirements of Section 315a of the German Commercial Code were also taken into account.
Bayer AG is a global enterprise based in Germany. Its registered office is at Kaiser-Wilhelm-Allee 1, 51368
Leverkusen. Its material business activities in the fields of health care, agriculture and high-tech polymer materials
took place in the reporting period in the HealthCare, CropScience and Covestro subgroups. The activities of the
various segments are outlined in note [5].
A declaration concerning the German Corporate Governance Code has been issued pursuant to Section 161 of the
German Stock Corporation Act and made available to stockholders.
The Board of Management of Bayer AG prepared the consolidated financial statements of the Bayer Group on
February 16, 2016. They were discussed by the Audit Committee of the Supervisory Board of Bayer AG at its meeting on February 23, 2016, and approved by the Supervisory Board at its plenary meeting on February 24, 2016.
In the income statement and statement of comprehensive income, statement of financial position, statement of cash
flows and statement of changes in equity, certain items are combined for the sake of clarity. These are explained in
the Notes. The income statement is prepared using the cost-of-sales method. Assets and liabilities are classified by
maturity. They are regarded as current if they mature within one year or within the normal business cycle of the
company or the Group, or are held for sale. The normal business cycle is defined for this purpose as beginning
with the procurement of the resources necessary for the production process and ending with the receipt of cash or
cash equivalents as consideration for the sale of the goods or services produced in that process. Inventories and
trade accounts receivable and payable are always presented as current items. Deferred tax assets and liabilities and
pension provisions are always presented as noncurrent items.
The consolidated financial statements of the Bayer Group are drawn up in euros. Amounts are stated in millions of
euros (â‚¬ million) except where otherwise indicated.
The financial statements of the individual consolidated companies are prepared as of the closing date of the Group
financial statements.

3. Effects of new financial reporting standards
FINANCIAL REPORTING STANDARDS APPLIED FOR THE FIRST TIME IN 2015
In December 2013, the iasb published the fifth and sixth sets of â€œAnnual Improvements to ifrss.â€ The amendments
address details of the recognition, measurement and disclosure of business transactions and serve to standardize
terminology. They consist mainly of editorial changes to existing standards. The first-time application of these
amendments had no material impact on the presentation of Bayerâ€™s financial position or results of operations, or on
earnings per share.
PUBLISHED FINANCIAL REPORTING STANDARDS THAT HAVE NOT YET BEEN APPLIED
The iasb and the ifrs Interpretations Committee have issued the following standards, amendments to standards,
and interpretations whose application was not yet mandatory for the 2015 fiscal year and is conditional upon their
endorsement by the European Union.

239

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In November 2009, the iasb issued ifrs 9 (Financial Instruments), containing rules for the classification and measurement of financial assets. In October 2010, it issued new requirements for the classification and measurement of
financial liabilities, incorporating them into ifrs 9. The new standard defines two instead of four measurement
categories for financial assets, with classification to be based partly on the companyâ€™s business model and partly on
the characteristics of the contractual cash flows from the respective financial asset. In the case of equity investments that are not held for trading, an entity may irrevocably opt at initial recognition to recognize future changes
in their fair value outside profit or loss in the statement of comprehensive income. In November 2013, the iasb
issued further amendments under the title â€œHedge Accounting and amendments to ifrs 9, ifrs 7 and ias 39.â€ The
focus of the amendments is on a thorough revision of hedge accounting rules with the aim of more appropriately
reflecting risk management activities in the financial statements. This involves additional disclosures in the notes.
In July 2014, the iasb published the new rules for the disclosure of financial instrument impairments. This new
impairment model is based on the principle of accounting for expected losses. It also introduces a third measurement category â€œfair value through other comprehensive incomeâ€ for certain debt instruments. ifrs 9 is to be applied for annual periods beginning on or after January 1, 2018. The standard has not yet been endorsed by the
European Union. Bayer is currently evaluating the impact the standard will have on the presentation of the Groupâ€™s
financial position and results of operations.
In January 2014, the iasb issued ifrs 14 (Regulatory Deferral Accounts). This standard addresses the accounting
for regulatory deferral account balances by first-time adopters of the ifrs and therefore does not apply to entities
that already prepare their financial statements according to the ifrs. ifrs 14 is to be applied for annual periods
beginning on or after January 1, 2016. The standard has not yet been endorsed by the European Union. ifrs 14 will
have no impact on the presentation of Bayerâ€™s financial position or results of operations.
In May 2014, the iasb published amendments to ias 16 (Property, Plant and Equipment) and ias 38 (Intangible
Assets) entitled "Clarification of Acceptable Methods of Depreciation and Amortisation." These amendments clarify
that revenue-based depreciation of property, plant and equipment or amortization of intangible assets is inappropriate. The amendments are to be applied for annual periods beginning on or after January 1, 2016. They will have
no impact on the presentation of Bayerâ€™s financial position or results of operations.
In May 2014, the iasb published amendments to ifrs 11 (Joint Arrangements) entitled "Accounting for Acquisitions
of Interests in Joint Operations." The amendments clarify the accounting for the acquisition of an interest in a joint
operation in which the activity constitutes a business. They are to be applied for annual periods beginning on or
after January 1, 2016. The possible impact on the future presentation of Bayerâ€™s financial position and results of
operations depends on future acquisitions of interests in joint operations. These cannot be reliably predicted.
In May 2014, the iasb issued ifrs 15 (Revenue from Contracts with Customers). ifrs 15 is the new standard for
revenue recognition. It clarifies that the expected consideration for goods or services must be recognized as revenue when the goods or intangible assets are transferred or the services are rendered to the customer. This principle is applied in five steps. In step 1, the contract with the customer is identified. In step 2, the distinct performance obligations in the contract are identified. In step 3, the transaction price is determined. In step 4, this transaction price is allocated to the distinct performance obligations. Finally, in step 5, revenue is recognized when the
identified distinct performance obligations are satisfied, either over time or at a point in time. ifrs 15 replaces
ias 11 (Construction Contracts), ias 18 (Revenue), ifric 13 (Customer Loyalty Programmes), ifric 15 (Agreements
for the Construction of Real Estate), ifric 18 (Transfers of Assets from Customers) and sic-31 (Revenue-Barter
Transactions Involving Advertising Services). An amendment to ifrs 15 was issued in September 2015, deferring
the date of first-time application from January 1, 2017 to January 1, 2018. The new standard is thus to be applied
for annual periods beginning on or after January 1, 2018. The standard has not yet been endorsed by the European
Union. Bayer is currently evaluating the impact the changes will have on the presentation of its financial position
and results of operations.

240

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In June 2014, the iasb issued amendments to ias 16 (Property, Plant and Equipment) and ias 41 (Agriculture) entitled "Agriculture: Bearer Plants." The amendments clarify that plants used solely to grow agricultural produce are
to be accounted for according to ias 16 (Property, Plant and Equipment). The amendments are to be applied for
annual periods beginning on or after January 1, 2016. The changes are not expected to have a material impact on
the presentation of Bayerâ€™s financial position or results of operations.
In September 2014, the iasb published the seventh set of â€œAnnual Improvements to ifrss.â€ The amendments address details of the recognition, measurement and disclosure of business transactions and serve to standardize
terminology. They consist mainly of editorial changes to existing standards. They are applicable for annual periods
beginning on or after July 1, 2016. The changes are not expected to have a material impact on the presentation of
Bayerâ€™s financial position or results of operations.
In September 2014, the iasb published amendments to ifrs 10 (Consolidated Financial Statements) and ias 28
(Investments in Associates and Joint Ventures) entitled "Sale or Contribution of Assets between an Investor and its
Associate or Joint Venture." The amendments clarify that in a transaction involving an associate or joint venture the
extent of gain or loss recognition depends on whether the assets sold or contributed constitute a business. An
amendment issued in December 2015 indefinitely defers the effective date of the September 2014 amendments,
which were originally intended to be applied for annual periods beginning on or after January 1, 2016. The iasb is
to set a new effective date.
In December 2014, further amendments were issued to ifrs 10 (Consolidated Financial Statements), ifrs 12 (Disclosure of Interests in Other Entities) and ias 28 (Investments in Associates and Joint Ventures) entitled "Investment Entities: Applying the Consolidation Exception." The amendments largely clarify which subsidiaries an investment entity must consolidate and which must be recognized at fair value through profit or loss. The amendments are to be applied for annual periods beginning on or after January 1, 2016. The amendments have not yet
been endorsed by the European Union. The changes are not expected to have a material impact on the presentation of Bayerâ€™s financial position or results of operations.
In December 2014, the iasb published amendments to ias 1 (Presentation of Financial Statements) under its Disclosure Initiative. The amendments are intended to clarify the disclosure requirements and relate to materiality,
line-item aggregation, subtotals, the structure of the notes to the financial statements, the identification of significant accounting policies and the separate disclosure of the other comprehensive income of associates and joint
ventures. The amendments are to be applied for annual periods beginning on or after January 1, 2016. The changes are not expected to have a material impact on the presentation of Bayerâ€™s financial position or results of operations.
In January 2016, the iasb issued ifrs 16 (Leases), the new standard for lease accounting. ifrs 16 introduces a
uniform lease accounting model for lessees, requiring recognition of assets and liabilities for all leases with a term
of more than 12 months unless such leases are immaterial. It will eliminate the current requirement for lessees to
classify leases as either operating leases â€“ without recognizing the respective assets or liabilities â€“ or as finance
leases. The new standard is to be applied for annual periods beginning on or after January 1, 2019. The standard
has not yet been endorsed by the European Union. Bayer is currently evaluating the impact the standard will have
on the presentation of its financial position and results of operations.
In January 2016, the iasb published amendments to ias 12 (Income Taxes) under the title â€œRecognition of Deferred
Tax Assets for Unrealised Losses.â€ These amendments clarify the accounting for deferred tax assets related to debt
instruments measured at fair value. The amendments are to be applied for annual periods beginning on or after
January 1, 2017. They have not yet been endorsed by the European Union. Bayer is currently evaluating the impact
the changes will have on the presentation of its financial position and results of operations.

241

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In January 2016, the iasb published amendments to ias 7 (Statement of Cash Flows) under its Disclosure Initiative.
The following changes in liabilities arising from financing activities must be disclosed in the future: (i) changes
from financing cash flows; (ii) changes arising from obtaining or losing control of subsidiaries or other businesses;
(iii) the effect of changes in foreign exchange rates; (iv) changes in fair values; (v) other changes. The amendments
are to be applied for annual periods beginning on or after January 1, 2017. They have not yet been endorsed by the
European Union. Bayer is currently evaluating the impact the changes will have on the presentation of its financial
position and results of operations.

4. Basic principles, methods and critical accounting estimates
The financial statements of the consolidated companies are prepared according to uniform accounting policies and
measurement principles.
The consolidated financial statements of the Group are based on the principle of the historical cost of acquisition,
construction or production, with the exception of the items reflected at fair value, such as financial assets held for
trading or available for sale, and derivatives.
In preparing the consolidated financial statements, the management has to make certain assumptions and estimates that may substantially impact the presentation of the Groupâ€™s financial position and / or results of operations.
Such estimates, assumptions or the exercise of discretion mainly relate to the useful life of noncurrent assets, the
discounted cash flows used for impairment testing and purchase price allocations, and the recognition of provisions, including those for litigation-related expenses, pensions and other benefits, taxes, environmental compliance
and remediation costs, sales allowances, product liability and guarantees. Essential estimates and assumptions that
may affect reporting in the various item categories of the financial statements are described in the following sections of this note. Estimates are based on historical experience and other assumptions that are considered reasonable under given circumstances. They are continually reviewed but may vary from the actual values.
Changes in accounting policies or measurement principles in light of new or revised standards are applied retrospectively, except as otherwise provided in the respective standard. The income statement for the previous year
and the opening statement of financial position for that year are adjusted as if the new accounting policies and / or
measurement principles had always been applied.
CONSOLIDATION
The consolidated financial statements include subsidiaries, joint arrangements and associates.
Subsidiaries are companies over which Bayer AG is currently able to exercise power by virtue of existing rights.
Power means the ability to direct the activities that significantly influence a companyâ€™s profitability. Control is
therefore only deemed to exist if Bayer AG is exposed, or has rights, to variable returns from its involvement with a
company and has the ability to use its power over that company to affect the amount of that companyâ€™s returns.
The ability to control another company generally derives from Bayer AGâ€™s direct or indirect ownership of a majority
of the voting rights. In the case of structured entities, however, control is based on contractual agreements. Inclusion of an entityâ€™s accounts in the consolidated financial statements begins when the Bayer Group is able to exercise control over the entity and ceases when it is no longer able to do so.
Sales revenues, income and expenses, and gains and losses arising from transactions among the consolidated
companies, along with receivables and liabilities existing between them, are eliminated. Deferred income tax effects are reflected in consolidation.

242

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Capital consolidation is performed by offsetting the carrying amounts of subsidiaries against their underlying equity. When a majority interest in a company is acquired, its pro-rated equity at the acquisition date is measured using
the acquisition method. Identifiable assets and liabilities (including contingent liabilities) are recognized at their
fair values along with attributable deferred tax assets and liabilities. Any remaining difference to the purchase price
is recognized as goodwill. The purchase prices of acquired companies domiciled outside the eurozone are translated at the exchange rates in effect at the respective dates of acquisition.
The purchase of shares from other owners is presented as an equity transaction. The difference between the equity
acquired from other owners and the purchase price is therefore directly offset against equity.
Joint operations and joint ventures are based on joint arrangements. A joint arrangement is deemed to exist if the
Bayer Group through a contractual agreement jointly controls activities managed with a third party. Joint control is
only deemed to exist if decisions regarding the relevant activities require the unanimous consent of the parties
sharing control.
A joint operation is a joint arrangement whereby the parties that have joint control of the arrangement have rights
to the assets, and obligations for the liabilities, relating to the arrangement. The Bayer Group recognizes the share
of assets, liabilities, revenues and expenses relating to its interest in a joint operation in accordance with its rights
and obligations.
A joint venture is a joint arrangement whereby the parties that have joint control of the arrangement have rights to
the net assets of the arrangement. Joint ventures are accounted for using the equity method.
Associates over which Bayer AG exerts significant influence, generally through an ownership interest between
20% and 50%, also are accounted for using the equity method.
The carrying amount of a company accounted for using the equity method is adjusted annually by the percentage
of any change in its equity corresponding to Bayerâ€™s percentage interest in the company. Differences arising upon
first-time inclusion using the equity method were accounted for according to full-consolidation principles. Bayerâ€™s
share of changes in these companiesâ€™ equities recognized in profit or loss â€“ including impairment losses recognized on goodwill â€“ are reflected in equity-method income / loss.
Companies that do not have a material impact on the Groupâ€™s financial position or results of operations, either
individually or in aggregate, are accounted for at cost of acquisition less any impairment losses.
FOREIGN CURRENCY TRANSLATION
The financial statements of the individual companies for inclusion in the consolidated financial statements are
prepared in their respective functional currencies. A companyâ€™s functional currency is that of the economic environment in which it primarily generates and expends cash. The majority of combined companies carry out their
activities autonomously from a financial, economic and organizational point of view, and their functional currencies
are therefore the respective local currencies.
In the separate financial statements of the individual consolidated companies, receivables and liabilities in currencies other than the respective functional currency are translated at closing rates. Related exchange differences are
recognized in profit or loss as exchange gains or losses under other financial income and expenses.
In the consolidated financial statements, the assets and liabilities of companies outside the eurozone at the start
and end of the year are translated into euros at closing rates. All changes occurring during the year and all income
and expense items and cash flows are translated into euros at average monthly rates. Equity components are translated at the historical exchange rates prevailing at the respective dates of their first-time recognition in Group
equity.

243

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The exchange differences arising between the resulting amounts and those obtained by translating at closing rates
are recognized outside profit or loss as â€œExchange differences on translation of operations outside the eurozoneâ€
(in other comprehensive income) or â€œExchange differencesâ€ (in the tables in the notes). When a company is deconsolidated, such exchange differences are reclassified from equity to profit or loss.
The exchange rates for major currencies against the euro varied as follows:

Exchange Rates for Major Currencies

[Table 4.8]
Closing rate

â‚¬1/

Average rate

2014

2015

2014

2015

3.22

4.31

3.12

3.64

BRL

Brazil

CAD

Canada

1.41

1.51

1.47

1.42

CHF

Switzerland

1.20

1.08

1.21

1.07

CNY

China

7.54

7.06

8.17

6.97

GBP

United Kingdom

0.78

0.73

0.81

0.73

JPY

Japan

145.23

131.07

140.32

134.28

MXN

Mexico

17.87

18.91

17.65

17.56

RUB

Russia

72.34

80.67

50.25

67.23

USD

United States

1.21

1.09

1.33

1.11

Subsidiaries whose functional currencies have experienced a cumulative inflation rate of more than 100% over the
past three years apply the rules of ias 29 (Financial Reporting in Hyperinflationary Economies). Gains and losses
incurred upon adjusting the carrying amounts of nonmonetary assets and liabilities for inflation are recognized in
other operating income and expenses.
In 2015, as in prior years, the rules of ias 29 were relevant for Bayer s.a., Venezuela.
Several widely differing official exchange rates for the Venezuelan bolivar (vef) against the u.s. dollar were published in 2014. Bayer s.a., Venezuela, was included in the consolidated financial statements for 2014 at the official
exchange rate potentially applicable to future capital transfers if permission for conversion into u.s. dollars is
granted (sicad i).
In 2015, a further official exchange rate (simadi) was introduced. In view of the low u.s. dollar allocation at the
more favorable government-subsidized exchange rates and the continued deterioration in the Venezuelan economy, currency translation was switched to the simadi rate. The resulting u.s. dollar amount is translated at the respective dollar / euro rate.
As of December 31, 2015, Bayer s.a., Venezuela, had trade accounts equivalent to â‚¬121 million (2014: â‚¬150 million)
payable to other Group companies in u.s. dollars. Impairment losses of â‚¬91 million were recognized on receivables
in 2015 because the Venezuelan exchange control authority did not allocate u.s. dollars at the subsidized exchange
rate with respect to the full amounts of older receivables. Hyperinflationary exchange gains of â‚¬43 million were
incurred in 2015 (2014: losses of â‚¬59 million), mainly from the net foreign currency position, in connection with the
depreciation of the vef against the u.s. dollar.
NET SALES AND OTHER OPERATING INCOME
All revenues derived from the selling of products or rendering of services or from licensing agreements are recognized as sales. Other operational revenues are recognized as other operating income. Sales are recognized in
profit or loss when the significant risks and rewards of ownership of the goods have been transferred to the customer, the company retains neither continuing managerial involvement to the degree usually associated with
ownership nor effective control over the goods sold, the amount of revenue and costs incurred or to be incurred
can be measured reliably, and it is sufficiently probable that the economic benefits associated with the transaction
will flow to the company.

244

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Sales are stated net of sales taxes, other taxes and sales deductions at the fair value of the consideration received
or to be received. Sales deductions are estimated amounts for rebates, cash discounts and product returns. They
are deducted at the time the sales are recognized, and appropriate provisions are recorded. Sales deductions are
estimated primarily on the basis of historical experience, specific contractual terms and future expectations of sales
development. It is unlikely that factors other than these could materially affect sales deductions in the Bayer Group.
Adjustments to provisions made in prior periods for rebates, cash discounts or product returns were of secondary
importance for income before income taxes in the years under report.
Provisions for rebates in 2015 amounted to 3.8% of total net sales (2014: 3.4%). In addition to rebates, Group
companies offer cash discounts for prompt payment in some countries. Provisions for cash discounts as of December 31, 2015 and December 31, 2014 were less than 0.1% of total net sales for the respective year.
Sales are reduced by the amount of the provisions for expected returns of defective goods or of saleable products
that may be returned under contractual arrangements. The net sales are reduced on the date of sale or on the date
when the amount of future returns can be reasonably estimated. Provisions for product returns in 2015 amounted
to 0.4% of total net sales (2014: 0.5%). If future product returns cannot be reasonably estimated and are significant to a sales transaction, the revenues and the related cost of sales are deferred until a reasonable estimate can
be made or the right to return the goods has expired.
Some of the Bayer Groupâ€™s revenues are generated on the basis of licensing agreements under which third parties
have been granted rights to products and technologies. Payments received, or expected to be received, that relate
to the sale or outlicensing of technologies or technological expertise are recognized in profit or loss as of the effective date of the respective agreement if all rights relating to the technologies and all obligations resulting from
them have been relinquished under the contract terms. However, if rights to the technologies continue to exist or
obligations resulting from them have yet to be fulfilled, the payments received are deferred accordingly. Upfront
payments and similar nonrefundable payments received under these agreements are recorded as other liabilities
and recognized in profit or loss according to the degree of performance over the estimated performance period
stipulated in the agreement.
License agreements and research and development collaboration agreements may be multiple-deliverable arrangements with varying consideration terms, such as upfront payments and milestone or similar payments. Such
agreements therefore have to be assessed to determine whether the revenues allocated to individual deliverables
must be recognized at different points in time and therefore form separate units of account.
To qualify as a separate unit of account for revenue recognition purposes, a deliverable must have value to the
licensee on a standalone basis. If this is not the case, the agreement as a whole or a combination of individual
deliverables that has value on a standalone basis forms a unit of account.
If necessary goods have yet to be delivered or necessary services provided for a unit of account and such delivery
or provision is probable, nonrefundable (royalty) payments already received are recognized through profit or loss
over the periods in which these goods are delivered or these services are provided.
Income may also arise from the exchange of intangible assets. The amount recognized is generally based on the
fair value of the assets given up, calculated using the discounted cash flow method. If the assets given up are internally generated, the gain from the exchange generally equals their fair value.

245

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

RESEARCH AND DEVELOPMENT EXPENSES
For accounting purposes, research expenses are defined as costs incurred for current or planned investigations
undertaken with the prospect of gaining new scientific or technical knowledge and understanding. Development
expenses are defined as costs incurred for the application of research findings or specialist knowledge to plans or
designs for the production, provision or development of new or substantially improved products, services or processes, respectively, prior to the commencement of commercial production or use.
Research and development expenses are incurred in the Bayer Group for in-house research and development activities as well as numerous research and development collaborations and alliances with third parties.
Research and development expenses mainly comprise the costs for active ingredient discovery, clinical studies,
research and development activities in the areas of application technology and engineering, field trials, regulatory
approvals and approval extensions.
Research costs cannot be capitalized. The conditions for capitalization of development costs are closely defined: an
intangible asset must be recognized if, and only if, there is reasonable certainty of receiving future cash flows that
will cover an assetâ€™s carrying amount. Since our own development projects are often subject to regulatory approval
procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied.
In the case of research and development collaborations, a distinction is generally made between payments on
contract signature, upfront payments, milestone payments and cost reimbursements for work performed. If an
intangible asset (such as the right to the use of an active ingredient) is acquired in connection with any of these
payment obligations, the respective payment is capitalized even if it is uncertain whether further development work
will ultimately lead to the production of a saleable product. Reimbursements of the cost of research or development
work are recognized in profit or loss, except where they are required to be capitalized.
INCOME TAXES
Income taxes comprise the taxes levied on taxable income in the individual countries along with changes in deferred tax assets and liabilities that are recognized in profit or loss. The income taxes recognized are reflected at
the amounts likely to be payable under the statutory regulations in force, or already enacted in relation to future
periods, at the end of the reporting period.
In compliance with ias 12 (Income Taxes), deferred taxes are recognized for temporary differences between the
carrying amounts of assets and liabilities in the statement of financial position prepared according to ifrs and their
tax bases. Deferred taxes are also recognized for consolidation measures and for tax loss carryforwards and tax
credits that are likely to be usable.
Deferred tax assets relating to deductible temporary differences, tax credits or tax loss carryforwards are recognized where it is sufficiently probable that taxable income will be available in the future to enable them to be used.
Deferred tax liabilities are recognized on temporary differences taxable in the future. Deferred taxes are calculated
at the rates which â€“ on the basis of the statutory regulations in force, or already enacted in relation to future periods, as of the closing date â€“ are expected to apply in the individual countries at the time of realization. Deferred tax
assets and deferred tax liabilities are offset if they relate to income taxes levied by the same taxation authority and
Bayer has a legal right to settle on a net basis. Material effects of changes in tax rates or tax law on deferred tax
assets and liabilities are generally accounted for in the period in which the changes are enacted. Such effects are
recognized in profit or loss except where they relate to deferred taxes that were recognized outside profit or loss,
in which case they are recognized in other comprehensive income.
Deferred and current taxes are recognized in profit or loss unless they relate to items recognized outside profit or
loss in other comprehensive income, in which case they, too, are recognized in other comprehensive income.

246

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The probability that deferred tax assets resulting from temporary differences or loss carryforwards can be used in
the future is the subject of forecasts by the individual consolidated companies regarding their future earnings
situation and other parameters.
Deferred tax liabilities are recognized on planned dividend payments by subsidiaries. Where no dividend payment
is planned for the foreseeable future, no deferred tax liability is recognized on the difference between the proportionate net assets according to ifrs and the tax base of the investment in the subsidiary.
GOODWILL
In a business combination, goodwill is capitalized at the acquisition date. It is measured at its cost of acquisition,
which is the excess of the acquisition price for shares in a company over the acquired net assets. The net assets are
the balance of the fair values of the acquired identifiable assets and the assumed liabilities and contingent liabilities.
Goodwill is not amortized, but tested annually for impairment. Details of the annual impairment tests are given
under â€œProcedure used in global impairment testing and its impact.â€ Once an impairment loss has been recognized
on goodwill, it is not reversed in subsequent periods.
OTHER INTANGIBLE ASSETS
An â€œother intangible assetâ€ is an identifiable nonmonetary asset without physical substance, other than goodwill
(such as a patent, a trademark or a marketing right). It is capitalized if the future economic benefits attributable to
the asset will probably flow to the company and the cost of acquisition or generation of the asset can be reliably
measured.
Other intangible assets are recognized at the cost of acquisition or generation. Those with a determinable useful
life are amortized accordingly on a straight-line basis over a period of up to 30 years, except where their actual
depletion demands a different amortization pattern. Determination of the expected useful lives of such assets and
the amortization patterns is based on estimates of the period for which they will generate cash flows. An impairment test is performed if there is an indication of possible impairment.
Other intangible assets with an indefinite life (such as the Bayer Cross trademark) and intangible assets not yet
available for use (such as research and development projects) are not amortized, but tested annually for impairment.
Any impairment losses are recognized in profit or loss. If the reasons for a previously recognized impairment loss
no longer apply, the impairment loss is reversed provided that the reversal does not cause the carrying amount to
exceed the (amortized) cost of acquisition or generation.
PROPERTY, PLANT AND EQUIPMENT
Property, plant and equipment is carried at the cost of acquisition or construction and depreciated over its estimated useful life. An impairment loss is recognized in addition if an assetâ€™s recoverable amount falls below its carrying
amount.
The cost of self-constructed property, plant and equipment comprises the direct cost of materials, direct manufacturing expenses, and appropriate allocations of material and manufacturing overheads. Where an obligation exists
to dismantle or remove an asset or restore a site to its former condition at the end of its useful life, the present
value of the related future payments is capitalized along with the cost of acquisition or construction upon completion and a corresponding liability is recognized.
If the construction phase of property, plant or equipment extends over a substantial period of time, the interest
incurred on borrowed capital up to the date of completion is capitalized as part of the cost of acquisition or construction in accordance with ias 23 (Borrowing Costs).

247

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Costs for regular, comprehensive maintenance work (such as the major overhaul of a technical facility) are capitalized as a separate component if they satisfy the recognition criteria.
Property, plant and equipment is depreciated by the straight-line method over an assetâ€™s useful life, except where
depreciation based on actual depletion is more appropriate.
The following depreciation periods are applied throughout the Group:

Useful Life of Property, Plant and Equipment

[Table 4.9]

Buildings

20 to 50 years

Outdoor infrastructure

10 to 20 years

Storage tanks and pipelines

10 to 20 years

Plant installations

6 to 20 years

Machinery and equipment

6 to 12 years

Furniture and fixtures

4 to 10 years

Vehicles

5 to 8 years

Computer equipment

3 to 5 years

Laboratory and research facilities

3 to 5 years

Significant asset components with different useful lives are accounted for and depreciated separately.
If there are indications that an individual item of property, plant and equipment may be impaired, the recoverable
amount is compared to the carrying amount. If the recoverable amount is less than the carrying amount, an impairment loss is recognized for the difference. If the reasons for a previously recognized impairment loss no longer
apply, the impairment loss is reversed provided that the reversal does not cause the carrying amount to exceed the
cost of acquisition or construction less depreciation.
When assets are sold, closed down or scrapped, the difference between the net proceeds and the net carrying
amount of the assets is recognized as a gain or loss in other operating income or expenses, respectively.
Investment property comprises land and buildings not being used for operational or administrative purposes. It is
measured using the cost model. The fair value of the investment property reported in the Notes is determined
using the discounted cash flow method, comparisons with the current market values of similar properties, or reports from external experts.
FINANCIAL ASSETS
Financial assets comprise loans and receivables, acquired equity and debt instruments, cash and cash equivalents,
and derivatives with positive fair values.
They are recognized and measured in accordance with ias 39 (Financial Instruments: Recognition and Measurement). Accordingly, financial assets are recognized in the consolidated financial statements if the Bayer Group has
a contractual right to receive cash or other financial assets from another entity. Regular-way purchases and sales of
financial assets are generally posted on the settlement date. Financial assets are initially recognized at fair value
plus transaction costs. The transaction costs incurred for the purchase of financial assets held at fair value through
profit or loss are expensed immediately. Interest-free or low-interest receivables are initially reflected at the present
value of the expected future cash flows. Upon first-time recognition, each financial asset is assigned to one of the
categories prescribed in ias 39. Subsequent measurement takes place according to the measurement rules for the
respective category. The measurement rules for each category are set forth below:

248

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Financial assets held at fair value through profit or loss comprise those financial assets that are held for trading.
Receivables from forward commodity contracts and receivables from other derivatives that are included in other
financial assets are allocated to this category, except where hedge accounting is used. Changes in the fair value of
financial assets in this category are recognized in profit or loss when the increase or decrease in fair value occurs.
Loans and receivables are nonderivative financial assets with fixed or determinable payments that are not quoted in
an active market. They are accounted for at amortized cost using the effective interest method. This category comprises trade accounts receivable, the loans and receivables included in other financial assets, the additional financial receivables reflected in other receivables, and cash and cash equivalents. Interest income from items assigned
to this category is determined using the effective interest method.
Held-to-maturity financial assets are nonderivative financial assets, with fixed or determinable payments, that the
Bayer Group is willing and able to hold until maturity. They are accounted for at amortized cost using the effective
interest method. Held-to-maturity financial investments are recognized in other financial assets.
Available-for-sale financial assets are those nonderivative financial assets that are not assigned to any of the above
categories. They mainly include equity instruments (such as shares), debt instruments with indefinite maturities,
and debt instruments not to be held to maturity that are included in other financial assets. After their first-time
recognition, available-for-sale financial assets are measured at fair value and any unrealized gains or losses are
recognized outside profit or loss in equity. These are only reclassified to profit or loss if the assets are sold or if
there are objective indications of impairment, in which case the accumulated loss is recognized in profit or loss. An
objective indication of impairment is a significant or prolonged decrease in the fair value of an equity instrument to
below its acquisition cost. Previously recognized impairment losses are reversed if the reasons for them no longer
apply. Impairment loss reversals for equity instruments are recognized outside profit or loss, while those for debt
instruments are recognized in profit or loss. Where possible, a fair value for equity and debt securities is derived
from market data. Financial assets for which no market price is available and whose fair value cannot be reasonably
estimated are recognized at cost less any impairment losses.
If there are substantial and objective indications of a decline in the value of loans and receivables, held-to-maturity
financial assets or available-for-sale financial assets, an impairment test is performed. Indications of possible impairment include a high probability of insolvency, a significant deterioration in credit standing, a material breach of
contract, operating losses reported by a company over several years, a reduction in market value, the financial
restructuring of the debtor, or the disappearance of an active market for the asset.
In the case of loans and receivables, and held-to-maturity financial assets, an impairment test is performed in
which the carrying amount is compared to the present value of the expected future cash flows, discounted at the
original effective interest rate. If the carrying amount exceeds the present value, an impairment loss is recognized
for the difference between the two amounts. If the reasons for previously recognized impairment losses no longer
apply, the impairment losses are reversed provided that this does not cause the carrying amounts to exceed the
amortized cost of acquisition.

249

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Financial assets are derecognized when contractual rights to receive cash flows from the financial assets expire or
the financial assets are transferred together with all material risks and benefits.
INVENTORIES
In accordance with ias 2 (Inventories), inventories encompass assets consumed in production or in the rendering
of services (raw materials and supplies), assets in the production process for sale (work in process), goods held for
sale in the ordinary course of business (finished goods and goods purchased for resale), and advance payments on
inventories. Inventories are recognized at their cost of acquisition or production â€“ calculated by the weightedaverage method â€“ or at their net realizable value, whichever is lower. The net realizable value is the estimated
selling price in the ordinary course of business less estimated cost to complete and selling expenses.
CASH AND CASH EQUIVALENTS
Cash and cash equivalents comprise cash, checks received, and balances with banks and companies. Cash equivalents are highly liquid short-term financial investments that are subject to an insignificant risk of changes in value,
are easily convertible into a known amount of cash and have a maturity of three months or less from the date of
acquisition or investment.
ASSETS HELD FOR SALE
Assets held for sale comprise noncurrent assets or disposal groups (together with any liabilities), the carrying
amounts of which will be realized principally through a highly probable sale transaction within the next twelve
months or an already contractually agreed sale transaction, and not through continued use. At the time of their
classification as â€œheld for sale,â€ such assets are collectively measured at the lower of the carrying amount and fair
value less costs of disposal, and depreciation or amortization ceases.
Groups of assets held for sale that represent a standalone business and correspond to at least one strategic business entity are combined in the income statement, statement of comprehensive income, statement of financial
position and statement of cash flows and reported under assets held for sale or discontinued operations.
PROVISIONS FOR PENSIONS AND OTHER POST-EMPLOYMENT BENEFITS
Within the Bayer Group, post-employment benefits are provided under defined contribution and / or defined benefit
plans. In the case of defined contribution plans, the company pays contributions to publicly or privately administered pension plans on a mandatory, contractual or voluntary basis. Once the contributions have been paid, the
company has no further payment obligations. The regular contributions constitute expenses for the year in which
they are due and as such are included in the functional cost items, and thus in ebit. All other post-employment
benefit systems are defined benefit plans, which may be either unfunded, i.e. financed by provisions, or funded, i.e.
financed through pension funds.
The present value of provisions for defined benefit plans and the resulting expense are calculated in accordance
with ias 19 (Employee Benefits) by the projected unit credit method. The future benefit obligations are valued by
actuarial methods and spread over the entire employment period on the basis of specific assumptions regarding
beneficiary structure and the economic environment. These relate mainly to the discount rate, future salary and
pension increases, variations in health care costs, and mortality rates.
The discount rates used are calculated from the yields of high-quality corporate bond portfolios in specific currencies with cash flows approximately equivalent to the expected disbursements from the pension plans. The uniform
discount rate derived from this interest-rate structure is thus based on the yields, at the closing date, of a portfolio
of â€œaaâ€ rated corporate bonds whose weighted residual maturities approximately correspond to the duration necessary to cover the entire benefit obligation.

250

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The fair value of plan assets is deducted from the present value of the defined benefit obligation for pensions and
other post-employment benefits to determine the net defined benefit liability. The obligations and plan assets are
valued at regular intervals of not more than three years. Comprehensive actuarial valuations for all major plans are
performed annually as of December 31. Plan assets in excess of the benefit obligation are reflected in other receivables, subject to the asset ceiling specified in ias 19 (Employee Benefits).
The balance of all income and expenses relating to defined benefit plans, except the net interest on the net liability,
is recognized in ebit. The net interest is reflected in the financial result under other financial income and expenses.
The effects of remeasurements of the net defined benefit liability are reflected in the statement of comprehensive
income as other comprehensive income. They consist of actuarial gains and losses, the return on plan assets and
changes in the effects of the asset ceiling, less the respective amounts included in net interest. Deferred taxes
relating to the effects of remeasurements are also recognized in other comprehensive income.
OTHER PROVISIONS
Other provisions are recognized for present legal and constructive obligations arising from past events that will
probably give rise to a future outflow of resources, provided that a reliable estimate can be made of the amount of
the obligations.
Other provisions are measured in accordance with ias 37 (Provisions, Contingent Liabilities and Contingent Assets)
or, where applicable, ias 19 (Employee Benefits). Where the cash outflow to settle an obligation is expected to
occur after one year, the provision is recognized at the present value of the expected cash outflow. Claims for reimbursements from third parties are separately reflected in other receivables if their realization is virtually certain.
If the projected obligation declines as a result of a change in the estimate, the provision is reversed by the corresponding amount and the resulting income recognized in the operating expense item(s) in which the original
charge was recognized.
To enhance the information content of the estimates, certain provisions that could have a material effect on the
financial position or results of operations of the Group are selected and tested for their sensitivity to changes in the
underlying parameters. To reflect uncertainty about the likelihood of the assumed events actually occurring, the
impact of a five-percentage-point change in the probability of occurrence is examined in each case. This analysis
has not shown other provisions to be materially sensitive.
Complex tax regulations may give rise to uncertainties with respect to their interpretation and the amount and
timing of future taxable income. Given the wide range of international business relationships and the long-term
nature and complexity of existing contractual agreements, differences arising between the actual results and the
assumptions made, or future changes to such assumptions, could necessitate adjustments to tax income and expense in future periods. The Group establishes provisions for taxes, based on reasonable estimates, for liabilities
to the tax authorities of the respective countries that are uncertain as to their amount and the probability of their
occurrence. The amount of such provisions is based on various factors, such as experience with previous tax audits
and differing legal interpretations by the taxable entity and the responsible tax authority.
Provisions for environmental protection are recorded if future cash outflows are likely to be necessary to ensure
compliance with environmental regulations or to carry out remediation work, such costs can be reliably estimated
and no future benefits are expected from such measures.

251

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Estimating the future costs of environmental protection and remediation involves many uncertainties, particularly
with regard to the status of laws, regulations and the information available about conditions in the various countries and at the individual sites. Significant factors in estimating the costs include previous experiences in similar
cases, the conclusions in expert opinions obtained regarding the Groupâ€™s environmental programs, current costs
and new developments affecting costs, managementâ€™s interpretation of current environmental laws and regulations,
the number and financial position of third parties that may become obligated to participate in any remediation
costs on the basis of joint liability, and the remediation methods likely to be deployed. Changes in these assumptions could impact future reported results.
Taking into consideration experience gained to date regarding environmental matters of a similar nature, provisions are believed to be adequate based upon currently available information. Given the difficulties inherent in
estimating liabilities in the businesses in which the Group operates, especially those for which the risk of environmental damage is greater in relative terms (CropScience and Covestro), it remains possible that material additional
costs will be incurred beyond the amounts accrued. It may transpire during remediation work that additional expenditures are necessary over an extended period and that these exceed existing provisions and cannot be reasonably estimated.
Provisions for restructuring only cover expenses that arise directly from restructuring measures, are necessary for
restructuring and are not related to future business operations. Such expenses include severance payments to
employees and compensation payments in respect of rented property that can no longer be used.
Restructuring measures may include the sale or termination of business units, site closures, relocations of business
activities or fundamental reorganizations of business units.
The respective provisions are established when a detailed restructuring plan has been drawn up, resolved upon by
the responsible decision-making level of management and communicated to the employees and / or their representatives. Provisions for restructuring are established at the present value of future disbursements.
Trade-related provisions are recorded mainly for the granting of rebates or discounts, product returns, or obligations in respect of services already received but not yet invoiced.
As a global enterprise with a diverse business portfolio, the Bayer Group is exposed to numerous legal risks for
which provisions for litigations must be established under certain conditions â€“ particularly in the areas of product
liability, competition and antitrust law, patent disputes, tax law and environmental protection.
Litigation and other judicial proceedings often raise complex issues and are subject to many uncertainties and
complexities including, but not limited to, the facts and circumstances of each particular case, the jurisdiction in
which each suit is brought and differences in applicable law. The outcomes of currently pending and future proceedings generally cannot be predicted. It is particularly difficult to assess the likely outcomes of class actions for
damages in the United States, which may give rise to significant financial risks for the Bayer Group. As a result of a
judgment in court proceedings, regulatory decisions or the conclusion of a settlement, the Bayer Group may incur
charges for which no accounting measures have yet been taken for lack of reasonable estimability or which exceed
presently established provisions and the insurance coverage.
The Bayer Group considers the need for accounting measures in respect of pending or future litigations, and the
extent of any such measures, on the basis of the information available to its legal department and in close consultation with legal counsel acting for the Bayer Group.

252

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Where it is more likely than not that such a litigation will result in an outflow of resources that is already reasonably
estimable, a provision for litigation is recorded in the amount of the present value of the expected cash outflows.
Such provisions cover the estimated payments to the plaintiffs, court and procedural costs, attorney costs and the
cost of potential settlements.
It is frequently impossible to reliably determine the existence of a present obligation or reasonably estimate the
probability that a potential outflow of resources will result from a pending or future litigation. The status of the
material â€œlegal risksâ€ is described in note [32]. Due to the special nature of these litigations, provisions generally
are not established until initial settlements allow an estimate of potential amounts or judgments have been issued.
Provisions for legal defense costs are established if it is probable that material costs will have to be incurred for
external legal counsel to defend the companyâ€™s legal position.
Internal and external legal counsel evaluate the current status of the Bayer Groupâ€™s material legal risks at the end
of each reporting period. The need to establish or adjust a provision and the amount of the provision or adjustment
are determined on this basis. Adjusting events are reflected up to the date of preparation of the consolidated financial statements. The measurement of provisions in the case of class actions or mass compensation claims is mainly
based on any settlements reached during the past year and on pending or anticipated future claims.
Personnel-related provisions are mainly those recorded for annual bonus payments, variable one-time payments,
individual performance awards, long-service awards, severance payments in connection with early retirement
arrangements, surpluses on long-term accounts and other personnel costs. Obligations under stock-based compensation programs that provide for awards payable in cash are also included here.
FINANCIAL LIABILITIES
Financial liabilities comprise primary financial liabilities and negative fair values of derivatives.
Primary financial liabilities are initially recognized in the consolidated financial statements at fair value if the
Bayer Group has a contractual obligation to transfer cash or other financial assets to another party. In subsequent
periods, such liabilities are measured at amortized cost using the effective interest method.
Liabilities for contingent consideration arising from business combinations are measured at fair value. Changes in
fair value are recognized through profit or loss as of the respective closing date.
Financial liabilities are derecognized when the contractual obligation is discharged or canceled, or has expired.
OTHER RECEIVABLES AND LIABILITIES
Accrued items and other nonfinancial assets and liabilities are carried at amortized cost. They are amortized to
income by the straight-line method or according to performance of the underlying transaction.
Grants and subsidies from third parties that serve to promote investment are reflected in the statement of financial
position under other liabilities and amortized to income over the useful lives of the respective investments or in line
with the terms of the grant or subsidy.
DERIVATIVES
The Bayer Group uses derivatives â€“ such as forward exchange contracts and interest-rate swaps â€“ to mitigate the
risk of changes in exchange rates, interest rates or prices. Derivatives are recognized at the trade date.
Contracts concluded in order to receive or deliver nonfinancial goods for the companyâ€™s own purposes are not
accounted for as derivatives but treated as pending transactions. Where embedded derivatives are identified that
are required to be separated from the pending transactions, they are accounted for separately. To take advantage of
market opportunities or cover possible peak demand, a nonmaterial volume of transactions may be entered into for
which the possibility of immediate resale cannot be excluded. Such transactions are allocated to separate portfolios
upon acquisition and accounted for as derivatives according to ias 39.

253

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Derivatives are carried at fair value. Positive fair values at the end of the reporting period are reflected in financial
assets, negative fair values in financial liabilities. Changes in the fair values of these derivatives are recognized
directly in profit or loss except where hedge accounting is used. Changes in the fair values of forward exchange
contracts and currency options serving as hedges of items in the statement of financial position are reflected in
other financial income and expenses as exchange gains or losses, while changes in the values of interest-rate
swaps and interest-rate options are recognized in interest income or expense. Changes in the fair values of commodity futures and options, and of forward exchange contracts used to hedge forecasted transactions in foreign
currencies, are recognized in other operating income or expenses.
Changes in the fair values of derivatives designated as fair-value hedges and the adjustments in the carrying
amounts of the underlying transactions are recognized in profit or loss.
Changes in the fair values of the effective portion of derivatives designated as cash flow hedges are initially recognized outside profit or loss in accumulated other comprehensive income. They are reclassified to profit or loss
when the underlying transaction is realized. If such a derivative is sold or ceases to qualify for hedge accounting,
the change in its value continues to be recognized in accumulated other comprehensive income until the forecasted
transaction is realized. If the forecasted transaction is no longer probable, the amount previously recognized in
accumulated other comprehensive income has to be reclassified to profit or loss. The ineffective portion of gains or
losses on derivatives designated as cash flow hedges is recognized either in other operating income or expenses or
in the financial result, depending on the type of underlying transaction.
The income and expense reflected in the financial result pertaining to the derivatives and the underlying transactions are shown separately. Income and expense are not offset.
LEASES
A lease is an agreement whereby the lessor assigns to the lessee the right to use an asset for an agreed period of
time in return for a payment or series of payments. Leases are classified as either finance or operating leases.
Lease transactions that transfer substantially all the risks and rewards incidental to ownership of the leased asset to
the lessee are treated as finance leases. All other lease agreements are classified as operating leases. Whether an
agreement constitutes a lease or contains a lease is determined upon inception of the lease.
Where the Bayer Group is the lessee in a finance lease, the leased asset is capitalized at the lower of the fair value
of the asset and the present value of the minimum lease payments at the beginning of the lease term and simultaneously recognized under financial liabilities. The minimum lease payments are divided into the principal portion
of the remaining obligation and the financing costs, which are determined using the effective-interest method. The
leased asset is depreciated by the straight-line method over the shorter of its estimated useful life or the lease term.
Where the Bayer Group is the lessee in an operating lease, the lease payments are expensed. Where it is the lessor,
the lease payments received are recognized in profit or loss. The leased asset continues to be recognized under
property, plant and equipment in the Bayer Groupâ€™s statement of financial position.
ACQUISITION ACCOUNTING
Acquired businesses are accounted for using the acquisition method, which requires that the assets acquired and
liabilities assumed be recorded at their respective fair values on the date Bayer obtains control. Ancillary acquisition costs are recognized as expenses in the periods in which they occur.

254

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The application of the acquisition method requires certain estimates and assumptions to be made, especially concerning the fair values of the acquired intangible assets, property, plant and equipment and the liabilities assumed
at the acquisition date, and the useful lives of the acquired intangible assets, property, plant and equipment.
Measurement is based to a large extent on anticipated cash flows. If actual cash flows vary from those used in
calculating fair values, this may materially affect the Groupâ€™s future results of operations. In particular, the estimation of discounted cash flows from intangible assets under development, patented and nonpatented technologies
and brands is based on assumptions concerning, for example:
â€¢
â€¢
â€¢
â€¢
â€¢

the outcomes of research and development activities regarding compound efficacy, results of clinical trials, etc.,
the probability of obtaining regulatory approvals in individual countries,
long-term sales trends,
possible selling price erosion due to generic competition in the market following patent expirations,
the behavior of competitors (launch of competing products, marketing initiatives, etc.).

For significant acquisitions, the purchase price allocation is carried out with assistance from independent thirdparty valuation specialists. The valuations are based on the information available at the acquisition date.
In step acquisitions, the fair values of the acquired entityâ€™s assets and liabilities are measured in accordance with
ifrs 3 (Business Combinations) at the date on which control is obtained. Any resulting adjustments to the fair value
of the existing interest are recognized in profit or loss. The carrying amount of the assets and liabilities already
recognized in the statement of financial position is then adjusted accordingly.
PROCEDURE USED IN GLOBAL IMPAIRMENT TESTING AND ITS IMPACT
Impairment tests are performed not only on individual items of intangible assets, property, plant and equipment,
but also at the level of cash-generating units or groups of cash-generating units. A cash-generating unit is the
smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows
from other assets or groups of assets. The Bayer Group regards its strategic business entities or groups of strategic
business entities, as well as certain product families, as cash-generating units and subjects them to global impairment testing. The strategic business entities constitute the second financial reporting level below the segments.
Cash-generating units and unit groups are globally tested if there is an indication of possible impairment. Those to
which goodwill is allocated are tested at least annually.
Impairment testing involves comparing the carrying amount of each cash-generating unit, unit group or item of
intangible assets, property, plant or equipment to the recoverable amount, which is the higher of its fair value less
costs of disposal or value in use. If the carrying amount exceeds the recoverable amount, an impairment loss must
be recognized for the difference. If a strategic business entity or entity group is found to be impaired, an impairment loss is first recognized on any goodwill allocated to it. Any remaining part of the impairment loss is then
allocated among the other noncurrent nonfinancial assets of the strategic business entity or entity group in proportion to their carrying amounts. The resulting expense is reflected in the functional item of the income statement in
which the depreciation or amortization of the respective assets is recognized. The same applies to income from
impairment loss reversals.

255

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The recoverable amount is generally determined on the basis of the fair value less costs of disposal, taking into
account the present value of the future net cash flows as market prices for the individual units are not normally
available. These are forecasted on the basis of the Bayer Groupâ€™s current planning, the planning horizon normally
being three to five years. Forecasting involves making assumptions, especially regarding future selling prices, sales
volumes, costs, market growth rates, economic cycles and exchange rates. These assumptions are based on internal estimates along with external market studies. Where the recoverable amount is the fair value less costs of disposal, the cash-generating unit or unit group is measured from the viewpoint of an independent market participant.
Where the recoverable amount is the value in use, the cash-generating unit, unit group or individual asset is measured as currently used. In either case, net cash flows beyond the planning period are determined on the basis of
long-term business expectations using the respective individual growth rates derived from market information. The
fair value less costs of disposal is determined on the basis of unobservable inputs (Level 3).
The net cash inflows are discounted at a rate equivalent to the weighted average cost of equity and debt capital. To
allow for the different risk and return profiles of the Bayer Groupâ€™s principal businesses, the after-tax cost of capital
is calculated separately for each subgroup and a subgroup-specific capital structure is defined by benchmarking
against comparable companies in the same industry sector. The cost of equity corresponds to the return expected
by stockholders, while the cost of debt is based on the conditions on which comparable companies can obtain longterm financing. Both components are derived from capital market information.
The growth rates applied for impairment testing in 2015 and 2014 and the capital cost factors used to discount the
expected cash flows are shown in the following table:

Impairment Testing Parameters

[Table 4.10]
Growth rate
2014

2015

After-tax cost of capital
2014

2015

%

%

%

%

Pharmaceuticals

0.0

0.0

6.5

6.2

Consumer Care

0.0

0.0

6.5

6.2

Radiology

0.0

0.0

6.5

6.2

Animal Health

0.0

0.0

6.5

6.2

Crop Protection

2.0

2.3

6.7

6.3

Seeds

2.8

1.9

6.7

6.3

Environmental Science

1.3

1.8

6.7

6.3

Diphenylmethane Diisocyanate (MDI)

1.5

2.0

6.0

6.1

â€“

2.0

â€“

6.1

Polyether (PET)

0.0

0.0

6.0

6.1

Polycarbonates (PCS)

1.5

2.0

6.0

6.1

Base & Modified Isocyanates (BMI)

2.0

2.0

6.0

6.1

Resins (RES)

2.0

2.0

6.0

6.1

Specialty Films (SF)

1.0

2.0

6.0

6.1

Toluene Diisocyanate (TDI)

No impairment losses were recognized on goodwill on the basis of the global annual impairment testing of the
cash-generating units and unit groups in 2015 or 2014. In 2014, a â‚¬6 million impairment loss was recognized on a
goodwill item following an impairment test performed in connection with a divestiture. Impairment losses on
goodwill, other intangible assets, property, plant and equipment â€“ net of â‚¬1 million (2014: â‚¬2 million) in impairment loss reversals â€“ totaled â‚¬229 million (2014: â‚¬223 million). Details are provided in notes [17] and [18].

256

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Although the estimates of the useful lives of certain assets, assumptions concerning the macroeconomic environment and developments in the industries in which the Bayer Group operates, and estimates of the discounted future cash flows are believed to be appropriate, changes in assumptions or circumstances could require changes in
the analysis. This could lead to additional impairment losses in the future or â€“ except in the case of goodwill â€“ to
reversals of previously recognized impairment losses if developments are contrary to expectations.
The sensitivity analysis for cash-generating units and unit groups to which goodwill is allocated was based on a
10% reduction in future cash flows, a 10% increase in the weighted average cost of capital or a one-percentagepoint reduction in the long-term growth rate. Bayer concluded that no impairment loss would need to be recognized on goodwill in any cash-generating unit or unit group under these conditions.

5. Segment reporting
At Bayer the Board of Management, as the chief operating decision maker, allocates resources to the operating
segments and assesses their performance. The reportable segments and regions are identified, and the disclosures
selected, in line with the internal financial reporting system (management approach) and based on the Group
accounting policies outlined in note [4].
As of December 31, 2015, the Bayer Group comprised three subgroups, with operations subdivided into strategic
business entities known as divisions (HealthCare), business groups (CropScience) or business units (Covestro;
formerly MaterialScience). Their activities were aggregated into four reportable segments according to economic
characteristics, products, production processes, customer relationships, methods of distribution and regulatory
environment.
The segmentsâ€™ activities were as follows:
Activities of the Segments

Subgroup / Segment

[Table 4.11]

Activities

HealthCare

Pharmaceuticals

Development, production and marketing of prescription pharmaceuticals, such as anticoagulants,
treatments for hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary hypertension,
high blood pressure and infectious diseases; and contraceptives

Consumer Health1

Development, production and marketing of over-the-counter medications, dermatology products,
nutritional supplements, veterinary medicines and animal grooming products; medical products
such as injection systems and contrast agents for diagnostic procedures

CropScience

CropScience

Development, production and marketing of a comprehensive product portfolio in the areas of
seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural
pest control

Covestro

Covestro

1

Development, production and marketing of raw materials for polyurethanes; polycarbonate resins
and sheets; raw materials for coatings, adhesives and sealants; and selected chemical
intermediates

The Diabetes Care business unit (diagnostic systems, such as blood glucose meters) was no longer reported under continuing operations in 2015 following the
signing of the agreement to sell it to Panasonic Healthcare Holdings, Ltd., Tokyo, Japan.

257

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Business activities that cannot be allocated to any other segment are reported under â€œAll other segments.â€ These
primarily include the services provided by the service areas: Business Services, Technology Services and Currenta.
The items in â€œCorporate Center and Consolidationâ€ comprise the activities of the Bayer holding companies, the
increase or decrease in expenses for Group-wide long-term stock-based compensation arising from fluctuations in
the performance of Bayer stock, and the consolidation of intersegment sales (2015: â‚¬2.4 billion; 2014: â‚¬2.5 billion).
The reconciliation in the table â€œKey Data by Regionâ€ eliminates interregional items and transactions and reflects
income, expenses, assets and liabilities not allocable to geographical areas, particularly those relating to the Corporate Center.
The segment data are calculated as follows:
â€¢ The intersegment sales reflect intra-Group transactions effected at transfer prices fixed on an armâ€™s-length basis.
â€¢ ebit â€“ income after income taxes, plus income taxes, plus financial result â€“ which is not defined in the International Financial Reporting Standards, is influenced by one-time special effects and by the amortization of intangible assets and depreciation of property, plant and equipment, along with impairment losses and impairment
loss reversals. To elucidate the effects of these parameters on the operational business and facilitate the comparability of operational earning power over time, we determine additional indicators: ebitda, ebit before special
items, ebitda before special items and the ebitda margin before special items. These indicators also are not defined in the International Financial Reporting Standards. ebitda (ebit plus the amortization of intangible assets
and the depreciation of property, plant and equipment, plus impairment losses, minus impairment loss reversals, recognized in profit or loss in the reporting period) serves to characterize the operational business irrespective of the effects of amortization, depreciation or impairment losses / impairment loss reversals. ebit before
special items and ebitda before special items show the development of the operational business irrespective of
the effects of special items â€“ those that are nonrecurring or do not regularly recur or attain similar magnitudes.
ebit before special items and ebitda before special items are determined by adding special charges and subtracting special gains. They constitute relevant key data for Bayer. The ebitda margin before special items,
which is calculated by dividing ebitda before special items by sales, serves as an indicator of relative operational earning power for purposes of internal and external comparison.
â€¢ The gross cash flow comprises income after income taxes, plus income taxes, plus financial result, minus income taxes paid or accrued, plus depreciation, amortization and impairment losses, minus impairment loss reversals, plus / minus changes in pension provisions, minus gains / plus losses on retirements of noncurrent assets,
minus gains from the remeasurement of already held assets in step acquisitions. The change in pension provisions includes the elimination of noncash components of ebit. It also contains benefit payments during the year.
Gross cash flow is not defined in the International Financial Reporting Standards.
â€¢ The net cash flow is the cash flow from operating activities as defined in ias 7 (Statement of Cash Flows).
â€¢ The capital invested and the segment assets include all assets serving the respective segment that are required
to yield a return on their cost of acquisition. Segment assets include, in addition, assets held for sale where the
return is covered by the sale proceeds. Similarly, the segment liabilities include the liabilities directly related to
assets held for sale. Also included in the capital invested and in segment assets are material participating interests of direct relevance to business operations. Intangible assets and property, plant and equipment are included
in the capital invested at cost of acquisition, generation or construction throughout their useful lives. Interestfree liabilities are deducted from the capital invested, which is stated as of December 31.
â€¢ The cfroi â€“ a measure of the return on the capital employed â€“ is the difference between the gross cash flow and
the cost of reproducing depletable assets, divided by the average capital invested for the year.
â€¢ The equity items reflect the earnings and carrying amounts of companies accounted for using the equity method.
â€¢ Since the financial management of Group companies is carried out centrally by Bayer AG, financial liabilities are
not directly allocated among the segments. Consequently, the liabilities shown for the individual segments do
not include financial liabilities. These are included in the reconciliation.
â€¢ The number of employees on either permanent or temporary contracts is stated in full-time equivalents (fte),
with part-time employees included on a pro-rated basis in line with their contractual working hours. The figures
do not include apprentices.

258

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

RECONCILIATIONS
The reconciliations of ebitda before special items, ebit before special items and ebit to Group income before income taxes and of the assets and liabilities of the segments to the assets and liabilities, respectively, of the Group
are given in the following tables:

Reconciliation of Segmentsâ€™ EBITDA Before Special Items to Group Income Before Income Taxes

EBITDA before special items of segments
EBITDA before special items of Corporate Center and Consolidation
EBITDA before special items
Depreciation, amortization and impairment losses / loss reversals before special items of segments
Depreciation, amortization and impairment losses / loss reversals before special items
of Corporate Center and Consolidation
Depreciation, amortization and impairment losses / loss reversals before special items
EBIT before special items of segments
EBIT before special items of Corporate Center and Consolidation

[Table 4.12]
2014

2015

â‚¬ million

â‚¬ million

9,104

10,732

(419)

(466)

8,685

10,266

(2,846)

(3,191)

(6)

(6)

(2,852)

(3,197)

6,258

7,541

(425)

(472)

EBIT before special items

5,833

7,069

Special items of segments

(438)

(792)

Special items of Corporate Center and Consolidation
Special items
EBIT of segments
EBIT of Corporate Center and Consolidation
EBIT
Financial result
Income before income taxes

â€“

(27)

(438)

(819)

5,820

6,749

(425)

(499)

5,395

6,250

(981)

(1,005)

4,414

5,245

2014 figures restated

Reconciliation of Segmentsâ€™ Assets to Group Assets

Assets of the operating segments
Corporate Center and Consolidation assets
Nonallocated assets
Assets of discontinued operations
Group assets

[Table 4.13]
2014

2015

â‚¬ million

â‚¬ million

63,040

65,654

195

181

6,999

7,899

â€“

183

70,234

73,917

2014 figures restated

Reconciliation of Segmentsâ€™ Liabilities to Group Liabilities

Liabilities of the operating segments
Corporate Center and Consolidation liabilities
Nonallocated liabilities
Liabilities directly related to discontinued operations
Group liabilities

[Table 4.14]
2014

2015

â‚¬ million

â‚¬ million

23,570

24,557

3,409

2,645

23,037

21,158

â€“

112

50,016

48,472

The reconciliation of segment sales to Group sales is apparent from the table of key data by segment in note [1].

259

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

INFORMATION ON GEOGRAPHICAL AREAS
The following table provides a regional breakdown of external sales by market and of intangible assets, property,
plant and equipment:

Information on Geographical Areas

[Table 4.15]

Net sales (external)
â€“ by market

Intangible assets and
property, plant and
equipment

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Germany

4,804

4,946

12,403

12,385

United States

8,715

11,286

17,486

14,420

China

3,597

4,213

3,102

3,260

625

691

905

5,298

Other

23,598

25,188

8,532

8,286

Total

41,339

46,324

42,428

43,649

Switzerland

2014 figures restated

INFORMATION ON MAJOR CUSTOMERS
Revenues from transactions with a single customer in no case exceeded 10% of Bayer Group sales in 2015
or 2014.
SEGMENT REPORTING EFFECTIVE 2016
In September 2015, it was decided to introduce a new organizational structure effective January 1, 2016, in line
with Bayerâ€™s focus on the Life Science businesses. The former Bayer HealthCare subgroup has now been dissolved
and the Radiology business assigned to the Pharmaceuticals Division. The Consumer Health Division now consists
entirely of the Consumer Care business. Animal Health has become a reportable segment. The Bayer CropScience
subgroup is now the Crop Science Division.
The segmentsâ€™ activities are as follows:
Activities of the Segments

[Table 4.16]

Division / Segment

Activities

Pharmaceuticals

Development, production and marketing of prescription pharmaceuticals, such as
anticoagulants, treatments for hemophilia, multiple sclerosis, cancer, eye diseases, pulmonary
hypertension, high blood pressure and infectious diseases; contraceptives; and medical products
such as injection systems and contrast agents for diagnostic procedures

Consumer Health

Development, production and marketing of over-the-counter medications, dermatology products
and nutritional supplements

Crop Science

Development, production and marketing of a comprehensive product portfolio in the areas of
seeds and plant traits, crop protection, home and garden, the green industry and nonagricultural
pest control

Animal Health

Development, production and marketing of veterinary medicines and animal grooming products

Covestro

Development, production and marketing of raw materials for polyurethanes; polycarbonate
resins and sheets; raw materials for coatings, adhesives and sealants; and selected chemical
intermediates

260

Bayer Annual Report 2015

261

Bayer Annual Report 2015
Consolidated Financial Statements

Consolidated Financial Statements

Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Consolidated Financial Statements of the Bayer Group

If the new organizational structure had already been in place as of December 31, 2015, selected segment reporting
items would appear as follows:

Selected Key Data by Segment

[Table 4.17]
Reconciliation
Pharmaceuticals

Consumer Health

Crop Science

Animal Health

All Other Segments

Corporate Center
and Consolidation

Life Sciences*

Covestro

Group

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

13,512

15,308

4,245

6,076

9,494

10,367

1,318

1,490

1,112

1,097

7

4

29,688

34,342

11,651

11,982

41,339

46,324

+6.3%

+13.3%

+8.7%

+43.1%

+7.7%

+9.2%

+0.9%

+13.1%

â€“4.9%

â€“1.3%

â€“

â€“42.9%

+6.4%

+15.7%

+3.7%

+2.8%

+5.6%

+12.1%

+10.0%

+8.7%

+13.6%

+40.4%

+11.4%

+2.3%

+4.0%

+4.5%

â€“4.4%

â€“0.8%

â€“

â€“42.9%

+10.1%

+10.6%

+4.5%

â€“5.1%

+8.5%

+6.2%

102

38

2

2

49

34

22

20

2,243

2,249

(2,477)

(2,407)

â€“

â€“

59

64

â€“

â€“

13,614

15,345

4,247

6,079

9,543

10,401

1,340

1,510

3,355

3,346

(2,470)

(2,403)

29,688

34,342

11,710

12,046

41,339

46,324

EBIT

2,627

3,027

609

769

1,806

2,103

234

254

(11)

(39)

(425)

(499)

4,840

5,615

555

635

5,395

6,250

EBIT before special items

2,836

3,327

731

1,005

1,838

1,881

234

318

21

43

(425)

(472)

5,235

6,102

598

967

5,833

7,069

EBITDA
before special items

4,081

4,615

991

1,456

2,360

2,416

285

348

200

238

(419)

(466)

7,498

8,607

1,187

1,659

8,685

10,266

226

331

147

(318)

(323)

5,746

5,886

961

1,113

6,707

6,999

348

360

26

(824)

287

4,817

5,395

880

1,452

5,697

6,847

Net sales (external)
Change
Currency-adjusted change
Intersegment sales
Net sales (total)

Gross cash flow
Net cash flow

2,996
3,533

3,009
3,157

685
564

886
816

1,835

1,941

950

217

761

234

* Including Currenta

GRI
G4-17

6. Scope of consolidation; subsidiaries and affiliates

Pure Salt Baytown llc, United States, is fully consolidated as a structured entity. The Bayer Group guarantees the
liabilities of Pure Salt Baytown llc to banks. These liabilities, which are reflected in full in the consolidated statement of financial position, amounted to â‚¬17 million as of December 31, 2015 (2014: â‚¬20 million).

6.1 Changes in the scope of consolidation
Changes in the scope of consolidation in 2015 were as follows:

Change in Number of Consolidated Companies

[Table 4.18]
Germany

Other countries

Total

Bayer AG and consolidated companies
December 31, 2014

67

235

302

Changes in scope of consolidation

2

8

10

Additions

2

6

8

Retirements

(3)

(10)

(13)

December 31, 2015

68

239

307

The increase in the total number of consolidated companies in 2015 was primarily due to changes in the scope of
consolidation and to acquisitions. Derecognitions were primarily due to mergers among Group companies.
Bayer Pearl Polyurethane Systems llc, United Arab Emirates, is fully consolidated because the Bayer Group holds
a majority of the voting rights.

The above table includes one joint operation, LyondellBasell Covestro Manufacturing Maasvlakte v.o.f., Netherlands, as of December 31, 2015, and December 31, 2014. Pursuant to ifrs 11, Bayerâ€™s share of this companyâ€™s
assets, liabilities, revenues and expenses are included in the consolidated financial statements in accordance with
Bayerâ€™s rights and obligations. The main purpose of LyondellBasell Covestro Manufacturing Maasvlakte v.o.f. is the
joint production of propylene oxide (po) for Bayer and its partner Lyondell.
In conjunction with the acquisition of the consumer care business of Merck & Co., Inc., United States, Bayer entered into a strategic collaboration with that company. This collaboration is included in the consolidated financial
statements as a joint operation. Bayer and Merck & Co., Inc., have mutually agreed to collaborate on the development, production, life-cycle management and marketing of active ingredients and products in the field of soluble
guanylate cyclase (sGC) modulation.
Four (2014: three) associates and three (2014: three) joint ventures were accounted for in the consolidated financial
statements using the equity method. Details of these companies are given in note [19].
Flagship Ventures V Agricultural Fund, l.p., United States, was included in the consolidated financial statements for
the first time in 2015 and classified as an associate. Bayer has no control over this associate despite owning 99.9%
of the capital, but is able to significantly influence its financial and operating policy decisions.
Nanjing Baijingyu Pharmaceutical Co., Ltd., China, was classified as an associate in view of Bayerâ€™s representation
on its executive committee and supervisory board. This enables Bayer to significantly influence its financial and
operating policy decisions despite owning only 15% of its voting rights and capital.

GRI
G4-17

262

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

GRI
G4-17

A total of 71 (2014: 78) subsidiaries, including one (2014: one) structured entity and 12 (2014: 12) associates or
joint ventures that in aggregate are immaterial to the Bayer Groupâ€™s financial position and results of operations are
not consolidated but recognized at cost. The immaterial subsidiaries accounted for less than 0.2% of Group sales,
less than 0.3% of equity and less than 0.2% of total assets.
Details of subsidiary and affiliated companies pursuant to Section 313 of the German Commercial Code can be
accessed at www.annualreport2015.bayer.com/companylist.pdf.
The following domestic subsidiaries availed themselves in 2015 of certain exemptions granted under Section 264,
Paragraph 3, and Section 264b of the German Commercial Code regarding the publication of legal-entity financial
statements:

German Exempt Subsidiaries

[Table 4.19]

Company Name

Place of Business

Bayerâ€™s interest

Adverio Pharma GmbH

SchÃ¶nefeld

100.0

AgrEvo Verwaltungsgesellschaft mbH

Frankfurt am Main

100.0

Alcafleu Management GmbH & Co. KG

SchÃ¶nefeld

99.9

Bayer 04 Immobilien GmbH

Leverkusen

100.0

Bayer 04 Leverkusen FuÃŸball GmbH

Leverkusen

100.0

Bayer Altersversorgung GmbH

Leverkusen

100.0

Bayer Animal Health GmbH

Leverkusen

100.0

Bayer Beteiligungsverwaltung Goslar GmbH

Leverkusen

100.0

Bayer Business Services GmbH

Leverkusen

100.0

Bayer Chemicals Aktiengesellschaft

Leverkusen

100.0

Bayer Consumer Care Deutschland GmbH

Berlin

100.0

Bayer CropScience Aktiengesellschaft

Monheim

100.0

Bayer CropScience Biologics GmbH

Wismar

100.0

Bayer CropScience Deutschland GmbH

Langenfeld

100.0

Bayer Direct Services GmbH

Leverkusen

100.0

Bayer Gastronomie GmbH

Leverkusen

100.0

Bayer Gesellschaft fÃ¼r Beteiligungen mbH

Leverkusen

100.0

Bayer HealthCare Aktiengesellschaft

Leverkusen

100.0

Bayer Innovation GmbH

Leverkusen

100.0

Bayer Intellectual Property GmbH

Monheim

100.0

Bayer Real Estate GmbH

Leverkusen

100.0

Bayer Schering Pharma AG

Berlin

100.0

Bayer Technology Services GmbH

Leverkusen

100.0

Bayer Vital GmbH

Leverkusen

100.0

Bayer Weimar GmbH und Co. KG

Weimar

100.0

Bayer-Handelsgesellschaft mit beschrÃ¤nkter Haftung

Leverkusen

100.0

BGI Deutschland GmbH

Leverkusen

100.0

Chemion Logistik GmbH

Leverkusen

100.0

Dritte Bayer Real Estate VV GmbH & Co. KG

SchÃ¶nefeld

100.0

Erste Bayer Real Estate VV GmbH & Co. KG

SchÃ¶nefeld

100.0

Erste K-W-A Beteiligungsgesellschaft mbH

Leverkusen

100.0

Euroservices Bayer GmbH

Leverkusen

100.0

FÃ¼nfte Bayer Real Estate VV GmbH & Co. KG

SchÃ¶nefeld

100.0

Generics Holding GmbH

Leverkusen

100.0

GP Grenzach Produktions GmbH

Grenzach-Wyhlen

100.0

%

263

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

German Exempt Subsidiaries

[Table 4.19] continued

Company Name

Place of Business

Bayerâ€™s interest

Hild Samen GmbH

Marbach am Neckar

100.0

Intendis GmbH

Berlin

100.0

Intraserv GmbH & Co. KG

SchÃ¶nefeld

100.0

Jenapharm GmbH & Co. KG

Jena

100.0

KOSINUS GrundstÃ¼cks-Verwaltungsgesellschaft mbH & Co. Gamma OHG

SchÃ¶nefeld

100.0

KVP Pharma+VeterinÃ¤r Produkte GmbH

Kiel

100.0

MENADIER Heilmittel GmbH

Berlin

100.0

Schering-Kahlbaum Gesellschaft mit beschrÃ¤nkter Haftung

Berlin

100.0

Sechste Bayer Real Estate VV GmbH & Co. KG

SchÃ¶nefeld

100.0

Siebte Bayer VV GmbH

Leverkusen

100.0

Steigerwald Arzneimittelwerk GmbH

Darmstadt

100.0

TECTRION GmbH

Leverkusen

100.0

TravelBoard GmbH

Leverkusen

100.0

Vierte Bayer Real Estate VV GmbH & Co. KG

SchÃ¶nefeld

100.0

Zweite Bayer Real Estate VV GmbH & Co. KG

SchÃ¶nefeld

100.0

Zweite K-W-A Beteiligungsgesellschaft mbH

Leverkusen

100.0

%

6.2 Business combinations and other acquisitions
ACQUISITIONS IN 2015
The purchase prices for the acquisitions made in 2015, along with adjustments to purchase prices and purchase
price allocations effected in 2015 relating to previous yearsâ€™ transactions, totaled â‚¬8 million (2014: â‚¬13,741 million). The purchase prices of the acquired companies or businesses were settled mainly in cash. Adjustments to
purchase price allocations and other adjustments reduced the total carrying amount of goodwill by â‚¬5 million
(2014: â‚¬5,169 million increase). The changes in goodwill mainly resulted from the following transactions:
On March 2, 2015, Covestro successfully completed the acquisition of all the shares of Thermoplast Composite
GmbH, Germany, a technology leader specializing in the production of thermoplastic fiber composites. The aim of
the acquisition is to expand the range of polycarbonate materials for major industries to include composites made
from continuous fiber-reinforced thermoplastics. A purchase price of â‚¬18 million was agreed. This includes a variable component of â‚¬4 million. The purchase price mainly pertained to patents and goodwill.
On July 1, 2015, CropScience completed the acquisition of all the shares of SeedWorks India Pvt. Ltd., based in
Hyderabad, India. The company is specialized in the breeding, production and marketing of hybrid seeds of tomato, hot pepper, okra and gourds. It has research and seed processing locations in Bangalore and Hyderabad, respectively. The purchase of SeedWorks India is intended to further strengthen CropScienceâ€™s vegetable seed business in India. A purchase price of â‚¬80 million was agreed, subject to the usual purchase price adjustments. The
purchase price mainly pertained to patents, research and development projects and goodwill.
As part of the acquisition of the consumer care business of Merck & Co., Inc., Whitehouse Station, New Jersey,
United States, the production facilities at the Pointe-Claire site in Canada were acquired on July 1, 2015. A purchase price of â‚¬67 million was agreed.
The global purchase price allocation for the consumer care business acquired from Merck & Co., Inc. in 2014 was
completed in September 2015.

264

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

This resulted in an adjustment to deferred tax assets due to temporary differences between the carrying amounts of
intangible assets in the ifrs financial statements and those reported for tax purposes, along with a corresponding
decline in goodwill in the statement of financial position. These deferred tax assets were retroactively restated to
the date of acquisition pursuant to ifrs 3.45ff.

Change in Purchase Price Allocation

[Table 4.20]
Dec. 31, 2014

Goodwill
Deferred taxes

Before change
in purchase price
allocation

Change
in purchase price
allocation

After change
in purchase price
allocation

â‚¬ million

â‚¬ million

â‚¬ million

16,168

(821)

15,347

2,981

821

3,802

In addition, the purchase price was reduced by â‚¬8 million in 2015 on the basis of agreed purchase price adjustment
mechanisms.
The court proceedings initiated by former minority stockholders of Bayer Pharma AG (formerly Bayer Schering
Pharma AG), Berlin, Germany, were settled in August 2015. The additional payment made as a result represents a
subsequent purchase price adjustment according to the March 31, 2004, version of ifrs 3 in effect at the acquisition date. The goodwill was increased by â‚¬261 million in 2013 based on the status of the proceedings at that time.
The settlements made it possible to finally determine the goodwill arising from the acquisition. It was therefore
necessary to reduce the goodwill amount by â‚¬115 million in 2015 as a result of the proceedings. Both the increase
and the reduction were recognized outside profit or loss against the liability resulting from the minority stockholdersâ€™ compensation claim.
The global purchase price allocation for Dihon Pharmaceutical Group Co. Ltd., Kunming, Yunnan, China, acquired
in 2014, was completed in October 2015. The purchase price was reduced by â‚¬43 million in 2015 due to adjustment mechanisms.
The purchase price allocations for SeedWorks India Pvt. Ltd. and the production facilities at the Pointe-Claire site
in Canada acquired from Merck & Co., Inc. currently remain incomplete pending compilation and review of the
relevant financial information. It is therefore possible that changes will be made in the allocation of the purchase
prices to the individual assets and liabilities.
The businesses of the above-mentioned acquired companies Thermoplast Composite GmbH and SeedWorks
India Pvt. Ltd. contributed a total of â‚¬5 million to Bayer Group sales in 2015. ebit of these businesses in 2015 totaled minus â‚¬5 million. Their total income after taxes since the respective dates of their first-time consolidation was
minus â‚¬5 million. This includes the financing costs incurred since the respective acquisition dates.
If the above acquisitions had already been made as of January 1, 2015, the Bayer Group would have had total
sales of â‚¬46,334 million in 2015. Group income after taxes and earnings per share would not have been materially
affected.

265

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The effects of these transactions and other, smaller transactions made in 2015 â€“ along with adjustments to purchase prices and purchase price allocations made in 2015 relating to previous yearsâ€™ transactions â€“ on the Groupâ€™s
assets and liabilities as of the respective acquisition or adjustment dates are shown in the table. Net of acquired
cash and cash equivalents, the transactions resulted in the following cash outflow:

Acquired Assets and Assumed Liabilities (Fair Values at the Respective Acquisition Dates)

2014

Of which
Merck CC

Of which
Dihon

[Table 4.21]

2015

Of which
Merck CC

Of which
Merck
Canada

Of which
Dihon

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Goodwill

5,169

4,316

96

(5)

49

3

1

Patents and technologies

1,762

â€“

â€“

39

â€“

â€“

â€“

Trademarks

5,672

5,362

295

53

35

â€“

18

Production rights

71

â€“

â€“

â€“

â€“

â€“

â€“

R&D projects

16

â€“

â€“

26

â€“

â€“

â€“

Other rights
Property, plant and equipment
Other noncurrent assets
Deferred tax assets

30

â€“

6

(20)

(20)

â€“

â€“

235

146

66

36

(23)

61

(2)

9

â€“

9

â€“

â€“

â€“

â€“

1,264

1,222

3

(5)

(5)

â€“

â€“

Inventories

331

295

18

(44)

(46)

4

(8)

Receivables

222

106

70

57

43

3

(4)

Other current assets
Cash and cash equivalents
Provisions for pensions and
other post-employment benefits

â€“

â€“

â€“

â€“

â€“

â€“

â€“

105

3

12

2

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

Other provisions

(105)

(101)

(3)

(85)

(50)

(3)

(19)

Financial liabilities

(213)

(20)

(65)

â€“

â€“

â€“

â€“

Other liabilities

(292)

(150)

(60)

(25)

7

(1)

(27)

Deferred tax liabilities
Net assets
Changes in noncontrolling
interest
Purchase price
Acquired cash and cash
equivalents
Advance purchase price
payments made in prior years

(535)

(2)

(46)

(21)

2

â€“

(2)

13,741

11,177

401

8

(8)

67

(43)

â€“

â€“

â€“

â€“

â€“

â€“

â€“

13,741

11,177

401

8

(8)

67

(43)

(105)

(3)

(12)

(2)

â€“

â€“

â€“

â€“

â€“

(11)

â€“

(11)

â€“

â€“

Settlement gain from
pre-existing relationship

(35)

â€“

â€“

111

â€“

â€“

â€“

Liabilities for future payments

(92)

(65)

â€“

â€“

â€“

â€“

â€“

Payments for previous yearsâ€™
acquisitions
Purchase price adjustment
Net cash outflow for
acquisitions

4

â€“

â€“

65

63

â€“

â€“

33

â€“

33

5

â€“

â€“

5

13,546

11,109

422

176

55

56

(38)

2014 figures restated

On December 19, 2015, Bayer entered into an agreement to create a joint venture with crispr Therapeutics AG,
Basel, Switzerland. The joint venture is to be established in the first quarter of 2016. Its purpose is the development and commercialization of new methods to treat blood disorders, blindness and heart diseases. As of December 31, 2015, Bayer had capital contribution commitments of us$370 million to crispr Therapeutics AG and the
joint venture yet to be established. These commitments mature on December 31, 2020, at the latest.

266

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

ACQUISITIONS IN 2014
In 2014, the following acquisitions were accounted for in accordance with ifrs 3:
On March 6, 2014, CropScience completed the acquisition of all the shares of Biagro Group, a producer and distributor of biological seed treatment solutions headquartered in General Las Heras in the province of Buenos Aires,
Argentina. The company operates production facilities in Argentina and Brazil. Its portfolio of established brands
includes seed-applied inoculants, plant-growth-promoting microorganisms and other products for integrated pest
management based on bacterial and fungal strains. The acquisition helps CropScience to build on the success of its
soybean seed business in Latin America. A one-time payment and purchase price adjustment totaling â‚¬10 million
were agreed upon along with potential milestone payments reflected at â‚¬6 million in the purchase price allocation.
The milestone payments are mainly dependent on the achievement of certain sales targets and product approvals.
The purchase price mainly pertained to the technology platform and goodwill.
In March 2014, HealthCare successfully completed the takeover offer for the shares of Algeta asa, Oslo, Norway,
and acquired 100% of the outstanding shares. Bayer issued a takeover offer for all the shares of Algeta at a price of
nok 362 per share in cash on January 20, 2014. On expiration of the offer deadline, Bayer had received acceptances from Algeta shareholders representing about 98% of the share capital. On March 14, 2014, a compulsory acquisition process was carried out to obtain the remaining 2% of the shares, also at a price of nok 362 per share.
Algeta creates novel cancer therapies based on its world-leading, patented technologies. The company develops
alpha-pharmaceuticals designed to target cancers using the unique properties of alpha particle radiation.
HealthCare and Algeta began collaborating in 2009 to develop and commercialize radium-223 dichloride, which
was approved in the United States in May 2013 under the tradename Xofigoâ„¢. The acquisition strengthened the
oncology business of Pharmaceuticals. The purchase price was â‚¬1,974 million, including â‚¬35 million for the settlement of the pre-existing relationship between Algeta and Bayer. The latter amount represented the value of the
advantage enjoyed by the acquirer from the contractual relationship that existed prior to the acquisition compared
to market conditions for similar collaborations. The settlement amount was reflected in other operating income and
at the same time increased the consideration transferred.
The purchase price mainly pertained to an intangible asset for the product-specific radium-223 technology along
with goodwill. The goodwill is mainly attributable to synergies in administration processes and infrastructure,
including cost savings in the selling, research and development, and general administration functions.
On September 30, 2014, CropScience completed the acquisition of the seeds business of Granar s.a., headquartered in EncarnaciÃ³n, Paraguay. Granar specializes in the breeding, production and marketing of improved seed,
especially soybean seed, that is adapted to the growing conditions in subtropical regions. It has a strong presence
in Paraguay and Uruguay and an increasing presence in Brazil. Granar continued to sell the seed for its own account for the 2014 / 15 sowing season. Bayer took over marketing in 2015. Part of the agreed one-time payment of
â‚¬15 million to acquire the business has been retained for disbursement over the next six years and is reflected at
â‚¬2 million in the purchase price allocation.
On October 1, 2014, HealthCare completed the acquisition of the consumer care business of u.s. company Merck &
Co., Inc., Whitehouse Station, New Jersey. The acquired business is primarily comprised of products in the cold,
allergy, sinus & flu, dermatology (including sun care), foot health and gastrointestinal categories. The most important brands are Claritinâ„¢ (allergy), Coppertoneâ„¢ (sun care), Miraâ„¢ (gastrointestinal) and Afrinâ„¢ (cold), and â€“
in North America and Latin America â€“ Dr. Schollâ€™sâ„¢ (foot health). These products complement Bayerâ€™s existing
range of nonprescription medicines.

267

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In those countries where the consumer care business was acquired via an asset deal, Merck & Co., Inc. continued
the sales activities in its own name for a transitional period until the marketing authorizations had been transferred
to Bayer or Bayer was able to take over the business as distributor. During this period, the economic rewards and
risks already accrued to Bayer, and Bayer received the operating profit on the business from Merck. The transitional period has ended.
Where the business was acquired via a share deal, Bayer purchased 100% of the respective companyâ€™s shares.
In 2014, Bayer paid a provisional purchase price of â‚¬11,177 million, less specific amounts that were retained pending the receipt of antitrust approvals in the Republic of Korea and the transfer of further assets. The provisional
purchase price allocation mainly comprised goodwill of â‚¬5,137 million and acquired trademarks valued at
â‚¬5,362 million. The goodwill amount was retroactively adjusted to â‚¬4,316 million as of the acquisition date. It is
largely based on cost synergies, especially in marketing and manufacturing, as well as on sales synergies resulting
from the increased distribution capability and use of the global infrastructure. As expected, a goodwill amount of
â‚¬2,084 million is tax-deductible.
Upon closure of this acquisition, the strategic pharmaceutical collaboration agreed between Bayer and Merck &
Co., Inc. in the field of soluble guanylate cyclase (sGC) modulation also came into effect. Bayerâ€™s aim in entering
into the global co-development and co-commercialization agreement, which has already received antitrust clearance, is to strengthen its development potential in the cardiovascular therapeutic area. In this connection, Merck &
Co., Inc. is to make payments to Bayer of up to us$2.1 billion, comprising an up-front payment of us$1.0 billion
(â‚¬793 million) made in 2014 and sales milestone payments of up to us$1.1 billion related to future joint activities
with certain compounds, including Adempasâ„¢ (riociguat) to treat pulmonary hypertension. The one-time payment
of â‚¬793 million is to be recognized in sales and earnings over a period of 13.5 years as the obligations are satisfied.
On November 1, 2014, Consumer Health acquired all the shares of Dihon Pharmaceutical Group Co. Ltd., Kunming,
Yunnan, China. Dihon is a pharmaceutical company specializing in the manufacture and marketing of over-thecounter (otc) and herbal traditional Chinese medicine products. A provisional purchase price of â‚¬401 million was
accounted for in 2014. This was based on a purchase price adjustment mechanism. The purchase price mainly
pertained to acquired trademarks and goodwill.
On December 1, 2014, CropScience completed the acquisition of land management assets in the United States,
Canada, Mexico, Australia and New Zealand from E. I. DuPont de Nemours and Company, United States. The acquisition provides CropScience with access to the growing forestry and range & pasture business segments in
North America. Bayer paid a provisional purchase price of â‚¬120 million in 2014. A potential milestone payment for
a successful registration was agreed upon in addition. This payment was included at â‚¬18 million in the purchase
price allocation. The purchase price mainly pertained to intangible assets for product-related technologies and
goodwill.

268

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

6.3 Divestitures, material sale transactions and discontinued operation
DIVESTITURES AND MATERIAL SALE TRANSACTIONS IN 2015
The effects of divestitures and material sale transactions made in 2015 and previous years on the consolidated
financial statements were as follows:
On March 2, 2015, Consumer Health completed the sale of two equine products, Legend / Hyonate and Marquis, to
Merial, Inc., Duluth, Georgia, United States. A purchase price of â‚¬120 million was agreed. The one-time payment is
accounted for as deferred income. The purchase prices for Legend / Hyonate and Marquis will be reflected in sales
and earnings over a four-year and a three-year period, respectively, as Bayer has entered into further significant
obligations.
No assets or liabilities were derecognized in 2015 as a result of this divestiture.

Divested Assets and Liabilities

[Table 4.22]
2014

2015

â‚¬ million

â‚¬ million

286

â€“

Patents and technologies

62

â€“

Other intangible assets

17

â€“

Property, plant and equipment

18

â€“

2

â€“

10

â€“

Other current assets

â€“

â€“

Other provisions

â€“

â€“

Other liabilities

â€“

â€“

395

â€“

Goodwill

Other noncurrent assets
Inventories

Divested net assets

DIVESTITURES AND MATERIAL SALE TRANSACTIONS IN 2014
On August 29, 2014, Consumer Health completed the sale of the Interventional device business to Boston Scientific Corporation, Natick, Massachusetts, United States. The sale comprised the AngioJetâ„¢ thrombectomy system
and the Jetstreamâ„¢ atherectomy system, as well as the Fetchâ„¢2 aspiration catheter used in cardiology, radiology
and peripheral vascular procedures. The total transaction price, including fees for transitional services to Boston
Scientific and before working capital adjustments, was â‚¬315 million. Disregarding the transitional services, a
special gain of â‚¬80 million was recognized in other operating income, and deferred income of â‚¬2 million was
recognized in liabilities.
On October 1, 2014, the strategic pharmaceutical collaboration agreed between Bayer and Merck & Co., Inc.,
United States, in the area of soluble guanylate cyclase (sGC) modulation came into effect. Pharmaceuticals and
Merck & Co., Inc. assumed joint control of the sGC modulators business. The collaboration agreement provides for
future net cash flows to be equally shared between Bayer and Merck & Co., Inc. Of the goodwill allocated to the
Pharmaceuticals segment, â‚¬173 million was derecognized through profit or loss as of the date the collaboration
came into effect.

269

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

DISCONTINUED OPERATION
On June 8, 2015, an agreement was signed to sell the Diabetes Care business to Panasonic Healthcare Holdings
Co., Ltd., Tokyo, Japan, for approximately â‚¬1 billion. The sale includes the leading Contourâ„¢ portfolio of blood
glucose monitoring meters and strips, as well as other products such as Breezeâ„¢2, Eliteâ„¢ and Microletâ„¢ lancing
devices. Implementation of the agreement began on January 4, 2016. Bayer has entered into further significant
obligations, which are to be met over the next two years.
The Diabetes Care activities are reported as a discontinued operation. The respective information is provided from
the standpoint of the Bayer Group and is not intended to present these activities as a separate entity.
The income statements for the discontinued operation are given below:

Income Statements for Discontinued Operations

Net sales
Cost of goods sold
Gross profit
Selling expenses

[Table 4.23]
2014

2015

â‚¬ million

â‚¬ million

900

947

(357)

(380)

543

567

(349)

(386)

Research and development expenses

(37)

(48)

General administration expenses

(38)

(36)

(8)

(20)

111

77

â€“

â€“

Income before income taxes

111

77

Income taxes

(11)

3

Income after income taxes

100

80

Other operating income / expenses
EBIT1
Financial result

1

EBIT = earnings before financial result and taxes

270

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The assets and liabilities of the discontinued operation are shown in the following table:

Assets and Liabilities of Discontinued Operations

[Table 4.24]
Dec. 31, 2015
â‚¬ million

Noncurrent assets
Goodwill

36

Other intangible assets

4

Property, plant and equipment

8
48

Current assets
Inventories

135
135

Total assets

183

Noncurrent liabilities
Provisions for pensions and other post-employment benefits

23
23

Current liabilities
Other provisions

89
89

Total liabilities

112

In addition to the assets of the discontinued Diabetes Care business amounting to â‚¬183 million, the statement of
financial position as of December 31, 2015, reflects a further â‚¬14 million in assets held for sale.
The discontinued operation affected the Bayer Group statement of cash flows as follows:

Cash Flows of Discontinued Operations

Net cash provided by (used in) operating activities (net cash flow)

[Table 4.25]
2014

2015

â‚¬ million

â‚¬ million

113

43

Net cash provided by (used in) investing activities

(6)

(4)

Net cash provided by (used in) financing activities

(107)

(39)

â€“

â€“

Change in cash and cash equivalents

271

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Income Statements
7. Net sales
Net sales are derived primarily from product deliveries. Total reported net sales for 2015 amounted to
â‚¬46,324 million, rising by â‚¬4,985 million, or 12.1%, compared to 2014. The increase resulted from the following
factors:

Factors in Sales Development

[Table 4.26]
2015

Volume
Price

â‚¬ million

%

1,817

+4.4

(713)

â€“1.7

Currency

2,420

+5.9

Portfolio

1,461

+3.5

Total

4,985

+12.1

Breakdowns of net sales by segment and by region are given in the table in note [1].

8. Selling expenses
Selling expenses comprise all expenses incurred in the reporting period for the sale, storage and transportation of
saleable products, advertising, the provision of advice to customers, and market research. Selling expenses were
comprised as follows:

Selling Expenses

[Table 4.27]
2014

2015

â‚¬ million

â‚¬ million

Internal and external sales force

4,452

4,808

Advertising and customer advice

2,491

3,006

Physical distribution and warehousing of finished products

1,139

1,273

Commission and licensing expenses

1,082

1,401

Other selling expenses

1,505

1,879

10,669

12,367

Total
2014 figures restated

9. Research and development expenses
Research and development expenses and their accounting treatment are defined in note [4]. Breakdowns of
research and development expenses by segment and region are given in note [1].

272

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

10. Other operating income
Other operating income was comprised as follows:

Other Operating Income

Gains on retirements of noncurrent assets

[Table 4.28]
2014

2015

â‚¬ million

â‚¬ million

133

137

Reversal of impairment losses on receivables

23

32

Reversals of unutilized provisions

44

25

Gains from derivatives

149

272

Miscellaneous operating income

361

644

Total

710

1,110

118

336

of which special items
2014 figures restated

Gains from the retirements of noncurrent assets included a â‚¬53 million gain from the sale of trademark rights for
the Biovitalâ„¢, Benervaâ„¢, Bactineâ„¢ and ProPlusâ„¢ brands (Consumer Health segment). In addition, a â‚¬29 million
gain was realized on the sale of transfer rights by Bayer 04 Leverkusen FuÃŸball GmbH. In the CropScience segment, a gain of â‚¬19 million was received from the sale of a parcel of land in Tolichowki, India. In the Covestro
segment, the sale of the polyurethanes production site in Anyer, Indonesia, yielded a gain of â‚¬13 million, and a
â‚¬6 million gain resulted from the sale of a parcel of land in Nanjing, China.
Miscellaneous operating income included â‚¬314 million in claims against Dow AgroSciences llc, United States, for
damages and royalty payments resulting from the infringement of Bayerâ€™s rights to the Liberty Linkâ„¢ weed control
system (CropScience segment). Also reflected here is a â‚¬16 million compensation payment for a production shortfall
in Toulouse, France. A â‚¬12 million gain was realized by Bayer 04 Leverkusen FuÃŸball GmbH from the sale of noncapitalized transfer rights.
In 2014, gains from the retirements of noncurrent assets included a gain of â‚¬80 million in the Consumer Health
segment from the divestiture of the Interventional device business to Boston Scientific Corporation, Natick, Massachusetts, United States. A gain of â‚¬9 million was also incurred from the sale of transfer rights by Bayer 04
Leverkusen FuÃŸball GmbH. The Consumer Health segment recorded a gain of â‚¬10 million from the termination of
the licensing and distribution agreement for the pain reliever Flectorâ„¢. The sale of the Monroe production site in
Argentina and the Xochimilco site in Mexico resulted in gains of â‚¬9 million and â‚¬6 million, respectively, in the
Pharmaceuticals segment.
The miscellaneous operating income in 2014 included a gain of â‚¬35 million in the Pharmaceuticals segment resulting from the pre-existing partnership between Algeta asa, Norway, and Bayer to develop and commercialize radium-223 dichloride. A gain of â‚¬21 million was recorded from the divestiture of the Consumer Health products Bronkaidâ„¢ and Neo-Synephrineâ„¢. A gain of â‚¬18 million resulted from the divestiture of the pharmaceutical product
Betapaceâ„¢. Also reflected in this item was income of â‚¬64 million from insurance reimbursements.

273

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

11. Other operating expenses
Other operating expenses were comprised as follows:

Other Operating Expenses

Losses on retirements of noncurrent assets
Impairment losses on receivables
Expenses related to significant legal risks
Losses from derivatives

[Table 4.29]
2014

2015

â‚¬ million

â‚¬ million

(198)

(32)

(87)

(183)

(168)

(151)

(74)

(628)

Miscellaneous operating expenses

(309)

(286)

Total

(836)

(1,280)

(356)

(247)

of which special items
2014 figures restated

The losses on retirements of noncurrent assets included â‚¬6 million in expenses for the termination of rice breeding
activities in Brazil.
Impairment losses of â‚¬91 million were recognized in 2015 on receivables from the Venezuelan exchange control
authority. Of this amount, the Pharmaceuticals segment accounted for â‚¬67 million, Consumer Health for â‚¬7 million,
CropScience for â‚¬13 million, Covestro for â‚¬3 million and the Corporate Center for â‚¬1 million. Details are provided in
note [4].
The â‚¬151 million in expenses for significant legal risks mainly included accounting measures taken in connection
with legal proceedings relating to the products Lunaâ„¢, ll Riceâ„¢ and Xareltoâ„¢.
The miscellaneous operating expenses included â‚¬38 million in restructuring charges related to the legal carve-out
of the Covestro Group, of which the Corporate Center segment accounted for â‚¬30 million and Covestro for
â‚¬8 million. Consumer Health incurred expenses of â‚¬41 million for the integration of the business acquired from
Merck & Co., Inc., United States.
As in the previous year, the remaining amount of miscellaneous operating expenses comprised a large number of
individually immaterial items at the subsidiaries.
In 2014, the losses on retirements of noncurrent assets included â‚¬173 million from the derecognition of the goodwill allocated to the Pharmaceuticals segment in connection with the pharmaceutical collaboration between Bayer
and Merck & Co., Inc., United States.
The miscellaneous operating expenses in 2014 included â‚¬10 million in restructuring charges, which were incurred
entirely by Covestro. Pharmaceuticals and Consumer Health incurred expenses of â‚¬12 million and â‚¬71 million,
respectively, for the integration of acquired businesses.

274

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

12. Personnel expenses and employee numbers
Personnel expenses for continuing operations rose in 2015 by â‚¬1,510 million to â‚¬11,203 million (2014: â‚¬9,693
million), mainly as a result of currency effects, the increase in the average number of employees, and higher employee bonuses based on the companyâ€™s financial success.

Personnel Expenses

[Table 4.30]
2014

2015

â‚¬ million

â‚¬ million

Salaries

7,875

9,012

Social expenses and expenses for pensions and other benefits

1,818

2,191

of which for defined contribution pension plans

483

559

of which for defined benefit and other pension plans

351

502

9,693

11,203

Total
2014 figures restated

The personnel expenses shown here do not contain the interest portion of the allocation to personnel-related provisions â€“ mainly for pensions and other post-employment benefits â€“ which is included in the financial result under
other financial expenses (note [13.3]).
The average numbers of employees, classified by corporate function, were as shown in the table below:

Employees

[Table 4.31]
2014

2015

Production

46,351

48,630

Marketing and distribution

44,150

45,078

Research and development

13,609

14,466

General administration
Total
Apprentices

9,006

9,377

113,116

117,551

2,349

2,332

2014 figures restated

The number of employees on either permanent or temporary contracts is stated in full-time equivalents, with
part-time employees included on a pro-rated basis in line with their contractual working hours. The figures do not
include apprentices.

13. Financial result
The financial result for 2015 was minus â‚¬1,005 million (2014: minus â‚¬981 million), comprising an equity-method
loss of â‚¬9 million (2014: â‚¬13 million), financial expenses of â‚¬1,367 million (2014: â‚¬1,311 million) and financial
income of â‚¬371 million (2014: â‚¬343 million). Details of the components of the financial result are provided below.

275

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

13.1 Income (loss) from investments in affiliated companies
The net income (loss) from investments in affiliated companies was comprised as follows:

Income (Loss) from Investments in Affiliated Companies

Net loss from investments accounted for using the equity method (equity-method loss)

[Table 4.32]
2014

2015

â‚¬ million

â‚¬ million

(13)

(9)

â€“

(1)

Expenses
Impairment losses on investments in affiliated companies
Gains
Impairment loss reversals on investments in affiliated companies

2

â€“

Gains / losses from investments in affiliated companies and from profit and loss transfer agreements (net)

1

3

â€“

31

(10)

24

Gains from the sale of investments in affiliated companies
Total

The main components of the income from investments in affiliated companies were a â‚¬29 million gain from the sale
of the interest in Kythera Biopharmaceuticals, Inc., United States, and the â‚¬23 million (2014: â‚¬18 million) equitymethod loss from the associate po jv, lp, United States. The â‚¬14 million (2014: â‚¬5 million) aggregate of the equitymethod gains and losses of the remaining joint ventures and associates accounted for using the equity method
included a â‚¬10 million gain from the sale of the interest in Bayer imsa, s.a. de c.v., Mexico.
Further details of the companies accounted for using the equity method are given in note [19].

13.2 Net interest expense
The net interest expense was comprised as follows:

Net Interest Expense

[Table 4.33]
2014

2015

â‚¬ million

â‚¬ million

Expenses
Interest and similar expenses
Interest expenses for derivatives (held for trading)

(618)

(752)

(75)

(25)

283

297

Income
Interest and similar income
Interest income from derivatives (held for trading)
Total

54

25

(356)

(455)

Interest and similar expenses included interest expense of â‚¬49 million (2014: â‚¬55 million) relating to nonfinancial
liabilities. Interest and similar income included interest income of â‚¬133 million (2014: â‚¬48 million) from nonfinancial assets. Interest income of â‚¬109 million resulted from claims against Dow AgroSciences llc, United States, for
damages and royalty payments resulting from the infringement of Bayerâ€™s rights to the Liberty Linkâ„¢ weed control
system.
Settlements were reached in August 2015 in the court proceedings initiated by former minority stockholders of
Bayer Pharma AG (formerly Bayer Schering Pharma AG). Further details are given in note [6.2]. The interest expense was reduced in 2015 by an aggregate of â‚¬24 million in connection with the additional payment agreed upon
(2014: increased by â‚¬10 million).

276

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The change in the liability for redeemable noncontrolling interest is reflected in interest income or expense. In
2015 a â‚¬5 million (2014: â‚¬46 million) decrease in this liability was recognized as interest income.

13.3 Other financial income and expenses
Other financial income and expenses were comprised as follows:

Other Financial Income and Expenses

[Table 4.34]
2014

2015

â‚¬ million

â‚¬ million

Expenses
Interest portion of interest-bearing provisions

(322)

(287)

Exchange loss

(248)

(254)

(48)

(48)

Miscellaneous financial expenses
Income
Miscellaneous financial income
Total

3

15

(615)

(574)

The interest portion of noncurrent provisions comprised â‚¬276 million (2014: â‚¬275 million) in interest expense for
pension and other post-employment benefit provisions plus â‚¬11 million (2014: â‚¬47 million) in effects of interest
expense and interest-rate fluctuations for other provisions and corresponding overfunding. The interest expense
for pension and other post-employment benefit provisions included â‚¬712 million (2014: â‚¬828 million) for the unwinding of discount on the present value of the defined benefit obligation and â‚¬436 million (2014: â‚¬553 million) in
interest income from plan assets.

14. Taxes
The breakdown of tax expenses by origin was as follows:

Tax Expense by Origin

[Table 4.35]

â‚¬ million

2014

2015

Of which
income
taxes

Of which
income
taxes

â‚¬ million

â‚¬ million

â‚¬ million

Taxes paid or accrued
Income taxes
Germany

(566)

(1,140)

other countries

(739)

(1,118)

Other taxes
Germany
other countries

(48)

(44)

(189)

(220)

(1,542)

(1,305)

(2,522)

(2,258)

Deferred taxes
from temporary differences
from tax loss carryforwards and tax credits

Total
2014 figures restated

164

1,056

70

(25)

234

234

1,031

1,031

(1,308)

(1,071)

(1,491)

(1,227)

277

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The other taxes mainly include land, vehicle and other indirect taxes. They are reflected in the respective functional
cost items.
The deferred tax assets and liabilities were allocable to the following items in the statement of financial position:

Deferred Tax Assets and Liabilities

[Table 4.36]
Dec. 31, 2014

Dec. 31, 2015

Deferred
tax assets

Deferred
tax liabilities

Deferred
tax assets

Deferred
tax liabilities

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

1,586

2,520

1,411

1,910

Property, plant and equipment

86

672

253

678

Financial assets

57

207

18

183

Inventories

652

50

943

63

Receivables

286

627

98

580

Intangible assets

Other assets

24

13

28

14

3,508

1,037

3,601

1,213

Other provisions

976

129

1,025

90

Liabilities

674

71

714

91

Tax loss carryforwards

446

â€“

393

â€“

Tax credits

144

â€“

191

â€“

8,439

5,326

8,675

4,822

Provisions for pensions and other post-employment benefits

of which noncurrent
Set-off
Total

7,182

4,912

7,398

4,750

(4,637)

(4,637)

(3,996)

(3,996)

3,802

689

4,679

826

2014 figures restated

Deferred taxes on remeasurements, recognized outside profit or loss, of the net liability for defined benefit pension
and other post-employment benefits diminished equity by â‚¬430 million (2014: increased equity by â‚¬1,621 million).
Deferred taxes on changes, recognized outside profit or loss, in fair values of available-for-sale financial assets and
derivatives designated as cash flow hedges diminished equity by â‚¬27 million (2014: increased equity by
â‚¬55 million). These effects on equity are reported in the statement of comprehensive income.
The use of tax loss carryforwards reduced the income taxes paid or accrued in 2015 by â‚¬136 million (2014:
â‚¬24 million). The use of tax credits reduced income taxes paid or accrued by â‚¬21 million (2014: â‚¬10 million).
Of the total tax loss carryforwards of â‚¬5,497 million in 2015 (2014: â‚¬4,535 million), an amount of â‚¬1,812 million
(2014: â‚¬1,737 million) is expected to be usable within a reasonable period. The increase in loss carryforwards was
mainly due to losses that newly arose in 2015 and tax reassessments for prior years. Deferred tax assets of
â‚¬393 million (2014: â‚¬446 million) were recognized for the amount of loss carryforwards expected to be usable. The
deferred tax assets included an amount of â‚¬0 million (2014: â‚¬39 million) that resulted from purchase price allocations and was recognized outside profit or loss.
The use of â‚¬3,685 million (2014: â‚¬2,798 million) of tax loss carryforwards was subject to legal or economic restrictions. Consequently, no deferred tax assets were recognized for this amount. If these tax loss carryforwards
had been fully usable, deferred tax assets of â‚¬322 million (2014: â‚¬138 million) would have been recognized.

278

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Tax credits of â‚¬191 million were recognized in 2015 (2014: â‚¬144 million) as deferred tax assets, including
â‚¬0 million (2014: â‚¬0 million) outside profit or loss. The use of â‚¬41 million (2014: â‚¬45 million) of tax credits was
subject to legal or economic restrictions. Consequently, no deferred tax assets were recognized for this amount.
Unusable tax credits and tax loss carryforwards will expire as follows:

Expiration of Unusable Tax Credits and Tax Loss Carryforwards

[Table 4.37]
Tax credits

Tax loss carryforwards

Dec. 31, 2014

Dec. 31, 2015

Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Within one year

4

4

14

17

Within two years

â€“

â€“

9

70

Within three years

3

4

3

25

Within four years

â€“

â€“

24

32

Within five years

23

26

82

234

Thereafter

15

6

2,666

3,307

Total

45

40

2,798

3,685

In 2015, subsidiaries that reported losses for 2015 or 2014 recognized net deferred tax assets totaling â‚¬2,455 million (2014: â‚¬2,117 million) from temporary differences and tax loss carryforwards. These assets were considered to
be unimpaired because the companies concerned were expected to generate taxable income in the future.
Deferred tax liabilities of â‚¬35 million were recognized in 2015 (2014: â‚¬6 million) for planned dividend payments by
subsidiaries. Deferred tax liabilities were not recognized for temporary differences on â‚¬12,087 million (2014:
â‚¬8,648 million) of retained earnings of subsidiaries because these earnings are to be reinvested for an indefinite
period.
The reported tax expense of â‚¬1,227 million for 2015 (2014: â‚¬1,071 million) differed by â‚¬119 million (2014:
â‚¬58 million) from the expected tax expense of â‚¬1,346 million (2014: â‚¬1,129 million) that would have resulted from
applying an expected weighted average tax rate to the pre-tax income of the Group. This average rate, derived
from the expected tax rates of the individual Group companies, was 25.7% in 2015 (2014: 25.6%). The effective
tax rate was 23.4% (2014: 24.3%).

279

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The reconciliation of expected to reported income tax expense and of the expected to the effective tax rate for the
Group was as follows:

Reconciliation of Expected to Actual Income Tax Expense

[Table 4.38]
2014

2015

â‚¬ million

%

â‚¬ million

%

1,129

25.6

1,346

25.7

(92)

(2.1)

(155)

(3.0)

(2)

â€“

(10)

(0.2)

First-time recognition of previously unrecognized deferred tax assets
on tax loss carryforwards

(15)

(0.3)

(30)

(0.6)

Use of tax loss carryforwards on which deferred tax assets were not
previously recognized

(1)

â€“

(6)

(0.1)

149

3.4

148

2.8

2

â€“

7

0.1

57

1.3

81

1.5

7

0.2

16

0.3

Expected income tax expense and expected tax rate
Reduction in taxes due to tax-free income
Income related to the operating business
Income from affiliated companies and divestiture proceeds

Increase in taxes due to non-tax-deductible expenses
Expenses related to the operating business
Impairment losses on investments in affiliated companies
New tax loss carryforwards unlikely to be usable
Existing tax loss carryforwards on which deferred tax assets were previously
recognized but which are unlikely to be usable
Tax income (â€“) and expenses (+) relating to other periods

(119)

(2.7)

(95)

(1.8)

Tax effects of changes in tax rates

(10)

(0.2)

(25)

(0.5)

Other tax effects

(34)

(0.9)

(50)

(0.8)

1,071

24.3

1,227

23.4

Actual income tax expense and effective tax rate
2014 figures restated

280

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

15. Income / losses attributable to noncontrolling interest
Income attributable to noncontrolling interest amounted to â‚¬115 million (2014: â‚¬19 million). Losses attributable to
noncontrolling interest amounted to â‚¬127 million (2014: â‚¬2 million).

16. Earnings per share
Earnings per share are determined according to ias 33 (Earnings per Share) by dividing net income by the
weighted average number of ordinary shares in issue during the year.

Earnings per Share

Income from continuing operations after income taxes
Income from discontinued operations after income taxes
Income after income taxes
of which attributable to noncontrolling interest
of which attributable to Bayer AG stockholders (net income)

[Table 4.39]
2014

2015

â‚¬ million

â‚¬ million

3,343

4,018

100

80

3,443

4,098

17

(12)

3,426

4,110

Shares

Shares

826,947,808

826,947,808

â‚¬

â‚¬

Basic

4.02

4.87

Diluted

4.02

4.87

Basic

0.12

0.10

Diluted

0.12

0.10

Basic

4.14

4.97

Diluted

4.14

4.97

Weighted average number of issued ordinary shares

Earnings per share
From continuing operations

From discontinued operations

From continuing and discontinued operations

2014 figures restated

281

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Statements of Financial Position
17. Goodwill and other intangible assets
Changes in intangible assets in 2015 were as follows:

Changes in Intangible Assets

Cost of acquisition
or generation,
December 31, 2014
Changes in scope
of consolidation
Acquisitions

[Table 4.40]

Acquired
goodwill

Patents and
technologies

Trademarks

Marketing
and
distribution
rights

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

15,347

12,827

10,242

1,808

2,168

882

3,189

46,463

Production
rights

R&D
projects

Other rights
and advance
payments

Total

â€“

4

â€“

â€“

â€“

â€“

1

5

(5)

39

53

â€“

â€“

26

(20)

93

Capital expenditures

â€“

77

â€“

52

â€“

107

152

388

Retirements

â€“

(33)

(35)

(55)

â€“

(7)

(966)

(1,096)

â€“

40

â€“

75

(2)

(113)

â€“

â€“

(34)

(2)

(14)

(33)

â€“

â€“

(20)

(103)

Transfers
Transfers (IFRS 5)
Inflation adjustment (IAS 29)
Exchange differences
December 31, 2015
Accumulated amortization
and impairment losses,
December 31, 2014

7

â€“

â€“

â€“

â€“

â€“

â€“

7

781

117

706

97

6

51

264

2,022

16,096

13,069

10,952

1,944

2,172

946

2,600

47,779

â€“

7,428

2,588

1,039

1,911

153

2,344

15,463

Changes in scope
of consolidation

â€“

4

â€“

â€“

â€“

â€“

â€“

4

Retirements

â€“

(17)

(31)

(55)

â€“

(7)

(949)

(1,059)

Amortization and
impairment losses in 2015

â€“

801

447

148

106

66

183

1,751

Amortization

â€“

801

422

147

106

â€“

161

1,637

Impairment losses

â€“

â€“

25

1

â€“

66

22

114

Impairment loss reversals

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

Transfers

â€“

â€“

1

1

(2)

â€“

â€“

â€“

Transfers (IFRS 5)

â€“

(1)

â€“

(25)

â€“

â€“

(19)

(45)

Exchange differences

â€“

62

78

26

6

13

206

391

December 31, 2015

â€“

8,277

3,083

1,134

2,021

225

1,765

16,505

Carrying amounts,
December 31, 2015

16,096

4,792

7,869

810

151

721

835

31,274

Carrying amounts,
December 31, 2014

15,347

5,399

7,654

769

257

729

845

31,000

2014 figures restated

The capitalized patents and technologies include an amount pertaining to the active ingredient alemtuzumab
(product name: Lemtrada) for the treatment of multiple sclerosis. Bayer gave back the worldwide distribution rights
for alemtuzumab to Genzyme Corp., United States, in 2009 and in return received global co-promotion rights and
an entitlement to royalties and revenue-based milestone payments. Genzyme Corp. received marketing approval for
alemtuzumab in Europe in 2013 and in the United States in 2014. Bayer has decided not to exercise its copromotion rights.

282

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Impairment losses of â‚¬114 million were recognized on intangible assets. In the Pharmaceuticals segment, development activities for an intangible asset in the oncology area were discontinued. A â‚¬42 million impairment loss was
recognized as a result. In the CropScience segment, impairment losses totaling â‚¬20 million were recognized on two
research and development projects in the crop protection area due to a delayed market introduction and new research findings. In the Consumer Health reporting segment, impairment losses totaling â‚¬17 million were recognized on trademarks based on a portfolio review associated with the closure of a production site.
Impairment losses were also recognized on further intangible assets in the Consumer Health segment (â‚¬23 million),
the CropScience segment (â‚¬9 million) and the Pharmaceuticals segment (â‚¬3 million).
Details of acquisitions and divestitures are provided in notes [6.2] and [6.3]. The impairment testing procedure for
goodwill and other intangible assets is explained in note [4].
Changes in intangible assets in 2014 were as follows:

Changes in Intangible Assets (Previous Year)

Cost of acquisition
or generation,
December 31, 2013
Changes in scope
of consolidation
Acquisitions
Capital expenditures
Retirements
Transfers
Transfers (IFRS 5)
Inflation adjustment (IAS 29)
Exchange differences
December 31, 2014
Accumulated amortization
and impairment losses,
December 31, 2013
Changes in scope
of consolidation
Retirements
Amortization and
impairment losses in 2014

[Table 4.41]

Acquired
goodwill

Patents and
technologies

Trademarks

Marketing
and
distribution
rights

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

9,862

11,021

4,282

1,598

2,062

775

2,994

32,594

Production
rights

R&D
projects

Other rights
and advance
payments

Total

â€“

â€“

â€“

â€“

â€“

â€“

2

2

5,169

1,762

5,672

â€“

71

16

30

12,720

â€“

39

18

124

â€“

115

127

423

(38)

(33)

(21)

(21)

(6)

(61)

(143)

(323)

â€“

9

â€“

18

34

(17)

(44)

â€“

(254)

(126)

(27)

â€“

â€“

â€“

â€“

(407)

6

â€“

â€“

â€“

â€“

â€“

â€“

6

602

155

318

89

7

54

223

1,448

15,347

12,827

10,242

1,808

2,168

882

3,189

46,463

â€“

6,653

2,262

834

1,773

131

2,165

13,818

â€“

â€“

â€“

â€“

â€“

â€“

2

2

(6)

(22)

(2)

(20)

(6)

(4)

(135)

(195)

6

803

269

188

104

15

182

1,567

Amortization

â€“

800

228

135

104

â€“

171

1,438

Impairment losses

6

3

41

53

â€“

15

11

129

Impairment loss reversals

â€“

(2)

â€“

â€“

â€“

â€“

â€“

(2)

Transfers

â€“

â€“

â€“

1

34

â€“

(35)

â€“

Transfers (IFRS 5)

â€“

(67)

(11)

â€“

â€“

â€“

â€“

(78)

Exchange differences

â€“

63

70

36

6

11

165

351

December 31, 2014

â€“

7,428

2,588

1,039

1,911

153

2,344

15,463

Carrying amounts,
December 31, 2014

15,347

5,399

7,654

769

257

729

845

31,000

Carrying amounts,
December 31, 2013

9,862

4,368

2,020

764

289

644

829

18,776

2014 figures restated

283

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Changes in the carrying amounts of goodwill for the reporting segments in 2015 and 2014 were as follows:

Goodwill by Reporting Segment

[Table 4.42]
Pharmaceuticals

Consumer
Health

HealthCare

CropScience

Covestro

Bayer Group

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

5,238

2,435

7,673

1,951

238

9,862

â€“

â€“

â€“

â€“

â€“

â€“

Acquisitions

751

4,349

5,100

69

â€“

5,169

Retirements

Carrying amounts, January 1, 2014
Change in scope of consolidation

(30)

(2)

(32)

â€“

â€“

(32)

Impairment losses in 2014

â€“

â€“

â€“

â€“

(6)

(6)

Transfers

â€“

â€“

â€“

â€“

â€“

â€“

(143)

(111)

(254)

â€“

â€“

(254)

Transfers (IFRS 5)
Inflation adjustment (IAS 29)
Exchange differences
Carrying amounts, December 31, 2014
Change in scope of consolidation

â€“

6

6

â€“

â€“

6

185

289

474

117

11

602

6,001

6,966

12,967

2,137

243

15,347

â€“

â€“

â€“

â€“

â€“

â€“

Acquisitions

(111)

49

(62)

50

7

(5)

Retirements

â€“

â€“

â€“

â€“

â€“

â€“

Impairment losses in 2015

â€“

â€“

â€“

â€“

â€“

â€“

Transfers

â€“

â€“

â€“

â€“

â€“

â€“

Transfers (IFRS 5)

â€“

(34)

(34)

â€“

â€“

(34)

Inflation adjustment (IAS 29)
Exchange differences
Carrying amounts, December 31, 2015
2014 figures restated

1

7

8

â€“

â€“

8

165

514

679

90

11

780

6,056

7,502

13,558

2,277

261

16,096

284

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Goodwill and other intangible assets with an indefinite useful life that are of material significance for the Bayer
Group are allocated to the following cash-generating units or unit groups as of the end of the reporting period:

Intangible Assets with an Indefinite Useful Life

Reporting segment

Cash-generating
unit / unit group

Pharmaceuticals

Pharmaceuticals

Consumer Health

[Table 4.43]

Goodwill

Material intangible assets with
an indefinite useful life

â‚¬ million

â‚¬ million

6,056

485

Consumer Care

6,187

22

CropScience

Crop Protection

1,287

74

CropScience

Seeds

507

149

In the case of research and development projects, the point in time from which a capitalized asset can be expected
to generate an economic benefit for the company cannot be determined. Such assets are therefore classified as
having an indefinite useful life. Development projects were capitalized at a total amount of â‚¬721 million as of the
end of 2015 (2014: â‚¬729 million).
Another intangible asset classified as having an indefinite useful life is the Bayer Cross, which was reacquired for
the North America region in 1994, having been awarded to the United States and Canada under the reparations
agreements at the end of the First World War. The period for which the Bayer Group will derive an economic benefit from this name cannot be determined as Bayer intends to make continuous use of it. The Bayer Cross is capitalized at â‚¬107 million.
PATENTS
The Bayer Group endeavors to obtain patent protection for its products and technologies in the major markets.

285

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The following table sets forth the expiration dates in our major markets of the most important patents covering
Adempasâ„¢, Avaloxâ„¢ / Aveloxâ„¢, Betaferonâ„¢ / Betaseronâ„¢, Eyleaâ„¢, Kogenateâ„¢, Levitraâ„¢, Mirenaâ„¢, Nexavarâ„¢,
Stivargaâ„¢, Xareltoâ„¢, Xofigoâ„¢, yazâ„¢, Yasminâ„¢ and Yasminelleâ„¢:
Patent Expiration Dates

[Table 4.44]
Market
Germany

France

U.K.

Italy

Spain

Japan

China

U.S.A.

Canada

Products
Adempasâ„¢
Active ingredient

2023a

2028i

2023a

2028i

2028i

2027i

2023

2023a

2023

Production process /
intermediate

2030

2030

2030

2030

2030

2030b

2030

2030

2030b

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

2015

Avaloxâ„¢ / Aveloxâ„¢
Active ingredient
Active ingredient
monohydrate

2016

2016

2016

2016

2016

2016

2016

2016

2016

Tablets

2019

2019

2019

2019

2019

2019

2019

2019

2019

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

2016

2025

2020a

2025

2025

2020

â€“

2020

Betaferonâ„¢ / Betaseronâ„¢
Active ingredient
Eyleaâ„¢
Active ingredient

2020a

2021a/f

Kogenateâ„¢
Active ingredient
Formulation

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

2021

2017

2017

2017

2017

2017

2020

2017

2016

2017

2018

2018

2018

2018

2018

2020

2018

2018

2018

Levitraâ„¢
Active ingredient
Mirenaâ„¢
Inserter

2015

2015

2015

2015

2015

â€“

2015

2015

2015

Inserter (improved)

2029d

2029d

2029d

2029d

2029d

2029

2029

2029b

2029b

Active ingredient

2021

2021

2021

2021

2021

2021g

2020

2020

2020

Polymorph

2025

2025

2025

2025

2025

2025h

2025

2027

2025

Formulation

2026

2026

2026

2026

2026

2026h

2026

2026k

2026

Active ingredient

2028i

2028

2024a

2028

2028

2026j

2024

2031c

2024

Formulation

2025

2025

2025

2025

2025

2026j

2025

2025b

2025

Production process

2031

2031

2031

2031

2031

2031

2031

2031

2031

Active ingredient

2023

2023

2023

2023

2023

2024

2020

2020l

2020

Formulation

2024

2024

2024

2024

2024

2025

2024

2024b

2024

Use

2024i

2024i

2024i

2024i

2024i

2019

2019

2020a

Production process

2031k

2031k

2031k

2031k

2031k

2031b

2031b

Nexavarâ„¢

Stivargaâ„¢

Xareltoâ„¢

Xofigoâ„¢
2031

2019
2031b

YAZâ„¢
Formulation
Production process

â€“

â€“

â€“

â€“

â€“

2021

2020

2025

2025

2025

2025

2025

2026

2026

â€“
2026c

2020
2026

Yasminâ„¢
Formulation
Production process

â€“

â€“

â€“

â€“

â€“

2020

2020

2025

2025

2025

2025

2025

2026

2026

â€“
2026c

2020
2026

Yasminelleâ„¢
Formulation
Production process
a
b
c
d
e
f
g
h
i
j
k
l

â€“

â€“

â€“

â€“

â€“

2020

2020

2025

2025

2025

2025

2025

2026

2026

Current expiration date; patent term extension applied for
Patent application pending
Patent term revised
Opposition to EP patent terminated; appeal possible
Additional patent term adjustment being calculated
Indication-specific term extensions until 2021 for AMD, until 2022 for CRVO and until 2023 for mCNV and DME
Patent term extension granted for kidney cancer until 2021, liver cancer until 2022, and thyroid cancer until 2025
Patent term extension granted for thyroid cancer until 2026 (polymorph) and 2027 (tablet)
Patent term extension granted
Patent term extension granted for colorectal cancer and GIST until 2026
Notice of allowance received
Patent term revised due to a terminal disclaimer; extension applied for

â€“
2026c

2020
2026

286

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

18. Property, plant and equipment
Changes in property, plant and equipment in 2015 were as follows:

Changes in Property, Plant and Equipment

Cost of acquisition or construction,
December 31, 2014
Changes in scope of consolidation
Acquisitions
Capital expenditures
Retirements
Transfers
Transfers (IFRS 5)
Inflation adjustment (IAS 29)

[Table 4.45]

Land and
buildings

Plant
installations
and
machinery

Furniture,
fixtures and
other
equipment

Construction
in progress
and advance
payments

Total

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

9,088

18,144

2,009

2,078

31,319

â€“

3

1

â€“

4

33

2

1

â€“

36

230

390

239

1,309

2,168

(167)

(429)

(185)

(58)

(839)

273

797

56

(1,126)

â€“

1

(64)

(4)

â€“

(67)

7

2

1

â€“

10

220

573

24

92

909

December 31, 2015

9,685

19,418

2,142

2,295

33,540

Accumulated depreciation
and impairment losses,
December 31, 2014

4,940

13,426

1,482

43

19,891

0

1

1

â€“

2

(101)

(397)

(156)

(72)

(726)

317

945

232

38

1,532

294

892

230

â€“

1,416

23

53

2

38

116

Impairment loss reversals

â€“

(1)

â€“

â€“

(1)

Transfers

â€“

(1)

1

â€“

â€“

Transfers (IFRS 5)

1

(57)

(3)

â€“

(59)

Exchange differences

Changes in scope of consolidation
Retirements
Depreciation and impairment losses in 2015
Depreciation
Impairment losses

Exchange differences

98

387

21

20

526

December 31, 2015

5,255

14,303

1,578

29

21,165

Carrying amounts, December 31, 2015

4,430

5,115

564

2,266

12,375

Carrying amounts, December 31, 2014

4,148

4,718

527

2,035

11,428

Impairment losses of â‚¬115 million, net of a â‚¬1 million impairment loss reversal, were recognized on property, plant
and equipment in the Covestro segment (â‚¬69 million), the Consumer Health segment (â‚¬33 million), the
CropScience segment (â‚¬6 million), the Pharmaceuticals segment (â‚¬3 million), and Other Segments (â‚¬4 million).
In 2015, borrowing costs of â‚¬33 million (2014: â‚¬32 million) were capitalized as components of the cost of acquisition or construction of qualifying assets, applying an average interest rate of 2.5% (2014: 3.1%).
Capitalized property, plant and equipment included assets with a total net value of â‚¬533 million (2014:
â‚¬504 million) held under finance leases. The cost of acquisition or construction of these assets as of the closing
date totaled â‚¬915 million (2014: â‚¬827 million). They comprised plant installations and machinery with a carrying
amount of â‚¬220 million (2014: â‚¬233 million), buildings with a carrying amount of â‚¬168 million (2014: â‚¬132 million)
and other property, plant and equipment with a carrying amount of â‚¬145 million (2014: â‚¬139 million). For information on the liabilities arising from finance leases, see note [27].

287

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In 2015, rental payments of â‚¬263 million (2014: â‚¬219 million) were made for assets leased under operating leases
as defined in ias 17 (Leases).
Lease payments of â‚¬2 million are expected to be received in 2016 from operating leases â€“ as defined in ias 17
(Leases) â€“ pertaining to property, plant and equipment, excluding the investment property stated below. Lease
payments totaling â‚¬7 million are expected to be received in 2017-2020 and lease payments totaling â‚¬1 million
after 2020.
INVESTMENT PROPERTY
The fair values of investment property are mainly determined using the income approach based on internal valuations for buildings and developed sites, and using the market comparison approach for undeveloped sites.
The total carrying amount of investment property as of December 31, 2015, was â‚¬164 million (December 31, 2014:
â‚¬175 million). The fair value of this property was â‚¬484 million (2014: â‚¬501 million). The rental income from investment property was â‚¬13 million (2014: â‚¬14 million), and the operating expenses directly allocable to this property
amounted to â‚¬8 million (2014: â‚¬9 million). A further amount of â‚¬1 million (2014: â‚¬2 million) in operating expenses
was directly allocable to investment property from which no rental income was derived.
Changes in property, plant and equipment in 2014 were as follows:

Changes in Property, Plant and Equipment (Previous Year)

Cost of acquisition or construction, December 31, 2013
Changes in scope of consolidation
Acquisitions
Capital expenditures

[Table 4.46]

Land and
buildings

Plant
installations
and
machinery

Furniture,
fixtures and
other
equipment

Construction
in progress
and advance
payments

Total

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

8,375

16,556

1,853

1,671

28,455

5

3

â€“

â€“

8

74

85

27

49

235

248

468

216

1,135

2,067

(165)

(351)

(176)

(6)

(698)

Transfers

233

611

34

(878)

â€“

Transfers (IFRS 5)

(11)

(6)

(5)

(1)

(23)

Retirements

Inflation adjustment (IAS 29)

5

1

â€“

2

8

324

777

60

106

1,267

December 31, 2014

9,088

18,144

2,009

2,078

31,319

Accumulated depreciation
and impairment losses,
December 31, 2013

4,630

12,414

1,390

6

18,440

4

3

â€“

â€“

7

(122)

(329)

(156)

(3)

(610)

282

819

205

39

1,345

258

786

205

â€“

1,249

24

33

â€“

39

96

Impairment loss reversals

â€“

â€“

â€“

â€“

â€“

Transfers

1

â€“

(1)

â€“

â€“

(1)

(3)

(2)

â€“

(6)

Exchange differences

Changes in scope of consolidation
Retirements
Depreciation and impairment losses in 2014
Depreciation
Impairment losses

Transfers (IFRS 5)
Exchange differences

146

522

46

1

715

December 31, 2014

4,940

13,426

1,482

43

19,891

Carrying amounts, December 31, 2014

4,148

4,718

527

2,035

11,428

Carrying amounts, December 31, 2013

3,745

4,142

463

1,665

10,015

288

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

19. Investments accounted for using the equity method
Four (2014: three) associates and three (2014: three) joint ventures were accounted for in the consolidated financial
statements using the equity method.

Associates and Joint Ventures Accounted for Using the Equity Method

Company Name

[Table 4.47]
Bayerâ€™s
interest

Place of Business

%

Associates
Flagship Ventures V Agricultural Fund, LP1

Cambridge, U.S.A.

Nanjing Baijingyu Pharmaceutical Co., Ltd.

Nanjing, China

Paltough Industries (1998) Ltd.

Kibbutz Ramat Yochanan, Israel

PO JV, LP

Wilmington, U.S.A.

99.9
15
25
39.4

Joint ventures
Bayer Zydus Pharma Private Limited

Mumbai, India

50

DCSO Deutsche Cyber-Sicherheitsorganisation GmbH

Berlin, Germany

25

DIC Covestro Polymer Ltd.

Tokyo, Japan

50

1

For information concerning the interest in this company see Note [6.1]

In 2000, Bayer acquired the polyols business and parts of the propylene oxide (po) production operations of Lyondell Chemicals with the objective of ensuring access to patented technologies and safeguarding the long-term
supply of po, a starting product for polyurethane. As part of this strategy, a company was established to produce po
(po jv, lp, United States, in which Covestro holds a 39.4% interest). Covestro benefits from fixed long-term supply
quotas / volumes of po from this companyâ€™s production. The two following tables contain summarized data from the
income statements and statements of financial position of the associated company po jv, lp, United States, which is
accounted for using the equity method, and show the respective amounts recognized in the consolidated financial
statements of the Bayer Group.

Income Statement Data of PO JV, LP, Accounted for Using the Equity Method

[Table 4.48]
2014

2015

â‚¬ million

â‚¬ million

2,414

1,695

Net loss after taxes

(44)

(56)

Share of net loss after taxes

(17)

(23)

Share of total comprehensive income after taxes

(17)

(23)

Net sales

Gain (loss) after taxes from impairments / derecognition of other interests
Recognized loss after taxes of PO JV, LP, accounted for using the equity method

(1)

â€“

(18)

(23)

Data from the Statements of Financial Position of PO JV, LP, Accounted for Using the Equity Method

[Table 4.49]
Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

Noncurrent assets

462

475

Equity

462

475

Share of equity

182

201

Other
Carrying amount of PO JV, LP, accounted for using the equity method

2

(3)

184

198

The item â€œOtherâ€ mainly comprised differences arising from adjustments of data to Bayerâ€™s uniform accounting
policies, along with purchase price allocations and their amortization in profit or loss.

289

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The following table contains a summary of the aggregated income statement data and aggregated carrying
amounts of the individually nonmaterial associates that are accounted for using the equity method.

Income Statement Data and Carrying Amount of Associates Accounted for Using the Equity Method

[Table 4.50]
2014

2015

â‚¬ million

â‚¬ million

Income after taxes

4

12

Share of income after taxes

1

1

Share of total comprehensive income after taxes

1

1

27

37

Carrying amount of associates accounted for using the equity method

The following table contains a summary of the aggregated income statement data and aggregated carrying
amounts of the individually nonmaterial joint ventures that are accounted for using the equity method.

Income Statement Data and Carrying Amount of Joint Ventures Accounted for Using the Equity Method

[Table 4.51]
2014

2015

â‚¬ million

â‚¬ million

Income after taxes

8

6

Share of income after taxes

4

3

Share of total comprehensive income after taxes

4

3

Gain (loss) after taxes from impairments / derecognition of other interests

â€“

â€“

Recognized income after taxes of joint ventures accounted for using the equity method
Carrying amount of joint ventures accounted for using the equity method

4

3

12

11

20. Other financial assets
The other financial assets were comprised as follows:

Other Financial Assets

[Table 4.52]
Dec. 31, 2014

Loans and receivables
Available-for-sale financial assets
of which debt instruments
of which equity instruments
Held-to-maturity financial investments
Receivables from derivatives
Receivables under lease agreements
Total

Dec. 31, 2015

Total

Of which
current

Total

Of which
current

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

170

127

65

21

1,099

193

1,177

266

1,006

186

1,092

262

93

7

85

4

69

11

73

6

484

392

526

463

8

â€“

7

â€“

1,830

723

1,848

756

2014 figures restated

The debt instruments reported as available-for-sale financial assets included capital of â‚¬610 million (2014:
â‚¬595 million) provided to Bayer-Pensionskasse VVaG (Bayer-Pensionskasse) for its effective initial fund, and
jouissance right capital (Genussrechtskapital) of â‚¬153 million (2014: â‚¬150 million), also provided to BayerPensionskasse. Also reported in this category were investments of â‚¬119 million (2014: â‚¬10 million) in money market funds along with German treasury bills in the amount of â‚¬125 million (2014: â‚¬125 million). These treasury bills,

290

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

which were lent to a bank, continue to be recognized as available-for-sale financial assets because the related risks
and rewards remain with Bayer. Upon maturity or redemption of the treasury bills, Bayer is obligated until June
2016 to replace them with German government securities.
The equity instruments reported as available-for-sale financial assets included â‚¬40 million (2014: â‚¬29 million) in
instruments whose fair value could not be determined from a stock exchange or other market price or by discounting reliably determinable future cash flows. These equity instruments were recognized at cost.
In 2015, impairment losses totaling â‚¬1 million (2014: impairment loss reversals totaling â‚¬2 million) on available-forsale financial assets were recognized in profit or loss.
Unimpaired other financial assets of â‚¬5 million (2014: â‚¬8 million) were past due on the closing date.
Further information on the accounting for receivables from derivatives is given in note [30].
Receivables under lease agreements relate to finance leases where Bayer is the lessor and the economic owner
of the leased assets is the lessee. These receivables comprised expected lease payments of â‚¬38 million (2014:
â‚¬46 million), including â‚¬31 million (2014: â‚¬37 million) in interest. Of the expected lease payments, â‚¬1 million
(2014: â‚¬1 million) is due within one year, â‚¬2 million (2014: â‚¬2 million) within the following four years and
â‚¬35 million (2014: â‚¬43 million) in subsequent years.

21. Inventories
Inventories were comprised as follows:

Inventories

[Table 4.53]
Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

Raw materials and supplies

1,603

2,296

Work in process, finished goods and goods purchased for resale

6,781

6,241

Advance payments
Total

94

13

8,478

8,550

Impairment losses recognized on inventories were reflected in the cost of goods sold. They were comprised
as follows:

Impairments of Inventories

Accumulated impairment losses, January 1
Changes in scope of consolidation

[Table 4.54]
2014

2015

â‚¬ million

â‚¬ million

(423)

(477)

â€“

(5)

(214)

(216)

Impairment loss reversals or utilization

176

246

Exchange differences

(16)

21

Impairment losses in the reporting period

Transfers (IFRS 5)
Accumulated impairment losses, December 31

â€“

4

(477)

(427)

291

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

22. Trade accounts receivable
Trade accounts receivable less impairment losses amounted to â‚¬9,933 million (2014: â‚¬9,097 million) on the closing
date and were comprised as follows:

Trade Accounts Receivable

[Table 4.55]

Trade accounts receivable (before impairments)
Accumulated impairment losses
Carrying amount, December 31
of which noncurrent

2014

2015

â‚¬ million

â‚¬ million

9,330

10,181

(233)

(248)

9,097

9,933

32

46

Changes in impairment losses on trade accounts receivable were as follows:

Impairments of Trade Accounts Receivable

[Table 4.56]

Accumulated impairment losses, January 1
Impairment losses in the reporting period
Impairment loss reversals or utilization
Exchange differences
Accumulated impairment losses, December 31

2014

2015

â‚¬ million

â‚¬ million

(200)

(233)

(73)

(84)

39

46

1

23

(233)

(248)

Trade accounts receivable amounting to â‚¬9,858 million (2014: â‚¬9,029 million) were not individually impaired.
Of this amount, â‚¬1,251 million (2014: â‚¬1,105 million) was past due or due immediately on the closing date.
The amounts of impaired and past-due trade accounts receivable are summarized in the following table:

Impaired and Past-Due Trade Accounts Receivable

[Table 4.57]
Of which
neither
impaired
nor past due
at the
closing date

Carrying
amount

Of which
unimpaired but
past due at the
closing date
up to
3 months

3â€“6
months

6 â€“ 12
months

more than
12 months

Of which
impaired
at the
closing date

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

December 31, 2015

9,933

8,607

823

202

109

117

â‚¬ million

75

December 31, 2014

9,097

7,924

738

165

85

117

68

The gross carrying amount of individually impaired trade accounts receivable was â‚¬245 million (2014:
â‚¬217 million). The impairment losses recognized on these assets totaled â‚¬170 million (2014: â‚¬149 million), resulting in a net carrying amount of â‚¬75 million (2014: â‚¬68 million).
The unimpaired receivables were deemed to be collectible on the basis of established credit management processes and individual assessments of customer risks. Recognized impairment losses included an appropriate allowance
for the default risk as of the end of the reporting period.

292

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Receivables from government health service institutions, especially in Greece, Italy, Portugal and Spain, are under
special observation in view of the government debt crisis. Although there were no material defaults on such
receivables in 2015 or 2014, it is possible that future developments in these countries could result in payment
delays and / or defaults. This could necessitate the recognition of impairment losses due to new occurrences. Trade
accounts receivable from government health service institutions in the above countries at the end of 2015 totaled
â‚¬168 million (2014: â‚¬183 million).
An excess-of-loss policy exists for the HealthCare subgroup as part of a global credit insurance program. More than
80% of the receivables of the HealthCare subgroup are insured up to a maximum total annual compensation payment of â‚¬100 million (2014: â‚¬100 million).
A further â‚¬559 million (2014: â‚¬459 million) of receivables was secured by advance payments, letters of credit or
guarantees or by liens on land, buildings or harvest yields.

23. Other receivables
Other receivables, after impairment losses of â‚¬55 million (2014: â‚¬3 million), were comprised as follows:

Other Receivables

[Table 4.58]
Dec. 31, 2014

Dec. 31, 2015

Total

Of which
current

Total

Of which
current

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Other tax receivables

612

528

746

658

Deferred charges

297

273

384

348

Reimbursement claims

127

113

97

81

Net defined benefit asset

41

â€“

30

â€“

Receivables from employees

48

44

39

36

810

530

1,151

894

1,935

1,488

2,447

2,017

Miscellaneous receivables
Total

The reimbursement claims of â‚¬97 million (2014: â‚¬127 million) mainly consisted of receivables from insurance companies in connection with product liability claims.
Miscellaneous receivables included a â‚¬423 million receivable from Dow AgroSciences llc, United States, for damages and royalty payments resulting from the infringement of Bayerâ€™s rights to the Liberty Linkâ„¢ weed control
system. In addition, there was a â‚¬62 million receivable from the Venezuelan exchange control authority reflecting
the right to receive u.s. dollars at a preferential rate. A â‚¬52 million impairment loss was recognized on this receivable.
Of the â‚¬565 million (2014: â‚¬678 million) in financial receivables included in other receivables, â‚¬564 million (2014:
â‚¬675 million) was unimpaired. Of this amount, â‚¬104 million (2014: â‚¬313 million) was past due or due immediately
on the closing date. The gross carrying amount of individually impaired other receivables was â‚¬4 million (2014:
â‚¬6 million). The impairment losses recognized on these assets totaled â‚¬3 million (2014: â‚¬3 million), resulting in a
net carrying amount of â‚¬1 million (2014: â‚¬3 million).

293

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The amounts of impaired and past-due financial receivables included in other receivables are summarized in the
following table:

Impaired and Past-Due Other Financial Receivables

[Table 4.59]
Of which
neither
impaired
nor past due
at the
closing date

Carrying
amount

Of which
unimpaired but
past due at the
closing date
up to
3 months

3â€“6
months

6 â€“ 12
months

more than
12 months

Of which
impaired
at the
closing date

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

December 31, 2015

565

460

65

13

15

11

1

December 31, 2014

678

362

259

17

9

28

3

24. Equity
The foremost objectives of our financial management are to help bring about a sustained increase in Bayerâ€™s value
for the benefit of all stakeholders, and to ensure the Groupâ€™s creditworthiness and liquidity. The pursuit of these
goals means reducing our cost of capital, optimizing our capital structure, improving our financing cash flow and
effectively managing risk.
The rating agencies commissioned by Bayer assess Bayerâ€™s creditworthiness as follows:

Rating

[Table 4.60]

Long-term rating

Outlook

Short-term rating

Standard & Poorâ€™s

A-

stable

A-2

Moodyâ€™s

A3

stable

P-2

These investment-grade ratings reflect the companyâ€™s good creditworthiness and ensure access to a broad investor
base. Bayerâ€™s financial management is partly based on the debt ratios published by rating agencies, which â€“ by
somewhat differing methods â€“ take into account the cash flows for a given period in relation to debt, for example.
Bayerâ€™s financial strategy focuses on an â€œaâ€ category rating and on preserving our financial flexibility. Apart from
utilizing cash inflows from our operating business to reduce net financial debt, we are implementing our financial
strategy by way of vehicles such as the subordinated hybrid bonds issued in July 2014 and April 2015, the authorized and conditional capital amounts created by resolutions of the Annual Stockholdersâ€™ Meeting, and a potential
share buyback program. Bayerâ€™s Articles of Incorporation do not stipulate capital ratios.
The changes in the various components of equity during 2014 and 2015 are shown in the consolidated statements
of changes in equity.
CAPITAL STOCK
The capital stock of Bayer AG on December 31, 2015 amounted to â‚¬2,117 million (2014: â‚¬2,117 million), divided
into 826,947,808 (2013: 826,947,808) registered shares, and was fully paid in. Each share confers one voting right.
AUTHORIZED CAPITAL
Authorized capital of â‚¬530 million was approved by the Annual Stockholdersâ€™ Meeting on April 29, 2014. It expires
on April 28, 2019. It can be used to increase the capital stock by issuing new no-par registered shares against cash
contributions and / or contributions in kind, but capital increases against contributions in kind may not exceed a
total of â‚¬423 million (Authorized Capital i). Stockholders must normally be granted subscription rights. However,
the Board of Management is authorized, with the consent of the Supervisory Board, to exclude stockholdersâ€™ sub-

294

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

scription rights where the subscription ratio gives rise to fractions in the case of capital increases against cash
and / or contributions in kind, and also to the extent necessary to grant the holders of bonds with warrants or conversion rights or obligations issued by the Company or its group companies a right to subscribe for new shares to
the extent to which they would be entitled after exercise of their warrants or conversion rights, or performance of
their exercise or conversion obligations. The Board of Management is also authorized, with the consent of the
Supervisory Board, to exclude stockholdersâ€™ subscription rights if the shares are issued in connection with the
admission of shares to a foreign stock exchange and the total interest in the capital stock attributable to the new
shares for which subscription rights are excluded does not exceed 10% of the existing capital stock on the date of
entry of the authorization in the commercial register or, in the event that this amount is lower, 10% of the existing
capital stock on the date of issuance of the new shares. The Board of Management is further authorized, with the
consent of the Supervisory Board, to exclude stockholdersâ€™ subscription rights if the capital is increased against
contributions in kind to issue shares either for the purpose of acquiring companies, parts of companies, interests in
companies, or other assets, or for the purpose of implementing a scrip dividend, where stockholders are given the
option of contributing their dividend entitlements to the Company (either in whole or in part) as a contribution in
kind against the issuance of new shares out of the Authorized Capital i. The amount of capital stock represented by
shares issued against cash contributions and / or contributions in kind without granting subscription rights to the
stockholders must not exceed a total of 20% of the capital stock that existed on the date the authorized capital was
approved by the Annual Stockholdersâ€™ Meeting.
Further authorized capital of â‚¬212 million was approved by the Annual Stockholdersâ€™ Meeting on April 29, 2014. It
expires on April 28, 2019. The Board of Management is authorized, with the consent of the Supervisory Board, to
increase the capital stock by up to a total of â‚¬212 million by issuing new no-par registered shares against cash
contributions (Authorized Capital ii). Stockholders must normally be granted subscription rights. However, the
Board of Management is authorized, with the consent of the Supervisory Board, to exclude stockholdersâ€™ subscription rights where the subscription ratio gives rise to fractions and also if the shares are issued against cash contributions and the total interest in the capital stock attributable to the new shares for which subscription rights are
excluded does not exceed 10% of the existing capital stock on the date of entry of the authorization in the commercial register or, in the event that this amount is lower, 10% of the existing capital stock on the date of issuance
of the new shares, and the issue price of the new shares is not significantly below the market price of the already
listed shares of the company of the same class at the time when the issue price is finalized by the Board of Management within the meaning of Section 203, Paragraphs 1 and 2, in conjunction with Section 186, Paragraph 3,
sentence 4, of the German Stock Corporation Act. Any own shares that are sold on or after April 29, 2014, while
excluding stockholdersâ€™ subscription rights pursuant to Section 71, Paragraph 1, No. 8, Sentence 5, in conjunction
with Section 186, Paragraph 3, Sentence 4, of the German Stock Corporation Act count toward the above 10%
limit. Shares that have been or may be issued to service bonds with warrants or conversion rights or obligations,
where such bonds are issued on or after April 29, 2014, while excluding stockholdersâ€™ subscription rights in analogous application of Section 186, Paragraph 3, Sentence 4, of the German Stock Corporation Act also count toward
this limit.
Neither of these authorized capital amounts has been utilized so far.
CONDITIONAL CAPITAL
The Annual Stockholdersâ€™ Meeting on April 29, 2014 approved the creation of Conditional Capital 2014, again
authorizing a conditional increase of up to â‚¬212 million in the capital stock through the issuance of up to
82,694,750 new no-par registered shares. The conditional capital increase serves to grant registered no-par value
shares to the holders of bonds with warrants or convertible bonds, profit participation certificates, or income bonds
(or combinations of these instruments) (collectively referred to as â€œdebt instrumentsâ€), each with options or conversion rights or obligations, that may be issued up to April 28, 2019, on the basis of the authorization resolved by
the Annual Stockholdersâ€™ Meeting on April 29, 2014, by Bayer AG or a group company of Bayer AG within the
meaning of Section 18 of the German Stock Corporation Act in which Bayer AG has a direct or indirect interest in
at least 90 % of the votes and capital. Such new shares are to be issued at the option premium or conversion price
to be determined in accordance with the authorizing resolution referred to above. The authorization to issue such
instruments is limited to a total nominal amount of â‚¬6 billion. In principle, stockholders have a statutory right to be
granted subscription rights to such instruments. However, the Board of Management is authorized, with the consent of the Supervisory Board, to exclude stockholdersâ€™ subscription rights where the subscription ratio gives rise
to fractions and also to the extent necessary to grant the holders of bonds with warrants or conversion rights or
obligations a right to subscribe for new shares to the extent to which they would be entitled after exercise of their

295

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

warrants or conversion rights, or performance of their exercise or conversion obligations. Furthermore, the Board
of Management is authorized, with the consent of the Supervisory Board, to fully exclude stockholdersâ€™ subscription rights to debt instruments with options or conversion rights or obligations issued against cash contributions if
the Board of Management, after due consideration, is of the opinion that the issue price of the debt instruments is
not significantly below their hypothetical fair value determined in accordance with accepted methods, and in particular, valuation techniques. This authorization to exclude subscription rights applies to bonds with warrants or
conversion rights or exercise or conversion obligations for shares with a proportionate interest in the capital stock
not exceeding 10% of the total capital stock either at the date when the resolution is adopted or, in the event that
this amount is lower, at the date on which this authorization is exercised. New shares that are issued on or after
April 29, 2014, while excluding stockholdersâ€™ subscription rights in accordance with Sections 203, Paragraphs 1
and 2, in conjunction with Section 186, Paragraph 3, Sentence 4, of the German Stock Corporation Act as well as
own shares that are sold on or after April 29, 2014, while excluding stockholdersâ€™ subscription rights pursuant to
Section 71, Paragraph 1, Number 8, Sentence 5, in conjunction with Section 186, Paragraph 3, Sentence 4, of the
German Stock Corporation Act also count toward this 10% limit.
Absent a further resolution of the Annual Stockholdersâ€™ Meeting on the exclusion of stockholdersâ€™ subscription
rights, the Board of Management will only use the existing authorizations to increase the capital stock out of the
Authorized Capital or the Conditional Capital â€“ while excluding stockholdersâ€™ subscription rights â€“ up to a total
amount of 20% of the capital stock that existed when the respective resolutions were adopted by the Annual
Stockholdersâ€™ Meeting on April 29, 2014. All issuances or sales of shares or of bonds with warrants or conversion
rights or obligations that are effected while excluding stockholdersâ€™ subscription rights also count toward this 20%
limit.
ACCUMULATED COMPREHENSIVE INCOME
Accumulated comprehensive income comprises retained earnings and accumulated other comprehensive income.
The retained earnings include prior yearsâ€™ undistributed income of consolidated companies and all remeasurements of the net liability for defined benefit pension and other post-employment benefit plans that are recognized
outside profit or loss. The accumulated other comprehensive income comprises exchange differences, the changes
in fair values of cash flow hedges and available-for-sale financial assets, and the revaluation surplus. In 2015, an
amount of â‚¬5 million (2014: â‚¬5 million) corresponding to the annual amortization / depreciation of the respective
assets was transferred from the revaluation surplus to retained earnings. The exchange differences included an
amount of minus â‚¬45 million (2014: minus â‚¬28 million) attributable to associates and joint ventures accounted for
using the equity method.
DIVIDEND
Under the German Stock Corporation Act (AktG), the dividend payment is determined by the distributable profit
reported in the annual financial statements of Bayer AG, which are prepared according to the German Commercial
Code. Retained earnings were diminished by payment of the dividend of â‚¬2.25 per share for 2014. The proposed
dividend for the 2015 fiscal year is â‚¬2.50 per share, which would result in a total dividend payment of â‚¬2,067 million. Payment of the proposed dividend is contingent upon approval by the stockholders at the Annual Stockholdersâ€™ Meeting and therefore is not recognized as a liability in the consolidated financial statements.
NONCONTROLLING INTEREST
The former MaterialScience subgroup became a separate economic and legal entity on September 1, 2015, operating under the name Covestro. Following the stock exchange listing of Covestro AG on October 6, 2015, 30.9% of
the shares in the equity of Covestro AG and its subsidiaries are reflected in noncontrolling interest.

296

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The changes in noncontrolling interest in equity during 2014 and 2015 are shown in the following table:

Components of Noncontrolling Interest in Equity

[Table 4.61]
2014

2015

â‚¬ million

â‚¬ million

86

112

Remeasurements of the net pension liability

â€“

10

Changes in fair value of cash flow hedges

â€“

â€“

Changes in fair value of securities

â€“

â€“

11

23

January 1
Changes in equity not recognized in profit or loss

Exchange differences on translation of operations outside the eurozone
Other changes in equity

â€“

1,055

Dividend payments

(2)

(8)

Changes in equity recognized in profit or loss

17

(12)

112

1,180

December 31

The exchange differences included an amount of minus â‚¬20 million (2014: â‚¬0 million) attributable to associates and
joint ventures accounted for using the equity method.
Noncontrolling interest mainly pertained to the following companies:

Material Noncontrolling Interests

[Table 4.62]

Covestro AG *)

Interest held
Voting rights

Bayer CropScience Limited,
India

2014

2015

2014

2015

%

â€“

30.9

31.4

31.4

%

â€“

30.9

31.4

31.4

Equity attributable to noncontrolling interest

â‚¬ million

â€“

1,092

85

73

Dividends paid to noncontrolling interest

â‚¬ million

â€“

â€“

1

3

Noncurrent assets

â‚¬ million

â€“

4,237

48

52

Current assets

â‚¬ million

â€“

6,294

317

304

Noncurrent liabilities

â‚¬ million

â€“

4,564

10

11

Current liabilities

â‚¬ million

â€“

2,355

85

92

Sales

â‚¬ million

â€“

12,082

410

465

Income (loss) after income taxes

â‚¬ million

â€“

352

45

6

Total comprehensive income

â‚¬ million

â€“

558

25

15
44

Net cash provided by (used in) operating activities

â‚¬ million

â€“

1,473

21

Net cash provided by (used in) investing activities

â‚¬ million

â€“

(380)

(1)

53

Net cash provided by (used in) financing activities

â‚¬ million

â€“

(645)

(5)

(79)

* including direct and indirect subsidiaries

297

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

25. Provisions for pensions and other post-employment
benefits
Provisions were established for defined benefit obligations pertaining to pensions and other post-employment
benefits. The net liability was accounted for as follows:

Net Defined Benefit Liability Reflected in the Statement of Financial Position

[Table 4.63]
Other post-employment
benefits

Pensions

Provisions for pensions and other postemployment benefits (net liability)

Total

Dec. 31,
2014

Dec. 31,
2015

Dec. 31,
2014

Dec. 31,
2015

Dec. 31,
2014

Dec. 31,
2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

11,796

10,454

440

419

12,236

10,873

10,336

8,972

â€“

â€“

10,336

8,972

1,460

1,482

440

419

1,900

1,901

38

29

3

1

41

30

of which Germany

22

23

â€“

â€“

22

23

of which other countries

16

6

3

1

19

7

11,758

10,425

437

418

12,195

10,843

10,314

8,949

â€“

â€“

10,314

8,949

1,444

1,476

437

418

1,881

1,894

of which Germany
of which other countries
Net defined benefit asset

Net defined benefit liability
of which Germany
of which other countries

The expenses for defined benefit plans for pensions and other post-employment benefits comprised the following
components:

Expenses for Defined Benefit Plans

[Table 4.64]

Pension plans
Germany

Other countries

Total

Other post-employment
benefit plans
Other countries

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

236

362

66

99

302

461

28

17

23

27

(25)

(3)

(2)

24

2

â€“

â€“

â€“

(15)

(2)

(15)

(2)

â€“

â€“

â€“

â€“

21

â€“

21

â€“

â€“

â€“

Net interest

223

204

34

52

257

256

18

20

Total

482

593

96

148

578

741

48

37

Current service cost
Past service cost
of which plan curtailments
Plan settlements

In addition, a total of â‚¬1,216 million in effects of remeasurements of the net defined benefit liability was recognized
in 2015 outside profit or loss (2014: minus â‚¬5,159 million). Of this amount, â‚¬1,185 million (2014: minus
â‚¬5,098 million) related to pension obligations, â‚¬53 million (2014: minus â‚¬61 million) to other post-employment
benefit obligations, and minus â‚¬22 million (2014: â‚¬0 million) to the effects of the asset ceiling.

298

Bayer Annual Report 2015

299

Bayer Annual Report 2015
Consolidated Financial Statements

Consolidated Financial Statements

Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Consolidated Financial Statements of the Bayer Group

The net defined benefit liability developed as follows:

Changes in Net Defined Benefit Liability

[Table 4.65]
Defined benefit obligation

Fair value of plan assets

Effects of the asset ceiling

Net defined benefit liability

2014

2015

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Germany
January 1

14,870

20,339

8,735

10,025

â€“

â€“

(6,135)

Acquisitions

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

Divestitures / changes in the scope of consolidation

â€“

21

â€“

17

â€“

â€“

â€“

(4)

236

362

(236)

(362)

23

27

(23)

(27)

â€“

â€“

â€“

â€“

553

425

(223)

(204)

5,254

(1,393)

(5,254)

1,393

5,208

(1,371)

(5,208)

1,371

â€“

â€“

â€“

â€“

46

(22)

(46)

22

802

(262)

Current service cost
Past service cost
Gains / losses from plan settlements
Net interest
Net actuarial (gain) loss
of which due to changes in financial assumptions
of which due to changes in demographic assumptions
of which due to experience adjustments
Return on plan assets excluding amounts recognized as interest income

330

802

221

â€“

Employer contributions

â€“

(262)

Remeasurement of asset ceiling
Employee contributions

â€“

â€“

(10,314)

â€“

â€“

331

387

331

387

38

37

38

37

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

Benefits paid out of plan assets

(211)

(215)

(211)

(215)

â€“

â€“

Benefits paid by the company

(424)

(433)

424

433

Payments due to plan settlements

Reclassification to current assets / liabilities held for sale
December 31

â€“

(22)

â€“

(11)

â€“

â€“

â€“

11

20,339

19,148

10,025

10,199

â€“

â€“

(10,314)

(8,949)

Other countries
January 1

5,812

7,432

4,705

5,560

(9)

(9)

(1,116)

(1,881)

Acquisitions

â€“

4

â€“

â€“

â€“

â€“

â€“

(4)

Divestitures / changes in the scope of consolidation

â€“

â€“

â€“

â€“

â€“

â€“

â€“

â€“

94

116

(94)

(116)

(23)

(3)

23

3

21

â€“

(21)

â€“

275

287

(52)

(72)

Current service cost
Past service cost
Gains / losses from plan settlements
Net interest
Net actuarial (gain) loss

223

215

â€“

â€“

1,094

(318)

(1,094)

318

of which due to changes in financial assumptions

815

(310)

(815)

310

of which due to changes in demographic assumptions

264

(79)

(264)

79

15

71

(15)

(71)

387

(211)

of which due to experience adjustments
Return on plan assets excluding amounts recognized as interest income

387

(211)

Remeasurement of asset ceiling

â€“

Employer contributions
Employee contributions
Payments due to plan settlements
Benefits paid out of plan assets
Benefits paid by the company

Exchange differences
December 31
of which other post-employment benefits
Total, December 31

â€“

(22)

130

148

130

148

9

11

9

11

â€“

â€“

(64)

â€“

(64)

â€“

â€“

â€“

(254)

(289)

(254)

(289)

â€“

â€“

(53)

(60)

53

60

â€“

(20)

Plan administration costs paid out of plan assets
Reclassification to current assets / liabilities held for sale

(22)

(1)

(1)

â€“

(8)

â€“

â€“

(1)

(1)

â€“

12

521

501

425

374

â€“

(1)

(96)

(128)

7,432

7,661

5,560

5,799

(9)

(32)

(1,881)

(1,894)

918

836

481

418

â€“

â€“

(437)

(418)

27,771

26,809

15,585

15,998

(9)

(32)

(12,195)

(10,843)

300

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The benefit obligations pertained mainly to Germany (71%; 2014: 73%), the United States (15%; 2014: 14%) and
the United Kingdom (7%; 2014: 6%). In Germany, current employees accounted for about 44% (2014: 45%),
retirees or their surviving dependents for about 49% (2014: 47%) and former employees with vested pension
rights for about 7% (2014: 8%) of entitlements under defined benefit plans. In the United States, current employees accounted for about 26% (2014: 26%), retirees or their surviving dependents for about 61% (2014: 61%) and
former employees with vested pension rights for about 13% (2014: 13%) of entitlements under defined benefit
plans.
The changes in the net defined benefit liability in Germany reported as due to changes in the scope of consolidation mainly resulted from employee transfers outside the consolidated group of companies.
The actual return on the assets of defined benefit plans for pensions or other post-employment benefits amounted
to minus â‚¬34 million (2014: â‚¬1,691 million) and minus â‚¬3 million (2014: â‚¬51 million), respectively.
The following table shows the defined benefit obligations for pensions and other post-employment benefits along
with the funded status of the funded obligations.

Defined Benefit Obligation and Funded Status

[Table 4.66]

Pension obligation

Defined benefit obligation
of which unfunded
of which funded

Other post-employment
benefit obligation

Total

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

26,853

25,973

918

836

27,771

26,809

1,117

1,126

104

101

1,221

1,227

25,736

24,847

814

735

26,550

25,582

Funded status of funded obligations
Overfunding
Underfunding

47

61

3

1

50

62

10,679

9,328

336

318

11,015

9,646

PENSION AND OTHER POST-EMPLOYMENT BENEFIT OBLIGATIONS
Group companies provide retirement benefits for most of their employees, either directly or by contributing to
privately or publicly administered funds. The way these benefits are provided varies according to the legal, fiscal
and economic conditions of each country, the benefits generally being based on employee compensation and years
of service. The obligations relate both to existing retireesâ€™ pensions and to pension entitlements of future retirees.
Bayer has set up funded pension plans for its employees in various countries. The most appropriate investment
strategy is determined for each defined benefit pension plan based on the risk structure of the obligations (especially demographics, the current funded status, the structure of the expected future cash flows, interest sensitivity,
biometric risks etc.), the regulatory environment and the existing level of risk tolerance or risk capacity. A strategic
target investment portfolio is then developed in line with the planâ€™s risk structure, taking capital market factors into
consideration. Further determinants are risk diversification, portfolio efficiency and the need for both a countryspecific and a global risk / return profile centered on ensuring the payment of all future benefits. As the capital
investment strategy for each pension plan is developed individually in light of the plan-specific conditions listed
above, the investment strategies for different pension plans may vary considerably. For example, the proportion of
plan assets invested in equities is greater with the non-German pension plans than with the plans domiciled in
Germany. The investment strategies are generally aligned less toward maximizing absolute returns and more toward the reasonable assurance of financing pension commitments over the long term. For plan assets, stress scenarios are simulated and other risk analyses (such as value at risk) undertaken with the aid of risk management
systems.

301

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Bayer-Pensionskasse VVaG (Bayer-Pensionskasse), Leverkusen, Germany, is by far the most significant of the pension plans. It was closed to new members effective January 1, 2005. This legally independent fund is regarded as a
life insurance company and therefore is subject to the German Insurance Supervision Act. The benefit obligations
covered by Bayer-Pensionskasse comprise retirement, surviving dependentsâ€™ and disability pensions. It constitutes
a multi-employer plan, to which the active members and their employers contribute. The company contribution is a
certain percentage of the employee contribution. This percentage is the same for all participating employers, including those outside the Bayer Group, and is set by agreement between the planâ€™s executive committee and its
supervisory board, acting on a proposal from the responsible actuary. It takes into account the differences between
the actuarial estimates and the actual values for the factors used to determine liabilities and contributions. Bayer
may also adjust the company contribution in agreement with the planâ€™s executive committee and its supervisory
board, acting on a proposal from the responsible actuary. The planâ€™s liability is governed by Section 1, Paragraph 1,
Sentence 3 of the German Law on the Improvement of Occupational Pensions. This means that if the pension plan
exercises its right under the articles of association to reduce benefits, each participating employer has to make up
the resulting difference. Bayer is not liable for the obligations of participating employers outside the Bayer Group,
even if they cease to participate in the plan.
Pension entitlements for people who joined Bayer in Germany on or after January 1, 2005, are granted via
Rheinische Pensionskasse VVaG, Leverkusen. Future pension payments from this plan are based on contributions
and the return on plan assets; a guaranteed interest rate applies.
Another important pension provision vehicle is Bayer Pension Trust e.V. (bpt). This covers further retirement provision arrangements of the Bayer Group, such as deferred compensation, pension obligations previously administered by Schering Altersversorgung Treuhand e.V., and components of other direct commitments. In October 2015,
a total of â‚¬293 million in investments, representing the equivalent of the Covestro groupâ€™s obligations, was transferred from Bayer Pension Trust to another trust fund, which now (partially) covers the respective obligations of
Covestro.
The defined benefit pension plans in the United States have been frozen for some years, and no significant new
entitlements can be earned under these plans. The assets of all the u.s. pension plans are held by a master trust for
reasons of efficiency. The applicable regulatory framework is based on the Employee Retirement Income Security
Act (erisa), which includes a statutory 80% minimum funding requirement to avoid benefit reductions. The actuarial risks, such as investment risk, interest-rate risk and longevity risk, remain with the company.
The defined benefit pension plans in the United Kingdom are closed to new members. Plan assets in the u.k. are
administered by independent trustees, who are legally obligated to act solely in the interests of the beneficiaries.
A technical assessment is performed every three years in line with u.k. regulations. This serves as the basis for
developing a plan to cover any potential financing requirements. Here, too, the actuarial risks remain with the
company.
The other post-employment benefit obligations outside Germany mainly comprised health care benefit payments
for retirees in the United States.

302

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The fair value of the plan assets to cover pension and other post-employment benefit obligations was as follows:

Fair Value of Plan Assets as of December 31

[Table 4.67]

Pension obligations
Germany

Other post-employment
obligations

Other countries

Other countries

2014

2015

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Plan assets based on quoted prices in active
markets
Real estate and special real estate funds

â€“

â€“

205

199

18

19

Equities and equity funds

1,941

2,105

1,669

1,855

125

130

Callable debt instruments

â€“

â€“

162

182

â€“

â€“

Noncallable debt instruments

â€“

112

690

752

110

121

3,345

3,543

1,509

1,744

90

90

28

18

86

(5)

â€“

â€“

409

158

98

84

14

8

Bond funds
Derivatives
Cash and cash equivalents
Other

â€“

â€“

236

4

â€“

â€“

5,723

5,936

4,655

4,815

357

368

Plan assets for which quoted prices in active
markets are not available
Real estate and special real estate funds

544

517

41

83

â€“

â€“

Equities and equity funds

70

90

59

59

â€“

â€“

Callable debt instruments

1,493

1,555

6

2

â€“

â€“

Noncallable debt instruments

1,931

1,832

â€“

â€“

â€“

â€“

Bond funds

â€“

â€“

60

60

â€“

â€“

Derivatives

(4)

(2)

â€“

â€“

â€“

â€“

268

271

258

362

124

50

Other
Total plan assets

4,302

4,263

424

566

124

50

10,025

10,199

5,079

5,381

481

418

The fair value of plan assets in Germany included real estate leased by Group companies, recognized at a fair value
of â‚¬61 million (2014: â‚¬65 million), and Bayer AG shares and bonds held through investment funds, recognized at
their fair value of â‚¬48 million (2014: â‚¬58 million) and â‚¬3 million (2014: â‚¬6 million), respectively. The other plan
assets comprised mortgage loans granted, other receivables and qualified insurance policies.
RISKS
The risks from defined benefit plans arise partly from the defined benefit obligations and partly from the investment in plan assets. The risks lie in the possibility that higher direct pension payments will have to be made to the
beneficiaries and / or that additional contributions will have to be made to plan assets in order to meet current and
future pension obligations.
Demographic / biometric risks
Since a large proportion of the defined benefit obligations comprises lifelong pension payments to retirees or surviving dependentsâ€™ pensions, longer claim periods or earlier claims may result in higher benefit obligations, higher
benefit expense and / or higher pension payments than previously anticipated.

303

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Investment risks
If the actual return on plan assets were below the return anticipated on the basis of the discount rate, the net defined benefit liability would increase, assuming there were no changes in other parameters. This could happen as a
result of a drop in share prices, increases in market rates of interest, default of individual debtors or the purchase
of low-risk but low-interest bonds, for example.
Interest-rate risk
A decline in capital market interest rates, especially for high-quality corporate bonds, would increase the defined
benefit obligation. This effect would be at least partially offset by the ensuing increase in the market values of the
debt instruments held.
MEASUREMENT PARAMETERS AND THEIR SENSITIVITIES
The following weighted parameters were used to measure the obligations for pensions and other post-employment
benefits as of December 31 of the respective year:

Parameters for Benefit Obligations

[Table 4.68]
Germany

Other countries

Total

2014

2015

2014

2015

2014

2015

%

%

%

%

%

%

2.00

2.40

Pension obligations
Discount rate

3.70

3.85

2.40

2.75

of which U.S.A.

3.70

4.00

3.70

4.00

of which U.K.

3.60

3.80

3.60

3.80

Projected future salary increases

3.00

3.00

3.65

3.35

3.15

3.10

Projected future benefit increases

1.75

1.75

3.30

3.20

2.10

2.15

â€“

â€“

3.95

4.45

3.95

4.45

Other post-employment benefit obligations
Discount rate

The data selection criteria used to determine the discount rate in the eurozone were modified at the beginning of
2015. The modification of the data selection criteria diminished provisions by â‚¬1.0 billion. The discount rate obtained by applying the previous data selection criteria would have been lower by 30 basis points as of December
31, 2015. The change in the way the discount rate is determined reduced the net pension expense for the 2015
fiscal year by â‚¬17 million. As before, the underlying bond portfolio consists entirely of high-quality corporate bonds
with a minimum aa or aaa rating. It no longer includes government-guaranteed or covered bonds.
In Germany the Heubeck 2005 G mortality tables were used, in the United States the rp-2014 Combined Healthy
Mortality Tables, and in the United Kingdom 95% of s1nxa. In the United States, adjustments contained in the mp2015 mortality improvement scale were taken into account in 2015. This led to an actuarial gain of approximately
â‚¬66 million.

304

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The following weighted parameters were used to measure the expense for pension and other post-employment
benefits in the respective year:

Parameters for Benefit Expense

[Table 4.69]
Germany

Other countries

Total

2014

2015

2014

2015

2014

2015

%

%

%

%

%

%

Discount rate

3.80

2.20

4.70

3.70

4.05

2.55

Projected future salary increases

3.00

3.00

3.95

3.65

3.95

3.15

Projected future benefit increases

1.75

1.75

3.60

3.30

3.60

2.10

â€“

â€“

4.90

3.95

4.90

3.95

Pension obligations

Other post-employment benefit obligations
Discount rate

The parameter sensitivities were computed by expert actuaries based on a detailed evaluation similar to that performed to obtain the data presented in Table 4.65. Altering individual parameters by 0.5 percentage points (mortality by 10% per beneficiary) while leaving the other parameters unchanged would have impacted pension and other
post-employment benefit obligations as of year end 2015 as follows:

Sensitivity of Benefit Obligations

[Table 4.70]
Germany

Other countries

Total

Increase

Decrease

Increase

Decrease

Increase

Decrease

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Pension obligations
0.5%-pt. change in discount rate

(1,544)

1,767

(450)

504

(1,994)

2,271

0.5%-pt. change in projected future
salary increases

121

(113)

47

(44)

168

(157)

0.5%-pt. change in projected future
benefit increases

1,006

(919)

127

(96)

1,133

(1,015)

(597)

669

(173)

185

(770)

854

0.5%-pt. change in discount rate

â€“

â€“

(46)

51

(46)

51

10% change in mortality

â€“

â€“

(21)

24

(21)

24

10% change in mortality
Other post-employment benefit obligations

305

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Sensitivity of Benefit Obligations (prior year)

[Table 4.71]
Germany

Other countries

Total

Increase

Decrease

Increase

Decrease

Increase

Decrease

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Pension obligations
0.5%-pt. change in discount rate

(1,712)

1,969

(441)

494

(2,153)

2,463

0.5%-pt. change in projected future
salary increases

145

(135)

44

(41)

189

(176)

0.5%-pt. change in projected future
benefit increases

1,119

(1,020)

106

(76)

1,225

(1,096)

(657)

737

(168)

179

(825)

916

0.5%-pt. change in discount rate

â€“

â€“

(51)

56

(51)

56

10% change in mortality

â€“

â€“

(22)

24

(22)

24

10% change in mortality
Other post-employment benefit obligations

Provisions are also set up for the obligations, mainly of u.s. subsidiaries, to provide post-employment benefits in
the form of health care cost payments for retirees. The valuation of health care costs was based on the assumption
that they will increase at a rate of 7.0%, which should gradually decline to 5.0% by 2023 (assumption in 2014:
7.0%, which should gradually decline to 5.0% by 2018). The following table shows the impact on other postemployment benefit obligations and total benefit expense of a one-percentage-point change in the assumed cost
increase rates:

Sensitivity to Health Care Cost Increases

[Table 4.72]
Increase of one percentage
point

Impact on other post-employment benefit obligations
Impact on benefit expense

Decrease of one percentage
point

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

86

79

(72)

(68)

4

5

(4)

(4)

306

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

PAYMENTS MADE AND EXPECTED FUTURE PAYMENTS
The following payments correspond to the employer contributions made or expected to be made to funded benefit
plans:

Employer Contributions Paid or Expected

[Table 4.73]
Germany

Pension obligations
Other post-employment benefit obligations
Total

Other countries

2014

2015

2016
expected

2014

2015

2016
expected

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

331

387

74

112

148

133

â€“

â€“

â€“

18

â€“

1

331

387

74

130

148

134

Bayer has currently committed to make deficit contributions for its u.k. pension plans of gbp 21 million in 2016 and
of approximately gbp 16 million annually thereafter through 2019 and expects to make payments of us$50 million
in 2016 for its u.s. pension plans, the latter amount being subject to change depending on future circumstances.
Pensions and other post-employment benefits payable in the future from funded and unfunded plans are estimated
as follows:

Future Benefit Payments

[Table 4.74]
Payments out of plan assets

Pensions

Other postemployment
benefits

Germany

Other
countries

Other
countries

Total

â‚¬ million

â‚¬ million

â‚¬ million

2016

219

303

2017

221

311

2018

224

2019
2020
2021-2025

Payments by the company

Pensions

Other postemployment
benefits

Germany

Other
countries

Other
countries

Total

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

9

531

447

66

35

548

9

541

451

68

37

556

322

10

556

458

71

39

568

229

328

9

566

470

71

42

583

234

340

9

583

476

75

43

594

1,260

1,763

46

3,069

2,471

436

241

3,148

The weighted average term of the pension obligations is 17.3 years (2014: 17.6 years) in Germany and 13.4 years
(2014: 13.9 years) in other countries. The weighted average term of the obligations for other post-employment
benefits in other countries is 11.5 years (2014: 12.1 years).

307

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

26. Other provisions
Changes in the various provision categories in 2015 were as follows:

Changes in Other Provisions

[Table 4.75]

Restructuring

Traderelated
commitments

â‚¬ million

â‚¬ million

65

283

â€“

â€“

Additions

37

Utilization

December 31, 2014
Acquisitions / divestments

Reversal

Other
Taxes

Environmental
protection

â‚¬ million

Litigations

Personnel
commitments

Miscellaneous

Total

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

173

1,851

770

2,751

230

6,123

â€“

48

26

â€“

2

76

51

290

4,297

97

2,836

292

7,900

(21)

(64)

(131)

(3,569)

(269)

(2,283)

(175)

(6,512)

(5)

(4)

(20)

(509)

(19)

(281)

(71)

(909)
(81)

Reclassification to current
liabilities

â€“

â€“

â€“

(76)

â€“

â€“

(5)

Interest cost

â€“

(1)

â€“

â€“

â€“

11

1

11

(11)

7

(6)

71

58

65

(7)

177

65

272

306

2,113

663

3,099

267

6,785

Exchange differences
December 31, 2015
2014 figures restated

The provisions recognized in the statement of financial position as of December 31, 2015 were expected to be
utilized as follows:














ExpectedUtilizationofOtherProvisions

[Table4.76]





Other
Taxes

EnvironÍ²
mental
protection



RestrucÍ²
turing

TradeÍ²
related
commitments

Litigations

Personnel
commitments

MiscellaÍ²
neous 

Total

Î¦million

â‚¬million

â‚¬million

â‚¬million

â‚¬million

â‚¬million

â‚¬million

â‚¬million

2016

28

31

102

2,006

539

2,123

216

5,045

2017

1

29

73

46

50

230

5

434

2018

â€“

27

78

33

5

152

1

296

2019

â€“

16

6

7

1

146

1

177

2020

1

4

5

6

3

55

1

75

35

165

42

15

65

393

43

758

272

306

2,113

663

3,099

2021 or later
Total




65





267



6,785

The provisions were partly offset by claims for refunds in the amount of â‚¬97 million (2014: â‚¬124 million), which
were recognized as receivables. These claims mainly related to product liability.

308

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

26.1 Other taxes
Provisions for other taxes mainly related to sales tax back-payments and to local taxes in Brazil.

26.2 Environmental protection
Provisions for environmental protection mainly related to the rehabilitation of contaminated land, recultivation of
landfills, and redevelopment and water protection measures.

26.3 Restructuring
Provisions for restructuring included â‚¬180 million (2014: â‚¬126 million) for severance payments and â‚¬126 million
(2014: â‚¬47 million) for other restructuring expenses, which mainly comprised other costs related to the closure of
production facilities.
At HealthCare â€“ as part of the Continuous Efficiency Program â€“ restructuring was carried out mainly in the areas of
marketing and supply network optimization. A further focus was on the continuing integration of the businesses
acquired the previous year in the Consumer Health segment. Provisions for the above and other restructuring
measures at HealthCare as of December 31, 2015, amounted to â‚¬94 million. Of this amount, severance payments
accounted for â‚¬83 million and other restructuring expenses for â‚¬11 million.
In CropScience, the restructuring initiated in the United States in prior years, involving the closure of several carbamate production facilities and a formulation plant, continued in 2015. At the same time, the provisions were
increased in view of expected future requirements. Provisions for the above and other restructuring measures at
CropScience as of December 31, 2015, amounted to â‚¬99 million, comprising â‚¬34 million for severance payments
and â‚¬65 million for other restructuring expenses.
Restructuring measures at Covestro mainly comprised the closure of the production facilities at Belford Roxo,
Brazil, and an mdi facility at the site in Tarragona, Spain. Both of these plant closures mainly related to the Polyurethanes business unit. Provisions for restructuring at Covestro as of December 31, 2015, amounted to â‚¬105 million,
consisting of â‚¬55 million for severance payments and â‚¬50 million for other restructuring expenses.
Restructuring was carried out in the central functions to increase efficiency. The restructuring provisions associated with these measures as of December 31, 2015, amounted to â‚¬8 million and pertained entirely to severance payments.

26.4 Trade-related commitments
Provisions for trade-related commitments comprised provisions for rebates, discounts and other price adjustments,
product returns, outstanding invoices, pending losses and onerous contracts.

26.5 Litigations
The legal risks currently considered to be material, and their development, are described in note [32].

309

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

26.6 Personnel commitments
Provisions for personnel commitments mainly include those for variable one-time payments under short-term incentive programs and for stock-based compensation. Also reflected here are commitments for service awards, early
retirements and pre-retirement part-time working arrangements. Provisions for severance payments resulting from
restructuring are reflected in provisions for restructuring.
STOCK-BASED COMPENSATION PROGRAMS
Bayer offers stock-based compensation programs collectively to different groups of employees. As required by ifrs
2 (Share-based Payment) for compensation systems involving cash settlement, awards to be made under the stockbased programs are covered by provisions in the amount of the fair value of the obligations existing as of the date
of the financial statements vis-Ã -vis the respective employee group. All resulting valuation adjustments are recognized in profit or loss.
The following table shows the changes in provisions for the various programs:

Changes in Provisions for Stock-Based Compensation Programs

[Table 4.77]

Aspire I
Four-Year
Program

Aspire II
Four-Year
Program

Aspire I
Four-Year
Program
Covestro

Aspire II
Four-Year
Program
Covestro

Total

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

142

311

0

0

453

Additions

81

229

2

5

317

Utilization

(57)

(106)

â€“

â€“

(163)

Reversal

(24)

(59)

â€“

â€“

(83)

Reallocation

(20)

(54)

20

54

â€“

3

18

â€“

â€“

21

125

339

22

59

545

December 31, 2014

Exchange differences
December 31, 2015

The value of the Aspire tranches that were fully earned at the end of 2015, resulting in payments at the beginning
of 2016, was â‚¬230 million (2014: â‚¬151 million).
The net expense for all stock-based compensation programs in 2015 was â‚¬248 million (2014: â‚¬212 million), including â‚¬6 million (2014: â‚¬5 million) for the BayShare stock participation program and â‚¬8 million (2014: â‚¬10 million) for
grants of virtual Bayer shares.
The fair value of obligations under the standard stock-based compensation programs was calculated using the
Monte Carlo simulation method based on the following key parameters:

Parameters for Monte Carlo Simulation

Dividend yield
Risk-free interest rate for the four-year program

[Table 4.78]
2014

2015

1.89%

1.96%

(0.079)%

(0.159)%

Volatility of Bayer stock

23.39%

25.61%

Volatility of the EURO STOXX 50

18.11%

19.08%

0.76

0.83

Correlation between Bayer stock price and the EURO STOXX 50

LONG-TERM INCENTIVE PROGRAM FOR MEMBERS OF THE BOARD OF MANAGEMENT AND OTHER
SENIOR EXECUTIVES (ASPIRE I)
Since 2005, members of the Board of Management and other senior executives have been entitled to participate in
Aspire i on the condition that they purchase a certain number of Bayer shares â€“ determined for each individual
according to specific guidelines â€“ and retain them for the full term of the program. A percentage of the executiveâ€™s
annual base salary â€“ according to his / her position â€“ is defined as a target for variable payments (Aspire target

310

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

opportunity). Depending on the performance of Bayer stock, both in absolute terms and relative to the euro stoxx
50 benchmark index during a four-year performance period, participants are granted an award of up to 300% of
their individual Aspire target opportunity. The start and end prices used to determine the amount of the award
are the averages of the official closing prices of Bayer shares over the last 30 stock-exchange trading days of the
respective year. The four-year tranche issued in 2011 expired at the end of 2014, and payment of the maximum
resulting amount (300%) was made at the beginning of 2015.
LONG-TERM INCENTIVE PROGRAM FOR MIDDLE MANAGEMENT (ASPIRE II)
Also since 2005, other senior managers and middle managers have been offered Aspire ii, which is similar to Aspire i but does not require a personal investment in Bayer shares. This program was extended to further managerial employees in 2012. The amount of the award is based entirely on the absolute performance of Bayer stock over a
four-year period. The maximum award is 250% of each managerâ€™s Aspire target opportunity. The start and end
prices used to determine the amount of the award are the averages of the official closing prices of Bayer shares
over the last 30 stock-exchange trading days of the respective year. The four-year tranche issued in 2011 expired at
the end of 2014, and payment of the maximum resulting amount (250%) was made at the beginning of 2015.
BAYSHARE 2015
All management levels and nonmanagerial employees are offered an annual stock participation program known as
BayShare, under which Bayer subsidizes their personal investments in the companyâ€™s stock. The discount under
this program is set separately each year. In 2015 it was 20% (2014: 20%) of the subscription amount. Employees
stated a fixed amount that they wished to invest in shares. The maximum subscription amount in Germany was set
at â‚¬2,500 (2014: â‚¬2,500) or â‚¬5,000 (2014: â‚¬5,000), depending on the employeeâ€™s position. The shares thus acquired
must be retained until December 31 of the year following the year of purchase, irrespective of continued employment with the Bayer Group.
In 2015, employees purchased a total of about 208,000 shares (2014: 225,000 shares) under the BayShare program.
SPECIAL ARRANGEMENT FOR COVESTRO EMPLOYEES CONCERNING THE ASPIRE PROGRAMS
The compensation programs described above were modified for Covestro employees in December 2015 in light of
the legal carve-out of the Covestro companies and the subsequent stock exchange listing of Covestro AG.
The arrangement for the 2012 tranches of both Aspire programs was the same as for Bayer employees. Based on
the development of Bayerâ€™s share price, the maximum award amounts were reached for both programs (Aspire i
and Aspire ii). Payments of 300% and 250%, respectively, were therefore made at the beginning of 2016.
Valuation for the other three current Aspire tranches issued in 2013, 2014 and 2015, respectively, was based on the
average price of Bayer shares on the last 30 trading days of 2015 (â‚¬119.17). This price was fixed in advance as the
end price. Thus the amounts of the payments from the three remaining tranches â€“ where these were fully vested â€“
were already finally determined at the end of 2015. A payment of at least 100% is guaranteed. This plan amendment gave rise to additional expenses of â‚¬7 million in 2015.

311

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

26.7 Miscellaneous provisions
Miscellaneous provisions included those for other liabilities, contingent liabilities from business combinations, and
asset retirement obligations (other than those included in provisions for environmental protection).

27. Financial liabilities
Financial liabilities were comprised as follows:

Financial Liabilities

[Table 4.79]
Dec. 31, 2014

Dec. 31, 2015

Total

Of which
current

Total

Of which
current

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

14,964

169

15,547

1,235

3,835

1,221

2,779

1,174

Liabilities under finance leases

441

53

474

59

Liabilities from derivatives

644

296

765

598

1,976

1,637

369

355

21,860

3,376

19,934

3,421

Bonds and notes / promissory notes
Liabilities to banks

Other financial liabilities
Total

A breakdown of financial liabilities by contractual maturity is given below:










MaturitiesofFinancialLiabilities


Maturity



[Table4.80]
Dec. 31, 2014
â‚¬million

Dec. 31, 2015

 Maturity




â‚¬million

2015

3,376

 2016

3,421

2016

2,191

 2017

2,245

2017

2,075

 2018

2,828

2018

3,359

 2019

2,066

2019

1,857

 2020

2020 or later

9,002

 2021 or later

Total


21,860

 Total

45
9,329


19,934

The Bayer Groupâ€™s financial liabilities are mostly unsecured and â€“ with the exception of the three subordinated
hybrid bonds with nominal volumes of â‚¬1,500 million, â‚¬1,750 million and â‚¬1,300 million â€“ are of equal priority.

312

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In addition to promissory notes in the amount of â‚¬120 million (2014: â‚¬120 million), the Bayer Group has issued the
following bonds and notes:

Bonds and Notes
Effective
interest rate

[Table 4.81]

Stated rate

Nominal volume

Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

Bayer AG, Germany
Floating1

Floating1

EMTN bond 2014 / 2016

EUR 500 million

500

500

1.253%

1.125%

EMTN bond 2014 / 2018

EUR 750 million

747

748

5.774%

5.625%

EMTN bond 2006 / 2018

GBP 250 million

319

339

5.541%

5.625%

EMTN bond 2006 / 2018 (increase)

GBP 100 million

129

137

2.086%

1.875%

EMTN bond 2014 / 2021

EUR 750 million

753

753

3.811%

3.750%

Hybrid bond 2014 / 20246 / 2074

EUR 1,500 million

1,493

1,493

2.517%

2.375%

Hybrid bond 2015 / 20226 / 2075

EUR 1,300 million

â€“

1,289

6

3.093%

3.000%

Hybrid bond 2014 / 2020 / 2075

EUR 1,750 million

1,742

1,743

5.155%

5.000%

Hybrid bond 2005 / 20156 / 2105

EUR 1,300 million

1,317

â€“

EUR 500 million

497

497

Bayer Capital Corporation B.V., Netherlands
1.333%

1.250%

EMTN bond 2014 / 2023
Bayer Corporation, U.S.A.

7.180%

7.125%

Notes 1995 / 2015

US$ 200 million

169

â€“

6.670%

6.650%

Notes 1998 / 2028

US$ 350 million

308

342

0.858%

0.816%

EMTN bond 2012 / 2017

JPY 30 billion

206

229

1.493%

1.459%

EMTN bond 2010 / 2017

JPY 10 billion

69

76

3.654%

3.575%

EMTN bond 2008 / 2018

JPY 15 billion

103

115

0.629%

0.594%

EMTN bond 2013 / 2019

JPY 10 billion

69

76

Bayer Holding Ltd., Japan

Bayer Nordic SE, Finland
Floating 2

Floating 2

EMTN bond 2013 / 2016

EUR 200 million

200

200

3

Floating 3

EMTN bond 2014 / 2017

EUR 500 million

499

500

Floating

Bayer U.S. Finance LLC, U.S.A.
Floating 4

Floating 4

Notes 2014 / 2016

US$ 500 million

411

459

5

Floating 5

Notes 2014 / 2017

US$ 400 million

329

367

1.615%

1.500%

Notes 2014 / 2017

US$ 850 million

698

779

2.564%

2.375%

Notes 2014 / 2019

US$ 2,000 million

1,635

1,826

3.096%

3.000%

Notes 2014 / 2021

US$ 1,500 million

1,230

1,372

3.579%

3.375%

Notes 2014 / 2024

US$ 1,750 million

1,421

1,587

14,844

15,427

Floating

Total
1 Floating-rate

coupon comprising three-month EURIBOR plus 22 basis points
coupon comprising three-month EURIBOR plus 35 basis points
coupon comprising three-month EURIBOR plus 22 basis points
4 Floating-rate coupon comprising three-month USD-LIBOR plus 25 basis points
5 Floating-rate coupon comprising three-month USD-LIBOR plus 28 basis points
6 Date of first option to early redeem the bond at par
2 Floating-rate
3 Floating-rate

313

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

MULTI-CURRENCY EUROPEAN MEDIUM TERM NOTES PROGRAM
An important means of external financing are the bonds issued under the multi-currency European Medium Term
Notes (emtn) program. The following transactions took place in 2015 and 2014:
In January 2014, Bayer AG issued three tranches of emtn bonds with a total nominal volume of â‚¬2 billion. One of
these tranches had a nominal volume of â‚¬500 million, and the other two had a nominal volume of â‚¬750 million
each. In March 2014, Bayer Nordic se issued an emtn bond with a nominal volume of â‚¬500 million. In November
2014, Bayer Capital Corporation b.v. issued an emtn bond with a nominal volume of â‚¬500 million.
OTHER BONDS
In October 2014, Bayer u.s. Finance llc issued six tranches of bonds in 144a / Reg S format with a total volume of
us$7,000 million. The six tranches had nominal volumes of us$500 million, us$400 million, us$850 million,
us$2,000 million, us$1,500 million and us$1,750 million.
In October 2015, Bayer Corporation redeemed at maturity the notes with a nominal volume of us$200 million issued in September 1995.
SUBORDINATED BONDS
In April 2015, Bayer AG issued a subordinated hybrid bond with a volume of â‚¬1,300 million, a final maturity of 60
years and a coupon of 2.375%, to be reset every five years starting in 2022 based on the five-year swap rate. Bayer
has the option to redeem the bond for the first time in October 2022. The issue is structured to receive equity credit
of 50% from Moodyâ€™s and Standard & Poorâ€™s.
In July 2014, Bayer AG issued two subordinated hybrid bonds with a total nominal volume of â‚¬3,250 million. The
first tranche of â‚¬1,750 million has a maturity of 61 years and a coupon of 3.0%. Bayer has an early redemption
option at par for the first time in 2020. The second tranche of â‚¬1,500 million has a maturity of 60 years and a coupon of 3.75%. On this tranche, Bayer has an early redemption option at par for the first time in 2024. From 2020
and 2024, respectively, the coupons will be reset every five years based on the five-year swap rate. Moodyâ€™s and
Standard & Poorâ€™s treat 50% of these two bonds as equity. They therefore have a more limited effect on the Groupâ€™s
rating-relevant debt indicators than conventional borrowings.
In July 2015, Bayer AG utilized its right to early redeem the 100-year subordinated hybrid bond with a nominal
volume of â‚¬1,300 million issued in July 2005.
Bayer AG guarantees all the bonds issued by subsidiaries.

314

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

LEASE LIABILITIES
Lease payments totaling â‚¬646 million (2014: â‚¬603 million), including â‚¬172 million (2014: â‚¬162 million) in interest,
are to be made under finance leases to the respective lessors in future years.
The liabilities under finance leases mature as follows:

Lease Liabilities

Maturity

[Table 4.82]
Dec. 31, 2014

Dec. 31, 2015

Lease
payments

Interest
component

Liabilities
under
finance
leases

Maturity

Lease
payments

Interest
component

Liabilities
under
finance
leases

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

2015

76

23

53

2016

86

27

59

2016

70

21

49

2017

76

23

53

2017

63

19

44

2018

68

20

48

2018

53

16

37

2019

60

18

42

2019

47

14

33

2020

60

15

45

2020 or later

294

69

225

2021 or later

296

69

227

Total

603

162

441

Total

646

172

474

OTHER FINANCIAL LIABILITIES
The other financial liabilities as of December 31, 2015, included commercial paper of â‚¬308 million (2014:
â‚¬1,433 million).
OTHER INFORMATION
As of December 31, 2015, the Group had credit facilities at its disposal totaling â‚¬9.0 billion (2014: â‚¬7.3 billion), of
which â‚¬2.8 billion (2014: â‚¬3.8 billion) was used and â‚¬6.2 billion (2014: â‚¬3.5 billion) was unused and thus available
for borrowing on an unsecured basis. Of the unused credit facilities, an amount of â‚¬2.7 billion pertains to Covestro.
Further information on the accounting for liabilities from derivatives is given in note [30].

28. Trade accounts payable
Trade accounts payable comprised â‚¬5,937 million (2014: â‚¬5,357 million) due within one year and â‚¬8 million (2014:
â‚¬6 million) due after one year.

315

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

29. Other liabilities
Other liabilities comprised:

Other Liabilities

[Table 4.83]
Dec. 31, 2014

Dec. 31, 2015

Total

Of which
current

Total

Of which
current

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

477

433

435

428

1,136

207

1,148

204

Liabilities to employees

196

185

217

210

Liabilities for social expenses

154

140

174

165

Accrued interest on liabilities

201

192

189

180

Miscellaneous liabilities

713

632

436

347

2,877

1,789

2,599

1,534

Other tax liabilities
Deferred income

Total

Deferred income included an upfront payment, originally amounting to us$1 billion, in connection with the strategic pharmaceutical collaboration agreed between Bayer and Merck & Co., Inc., United States, in the field of soluble
guanylate cyclase (sGC) modulation. The deferred income is being amortized over a period of 13.5 years as the
obligations are satisfied. The remaining amount deferred at the end of 2015 was â‚¬719 million (2014: â‚¬778 million).
The amount amortized in 2015 was â‚¬59 million (2014: â‚¬15 million).
The deferred income included â‚¬62 million (2014: â‚¬70 million) in grants and subsidies received from governments,
of which â‚¬7 million (2014: â‚¬8 million) was reversed and recognized in profit or loss.
The miscellaneous liabilities included â‚¬125 million (2014: â‚¬204 million) from derivatives.

30. Financial instruments
The system used by the Bayer Group to manage credit risks, liquidity risks and the various types of market risks
(interest-rate, currency and other price risks), together with its objectives, methods and procedures, is outlined in
the Risk Report, which forms part of the Combined Management Report.

30.1 Financial instruments by category
The following table shows the carrying amounts and fair values of financial assets and liabilities for each financial
instrument category and a reconciliation to the corresponding line item in the statements of financial position.
Since the line items â€œOther receivables,â€ â€œTrade accounts payableâ€ and â€œOther liabilitiesâ€ contain both financial
instruments and nonfinancial assets or liabilities (such as other tax receivables or advance payments for services to
be received in the future), the reconciliation is shown in the column headed â€œNonfinancial assets / liabilities.â€

316

Bayer Annual Report 2015

317

Bayer Annual Report 2015
Consolidated Financial Statements

Consolidated Financial Statements

Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Consolidated Financial Statements of the Bayer Group

Carrying Amounts and Fair Values of Financial Instruments

[Table 4.84]
Dec. 31, 2014
Carried at
amortized
cost

Trade accounts receivable
Loans and receivables
Other financial assets
Loans and receivables

Carried at fair value
[Fair Value for information1]
Based on
quoted
prices in
active
markets
(Level 1)

Based on
observable
market data
(Level 2)

Based on
unobservable
inputs
(Level 3)

Carrying
amount

Carrying
amount

Carrying
amount

Carrying
amount

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

69

Derivatives that do not qualify for hedge accounting

Carrying
amount

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

450

779

1,830

185

[170]

[19]

178

72

745

1,099

40

[70]

69

73

189

189

261
620

34
58

620

58

Nonfinancial assets
1,853

Loans and receivables

1,853

[1,853]

11,846

325

450

837

11,748
29

325

506

620

506

803

1,853

1,859

1,853

1,859

13,458

12,483

11,748

12,370

1,157

40
19,169
19,169

Derivatives that qualify for hedge accounting

284

Derivatives that do not qualify for hedge accounting

360

Trade accounts payable
Carried at amortized cost

[15,129]

5,113

250

5,113

Nonfinancial liabilities
Other liabilities
Carried at amortized cost

790

176

790

[790]

Carried at fair value (nonderivative)

59

20

of which carried at amortized cost

820

59

27,119

of which derivatives that qualify for hedge accounting

440

of which derivatives that do not qualify
for hedge accounting

380

2014 figures restated
1 The exemption provisions under IFRS 7.29a were applied for information on specific fair values.

28

73

125

125
17
59

401
1,882

[506]

2,447
506
59
1,882
1,859

[1,859]
363

509

1,859
850

14,205
12,370

363

833

1,236

765

19,934

[4,121]

19,169

284

470

470

360

295

5,363

5,680

5,113

5,680

[15,440]

295
265

606

117

790

606

[606]

45

265

265

1,831

2,599
606

37

31
156

93

48

24

37
93

8

32
1,831

1,852
27,998

25,455

27,119

25,455

5,945
5,680

2,877

1,852
27,119

1,848

[74]

1,852

28

Nonfinancial liabilities
Total financial liabilities

1,177

250

156

Derivatives that do not qualify for hedge accounting

72

774

363

250

31

Derivatives that qualify for hedge accounting

[18]

1,882

21,216

21,216

[64]

1,257

21,860

21,216

791

59

644

Carried at amortized cost

509

384

1,935

[6,628]

Financial liabilities

9,933
363

58
1,257

Cash and cash equivalents

9,933

295
1,257

[620]

Available-for-sale financial assets

of which available-for-sale financial assets

Carrying
amount

9,933

Derivatives that qualify for hedge accounting

of which loans and receivables

Carrying
amount

9,097

Held-to-maturity financial assets

Total financial assets

Carrying
amount

9,097

325

Based on
unobservable
inputs
(Level 3)

Carrying
amount

9,933

178

Based on
observable
market data
(Level 2)

Carrying
amount

â‚¬ million

325

Based on
quoted
prices in
active
markets
(Level 1)

Carrying
amount
in the
statement
of financial
position

9,097

276

Carried at fair value
[Fair value for information1]

Nonfinancial
assets /
liabilities

Carrying
amount
in the
statement
of financial
position
â‚¬ million

29

Loans and receivables

Dec. 31, 2015
Carried at
amortized
cost

9,097

Available-for-sale financial assets

Other receivables

Nonfinancial
assets /
liabilities

882

45

1,831
26,382
25,455

440

563

408

319

563
8

327

318

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The loans and receivables reflected in other financial assets and the liabilities measured at amortized cost also
include receivables and liabilities under finance leases in which Bayer is the lessor or lessee and which are therefore measured in accordance with ias 17.
Because of the short maturities of most trade accounts receivable and payable, other receivables and liabilities, and
cash and cash equivalents, their carrying amounts at the closing date did not significantly differ from the fair values.
The fair values of loans and receivables, held-to-maturity financial investments and of financial liabilities carried at
amortized cost that are given for information are the present values of the respective future cash flows. The present
values were determined by discounting the cash flows at a closing-date interest rate, taking into account the term
of the assets or liabilities and the creditworthiness of the counterparty. Where a market price was available, however, this was deemed to be the fair value.
The fair values of available-for-sale financial assets correspond to quoted prices in active markets (Level 1) or are
the present values of the respective future cash flows, determined on the basis of unobservable inputs (Level 3).
The fair values of derivatives for which no publicly quoted prices existed in active markets (Level 1) were determined using valuation techniques based on observable market data as of the end of the reporting period (Level 2).
In applying valuation techniques, credit value adjustments were determined to allow for the contracting partyâ€™s
credit risk.
Currency and commodity forward contracts were measured individually at their forward rates or forward prices on
the closing date. These depend on spot rates or prices, including time spreads. The fair values of interest-rate
hedging instruments and cross-currency interest-rate swaps were determined by discounting future cash flows
over the remaining terms of the instruments at market rates of interest, taking into account any foreign currency
translation as of the closing date.
Fair values measured using unobservable inputs are categorized within Level 3 of the fair value hierarchy. This
applies to certain available-for-sale debt or equity instruments, in some cases to the fair values of embedded derivatives, and to obligations for contingent consideration in business combinations. Credit risk is frequently the principal unobservable input used to determine the fair values of debt instruments classified as available-for-sale financial assets by the discounted cash flow method. Here we refer to credit spreads of comparable issuers. A significant
increase in credit risk could result in a lower fair value, whereas a significant decrease could result in a higher fair
value. However, a 10% relative change in the credit spread would not materially affect fair value.
Embedded derivatives are separated from their respective host contracts. Such host contracts are generally sales or
purchase agreements relating to the operational business. The embedded derivatives cause the cash flows from the
contracts to vary with exchange-rate or price fluctuations. The internal measurement of embedded derivatives is
mainly performed using the discounted cash flow method, which is based on unobservable inputs. These included
planned sales and purchase volumes, and prices derived from market data. Regular monitoring is carried out based
on these fair values as part of quarterly reporting.

319

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The changes in the amount of financial assets and liabilities recognized at fair value based on unobservable inputs
(Level 3) for each financial instrument category were as follows:

Changes in the Amount of Financial Assets and Liabilities Recognized at Fair Value Based on Unobservable Inputs

[Table 4.85]

2014

Carrying amounts of net
assets / (net liabilities), Jan. 1
Gains (losses) recognized in
profit or loss
of which related to
assets / liabilities recognized
in the statements of financial
position

Availablefor-sale
financial
assets

Derivatives
(net)

Liabilities
measured at
fair value
(nonderivative)

â‚¬ million

â‚¬ million

2015

Total

Availablefor-sale
financial
assets

Derivatives
(net)

Liabilities
measured at
fair value
(nonderivative)

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Total
â‚¬ million

824

(7)

â€“

817

803

6

(31)

778

10

(8)

â€“

2

22

(12)

(3)

7

â€“

2

22

(17)

(3)

2

10

(8)

Gains (losses) recognized
outside profit or loss

â€“

â€“

â€“

â€“

19

â€“

â€“

19

Additions of assets / (liabilities)

â€“

â€“

(31)

(31)

11

â€“

(4)

7

Settlements of
(assets) / liabilities

(31)

21

â€“

(10)

(22)

9

1

(12)

Transfers (IFRS 5)

â€“

â€“

â€“

â€“

â€“

6

â€“

6

803

6

(31)

778

833

9

(37)

805

Carrying amounts of net
assets/(net liabilities), Dec. 31
2014 figures restated

The changes recognized in profit or loss were included in other operating income / expenses, interest income or
exchange gains / losses.

320

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Income, expense, gains and losses on financial instruments can be assigned to the following categories:

Income, Expense, Gains and Losses on Financial Instruments

[Table 4.86]
2015

Loans and
receivables

Held-tomaturity
financial
investments

Availablefor-sale
financial
assets

â‚¬ million

â‚¬ million

55

1

Interest expense

â€“

Income/expenses from affiliated companies
Changes in fair value

Interest income

Impairment losses
Impairment loss reversals
Exchange gains / losses
Gains / losses from retirements
Other financial income/expenses
Net result

Held for
trading

Liabilities
carried at
amortized
cost

Total

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

22

25

86

189

â€“

â€“

(25)

(703)

(728)

â€“

â€“

3

â€“

â€“

3

â€“

â€“

â€“

147

â€“

147

(93)

â€“

(1)

â€“

â€“

(94)

32

â€“

â€“

â€“

â€“

32

450

â€“

â€“

(235)

(679)

(464)
31

â€“

â€“

31

â€“

â€“

(1)

â€“

13

â€“

(12)

â€“

443

1

68

(88)

(1,308)

(884)

Income, Expense, Gains and Losses on Financial Instruments (Previous Year)

[Table 4.87]
2014

Loans and
receivables

Held-tomaturity
financial
investments

Availablefor-sale
financial
assets

Held for
trading

Liabilities
carried at
amortized
cost

Total

â‚¬ million

â‚¬ million

88

1

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

11

54

122

â€“

276

â€“

â€“

(75)

(550)

(625)

Income / expenses from affiliated companies
Changes in fair value

â€“

â€“

1

â€“

â€“

1

â€“

â€“

â€“

32

â€“

32

(87)
24

â€“

â€“

â€“

â€“

(87)

â€“

2

â€“

â€“

26

590

â€“

â€“

(245)

(552)

(207)

Gains / losses from retirements

â€“

â€“

â€“

â€“

â€“

â€“

Other financial income/expenses

â€“

â€“

â€“

â€“

(44)

(44)

615

1

14

(234)

(1,024)

(628)

Interest income
Interest expense

Impairment losses
Impairment loss reversals
Exchange gains / losses

Net result
2014 figures restated

321

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The interest expense of â‚¬703 million (2014: â‚¬550 million) from nonderivative financial liabilities also included the
income and expense from interest-rate swaps that qualified for hedge accounting. Interest income from financial
assets not measured at fair value through profit or loss amounted to â‚¬73 million (2014: â‚¬54 million). Interest income from interest-rate derivatives that qualified for hedge accounting was â‚¬86 million (2014: â‚¬122 million). The
changes in fair values of financial assets held for trading related mainly to forward commodity contracts and embedded derivatives.
Derivatives that constitute financial assets and form part of a master netting arrangement but do not satisfy, or only
partially satisfy, the offsetting criteria and are only enforceable in the event of breach of contract by, or insolvency
of, one of the contracting parties amounted to â‚¬415 million (2014: â‚¬360 million), the related financial liabilities
(derivatives) to â‚¬256 million (2014: â‚¬242 million). Derivatives classified as financial liabilities and forming part of a
master netting arrangement amounted to â‚¬761 million (2014: â‚¬773 million), the related financial assets (derivatives) to â‚¬256 million (2014: â‚¬242 million).

30.2 Maturity analysis
The liquidity risks to which the Bayer Group was exposed from its financial instruments at the end of the reporting
period comprised obligations for future interest and repayment installments on financial liabilities and the liquidity
risk arising from derivatives, as shown in the table in note [30.3].
In addition, loan commitments existed for an as yet unpaid â‚¬1,213 million (2014: â‚¬1,005 million) portion of the
effective initial fund of Bayer-Pensionskasse VVaG, which may result in further payments by Bayer AG
(â‚¬1,005 million) and / or Covestro AG (â‚¬208 million) in subsequent years.

322

Bayer Annual Report 2015

323

Bayer Annual Report 2015
Consolidated Financial Statements

Consolidated Financial Statements

Notes to the Consolidated Financial Statements of the Bayer Group

Notes to the Consolidated Financial Statements of the Bayer Group

Maturity Analysis of Financial Instruments

[Table 4.88]
Dec. 31, 2015

Cash flows 2016

Cash flows 2017

Cash flows 2018

Cash flows 2019

Cash flows 2020

Cash flows after 2020

Carrying
amount

Interest and
repayment

Interest and
repayment

Interest and
repayment

Interest and
repayment

Interest and
repayment

Interest and
repayment

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

15,547

1,475

2,334

1,704

2,282

277

9,845

2,779

1,221

298

1,387

38

â€“

10

Remaining liabilities

843

440

79

69

60

61

307

Trade accounts payable

5,680

5,673

3

3

2

â€“

â€“

Accrued interest on liabilities

189

180

1

2

1

1

4

Remaining liabilities

454

420

5

2

1

1

25

Derivatives that qualify for hedge accounting

563

397

11

122

50

â€“

â€“

Derivatives that do not qualify for hedge accounting

327

312

8

1

3

1

2

Financial liabilities
Bonds and notes / promissory notes
Liabilities to banks

Other liabilities

Liabilities from derivatives

Receivables from derivatives
Derivatives that qualify for hedge accounting

125

66

26

13

2

2

1

Derivatives that do not qualify for hedge accounting

401

379

2

3

2

2

4

Loan commitments

â€“

1,213

â€“

â€“

â€“

â€“

â€“

Financial guarantees

â€“

14

â€“

â€“

â€“

â€“

2

Dec. 31, 2014

Cash flows 2015

Cash flows 2016

Cash flows 2017

Cash flows 2018

Cash flows 2019

Cash flows after 2019

Carrying
amount

Interest and
repayment

Interest and
repayment

Interest and
repayment

Interest and
repayment

Interest and
repayment

Interest and
repayment

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

8,353

Financial liabilities
14,964

1,690

1,521

2,131

1,612

2,037

Liabilities to banks

3,835

1,281

475

277

1,921

65

18

Remaining liabilities

2,417

1,714

405

65

55

48

294

Trade accounts payable

5,113

5,114

6

3

1

â€“

â€“

Accrued interest on liabilities

201

192

2

1

1

1

4

Remaining liabilities

620

582

6

9

4

1

21

Derivatives that qualify for hedge accounting

440

169

131

11

109

24

â€“

Derivatives that do not qualify for hedge accounting

408

311

80

13

1

1

3

Derivatives that qualify for hedge accounting

189

144

21

21

2

2

3

Derivatives that do not qualify for hedge accounting

295

257

2

23

2

1

14

Loan commitments

â€“

1,006

â€“

â€“

â€“

â€“

â€“

Financial guarantees

â€“

25

â€“

â€“

â€“

â€“

2

Bonds and notes / promissory notes 1

Other liabilities

Liabilities from derivatives

Receivables from derivatives

1

Repayment of the â‚¬1,300 million 100-year hybrid bond is reflected at the earliest possible repayment date in 2015.

324

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

30.3 Information on derivatives
Asset and liability fair values and future cash flows are exposed to currency, interest-rate and commodity price
risks. Derivatives are used to reduce this risk. In some cases they are designated as hedging instruments in a
hedge accounting relationship.
CURRENCY RISKS
Foreign currency receivables and liabilities are hedged using foreign exchange derivatives without the existence of
a hedge accounting relationship. A bond of Bayer AG denominated in British pounds was swapped on the issuance
date into a fixed-rate euro bond by means of a cross-currency interest-rate swap, which was designated as a cash
flow hedge. Certain forward exchange contracts and cross-currency interest-rate swaps used to hedge intra-Group
loans are also designated as cash flow hedges.
Fluctuations in future cash flows resulting from forecasted foreign currency transactions and procurement activities
are avoided partly through derivatives contracts, most of which are designated as cash flow hedges.
INTEREST-RATE RISKS
The interest-rate risks from fixed-interest borrowings are managed in part using interest-rate swaps. This applies
mainly to the â‚¬750 million bond issued in 2014, which matures in 2021. Hedge accounting is applied to the respective borrowings and hedging instruments (fair-value hedge).
Losses of â‚¬26 million (2014: â‚¬47 million) were recorded on fair-value hedging instruments in 2015. Gains of
â‚¬25 million (2014: â‚¬47 million) were recorded on the underlying hedged items.
COMMODITY PRICE RISKS
Hedging contracts are also used to partly reduce exposure to fluctuations in future cash outflows resulting from
price changes on procurement markets.
HEDGING OF OBLIGATIONS UNDER STOCK-BASED EMPLOYEE COMPENSATION PROGRAMS
A portion of the obligations to make variable payments to employees under stock-based compensation programs
(Aspire) is hedged against share price fluctuations using derivatives contracts that are settled in cash at maturity.
These derivatives are designated as cash flow hedges.
FURTHER INFORMATION ON CASH FLOW HEDGES
Accumulated other comprehensive income from cash flow hedges in 2015 decreased by â‚¬203 million (2014:
â‚¬102 million) due to changes in the fair values of derivatives net of tax. Losses of â‚¬304 million (2014: gains of
â‚¬46 million) from fair-value changes â€“ originally recognized in accumulated other comprehensive income â€“ of
derivatives designated as cash flow hedges were reclassified to profit or loss. The respective pro-rated deferred
tax income of â‚¬88 million (2014: deferred tax expense of â‚¬13 million) was likewise reclassified to profit or loss.
No material ineffective portions of hedges required recognition in profit or loss in 2015 or 2014.
The income and expense from cash flow hedges recognized in accumulated other comprehensive income mainly
comprised gains of â‚¬91 million (2014: â‚¬115 million) and losses of â‚¬90 million (2014: â‚¬156 million) from the hedging
of forecasted transactions in foreign currencies. Of these gains and losses, gains of â‚¬79 million (2014: â‚¬81 million)
and losses of â‚¬84 million (2014: â‚¬152 million) will be reclassifiable to profit or loss within one year and gains of
â‚¬12 million (2014: â‚¬34 million) and losses of â‚¬6 million (2014: â‚¬4 million) in subsequent years.

325

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The fair values of existing contracts in the major categories at the end of the reporting period are indicated in the
following table together with the included volumes of cash flow hedges.

Fair Values of Derivatives

[Table 4.89]
Dec. 31, 2014
Notional
amount 1

Positive
fair value

Negative
fair value
â‚¬ million

Dec. 31, 2015
Notional
amount1

Positive
fair value

Negative
fair value
â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Currency hedging of recorded transactions

14,023

176

(618)

22,275

337

(753)

Forward exchange contracts

11,754

176

(334)

19,896

336

(283)

â€“

â€“

â€“

â€“

â€“

â€“

2,269

â€“

(284)

2,379

1

(470)

2,269

â€“

(284)

2,362

â€“

(470)

Currency hedging of forecasted transactions

3,743

117

(159)

4,082

99

(100)

Forward exchange contracts

3,230

83

(151)

3,627

86

(99)

3,158

82

(150)

3,255

78

(90)

513

34

(8)

455

13

(1)

430

33

(6)

368

13

(1)

Interest-rate hedging of recorded
transactions

2,771

83

(24)

200

13

â€“

Interest-rate swaps

2,771

83

(24)

200

13

â€“

1,665

62

â€“

200

13

â€“

27

3

(2)

91

14

(12)

5

1

â€“

86

12

(10)

Commodity option contracts

22

2

(2)

5

2

(2)

Hedging of stock-based employee
compensation programs

14

12

â€“

80

21

(2)

Share price options

14

12

â€“

30

21

â€“

14

12

â€“

30

21

â€“

â€“

â€“

â€“

50

â€“

(2)

â€“

â€“

â€“

50

â€“

(2)

Total

20,578

391

(803)

26,728

484

(867)

of which current derivatives

17,092

329

(455)

25,022

435

(692)

14,494

251

(429)

24,931

420

(680)

2,571

75

(24)

â€“

1

â€“

27

3

(2)

91

14

(12)

â€“

â€“

â€“

â€“

â€“

â€“

of which cash flow hedges
Cross-currency interest-rate swaps
of which cash flow hedges

of which cash flow hedges
Currency options
of which cash flow hedges

of which fair value hedges
Commodity price hedging
Forward commodity contracts

of which cash flow hedges
Share price forwards
of which cash flow hedges

for currency hedging
for interest-rate hedging2
for commodity hedging
for hedging of stock-based employee
compensation programs
1 The

notional amount is reported as gross volume, which also contains economically closed hedges.
2 The portion of the fair value of long-term interest-rate swaps that relates to current interest payments was classified as current.

326

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

31. Contingent liabilities and other financial commitments
CONTINGENT LIABILITIES
The following warranty contracts, guarantees and other contingent liabilities existed at the end of the reporting
period:

Contingent Liabilities

[Table 4.90]
Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

Warranties

95

99

Guarantees

144

123

Other contingent liabilities

486

562

Total

725

784

2014 figures restated

The guarantees mainly comprise a declaration issued by Bayer AG to the trustees of the u.k. pension plans guaranteeing the pension obligations of Bayer Public Limited Company and Bayer CropScience Limited. Under the declaration, Bayer AG â€“ in addition to the two companies â€“ undertakes to make further payments into the plans upon
receipt of a payment request from the trustees. The net liability with respect to these defined benefit plans as of
December 31, 2015, amounted to â‚¬123 million (2014: â‚¬144 million).
OTHER FINANCIAL COMMITMENTS
The other financial commitments were as follows:

Other Financial Commitments

[Table 4.91]
Dec. 31, 2014

Dec. 31, 2015

â‚¬ million

â‚¬ million

Operating leases

671

891

Orders already placed under purchase agreements

476

690

Capital contribution commitments

48

391

Unpaid portion of the effective initial fund

1,005

1,213

Potential payment obligations under R&D collaboration agreements

2,427

2,887

Revenue-based milestone payment commitments

2,169

2,241

Total

6,796

8,313

2014 figures restated

The nondiscounted future minimum lease payments relating to operating leases totaled â‚¬891 million (2014:
â‚¬671 million). The maturities of the respective payment obligations were as follows:

Operating Leases
Maturing in

[Table 4.92]
Dec. 31, 2014

Maturing in

â‚¬ million

Dec. 31, 2015
â‚¬ million

2015

174

2016

195

2016

125

2017

155

2017

98

2018

110

2018

70

2019

94

2019

59

2020

79

2020 or later

145

2021 or later

258

Total

671

Total

891

327

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Financial commitments resulting from orders already placed under purchase agreements related to planned or
ongoing capital expenditure projects totaled â‚¬690 million (2014: â‚¬476 million).
On December 19, 2015, Bayer entered into an agreement to create a joint venture with crispr therapeutics ag,
Basel, Switzerland. As of December 31, 2015, Bayer had capital contribution obligations of us$370 million in this
connection to crispr therapeutics ag and the joint venture yet to be established. These obligations mature on
December 31, 2020, at the latest.
The Bayer Group has entered into cooperation agreements with third parties under which it has agreed to fund
various research and development projects or has assumed other payment obligations based on the achievement of
certain milestones or other specific conditions. If all of these payments have to be made, their maturity distribution
as of December 31, 2015, was expected to be as set forth in the following table. The amounts shown represent the
maximum payments to be made, and it is unlikely that they will all fall due. Since the achievement of the conditions
for payment is highly uncertain, both the amounts and the dates of the actual payments may vary considerably
from those stated in the table.

Potential Payment Obligations Under R&D Collaboration Agreements
Maturing in

Dec. 31, 2014

[Table 4.93]
Maturing in

â‚¬ million

Dec. 31, 2015
â‚¬ million

2015

155

2016

262

2016

198

2017

229

2017

164

2018

96

2018

130

2019

240

2019

203

2020

78

2020 or later

1,577

2021 or later

1,982

Total

2,427

Total

2,887

In addition to the above commitments, there were also revenue-based milestone payment commitments totaling
â‚¬2,241 million (2014: â‚¬2,169 million), of which â‚¬2,237 million (2014: â‚¬2,157 million) was not expected to fall due
until 2021 (2014: 2020) or later. These commitments are also highly uncertain.

32. Legal risks
As a global company with a diverse business portfolio, the Bayer Group is exposed to numerous legal risks, particularly in the areas of product liability, competition and antitrust law, patent disputes, tax assessments and environmental matters. The outcome of any current or future proceedings cannot normally be predicted. It is therefore
possible that legal or regulatory judgments or future settlements could give rise to expenses that are not covered,
or not fully covered, by insurersâ€™ compensation payments and could significantly affect our revenues and earnings.
Legal proceedings currently considered to involve material risks are outlined below. The legal proceedings referred
to do not represent an exhaustive list.
PRODUCT-RELATED LITIGATION
Yasminâ„¢ / yazâ„¢: As of January 25, 2016, the number of claimants in the pending lawsuits and claims in the United States totaled about 2,300 (excluding claims already settled). Claimants allege that users have suffered personal
injuries, some of them fatal, from the use of Bayerâ€™s drospirenone-containing oral contraceptive products such as
Yasminâ„¢ and / or yazâ„¢ or from the use of Ocellaâ„¢ and / or Gianviâ„¢, generic versions of Yasminâ„¢ and yazâ„¢, respectively, marketed by Barr Laboratories, Inc. in the United States. Claimants seek compensatory and punitive damages, claiming, in particular, that Bayer knew or should have known of the alleged risks and should be held liable for
having failed to disclose them or adequately warn users. All cases pending in u.s. federal courts have been consolidated in a multidistrict litigation proceeding for common pre-trial management.

328

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

A few State Attorney Generals in the United States are investigating an alleged off-label promotion of Yasminâ„¢ and
yazâ„¢ as well as an alleged failure to warn about an alleged increased risk of developing blood clots in violation of
consumer protection statutes. One Attorney General has filed an action against Bayer.
As of January 25, 2016, 13 lawsuits seeking class action certification had been served upon Bayer in Canada. In
one of these lawsuits a class has been certified. Two motions for certification of a class action are pending in Israel.
As of January 25, 2016, Bayer had reached agreements, without admission of liability, to settle approximately
10,300 claims for venous clot injuries (deep vein thrombosis or pulmonary embolism) for a total amount of about
us$2.04 billion and approximately 7,200 claims for gallbladder injuries for a total amount of about us$21.5 million
in the United States. Bayer will continue to consider the option of settling venous clot injury claims after a casespecific analysis of medical records. At present, about 300 such claims are under review.
In August 2015, Bayer reached an agreement to settle, without admission of liability, lawsuits and claims in which
plaintiffs allege an arterial thromboembolic injury (primarily strokes and heart attacks) for a total maximum aggregate amount of us$56.9 million. Bayer may withdraw from the settlement if fewer than 97.5% of those who are
eligible, and / or fewer than 96% of those who are eligible and allege death or catastrophic injuries, choose to participate. As of January 25, 2016, about 1,200 of the 2,300 above-mentioned claimants alleged arterial thromboembolic injuries.
In August 2015, the u.s. multidistrict and state coordinating courts overseeing the litigation issued case management orders governing all cases before them (regardless of alleged injury), imposing much stricter threshold requirements for litigating the remaining unsettled cases and for filing of new cases. Failing compliance with these
requirements, such cases will be dismissed.
Additional lawsuits are anticipated. Bayer believes that it has meritorious defenses and will continue to defend
itself vigorously against all claims that are not considered for settlement. Bayer has taken appropriate accounting
measures for anticipated defense costs and for agreed and anticipated future settlements based on the information
currently available and based on the number of pending and estimated future claims alleging venous clot injuries.
Mirenaâ„¢: As of January 25, 2016, lawsuits from approximately 3,500 users of Mirenaâ„¢, a levonorgestrel-releasing
intrauterine system providing long-term contraception, had been served upon Bayer in the United States (excluding lawsuits no longer pending). Most of the cases pending in u.s. federal courts have been consolidated in a multidistrict litigation proceeding for common pre-trial management. Additional lawsuits are anticipated. Plaintiffs
allege personal injuries resulting from the use of Mirenaâ„¢, including perforation of the uterus, ectopic pregnancy,
or idiopathic intracranial hypertension, and seek compensatory and punitive damages. Plaintiffs claim, inter alia,
that Mirenaâ„¢ is defective and that Bayer knew or should have known of the risks associated with it and failed to
adequately warn its users. As of January 25, 2016, five lawsuits relating to Mirenaâ„¢ seeking class action certification had been served upon Bayer in Canada. Bayer believes it has meritorious defenses and intends to defend itself
vigorously. Based on the information currently available, Bayer has taken appropriate accounting measures for
anticipated defense costs.

329

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Xareltoâ„¢: As of January 25, 2016, in the United States, lawsuits from approximately 4,300 recipients of Xareltoâ„¢,
an oral anticoagulant for the treatment and prevention of blood clots, had been served upon Bayer. Plaintiffs allege
personal injuries from the use of Xareltoâ„¢, including cerebral, gastrointestinal or other bleeding and death, and
seek compensatory and punitive damages. They claim, amongst other things, that Xareltoâ„¢ is defective and that
Bayer knew or should have known of the risks associated with the use of Xareltoâ„¢ and failed to adequately warn its
users. Additional lawsuits are anticipated. Cases pending in u.s. federal courts have been consolidated in a multidistrict litigation for common pre-trial management. As of January 25, 2016, eight lawsuits relating to Xareltoâ„¢
seeking class action certification had been served upon Bayer in Canada. Bayer believes it has meritorious defenses and intends to defend itself vigorously. Based on the information currently available, Bayer has taken appropriate accounting measures for anticipated defense costs.
In connection with the above proceedings concerning Yasminâ„¢ / yazâ„¢, Mirenaâ„¢ and Xareltoâ„¢, Bayer is insured
against product liability risks to the extent customary in the industry. However, the accounting measures taken with
regard to the Yasminâ„¢ / yazâ„¢ claims exceed the available insurance coverage.
COMPETITION LAW PROCEEDINGS
Phillipsâ€™ Colon Health / Department of Justice: In 2014, the United States Department of Justice, representing the
United States Federal Trade Commission (ftc), filed a motion in a New Jersey federal court contending that Bayer
did not have the requisite support for claims made with respect to Phillipsâ€™ Colon Health probiotics. The motion
sought to hold Bayer in contempt of a prior consent order that required Bayer to have competent and reliable scientific evidence to substantiate dietary supplement claims. In September 2015, the New Jersey federal court ruled
that the United States failed to satisfy its burden of proving that Bayer failed to possess competent and reliable
scientific evidence. Thus, the court found that Bayer did not violate the consent order. The decision is final.
PATENT DISPUTES
Beyazâ„¢ / Safyralâ„¢: Beyazâ„¢ and Safyralâ„¢ are Bayerâ€™s oral contraceptives containing folate. In September 2015, a
u.s. federal court ruled in favor of Bayer regarding both the validity of its patent and the infringement thereof by
Watson Laboratories, Inc. Watson had filed Abbreviated New Drug Applications with a Paragraph iv certification
(â€œanda ivâ€) seeking approval of generic versions of both Beyazâ„¢ and Safyralâ„¢ in the United States. Watson appealed the decision. In May and October 2015, Bayer filed two suits against Lupin Ltd. and Lupin Pharmaceuticals,
Inc. (together â€œLupinâ€) in u.s. federal court for infringement of the same patent. In April and September 2015,
Bayer had received two notices of an anda iv by Lupin seeking approval to market generic versions of Safyralâ„¢ and
Beyazâ„¢ in the United States.
Betaferonâ„¢ / Betaseronâ„¢: In 2010, Bayer filed a complaint against Biogen Idec ma Inc. in u.s. federal court seeking a declaration by the court that a patent issued to Biogen in 2009 is invalid and not infringed by Bayerâ€™s production and distribution of Betaseronâ„¢, Bayerâ€™s drug product for the treatment of multiple sclerosis. Biogen is alleging
patent infringement by Bayer through Bayerâ€™s production and distribution of Betaseronâ„¢ and Extaviaâ„¢ and has
sued Bayer accordingly. Bayer manufactures Betaseronâ„¢ and distributes the product in the United States. Extaviaâ„¢
is also a drug product for the treatment of multiple sclerosis; it is manufactured by Bayer, but distributed in the
United States by Novartis Pharmaceuticals Corporation, another defendant in the lawsuit.

330

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Finaceaâ„¢: In July 2015, a u.s. federal court found that Bayerâ€™s patent relating to Finaceaâ„¢ topical gel is valid and
infringed by Glenmark Generics Ltd. Glenmark had filed an anda iv seeking approval of a generic version of Finaceaâ„¢ in the United States, and Glenmark appealed the us federal court decision.
Damoctocog alfa pegol (bay 94-9027, long-acting rFVIII): In 2013, Bayer filed a lawsuit against Nektar Therapeutics in the district court of Munich, Germany. In this proceeding, Bayer claims rights to certain European patent
applications based on a past collaboration between Bayer and Nektar in the field of hemophilia. The European
patent applications with the title â€œPolymer-factor viii moiety conjugatesâ€ are part of a patent family registered in
the name of Nektar comprising further patent applications and patents in other countries including the United
States. However, Bayer believes that the patent family does not include any valid patent claim relevant for Bayerâ€™s
drug candidate bay 94-9027 for the treatment of hemophilia a.
Nexavarâ„¢: In January and December 2015, Bayer filed patent infringement lawsuits in a u.s. federal court against
Mylan Pharmaceuticals Inc. and Mylan Inc. (together â€œMylanâ€). In December 2014 and in November 2015, Bayer
had received notices of anda iv applications pursuant to which Mylan seeks approval of a generic version of
BayerÂ´s cancer drug Nexavarâ„¢ in the United States.
Staxynâ„¢: Staxynâ„¢ is a Bayer product for erectile dysfunction treatment. It is an orodispersible (orally disintegrating) formulation of Levitraâ„¢. Both drug products contain the same active ingredient, which is protected in the
United States by two patents expiring in 2018. In 2012, Bayer received notice of an anda iv application pursuant to
which Watson seeks approval to market a generic version of Bayerâ€™s erectile dysfunction treatment Staxynâ„¢ prior
to patent expiration in the United States. Bayer filed a patent infringement suit in a u.s. federal court against Watson Laboratories, Inc. In April 2015, the court ruled that both of Bayerâ€™s compound patents are valid and infringed.
Watson may appeal.
Xareltoâ„¢: In October 2015, Bayer and Janssen Pharmaceuticals, Inc. filed a patent infringement suit in a u.s.
federal court against Aurobindo Pharma Limited, Aurobindo Pharma usa, Inc. (together â€œAurobindoâ€), Breckenridge Pharmaceutical Inc. (â€œBreckenridgeâ€), Micro Labs Ltd., Micro Labs usa Inc. (together â€œMicro Labsâ€), Mylan
Pharmaceuticals Inc., Mylan Inc. (together â€œMylanâ€), Prinston Pharmaceutical Inc. (â€œPrinstonâ€), Sigmapharm Laboratories, llc (â€œSigmapharmâ€), Torrent Pharmaceuticals, Limited and Torrent Pharma Inc. (together â€œTorrentâ€). In
September 2015, Bayer had received notices of an anda iv application by Aurobindo, Breckenridge, Micro Labs,
Mylan, Prinston, Sigmapharm and Torrent, each seeking approval to market a generic version of Xareltoâ„¢, an oral
anticoagulant for the treatment and prevention of blood clots, in the United States. In January 2016, Bayer received
another notice of such an anda iv application by InvaGen Pharmaceuticals, Inc. (â€œInvaGenâ€). In February 2016,
Bayer and Janssen Pharmaceuticals, Inc. filed a patent infringement suit against InvaGen in the same u.s. federal
court.
Bayer believes it has meritorious defenses in the above patent disputes and intends to defend itself vigorously.
FURTHER LEGAL PROCEEDINGS
Trasylolâ„¢ / Aveloxâ„¢: A qui tam complaint relating to marketing practices for Trasylolâ„¢ (aprotinin) and Aveloxâ„¢
(moxifloxacin) filed by a former Bayer employee is pending in the United States District Court in New Jersey. The
u.s. government has declined to intervene at the present time.
Newark Bay Environmental Matters: In the United States, Bayer is one of numerous parties involved in a series of
claims brought by federal and state environmental protection agencies. The claims arise from operations by entities
which historically were conducted near Newark Bay or surrounding bodies of water, or which allegedly discharged
hazardous waste into these waterways or onto nearby land. Bayer and the other potentially responsible parties are
being asked to remediate and contribute to the payment of past and future remediation or restoration costs and
damages.

331

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

In the Lower Passaic River matter, a group of more than sixty companies including Bayer is investigating contaminated sediments in the riverbed under the supervision of the United States Environmental Protection Agency (epa)
and other governmental authorities. Future remediation will involve some form of dredging, the nature and scope
of which are not yet defined, and potentially other tasks. The cost of the investigation and the remediation work
may be substantial if the final remedy involves extensive dredging and disposal of impacted sediments. In the
Newark Bay matter, an unaffiliated party is currently conducting an investigation of sediments in Newark Bay
under epa supervision. The investigation is in a preliminary stage. Bayer has contributed to certain investigation
costs in the past and may incur costs for future investigation and remediation activities in Newark Bay.
Bayer has also been notified by governmental authorities acting as natural resource trustees that it may have liability for natural resource damages arising from the contamination of the Lower Passaic River, Newark Bay and surrounding water bodies. Bayer is currently unable to determine the extent of its liability.
Asbestos: A further risk may arise from asbestos litigation in the United States. In many cases, the plaintiffs allege
that Bayer and co-defendants employed third parties on their sites in past decades without providing them with
sufficient warnings or protection against the known dangers of asbestos. Additionally, a Bayer affiliate in the United States is the legal successor to companies that sold asbestos products until 1976. Union Carbide has agreed to
indemnify Bayer for this liability. Bayer believes it has meritorious defenses and intends to defend itself vigorously.
TAX PROCEEDINGS
Stamp taxes in Greece: In 2014, a Greek administrative court of first instance dismissed Bayerâ€™s lawsuit against
the assessment of stamp taxes and contingent penalties in the total amount of approximately â‚¬23 million on certain
intra-Group loans to a Greek subsidiary. Bayer is convinced that the decision is wrong and has appealed. In two
additional court proceeding of first instance before the same court, Bayer has filed lawsuits against the assessment
of stamp taxes and contingent penalties in an amount of approximately â‚¬90 million and a further amount of approximately â‚¬16 million. Bayer believes it has meritorious arguments to support its legal position and intends to defend
itself vigorously.

Notes to the Statements of Cash Flows
The statement of cash flows shows how cash inflows and outflows during the fiscal year affected the cash and cash
equivalents of the Bayer Group. Cash flows are classified by operating, investing and financing activities in accordance with ias 7 (Statement of Cash Flows). Effects of changes in the scope of consolidation are stated separately.
Of the cash and cash equivalents, an amount of â‚¬17 million (2014: â‚¬72 million) had limited availability due to foreign exchange restrictions. Past experience has shown such restrictions to be of short duration. The above amount
included â‚¬3 million (2014: â‚¬64 million) of exchange-restricted cash in Venezuela. The conversion of cash from
Venezuelan bolivars (vef) into u.s. dollars is subject to a government approval process.
The cash flows reported by consolidated companies outside the eurozone are translated at average monthly exchange rates, with the exception of cash and cash equivalents, which are translated at closing rates. The â€œChange
in cash and cash equivalents due to exchange rate movementsâ€ is reported in a separate line item.

332

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

33. Net cash provided by (used in) operating activities
The gross cash flow from continuing operations, amounting in 2015 to â‚¬6,999 million (2014: â‚¬6,707 million), is the
cash surplus from operating activities before any changes in working capital. The cash flows by segment are shown
in note [1].
The net operating cash flow (total) of â‚¬6,890 million (2014: â‚¬5,810 million) also takes into account the changes in
working capital and other noncash transactions.
An income-tax-related net cash outflow of â‚¬1,699 million (2014: â‚¬1,835 million) is included in the net cash flow for
2015. The changes in income tax liabilities, income tax provisions and claims for reimbursement of income taxes
are shown in the line item â€œChanges in other working capital, other noncash items.â€
The transfers of bonds with a total value of â‚¬300 million (2014: â‚¬250 million) to pension funds were noncash transactions and therefore did not result in an operating cash outflow.

34. Net cash provided by (used in) investing activities
The net cash outflow for investing activities in 2015 amounted to â‚¬2,762 million (2014: â‚¬15,539 million).
Additions to property, plant and equipment and intangible assets in 2015 resulted in a cash outflow of
â‚¬2,517 million (2014: â‚¬2,371 million). Cash inflows from sales of property, plant and equipment and intangible
assets amounted to â‚¬193 million (2014: â‚¬143 million).
The cash outflows of â‚¬176 million (2014: â‚¬13,545 million) for acquisitions primarily related to the acquisition of
SeedWorks India Pvt. Ltd., Hyderabad, India, and further payments in connection with the acquisition of the consumer care business of Merck & Co., Inc., United States. The prior-year figure mainly comprised the acquisitions of
the consumer care business of Merck & Co., Inc., United States, and Algeta asa, Norway. Further details of acquisitions and divestitures are given in notes [6.2] and [6.3], respectively.
The net cash outflow for noncurrent and current financial assets amounted to â‚¬370 million (2014: â‚¬177 million).
The transfers of bonds with a total value of â‚¬300 million (2014: â‚¬250 million) to pension funds were noncash transactions and therefore did not result in an investing cash inflow.

35. Net cash provided by (used in) financing activities
In 2015 there was a net cash outflow of â‚¬3,974 million (2014: inflow of â‚¬9,736 million) for financing activities.
Net loan repayments amounted to â‚¬2,929 million (2014: net borrowings of â‚¬11,838 million).
Cash outflows for dividend payments amounted to â‚¬1,869 million (2014: â‚¬1,739 million). Net interest payments â€“
including payments for and receipts from interest-rate swaps â€“ rose to â‚¬652 million (2014: â‚¬362 million). The proceeds from the stock market flotation of Covestro AG amounted to â‚¬1,490 million.

333

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Other Information
36. Audit fees
The following fees for the services of the worldwide network of PricewaterhouseCoopers (PwC), including PricewaterhouseCoopers Aktiengesellschaft WirtschaftsprÃ¼fungsgesellschaft (PwC AG wpg), were recognized as expenses:

Audit Fees

[Table 4.94]
PwC

of which PwC AG WPG

2014

2015

2014

2015

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

12

17

4

7

Audit-related services and other audit work

4

9

3

9

Tax consultancy

2

3

â€“

â€“

Other services

6

7

â€“

5

24

36

7

21

Financial statements auditing

Total

The fees for the auditing of financial statements mainly comprised those for the audits of the consolidated financial
statements of the Bayer Group and the financial statements of Bayer AG and its subsidiaries. The increase in fees
for financial statements auditing and for audit-related services and other audit work mainly resulted from the carveout and stock market flotation of Covestro.
The Independent Auditorâ€™s Report on the consolidated financial statements for fiscal 2015 was signed by Dr. Peter
Bartels and Eckhard Sprinkmeier. Dr. Peter Bartels signed the Independent Auditorâ€™s Report for the first time for
the year ended December 31, 2012, and Eckhard Sprinkmeier for the year ended December 31, 2014. PwC has
served as the auditor of Bayerâ€™s consolidated financial statements since the merger of Price Waterhouse Deutschland and Coopers & Lybrand Deutsche Revision in 1998. The predecessor firm of Coopers & Lybrand Deutsche
Revision had already audited Bayerâ€™s consolidated financial statements for some years prior to that date.

37. Related parties
Related parties as defined in ias 24 (Related Party Disclosures) are those legal entities and natural persons that are
able to exert influence on Bayer AG and its subsidiaries or over which Bayer AG or its subsidiaries exercise control
or joint control or have a significant influence. They include, in particular, nonconsolidated subsidiaries, joint ventures and associates included in the consolidated financial statements at cost of acquisition or using the equity
method, and post-employment benefit plans, as well as the corporate officers of Bayer AG whose compensation is
reported in note [38] and in the Compensation Report, which forms part of the Combined Management Report.

334

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

Transactions with nonconsolidated subsidiaries, joint ventures and associates included in the consolidated financial
statements at cost of acquisition or using the equity method, and post-employment benefit plans are carried out on
an armâ€™s-length basis.
The following table shows the volume of transactions with related parties included in the consolidated financial
statements of the Bayer Group at amortized cost or using the equity method, and with post-employment benefit
plans:

Related Parties

[Table 4.95]
2014
Sales of
goods and
services

Purchases of
goods and
services

Receivables

2015

Liabilities

Sales of
goods and
services

Purchases of
goods and
services

Receivables

Liabilities

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

â‚¬ million

Nonconsolidated
subsidiaries

21

4

8

18

21

4

11

22

Joint ventures

29

â€“

4

â€“

25

â€“

4

1

Associates

33

758

5

5

36

645

â€“

4

â€“

â€“

803

64

â€“

â€“

822

68

Post-employment
benefit plans

Goods and services in the amount of â‚¬609 million (2014: â‚¬737 million) were purchased from the associate po jv, lp,
Wilmington, United States, mainly in the course of day-to-day business operations.
Intercompany profits and losses for companies accounted for in the consolidated financial statements using the
equity method were immaterial in 2015 and 2014.
Bayer AG has undertaken to provide jouissance right capital (Genussrechtskapital) in the form of an interestbearing loan with a nominal volume of â‚¬150 million (2014: â‚¬150 million) for Bayer-Pensionskasse VVaG. The entire
amount remained drawn as of December 31, 2015. The carrying amount as of December 31, 2015, was â‚¬153 million (2014: â‚¬150 million). Loan capital was first provided to Bayer-Pensionskasse VVaG in 2008 for its effective
initial fund. This capital had a nominal volume of â‚¬595 million as of December 31, 2015 (2014: â‚¬595 million). The
carrying amount as of December 31, 2015, was â‚¬610 million (2014: â‚¬595 million). The outstanding receivables,
comprised of different tranches, are each subject to a five-year interest-rate adjustment mechanism. Net interest
income of â‚¬22 million was recognized for 2015 (2014: â‚¬10 million).
No impairment losses were recognized on receivables from related parties in 2015 or 2014.

335

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

38. Total compensation of the Board of Management
and the Supervisory Board, advances and loans
The compensation of the Board of Management comprises short-term payments, stock-based payments and postemployment benefits.
The following table shows the individual components of the Board of Managementâ€™s compensation according
to ifrs:

Board of Management Compensation according to IFRS

Fixed annual compensation
Fringe benefits

[Table 4.96]
2014

2015

â‚¬ thousand

â‚¬ thousand

4,118

4,455

443

207

Total short-term non-performance-related compensation

4,561

4,662

Short-term performance-related cash compensation

5,051

5,983

Total short-term compensation

9,612

10,645

Stock-based compensation (virtual Bayer shares) earned in the respective year

5,058

5,983

Change in value of existing entitlements to stock-based compensation (virtual Bayer shares)

1,559

556

Stock-based compensation (Aspire) earned in the respective year

3,602

2,330

Change in value of existing entitlements to stock-based compensation (Aspire)
Total stock-based compensation (long-term incentive)
Service cost for pension entitlements earned in the respective year
Total long-term compensation
Severance indemnity in connection with the termination of a service contract
Aggregate compensation (IFRS)

687

272

10,906

9,141

1,716

2,891

12,622

12,032

â€“

1,131

22,234

23,808

In addition to the above compensation, actuarial gains of â‚¬2,309 thousand (2014: losses of â‚¬11,311 thousand)
incurred in connection with pension obligations to the currently serving members of the Board of Management
were recognized outside profit or loss. These changes mainly resulted from the slight increase (2014: sharp decline) in the level of interest rates.
Further details are provided in the Compensation Report, which forms part of the Combined Management Report.
In addition to the provisions of â‚¬5,983 thousand (2014: â‚¬4,771 thousand) for the short-term variable cash compensation, an amount of â‚¬18,663 thousand (2014: â‚¬17,775 thousand) was recognized in the statement of financial
position for future payments of stock-based compensation based on virtual shares to the members of the Board of
Management serving as of December 31, 2015.
An amount of â‚¬7,110 thousand (2014: â‚¬7,155 thousand) was recognized in the statement of financial position for
future payments of stock-based compensation based on the Aspire program to the members of the Board of Management serving as of December 31, 2015.
The present value of the defined benefit pension obligation for the members of the Board of Management serving
as of December 31, 2015, was â‚¬33,491 thousand (2014: â‚¬32,248 thousand).
Pension payments to former members of the Board of Management and their surviving dependents amounted to
â‚¬13,416 thousand (2014: â‚¬13,457 thousand). The defined benefit obligation for former members of the Board of
Management and their surviving dependents amounted to â‚¬172,767 thousand (2014: â‚¬187,759 thousand).

336

Bayer Annual Report 2015
Consolidated Financial Statements
Notes to the Consolidated Financial Statements of the Bayer Group

The compensation of the Supervisory Board amounted to â‚¬3,291 thousand (2014: â‚¬3,286 thousand).
In addition to their compensation as members of the Supervisory Board, those employee representatives who are
employees of Bayer Group companies receive compensation unrelated to their service on the Supervisory Board.
The total amount of such compensation in 2015 was â‚¬741 thousand (2014: â‚¬737 thousand).
Pension obligations for employee representatives on the Supervisory Board amounted to â‚¬3,756 thousand (2014:
â‚¬3,623 thousand).
There were no advances or loans to members of the Board of Management or the Supervisory Board outstanding
as of December 31, 2015, nor at any time during 2015 or 2014.

39. Events after the end of the reporting period
DIABETES CARE BUSINESS
Implementation of the agreement concerning the sale of the Diabetes Care business to Panasonic Healthcare Holdings Co, Ltd., Tokyo, Japan, began on January 4, 2016, and thus after the closing date for the financial statements.
A payment of â‚¬0.9 billion was made in January 2016 in connection with the sale. Bayer has entered into further
significant obligations, which are to be met over the next two years.
REDEMPTION OF FINANCIAL LIABILITIES
On January 25, 2016, Bayer AG redeemed at maturity a bond with a nominal volume of â‚¬500 million issued under
the multi-currency European Medium Term Notes program. In addition, commercial paper and promissory notes in
a total amount of â‚¬383 million were repaid in January and February, 2016, respectively.

Leverkusen, February 16, 2016
Bayer Aktiengesellschaft

The Board of Management

337

Bayer Annual Report 2015
Responsibility Statement

Responsibility
Statement
To the best of our knowledge, and in accordance with the applicable reporting principles for financial
reporting, the consolidated financial statements give a true and fair view of the assets, liabilities,
financial position and profit or loss of the Bayer Group, and the combined management report includes
a fair review of the development and performance of the business and the position of the Bayer Group
and Bayer AG, together with a description of the principal opportunities and risks associated with the
expected development of the Bayer Group and Bayer AG.
Leverkusen, February 16, 2016
Bayer Aktiengesellschaft
The Board of Management

Dr. Marijn Dekkers
Chairman

Liam Condon

Werner Baumann

Johannes Dietsch

Erica Mann

Kemal Malik

Dieter Weinand

Dr. Hartmut Klusik

338

Bayer Annual Report 2015
Independent Auditorâ€™s Report

Independent Auditorâ€™s
Report
Report of the independent auditor of the consolidated financial statements
To Bayer Aktiengesellschaft, Leverkusen
The following Independent Auditorâ€™s Report was issued for the complete set of consolidated financial
statements and the combined management report of Bayer Aktiengesellschaft, Leverkusen, and its
subsidiaries. For reasons of clarity, the notes to the consolidated financial statements, to which this
Independent Auditorâ€™s Report also refers, are not included in this print version of the Annual Report.
The consolidated financial statements including the notes thereto are published in German and English
in the electronic version of the German Federal Gazette and will also be included in an augmented German print version of the Annual Report to be available at the Annual Stockholdersâ€™ Meeting of Bayer AG
on April 29, 2016.
REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS
We have audited the accompanying consolidated financial statements of Bayer Aktiengesellschaft and
its subsidiaries, which comprise the consolidated income statement and statement of comprehensive
income, the consolidated statement of financial position, the consolidated statement of cash flows, the
consolidated statement of changes in equity and the notes to the consolidated financial statements for
the business year from January 1, 2015 to December 31, 2015.
Board of Managementâ€™s Responsibility for the Consolidated Financial Statements
The Board of Management of Bayer Aktiengesellschaft is responsible for the preparation of these consolidated financial statements. This responsibility includes that these consolidated financial statements
are prepared in accordance with International Financial Reporting Standards, as adopted by the e.u.,
and the additional requirements of German commercial law pursuant to Â§ (Article) 315a Abs. (paragraph) 1 hgb (â€œHandelsgesetzbuchâ€: German Commercial Code) and that these consolidated financial
statements give a true and fair view of the net assets, financial position and results of operations of the
Group in accordance with these requirements. The Board of Management is also responsible for the
internal controls as the Board of Management determines are necessary to enable the preparation of
consolidated financial statements that are free from material misstatement, whether due to fraud or
error.
Auditorâ€™s Responsibility
Our responsibility is to express an opinion on these consolidated financial statements based on our
audit. We conducted our audit in accordance with Â§ 317 hgb and German generally accepted standards
for the audit of financial statements promulgated by the Institut der WirtschaftsprÃ¼fer (Institute of
Public Auditors in Germany) (idw) and additionally observed the International Standards on Auditing
(isa). Accordingly, we are required to comply with ethical requirements and plan and perform the audit
to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.
An audit involves performing audit procedures to obtain audit evidence about the amounts and
disclosures in the consolidated financial statements. The selection of audit procedures depends on the
auditorâ€™s professional judgment. This includes the assessment of the risks of material misstatement of
the consolidated financial statements, whether due to fraud or error. In assessing those risks, the auditor considers the internal control system relevant to the entityâ€™s preparation of consolidated financial
statements that give a true and fair view. The aim of this is to plan and perform audit procedures that
are appropriate in the given circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the Groupâ€™s internal control system. An audit also includes evaluating the appropriate-

339

Bayer Annual Report 2015
Independent Auditorâ€™s Report

ness of accounting policies used and the reasonableness of accounting estimates made by the Board of
Management, as well as evaluating the overall presentation of the consolidated financial statements.
We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for
our audit opinion.
Audit Opinion
According to Â§ 322 Abs. 3 Satz (sentence) 1 hgb, we state that our audit of the consolidated financial
statements has not led to any reservations.
In our opinion based on the findings of our audit, the consolidated financial statements comply, in all
material respects, with ifrss, as adopted by the e.u., and the additional requirements of German commercial law pursuant to Â§ 315a Abs. 1 hgb and give a true and fair view of the net assets and financial
position of the Group as at December 31, 2015 as well as the results of operations for the business year
then ended, in accordance with these requirements..
REPORT ON THE COMBINED MANAGEMENT REPORT
We have audited the accompanying Group management report of Bayer Aktiengesellschaft for the business year from January 1, 2015 to December 31, 2015, which is combined with the management report
of the company. The Board of Management of Bayer Aktiengesellschaft is responsible for the preparation of the combined management report in accordance with the requirements of German commercial
law applicable pursuant to Â§ 315a Abs. 1 hgb. We conducted our audit in accordance with Â§ 317 Abs. 2
hgb and German generally accepted standards for the audit of the combined management report promulgated by the Institut der WirtschaftsprÃ¼fer (Institute of Public Auditors in Germany) (idw). Accordingly, we are required to plan and perform the audit of the combined management report to obtain
reasonable assurance about whether the combined management report is consistent with the consolidated financial statements and the audit findings, as a whole provides a suitable view of the Groupâ€™s
position and suitably presents the opportunities and risks of future development.
According to Â§ 322 Abs. 3 Satz 1 hgb, we state that our audit of the combined management report has
not led to any reservations.
In our opinion based on the findings of our audit of the consolidated financial statements and combined
management report, the combined management report is consistent with the consolidated financial
statements, as a whole provides a suitable view of the Groupâ€™s position and suitably presents the opportunities and risks of future development.
Essen, February 17, 2016
PricewaterhouseCoopers
Aktiengesellschaft
WirtschaftsprÃ¼fungsgesellschaft

Dr. Peter Bartels
WirtschaftsprÃ¼fer

Eckhard Sprinkmeier
WirtschaftsprÃ¼fer

340

Bayer Annual Report 2015
Independent Assurance Report

Independent Practitionerâ€™s Limited Assurance
Report on the sustainability information in the
online annexes of the augmented online
version of the Annual Report of Bayer AG 2015
To Bayer AG, Leverkusen
We have been engaged to perform a limited assurance engagement on the sustainability information
marked with â€limited assuranceâ€œ in the online annexes of the augmented online version of the Annual
Report of Bayer AG, Leverkusen, (hereinafter: the â€œCompanyâ€) for the period January 1, 2015 to
December 31, 2015 (â€œAnnual Report 2015 â€“ Augmented Versionâ€; hereinafter: â€œOnline Versionâ€).
MANAGEMENTâ€™S RESPONSIBILITY
Companyâ€™s Management is responsible for the preparation and presentation of the Online Version in
accordance with the criteria as set out in the g4 Sustainability Reporting Guidelines of the Global
Reporting Initiative (gri) (hereafter the â€œgri-Criteriaâ€) and for the selection of the information to be
assessed.
This responsibility includes the selection and application of appropriate methods to prepare the Online
Version as well as the use of assumptions and estimates for individual sustainability disclosures which
are reasonable in the circumstances. Furthermore, the responsibility includes designing, implementing
and maintaining systems and processes relevant for the preparation of the Online Version, which is free
of material misstatements due to intentional or unintentional errors.
AUDIT FIRMâ€™S INDEPENDENCE AND QUALITY CONTROL
We have complied with the German professional provisions regarding independence as well as other
ethical requirements.
The audit firm applies the national legal requirements and professional standards â€“ in particular the
Professional Code for German Public Auditors and German Chartered Auditors (â€œBerufssatzung fÃ¼r
WirtschaftsprÃ¼fer und vereidigte BuchprÃ¼ferâ€œ: â€œbs wp/vBPâ€) as well as the joint opinion of the
WirtschaftsprÃ¼ferkammer (Chamber of German Public Auditors; wpk) and the Institut der WirtschaftsprÃ¼fer (Institute of Public Auditors in Germany; idw): Requirements to quality control for audit firms
(â€œGemeinsamen Stellungnahme der wpk und des idw: Anforderungen an die QualitÃ¤tssicherung in der
WirtschaftsprÃ¼ferpraxisâ€: â€œvo 1/2006â€) â€“ and accordingly maintains a comprehensive system of quality
control including documented policies and procedures regarding compliance with ethical requirements,
professional standards and applicable legal and regulatory requirements.
PRACTITIONERâ€™S RESPONSIBILITY
Our responsibility is to express an opinion on the sustainability information marked with â€limited assuranceâ€œ in the Online Version based on our work performed.
Within the scope of our engagement we did not perform an audit on external sources of information or
expert opinions, referred to in the Online Version.
We conducted our work in accordance with the International Standard on Assurance Engagements
(isae) 3000 (Revised): â€œAssurance Engagements other than Audits or Reviews of Historical Financial
Informationâ€ published by iaasb. This Standard requires that we plan and perform the assurance engagement to obtain limited assurance whether any matters have come to our attention that cause us to
believe that the sustainability information marked with â€ limited assuranceâ€œ in the Online Version has
not been prepared, in all material respects, in accordance with the gri-Criteria.

341

Bayer Annual Report 2015
Independent Assurance Report

In a limited assurance engagement the evidence-gathering procedures are more limited than for a reasonable assurance engagement and therefore significantly less assurance is obtained than in a reasonable assurance engagement. The procedures selected depend on the practitioner's judgement. This
includes the assessment of the risks of material misstatements of the sustainability information marked
with â€ limited assuranceâ€œin the Online Version with regard to the gri-Criteria.
Within the scope of our work, we performed amongst others the following procedures:
â€¢ Obtaining an understanding of the structure of the sustainability organization and of the stakeholder
engagement;
â€¢ Inquiries of personnel involved in the preparation of the Report regarding the preparation process
and the underlying internal control system;
â€¢ Documentation of the processes and inspection of the systems and processes regarding the
collection of the sustainability information as well as sample testing;
â€¢ Site visits as part of the inspection of processes and analysis of selected data at the following sites:
â€“ Bayer HealthCare, Berkeley, usa
â€“ Bayer CropScience, Muskegon, usa
â€“ Covestro, Maasvlakte, Niederlande
â€“ Covestro, Map Ta Phut, Thailand
â€“ Sites on the Lower Rhine, Germany;
â€¢ Analytical procedures on selected sustainability information of the Online Version;
â€¢ Inspection of internal documents, contracts and invoices as well as reports.
CONCLUSION
Based on our limited assurance engagement, nothing has come to our attention that causes us to believe that the sustainability information marked with â€ limited assuranceâ€œ in the Online Version of the
Company for the period January 1, 2015 to December 31, 2015 has not been prepared, in all material
respects, in accordance with the gri-Criteria.
EMPHASIS OF MATTER â€“ RECOMMENDATIONS
Without qualifying our conclusion above, we make the following recommendations for the further
development of the Company's sustainability management and sustainability reporting:
â€¢ Further alignment of the sustainability reporting in consideration of the changing focus topics of a
life science company:
â€¢ Further development of the management approaches and their presentation in the integrated
reporting;
â€¢ Further focusing, improving and formalizing internal control systems at central level and at the level
of individual sites.
RESTRICTION ON USE AND DISTRIBUTION
We issue this report on the basis of the engagement agreed with Bayer AG. The audit has been
performed for purposes of Bayer AG and is solely intended to inform Bayer AG about the results of the
audit. The report is not intended for any third parties to base any (financial) decision thereon.
We do not assume any responsibility towards third parties.
Munich, February 25, 2016
PricewaterhouseCoopers
Aktiengesellschaft
WirtschaftsprÃ¼fungsgesellschaft
Hendrik Fink
WirtschaftsprÃ¼fer
(German Public Auditor)

ppa. Pia SchnÃ¼ck

342

Bayer Annual Report 2015
Further Information

03
Further Information
Governance Bodies
Organization Chart
GRI G4 Content Index with UNGC Principles
Glossary
Financial Calendar

343
346
348
362
366

343

Bayer Annual Report 2015
Further Information
Governance Bodies

Governance Bodies
Supervisory Board
Members of the Supervisory Board held offices as members of the supervisory board or a comparable supervising body
of the corporations listed (as at December 31, 2015 or the date on which they ceased to be members of the Supervisory Board
of Bayer AG):

WERNER WENNING

DR. PAUL ACHLEITNER

DR. CLEMENS BÃ–RSIG

DR.-ING. THOMAS FISCHER

Leverkusen, Germany
(born October 21, 1946)

Munich, Germany
(born September 28, 1956)

Frankfurt am Main, Germany
(born July 27, 1948)

Krefeld, Germany
(born August 27, 1955)

Chairman of the Supervisory
Board effective October 2012

Member of the Supervisory
Board effective April 2002

Member of the Supervisory
Board effective April 2007

Member of the Supervisory
Board effective October 2005

Chairman of the Supervisory
Board of Bayer AG and
Chairman of the Supervisory
Board of E.ON SE

Chairman of the Supervisory
Board of Deutsche Bank AG

Member of various
supervisory boards

Memberships on other
supervisory boards:

Memberships on other
supervisory boards:

Memberships on other
supervisory boards:

â€¢ Daimler AG

â€¢ Daimler AG

Chairman of the Managerial
Employeesâ€™ Committee of
Covestro Deutschland AG
(formerly
Bayer MaterialScience AG)

â€¢ Deutsche Bank AG
(Chairman)

â€¢ Linde AG

â€¢ E.ON SE (Chairman)
â€¢ Henkel Management AG
â€¢ Siemens AG
(Vice Chairman)

Memberships in comparable
supervising bodies of German
or foreign corporations:

Memberships in comparable
supervising bodies of German
or foreign corporations:

â€¢ Henkel AG & Co. KGaA
(Member of the
Shareholdersâ€™ Committee)

â€¢ Henkel AG & Co. KGaA
(Member of the
Shareholdersâ€™ Committee)

DR. RER. NAT. SIMONE
BAGEL-TRAH

OLIVER ZÃœHLKE

Solingen, Germany
(born December 11, 1968)

Member of the Supervisory
Board effective April 2014

Vice Chairman of the
Supervisory Board effective
July 2015

Chairwoman of the
Supervisory Board of Henkel
AG & Co. KGaA and Henkel
Management AG and
Shareholdersâ€™ Committee of
Henkel AG & Co. KGaA

Chairman of the Bayer Central
Works Council
Memberships on other
supervisory boards:
â€¢ Bayer Pharma AG
THOMAS DE WIN

Cologne, Germany
(born November 21, 1958)
Vice Chairman of the
Supervisory Board until
June 2015
Memberships on other
supervisory boards:
â€¢ Covestro Deutschland AG
(formerly
Bayer MaterialScience AG)
(until June 2015)

â€¢ Emerson Electric Co.
â€¢ Istituto per le Opere di
Religione (Member of the
Board of Superintendence)

â€¢ Covestro AG
(effective October 2015)
â€¢ Covestro Deutschland AG
(formerly
Bayer MaterialScience AG)

PETER HAUSMANN

DÃ¼sseldorf, Germany
(born January 10, 1969)

Member of the Supervisory
Board effective April 2007

Memberships in comparable
supervising bodies of German
or foreign corporations:

Memberships on other
supervisory boards:

ANDRÃ‰ VAN BROICH

Dormagen, Germany
(born June 19, 1970)
Member of the Supervisory
Board effective April 2012

Winsen / Aller, Germany
(born February 13, 1954)
Member of the Supervisory
Board until October 2015

Chairman of the Works Council
of the Dormagen site

Member of the Executive
Committee of the German
Mining, Chemical and
Energy Industrial Union

Memberships on other
supervisory boards:

Memberships on other
supervisory boards:

â€¢ Bayer CropScience AG

â€¢ Covestro AG
(effective October 2015)

Memberships on other
supervisory boards:

THOMAS EBELING

â€¢ Henkel AG & Co. KGaA
(Chairwoman)

Muri bei Bern, Switzerland
(born February 9, 1959)

â€¢ Heraeus Holding GmbH

Member of the Supervisory
Board effective April 2012

â€¢ Continental AG

Chief Executive Officer of
ProSiebenSat.1 Media AG

â€¢ 50Hertz Transmission GmbH

Memberships in comparable
supervising bodies of German
or foreign corporations:
â€¢ Henkel AG & Co. KGaA
(Chairwoman of the
Shareholdersâ€™ Committee)

Memberships in comparable
supervising bodies of German
or foreign corporations:
â€¢ Lonza Group AG

â€¢ Covestro Deutschland AG
(formerly
Bayer MaterialScience AG)
(effective September 2015)
â€¢ Henkel AG & Co. KGaA
â€¢ Vivawest Wohnen GmbH

REINER HOFFMANN

Wuppertal, Germany
(born May 30, 1955)
Member of the Supervisory
Board effective October 2006
Chairman of the German
Trade Union Confederation

344

Bayer Annual Report 2015
Further Information
Governance Bodies

YÃœKSEL KARAASLAN

DR. RER. NAT. HELMUT PANKE

DR. KLAUS STURANY*

Hohen Neuendorf, Germany
(born March 1, 1968)

Munich, Germany
(born August 31, 1946)

Ascona, Switzerland
(born October 23, 1946)

Member of the Supervisory
Board effective April 2012

Member of the Supervisory
Board effective April 2007

Member of the Supervisory
Board effective April 2007

Chairman of the Bayer Group
Works Council

Member of various
supervisory boards

Member of various
supervisory boards

Vice Chairman of the Bayer
Central Works Council

Memberships in comparable
supervising bodies of German
or foreign corporations:

Memberships on other
supervisory boards:

Chairman of the Works Council
of the Berlin site
Memberships on other
supervisory boards:
â€¢ Bayer Pharma AG

â€¢ Microsoft Corporation
â€¢ Singapore Airlines Limited
â€¢ UBS AG (until May 2015)

â€¢ Hannover RÃ¼ck SE
(Vice Chairman)
Memberships in comparable
supervising bodies of German
or foreign corporations:
â€¢ Sulzer AG

Standing committees
of the Supervisory Board
of Bayer AG
(as at December 31, 2015)

PRESIDIAL COMMITTEEà¯—/à¯—
MEDIATION COMMITTEE

Wenning (Chairman),
Achleitner, Reinbold-Knape,
ZÃ¼hlke
AUDIT COMMITTEE

Sturany* (Chairman),
Fischer, Hoffmann, Panke,
Wenning, ZÃ¼hlke

SUE H. RATAJ
PETRA KRONEN

Krefeld, Germany
(born August 22, 1964)
Member of the Supervisory
Board effective July 2000
Chairwoman of the Works
Council of the Uerdingen site
Memberships on other
supervisory boards:
â€¢ Covestro AG (Vice Chairwoman) (effective October
2015)
â€¢ Covestro Deutschland AG
(formerly
Bayer MaterialScience AG)
(Vice Chairwoman)

FRANK LÃ–LLGEN

Cologne, Germany
(born June 14, 1961)
Member of the Supervisory
Board effective November
2015
North Rhine District
Secretary of the German
Mining, Chemical and
Energy Industrial Union
Memberships on other
supervisory boards:
â€¢ Evonik Industries AG
â€¢ IRR-Innovationsregion
Rheinisches Revier GmbH

Sebastopol, U.S.A.
(born January 8, 1957)
Member of the Supervisory
Board effective April 2012
Member of the Board of
Directors of Cabot
Corporation, Boston, U.S.A.
Member of the Board of
Directors of Agilent Technologies Inc., Santa Clara, U.S.A.

PETRA REINBOLD-KNAPE

Berlin, Germany
(born April 16, 1959)

HEINZ GEORG WEBERS

Bergkamen, Germany
(born December 27, 1959)
Member of the Supervisory
Board effective July 2015
Chairman of the
Bayer European Forum
Chairman of the Works Council
of the Bergkamen site
Memberships on other
supervisory boards:
â€¢ Bayer Pharma AG

Member of the Supervisory
Board effective April 2012

PROF. DR. DR. H.C.
OTMAR D. WIESTLER

Member of the Executive
Committee of the German
Mining, Chemical and Energy
Industrial Union

Berlin, Germany
(born November 6, 1956)
Member of the Supervisory
Board effective October 2014

Memberships on other supervisory boards:

President of the
Helmholtz Association of
German Research Centers

â€¢ envia Mitteldeutsche
Energie AG
â€¢ Vattenfall Europe
Generation AG
â€¢ Vattenfall Europe Mining
AG (Vice Chairwoman)
(effective June 2015)
Memberships in comparable
supervising bodies of German
or foreign corporations:
â€¢ MDSE Mitteldeutsche
Sanierungs- und Entsorgungsgesellschaft mbH

MICHAEL SCHMIDT-KIESSLING

Schwelm, Germany
(born March 24, 1959)
Member of the Supervisory
Board effective April 2012
Chairman of the Works Council
of the Elberfeld site

PROF. DR. DR. H.C. MULT.
ERNST-LUDWIG WINNACKER

Munich, Germany
(born July 26, 1941)
Member of the Supervisory
Board effective April 1997
Professor-Emeritus of LudwigMaximilians University Munich
Memberships on other
supervisory boards:
â€¢ Wacker Chemie AG

HUMAN RESOURCES
COMMITTEE

Wenning (Chairman),
Achleitner, Karaaslan,
Kronen
NOMINATIONS COMMITTEE

Wenning (Chairman),
Achleitner
INNOVATION COMMITTEE

Winnacker (Chairman), van
Broich, Reinbold-Knape,
Wenning, Wiestler, ZÃ¼hlke
* Independent expert member pursuant
to Section 100 Paragraph 5 of the German
Stock Corporation Act (AktG)

345

Bayer Annual Report 2015
Further Information
Governance Bodies

Board of Management
Members of the Board of Management held offices as members of the supervisory board or a comparable supervising
body of the corporations listed (as at December 31, 2015):

DR. MARIJN DEKKERS

WERNER BAUMANN

LIAM CONDON

JOHANNES DIETSCH

(born September 22, 1957)

(born October 6, 1962)

(born February 27, 1968)

(born January 2, 1962)

Chairman
(effective October 1, 2010)

Member of the Board of
Management effective
January 1, 2010, appointed
until December 31, 2017

Member of the Board of
Management effective
January 1, 2016, appointed
until December 31, 2018

Member of the Board of
Management effective
September 1, 2014, appointed
until August 31, 2017

Member of the Board of
Management effective
January 1, 2010, appointed
until December 31, 2016
â€¢ Board of Directors of
General Electric Company

â€¢ Bayer CropScience AG
(Chairman)

â€¢ Bayer Business Services
GmbH (Chairman)

â€¢ Covestro Deutschland AG
(formerly Bayer
MaterialScience AG)
(Chairman)
(until March 2015)

â€¢ Covestro AG
(effective August 2015)
â€¢ Covestro Deutschland AG
(formerly Bayer
MaterialScience AG)
(effective June 2015)

â€¢ Bayer Pharma AG
(effective March 2015)
DR. HARTMUT KLUSIK

KEMAL MALIK

ERICA MANN

DIETER WEINAND

(born July 30, 1956)

(born September 29, 1962)

(born October 11, 1958)

(born August 16, 1960)

Member of the Board of
Management effective
January 1, 2016, appointed
until December 31, 2018

Member of the Board of
Management effective
February 1, 2014, appointed
until January 31, 2017

Member of the Board of
Management effective
January 1, 2016, appointed
until December 31, 2018

Member of the Board of
Management effective
January 1, 2016, appointed
until December 31, 2018

Labor Director
(effective January 2016)
â€¢ Bayer HealthCare AG
(Chairman)
(effective January 2016)
â€¢ Bayer Pharma AG
(Chairman)
(effective January 2016)
â€¢ Bayer Technology Services
GmbH (Chairman)
(effective January 2016)
â€¢ Currenta GeschÃ¤ftsfÃ¼hrungsGmbH (Chairman)
(effective January 2016)

MICHAEL KÃ–NIG

(born September 3, 1963)
Member of the Board
of Management until
December 31, 2015
Labor Director
â€¢ Bayer HealthCare AG
(Chairman)
â€¢ Bayer Pharma AG
(Chairman)
â€¢ Bayer Technology Services
GmbH (Chairman)
â€¢ Currenta GeschÃ¤ftsfÃ¼hrungsGmbH (Chairman)

â€¢ Board of Directors of
HealthPrize Technologies
LLC

346

Bayer Annual Report 2015
Further Information
Organization Chart

Organization Chart

MARIJN DEKKERS 1

JOHANNES DIETSCH

Chairman

Finance

WERNER BAUMANN 1

Strategy & Portfolio
Management

HARTMUT KLUSIK *

Human Resources,
Technology & Sustainability

M. Arnold

P. MÃ¼ller

T.-P. Hausner

H.-U. Groh

&RUSRUDWH2IÄŸFH

Finance

Strategy

H. Heitmann

U. Rahenbrock 2

F. Rittgen

Human Resources
& Organization

&RPPXQLFDWLRQV*RYHUQPHQW
5HODWLRQVDQG&RUSRUDWH%UDQG

Accounting

0HUJHUV $FTXLVLWLRQV

C. PÃ¶rtner

G. Schildmeyer

M. Vehreschild

&RUSRUDWH&RQWUROOLQJ

Country & Functional
Excellence

&RUSRUDWH7HFKQRORJ\
& Manufacturing

A. Rosar

Investor Relations
R. Schwarz

Internal Audit

B.-P. Bier

Taxes
R. Hartwig

A. Knors

Technology Services
W. GroÃŸe Entrup 3

Environment & Sustainability

/DZ3DWHQWV &RPSOLDQFH
T. Udesen

Procurement
V. Hahn

Regional Coordination
D. Hartert

Business Services

*

Labor Director

Effective May 1, 2016,:HUQHU%DXPDQQZLOOEHFRPHWKHQHZ&KDLUPDQRIWKH%RDUGRI0DQDJHPHQWRI%D\HUb$*
'U0DULMQ'HNNHUVZLOOOHDYHWKHFRPSDQ\DWKLVRZQUHTXHVWRQ$SULO30, 2016
Until March 31, 2016%3%LHUIURP$SULO
3
From July 1, 2016SDUWRIWKH&RUSRUDWH+HDOWK6DIHW\ 6XVWDLQDELOLW\IXQFWLRQKHDGHGE\.YDQ/DDN
4
+DUWPXW.OXVLNZLOOUHPDLQLQFKDUJHRIWKHFXUUHQW3URGXFW6XSSO\IXQFWLRQIRU3KDUPDFHXWLFDOV&RQVXPHU
+HDOWKDQG$QLPDO+HDOWKGXULQJWKHWUDQVLWLRQDOSKDVHXQWLOWKHFRUUHVSRQGLQJXQLWVKDYHEHHQVHWXSLQWKH
3KDUPDFHXWLFDOVDQG&RQVXPHU+HDOWKGLYLVLRQVDQGDW$QLPDO+HDOWKDQGDUHIXOO\RSHUDWLRQDO
5
(XURSH0LGGOH(DVW$IULFD

$VLD3DFLÄŸF
1

2

$VRI)HEUXDU\b1, 2016

H. Klusik

3URGXFW6XSSO\4
G. Hilken

Currenta

347

Bayer Annual Report 2015
Further Information
Organization Chart

[Graphic 5.1]

KEMAL MALIK

ERICA MANN

LIAM CONDON

Pharmaceuticals

Consumer Health

&URS6FLHQFH

A. Bouchon

J. Triana

O. Mauroy-Bressier

M. A. Schulz

Bayer Life Science Center

Finance

Finance

Finance

M. Lessl

S. Guth

N. N.

D. Backhaus

&RUSRUDWH,QQRYDWLRQDQG
5HVHDUFK 'HYHORSPHQW

6WUDWHJLF0DUNHWLQJ

6WUDWHJLF0DUNHWLQJ

3URGXFW6XSSO\

A. Busch

J. Oâ€™Mullane

M. Reichardt

Drug Discovery

,QQRYDWLRQ 'HYHORSPHQW

J. MÃ¶ller

J. Ohle

Agricultural Commercial
2SHUDWLRQV

'HYHORSPHQW

&RPPHUFLDO2SHUDWLRQV
International

A. Percy

&KLHI0HGLFDO2IÄŸFHU

N. Bartner

M. Kremer

R. Franzen

&RPPHUFLDO2SHUDWLRQV
North America

&URS6WUDWHJLHV
& Portfolio Management

Innovation

J. Federer

'LJLWDO'HYHORSPHQW

DIETER WEINAND

M. Devoy

&RPPHUFLDO2SHUDWLRQV
EMEA 5
P. Blake

&RPPHUFLDO2SHUDWLRQV
Americas

5HVHDUFK 'HYHORSPHQW

L. Yuen

B. Naaf

&RPPHUFLDO2SHUDWLRQV&KLQD

Business Affairs
& Communications

N. N.

'LYLVLRQ2SHUDWLRQV

W. Jiang

T. Hayes

&RPPHUFLDO2SHUDWLRQV
China & APAC 

Integration

T. Menne

Digital Farming
J. Applegate

Environmental Science

C. Brunn

&RPPHUFLDO2SHUDWLRQV-DSDQ
D. Ehle

Animal Health

348

Bayer Annual Report 2015
Further Information
GRI Content Index

G4 Content Index of the Global Reporting Initiative (GRI) with the 10 Principles
of the U.N. Global Compact
For fiscal 2015, we are applying the gri g4 Guidelines in compliance with the â€œcomprehensiveâ€ option for the first time.
Where there is insufficient information for a particular gri indicator, we have explained this. In addition, the detailed gri Content Index includes the corresponding principles of the ungc and the assignment of our areas of activity to the gri aspects.
Moreover, we indicate whether our scope to exercise influence lies within or outside the company (gri g4-19, g4-20, g4-21).
For the implementation of the gri Materiality Disclosure Service the gri had access to the â€œAnnual Report 2015 â€“ Augmented
Version.â€ The correct positioning of the â€œg4 materiality disclosuresâ€ (g4-17 â€“ g4-27) was confirmed by the gri.

GRI G4 Content Index
UNGC
Principles

G4 Standard Disclosures

Page

GRI aspect
limitation

within

Strategy and Analysis
G4 â€“ 1

Statement from the most
senior decision-maker

1â€“7

G4 â€“ 2

Key impacts, risks,
and opportunities
concerning sustainability

48, 51 â€“ 55, 57,
59 â€“ 61, 79 â€“ 82,
100, 104, 218

Organizational Profile

3

Bayer area of acticivity

G4-20
General Standard Disclosures

6

Comments

G4 â€“ 3

Name of the
organization

49

G4 â€“ 4

Primary brands,
products, and services

48, 51

G4 â€“ 5

Location of the
organizationâ€™s
headquarters

49

G4 â€“ 6

Countries with
significant operations

46 â€“ 47, 49

G4 â€“ 7

Nature of ownership
and legal form

42 â€“ 43, 49

G4 â€“ 8

Markets served

46 â€“ 47, 108,
110 â€“ 112

G4 â€“ 9

Scale of the
organization

46 â€“ 47, 86, 104,
230, 232

G4 â€“ 10

Employees by
employment type,
gender and region

46 â€“ 47, 86,
88 â€“ 89, 91

G4 â€“ 11

Percentage of employees
covered by collective
bargaining agreements

96

G4-21
outside

349

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

General Standard Disclosures

within

G4 â€“ 12

Description of the
supply chain

97 â€“ 98

G4 â€“ 13

Significant changes
during the reporting
period

48 â€“ 50, 76, 98,
263, 268 â€“ 269

G4 â€“ 14

Implementation of the
precautionary principle

113

G4 â€“ 15

External initiatives
that the organization
endorses

30, 78 â€“ 79, 84,
95, 113, 132,
138

G4 â€“ 16

Significant memberships
in industry and business
associations

83, 93, 100, 113,
115 â€“ 116, 119,
127

Identified Material Aspects and Boundaries

G4 â€“ 17

Entities included in the
consolidated financial
statements

30,
260 â€“ 263

G4 â€“ 18

Process for defining
the report content

80

Material Aspects
identified

348, 352 â€“ 361;
GRI Index;
www.bayer.com/
key-areas-ofactivity

Aspect Boundaries
within the organization

348 â€“ 361; GRI
Index;
www.bayer.com/
key-areas-ofactivity

G4 â€“ 21

Aspect Boundaries
outside the organization

348 â€“ 361, GRI
Index;
www.bayer.com/
key-areas-ofactivity

G4 â€“ 22

Restatements of
information provided
in previous reports

30

G4 â€“ 23

Significant changes in
the Scope and Aspect
Boundaries

30

G4 â€“ 19

G4 â€“ 20

Stakeholder Engagement
G4 â€“ 24

Stakeholder groups
engaged

58, 82

G4 â€“ 25

Identification and
selection of stakeholders

57, 81â€“ 82

G4 â€“ 26

Approach to stakeholder
engagement and
frequency

42, 57, 64, 80,
82â€“ 85, 92, 103,
110 â€“111, 146,
188

G4 â€“ 27

Key topics and concerns
raised through
stakeholder engagement
and response

57, 80, 82 â€“ 85

G4-21
outside

350

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

General Standard Disclosures

within

Report Profile
G4 â€“ 28

Reporting period

30

G4 â€“ 29

Date of most recent
previous report

Annual Report:
2015-02-25

G4 â€“ 30

Reporting cycle

Annually

G4 â€“ 31

Contact point for
questions regarding
the report

367 (back inside
cover)

G4 â€“ 32

â€œIn accordanceâ€ option
with GRI and Content
Index chosen

30, 348 â€“ 361

G4 â€“ 33

External verification
of the report

31, 338 â€“ 341

Governance

G4 â€“ 34

Governance structure,
incl. committees of the
highest governance
body

32 â€“ 37, 183 â€“ 185

G4 â€“ 35

Process for delegating
authority for economic,
environmental and social
topics

79 â€“ 80, 183, 189

G4 â€“ 36

Executive-level position
with responsibility for
economic, environmental and social topics

38, 79 â€“ 80, 86,
183 â€“ 184, 215

G4 â€“ 37

Processes for
consultation between
stakeholders and the
highest governance
body

43, 188, 366

G4 â€“ 38

Composition of the
highest governance
body and its committees

184 â€“ 186

G4 â€“ 39

Independence of the
Chair of the highest
governance body

34 â€“ 38, 184

G4 â€“ 40

Nomination and
selection processes for
the highest governance
body and its committees

184 â€“ 186

G4 â€“ 41

Process for avoiding
conflicts of interest

185 â€“ 186

G4 â€“ 42

Highest governance
body's role concerning
strategy and goals

183 â€“ 184

G4 â€“ 43

Measures taken
concerning the highest
governance bodyâ€™s
knowledge in
sustainability issues

36

G4-21
outside

351

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

General Standard Disclosures

within

G4 â€“ 44

Evaluation of the highest
governance bodyâ€™s
performance concerning
sustainability

35

G4 â€“ 45

Highest governance
bodyâ€™s role concerning
sustainability impacts,
risks, and opportunities

184, 189

G4 â€“ 46

Highest governance
bodyâ€™s role concerning
the effectiveness of the
risk management

35 â€“ 37, 184,
215â€“ 216

G4 â€“ 47

Frequency of the highest
governance bodyâ€™s
review of sustainability
impacts, risks, and
opportunities

35, 37, 217

G4 â€“ 48

Highest committee
that formally reviews
and approves the
sustainability report

80

G4 â€“ 49

Process for
communicating critical
concerns to the highest
governance body

35 â€“ 36, 43,
189 â€“190,
214 â€“ 223;
www.bayer.com/
stockholdersmeeting

G4 â€“ 50

Critical concerns that
were communicated to
the highest governance
body

35 â€“ 36;
www.bayer.com/
stockholdersmeeting

G4 â€“ 51

Remuneration policies
for the highest
governance body and
senior executives

189, 192 â€“ 196,
200 â€“ 201, 206,
208

G4 â€“ 52

Process for determining
remuneration

192 â€“ 194,
200 â€“ 201, 206

Stakeholdersâ€™ views
regarding remuneration

200, 206;
www.bayer.com/
stockholdersmeeting

G4 â€“ 53

G4 â€“ 54

G4 â€“ 55

Ratio of the highest
annual total
compensation to the
median annual total
compensation

Not available: we do not consider this
compensation detail to be of informative value
for the evaluation of the appropriateness of our
compensation structures. We report on these
in detail in Chapter 6.3 â€œEmployee
Compensation and Variable Payâ€ and in our
Compensation Report.

Ratio of percentage
increase in the
highest annual total
compensation

Not available: we do not consider this
compensation detail to be of informative value
for the evaluation of the appropriateness of our
compensation structures. We report on these
in detail in Chapter 6.3 â€œEmployee
Compensation and Variable Payâ€ and in our
Compensation Report.

G4-21
outside

352

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

General Standard Disclosures

G4-21

within

outside

within

outside

Ethics and Integrity

10

10

10

G4 â€“ 56

Values, principles,
standards and norms of
behavior

48, 80, 90, 95,
187, 189

G4 â€“ 57

Mechanisms for seeking
advice on ethical and
lawful behavior

189

G4 â€“ 58

Mechanisms for
reporting concerns
about unethical or
unlawful behavior

95, 189 â€“ 190

Specific Standard Disclosures

G4-19

Economic

7

7

6

6

6

Aspect: Economic Performance â€“
Management Approach

56, 143 â€“ 144

G4-EC1

Direct economic value
created and distributed

56, 94 â€“ 95,
143 â€“ 144,
276 â€“ 279

G4-EC2

Financial implications
and other risks and
opportunities due to
climate change

219, 221â€“ 222;
www.bayer.com/
CDP-climate

G4-EC3

Coverage of benefit plan
obligations

94 â€“ 96, 297â€“ 306

G4-EC4

Financial assistance
received from
government

64

Aspect: Market Presence â€“
Management Approach

G4-EC5

Ratios of standard entry
level wage compared to
local minimum wage

G4-EC6

Proportion of senior
management hired from
the local community

93 â€“ 94
We align our compensation with local market
conditions in Emerging Markets and
developing countries. Furthermore, in keeping
with our human rights position, we pursue the
goal of paying adequate salaries that ensure a
suitable standard of living for our employees
and their families. In all Emerging Markets
where we are active, the lowest salary paid by
Bayer is at least in line with the applicable
minimum wage and in most cases higher. We
are not currently reporting on the margin
between standard entry salary and minimum
wage. We intend to perform a new survey on
this aspect.

93

Human capital

X

Product and
process
innovation

X

X

Environmental
protection

X

X

Human capital

X

353

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

Specific Standard Disclosures

G4-19

Aspect: Indirect Economic
Impacts â€“ Management Approach

within

56, 143 â€“ 145

G4-EC7

Infrastructure
investments and
services provided

59, 102,
144 â€“ 146,
167 â€“ 168

G4-EC8

Indirect economic
impacts

56, 167 â€“ 168

Aspect: Procurement Practices â€“
Management Approach
G4-EC9

Proportion of spending
on local suppliers

97 â€“ 98
98, 365

G4-21
outside

Sustainable food
supply

X

Access to
health care

X

Supplier
management

X

For a declaration on the main business locations
see the precise page in the glossary.

Environmental

7, 8

7, 8

Aspect: Materials â€“
Management Approach

G4-EN1

Materials used by
weight or volume

Percentage of materials
used that are recycled
input materials

8

G4-EN2

7, 8, 9

Aspect: Energy â€“
Management Approach

7, 8

G4-EN3

Energy consumption
within the organization

55, 104,
131 â€“ 132

99

We do not report on the weight and volume of
the materials used.
This information constitutes a business secret.

141 â€“ 142

We do not provide any information on volumes
relating to the total material use of secondary
raw materials since this also constitutes a
business secret. We do provide information on
production-, material- and, where possible,
product-related recycling.

54 â€“ 55, 104,
131 â€“ 134

X

X

Environmental
protection

X

X

Environmental
protection

X

X

132 â€“ 134

G4-EN4

Energy consumption
outside of the
organization

8

G4-EN5

Energy intensity

133

8, 9

G4-EN6

Reduction of energy
consumption

133 â€“ 134

8, 9

G4-EN7

Reductions in energy
requirements of
products and services

7, 8

Aspect: Water â€“
Management Approach

7, 8

G4-EN8

Total water with
drawal by source

Environmental
protection

Such energy consumption is contained in the
details of greenhouse gas emissions for Scope
3, which we publish in the CDP Report.

We do not consider this indicator to be
applicable to our product portfolio as a Life
Science company. Data are therefore not
available.
54 â€“ 55, 104,
131 â€“ 132, 138
138 â€“ 139

354

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Bayer area of acticivity

GRI aspect
limitation
G4-20

Specific Standard Disclosures

G4-19

8

G4-EN9

Water resources
significantly affected

8

G4EN10

Water recycled and
reused

7, 8, 9

Aspect: Emissions â€“
Management Approach

within

138;
www.bayer.com/
CDP-water
138 â€“ 139
54 â€“ 55, 104,
131 â€“ 132,
134 â€“ 136

7, 8

G4EN15

Direct greenhouse gas
(GHG) emissions
(Scope 1)

7, 8

G4EN16

Energy indirect
greenhouse gas (GHG)
emissions (Scope 2)

135 â€“ 136

7, 8

G4EN17

Other indirect
greenhouse gas (GHG)
emissions (Scope 3)

134, 136;
www.bayer.com/
CDP-climate

8

G4EN18

Greenhouse gas (GHG)
emissions intensity

135

8, 9

G4EN19

Reduction of greenhouse
gas (GHG) emissions

136

7;8

G4EN20

Emissions of ozonedepleting substances
(ODS)

137

7, 8

G4EN21

NOx, SOx and other
significant air emissions

137

8

Aspect: Effluents and Waste â€“
Management Approach

55, 104,
131 â€“ 132, 138,
140

8

G4EN22

Total water discharge by
quality and destination

138 â€“ 140

8

G4EN23

Total weight of waste
by type and disposal
method

140 â€“ 141

8

G4EN24

Total number and
volume of significant
spills

129 â€“ 130

8

G4EN25

Handling of hazardous
waste

140 â€“ 142

G4EN26

Water bodies
significantly affected
by discharges of water
and runoff

8

Comments

7, 8, 9

Aspect: Products and Services â€“
Management Approach

7, 8, 9

G4EN27

Mitigation of
environmental impacts
of products and services

135 â€“ 136

131

118 â€“ 121,
131 â€“ 132, 134,
142
61, 119,
121 â€“ 122, 134

G4-21
outside

Environmental
protection

X

X

Environmental
protection

X

X

We give detailed information on all water-related
issues in our CDP Water Report
www.bayer.com/CDP-water
Product and
process innovation

X

X

Product
stewardship

X

X

Environmental
protection

X

X

355

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

8

G4EN28

8

Aspect: Compliance â€“
Management Approach

8

G4EN29

Reclaimed products
and packaging

Fines and sanctions
for non-compliance
with environmental
regulations

Aspect: Transport â€“
Management Approach
Significant
environmental impacts
of transporting products

G4EN30

8

Aspect: Supplier Environmental
Assessment â€“ Management
Approach

G4EN32

Percentage of new
suppliers that were
screened using
environmental criteria

8

G4EN33

Significant
environmental impacts
in the supply chain

8

Aspect: Environmental
Grievance Mechanisms â€“
Management Approach

8

Bayer area of acticivity

G4-19

8

8

Comments

GRI aspect
limitation
G4-20

Specific Standard Disclosures

8

Page

G4EN34

Grievances about
environmental impacts

within

6

6

Aspect: Employment â€“
Management Approach

outside

142
54, 188 â€“ 191,
216, 223

Business ethics

X

X

Safety

X

X

Environmental
protection

X

X

307, 327,
330 â€“ 331

55, 107,
131 â€“ 132, 134

107 â€“ 108, 134
53, 55, 97, 100,
102 â€“ 103, 221

Supplier
management

102 â€“ 103

We do not report on the percentage of new
suppliers screened using environmental
criteria because these data are not available.
We report on the procedure used for
assessment.

102 â€“ 103

We do not report in detail on the negative
environmental impact determined during
supplier evaluation. We give details on the areas
in which corrective measures were defined.

189 â€“ 190

112, 120,190

X

Business ethics

X

Human capital

X

We do not report on the number of grievances
with respect to negative environmental impact.
We report on the total number of notifications
registered with the compliance hotline. We
internally record the precise reason for the
grievance, track how it is followed up and take
corresponding action in line with our Group
regulation. More detailed information on this
would constitute a business secret.

Labor Practices and Decent Work
6

G4-21

52, 86, 91, 222

G4-LA1

New employee hires
and employee turnover

87 â€“ 89

G4-LA2

Benefits provided to
full-time employees

94, 96

G4-LA3

Return to work and
retention rates after
parental leave

91 â€“ 92

We are currently not reporting on new hires by
age group. We plan to start reporting on this
from 2018.

X

356

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Bayer area of acticivity

G4-19

Aspect: Labor / Management
Relations â€“ Management Approach
Minimum notice
period(s) regarding
operational changes

3

G4-LA4

1, 6

Aspect: Occupational Health and
Safety â€“ Management Approach

GRI aspect
limitation

within

92

54, 55, 96 â€“ 97,
104, 123 â€“ 126,
221
We do not report on the percentage of the total
workforce represented in health and safety
committees as these data are not available. We
plan to record these data in the future.

G4-LA6

Injuries, occupational
diseases, lost days, and
work-related fatalities

124 â€“ 125

We do not report on occupational injuries by
gender, as these data have to be collected in
certain regions anonymously. It is important
for us to have classification by incident type
and a detailed analysis of the causes of the
individual incidents.

G4-LA7

Workers with high
incidence or risk of
diseases

125

G4-LA8

Health and safety topics
covered in formal
agreements with trade
unions

126

6

Aspect: Training and Education â€“
Management Approach

6

G4-LA9

Average hours of
training

90

G4LA10

Programs that support
the continued
employability of
employees

90, 126

6

G4LA11

Percentage of employees
receiving regular
performance and career
development reviews

89 â€“ 91

1, 6

Aspect: Diversity and
Equal Opportunity â€“
Management Approach
Composition of
governance bodies and
breakdown of employees
by aspects of diversity

6

G4LA12

6

Aspect: Equal Remuneration
for Women and Men â€“
Management Approach

G4LA13

Ratio of basic salary
and remuneration of
women to men

Aspect: Supplier Assessment
for Labor Practices â€“
Management Approach

Human capital

X

Safety

X

Human capital

X

Human capital

X

Human capital

X

G4-21
outside

92

Percentage of total
workforce represented
in health and safety
committees

G4-LA5

6

Comments

G4-20
Specific Standard Disclosures

3

Page

52, 86 â€“ 87,
89 â€“ 91, 222

52, 54, 92 â€“ 93,
222

88, 93, 96, 186,
343 â€“ 345

We do not report on minorities, as these data
may not be recorded in some countries on
grounds of protection of personal rights.

93 â€“ 94

93 â€“ 94

53, 55, 97, 100,
102 â€“ 103, 221

X

We do not report quantitatively on the ratio of
the basic salary and compensation of women
to men. Male and female employees at Bayer
receive equal compensation. It is awarded on
the basis of qualifications and responsibility.

Supplier
management

X

357

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

Specific Standard Disclosures

G4LA14

G4LA15

G4-19

Percentage of new
suppliers that were
screened using labor
practices criteria

Significant impacts
for labor practices in
the supply chain

Aspect: Labor Practices
Grievance Mechanisms â€“
Management Approach

G4LA16

Grievances about
labor practices

within

102 â€“ 103

We do not report on the percentage of new
suppliers screened using labor practices
criteria because these data are not available.
We report on the procedure used for
assessment.

102 â€“ 103

We do not report in detail on the negative
impact on labor practices determined during
supplier assessment. We give details on the
areas in which corrective measures were
defined.

95, 189 â€“ 190

190

G4-21
outside

Business ethics

X

X

Business ethics

X

X

We do not report on the number of grievances
with respect to the negative impact on labor
practices. We report on the total number of
notifications registered with the compliance
hotline. We internally record the precise
reason for the grievance, track how it is
followed up and take corresponding action in
line with our Group regulation. More detailed
information on this would constitute a
business secret.

Human Rights
6

Aspect: Non-discrimination â€“
Management Approach

Incidents of
discrimination and
corrective actions taken

6

G4HR3

2, 3

Aspect: Freedom of Association
and Collective Bargaining â€“
Management Approach

2, 3

2, 5

2, 5

G4HR4

Operations and suppliers
identified in which the
right to exercise
freedom of association
may be violated or at
risk, and measures taken

Aspect: Child Labor â€“
Management Approach

G4HR5

Operations and suppliers
having significant risk
for incidents of child
labor, and measures
taken

90, 95, 189 â€“ 190

190

We do not report on the number of incidents
of discrimination. We report on the total
number of notifications registered with the
compliance hotline. We internally record the
precise reason for the grievance, track how it
is followed up and take corresponding action
in line with our Group regulation. More
detailed information on this would constitute a
business secret.
Human capital

95 â€“ 96, 100, 102,
189

X

Supplier
management

X

Human capital

X

Supplier
management

X

X

95 â€“ 96, 100, 102

95, 100, 189

95, 100 â€“ 102

X

358

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Operations and suppliers
having significant risk
for incidents of forced or
compulsory labor, and
measures taken

G4HR6

1

Aspect: Security Practices â€“
Management Approach

1

G4HR7

2

Aspect: Supplier Human Rights
Assessment â€“ Management
Approach

G4HR10

Percentage of security
personnel trained in the
field of human rights

Percentage of new
suppliers that were
screened using human
rights criteria

Significant human rights
impacts in the supply
chain

2

G4HR11

1

Aspect: Human Rights
Grievance Mechanisms â€“
Management Approach

1

Bayer area of acticivity

G4-19

Aspect: Forced or Compulsory
Labor â€“ Management Approach

2, 4

2

Comments

GRI aspect
limitation
G4-20

Specific Standard Disclosures

2, 4

Page

G4HR12

Grievances about
human rights impacts

within

95, 100, 102,
189

Human capital

X

Supplier
management

X

Human capital

X

G4-21
outside

X

95, 100, 102
95

95
53, 55, 97, 100,
102 â€“ 103, 221

Supplier
management

102 â€“ 103

We do not report on the percentage of new
suppliers screened using human rights criteria
because these data are not available. We
report on the procedure used for assessment.

102 â€“ 103

We do not report in detail on the negative
impact on human rights determined during
supplier evaluation. We give details on the
areas in which corrective measures were
defined.

95, 189 â€“ 190

190

X

Business ethics

X

X

Safety

X

X

Stakeholder
engagement /
partnering

X

X

Societal
engagement

X

X

We do not report on the number of formal
grievances with respect to human rights
violations. We report on the total number of
notifications registered with the compliance
hotline. We internally record the precise
reason for the grievance, track how it is
followed up and take corresponding action in
line with our Group regulation. More detailed
information on this would constitute a
business secret.

Society

1

1

1

Aspect: Local Communities â€“
Management Approach

54, 85, 104, 107,
123, 126 â€“ 128,
138, 221

G4-SO1

Percentage of operations
with implemented local
community engagement,
impact assessments, and
development programs

81 â€“ 82

G4-SO2

Operations with actual
and potential negative
impacts on local
communities

126 â€“ 127, 129,
138

359

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

10

10

Bayer area of acticivity

G4-19

Aspect: Anti-corruption â€“
Management Approach

G4-SO3

G4-SO4

Percentage of operations
assessed for risks related
to corruption and risks
identified

Communication
and training on
anti-corruption

Confirmed incidents of
corruption and actions
taken

10

G4-SO5

10

Aspect: Public Policy â€“
Management Approach

10

G4-SO6

Total value of political
contributions

Aspect: Anti-competitive Behavior â€“
Management Approach

G4-SO7

Legal actions for anticompetitive behavior,
anti-trust, and monopoly
practices

Aspect: Compliance â€“
Management Approach

G4-SO8

2

Comments

GRI aspect
limitation
G4-20

Specific Standard Disclosures

10

Page

Fines and sanctions for
non-compliance with
laws and regulations

Aspect: Supplier Assessment
for Impacts on Society â€“
Management Approach

G4-SO9

Percentage of new
suppliers that were
screened using criteria
for impacts on society

2

G4SO10

Negative impacts on
society in the supply
chain and actions taken

2, 3

Aspect: Grievance Mechanisms
for Impacts on Society â€“
Management Approach

within

54, 109, 112,
188 â€“ 191, 216

189 â€“ 190

We do not report such risks in relation to
operations but in relation to sales. Complete
coverage across business units and subgroups
is key in compliance / anti-corruption in the
first instance. Areas at risk are monitored more
frequently than others.

191

We do not report quantitatively on training for
the Board of Management, Supervisory Board
and business partners. Anti-corruption training
is performed globally, we therefore do not
disclose such information explicitly according
to region.

190

We do not report on the number of confirmed
incidents of corruption. We report on the total
number of notifications registered with the
compliance hotline. We internally record the
precise reason for the grievance, track how it
is followed up and take corresponding action
in line with our Group regulation. More
detailed information on this would constitute a
business secret.

65, 83 â€“ 84

G4-21
outside

Business ethics

X

X

Business ethics

X

X

Business ethics

X

X

Business ethics

X

X

84
54, 112,
188 â€“ 190, 216,
223

307, 327, 329
54, 188 â€“ 191,
216, 223
307, 327,
329 â€“ 331
53, 55, 97, 100,
102 â€“ 103, 128,
221

Supplier
management

102 â€“ 103, 128

We do not report on the percentage of new
suppliers screened using criteria for impact on
society because these data are not available.
We report on the procedure used for
assessment.

102 â€“ 103, 128

We do not report in detail on the negative
impact on society determined during supplier
evaluation. We give details on the areas in
which corrective measures were defined.

82, 85, 189 â€“ 190

Business ethics

X

X

X

360

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Comments

Bayer area of acticivity

GRI aspect
limitation
G4-20

Specific Standard Disclosures

2, 3

Page

G4SO11

G4-19

Number of grievances
about impacts on society

within

190

G4-21
outside

We do not report on the number of formal
grievances with respect to the negative impact
on society. We report on the total number of
notifications registered with the compliance
hotline. We internally record the precise
reason for the grievance, track how it is
followed up and take corresponding action in
line with our Group regulation. More detailed
information on this would constitute a
business secret.

Product Responsibility

Aspect:
Customer Health and Safety â€“
Management Approach

7

7

G4-PR1

Percentage of significant
product and service
categories for which
health and safety
impacts are assessed

G4-PR2

Incidents of noncompliance with
regulations and
voluntary codes
concerning the health
and safety impacts of
products and services

Aspect: Product and Service
Labelling â€“ Management Approach

307, 327 â€“ 329

G4-PR4

Incidents of noncompliance with
regulations and
voluntary codes
concerning product
and service information
and labeling

327 â€“ 329

G4-PR5

Results of surveys
measuring customer
satisfaction

110 â€“ 112

7

G4-PR6

Sale of banned or
disputed products

G4-PR7

Incidents of noncompliance with
regulations and
voluntary codes
concerning marketing
communications

Aspect: Compliance â€“
Management Approach

Product
stewardship

X

X

Product
stewardship

X

X

Product
stewardship

X

X

Business ethics

X

X

We do not report on the number of incidents
of non-compliance with regulations and
voluntary codes concerning the health and
safety impact of products and services. Any
proceedings on account of violations would be
reported in the Chapter â€œLegal Risks.â€

55, 108 â€“ 114,
120

G4-PR3

7

X

67, 112 â€“ 114,
117 â€“ 119,
121 â€“ 123

Principles / procedures
for product and service
information and labelling

Aspect:
Marketing Communications â€“
Management Approach

Sustainable food
supply

54, 55, 112 â€“ 115,
117 â€“ 119,
121 â€“ 123,
220 â€“ 221

113 â€“ 114, 117,
120, 122 â€“ 123
We do not report on the number of incidents
of non-compliance with regulations and
voluntary codes concerning product and
service information and labeling. Any
proceedings on account of violations would be
reported in the Chapter â€œLegal Risks.â€

108 â€“ 109,
111 â€“ 112
115, 122, 123

327 â€“ 329
54, 188 â€“ 191,
216, 223

We do not report on the number of incidents
of noncompliance with regulations and
voluntary codes concerning marketing
communications. Any proceedings on account
of violations would be reported in the Chapter
â€œLegal Risks.â€

361

Bayer Annual Report 2015
Further Information
GRI Content Index

UNGC
Principles

G4 Standard Disclosures

Page

Comments

G4-PR9

G4-19

Significant fines
concerning the provision
and use of products and
services

within

307, 327â€“ 329

Further G4 Standard Disclosures
Aspect: Biodiversity â€“
Management Approach

55, 104,
131 â€“ 132,
142 â€“ 143

G4EN11

Operational sites
in protected areas

143

G4EN12

Impacts on protected
areas or areas of high
biodiversity value

142 â€“ 143

2

G4HR1

Significant investment
agreements and
contracts that include
human rights clauses
or screening

131

1

G4HR2

Employee training on
human rights issues

95

8

8

GRI aspect
limitation
G4-20

Specific Standard Disclosures

8

Bayer area of acticivity

Aspect: Customer Privacy â€“
Management Approach

G4-PR8

Substantiated
complaints regarding
breaches of customer
privacy

222

222

We use our site register to record all siterelated data (including size). For
confidentiality reasons, we do not publish any
size data on our sites, for example.

G4-21
outside

362

Bayer Annual Report 2015
Further Information
Glossary

Glossary
B

Biocides are substances and
products that control pests
such as insects, mice and rats,
as well as algae, fungi and
bacteria.

C

cagr Abbreviation for compound annual growth rate
Capital invested (ci) Capital
invested comprises the assets
on which the company must
obtain a return by generating
an appropriate cash inflow; in
some cases, the cost of ultimately reproducing the assets
must be earned in addition.
Cash flow Key indicator for
assessing a companyâ€™s financial strength; in addition to
gross cash flow, the statement
of cash flows also reports the
cash flow from operating
activities (net cash flow),
which shows the amount of
funds available from operating
activities for financing investments, repaying debts or
distributing dividends. The
cash flows from investing and
financing activities are also
reported.

Cash flow return on investment (cfroi) The cfroi is the
difference between the gross
cash flow in the reporting
period and the cost of reproducing depletable assets,
divided by the capital invested. The cfroi is thus a measure of the return on capital
employed in the reporting
period.

Conflict minerals are those
mined in conflict regions.
They include tin, tungsten and
tantalum ores, gold or their
derivatives. Among the regions in which armed conflicts
over the control of these
resources occur are the eastern part of the Democratic
Republic of Congo and neighboring countries.

Cash value added (cva) This
is the difference between the
gross cash flow and the gross
cash flow hurdle. It is therefore the amount by which the
gross cash flow exceeds the
return and reproduction requirements. If cva is positive,
the investorsâ€™ return and
reproduction requirements
have been satisfied and value
has been created for the company.

Continuing operations Revenue and earnings reporting
for continuing operations
pertains only to business
operations that are expected
to remain in the companyâ€™s
portfolio for the foreseeable
future; opposite of discontinued operations.

cdp (formerly Carbon Disclosure Project) is an independent, not-for-profit organization that works on behalf of
analysts and investors to
promote the transparent reporting of greenhouse gas
emissions and water use
(Water Disclosure Report) by
companies. cdp publishes two
climate rankings each year:
the Climate Disclosure Leadership Index (cdli) rates the
extent and quality of the
disclosure of climate-relevant
data, while the best-rated
companies are additionally
listed in the Climate Performance Leadership Index
(cpli).
Compounding Tailored optimization of plastic properties
through admixture of fillers
and additives

Core earnings per share
Earnings per share, plus /
minus amortization and impairment losses / impairment
loss reversals of intangible
assets and impairment losses /
impairment loss reversals on
property, plant and equipment, plus special charges,
minus special gains (other
than amortization and impairment losses / impairment
loss reversals), plus / minus
the related tax effects and the
share of the adjustments
attributable to noncontrolling
interest; this indicator facilitates the comparability
of performance over time. It is
not defined in the International Financial Reporting Standards.

(Corporate) compliance
comprises the observance of
statutory and company regulations on lawful and responsible conduct.
Corporate governance comprises the long-term management and oversight of the
company in accordance with
the principles of responsibility
and transparency. The German Corporate Governance
Code sets out basic principles
for the management and
oversight of listed companies.
Credit default swaps (cds)
are tradable insurance contracts used to hedge against
the default of a borrower.

D

Denitrification is the bacterial
breakdown of nitrate into
nitrogen and oxygen through
certain microorganisms
known as denitrifiers. The
process is used in biological
wastewater treatment to break
down nitrogen compounds.
Discontinued operations
Business operations already
divested or earmarked for
divestiture in the near future;
opposite of continuing operations
Diversity designates the
variation within the workforce
in terms of gender, origin,
nationality, age, religion and
physical capability.

363

Bayer Annual Report 2015
Further Information
Glossary

E

ebit Income after income
taxes, plus income taxes, plus
financial result; ebit is not
defined in the International
Financial Reporting Standards.
ebit before special items
ebit plus special charges,
minus special gains; this
indicator is not defined in the
International Financial Reporting Standards.
ebitda ebit plus the amortization of intangible assets and
the depreciation of property,
plant and equipment, plus
impairment losses and minus
impairment loss reversals,
recognized in profit or loss
during the reporting period;
this indicator is not defined in
the International Financial
Reporting Standards.
ebitda before special items
ebitda plus special charges,
minus special gains; this
indicator is not defined in the
International Financial Reporting Standards.

G

ebitda margin before special
items The ebitda margin
before special items is calculated by dividing ebitda before special items by sales.
This indicator is not defined in
the International Financial
Reporting Standards.
emtn program The multicurrency European Medium
Term Notes (emtn) program
is a documentation platform
that enables Bayer to raise
capital by quickly issuing debt
on the global capital market.
Maturities, currencies and
conditions can be very flexibly designed.

F

fgd gypsum is a by-product
of flue-gas desulfurization
(fgd).
Foreign exchange Claims for
payments in foreign currencies traded on foreign stock
exchanges, usually in the
form of assets held in foreign
banks or bills of exchange or
checks payable abroad; banknotes and coins denominated
in foreign currencies are not
considered to be foreign
exchange.
Fx & p adj. Abbreviation for
currency- and portfolioadjusted

ghg protocol The Greenhouse
Gas Protocol Corporate Standard is an internationally
recognized standard for the
recording and reporting of
greenhouse gas emissions. It
covers direct (Scope 1) and
indirect (Scope 2) greenhouse
gas emissions relating to a
companyâ€™s value-added chain,
as well as emissions resulting
from third-party and acquired
upstream services (Scope 3).
Dual reporting was introduced
in 2015 with the updating of
the ghg guidelines for Scope
2. Indirect emissions have
now to be reported using both
the location-based and the
market-based methods. The
location-based method uses
regional or national average
emissions factors, while the
market-based method applies
provider- or product-specific
emissions factors based on
contractual instruments.
Global commercial paper
program Commercial paper
(cp) issued under Bayerâ€™s
program is a short-term,
unsecured debt instrument
normally issued at a discount
and redeemed at nominal
value. It is a flexible way of
obtaining short-term funding
on the capital market. Bayerâ€™s
commercial paper program
allows the company to issue
commercial paper on both the
u.s. and European markets.

globalg.a.p is a globally
recognized quality assurance
system in the agriculture industry that is focused on food
safety and good agricultural
practice. It employs modular
and customer-specific solutions for the certification and
inspection of agricultural
enterprises and the establishment of training programs. globalg.a.p standards
focus on product safety, environmental compatibility and
the health, safety and wellbeing of people and animals.
gri (Global Reporting Initiative) is a nonprofit organization that works to promote the
dissemination and optimization of sustainability reporting. The gri guidelines are
considered the most frequently used and internationally
most recognized standard for
sustainability reporting. These
guidelines are evolved in a
multi-stakeholder process. gri
was established in 1997 by
ceres (Coalition for Environmentally Responsible Economies) and unep (United
Nations Environment Programme).

364

Bayer Annual Report 2015
Further Information
Glossary

Gross cash flow Income after
income taxes, plus income
taxes, plus financial result,
minus income taxes paid or
accrued, plus depreciation,
amortization and impairment
losses, minus impairment loss
reversals, plus / minus changes
in pension provisions, minus
gains / plus losses on retirements of noncurrent assets,
minus gains from the remeasurement of already held assets
in step acquisitions; the
change in pension provisions
includes the elimination of
noncash components of ebit.
It also contains benefit payments during the year. This
indicator is not defined in the
International Financial Reporting Standards.

GxP is a collective term for all
guidelines that govern â€œgood
working practiceâ€ and are
particularly relevant for the
fields of medicine, pharmacy
and pharmaceutical chemistry.
The â€œgâ€ stands for â€œGoodâ€ and
the â€œpâ€ for â€œPractice,â€ while
the â€œxâ€ in the middle is replaced by the respective abbreviation for the specific area
of application â€“ such as Good
Manufacturing Practice (gmp),
Good Laboratory Practice
(glp), Good Clinical Practice
(gcp) or Good Agricultural
Practice (gap). These guidelines are established by institutions such as the European
Medicines Agency or the u.s.
Food and Drug Administration.

Gross cash flow (gcf) hurdle
The gcf hurdle is the gross
cash flow that needs to be
generated to satisfy investorsâ€™
return and reproduction requirements.

H

hseq stands for health, safety,
environment and quality.
Hybrid bond A hybrid bond is
a corporate bond with equityequivalent properties, usually
with either no maturity date or
a very long maturity. Due to
its subordination, it has a
lower likelihood of repayment
than a normal bond in the
event of issuer bankruptcy.

I

L

ilo core labor standards The
eight core labor standards of
the ilo (International Labour
Organization) that define the
minimum requirements for
humane working conditions
are internationally recognized
â€œqualitative social standards.â€
They represent universal
human rights that are deemed
valid in all countries regardless of their economic development status.

Life Sciences Field of activities comprising particularly
health care and agriculture;
at Bayer this refers to the
activities of the Pharmaceuticals, Consumer Health and
Crop Science divisions and the
Animal Health business unit.

Innovative Medicine Initiative (imi) is a public-private
partnership developed by the
European Commission and the
European Federation of Pharmaceutical Industries and
Associations (efpia) with the
goal of promoting biomedical
research in Europe. imi finances research projects
aimed at overcoming the
major bottlenecks in the research and development of
new pharmaceuticals. The
partnership provides funding
to project participants from
academic institutes, small and
medium-sized businesses,
patient organizations and
other institutions. The pharmaceutical industry contributes to these projects by donating capacities and resources.

Neonicotinoids Chemical
class of systemic insecticides

N

O

otc At Bayer, otc (over-thecounter) medicines are those
obtainable without a prescription. In finance, otc represents trade between financial
market participants outside of
an organized exchange. otc
transactions are nevertheless
subject to securities trading
laws.

P

Pharmacovigilance is defined
as the science of, and activities related to, the identification, assessment, comprehension and prevention of side
effects or other problems
associated with pharmaceutical products.

365

Bayer Annual Report 2015
Further Information
Glossary

R

Phase i-iv studies are clinical
phases in the development of
a drug product. The active
ingredient candidate is generally tested in healthy subjects
in Phase i, and in patients in
Phases ii and iii. The studies
test the therapeutic tolerability and efficacy of active ingredients in a specific indication. Phase iv studies are
conducted following the approval of a new drug product
to monitor its safety and efficacy over an extended period
of time. The studies are subject to strict legal requirements and documentation
procedures.
Price / cash flow ratio The
price / cash flow ratio is the
ratio of the share price to
gross cash flow per share. It
shows how long it would take
for the companyâ€™s cash flow to
cover the share price.
Price / earnings ratio This is
the ratio of the current share
price to earnings per share
(eps). A high price / earnings
ratio indicates that the market
assigns a high value to the
stock in the expectation of
future earnings growth.

3rs principle (replace, reduce, refine) Replace: prior to
each project, Bayer checks
whether an approved method
is available that does not rely
on animal studies and then
applies it. Reduce: in case no
alternative method exists, only
as many animals are used as
are needed to achieve scientifically meaningful results
based on statutory requirements. Refine: Bayer ensures
that animal studies are performed in a way that minimizes the animalsâ€™ suffering.
re-diss (Reliable Disclosure
Systems for Europe) is a
project aimed at the Europewide coordination of electricity disclosure information to
avoid double counting.

S

Short-Term Incentive program (sti program) is a variable income component for all
managerial staff.
Significant locations of operation A selection of countries
that account for about 68%
of total Bayer Group sales
(United States, Puerto Rico,
Germany, China, Brazil, Japan,
Canada, Italy, U.K., Ireland,
Mexico, Poland, Czech Republic, Slovakia, Hungary, Spain,
Portugal)

W

Syndicated credit facility
Credit line agreed with a
group of banks; generally
used for extensive financing
requirements, such as when
making an acquisition, to
increase available liquidity or
as security for the issuance of
debt instruments. The credit
facility can be utilized and
repaid flexibly, either in full or
in portions, during its term.

U

ungc (United Nations Global
Compact) The un Global
Compact is a strategic policy
initiative for businesses that
are committed to aligning
their operations and strategies
with ten universally accepted
principles in the areas of
human rights, labor, environment and anticorruption. By
doing so, business â€“ as a
primary driver of globalization
â€“ can help ensure that markets, commerce, technology
and finance advance in ways
that benefit economies and
societies everywhere. By
committing to the ungc, companies agree to document
each year their efforts to
uphold the ten principles.

Weighted average cost of
capital (wacc) The weighted
average cost of capital (wacc)
represents the return expected by investors on the
capital invested in the company. It is computed as a
weighted average of the cost
of equity and debt. The cost of
equity is derived from capital
market information and represents the return expected by
stockholders, while the cost of
debt represents the conditions
at which the company can
borrow money over the long
term.
Working capital is the difference between short-term
current assets and short-term
liabilities; it is calculated by
deducting short-term liabilities from current assets (excluding cash and cash equivalents). In financial accounting,
the change in working capital
is one of the variables used to
assess a companyâ€™s financial
health. The objective of working capital management is to
reduce working capital by
minimizing the â€œfinancing
gapâ€ caused by the time lapse
between the disbursement of
funds (= payment for necessary raw materials) and the
receipt of funds for the finished product.

366

Bayer Annual Report 2015
Combined Management Report
Financial Calendar

Financial Calendar

q1 2016 Interim Report

April 26, 2016

Annual Stockholdersâ€™ Meeting 2016

April 29, 2016

Planned dividend payment date

May 2, 2016

q2 2016 Interim Report

July 27, 2016

q3 2016 Interim Report

October 26, 2016

2016 Annual Report

February 22, 2017

q1 2017 Interim Report

April 27, 2017

Annual Stockholdersâ€™ Meeting 2017

April 28, 2017

Masthead

Publisher

Editor

Investor Relations

Bayer AG, 51368 Leverkusen,
Germany

JÃ¶rg SchÃ¤fer, Tel. +49 214 30 39136
email: joerg.schaefer@bayer.com

Peter Dahlhoff, Tel. +49 214 30 33022
email: peter.dahlhoff@bayer.com

Date of publication

Environment & Sustainability

English edition
Currenta GmbH & Co. ohg
Language Service

Thursday, February 25, 2016

Dagmar Jost, Tel. +49 214 30 75284
email: dagmar.jost@bayer.com

issn 0343 / 1975

&RPELQHG0DQDJHPHQW5HSRUWDQGFRQVROLGDWHGÄŸQDQFLDOVWDWHPHQWVSURGXFHGLQKRXVHZLWK),5(V\V

The paper this report is printed on is derived from sources managed in line with social, economic
and ecological principles and therefore bears the seal of the Forest Stewardship CouncilÂ® (fsc Mix
Credit). The inside section was produced using 100%UHF\FOHGÄŸEHUVÅ‹DVJXDUDQWHHGE\WKHe.u.
(FRODEHOFHUWLÄŸFDWLRQ SDSHUUHJQRfr / 011 / 003).

For fast and easy access to our online services, thereâ€™s no need to copy down the internet addresses.
Simply scan the codes below with your smartphone and an appropriate app:

Annual Report online
Available at:
bayer.com / ar15

Annual Stockholdersâ€™
Meeting 2016
,QIRUPDWLRQDYDLODEOH
at: bayer.com / asm

Other publications
Overview available at:
bayer.com / publications

Bayer on the internet: www.bayer.com

Forward-Looking Statements
This Annual Report may contain forward-looking
statements based on current assumptions and
forecasts made by Bayer management. Various
known and unknown risks, uncertainties and
other factors could lead to material differences
EHWZHHQWKHDFWXDOIXWXUHUHVXOWVÄŸQDQFLDOVLWXDtion, development or performance of the company and the estimates given here. These factors
include those discussed in Bayerâ€™s public reports

which are available on the Bayer website at
http://www.bayer.com/. The company assumes
no liability whatsoever to update these forwardlooking statements or to conform them to future
events or developments.

Legal Notice
The product names designated with â„¢ are
brands of the Bayer Group or our distribution
partners and are registered trademarks in
many countries.

